<SEC-DOCUMENT>0000950170-22-024695.txt : 20221114
<SEC-HEADER>0000950170-22-024695.hdr.sgml : 20221114
<ACCEPTANCE-DATETIME>20221114073124
ACCESSION NUMBER:		0000950170-22-024695
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221114
DATE AS OF CHANGE:		20221114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alaunos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001107421
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841475642
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33038
		FILM NUMBER:		221380279

	BUSINESS ADDRESS:	
		STREET 1:		8030 EL RIO STREET
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054
		BUSINESS PHONE:		(346) 355-4099

	MAIL ADDRESS:	
		STREET 1:		8030 EL RIO STREET
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZIOPHARM ONCOLOGY INC
		DATE OF NAME CHANGE:	20050919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EASYWEB INC
		DATE OF NAME CHANGE:	20010213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tcrt-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-11-14T01:22:05.7681+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:tcrt="http://alaunos.com/20220930" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_6d7f681b-28a7-43ca-b90c-86f100ef11da" name="dei:CurrentFiscalYearEndDate" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317">--12-31</ix:nonNumeric><ix:nonNumeric id="F_8bb8fe40-36d1-44f3-9dfe-c009108bcb68" name="dei:AmendmentFlag" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonFraction id="F_541a6189-2782-4c24-a058-0c6f39bcf8ff" name="us-gaap:CommitmentsAndContingencies" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_62f37d4f-d871-46f0-9b1f-f747f80e2282" name="us-gaap:CommitmentsAndContingencies" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_9259c4f9-b69b-4b2f-a1b0-998dafd316f9" name="dei:EntityCentralIndexKey" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317">0001107421</ix:nonNumeric><ix:nonNumeric id="F_414c6922-9484-41e3-94da-3c97f527a5d5" name="dei:DocumentFiscalPeriodFocus" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317">Q3</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tcrt-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_93030e80-98ca-4f83-b767-ef2910a9d17a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:NewWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a649b50f-8367-4a1c-9108-4b85ebc15317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bca986a-5228-45f5-a440-a7d273a6f156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4a8cbd7-35ae-461e-b1af-edf4446dbfd9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:WatermillAndRobertWPostmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-19</xbrli:startDate><xbrli:endDate>2021-02-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30990001-d5dc-4069-a5b6-498c28245fdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_afa5d5a2-bab5-4430-b57c-13817635e7f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ec0e0fa-abc4-4590-ac2a-da156b639f99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c96f4f1f-d9a3-4eec-bc21-3fbaa7eeea85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f43bb33-c6dd-42f3-b81e-2d16c0d279f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fba5838-cd3f-40d2-8f7f-5f1b833834f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4466f87e-f227-46f8-9092-8a32178d41c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_808c9e76-ba2c-4353-bc47-63c7e812ba3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tcrt:OtherIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3996230c-eb63-4bd8-8c4e-4eda38f443db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5478d947-5881-4b9c-a88f-5e7d9771c267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82a2d9da-2739-4328-a38b-dd5018876817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a553ea37-cf6b-45d6-ab63-a4294c165977"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3dfd279-a1be-4e60-9b23-62f589a95c69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d15c91c-08c2-4355-817a-d947ee9b15f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_acc8d98b-3c82-4d2e-af71-6452e557354e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9aba2ab5-4f85-4c2d-b196-c03836210ab0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80a697e6-5126-46ff-850f-6f438cf69024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eab945c1-a1b6-41ab-91d4-85e2fc2020c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:EdenBiocellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-18</xbrli:startDate><xbrli:endDate>2018-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3da54949-f086-4986-984c-e1d5c3f603ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66586099-2ff8-40bd-a3af-a61d770bbd1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3be7956-1a1a-486d-a035-b032462f33aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d9975fc-c543-4fdc-bc21-cb9c1de3ac67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_17466d85-cda1-4e4a-b4fb-9d479415d434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71ac7c9c-ed62-4708-9f1f-3794c7da2b64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a1e5081-81c7-406f-aac2-68d4a56e7396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:TcellReceptorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0af67efe-5cc6-4bd3-95da-2269b35a5117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-11</xbrli:startDate><xbrli:endDate>2018-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fee32fa6-5000-4631-b097-9b1fea30a290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:CARProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29c774b1-4d47-4209-8c47-fcd96e1f3895"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e42a7258-b17a-4571-a2b7-a79071424b63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b60904b-b0fd-4742-a7f1-5ed95c47a6af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0aa8acc8-3dfc-4c50-ae31-5fef3f1e4dce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:NewWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-12</xbrli:startDate><xbrli:endDate>2019-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5b94b60-824a-4f1d-94d2-dc6c1840957d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5a16ee8-f8ba-419a-ad14-c822ec3582a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c362f59-d6f4-4a7a-a1c8-b74ebbed16b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:ClassOfWarrantOrRightAxisAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7ec9466-e3f0-4f95-aecc-fbe0889180ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f915cb95-5e51-4689-a7fd-3b9969b8b324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18e705d4-75c3-4f8b-9dd7-e32c9e97b572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ecb5cc8-f37c-4b95-98a1-b053f202010f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db352027-c319-4fed-873e-eafcb7007f91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89811c97-bb62-4965-936e-16929f7b6833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84042aae-9850-43a9-a32f-e85af10ed288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4b5db92-6383-4c43-b62a-d3bc3bc3fc9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b761c5a5-7e64-42b4-b347-bff79c80c526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tcrt:OtherIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18443f2c-6ffb-47e1-8f0b-7587c06dbd8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a8ceb76-7648-4132-8aa2-02c65b7eb518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a1f34d1-4746-4f1f-bc5a-c6ce280ea3a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba03628a-d489-4082-b85c-544300569f10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1c90eed-e7e4-4ee2-b023-7eca1c8b450c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-12</xbrli:startDate><xbrli:endDate>2019-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11eda09f-c5af-4a19-be29-445f8325d410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26c0546e-3ae0-436e-bf65-3135619b6131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d882f9ce-a213-4796-9543-c22ad26eb67a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-28</xbrli:startDate><xbrli:endDate>2021-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a3c172f-d546-462c-a72b-21a8a3e086bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_429d7895-53ce-476f-b62a-71d570bab848"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f90f3da9-4b30-43f4-8f71-7dedd967f4ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5ce15ce-9e47-4fdd-9332-0e26a6a95756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de243d37-ed59-4bdb-a446-2678a29190e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72bda269-9480-4b72-b4ce-a8fa1e5d2d6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84332a9b-1768-4928-b9c2-d0cfdbef460f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8607731b-da93-4afa-873b-c41bd854fae0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7384efec-4e47-4d02-8bce-8365f7e0295a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2dfd9017-3654-4240-b560-4fa92df974b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2de808d8-5984-43d6-9ce6-49b4e1114951"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9975e9e7-b6d2-44f8-8f9b-4428ca4a25ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87c24bba-d603-4bbb-92e5-692a66baf6fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a801914-4bd9-4d79-be9c-781ec8a7881d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00a63ae4-63b6-4ac6-941f-4be4fd9e3e98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11392846-50b9-4407-b98d-7bf6aba70e2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eddf6b5e-242d-4045-be96-1b91012cb2f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-28</xbrli:startDate><xbrli:endDate>2021-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23567fca-d299-4618-8b07-c800715f57a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:AgreementTypeAxis">tcrt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-11</xbrli:startDate><xbrli:endDate>2018-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56ad9b91-5908-46ac-b885-5f4b458e6dd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ecd0af9-f624-419c-bc04-78328b1a47e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4cbcc52b-1414-4969-a546-6beaa8636012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23eae7ee-dd71-428c-93da-1b90bf020452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:VinetiIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_516cb031-f3e7-4387-8ebb-eb61b7eb9ea0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dfc4b9a9-6363-4eb4-84cc-324cdd9e5c5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2619a848-009e-46c2-a1f5-04328671628d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79174d62-d06a-4299-a8be-9fb31ca9fadb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efc00410-6d5c-495a-a72b-6d6351214b08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d490f67-76f7-406e-84c4-387e0d9d6db5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_243ddad6-e77f-4cec-bf28-7f9b590baafd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-28</xbrli:startDate><xbrli:endDate>2019-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f647c291-0b62-43fd-84a5-54f70a4da70b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c328dc7e-2261-4512-872c-da4fb630f2c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41ac8d4f-13d9-476b-a18c-5b3fef9ae897"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a8415e0-ec1d-4ed0-a8c1-83dd21690b46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e4f7846-958f-4ab8-a4e6-79d28f2b664d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-22</xbrli:startDate><xbrli:endDate>2019-10-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9dc3ba53-2c20-4736-8bee-cb0366b44f23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tcrt:InducementStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95ff3701-048e-464c-829f-6c697a0744f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tcrt:InducementStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e52479f-7e44-4216-b266-a0446569c844"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:WatermillAndRobertWPostmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-04</xbrli:startDate><xbrli:endDate>2021-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49c4b845-edf1-48ac-b363-86d2eb87b129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9a0185b-e5d0-4a1e-9377-e759cf76ceb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1c325e4-fe22-4b5f-8e61-12cd0023447b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5278975e-6f79-4550-9b7e-1506a2f6d459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_464be36f-cadb-4d42-b6ec-60d3e858ae0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c370e803-a7b8-487c-bccf-7d82d4dbd10d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd378eef-0abd-4f06-8c55-ed8f64bbee7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">tcrt:EdenBioCellMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">tcrt:ZiopharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6c3e2ec-e88b-4a8e-a9a1-8a82c2d398ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2004-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc8e2d26-10b6-486b-8a26-6ca99f89115b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e81d9a09-eee0-481c-8976-f48c00938da7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d40e9e7-c9cf-4667-ba64-23d8853c4fdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c14220fc-6b7b-43f8-af8e-400952313273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:PerformanceBasedPaymentsMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:DueDateAxis">tcrt:PostMarketingApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90eeab4e-d329-4773-9ae7-51f760c71986"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ea0be7a-caae-4842-adc5-35fca4e7eea4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5748e941-3c1c-4556-8329-7aeb6d259272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba7ea719-3efa-42ac-a0b2-dbaed33d86b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_baf45bdc-d90e-4313-afd6-a2ad17b87cdf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a85659d-9529-4877-90ee-9305d6b05bd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c373b210-56f0-4a58-9d24-8f12d518d218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:VinetiIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89339f1e-48c2-46f1-afa9-1bd72a4dccef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:VinetiIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d56c397d-06d5-47bb-8033-e0542dd94f41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonAgreementAndWorldwideLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-13</xbrli:startDate><xbrli:endDate>2015-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d421d03-41e0-4a9e-bb6e-dcc0101f73f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35c36f71-52c6-4199-9a71-a3ae673b76aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1e34188-3704-4285-90a2-81f9b25a98ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf4cb307-d956-44e9-9223-82983a351431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9980554-eb5e-4c04-98a8-4a1d013e4bb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0eb70e2-a850-4290-9f2b-2c099994757c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28481c26-2de7-4e94-9943-6a2deb168a5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef34299f-cc59-4eaa-9859-4aff997142c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05de267d-66f3-4500-b8af-4de14cc90182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7dcce1df-cf39-47fd-a123-bd1b19d85aed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db440a89-812a-473c-bea3-ef4ccf784d27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf9a58e2-50b7-4e9f-b6e9-8386b05eaea6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5eb44bc0-03fd-4514-a7c0-b540f7cb6ad2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3064554-7470-4ef4-931d-019f0af3c58c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f490ba4-b156-491d-bf6f-129ecf662eb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3c976de-0ee5-455d-bee2-a9edd8244900"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b2f5a35-750a-426b-8208-95bde28e9376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">tcrt:EightScheduledPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-28</xbrli:startDate><xbrli:endDate>2021-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9252104-b0ce-41b0-bd34-3724646ef25e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e455d27-ae8e-4cd2-8656-5e6b3044aec4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-12</xbrli:startDate><xbrli:endDate>2019-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bcd49289-aef5-458e-9a35-82903fd7c003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b8825bb-408d-4786-bba0-1843af5bb11e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_399029cd-00f2-489c-89bd-afddf96d9013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c30b44b-f58e-4273-8a2f-4d08ae4922ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5737b6f-9713-4bf0-9447-bffb6837ae58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0485a7c-1400-45f5-9110-483d8d21ebfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72dbe520-f3b4-4e1f-9462-73da4d9acb9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_682aeb79-9f3f-49f6-9a66-66cc8398ab88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4985865-020d-4fdb-bec6-b066804fcca8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:PerformanceBasedPaymentsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c32ad95-bd53-4f35-853e-22b717e70798"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5287bb43-2308-4e1c-a17a-766d2905368b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:VinetiIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c77e152-785d-4e6f-99b7-b0d56fb1dc63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">tcrt:TenthScheduledPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-28</xbrli:startDate><xbrli:endDate>2021-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2daa022b-a09a-4371-9536-aff338b7b832"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce1c210f-7d8b-4de3-bdac-77591a3466bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0570a01-faa7-4744-91fc-66333e256702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36e64732-f6d5-4615-89f1-3872af4ff2ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-17</xbrli:startDate><xbrli:endDate>2015-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7dd83c2e-6421-445b-a010-82fe8ad08521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba706fc5-e9e4-4f6d-9180-2a783ebf0530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6a2cd0a-f5d0-4a9f-af29-87bb8204f6f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_168c2abe-f9d8-4189-b7ee-13828dea54d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:EdenBiocellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ed707b3-bea7-4926-b6bd-f4064815e868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fcea062a-308f-4809-8835-154dace3f34b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7baac48-135d-4e1f-805c-4570972d3951"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-17</xbrli:startDate><xbrli:endDate>2015-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90c6bc67-1b17-4053-8728-b194d7b2b725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2cec0f62-e0a7-444b-9c62-04422644e817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8f27772-b294-42ff-a235-56681aee8001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a89460f1-fee5-4a24-9dc9-1ef04a688e53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51a11843-7d5f-4914-9b59-f8771ccffffc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07609204-d289-4b94-b19f-777a70145f62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d8421da-db98-4345-93d7-f06de09f53d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d739f65-8890-4484-9fa8-db2c2788d308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-12</xbrli:startDate><xbrli:endDate>2022-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4d2468d-d204-46a0-a52f-8c6f952adf7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4abb6de4-1411-454e-b48d-575b66944575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5dd32c50-d442-41ca-9a9b-395b972f0c54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43bf232f-663e-498c-8a53-386a3a861e53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:LicensedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-28</xbrli:startDate><xbrli:endDate>2019-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5987d6f3-3485-4951-8af9-679dc649bb35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:5.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4429bf30-fa90-413c-864e-749d3ef038c6" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:5.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Mark One)</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.998%;"></td>
    <td style="width:96.002%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_471d5552-4ae9-4207-8302-37e192a6990f" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:DocumentQuarterlyReport" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bd171d35-9254-45e1-bed9-931174218030" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8eca71a0-168d-4ba4-8adc-bd9a86097197" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.998%;"></td>
    <td style="width:96.002%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a01d15a2-304c-4ef6-b474-db5228d80811" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:DocumentTransitionReport" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_06c62e7e-2e8d-45f7-8d15-8c95bb56dbcb" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-33038</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:5.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_51ed4df5-4bb9-4887-b398-ec6a13fb6f08" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_38c80208-8e2d-4cf8-ac5c-e1469367b6e1" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9b6eaecb-abad-4601-a903-b9210367d4ee" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84-1475642</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0b67f143-0e1e-4826-bbe4-95070fd2c6d1" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8030 El Rio Street</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_56494f64-71c0-419a-9eed-d34f44a4294f" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Houston</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f5804463-e19b-44a8-9f69-191a95b8003e" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TX</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_814343ab-9f6b-45b8-8923-d5e371cc5e78" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77054</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_100b0d39-8883-4913-ba9b-7075aef022fa" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">346</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ce165e6f-3b59-4673-a37c-b42aa07cd7f2" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">355-4099</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:5.333%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_06473b7a-acd3-4a83-ad69-fea7aea9dd36" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b07e9cfe-8ace-4e78-af2d-37617187a3fa" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TCRT</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_02e74f8f-139a-482a-88ff-61cf00b49806" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:5.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c036c237-945d-49d4-920d-559163a9eec7" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:5.333%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_16eccd87-d2cd-4983-8238-ff3fb26dc9d5" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:5.333%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.998%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:2.003%;"></td>
    <td style="width:29.994%;"></td>
    <td style="width:31.998%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:2.003%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large Accelerated Filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated Filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7a8b07f3-7dc3-47fb-8556-d65b019cb51b" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Accelerated Filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller Reporting Company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1f6fea9b-0444-4792-90c4-ba0522368bac" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging Growth Company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_26b1fde3-4819-4702-8606-5f950eafe3d4" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:EntityEmergingGrowthCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:5.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>
  <p style="text-indent:5.333%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  &#9744;    No  </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b83de4a8-0c56-4add-be25-2bbe66c0d360" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:5.333%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of November 9, 2022, the number of outstanding shares of the registrant's common stock, $0.001 par value, was </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7668cf4d-a5be-402c-8268-7766b3b088e1" contextRef="C_90c6bc67-1b17-4053-8728-b194d7b2b725" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">216,182,042</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares.</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are all statements contained in this Quarterly Report that are not historical fact, and in some cases can be identified by terms such as: &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;forecast,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;project,&#x201d; &#x201c;target,&#x201d; &#x201c;will&#x201d; and other words and terms of similar meaning.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These statements are based on management&#x2019;s current beliefs and assumptions and on information currently available to management. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to raise substantial additional capital to continue as a going concern, fund our planned operations and repay our existing indebtedness; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">estimates regarding our expenses, use of cash, timing of future cash needs and anticipated capital requirements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the development of our product candidates, including statements regarding the initiation, timing, progress and results of our preclinical studies, clinical trials and research and development programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to advance our product candidates through various stages of development, especially through pivotal safety and efficacy trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk that final trial data may not support interim analysis of the viability of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectation regarding the safety and efficacy of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing, scope or likelihood of regulatory filings and approvals from the U.S. Food and Drug Administration, or FDA, or equivalent foreign regulatory agencies for our product candidates and for which indications; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to license additional intellectual property relating to our product candidates from third parties and to comply with our existing license agreements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to enter into partnerships or strategic collaboration agreements and our ability to achieve the results and potential benefits contemplated from relationships with collaborators; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain and establish collaborations and licenses; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectation of developments and projections relating to competition from other pharmaceutical and biotechnology companies or our industry; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our estimates regarding the potential market opportunity for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the anticipated rate and degree of commercial scope and potential, as well as market acceptance of our product candidates for any indication, if approved; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the anticipated amount, timing and accounting of contract liabilities, milestones and other payments under licensing, collaboration or acquisition agreements, research and development costs and other expenses;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our intellectual property position, including the strength and enforceability of our intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to attract and retain qualified employees and key personnel; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact on our business from a pandemic, epidemic or outbreak, including the COVID-19 pandemic.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item 1A, &#x201c;Risk Factors&#x201d; and elsewhere in this Quarterly Report on Form 10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless the context requires otherwise, references in this Quarterly Report to &#x201c;Alaunos,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d; refer to Alaunos Therapeutics, Inc., and its subsidiaries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We own or have rights to trademarks, service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. We own the trademarks Alaunos&#153;, Ziopharm&#174; and hunTR&#153; as well as the graphic trademark found on our website. Other trademarks, service marks and trade names appearing in this Quarterly Report are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in this Quarterly Report are listed without the &#174; and &#153; symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks, service marks and trade names.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUMMARY OF SELECTED RISKS ASSOCIATED WITH OUR BUSINESS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business faces significant risks and uncertainties. If any of the following risks are realized, our business, financial condition and results of operations could be materially and adversely affected. You should carefully review and consider the full discussion of our risk factors in the section titled &#x201c;Risk Factors&#x201d; in Part II, Item 1A of this Quarterly Report. Some of the more significant risks include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will require substantial additional financial resources to continue as a going concern, continue ongoing development of our product candidates and pursue our business objectives; if we are unable to obtain these additional resources when needed, we may be forced to delay or discontinue our planned operations, including clinical testing of our product candidates. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our plans to develop and commercialize non-viral adoptive cellular therapies based on T-cell receptor, or TCR, therapies can be considered as new approaches to cancer treatment, the successful development of which is subject to significant challenges. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current product candidates are based on novel technologies and are supported by limited clinical data and we cannot assure you that our current and planned clinical trials will produce data that supports regulatory approval of one or more of these product candidates. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will need to attract, recruit and retain qualified personnel, and we will continue to rely on key scientific and medical advisors, and their knowledge of our business and technical expertise would be difficult to replace.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our existing indebtedness, together with our other financial obligations and contractual commitments, could adversely affect our financial condition and restrict our future operations. For instance, we were required to deposit a significant amount of cash into an account to be held as collateral.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain the necessary United States or worldwide regulatory approvals to commercialize any product candidate, our business will suffer. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates are in various stages of clinical trials, which are very expensive and time-consuming. We cannot be certain when we will be able to submit a Biologics License Application, or BLA, to the FDA and any failure or delay in completing clinical trials for our product candidates could harm our business. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our cellular immuno-oncology product candidates rely on the availability of reagents, specialized equipment, and other specialty materials and infrastructure, which may not be available to us on acceptable terms or at all. For some of these reagents, equipment, and materials, we rely or may rely on sole source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable either to create sales, marketing and distribution capabilities or enter into agreements with third parties to perform these functions, we will be unable to commercialize our product candidates successfully. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our immuno-oncology product candidates may face competition in the future from biosimilars. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or our licensors fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish and our ability to successfully commercialize our products may be impaired. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our stock price has been, and may continue to be, volatile. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">iii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.102%;"></td>
    <td style="width:82.82%;"></td>
    <td style="width:7.078%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FINANCIAL INFORMATION</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements (unaudited)</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balance_sheet_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheets as of September 30, 2022 (unaudited) and December 31, 2021</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_of_operation_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Operations for the three and nine months ended September 30, 2022 and 2021 (unaudited)</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#stockholders_equity_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Changes in Stockholders&#x2019; Equity for the three and nine months ended September 30, 2022 and 2021 (unaudited)</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#cashflow_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Cash Flows for the nine months ended September 30, 2022 and 2021 (unaudited)</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements (unaudited)</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OTHER INFORMATION</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_legal_proceeding_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factor_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_unregistered_sale_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_default_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Defaults Upon Senior Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_other_information_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_exhibit_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I&#x2014;FINANCIAL INFORMATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 1. Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheet_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BALANCE SHEETS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.997%;"></td>
    <td style="width:1.623%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.878%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.623%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.878%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASSETS:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97df6927-ebd6-4a9f-a9df-7439bf6fb361" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,807</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d35b4e28-c39d-4431-b1ba-3d92ee7cd2be" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,054</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acd3db16-2978-456f-963b-ee83b280061e" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,938</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be2fa4f6-c75f-4765-8145-ea42d6db6605" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Receivables</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bbeb6729-e290-47ba-935a-9c9545adb5f8" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,911</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dfbc6008-2c61-4358-a3f4-5835b7f4a2c4" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,111</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1d12d08-94c1-412a-b057-c58269b11c3e" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">849</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c59afb90-e9b7-4d08-bf55-49730566844d" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,666</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_724837c8-48e2-4ce8-95e0-821e16fcfd68" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,505</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93918fc0-6eb7-4164-81cc-0bbc6de9c925" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78,831</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c059a35-d576-4943-9bbb-4ccc19745b7d" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,050</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a7ae154-5da6-4397-88ed-f7a7f34b8452" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,941</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use asset</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5129ef6-89a2-46e9-891c-5820afac7005" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,247</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_daaf7519-083b-4a60-8960-e2fc4e9f4342" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,420</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deposits</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54bb4a87-89e2-46bf-a677-d36485c14d84" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:DepositsAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f51f3f78-bcbe-4992-905a-1331e5afa03c" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:DepositsAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f7d853e-83be-4b9c-a574-cc5c74bb5b62" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f67a3214-3c58-40eb-afbd-96dac7cfb594" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">631</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:50.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:50.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d59f003e-b032-472c-a0fd-1106fe71f0f3" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,344</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2bbf632-090b-422a-bb6e-2f65ce729e2e" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94,865</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS' EQUITY</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffefe0e0-7caf-4a2d-bb3e-3cd9201d1b12" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,984</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3dc238a8-6242-40bf-999b-0f0fe2e82eff" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,368</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of long-term debt</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4334e6c-ab2d-44fe-8828-ca93be7f4079" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,668</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a025654d-9ce3-4af4-9c13-f9ed5cd6a94d" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,868</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc21524d-e485-4764-9e53-739f5122d934" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,675</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33ce52be-a203-4dac-b25b-f611590880b1" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,076</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability, current</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82eb5a9a-d742-4bf8-9efc-cf6f69808142" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">542</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f49573fe-2bdc-4476-8a69-fc58a8e707a3" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">729</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a802d7b-0d9d-497e-a972-9ef68f9f796f" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,869</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f38b62d-6c04-4a4e-9d1c-2901f3da30d3" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,041</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term debt</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72275e87-182e-4066-85b1-29721f908af7" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4dece6d-b4c5-4d14-b23c-d6a25fcb7d2a" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,250</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability, non-current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_744f530b-9c9f-461d-a1df-292ab3dfd222" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,334</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7da3a00-6a86-4fd2-8aef-f15dc2bcbd74" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,518</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other non-current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4f39d91-81ab-4783-9f34-4171aed983b0" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d659bd1a-a121-4c94-b846-a6b99803114d" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed5f66c5-2dea-4f33-aa72-cd62b4f5ea03" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,231</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0e0f1ff-cf8d-47ad-994c-cd469ec9289a" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,809</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_62f37d4f-d871-46f0-9b1f-f747f80e2282;"><span style="-sec-ix-hidden:F_541a6189-2782-4c24-a058-0c6f39bcf8ff;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (Note 9)</span></span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49ffba22-bad0-4f90-9c32-8746346263c3" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="3" format="ixt:numdotdecimal"><ix:nonFraction id="F_9169ab67-8942-451f-a9be-baf59935e413" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f90bfc3-1a3a-4b2c-906f-c3a34f612f15" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">420,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebfffcae-8dae-40df-b0f1-b1a48b2d0a94" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_767abb74-696d-4112-bfc7-857e26fd6436" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">216,182,042</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding at September 30, 2022 and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_570ed151-09b2-45e4-9e3d-a3d5b19f7c8b" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">350,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7983aaa2-fe12-4634-b89c-6147d53734ba" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_0f23e264-cd70-4b5c-a09e-ccd91f997e8f" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">216,127,443</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ed00a0a-ded4-45c0-a549-5a664fe32432" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be583140-ad70-4bd5-bd30-d1eb43453aa8" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9479ba3c-c9e3-4a4c-81b3-2a1ffc5ff60e" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">903,365</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e81bc8e-2559-4edb-a397-0206701dbbd3" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">900,693</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e95d8395-d4df-4c99-bc64-0cd2d91ee660" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">871,468</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94f2071c-5942-4f34-8834-15aa0510a0b0" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">842,852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1b91799-90dc-4fe3-8265-f5ac6b4603c5" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,113</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69ac99ce-2539-47ba-bf72-ab1f84847a6f" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,057</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:40.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbc50839-3f70-4016-88f9-49a3aa2dad08" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,344</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd991104-a9f2-4961-9466-51d4270dce33" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94,865</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_of_operation_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STATEMENTS OF OPERATIONS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.202%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.052999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.248%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.052999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.433%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Three Months Ended September 30,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Nine Months Ended September 30,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f0c489c-502a-44f1-b4ce-55d7bdceb59a" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,911</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d4a493e-4c83-4b11-83b9-f69753ba6d7d" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">398</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4f97d9f-ac46-4e85-922c-64f1b705692a" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,911</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b69fb25b-f38c-475f-8506-c5fd5d5a215c" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">398</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25c9e908-bb9a-4f21-8b67-4fc43e648a61" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,893</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0d44ca7-a8e2-4eb6-b2a3-fa0a2166799f" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,521</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f955f06-bfac-4479-a13f-4144ff6be45d" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,411</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_716215a2-890d-4a0a-bced-6149b54a897b" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,427</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ce4997a-4269-45c1-85fc-262e27faca7b" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,282</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff9fde76-6c47-4ce1-bbc1-b6aca536150a" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,173</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b595b859-9c41-48d2-84fe-6bd719a35400" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9dd01eba-1586-49a1-a4a5-5bb2ccf3a7f9" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,469</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gain on lease modification</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_172ad272-9ce0-45ad-963b-f951a4139565" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="tcrt:GainLossOnOperatingLeaseModification" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08886c53-fa3c-49bc-b45f-ae0f6a2672cd" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="tcrt:GainLossOnOperatingLeaseModification" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4b1792d-15a5-4aef-a449-df5f45b3e38d" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="tcrt:GainLossOnOperatingLeaseModification" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6eeebfb0-842f-4964-9c4b-56f9bbf9abb0" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="tcrt:GainLossOnOperatingLeaseModification" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b867378-9dd1-482e-a48c-38c00f9640ef" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,175</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_575f71d7-fd94-4508-90d8-587a016c26d7" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,694</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df3b2cea-1e63-4442-84d4-a95b22dd4d1e" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,495</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7cb5cba-168d-4d45-a13e-3c99840bca5a" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,896</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16031e3a-54be-42da-9786-0a84528b9f73" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,264</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a334fc99-1419-49e5-b57a-8bd49f12b221" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">22,296</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3e4ce54-b766-44c8-b779-5544cae72ec7" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">26,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ee86fff-9fd9-4d20-8b0b-3976eeb89e3f" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,498</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_641e7d05-8cb6-42f5-a345-fae780cb18bf" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">841</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57953f83-6944-40b4-b3fa-175358fcd1c6" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">444</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84d59aed-deeb-47e1-84be-02ebc72cb55e" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,266</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38a4f1db-d710-4139-905d-bcf57d1c3329" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">444</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_546af589-fbff-4a54-830c-5eb6179fd17a" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">254</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e239db7-ddb8-4b27-ad99-deda17705d19" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b48ffb0f-56ce-408b-9612-de61c0f76666" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">279</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3e3909c-c9e7-4cba-ba25-743648ce0d4a" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd2f8df2-a888-4286-a235-ac15c64dd35b" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">587</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef8b6dc8-dcd1-491b-ac96-f89d64686bcd" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">437</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_748ae110-1811-440b-bd5a-cca60a564bee" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,987</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_264d3dbd-31dd-4300-93a5-f72dfbd1f544" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">459</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_872feaaa-2fdf-47ec-9b1d-e3aa0137912e" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,851</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa66adad-25db-4564-9aaf-6d9466b9b951" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">22,733</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af292e37-7ffa-459a-ba06-0058e658af44" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">28,571</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_100b27a5-45ba-4c84-86af-f1e5e4e038e5" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,957</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_601dae83-602c-4512-9ada-8b1f29868a20" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_002e8620-1823-4eb3-b960-5f7fcdae78a4" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.04</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26c7eb5a-5090-44aa-8355-e4ecdeee6fe8" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_0c138377-8a23-4df5-afc6-4598a1ec26b7" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.11</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c353d5c-6267-45a6-9525-49991e5ccdcf" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_17037473-b4a5-4d22-81af-259eb648d18e" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.13</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f325bda-d220-4796-85a6-a3de2ae051c2" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_9e6bc9c1-0035-4885-b666-0a982f6e6c58" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.31</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average common shares outstanding, basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdd544c6-f0b8-4573-8b5f-dc93666a72cb" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_8de78eb0-e256-40b4-9d3f-2abb1362d6e4" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">215,098,995</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ce3ca5f-cf9e-49da-8633-e5cab987fd38" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_d94e214c-fa93-4b71-ba1b-7530b1a989f1" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">214,542,465</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30ecadcd-83e0-4d59-b7d8-4740762cfe82" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_0547b53a-c9e0-4443-aee6-5c875328c449" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">215,015,377</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59f0e52a-305b-445a-a77d-8ce831dae04e" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_2fe1a0c8-b4d2-4032-805a-ab6137c50308" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">214,310,349</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="stockholders_equity_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STATEMENTS OF CHANGES IN STOCKHOLDERS&#x2019; EQUITY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Three Months Ended September 30, 2022</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.843%;"></td>
    <td style="width:1.008%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.556000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.092%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.16%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.092%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.889%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.092%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.952%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.092%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.223%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Paid in Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Stockholders' Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at June 30, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef13180e-9e19-419d-a577-ed39ad07ee55" contextRef="C_ef34299f-cc59-4eaa-9859-4aff997142c7" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">216,174,542</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58637450-8ed7-4a19-9a73-c0d9c4af9b13" contextRef="C_ef34299f-cc59-4eaa-9859-4aff997142c7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5d83ea2-0e18-425a-96c8-35b410379c06" contextRef="C_7b60904b-b0fd-4742-a7f1-5ed95c47a6af" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">902,536</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_669a5f41-88bb-4ac3-9d63-ae19676a3f65" contextRef="C_baf45bdc-d90e-4313-afd6-a2ad17b87cdf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">862,572</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bbddab63-fab8-4a4f-a695-5c19ce124e8c" contextRef="C_c96f4f1f-d9a3-4eec-bc21-3fbaa7eeea85" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,180</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_639e5eea-00ef-4656-9a1a-3395d4e8db39" contextRef="C_84042aae-9850-43a9-a32f-e85af10ed288" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">808</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee99f9f8-1694-429c-9307-0006365cdea7" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">808</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of employee stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eef1ce40-a777-485a-bbc6-0963c4dc9a6f" contextRef="C_9b8825bb-408d-4786-bba0-1843af5bb11e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,250</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75ac78c5-a8ca-48d0-9ca0-f2551415affa" contextRef="C_84042aae-9850-43a9-a32f-e85af10ed288" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4616741-3d81-463b-9659-e03123227898" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_423567fa-08d3-4bee-99f3-33b5baa0afc8" contextRef="C_9b8825bb-408d-4786-bba0-1843af5bb11e" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,750</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_998d7299-5a9e-4328-bc5b-468726c405fe" contextRef="C_84332a9b-1768-4928-b9c2-d0cfdbef460f" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_272052e2-01fe-4826-84ca-da60bc0fd5b2" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77eff0f4-35ee-46b7-8264-37ffb8194b8f" contextRef="C_84332a9b-1768-4928-b9c2-d0cfdbef460f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,851</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2b386ae-f713-4605-914c-9cbec2998921" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,851</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at September 30, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_205e50ea-fdec-4add-b09a-60980ab627d9" contextRef="C_72bda269-9480-4b72-b4ce-a8fa1e5d2d6a" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">216,182,042</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_883a2d32-b9dd-496f-b709-fa9d2a3f5b0e" contextRef="C_72bda269-9480-4b72-b4ce-a8fa1e5d2d6a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bc1aa71-48e5-4d6d-90b9-66bc5ef3749c" contextRef="C_28481c26-2de7-4e94-9943-6a2deb168a5e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">903,365</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a690394a-40e1-4dd8-880b-cf7b0d381d44" contextRef="C_5eb44bc0-03fd-4514-a7c0-b540f7cb6ad2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">871,468</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08f97fb1-c5d3-4661-94f5-abf61b576db9" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,113</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Nine Months Ended September 30, 2022</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.902%;"></td>
    <td style="width:1.008%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.57%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.092%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.167%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.092%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.896%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.092%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.959%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.092%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.126%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Paid in Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Stockholders' Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92027dfc-1320-4a03-bf09-49b2a310a514" contextRef="C_05de267d-66f3-4500-b8af-4de14cc90182" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">216,127,443</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a208da07-eeaa-482e-bcce-d71d0d47410d" contextRef="C_05de267d-66f3-4500-b8af-4de14cc90182" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b7b6d27-357f-4810-8815-ebed9a02885e" contextRef="C_e42a7258-b17a-4571-a2b7-a79071424b63" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">900,693</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12d5c7ff-0547-4e13-9f9c-73b3a85702db" contextRef="C_4cbcc52b-1414-4969-a546-6beaa8636012" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">842,852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdfe9485-c690-43b6-9c97-43880b0abf72" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,057</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c48535c4-b04c-4eb3-9b11-ec971dc4c82c" contextRef="C_41ac8d4f-13d9-476b-a18c-5b3fef9ae897" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,651</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_741b4f59-53d9-4f90-8d76-401b2b6b8677" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,651</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock awards</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b601c7d9-39c2-4f97-ba68-d5d72f50d304" contextRef="C_e1e34188-3704-4285-90a2-81f9b25a98ba" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">280,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled restricted common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8858a49b-d47a-429c-b81f-e13a59efbbe0" contextRef="C_e1e34188-3704-4285-90a2-81f9b25a98ba" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">232,901</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of employee stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54ce7a58-fd5d-4fcc-b99e-95c5a6150f81" contextRef="C_e1e34188-3704-4285-90a2-81f9b25a98ba" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,250</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aefadc33-4ce5-4c7e-a94d-996dd8bb486a" contextRef="C_41ac8d4f-13d9-476b-a18c-5b3fef9ae897" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c2c1062-9b17-4400-adaf-9b4a1ff68367" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f217acc-8bc1-4a95-a84c-26e6ddbe046c" contextRef="C_e1e34188-3704-4285-90a2-81f9b25a98ba" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,750</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61be8d68-7f28-4c5b-ab5f-3fc3da821281" contextRef="C_c370e803-a7b8-487c-bccf-7d82d4dbd10d" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c4e881b-fc0d-463e-926f-4afc1670e2ce" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9cc13728-22ad-46de-8a14-609c416d5483" contextRef="C_c370e803-a7b8-487c-bccf-7d82d4dbd10d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">28,571</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_767839c3-5903-4bfe-aec7-5a64a85d9593" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">28,571</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at September 30, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86941a1d-1f22-4925-a958-d1c66bf5d2d2" contextRef="C_72bda269-9480-4b72-b4ce-a8fa1e5d2d6a" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">216,182,042</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e22f66a7-9d52-4052-9589-5941c6b51cd9" contextRef="C_72bda269-9480-4b72-b4ce-a8fa1e5d2d6a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ef6bb5c-f011-451c-bd75-aad707ae2673" contextRef="C_28481c26-2de7-4e94-9943-6a2deb168a5e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">903,365</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d6b1f8e-0594-4887-8710-a5b673135d42" contextRef="C_5eb44bc0-03fd-4514-a7c0-b540f7cb6ad2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">871,468</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_210fde09-7480-49be-8723-8ad1eebf22e2" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,113</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Three Months Ended September 30, 2021</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:41.696%;"></td>
    <td style="width:1.015%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.957%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.015%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.181%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.015%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.931%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.015%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.994000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.015%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.161%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Paid in Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Stockholders' Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at June 30, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4deed38a-0b0a-4843-be37-be66cb278519" contextRef="C_18e705d4-75c3-4f8b-9dd7-e32c9e97b572" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">215,559,148</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83f66155-1e6c-4638-8cd6-cad29565cfc7" contextRef="C_18e705d4-75c3-4f8b-9dd7-e32c9e97b572" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_748d986b-9dc0-44ea-88e5-daf862aa238b" contextRef="C_4f490ba4-b156-491d-bf6f-129ecf662eb2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">896,390</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c11e9991-e2ec-4bb5-bf21-5d8be78c1084" contextRef="C_a89460f1-fee5-4a24-9dc9-1ef04a688e53" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">808,325</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_890830c4-4bb6-45a0-96e9-2be724c92055" contextRef="C_4ecb5cc8-f37c-4b95-98a1-b053f202010f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,281</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7954524-5c64-451f-8423-ba86bd1c3936" contextRef="C_7a3c172f-d546-462c-a72b-21a8a3e086bd" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,371</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f5f3016-89fe-4ca0-929b-1e527413d4c2" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,371</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock awards</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b897ccc-cc4f-4f46-9ac2-2b1f4b6aa7fe" contextRef="C_7dcce1df-cf39-47fd-a123-bd1b19d85aed" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">875,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled restricted common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81413e12-e48e-4c06-b0b6-63c85d610069" contextRef="C_7dcce1df-cf39-47fd-a123-bd1b19d85aed" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">288,344</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of warrants</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7875702f-76b3-44a7-a469-1756ea5c8b60" contextRef="C_7a3c172f-d546-462c-a72b-21a8a3e086bd" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">788</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f127040-58ef-41ea-8838-6c7cabaf60b4" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">788</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03cc99e6-c258-45cd-beec-e617f89b81bf" contextRef="C_5dd32c50-d442-41ca-9a9b-395b972f0c54" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">22,733</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9aed183-de34-45a5-bdc2-0101fc533adf" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">22,733</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at September 30, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7e8503e-c2f0-4cc0-a14e-f884146950f6" contextRef="C_5987d6f3-3485-4951-8af9-679dc649bb35" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">216,145,804</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ce9c0cf-87b7-4316-889f-d2a20190cb20" contextRef="C_5987d6f3-3485-4951-8af9-679dc649bb35" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9826dcf4-989e-4284-a53c-97e627ac72c1" contextRef="C_6c30b44b-f58e-4273-8a2f-4d08ae4922ef" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">899,549</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ac7142d-3cc2-43eb-92d9-2738b7fe5477" contextRef="C_0d490f67-76f7-406e-84c4-387e0d9d6db5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">831,058</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11d219a8-2c9c-43f2-a85e-77b1628639e4" contextRef="C_e81d9a09-eee0-481c-8976-f48c00938da7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,707</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Nine Months Ended September 30, 2021</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.923%;"></td>
    <td style="width:1.008%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.57%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.092%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.174%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.092%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.903%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.092%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.965999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.092%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.084%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Paid in Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Stockholders' Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e05d8372-5652-43d4-9e00-f91465306ef1" contextRef="C_80a697e6-5126-46ff-850f-6f438cf69024" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">214,591,906</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88c2628e-b6fe-4e95-bbed-0f93d8c3b1ff" contextRef="C_80a697e6-5126-46ff-850f-6f438cf69024" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">215</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e093bc0-dd8b-4d99-9cb3-a6b8a835f549" contextRef="C_d9980554-eb5e-4c04-98a8-4a1d013e4bb7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">887,868</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a97651d-1813-409d-a1c9-4b4de2c3d827" contextRef="C_429d7895-53ce-476f-b62a-71d570bab848" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">764,101</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c172936c-deda-4147-b90f-9fe1de55f49d" contextRef="C_afa5d5a2-bab5-4430-b57c-13817635e7f3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123,982</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70ce1b24-4554-41af-8dff-aaee471c1e8a" contextRef="C_9aba2ab5-4f85-4c2d-b196-c03836210ab0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9759f197-2cf3-4fde-8e2a-5585e2ee9096" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of employee stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf2676af-4104-42c6-a082-ebef18af3d91" contextRef="C_682aeb79-9f3f-49f6-9a66-66cc8398ab88" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">363,109</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1eb2fbe5-1ce9-418c-abf2-9184bf540721" contextRef="C_9aba2ab5-4f85-4c2d-b196-c03836210ab0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,037</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a1c02ce-2cbc-4918-9115-7e05d66739cd" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,037</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock awards</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7c3c765-8531-4c43-822d-e99f8e8d00cd" contextRef="C_682aeb79-9f3f-49f6-9a66-66cc8398ab88" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,601,224</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eaab58c0-7bb8-4045-ad77-545dfc1c1a2e" contextRef="C_682aeb79-9f3f-49f6-9a66-66cc8398ab88" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3dacd262-7a28-424e-a993-2dd885ebb23e" contextRef="C_9aba2ab5-4f85-4c2d-b196-c03836210ab0" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4697c336-dbb4-466c-b3a6-4c03120a230e" contextRef="C_682aeb79-9f3f-49f6-9a66-66cc8398ab88" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">410,435</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of warrants</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b91b585-669d-410c-8814-698cee341b5d" contextRef="C_9aba2ab5-4f85-4c2d-b196-c03836210ab0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">788</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b46386b-dc80-494d-82db-3f0d17d4ae5b" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">788</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02ff9cee-211a-48ad-aaf5-7c996b8fe179" contextRef="C_d7ec9466-e3f0-4f95-aecc-fbe0889180ae" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,957</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44565491-e261-4394-8301-955e00101340" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,957</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at September 30, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22c42067-9977-4601-bb55-078925f335fe" contextRef="C_5987d6f3-3485-4951-8af9-679dc649bb35" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">216,145,804</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23119875-b08b-458e-9788-ee012a3a51c8" contextRef="C_5987d6f3-3485-4951-8af9-679dc649bb35" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f276b37d-fa28-4145-bcd9-2aba64112106" contextRef="C_6c30b44b-f58e-4273-8a2f-4d08ae4922ef" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">899,549</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d822a07b-e456-4a49-a94d-333ce438cf77" contextRef="C_0d490f67-76f7-406e-84c4-387e0d9d6db5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">831,058</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2b29bc3-26cf-4a62-8689-e69da676d1a7" contextRef="C_e81d9a09-eee0-481c-8976-f48c00938da7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,707</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="cashflow_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STATEMENTS OF CASH FLOWS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.997%;"></td>
    <td style="width:1.623%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.767000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.623%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.99%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Nine Months Ended September 30,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79807d8a-5180-4626-b94b-2a9894f7c294" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">28,571</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_504c31bf-3329-4af7-929b-86b9be7cced7" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,957</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08c223ab-6342-4a31-9390-54f421c99c1f" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,065</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0032066f-647d-4278-a6a5-0affeef91eb6" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,892</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of financing costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29965212-16b7-48c4-bcf6-00baedaee445" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">634</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1ac340d-c936-4a3b-8a8c-83589c246b4b" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">148</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14ecd888-e820-44a5-bb3d-947a8d8e89a2" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,651</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87dc58a7-973e-4a14-832c-7a5b5ad27eb3" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Decrease (increase) in the carrying amount of right-of-use assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5df1ab5-29d7-4e62-82ee-a240f688ef9b" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="tcrt:IncreaseDecreaseInRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,306</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1b6e810-0cba-4e77-ae43-c7e41b23d5cb" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="tcrt:IncreaseDecreaseInRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">529</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gain on lease modification</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a7f3925-6a1d-4a15-a52b-916274ff764e" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:GainLossOnTerminationOfLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3add78b6-08b7-4418-b650-d5815025adb4" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:GainLossOnTerminationOfLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Increase) decrease in:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Receivables</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_582f1e28-2291-42fb-aecb-e25731c5461a" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:IncreaseDecreaseInReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,800</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_deabc69b-f487-4db8-b568-907cc8aa5f9f" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:IncreaseDecreaseInReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,155</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c93901ab-4139-4841-bcbe-73d408e84b02" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">817</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba337cbb-79e7-403d-95ee-222ff31c2215" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,646</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4e6eecc-4b00-4325-b498-2a6f3bc21c96" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">131</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea0fed07-354d-4647-804a-67b0a20d5b43" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">508</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase (decrease) in:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdbc961b-716d-490d-8dd5-1f2238425e37" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">616</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0724f86a-c6df-4e99-b847-2ccbacc01714" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">503</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80e6e1bd-3bbb-4d18-af44-18b049dc473b" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,525</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a137e622-7d15-4753-a776-043f6414a70b" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,169</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d635498e-863e-40b5-ad60-0314bd42a24d" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="tcrt:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,371</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1aa0997-325e-4a51-8dc0-18118bec6b98" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="tcrt:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">604</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other non-current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08aae338-0461-44c8-8cbd-bb6c969a412d" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5053c281-0e8e-4827-8393-a01930cc2c69" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:40.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_884d9cc2-aaa6-4395-bdca-b0e88c6c1506" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">22,102</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ae5421d-141a-481c-8c9c-b8b0d50ab41a" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">46,342</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c34c10e-b6fd-476a-9863-bb30a5c94556" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95f00470-3cdd-4db0-8953-b1697c4fa289" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,964</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:40.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4706655-a6e5-4630-bf67-31725c8b1261" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb9b6dc9-8b5d-4961-8041-82de1296552f" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,964</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from long-term debt borrowing</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f66483e0-2539-4ad1-bd82-1b00625fa3a8" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6dfb381-6c9a-4974-89b3-e77b53966160" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c923977-d192-44ec-806f-6c80808ed4ce" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c94694c-44f6-4331-8c8c-ce5c04d79a03" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from the exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da35d6c7-5ae3-4368-a0d1-d5db9a08e4bf" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_335392df-075e-4d42-9531-90de09e323ba" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,037</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_adb1f63c-fb01-4c76-a98a-e9c6c38792cb" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_900ca4d7-4748-4221-bae6-96d3aec0291f" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repayment of long-term debt</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a86d5ecf-1acd-4111-8e88-a7c6bbf3a947" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,083</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d041207-3074-4f47-b977-96a5ade07e49" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in) financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b04c175-6159-4ca2-8d96-9d00e041460a" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,107</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79bb2c8a-c9a0-42d2-a5b7-299b2a524acb" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,962</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e148e53-acc2-46be-8cc0-8b9dc7bab5bb" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24,309</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66f45f94-fadc-491a-a153-4df9beef2980" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">23,344</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash, beginning of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_efca6a10-1720-473d-aae1-cf523f91a7e6" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,054</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1526e1d8-bb58-47b0-877b-3c1f8c624ff1" contextRef="C_afa5d5a2-bab5-4430-b57c-13817635e7f3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115,069</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash, end of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e01d6279-62a0-494a-8684-56e51c56eb4b" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,745</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5144cfc-b6e4-4b2f-b6f3-c4e6d52da3dc" contextRef="C_e81d9a09-eee0-481c-8976-f48c00938da7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">91,725</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplementary disclosure of cash flow information:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b99dffb6-1e3e-4a1f-8d9e-290a5ee84a76" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,603</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dca8541-b38b-489b-89ec-65953287f634" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">136</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts included in accrued expenses and accounts payable related to property and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75714469-62e0-41f2-9a07-d133a178cfb3" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f19eddfc-9ed1-404b-b063-b93a8e3fda6e" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="notes_">&#160;</p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_35241444-fb80-4e04-acc7-598acb04ca6d" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Organization</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc., which is referred to herein as &#x201c;Alaunos,&#x201d; or the &#x201c;Company,&#x201d; is a clinical-stage oncology-focused cell therapy company developing adoptive TCR-T cell therapies, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. On January 25, 2022, the Company changed its corporate name from ZIOPHARM Oncology, Inc. to Alaunos Therapeutics, Inc. The Company is leveraging its proprietary, non-viral </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">gene transfer platform and its cancer hotspot mutation TCR library to design and manufacture autologous cell therapies that target neoantigens arising from shared tumor-specific mutations in key oncogenic genes, including </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS, TP53 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s operations to date have consisted primarily of conducting research and development and raising capital to fund those efforts. In May 2021, the Company announced that it will be winding down its existing Controlled IL-12 clinical program. The Company continues to seek a partner for this program.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company follows the guidance of Accounting Standards Codification (&#34;ASC&#34;) Topic 205-40, Presentation of Financial Statements - Going Concern, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its financial statements are issued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has operated at a loss since its inception in 2003 and has no recurring revenue from operations.&#x202f;The Company anticipates that losses will continue for the foreseeable future. As of September 30, 2022, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43acf8f9-2b29-464a-95d5-a3d0922961c0" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x202f;million of cash and cash equivalents and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15468392-b587-4740-a174-386cb6b9b112" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of restricted cash related to the Company's debt agreement (see Note 4). The Company&#x2019;s accumulated deficit at September 30, 2022 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eebb403c-89ce-40e1-b75f-7860815e381e" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">871.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x202f;million.&#x202f;Given its current development plans and cash management efforts, the Company anticipates cash resources will be sufficient to fund operations into the second quarter of 2023.&#x202f;The Company&#x2019;s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in the Company&#x2019;s focus and direction of its research and development programs, competitive and technical advances, patent developments, regulatory changes or other developments. If adequate additional funds are not available when required, management may need to curtail its development efforts and planned operations to conserve cash.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the current cash forecast, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements, which raises substantial doubt as to the Company's ability to continue as a going concern. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of September 30, 2022, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e85d2dbb-f1ad-4ca7-81bb-e4eff183e555" contextRef="C_72bda269-9480-4b72-b4ce-a8fa1e5d2d6a" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">216,182,042</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock outstanding and an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6c6f7fa-8bc6-48ba-a8ef-d26387531833" contextRef="C_72bda269-9480-4b72-b4ce-a8fa1e5d2d6a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">33,545,557</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock reserved for issuance pursuant to outstanding stock options and warrants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f44fbbdf-5a95-4876-b1fe-d2b80857a358" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures required by generally accepted accounting principles in the United States, or GAAP, have been condensed or omitted pursuant to such rules and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is management&#x2019;s opinion that the accompanying unaudited interim financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair presentation of the financial position of the Company and its results of operations and cash flows for the periods presented. The unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2021, included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on March 30, 2022, or the Annual Report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results disclosed in the statements of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full fiscal year 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f7e8308f-effb-45bc-8499-5a1071e316c1" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(unaudited)</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">statements </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_11468af4-be45-4642-aa7e-3153df992d66" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="tcrt:FinancingArrangementsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financings</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Loan and Security Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2021, the Company entered into a Loan and Security Agreement (the &#34;Loan and Security Agreement&#34;) with Silicon Valley Bank and affiliates of Silicon Valley Bank (collectively, &#34;SVB&#34;).  The Loan and Security Agreement provided for an initial term loan of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28036758-d1bd-4ac9-9528-60ae45bc417f" contextRef="C_4466f87e-f227-46f8-9092-8a32178d41c0" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million funded at the closing (the &#34;Term A Tranche&#34;), with an additional tranche of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a4b0616-ec80-4c24-aac2-10bcd61a3784" contextRef="C_72dbe520-f3b4-4e1f-9462-73da4d9acb9e" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million available if certain funding and clinical milestones were met by August 31, 2022 (the &#34;Term B Tranche&#34;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective December 28, 2021, the Company, entered into a First Amendment (the &#x201c;Amendment&#x201d;) to the Loan and Security Agreement (as so amended, the &#34;Amended Loan and Security Agreement&#34;).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Amended Loan and Security Agreement extended the interest-only period through August 31, 2022. The Amended Milestones (as defined below) were not met by the Company on or prior to August 31, 2022, and therefore, the interest-only period was not extended beyond August 31, 2022. The Amendment also eliminated the Term B Tranche, which remained unfunded, leaving only the Term A Tranche (the &#34;SVB Facility&#34;). Under the Amended Loan and Security Agreement, the SVB Facility will mature on August 1, 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Please refer to Note 4 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for further discussion of the Loan and Security Agreement and the Amended Loan and Security Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2022 Equity Distribution Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 12, 2022, the Company entered into an Equity Distribution Agreement (the &#34;Equity Distribution Agreement&#34;) with Piper Sandler &amp; Co. (&#34;Piper Sandler&#34;), pursuant to which the Company can offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79face5d-dd15-4e61-8dc9-165f0c9ec7ac" contextRef="C_8d739f65-8890-4484-9fa8-db2c2788d308" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million through Piper Sandler as its sales agent in an &#34;at the market offering.&#34; Piper Sandler will receive a commission of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eea2f425-81cc-4190-83e1-6de0515f8218" contextRef="C_8d739f65-8890-4484-9fa8-db2c2788d308" name="tcrt:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the gross proceeds of any common stock sold under the Equity Distribution Agreement. During the three and nine months ended September 30, 2022, there have been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c2d7822-db45-4b1f-8531-2015f07dd976" contextRef="C_bcd49289-aef5-458e-9a35-82903fd7c003" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f6cfe0c9-63d7-4169-bb82-68d5efd0cdbd" contextRef="C_90eeab4e-d329-4773-9ae7-51f760c71986" name="tcrt:StockOfferedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> sales of the Company's common stock under the Equity Distribution Agreement.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c7f83ce8-6c2f-436e-8a80-e4da5cd51e0b" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Significant Accounting Policies</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s significant accounting policies were identified in the Company&#x2019;s Annual Report. There have been no material changes in those policies since the filing of its Annual Report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_46670282-984e-4637-bd32-c1dc6f8e98b9" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:DebtDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f382e4c9-0139-4f45-a4f6-31125a5f6fd0" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ScheduleOfDebtTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying values of the Company's debt obligation were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.682%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.092%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.998000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loan and Security Agreement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b844576-247a-4f7d-afde-3ed59082516f" contextRef="C_c5ce15ce-9e47-4fdd-9332-0e26a6a95756" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,461</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86c5b3e8-ac0a-4501-9d2d-f7e58e257d95" contextRef="C_56ad9b91-5908-46ac-b885-5f4b458e6dd0" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,209</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized discount on Loan and Security Agreement</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f5a1d2d-e6af-42b4-b791-96b02c105257" contextRef="C_c5ce15ce-9e47-4fdd-9332-0e26a6a95756" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">793</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_abd28360-240e-4ea2-99ac-cf2b98dbac94" contextRef="C_56ad9b91-5908-46ac-b885-5f4b458e6dd0" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,091</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aae27ef6-eaff-4760-811d-74a9774c1182" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,668</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8dc55dde-6945-4874-85a7-ad6b7e176fb2" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,118</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of September 30, 2022, the SVB Facility was fully drawn in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6682325a-e523-4dd5-b2d7-3aeb7bf04a20" contextRef="C_49c4b845-edf1-48ac-b363-86d2eb87b129" name="tcrt:FullyDrawnAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c814b7b9-424c-4398-9462-3c4cc8361d64" contextRef="C_399029cd-00f2-489c-89bd-afddf96d9013" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The SVB Facility bears interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25ac0de1-e0af-4243-98b3-8ad1a0e83317" contextRef="C_29c774b1-4d47-4209-8c47-fcd96e1f3895" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">7.75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and (b) the current published U.S. prime rate, plus a margin of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89198912-e623-4de2-81ab-91e26f57baa9" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of September 30, 2022, interest on the outstanding loans was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d654d37f-f106-44d1-b8f6-ffe31fce61c4" contextRef="C_29c774b1-4d47-4209-8c47-fcd96e1f3895" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">10.75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. The Amended Loan and Security Agreement provided for an interest-only period through August 31, 2022. On or prior to August 31, 2022, the Company had not (i) received at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb080228-d0f7-471a-a145-e0027adff5d4" contextRef="C_1d421d03-41e0-4a9e-bb6e-dcc0101f73f0" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net cash proceeds from the sale of the Company&#x2019;s equity securities after the date of the Amended Loan and Security Agreement, on terms acceptable to SVB, nor (ii) achieved positive data in the first cohort of the Library TCR-T Trial endorsed by an independent safety monitoring committee as a safe dose to proceed (together, the &#x201c;Amended Milestones&#x201d;), and, therefore, the interest-only period was not extended beyond August 31, 2022. Commencing on September 1, 2022, aggregate outstanding borrowings are payable in twelve consecutive, equal monthly installments of principal plus accrued interest.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All outstanding obligations under the Amended Loan and Security Agreement are due and payable on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9dd20f19-44ec-4d13-a455-6f41cc99b2db" contextRef="C_399029cd-00f2-489c-89bd-afddf96d9013" name="us-gaap:DebtInstrumentMaturityDateRangeStart1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 1, 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c658d6d2-d550-448e-91ce-3d7dbb22f4f8" contextRef="C_464be36f-cadb-4d42-b6ec-60d3e858ae0d" name="us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" continuedAt="F_c658d6d2-d550-448e-91ce-3d7dbb22f4f8_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will also owe SVB </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e384f61-0a50-4031-94a6-26baa238d531" contextRef="C_1d421d03-41e0-4a9e-bb6e-dcc0101f73f0" name="tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the original principal amounts borrowed as a final payment (the &#34;Final Payment&#34;). The Company is </span></ix:nonNumeric></span><span style=""></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(unaudited)</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_c658d6d2-d550-448e-91ce-3d7dbb22f4f8_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">permitted </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to make up to two prepayments, subject to a prepayment premium of the amount being prepaid, ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c85d903c-db2e-44ff-8ca3-4f8f3c286817" contextRef="C_35c36f71-52c6-4199-9a71-a3ae673b76aa" name="tcrt:PercentageOfPrepaymentsPremium" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab00b8cf-4a12-456f-8252-0fa6db007d31" contextRef="C_a1c325e4-fe22-4b5f-8e61-12cd0023447b" name="tcrt:PercentageOfPrepaymentsPremium" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, of the SVB Facility, each such prepayment to be at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9800f153-8bae-4276-853f-9e027644af27" contextRef="C_464be36f-cadb-4d42-b6ec-60d3e858ae0d" name="tcrt:DebtInstrumentPrepaymentPremium" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million plus all accrued and unpaid interest on the portion being prepaid.</span></p></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of not achieving the Amended Milestones on or prior to August 31, 2022, the Amended Loan and Security Agreement required the Company to cash collateralize half of the sum of the then-outstanding principal amount of the SVB Facility, plus an amount equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6beac48-fa88-4b2d-8ba9-f0fad9e5869a" contextRef="C_1d421d03-41e0-4a9e-bb6e-dcc0101f73f0" name="tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the original principal amount of the SVB Facility. As of September 30, 2022, the Company has collateralized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e55386df-d65c-4bc2-bced-2c86d71e5c74" contextRef="C_e0eb70e2-a850-4290-9f2b-2c099994757c" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is classified as restricted cash on the balance sheet. So long as no event of default has occurred and subject to certain other terms related to the remaining outstanding balance under the SVB Facility being satisfied, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_846b84ed-9506-4760-a31e-2bc553e42618" contextRef="C_9b2f5a35-750a-426b-8208-95bde28e9376" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million will be released from the collateral account following the eighth scheduled payment of principal and interest, and a further $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_367e9cb4-eeb6-4532-a235-68015917d0d0" contextRef="C_9c77e152-785d-4e6f-99b7-b0d56fb1dc63" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million will be released following the tenth scheduled payment of principal and interest. The SVB Facility and related obligations under the Amended Loan and Security Agreement are secured by substantially all of the Company&#x2019;s properties, rights and assets, except for its intellectual property (which is subject to a negative pledge under the Amended Loan and Security Agreement). In addition, the Amended Loan and Security Agreement contains customary representations, warranties, events of default and covenants.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with its entry into the Loan and Security Agreement, the Company issued to SVB warrants to purchase (i) up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d6d62e0-7abc-4b5a-b316-a1ba4e3b76ff" contextRef="C_0ecd0af9-f624-419c-bc04-78328b1a47e8" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">432,844</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock, in the aggregate, and (ii) up to an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_665a5171-2d70-4b87-b06a-58477ee1bf97" contextRef="C_0ecd0af9-f624-419c-bc04-78328b1a47e8" name="tcrt:AdditionalNumberOfWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">432,842</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, in the aggregate, in the event the Company achieved certain clinical milestones, in each case at an exercise price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea2f1ba3-3c06-4fec-b16f-f55d97fa3121" contextRef="C_0ecd0af9-f624-419c-bc04-78328b1a47e8" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.22</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with its entry into the Amendment, the Company amended and restated the warrants issued to SVB. As amended and restated, the warrants are for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ee10e58-3f86-41e5-899f-5cae6f9c6f7f" contextRef="C_eddf6b5e-242d-4045-be96-1b91012cb2f2" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">649,615</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock, in the aggregate, at an exercise price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52edac97-80ef-4313-a7a1-988ace427f59" contextRef="C_c3dfd279-a1be-4e60-9b23-62f589a95c69" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" decimals="INF" format="ixt:numdotdecimal">1.16</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or the SVB Warrants. The SVB Warrants expire on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_771aaf27-e16a-4c72-bdac-38f7975fe4a5" contextRef="C_eddf6b5e-242d-4045-be96-1b91012cb2f2" name="tcrt:WarrantsExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 6, 2031</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance costs for the Loan and Security Agreement, including the Amended Loan and Security Agreement, were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ff0655d-a618-4ded-b67a-5219c3e2a404" contextRef="C_ba7ea719-3efa-42ac-a0b2-dbaed33d86b1" name="us-gaap:DeferredFinanceCostsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and primarily related to the SVB Warrants, which will be amortized into interest expense over the period to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_17bd9ba1-ab6d-4b68-bc4b-57ef610e07a7" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="tcrt:InterestExpenseAmortizedDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 1, 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Interest expense was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d29451f-792b-4291-a42b-15b9ee4df3ea" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the three months ended September 30, 2022 and was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8bef313-ec41-4a00-8e47-975a4f86e6eb" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the nine months ended September 30, 2022, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c4b0896-a88a-40ce-b8a7-81d45d0ab582" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_1313daf2-866f-4edb-95b2-b13844437498" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the three and nine months ended September 30, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of the Amended Loan and Security Agreement as of September 30, 2022 approximates its face value.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_644b72b2-b150-4f2d-adaa-e4399b7b859a" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></p><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2&#x2014;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7f3ca421-5c4b-44b8-a9a0-807fab42d953" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of September 30, 2022 and December 31, 2021 are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.66%;"></td>
        <td style="width:0.992%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.277000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.992%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.288%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.113%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.058%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.113%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.504999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of<br />September 30,<br />2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br />Active Markets<br />for Identical<br />Assets/Liabilities<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Unobservable<br />Inputs<br />(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_551a17d7-4588-493c-9359-3cd2b390e35a" contextRef="C_e3064554-7470-4ef4-931d-019f0af3c58c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,807</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e15ddf23-0688-4adf-8fc2-fb1dcfaa7e0c" contextRef="C_2a8ceb76-7648-4132-8aa2-02c65b7eb518" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,807</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.388%;"></td>
        <td style="width:0.965%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.998%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.965%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.274%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.076%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.905%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.076%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.353%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of<br />December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br />Active Markets<br />for Identical<br />Assets/Liabilities<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Unobservable<br />Inputs<br />(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e301820b-59a1-4925-8a09-b39cb68ee077" contextRef="C_e0570a01-faa7-4744-91fc-66333e256702" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75,222</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_392119fa-3bf8-496b-bcf6-578e0c38859e" contextRef="C_ba706fc5-e9e4-4f6d-9180-2a783ebf0530" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75,222</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(unaudited)</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been no changes to the valuation methods during the nine months ended September 30, 2022. We had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb3d9694-43e1-46c0-8743-5c16c60f5303" contextRef="C_00a63ae4-63b6-4ac6-941f-4be4fd9e3e98" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> financial assets or liabilities that were classified as Level 2 or Level 3 during the nine months ended September 30, 2022.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_04dad3dd-6544-4265-a027-765e7788ebae" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:EarningsPerShareTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">6.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, inducement stock options, unvested restricted stock and warrants, have not been included in the computation of diluted net loss per share for any of the periods presented as the result would be anti-dilutive. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5c61c2ae-c1af-440b-bba1-a8c7d834ed99" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_5c61c2ae-c1af-440b-bba1-a8c7d834ed99_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such potentially dilutive shares of common stock consisted of the following as of September 30, 2022 and 2021, respectively:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_5c61c2ae-c1af-440b-bba1-a8c7d834ed99_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.904%;"></td>
        <td style="width:1.642%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.202%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.642%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.61%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed91dd71-07ed-43a4-a6ff-64b163e02aa1" contextRef="C_5c32ad95-bd53-4f35-853e-22b717e70798" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">10,623,215</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_851c7875-3601-4194-b468-bc408d9ad70a" contextRef="C_82a2d9da-2739-4328-a38b-dd5018876817" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">11,072,894</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inducement stock options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25723390-feee-44e8-8de0-79e8919b9560" contextRef="C_95ff3701-048e-464c-829f-6c697a0744f3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9b63b25-7293-460e-b9d3-0144ba2ef3ae" contextRef="C_9dc3ba53-2c20-4736-8bee-cb0366b44f23" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">97,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1b4cd68-0a43-4fab-bffb-af361040ee39" contextRef="C_cf9a58e2-50b7-4e9f-b6e9-8386b05eaea6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">940,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_771c1fbe-a3ca-4f20-91a6-863f59c32779" contextRef="C_d5737b6f-9713-4bf0-9447-bffb6837ae58" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,510,655</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d387ed0-cd07-431a-807f-10e500e910f4" contextRef="C_b6a2cd0a-f5d0-4a9f-af29-87bb8204f6f6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">22,922,342</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a42d2109-2765-485a-9ce3-e643465231f4" contextRef="C_f3be7956-1a1a-486d-a035-b032462f33aa" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">22,705,571</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a81240f8-a984-43c8-9f1b-ef2f2efe8c0f" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">34,485,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce3fddaa-f3cd-40cf-8120-e1f97dc4dea5" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">35,386,620</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c47e7dfd-fc8a-4a89-876b-70fb20361d09" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">7.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related Party Transactions</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration with Vineti Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 9, 2020, the Company entered into a master service agreement and statement of work with Vineti, Inc. (&#34;Vineti&#34;). Pursuant to the agreement, Vineti has been developing a software platform to coordinate and orchestrate the order, cell collection and manufacturing process for the Company&#x2019;s T-cell therapy, or TCR-T, clinical programs. Heidi Hagen, who became a director of the Company in June 2019 and resigned November 2, 2021 and the Company's Interim Chief Executive Officer on February 25, 2021 and resigned on August 30, 2021, is a co-founder and former officer of Vineti. During the three and nine months ended September 30, 2022, the Company recorded </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97977de9-be28-4ddb-b330-7697d17a7440" contextRef="C_23eae7ee-dd71-428c-93da-1b90bf020452" name="tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_02148956-a162-4b15-a733-652e404f7a01" contextRef="C_89339f1e-48c2-46f1-afa9-1bd72a4dccef" name="tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expenses for Vineti, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_866b4e7f-20d9-4bd1-9769-ae4db91c528c" contextRef="C_5287bb43-2308-4e1c-a17a-766d2905368b" name="tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of expenses for the three months ended September 30, 2021 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45edc4e8-26d7-45de-a904-bfdd3fd8dfa4" contextRef="C_c373b210-56f0-4a58-9d24-8f12d518d218" name="tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the nine months ended September 30, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">WaterMill Settlement Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 4, 2021, the Company entered into an agreement, or the Settlement Agreement, with WaterMill Asset Management Corp. and Robert W. Postma (collectively, the &#34;WaterMill Parties&#34;). Pursuant to the Settlement Agreement, the Company increased the size of its board of directors from eight to nine directors and appointed Mr. Postma to fill the newly created directorship.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with the Settlement Agreement, the Company agreed to reimburse the WaterMill Parties for up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5c23bc4-5680-4af4-8e53-e75da5c3b54a" contextRef="C_1e52479f-7e44-4216-b266-a0446569c844" name="tcrt:PocketExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of their reasonable out-of-pocket expenses out of a total of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f620b3d0-031f-486d-9a7d-e097047b64a7" contextRef="C_1e52479f-7e44-4216-b266-a0446569c844" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in fees and expenses actually incurred by the WaterMill Parties in connection with (i) the WaterMill Parties' solicitation of written consents from the Company's stockholders to vote in favor of certain proposals, as set forth in the definitive consent statement filed by the WaterMill Parties on October 30, 2020, and (ii) the negotiation, execution, and effectuation of the Settlement Agreement. As of February 19, 2021, the Company has fully reimbursed the WaterMill Parties an aggregate amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10a9649a-fc6b-4e96-8d45-1e33a8759c5f" contextRef="C_e4a8cbd7-35ae-461e-b1af-edf4446dbfd9" name="tcrt:RelatedPartyTransactionReimbursedAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Joint Venture with TriArm Therapeutics/Eden BioCell</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 18, 2018, the Company and TriArm Therapeutics, Ltd. (&#x201c;TriArm&#x201d;) launched Eden BioCell, Ltd. (&#x201c;Eden BioCell&#x201d;) as a joint venture to lead commercialization of the Company&#x2019;s </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-generated CAR-T therapies in the People&#x2019;s Republic of China (including Macau and Hong Kong), Taiwan and Korea. The Company licensed to Eden BioCell the rights in Greater China for its third-generation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-generated CAR-T therapies targeting the CD19 antigen. Eden BioCell is owned equally by the Company and TriArm and the parties share decision-making authority. TriArm has contributed $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22c6c99d-0cb2-4a28-8439-542c878e4c16" contextRef="C_eab945c1-a1b6-41ab-91d4-85e2fc2020c5" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to Eden BioCell and has committed up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e008a291-4658-4661-b3dd-7ceba339b7cc" contextRef="C_168c2abe-f9d8-4189-b7ee-13828dea54d1" name="tcrt:AdditionalLoansCommitted" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to this joint venture. TriArm also manages all clinical development in the territory pursuant to a master services agreement between TriArm and Eden BioCell. James Huang was the founder and serves as managing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(unaudited)</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">partner </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of Panacea Venture, which is an investor in TriArm. Mr. Huang is the Chair of the Company's board of directors and has been a director since July 2020. He also serves as a member of Eden BioCell&#x2019;s board of directors.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three and nine months ended September 30, 2022, Eden BioCell incurred a net loss and the Company continues to have no commitment to fund its operations. In September 2021, TriArm and Alaunos mutually agreed to dissolve the Eden BioCell joint venture. Refer to Note 12 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Joint Venture</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for further details.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d218845c-6d2f-4db2-aebf-e59ffc865dcd" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">8.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, the Company modified its real estate lease agreement executed on December 15, 2020 with MD Anderson for office space in Houston, which reduced the Company's leased space from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f552206d-aab1-4765-95c2-ec21c0083758" contextRef="C_5478d947-5881-4b9c-a88f-5e7d9771c267" name="tcrt:OperatingLeaseArea" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">18,111</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd8ca9ee-7316-456e-b733-14ed95071300" contextRef="C_1d8421da-db98-4345-93d7-f06de09f53d0" name="tcrt:OperatingLeaseArea" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">3,228</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet. As a result, the associated lease liability and right-of-use asset were remeasured to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_740c9266-cd4c-465d-bed3-3df3426b9027" contextRef="C_1d8421da-db98-4345-93d7-f06de09f53d0" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million based on revised lease payments. A gain of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6660854-d450-4844-8f66-533b3e9ceb12" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="tcrt:GainLossOnModificationOfLease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded on the lease modification during the nine months ended September 30, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, the Company executed an agreement to sub-sublease </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed8cab77-346e-4f0e-87cd-f03b68e6e9f1" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="tcrt:SubleaseArea" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">4,772</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of subleased office space in Boston. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a1c3a241-5a9e-4936-97e1-3f90ac04a33d" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the sub-sublease is from July 1, 2022 to June 30, 2025 and provides the sub-subtenant with an option to extend through to July 31, 2026</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. For the three and nine months ended September 30, 2022, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_408a27ab-2b23-4d68-a504-5dfb646a0aea" contextRef="C_b761c5a5-7e64-42b4-b347-bff79c80c526" name="us-gaap:LeaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_5d9d61c4-63f7-4428-b69f-04972473203e" contextRef="C_808c9e76-ba2c-4353-bc47-63c7e812ba3d" name="us-gaap:LeaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand in lease income, which is classified within other income (expense), net in the statement of operations.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7d4809ad-f7b1-4fd5-abb2-72dc00f760a7" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">9.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive License Agreement with PGEN Therapeutics</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 5, 2018, the Company entered into an exclusive license agreement, or License Agreement, with PGEN Therapeutics, or PGEN, a wholly owned subsidiary of Precigen Inc., or Precigen, which was formerly known as Intrexon Corporation. Pursuant to the terms of the License Agreement, the Company has exclusive, worldwide rights to research, develop and commercialize (i) TCR products designed for neoantigens for the treatment of cancer, (ii) products utilizing Precigen&#x2019;s RheoSwitch&#174; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (iii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the Ares Trading Agreement. Under the License Agreement, the Company also has exclusive, worldwide rights for certain patents relating to the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The Company is required to use commercially reasonable efforts, as defined in the License Agreement, to develop and commercialize IL-12 products, CD19 products, BCMA products and TCR Products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In consideration of the licenses and other rights granted by PGEN, the Company will pay PGEN an annual license fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db8e3685-57dc-4eb1-93a4-b3b6b0d7260a" contextRef="C_2bca986a-5228-45f5-a440-a7d273a6f156" name="tcrt:AnnualLicenseFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the Company has agreed to reimburse PGEN for certain historical costs of the licensed programs up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb4dfb10-bca1-4163-bad4-1c1edf205d2e" contextRef="C_30990001-d5dc-4069-a5b6-498c28245fdb" name="tcrt:PaymentForHistoricalCostsOfTheLicensedPrograms" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which was fully paid during the year ended December 31, 2019.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will make milestone payments totaling up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ecd849b-bd6c-451a-b218-8efc70ea989e" contextRef="C_2bca986a-5228-45f5-a440-a7d273a6f156" name="tcrt:MaximumAmountOfAdditionalMilestonesPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">52.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for each exclusively licensed program upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions. In addition, the Company will pay PGEN tiered royalties ranging from low-single digits to high-single digits on the net sales derived from the sale of any approved IL-12 products and CAR products. The Company will also pay PGEN royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of any approved TCR products, up to a maximum royalty amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88ff903a-f585-470f-bfa8-907925676e05" contextRef="C_1a1e5081-81c7-406f-aac2-68d4a56e7396" name="tcrt:MaximumAmountOfRoyaltyPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate. The Company will also pay PGEN </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9362cea4-258e-4b3a-8c60-79f4b9f93b40" contextRef="C_1a1e5081-81c7-406f-aac2-68d4a56e7396" name="tcrt:PercentageOfSubLicensingIncomePayableToRelatedParty" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">twenty</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> percent of any sublicensing income received by us relating to the licensed products. The Company is responsible for all development costs associated with each of the licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PGEN will pay the Company royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of PGEN&#x2019;s CAR products, up to a maximum royalty amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6562155d-537a-4b10-8752-c10922ddf755" contextRef="C_fee32fa6-5000-4631-b097-9b1fea30a290" name="tcrt:MaximumRoyaltyAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the Company entered into an amendment to the License Agreement relating to the transfer of certain materials and PGEN&#x2019;s obligations to provide transition assistance relating to the IL-12 products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(unaudited)</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement and 2015 Research and Development Agreement &#x2014;The University of Texas MD Anderson Cancer Center</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bc60de9a-4587-4872-9891-fd2e53c7e61a" contextRef="C_d56c397d-06d5-47bb-8033-e0542dd94f41" name="tcrt:LicenseAgreementCommencingDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 13, 2015</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company, together with Precigen, entered into the MD Anderson License with MD Anderson (which Precigen subsequently assigned to PGEN). Pursuant to the MD Anderson License, the Company, together with PGEN, holds an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs, arising from the laboratory of Laurence Cooper, M.D., Ph.D., who served as the Company&#x2019;s Chief Executive Officer from May 2015 until February 2021 and was formerly a tenured professor of pediatrics at MD Anderson.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 17, 2015, the Company, Precigen and MD Anderson entered into the 2015 R&amp;D Agreement to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. The rights and obligations of Precigen under the 2015 R&amp;D Agreement were assigned to the Company pursuant to the Fourth Amendment to 2015 R&amp;D Agreement which was entered into on September 19, 2019 (the &#x201c;Fourth Amendment&#x201d;) with an effective date of October 5, 2018. The activities under the 2015 R&amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the 2015 R&amp;D Agreement for a period of three years and in an amount of no less than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c4a9389-7811-42ef-8811-a4c5be10ae2c" contextRef="C_d7baac48-135d-4e1f-805c-4570972d3951" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and no greater than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc742c35-5a77-4ee9-9d59-844fb369e106" contextRef="C_36e64732-f6d5-4615-89f1-3872af4ff2ea" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per year. On November 14, 2017, the Company entered into an amendment to the 2015 R&amp;D Agreement, extending its term until April 15, 2021. In connection with the execution of the 2019 R&amp;D Agreement described below, on October 22, 2019, the Company amended the 2015 R&amp;D Agreement to extend the term of the 2015 R&amp;D Agreement until December 31, 2026 and to allow cash resources on hand at MD Anderson under the 2015 R&amp;D Agreement to be used for development costs under the 2019 R&amp;D Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson License, the Company, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if the Company and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if the Company and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by the Company and Precigen, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both the Company and Precigen and may be terminated by the mutual written agreement of the Company, PGEN, and MD Anderson.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2019 Research and Development Agreement&#x2014;The University of Texas MD Anderson Cancer Center</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 22, 2019, the Company entered into the 2019 Research and Development Agreement, or the 2019 R&amp;D Agreement, with MD Anderson, pursuant to which the parties agreed to collaborate with respect to the TCR program. Under the 2019 R&amp;D Agreement, the parties will, among other things, collaborate on programs to expand the Company's TCR library and conduct clinical trials. The activities under the 2019 R&amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will own all inventions and intellectual property developed under the 2019 R&amp;D Agreement and the Company will retain all rights to intellectual property for oncology products manufactured using non-viral gene transfer technologies under the 2019 R&amp;D Agreement, including the Company's</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology. The Company has granted MD Anderson an exclusive license for such intellectual property outside the field of oncology and to develop and commercialize TCR products manufactured using viral gene transfer technologies limited to autologous products if used for cancer treatment or prevention, and a non-exclusive license for allogenic anti-tumor TCR products manufactured using viral-based technologies.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2019 R&amp;D Agreement, the Company agreed, beginning on January 1, 2021, to reimburse MD Anderson up to a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69ef0c35-0827-408e-89cc-7a17a28dd2e4" contextRef="C_2cec0f62-e0a7-444b-9c62-04422644e817" name="tcrt:AggregateAmountPotentiallyReimburseableAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for development costs under the 2019 R&amp;D Agreement, after the funds from the 2015 R&amp;D Agreement are exhausted. In addition, the Company will pay MD Anderson royalties on net sales of its TCR products. The Company is required to make performance-based payments upon the successful completion of clinical and regulatory benchmarks relating to its TCR products. The aggregate potential benchmark payments are $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f200c14-7dde-45d3-b2d8-99647ee6e984" contextRef="C_2cec0f62-e0a7-444b-9c62-04422644e817" name="tcrt:AggregatePotentialBenchmarkPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">36.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, of which only $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9da9e07e-ad09-43d0-979c-98b49bf4ac6e" contextRef="C_2cec0f62-e0a7-444b-9c62-04422644e817" name="tcrt:AccrualsPriorToFirstMarketingApproval" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">will be due prior to the first marketing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(unaudited)</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the Company's TCR products. The royalty rates and benchmark payments owed to MD Anderson may be reduced upon the occurrence of certain events. The Company also agreed to sell its TCR products to MD Anderson at preferential prices and will sell the Company's TCR products in Texas exclusively to MD Anderson for a limited period of time following the first commercial sale of the Company's TCR products. For the three months ended September 30, 2022, the Company incurred clinical expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a16b89bd-8f3f-4155-b385-0cf440bf57e3" contextRef="C_66586099-2ff8-40bd-a3af-a61d770bbd1b" name="tcrt:QuarterlyExpenseIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from MD Anderson related to this agreement compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f12bd33e-0e34-429c-ac7c-ab5d3670ee6d" contextRef="C_9975e9e7-b6d2-44f8-8f9b-4428ca4a25ee" name="tcrt:QuarterlyExpenseIncurred" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the three months ended September 30, 2021. For the nine months ended September 30, 2022, the Company incurred clinical expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80927a17-415a-46b1-9571-0b00472f3d22" contextRef="C_3da54949-f086-4986-984c-e1d5c3f603ff" name="tcrt:QuarterlyExpenseIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from MD Anderson related to this agreement compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fba0c194-ad56-4a84-a629-03620f4da7dd" contextRef="C_2fba5838-cd3f-40d2-8f7f-5f1b833834f5" name="tcrt:QuarterlyExpenseIncurred" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the nine months ended September 30, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2019 R&amp;D Agreement will terminate on December 31, 2026 and either party may terminate the 2019 R&amp;D Agreement following written notice of a material breach. The 2019 R&amp;D Agreement also contains customary provisions related to indemnification obligations, confidentiality and other matters.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the execution of the 2019 R&amp;D Agreement, on October 22, 2019, the Company issued MD Anderson a warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76121070-0385-488f-9f4e-3bbaf07ab676" contextRef="C_7c362f59-d6f4-4a7a-a1c8-b74ebbed16b4" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,333,333</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock, which is referred to as the MD Anderson Warrant. Please refer to Note 11 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrants</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for further discussion of the MD Anderson Warrant. The MD Anderson Warrant has an initial exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14a18581-ec65-4c6c-9069-816da1137f9f" contextRef="C_7c362f59-d6f4-4a7a-a1c8-b74ebbed16b4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" decimals="INF" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3eac6cd2-b125-435e-b937-77c93b1e0448" contextRef="C_7c362f59-d6f4-4a7a-a1c8-b74ebbed16b4" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2026</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and vests upon the occurrence of certain clinical milestones. As of September 30, 2022, the milestones have not been met.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with the NCI</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 28, 2019, the Company entered into a patent license agreement, or the Patent License, with the National Cancer Institute, or the NCI. Pursuant to the Patent License, the Company holds an exclusive, worldwide license to certain intellectual property to develop and commercialize patient-derived (autologous), peripheral blood T-cell therapy products engineered by transposon-mediated gene transfer to express TCRs reactive to mutated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neoantigens. In addition, pursuant to the Patent License, the Company holds an exclusive, worldwide license to certain intellectual property for manufacturing technologies to develop and commercialize autologous, peripheral blood T-cell therapy products engineered by non-viral gene transfer to express TCRs, as well as a non-exclusive, worldwide license to certain additional manufacturing technologies. On May 29, 2019, January 8, 2020, September 28, 2020, April 16, 2021, May 4, 2021, and August 13, 2021 the Company amended the Patent License to expand its TCR library to include additional TCRs reactive to mutated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TP53 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neoantigens licensed from the NCI.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms of the Patent License require the Company to pay the NCI minimum annual royalties in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77098cef-e0d6-43b7-b207-d47d54856ae0" contextRef="C_2619a848-009e-46c2-a1f5-04328671628d" name="tcrt:MinimumRoyaltiesAmountPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which amount will be reduced to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c57210e-9304-4b09-a83a-3bfb09c66885" contextRef="C_2619a848-009e-46c2-a1f5-04328671628d" name="tcrt:RoyaltiesAmountPayableThereafter" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million once the aggregate minimum annual royalties paid by the Company equals $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ca84d7f-12f3-4073-841a-f0354033c81d" contextRef="C_2619a848-009e-46c2-a1f5-04328671628d" name="tcrt:AggregateMinimumAnnualRoyaltiesPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is also required to make performance-based payments upon successful completion of clinical and regulatory benchmarks relating to the licensed products. Of such payments, the aggregate potential benchmark payments are $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86434bb6-a7c6-4b13-94b5-479c1d38124e" contextRef="C_c4985865-020d-4fdb-bec6-b066804fcca8" name="tcrt:AggregateBenchmarkPaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, of which aggregate payments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6a8dfd4-bf56-47ba-b15f-9e0eec5e803a" contextRef="C_c14220fc-6b7b-43f8-af8e-400952313273" name="tcrt:AggregateBenchmarkPaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million are due only after marketing approval in the United States or in Europe, Japan, Australia, China or India. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_513e25a6-7938-4780-875d-9a13116aa4de" contextRef="C_243ddad6-e77f-4cec-bf28-7f9b590baafd" name="tcrt:DescriptionOfFirstBenchmarkPayable"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The first benchmark payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40dc79f8-9fd1-4ff8-9441-fb89e53d904e" contextRef="C_c4d2468d-d204-46a0-a52f-8c6f952adf7a" name="tcrt:InitialBenchmarkPaymentDue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was due upon the initiation of the Company's first sponsored Phase 1 clinical trial of a licensed product or licensed process in the field of use licensed under the Patent License. The Company paid the first benchmark payment during the nine months ended September 30, 2022.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the Company is required to pay the NCI one-time benchmark payments following aggregate net sales of licensed products at certain aggregate net sales ranging from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff7d0003-0dfc-46d8-b5c5-202158d79e8c" contextRef="C_43bf232f-663e-498c-8a53-386a3a861e53" name="tcrt:MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">250.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c5897fc-996a-4c1a-8061-c8441cde1655" contextRef="C_43bf232f-663e-498c-8a53-386a3a861e53" name="tcrt:MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion. The aggregate potential amount of these benchmark payments is $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6553bcd0-b78d-4cea-8903-ad75037ea723" contextRef="C_db352027-c319-4fed-873e-eafcb7007f91" name="tcrt:PotentialBenchmarkPaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company must also pay the NCI royalties on net sales of products covered by the Patent License at rates in the low to mid-single digits depending upon the technology included in a licensed product. To the extent the Company enters into a sublicensing agreement relating to a licensed product, the Company is required to pay the NCI a percentage of all consideration received from a sublicensee, which percentage will decrease based on the stage of development of the licensed product at the time of the sublicense.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Patent License will expire upon expiration of the last patent contained in the licensed patent rights, unless terminated earlier. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_87c515fd-7c41-4832-a9ea-fa5703ce02bf" contextRef="C_243ddad6-e77f-4cec-bf28-7f9b590baafd" name="tcrt:DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The NCI may terminate or modify the Patent License in the event of a material breach, including if the Company does not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company may terminate the Patent License, or any portion thereof, in the Company's sole discretion at any time upon </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f2c69e5d-75f8-4f94-a01c-a8f6dc7d1ccf" contextRef="C_243ddad6-e77f-4cec-bf28-7f9b590baafd" name="tcrt:AgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#x2019; written notice to the NCI. In addition, the NCI has the right to: (i) require the Company to sublicense the rights to the product candidates covered by the Patent License upon certain conditions, including if the Company is not reasonably satisfying required health and safety needs and (ii) terminate or modify the Patent License, including if the Company is not satisfying requirements for public use as specified by federal regulations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three months ended September 30, 2022, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79f36641-5fb6-48fa-b537-dcc8a3695476" contextRef="C_f90f3da9-4b30-43f4-8f71-7dedd967f4ce" name="tcrt:LicenseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in license payments to the NCI under this agreement, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f75f11df-138e-49ec-9f04-7978cc401260" contextRef="C_c3c976de-0ee5-455d-bee2-a9edd8244900" name="tcrt:LicenseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the three months ended September 30, 2021.  For the nine months ended September 30, 2022,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(unaudited)</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_365e0291-a6c4-42c0-97b2-d817b6fc9a73" contextRef="C_0ed707b3-bea7-4926-b6bd-f4064815e868" name="tcrt:LicenseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in license payments to the NCI under this agreement, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f60fe3c-8123-4185-8452-810716e07a86" contextRef="C_a553ea37-cf6b-45d6-ab63-a4294c165977" name="tcrt:LicenseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the nine months ended September 30, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cooperative Research and Development Agreement (CRADA) with the NCI</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 9, 2017, the Company entered into a Cooperative Research and Development Agreement (the &#x201c;CRADA&#x201d;) with the NCI. The purpose of this collaboration was to advance a personalized TCR-T approach for the treatment of solid tumors. Using the Company's </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology, the NCI would analyze a patient&#x2019;s own cancer cells, identify their unique neoantigens and TCRs reactive against those neoantigens and then use the Company's </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology to transpose one or more TCRs into T cells for re-infusion. Research conducted under the CRADA will be at the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI, in collaboration with the Company's researchers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is responsible for providing the NCI with the test materials necessary for them to conduct their studies, and eventually, clinical trials pursuant to the CRADA. Inventions, data and materials discovered or produced in connection with performance of the research plan under the CRADA will remain the sole property of the party who produced the discovery. The parties will jointly own all inventions jointly discovered under the research plan. The owner of any invention under the CRADA will make the decision to file a patent covering the invention, or in the case of a jointly owned invention, the Company will have the first opportunity to file a patent covering the invention. If the Company fails to provide timely notice of its decision to the NCI or decide not to file a patent covering the joint invention, the NCI has the right to make the filing. For any invention solely owned by the NCI or jointly made by the NCI and the Company for which a patent application was filed, the U.S. Public Health service grants the Company an exclusive option to elect an exclusive or non-exclusive commercialization license. For inventions owned solely by the NCI or jointly owned by the NCI and the Company, which are licensed according to the terms described above, the Company agreed to grant to the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world. The Company is also required to grant the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world for any of the Company's solely owned inventions. The agreement may be terminated by any of the parties upon 60 days prior written consent.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The NCI has a cleared Investigational New Drug Application, or IND, that would permit them to begin this trial. To the Company's knowledge, the trial has not yet enrolled due to matters internal to the NCI and unrelated to the Company's technology. The progress and timeline for this trial, including the timeline for dosing patients, are under control of the NCI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2019, the Company extended the CRADA with the NCI until January 9, 2022, committing an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee83fe60-202f-408e-8b25-fc186612a731" contextRef="C_dfc4b9a9-6363-4eb4-84cc-324cdd9e5c5a" name="tcrt:ObligationsDueUnderContract" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to this program. In March 2022, the Company entered into an amendment to the CRADA that is retroactive, effective January 9, 2022 to extend the term of the CRADA until January 9, 2023. In June 2022, the Company entered into the Fourth Amendment to the CRADA (the &#34;CRADA Fourth Amendment&#34;) which, among other things, extended the term of the CRADA until January 9, 2025. In connection with the CRADA Fourth Amendment, the Company agreed to contribute $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37e50be6-8062-4a74-b157-489407a73aed" contextRef="C_e5a16ee8-f8ba-419a-ad14-c822ec3582a9" name="tcrt:ContributionPayableOnPerAnnumBasis" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per year, payable on a quarterly basis, beginning in the first quarter of 2023. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4d02c65-ac0c-4b9c-898c-3b821c123d28" contextRef="C_efc00410-6d5c-495a-a72b-6d6351214b08" name="tcrt:QuarterlyExpenseIncurred" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_15edb454-1965-4d50-96ca-ddb7e404bd16" contextRef="C_11eda09f-c5af-4a19-be29-445f8325d410" name="tcrt:QuarterlyExpenseIncurred" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t record expenses under the CRADA for the three and nine months ended September 30, 2022, as compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17543f92-4df0-4958-9ba2-b2d8fb6291a8" contextRef="C_db440a89-812a-473c-bea3-ef4ccf784d27" name="tcrt:QuarterlyExpenseIncurred" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the three months ended September 30, 2021 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_491de165-9081-413c-930c-01cf7a3c1b42" contextRef="C_2daa022b-a09a-4371-9536-aff338b7b832" name="tcrt:QuarterlyExpenseIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the nine months ended September 30, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent and Technology License Agreement&#x2014;The University of Texas MD Anderson Cancer Center and the Texas A&amp;M University System</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&amp;M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the agreement, the Company may be required to make additional payments to the Licensors upon achievement of certain milestones in varying amounts which, on a cumulative basis could total up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13de0d8c-b20a-4f88-af08-e6ae512c2a5a" contextRef="C_e6c3e2ec-e88b-4a8e-a9a1-8a82c2d398ef" name="tcrt:MilestonePaymentsMaximumAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. In addition, the Licensors are entitled to receive royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. During the three and nine months ended September 30, 2022, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18de2c69-ef24-4128-9db5-0c0ff4089297" contextRef="C_8d40e9e7-c9cf-4667-ba64-23d8853c4fdb" name="tcrt:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_dee5f538-9927-48f6-825d-68d03c2e4a39" contextRef="C_0a8415e0-ec1d-4ed0-a8c1-83dd21690b46" name="tcrt:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was expensed as a one-time milestone payment under the terms of the agreement, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ea13ed6-b94d-4bf9-9c4d-dbb595b42525" contextRef="C_6a801914-4bd9-4d79-be9c-781ec8a7881d" name="tcrt:PaymentUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_48c9e808-a340-495b-be1a-8908c410bd17" contextRef="C_7d15c91c-08c2-4355-817a-d947ee9b15f8" name="tcrt:PaymentUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the three and nine months ended September 30, 2021. During the three and nine months ended September 30, 2022 and 2021, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5bde8d2f-6b6b-49ac-862c-ca5c23402723" contextRef="C_d9252104-b0ce-41b0-bd34-3724646ef25e" name="tcrt:PaymentUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_25cd61f9-5538-40c0-a52e-ecfdbb786770" contextRef="C_2dfd9017-3654-4240-b560-4fa92df974b8" name="tcrt:PaymentUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_221d4ff7-4dbf-4d81-9b51-3ddf6a349236" contextRef="C_7384efec-4e47-4d02-8bce-8365f7e0295a" name="tcrt:PaymentUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c2fa0858-1b82-45ae-ac6a-e8b7235e1ff0" contextRef="C_4d9975fc-c543-4fdc-bc21-cb9c1de3ac67" name="tcrt:PaymentUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t incur royalty expenses on sales under this agreement.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(unaudited)</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreement with Solasia Pharma K.K.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia Pharma K. K. (&#34;Solasia&#34;), which was amended on July 31, 2014 to include an exclusive worldwide license and amended on October 14, 2021 to revise certain payment schedule details (as so amended, the &#34;Solasia License and Collaboration Agreement&#34;). Pursuant to the Solasia License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the license, the Company is eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenue generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company&#x2019;s licensors, as defined in the Solasia License and Collaboration Agreement, will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Solasia License and Collaboration Agreement with the licensors, as described above.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, Solasia announced that darinaparsin had been approved from relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare in Japan. During the three and nine months ended September 30, 2022, the Company recorded $2.9 million of collaboration revenue under the Solasia License and Collaboration Agreement primarily related to Solasia's achievement of certain sales-based milestones in Japan. During the three and nine months ended September 30, 2021, the Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4572780-244a-4f58-b1f6-61b0e252bb9d" contextRef="C_e9a0185b-e5d0-4a1e-9377-e759cf76ceb3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_80dd405d-ccbf-4b81-8f70-2e5c6bb6f899" contextRef="C_71ac7c9c-ed62-4708-9f1f-3794c7da2b64" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of collaboration revenue under the Solasia License and Collaboration Agreement. During the three and nine months ended September 30, 2022 and 2021, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3edc1962-9f34-488a-980f-a0464064be33" contextRef="C_bf4cb307-d956-44e9-9223-82983a351431" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9b8cf53f-9560-4ef6-9154-d745d9100a93" contextRef="C_0ea0be7a-caae-4842-adc5-35fca4e7eea4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_08386ddc-7276-44d7-a4fe-d33126d3e90e" contextRef="C_7ec0e0fa-abc4-4590-ac2a-da156b639f99" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7796408f-d01d-4119-ac17-7f8430b077da" contextRef="C_ce1c210f-7d8b-4de3-bdac-77591a3466bd" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t record royalty revenues on net sales of darinaparsin under this agreement.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2a162be2-ea9d-4f74-95e6-1a27720e05a5" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="tcrt:StockOptionsAndRestrictedStockAwardsTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">10.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-Based Compensation</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e65d3119-73f2-4de1-b4bc-b2cf512de8fe" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.367%;"></td>
        <td style="width:3.316%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.553%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.665%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.641%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.665%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.789%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.665%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.338999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Three Months Ended September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Nine Months Ended September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d24de701-b315-43e8-9b5e-c91694195219" contextRef="C_b8f27772-b294-42ff-a235-56681aee8001" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03d9a475-706b-4d8f-82aa-9d91945532a4" contextRef="C_26c0546e-3ae0-436e-bf65-3135619b6131" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">535</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a67126d-8fe6-4555-9189-83e863294aa9" contextRef="C_2a85659d-9529-4877-90ee-9305d6b05bd2" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">673</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9b61b5b-5958-4061-b945-c70151814367" contextRef="C_3996230c-eb63-4bd8-8c4e-4eda38f443db" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,115</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_278da34f-4aef-47f7-badf-82026555d821" contextRef="C_e5b94b60-824a-4f1d-94d2-dc6c1840957d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">663</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef7e5e8b-9ef5-4e55-a8b6-9c8faf268250" contextRef="C_d0485a7c-1400-45f5-9110-483d8d21ebfb" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,836</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19d6dee1-af93-4894-90df-f90d796a6271" contextRef="C_d4b5db92-6383-4c43-b62a-d3bc3bc3fc9f" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,978</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4ec8cde-21a7-43b2-806f-1a9945b81c59" contextRef="C_8607731b-da93-4afa-873b-c41bd854fae0" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,742</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b050ce03-f836-4f31-8c50-684e6d76a2f2" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">808</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f4820b2-b9a2-42b2-aeda-60bc5b47c12c" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c551c1dc-c534-4634-af48-e33c8f625b58" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,651</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f43a2e95-2a3e-4ef1-83c8-ffd3ac2b0d74" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,857</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company granted an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef6596c3-f460-4a0f-865b-193c115c378e" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,275,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stock options during the three months ended September 30, 2022, with a weighted-average grant date fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15d1bc8a-8209-4c31-ba35-01aa1efde061" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.52</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, and granted an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_129f95f4-9f04-4614-ace7-ebcf40a300e4" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,667,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stock options during the nine months ended September 30, 2022, with a weighted-average grant date fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae3017d9-564a-4262-a9bf-658687827600" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.67</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The Company granted an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5879f203-0b6c-42b5-adb7-9e3b45e44a14" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,755,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">stock options during the three months ended September 30, 2021, with a weighted-average grant date fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_081e83e2-3cb1-4244-84f6-b8c9ebede9cb" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.08</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, and granted an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_874c064b-bbbd-4c64-aa62-7c55cdd0879c" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,150,438</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stock options during the nine months ended September 30, 2021, with a weighted-average grant date fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11dacdbf-bf15-43fe-bb44-edec89fe8d4d" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.91</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a294ebf0-b3e8-4ffe-97d0-fd9fd4517136" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three and nine months ended September 30, 2022 and 2021, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.661%;"></td>
        <td style="width:1.336%;"></td>
        <td style="width:15.999%;"></td>
        <td style="width:1.336%;"></td>
        <td style="width:15.999%;"></td>
        <td style="width:1.336%;"></td>
        <td style="width:15.999%;"></td>
        <td style="width:1.336%;"></td>
        <td style="width:15.999%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Three Months Ended September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Nine Months Ended September 30,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b25347c6-a809-4957-b411-217cda196358" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.94</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b3e355f-e910-4c49-9682-51ab6d20d20d" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">3.62</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_365fda4d-b0c9-4664-80a1-636ec2835f06" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.89</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1d2a678-24c4-4532-90ca-fe6f55a4f0f9" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.96</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7767e33b-c9d7-4fb5-9947-7c077d2804f3" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.63</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4724a64-10f4-418e-b4e5-62f736ed38a7" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">3.62</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_766d97c0-3888-4652-ab3a-604cdaeeb7bd" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35f8b731-c2cd-46fd-b110-55642a9b385d" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected life in years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_abe0c6da-1820-4963-aeb3-b21c8bae2430" contextRef="C_c328dc7e-2261-4512-872c-da4fb630f2c8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.23</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_954d6bc6-5551-4738-815a-81fd088dd657" contextRef="C_5f43bb33-c6dd-42f3-b81e-2d16c0d279f7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7be184cd-eabd-4650-8225-313d31f01502" contextRef="C_fcea062a-308f-4809-8835-154dace3f34b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2bebfcd8-0302-4b48-b315-07f94f34531e" contextRef="C_ba03628a-d489-4082-b85c-544300569f10" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5de20be7-ee71-4fb4-8399-ec35624dda83" contextRef="C_18443f2c-6ffb-47e1-8f0b-7587c06dbd8e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.27</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7ee3bab0-318c-4128-8c09-b5a8fbbc8aac" contextRef="C_07609204-d289-4b94-b19f-777a70145f62" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_19fb3e39-a5dc-436b-95e2-2ce9778021c1" contextRef="C_5278975e-6f79-4550-9b7e-1506a2f6d459" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5fe80b44-0300-46df-ad04-f53cfd187a71" contextRef="C_dc8e2d26-10b6-486b-8a26-6ca99f89115b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d86c1b9e-84b5-46ae-a820-87035b36eb1b" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">82.43</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f225883-8431-4bf9-af09-f5b6d5957014" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">85.89</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f978dda6-fdc7-4b45-b0d7-cc90b85c93f1" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">72.53</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9570dbc3-15eb-408d-8414-9062e55673f5" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">72.84</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69b34ed6-4fa3-48a9-8737-93c8e925f36f" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">74.49</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f27277bc-6808-46cd-89de-ea08b4b605dc" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">85.89</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89a1fcba-6da0-47d2-a02a-be66e26e5d29" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">72.53</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_deddf4a3-6a63-4641-9add-725017c0b9e0" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">74.80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2560bcb9-5dcb-4b5d-8cd5-dd2d9fc454a3" contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44e504ff-b5a6-4c2a-82a9-b29f01509fa1" contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa6eeee9-4ba4-46a2-98b2-9ba0a546477e" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d81d177-0089-457e-99da-d67017eb036c" contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.528%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:1.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.743198935713313%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e21738cb-85ec-4437-ac68-7c9164337520" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock option activity under the Company&#x2019;s stock option plans for the nine months ended September 30, 2022 is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(unaudited)</span></p></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.903%;"></td>
        <td style="width:0.993%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.799%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.215%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.504%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.993%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.828999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.215%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.551%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted- Average Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted- Average Contractual Term (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef66c0d3-4230-4a2c-9248-d0f4229c5f37" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">10,665,869</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_553e6a5b-6bdc-409b-8c4b-8c1ad2c87429" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.87</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7264033e-e238-484a-be32-993d5698b43f" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,667,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6af5ff9-8b5d-4abf-aa6e-6adb9961f97c" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.08</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bd5157f-18be-4c0b-91df-b8d5834d979e" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">26,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79aed0c5-9421-4737-8d5f-c432d180ac4a" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.80</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ae6dd64-5de8-440a-98d2-60e78d61df4d" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,683,904</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ccf7dc6f-fab0-45e4-9a0d-5996ab81a6fe" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.40</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, September 30, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8cf0a894-244c-4d2b-ad1b-acb5e60bfaee" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">10,623,215</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a12a1727-e08a-4d7a-8194-b9db343b56fe" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.85</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3f9c00db-2380-43b7-8393-a144ab1eefbb" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.27</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92455ec2-73a1-494d-a849-9e10c183cf73" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,572</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable, September 30, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0dde0b43-7914-4e4d-ac68-1af033ad877d" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,211,631</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d56e70a-5bb1-4b06-8692-f30f98bef1e5" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.69</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_25b4afe2-b8a3-4455-9276-6ad85069f814" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.01</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93d008e8-7127-473a-ab95-b94d621e3c5e" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">510</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ed8dbc7-564e-4619-8d77-5297b62b3a6b" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,410,312</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4980b213-015e-41ec-9d91-ed05d26698a6" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.85</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_adf42ec7-58c0-4d9f-a17f-693dde340498" contextRef="C_f915cb95-5e51-4689-a7fd-3b9969b8b324" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.53</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c94b6a0-9db3-484f-8eb6-357447bd591b" contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options available for future grant, September 30, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f516dbd-f486-4cc1-83fe-0efbdf107820" contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">15,245,494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At September 30, 2022, total unrecognized compensation costs related to unvested stock options outstanding amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a8463e6-9762-4801-a3ba-a474ef7eedd5" contextRef="C_f647c291-0b62-43fd-84a5-54f70a4da70b" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The cost is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4b9d3b43-3a3d-4b99-9f12-5484bd3f2d75" contextRef="C_de243d37-ed59-4bdb-a446-2678a29190e9" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.01</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3a8a09a3-c235-4e23-8e06-f8f09356b7e7" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the status of unvested restricted stock for the nine months ended September 30, 2022 is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.459%;"></td>
        <td style="width:1.154%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.669%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.605%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.115%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8bb85fa2-bce5-4042-8543-f1dc428197bd" contextRef="C_87c24bba-d603-4bbb-92e5-692a66baf6fa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,198,580</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81bdcbcb-7cc8-4f19-9133-3a1e5e829eb3" contextRef="C_87c24bba-d603-4bbb-92e5-692a66baf6fa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8dc808c9-8de2-4d57-b987-8a82e3963341" contextRef="C_51a11843-7d5f-4914-9b59-f8771ccffffc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">280,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1c13d6d-771a-4f3d-a9cd-c5d69808a1f1" contextRef="C_51a11843-7d5f-4914-9b59-f8771ccffffc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.82</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45154115-dd79-418f-a229-4272306b2847" contextRef="C_51a11843-7d5f-4914-9b59-f8771ccffffc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">305,679</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26631d21-f6c8-48a2-8084-d069031cafd7" contextRef="C_51a11843-7d5f-4914-9b59-f8771ccffffc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.28</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acf8e23e-9772-4d58-91e3-b186ca3051cd" contextRef="C_51a11843-7d5f-4914-9b59-f8771ccffffc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">232,901</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_902d8824-0ff8-43b2-8386-79ccde0111cd" contextRef="C_51a11843-7d5f-4914-9b59-f8771ccffffc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested, September 30, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c666ab8a-d3a8-45eb-b8b8-c205b517fa96" contextRef="C_516cb031-f3e7-4387-8ebb-eb61b7eb9ea0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">940,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51ed11d6-f913-4862-a270-6a7e53f8aa8d" contextRef="C_516cb031-f3e7-4387-8ebb-eb61b7eb9ea0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.41</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At September 30, 2022, total unrecognized compensation costs related to unvested restricted stock outstanding amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32a89054-7256-428c-950a-582bf2376107" contextRef="C_516cb031-f3e7-4387-8ebb-eb61b7eb9ea0" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The cost is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1a1bb154-2d9f-4e1f-b303-cbc0a832359b" contextRef="C_51a11843-7d5f-4914-9b59-f8771ccffffc" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.83</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2e6d97ab-dd44-48dc-aa03-22307c85acca" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="tcrt:WarrantTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">11.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Company&#x2019;s November 2018 private placement that provided net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64224953-b318-40fe-a6dd-8b499c586b8a" contextRef="C_23567fca-d299-4618-8b07-c800715f57a9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">47.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, the Company issued warrants to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33cc90d5-d850-48b9-9756-62368b3fa452" contextRef="C_89811c97-bb62-4965-936e-16929f7b6833" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">18,939,394</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, which became exercisable six months after the closing of the private placement (the &#34;November 2018 Warrants&#34;). The November 2018 Warrants had an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0b5e686-af0b-464c-b65f-2e7baf7389b4" contextRef="C_89811c97-bb62-4965-936e-16929f7b6833" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.01</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and have a five-year term. The fair value of the November 2018 Warrants was estimated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bcafc571-c668-46ee-8a6f-7f90517cfb78" contextRef="C_0af67efe-5cc6-4bd3-95da-2269b35a5117" name="tcrt:FairValueOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million using a Black-Scholes model with the following assumptions: expected volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e78e08c-0a28-4d9d-b1b0-6d73f0691085" contextRef="C_0af67efe-5cc6-4bd3-95da-2269b35a5117" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">71</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2592c32-dd5d-403d-88bd-b58e0fe30327" contextRef="C_0af67efe-5cc6-4bd3-95da-2269b35a5117" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, expected life of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_de317674-1db9-4a53-820c-85cbb9269459" contextRef="C_0af67efe-5cc6-4bd3-95da-2269b35a5117" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70586038-c5ee-4223-89c3-1ce1a2fff08b" contextRef="C_0af67efe-5cc6-4bd3-95da-2269b35a5117" name="us-gaap:Dividends" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 26, 2019 and September 12, 2019, the Company entered into agreements with existing investors whereby the investors exercised the November 2018 Warrants for an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80f9d57b-cf73-48c6-be2b-913a1a5f68aa" contextRef="C_79174d62-d06a-4299-a8be-9fb31ca9fadb" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">17,803,031</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de256e7b-d437-4cfa-9610-0bde5c3a072e" contextRef="C_79174d62-d06a-4299-a8be-9fb31ca9fadb" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.01</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. Proceeds from the warrant exercise after deducting placement agent fees and other related expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ddb3763-bb15-4205-89cf-93edb397ac7b" contextRef="C_f1c90eed-e7e4-4ee2-b023-7eca1c8b450c" name="tcrt:PlacementAgentFeesAndOtherRelatedExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29654b7a-9525-4cbe-a5aa-2d857d7e5033" contextRef="C_6e455d27-ae8e-4cd2-8656-5e6b3044aec4" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">52.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company issued participating investors new warrants to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b97d79d-10e0-4005-b53e-c12d835bbc69" contextRef="C_93030e80-98ca-4f83-b767-ef2910a9d17a" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">17,803,031</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of common stock (the &#34;2019 Warrants&#34;) as consideration for the warrant holders to exercise their November 2018 Warrants. The 2019 Warrants will expire on the fifth anniversary of the initial exercise date and have an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6677198-65cf-44f1-84fb-0c5e75a503b8" contextRef="C_93030e80-98ca-4f83-b767-ef2910a9d17a" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">7.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The 2019 Warrants were valued using a Black-Scholes valuation model and resulted in a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d4c445f-f11c-4102-83f5-3bcb41285be6" contextRef="C_0aa8acc8-3dfc-4c50-ae31-5fef3f1e4dce" name="tcrt:NonOperatingIncomeExpenseInducementOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">60.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million non-cash charge in the Company&#x2019;s statement of operations in 2019.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 22, 2019, the Company entered into the 2019 R&amp;D Agreement with MD Anderson. In connection with the execution of the 2019 R&amp;D Agreement, the Company issued the MD Anderson Warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53d8bc80-c787-428b-abb6-1e57d5255a4b" contextRef="C_2de808d8-5984-43d6-9ce6-49b4e1114951" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,333,333</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. The MD Anderson Warrant has an initial exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbedb509-2330-496a-b7d8-990fd30e3eb9" contextRef="C_2de808d8-5984-43d6-9ce6-49b4e1114951" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and grant date fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_339881bf-8874-4cd3-99ee-235aa8033b41" contextRef="C_1e4f7846-958f-4ab8-a4e6-79d28f2b664d" name="tcrt:FairValueOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The MD Anderson Warrant expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_88e80d37-79bd-40a5-9dfb-bf6e2f543e20" contextRef="C_2de808d8-5984-43d6-9ce6-49b4e1114951" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2026 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and vests upon the occurrence of certain clinical milestones. The Company will recognize expense on the MD Anderson Warrant in the same manner as if the Company paid cash for services to be rendered. For the three and nine months ended September 30, 2022 and September 30, 2021, the Company did not recognize any expense related to the MD Anderson Warrant as the clinical milestones had not been achieved.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. Refer to Note 4 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In connection with the Loan and Security Agreement, the Company issued SVB warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76d78735-454e-4ef2-933d-a584397d7977" contextRef="C_9a1f34d1-4746-4f1f-bc5a-c6ce280ea3a7" name="us-gaap:CommonStockSharesSubscribedButUnissued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">432,844</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of common stock with an exercise</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(unaudited)</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">price </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fd2a54ef-6509-4c2a-9e1f-d487fa4c6aa5" contextRef="C_4abb6de4-1411-454e-b48d-575b66944575" name="us-gaap:CommonStockCallOrExerciseFeatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$2.22</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The warrants have a</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c701b5e0-3232-4a3c-90e2-30413774e8b5" contextRef="C_9a1f34d1-4746-4f1f-bc5a-c6ce280ea3a7" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ten-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> life and were fully vested upon issuance. The fair value of the warrants was estimated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52c42325-1006-40be-ac33-9e0527845a29" contextRef="C_17466d85-cda1-4e4a-b4fb-9d479415d434" name="tcrt:FairValueOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million using a Black-Scholes model with the following assumptions: expected volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_804d3ebf-d5b9-468f-b48e-ecbf034fd8c7" contextRef="C_17466d85-cda1-4e4a-b4fb-9d479415d434" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">79</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a1ab74c-0b4a-4b97-af53-c0f54a5c0dd4" contextRef="C_17466d85-cda1-4e4a-b4fb-9d479415d434" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.31</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, expected life of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4c8d7347-ff59-4dd2-8f52-baee5a119d1b" contextRef="C_17466d85-cda1-4e4a-b4fb-9d479415d434" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2bda0c60-1cb6-46a6-912d-ee31e06fda3c" contextRef="C_17466d85-cda1-4e4a-b4fb-9d479415d434" name="us-gaap:Dividends" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends. On December 28, 2021, the Company entered into the Amendment, as described in Note 4 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in connection with which, the original warrants issued to SVB were amended and restated. As amended and restated, the SVB Warrants are for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c3fd316-4924-4e3d-b0ca-e83180c8034c" contextRef="C_11392846-50b9-4407-b98d-7bf6aba70e2a" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">649,615</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, in the aggregate, at an exercise price per share of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f20f2f3f-4949-4ea1-bbf4-2d59a9cfd209" contextRef="C_d882f9ce-a213-4796-9543-c22ad26eb67a" name="us-gaap:CommonStockCallOrExerciseFeatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$1.16</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The SVB Warrants expire on August 6, 2031 and were fully vested upon issuance. Using a Black-Scholes model with an expected volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37764230-5aa6-443b-951b-dc1798e5605b" contextRef="C_d882f9ce-a213-4796-9543-c22ad26eb67a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">81</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fcad4f7b-1068-41cf-b48d-ace53ef7b487" contextRef="C_d882f9ce-a213-4796-9543-c22ad26eb67a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.49</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, expected life of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0bb384aa-14df-4d7e-a8ae-4ac21707efba" contextRef="C_d882f9ce-a213-4796-9543-c22ad26eb67a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3568b1b-efc5-4e46-8041-7ab2d92f5ed8" contextRef="C_d882f9ce-a213-4796-9543-c22ad26eb67a" name="us-gaap:Dividends" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends, the Company recorded a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_daba5fbe-ca7d-46eb-b4d0-73e8dfbe0081" contextRef="C_d882f9ce-a213-4796-9543-c22ad26eb67a" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million increase in the fair value of the SVB Warrants due to the modification of the SVB Warrants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed whether the SVB Warrants require accounting as derivatives. The Company determined that the SVB Warrants were (1) indexed to the Company&#x2019;s own stock and (2) classified in stockholders&#x2019; equity in accordance with FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As such, the Company has concluded the SVB Warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#x2019; equity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c0532276-1cc3-4f3a-a771-b733ccc97d40" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">12.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Joint Venture</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 18, 2018, the Company entered into a Framework Agreement with TriArm whereby the parties agreed to launch Eden BioCell, to lead clinical development and commercialization of certain </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-generated CAR-T therapies as set forth in a separate license agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 3, 2019, Eden BioCell was incorporated in Hong Kong as a private company. Eden BioCell, the Company and TriArm entered into a Share Subscription Agreement on January 23, 2019, where the Company and TriArm agreed to contribute certain intellectual property, services and cash (only with respect to TriArm) to Eden BioCell to subscribe for a certain number of newly issued ordinary shares in the share capital of Eden BioCell.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The closing of the transaction occurred on July 5, 2019. The Framework Agreement and Share Subscription Agreements were each respectively amended to be effective as of this date. Upon consummation of the joint venture, Eden BioCell and the Company also entered into a license agreement, pursuant to which the Company licensed the rights to Eden BioCell for third generation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-generated CAR-T therapies targeting the CD19 antigen for the territory of China (including Macau and Hong Kong), Taiwan and Korea. TriArm and the Company each received a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39ea0984-f770-4c39-b7b9-94941ad26be9" contextRef="C_bd378eef-0abd-4f06-8c55-ed8f64bbee7f" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% equity interest in the joint venture in exchange for their contributions to Eden BioCell.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that Eden BioCell was considered a variable interest entity, or VIE, and concluded that it is not the primary beneficiary of the VIE as it did not have the power to direct the activities of the VIE. As a result, the Company accounts for the equity interest in Eden BioCell under the equity method of accounting as it has the ability to exercise significant influence.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, Eden BioCell began treating patients in a clinical trial with the Company&#x2019;s investigational CD19 RPM CAR-T cell therapy, under the IND cleared by the Taiwan FDA in December 2020. In the first half of 2021, two patients were treated in this trial. The lead investigator at National Taiwan University in Taipei, has reported no serious adverse safety events in either of these patients. Laboratory results continue to support, as previously published, that non-viral </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gene transfer is effective in genetically modifying autologous T-cells. Patients were infused two days after gene transfer, thus shortening the turnaround time and demonstrating an advantage over viral methods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on laboratory data from the first two patients generated between March and May 2021, the TriArm/Eden team concluded, in concert with the investigator and the Company, that further process development work is required.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2021, TriArm and the Company mutually agreed to dissolve the joint venture.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three and nine months ended September 30, 2022 and September 30, 2021, Eden BioCell incurred a net loss. The Company continues to have no commitment to fund its operations.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b0476faf-6f69-4792-bd65-a4512d46c5fa" contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317" name="us-gaap:SubsequentEventsTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">13.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent Events</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has evaluated subsequent events from the balance sheet date through the date on which these financial statements were issued. The Company did not have any material subsequent events that impacted its financial statements or disclosures.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 2. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The following information should be read in conjunction with our unaudited condensed financial statements and the notes thereto included in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission, or the SEC, on March 30, 2022, or the Annual Report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Except for the historical information contained herein, the matters discussed in this Quarterly Report on Form 10-Q may be deemed to be forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. In this Quarterly Report on Form 10-Q, words such as &#x201c;may,&#x201d; &#x201c;expect,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;estimate,&#x201d; &#x201c;intend,&#x201d; &#x201c;plan&#x201d; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our actual results and the timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report. In addition, even if our results of operations, financial condition and liquidity and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report, they may not be predictive of results or developments in future periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report on Form 10-Q, including those risks identified under Part II, Item 1A. Risk Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage oncology-focused cell therapy company developing adoptive TCR-T cell therapy, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. We are leveraging our cancer hotspot mutation TCR library and our proprietary, non-viral </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gene transfer platform to design and manufacture patient-specific cell therapies that target neoantigens arising from shared tumor-specific mutations in key oncogenic genes, including </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In collaboration with the MD Anderson Cancer Center, or MD Anderson, we are currently enrolling and treating patients for a Phase 1/2 clinical trial evaluating 10 TCRs reactive to mutated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">from our TCR library for the investigational treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers, which we refer to as our TCR-T Library Phase 1/2 Trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not generated any product revenue and have incurred significant net losses in each year since our inception. For the nine months ended September 30, 2022, we had a net loss of $28.6 million, and as of September 30, 2022, we have incurred approximately $871.5 million of accumulated deficit since our inception in 2003. We expect to continue to incur significant operating expenditures and net losses. Further development of our product candidates will likely require substantial increases in our expenses as we:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to undertake clinical trials for product candidates;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek regulatory approvals for product candidates;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">work with regulatory authorities to identify and address program-related inquiries;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">implement additional internal systems and infrastructure;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hire additional personnel; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">scale-up the formulation and manufacturing of our product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continue to seek additional financial resources to fund the further development of our product candidates. If we are unable to obtain sufficient additional capital, one or more of these programs could be delayed, and we may be unable to continue our operations at planned levels and be forced to reduce our operations. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Developments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TCR-T Library Phase 1/2 Trial</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have seen encouraging early clinical safety, persistence and efficacy data in our first-in-human </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> TCR-T Library Phase 1/2 Trial that is actively enrolling patients with solid tumor cancers at MD Anderson Cancer Center. We presented information on the first two patients treated in September 2022 at the CRI-ENCI-AACR International Cancer Immunotherapy Conference, or CICON. We continue to perform translational assessments to assess the biological activity of our TCR-T cells in the first two patients. We believe that these data provide early clinical validation of the potential of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> TCR-T cell therapy in high value indications with significant unmet need. Key takeaways from the clinical experience to date are:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients 1 and 2 demonstrated manageable safety profiles with no dose limiting toxicities (DLTs) or immune effector cell-associated neurotoxicity syndrome (ICANS);</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Persistence of the TCR-T cells were evident in both patients. Patient 1 had persistence at 24 weeks with approximately 30% of the patient's total CD3+ T cells comprising TCR-T cells in peripheral blood after treatment with KRAS-G12D/HLA-A*11:01 mutation-specific TCR-T cells at dose level 1 (9x10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cells). Patient 2 had persistence at 12 weeks with approximately 20% of the patient's total CD3+ T cells comprising TCR-T cells in peripheral blood after treatment with TP53-R175H/HLA-A*02:01 mutation-specific TCR-T cells at dose level 2 (64x10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cells);</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Demonstrating six month progression-free survival, Patient 1 had best overall response of objective, partial response with regression of greater than 50% of target lesions at 12 weeks post-cell therapy. Patient 2 had best overall response of stable disease at six weeks with 12 week progression-free survival. Progressive disease was observed in Patient 1 and Patient 2 at week 24 and week 12, respectively, and each patient subsequently went off study;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The targeted mutations, KRAS-G12D and TP53-R175H, were detected in progressing tumor biopsies suggesting no antigen loss; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tumor homing was observed in Patient 1 with infiltration of both CD4 and CD8 TCR-T cells six months post-TCR-T cell therapy.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To our knowledge, achievement of an objective clinical response resulting from treatment with KRAS-G12D and HLA-A*11:01 specific TCR-T cells has not been reported until Patient 1 in our TCR-T Library Phase 1/2 Trial. Patient 1&#x2019;s infusion product was high quality with 97.3% viability, 99.7% CD3+ purity and 95.2% TCR positivity. Patient 1&#x2019;s target lesions were reduced compared to baseline by 46% at six weeks, 51% at 12 weeks and 46% at 24 weeks.  At six months following treatment, an elective tumor biopsy of non-measurable disease in the right lung showed continued presence of tumor cells, KRAS-G12D mutation and HLA-A*11:01 allele which was corroborated by another elective scan at seven months. Patient 1 is now off study.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scans of Patient 1&#x2019;s target lesions suggest the depth of the clinical response with evidence of durable and complete resolution of the right lower lobe target lesion (red circle) and non-measurable lymphogenic spread (orange circle) through week 24 (Image A) and reduction in the size of the three target lesions. Similar sustained reduction of the right upper lobe lesion (red circle) was observed through week 24 (Image B). The hilar lymph node (red circles) and non-measurable right lung disease (orange circle) appear to have reduced in size at week 24 compared to baseline measurements (Image C). Measurements of Patient 1's lesions are provided at Table D.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(A)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img159889792_0.jpg" alt="img159889792_0.jpg" style="width:720px;height:198px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(B)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img159889792_1.jpg" alt="img159889792_1.jpg" style="width:720px;height:177px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(C)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img159889792_2.jpg" alt="img159889792_2.jpg" style="width:720px;height:194px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(D)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img159889792_3.jpg" alt="img159889792_3.jpg" style="width:605px;height:239px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patient 2's treatment was the first-in-human </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TCR-T cell therapy targeting </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hotspot mutations and was well tolerated. The TCR-T cells demonstrated persistence and the patient showed signs of clinical efficacy. The same TCR used by the NCI to treat breast cancer, which resulted in a 6-month confirmed, objective partial response, was used to treat Patient 2. Patient 2 received highly pure TCR-T cells (92.5% viability, 99% CD3+ purity, and 92% TCR positivity). Reduction of target lesions by 15% from baseline was observed at six weeks post-infusion, but we observed 21.8% growth of lesions from the week six measurements and appearance of new liver and lung metastases at week 12 signaled progressive disease in Patient 2, who is now off study. Lesion measurement data for Patient 2 are available at Table E. We anticipate treating our next patient before the end of 2022 and presenting an update on our TCR-T Library Phase 1/2 Trial in 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(E)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img159889792_4.jpg" alt="img159889792_4.jpg" style="width:552px;height:230px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to file an IND amendment to incorporate cryopreserved TCR-T cells in our clinical protocol by the end of 2022. This process improvement will also shorten the manufacturing time from 30 days to 26 days. Our IND amendment will also include two new TCRs, expanding our clinical library and further increasing the addressable market. Three of these 10 TCRs already in our clinical library have been associated with confirmed partial responses in a clinical setting, giving us great confidence in the power of TCRs to treat solid tumors. We have also updated our standard operating procedures to allow for simultaneous manufacture of two product candidates in our cGMP suite. We have increased our existing manufacturing capacity to produce two products simultaneously.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">mbIL-15 Program</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are continuing to advance our mbIL-15 program towards an IND filing in the second half of 2023 and believe that this program has the potential to increase the survival of TCR-T cells in the harsh tumor microenvironment and deepen clinical responses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Solasia License and Collaboration Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, Solasia Pharma K. K. (&#34;Solasia&#34;) announced that darinaparsin has been approved for relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare in Japan. During the third quarter of 2022, the Company recorded $2.9 million of collaboration revenue under the Solasia License and Collaboration Agreement primarily related to Solasia's achievement of certain sales-based milestones in Japan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of a patent and technology license agreement with MD Anderson and the Texas A&amp;M University System, following Solasia's achievement of sales-based milestones, the Company also recorded a one-time $2.5 million expense during the third quarter of 2022 to MD Anderson.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Revenue</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize research and development funding revenue over the estimated period of performance. To date we have not generated product revenue. Unless and until we receive approval from the FDA and/or other regulatory authorities for our product candidates, we cannot sell our products and will not have product revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development expenses consist primarily of salaries and related expenses for personnel, costs of contract manufacturing services, costs of facilities, reagents, and equipment, fees paid to professional service providers in conjunction with our clinical trials, fees paid to contract research organizations in conjunction with clinical trials, fees paid to contract research organizations in conjunction with costs of materials used in research and development, consulting, license and milestone payments and sponsored research fees paid to third parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future research and development expenses in support of our current and future programs will be subject to numerous uncertainties in timing and cost to completion. We test potential products in numerous preclinical studies for safety, toxicology and efficacy. We may conduct multiple clinical trials for each product. As we obtain results from trials, we may elect to discontinue or delay clinical trials for certain products in order to focus our resources on more promising products or indications. Completion of clinical trials may take several years or more, and the length of time generally varies substantially according to the type, complexity, novelty and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">intended use of a product. It is not unusual for preclinical and clinical development of each of these types of products to require the expenditure of substantial resources.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The duration and the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others, the following:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of clinical sites included in the trials;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The length of time required to enroll suitable patients;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of patients that ultimately participate in the trials;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The length of time and cost to develop and optimize manufacturing processes;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost to manufacture the clinical products for patients; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The duration of patient follow-up to ensure the absence of long-term product-related adverse events; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The efficacy and safety profile of the product.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our programs or when and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our programs in a timely manner or our failure to enter into appropriate collaborative agreements could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to reduce or eliminate our activities in one or more of our programs or seek additional, external sources of financing from time-to-time in order to continue with our product development strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses consist primarily of salaries, benefits and stock-based compensation, consulting and professional fees, including patent related costs, general corporate costs and facility costs not otherwise included in research and development expenses or cost of product revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Expense)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense) consists of interest expense associated with our Amended Loan and Security Agreement, as defined below, and sublease income, which started accruing on July 1, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview of Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Three and Nine Months Ended September 30, 2022 Compared to Three and Nine Months Ended September 30, 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Revenue</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue during the three and nine months ended September 30, 2022 and 2021 was as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.643%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.8759999999999994%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.275%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.792999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.222%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.8759999999999994%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.275%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.792999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.222%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended September 30,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,911</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">398</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,513</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">631</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,911</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">398</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,513</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">631</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue during the three and nine months ended September 30, 2022 was $2.9 million as compared to $0.4 million during the three and nine months ended September 30, 2021, due to revenue earned under the Solasia License and Collaboration Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses during the three and nine months ended September 30, 2022 and 2021 were as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:27.986%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.602%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.795999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.604%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.495%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.494999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended September 30,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,893</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,521</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(6,628</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(46</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,411</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,427</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(22,016</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(53</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses for the three months ended September 30, 2022 decreased by $6.6 million when compared to the three months ended September 30, 2021 primarily due to a decrease in program-related costs of $3.6 million, mainly related to the winding down of our IL-12 and CAR-T programs, a $4.9 million decrease in employee related expenses due to our reduced headcount, including a $2.2 million restructuring charge in the third quarter of 2021, following our strategic restructuring event, a $0.4 million decrease in consulting expenses due to reduced use of consultants and a $0.2 million decrease in facilities costs due to the partial termination of one of our leases. These decreases were partially offset by a one-time $2.5 million expense to MD Anderson under the terms of our patent and technology license agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses for the nine months ended September 30, 2022 decreased by $22.0 million when compared to the nine months ended September 30, 2021 primarily due to a decrease in program-related costs of $8.4 million, mainly related to the winding down of our IL-12 and CAR-T programs, a $14.7 million decrease in employee related expenses due to our reduced headcount, including a $2.2 million restructuring charge in the third quarter of 2021, following our strategic restructuring event, a $1.0 million decrease in consulting expenses due to reduced use of consultants and a $0.2 million decrease in facilities costs due to the partial termination of one of our leases. These decreases were partially offset by a one-time $2.5 million expense to MD Anderson under the terms of our patent and technology license agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three and nine months ended September 30, 2022, our clinical stage projects included our TCR-T Library Phase 1/2 Trial evaluating TCRs from our library for the investigational treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and administrative expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses during the three and nine months ended September 30, 2022 and 2021 were as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:27.983%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.603%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.0009999999999994%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.0009999999999994%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.795999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.603%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.0009999999999994%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.502%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.494%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended September 30,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,282</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,173</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4,891</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(60</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,217</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,469</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(15,252</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(60</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses for the three months ended September 30, 2022 decreased by $4.9 million as compared to the three months ended September 30, 2021, primarily due to a $3.2 million decrease in employee related expenses due to our reduced headcount, including a $1.3 million restructuring charge in the third quarter of 2021, following our strategic restructuring event and a $1.7 million decrease in consulting and professional services expenses due to lower legal costs and reduced use of consultants.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses for the nine months ended September 30, 2022 decreased by $15.3 million as compared to the nine months ended September 30, 2021, primarily due to a $12.4 million decrease in employee related expenses due to our reduced headcount, including a $1.3 million restructuring charge in the third quarter of 2021, following our strategic restructuring event, a $2.8 million decrease in consulting and professional services expenses due to lower legal costs and reduced use of consultants and a $0.2 million decrease in facilities-related costs due to the expiration of two of our leases during 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Gain on lease modification</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gain on lease modifications during the three and nine months ended September 30, 2022 and 2021 was as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.525%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.059%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.449%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.254%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:7.31%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.059%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.365%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.772%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.192%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended September 30,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gain on lease modification</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;%</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(133</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(133</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There was no gain on lease modification during the three months ended September 30, 2022 and 2021. Gain on lease modification during the nine months ended September 30, 2022 was $0.1 million as compared to $0 during the nine months ended September 30, 2021. As a result of a real estate lease modification during the second quarter of 2022, the associated lease liability and right-of-use asset were remeasured based on the revised lease payments, resulting in a gain of $0.1 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other income (expense), net</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net during the three and nine months ended September 30, 2022 and 2021 was as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.262%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.848%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.219%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.745%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.156000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.856999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.219%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.792%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.962999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended September 30,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(841</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(444</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(397</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,266</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(444</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,822</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">410</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">254</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">247</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3529</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">279</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(15</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">294</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1960</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(587</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(437</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(150</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,987</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(459</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,528</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net for the three months ended September 30, 2022 increased by $0.2 million as compared to the three months ended September 30, 2021, primarily due to $0.4 million of interest expense associated with our Amended Loan and Security Agreement, partially offset by $0.2 million of interest income.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net for the nine months ended September 30, 2022 increased by $1.5 million as compared to the nine months ended September 30, 2021, primarily due to $1.8 million of interest expense associated with our Amended Loan and Security Agreement, partially offset by $0.3 million of interest income.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sources of Liquidity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not generated any revenue from product sales. Since inception, we have incurred net losses and negative cash flows from our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have financed our operations primarily through public offerings of our common stock, private placements of our convertible equity securities, term debt and collaborations. Through September 30, 2022, we have received an aggregate of $714.1 million from issuances of equity and $25.0 million from our Amended Loan and Security Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We follow the guidance of Accounting Standards Codification (&#34;ASC&#34;) Topic 205-40, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, in order to determine whether there is substantial doubt about our ability to continue as a going concern for one year after the date our financial statements are issued. Given our current development plans and cash management efforts, we anticipate that our cash resources will be sufficient to fund operations into the second quarter of 2023. Our ability to continue operations after our current cash resources are exhausted depends on our ability to obtain additional financing, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in our focus and direction of our research and development programs, competitive and technical advances, patent developments, regulatory changes or other developments. If adequate additional funds are not available when required, management may need to curtail its development efforts and planned operations to conserve cash.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the current cash forecast, management has determined that our present capital resources will not be sufficient to fund our planned operations for at least one year from the issuance date of the financial statements, which raises substantial doubt as to our ability to continue as a going concern. This forecast of cash resources and planned operations is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2022 Equity Distribution Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 12, 2022, we entered into an Equity Distribution Agreement (the &#x201c;Equity Distribution Agreement&#x201d;) with Piper Sandler &amp; Co. (&#x201c;Piper Sandler&#x201d;), pursuant to which we can offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $50 million through Piper Sandler as our sales agent in an &#x201c;at the market offering.&#x201d; Piper Sandler will receive a commission of 3.0% of the gross proceeds of any common stock sold under the Equity Distribution Agreement. During the three and nine months ended September 30, 2022, there were no sales of our common stock under the Equity Distribution Agreement. In connection with entering into the Equity Distribution Agreement, we concurrently terminated, effective August 12, 2022, the Open Market Sale Agreement, dated June 21, 2019, governing our former &#x201c;at the market offering&#x201d; program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Loan and Security Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2021, we entered into a Loan and Security Agreement (the &#34;Loan and Security Agreement&#34;) with Silicon Valley Bank and affiliates of Silicon Valley Bank (collectively, &#34;SVB&#34;). The Loan and Security Agreement provided for an initial term loan of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$25.0 million funded at the closing (the &#34;Term A Tranche&#34;), with an additional tranche of $25.0 million available if certain funding and clinical milestones were met by August 31, 2022 (the &#34;Term B Tranche&#34;).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective December 28, 2021, we entered into a First Amendment (the &#34;Amendment&#34;) to the Loan and Security Agreement (as so amended, the &#34;Amended Loan and Security Agreement&#34;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of September 30, 2022, the SVB Facility was fully drawn in the amount of $25.0 million. The SVB Facility bears interest at a floating rate per annum on the outstanding loans, payable monthly, at the greater of (a) 7.75% and (b) the current published U.S. prime rate, plus a margin of 4.5%. The Amended Loan and Security Agreement provided for an interest-only period which extended through August 31, 2022, as compared to March 31, 2022 in the Loan and Security Agreement. On or prior to August 31, 2022, we had not (i) received at least $50.0 million in net cash proceeds from the sale of our equity securities after the date of the Amended Loan and Security Agreement, on terms acceptable to SVB, nor (ii) achieved positive data in the first cohort of the TCR-T Library Phase 1/2 Trial endorsed by an independent safety monitoring committee as a safe dose to proceed (together, the &#x201c;Amended Milestones&#x201d;), and therefore, the interest-only period was not extended beyond August 31, 2022. Commencing on September 1, 2022, aggregate outstanding borrowings are repayable in twelve consecutive, equal monthly installments of principal plus accrued interest.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All outstanding obligations under the Amended Loan and Security Agreement are due and payable on August 1, 2023. We will also owe SVB 5.75% of the original principal amounts borrowed as a final payment (the &#34;Final Payment&#34;). We are permitted to make up to two prepayments, subject to a prepayment premium of the amount being prepaid, ranging from 1.00% to 2.00%, of the SVB Facility, each such prepayment to be at least $5.0 million plus all accrued and unpaid interest on the portion being prepaid.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of not achieving the Amended Milestones on or prior to August 31, 2022, the Amended Loan and Security Agreement requires us to cash collateralize half of the sum of the then-outstanding principal amount of the SVB Facility, plus an amount equal to 5.75% of the original principal amount of the SVB Facility. As of September 30, 2022, we have collateralized $13.9 million, which is classified as restricted cash on the balance sheet. So long as no event of default has occurred and subject to certain other terms related to the remaining outstanding balance under the SVB Facility being satisfied, $2.5 million will be released from the collateral account following the eighth scheduled payment of principal and interest, and a further $4.0 million will be released following the tenth scheduled payment of principal and interest. The SVB Facility and related obligations under the Amended Loan and Security Agreement are secured by substantially all of our properties, rights and assets, except for its intellectual property (which is subject to a negative pledge under the Amended Loan and Security Agreement). In addition, the Amended Loan and Security Agreement contains customary representations, warranties, events of default and covenants.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our entry into the Loan and Security Agreement, we issued to SVB warrants to purchase (i) up to 432,844 shares of our common stock, in the aggregate, and (ii) up to an additional 432,842 shares of Common Stock, in the aggregate, in the event we achieved certain clinical milestones, in each case at an exercise price per share of $2.22. In connection with our entry into the Amendment, we amended and restated the warrants issued to SVB. As amended and restated, the warrants are for up to 649,615 shares of our common stock, in the aggregate, at an exercise price per share of $1.16, or the SVB Warrants. The SVB Warrants expire on August 6, 2031.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance costs for the Loan and Security Agreement, including the Amended Loan and Security Agreement, were approximately $1.2 million and primarily related to the SVB Warrants, which will be amortized into interest expense over the period to August 1, 2023. Interest expense was $0.8 million for the three months ended September 30, 2022 and was $2.3 million for the nine months ended September 30, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of the Amended Loan and Security Agreement as of September 30, 2022 approximates its face value.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our net decrease in cash and cash equivalents for the nine months ended September 30, 2022 and 2021:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.997%;"></td>
    <td style="width:1.623%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.767000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.623%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.99%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(22,102</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(46,342</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(100</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,964</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,107</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,962</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(24,309</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(23,344</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Operating activities is derived by adjusting our net loss for:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash operating items such as depreciation and stock-based compensation; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities for the nine months ended September 30, 2022 was $22.1 million, as compared to net cash used in operating activities of $46.3 million for the nine months ended September 30, 2021. The net cash used in operating activities for the nine months ended September 30, 2022 was primarily due to our net loss of $28.6 million, adjusted for $7.5 million of non-cash items such as depreciation, stock-based compensation and a decrease in the carrying amount of right-of-use lease assets, a $2.4 million decrease in lease liabilities, a $1.8 million increase in accounts receivable, offset by an increase in accounts payable of $0.6 million, a $1.5 million increase in accrued expenses, and a decrease to prepaid expenses and other assets of $0.9 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities was $0.1 million for the nine months ended September 30, 2022, compared to $3.0 million for the nine months ended September 30, 2021. The decrease was primarily a result of the decision to use available cash to expand our internal cell therapy capabilities in our Houston, Texas facilities during the first half of 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in financing activities for the nine months ended September 30, 2022 was $2.1 million, primarily related to the repayment of long-term debt. Net cash provided by financing activities during the nine months ended September 30, 2021 was $26.0 million, related primarily to proceeds from the issuance of long-term debt and proceeds from the exercise of stock options.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Capital and Capital Expenditure Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate that losses will continue for the foreseeable future. As of September 30, 2022, our accumulated deficit was approximately $871.5 million. Our actual cash requirements may vary materially from those planned because of a number of factors, including:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the focus, direction and pace of our development programs;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effect of competing technologies and market developments;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, progress, timing, costs and results of our TCR-T Library Phase 1/2 Trial for the treatment of certain solid tumors and costs associated with the development of our product candidates;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our headcount growth focused on our TCR program and scaling our manufacturing capabilities;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to secure partnering arrangements; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs of filing, prosecuting, defending and enforcing any patent claims and any other intellectual property rights, or other developments.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of September 30, 2022, we had approximately $37.8&#x202f;million of cash and cash equivalents and $13.9 million of restricted cash related to the Amended Loan and Security Agreement. Given our current development plans, we anticipate our cash resources will be sufficient to fund our operations into the second quarter of 2023. In order to continue our operations beyond our forecasted runway, we will need to raise additional capital, and we have no committed sources of additional capital at this time. The forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of our expenses could vary materially and adversely as a result of a number of factors. We have based our estimates on assumptions that may prove to be wrong, and our expenses could prove to be significantly higher than we currently anticipate. Management does not know whether additional financing will be on terms favorable or acceptable to us when needed, if at all. If adequate additional funds are not available when required, management may need to curtail its development efforts and planned operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Working capital, which excludes restricted cash, as of September 30, 2022 was $8.7 million, consisting of $41.6 million in current assets and $32.9 million in current liabilities. Working capital as of December 31, 2021 was $62.8 million, consisting of $78.8 million in current assets and $16.0 million in current liabilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commitments for operating leases relate to laboratory and office space in Houston, Texas and office space in Boston, Massachusetts. On December 21, 2015 and April 15, 2016, we renewed the sublease for our office space in Boston through August 31, 2021. On April 22, 2021, we extended our sublease for a portion of office space at our office in Boston through August 31, 2026.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 12, 2019, we entered into a lease agreement for office space in Houston at MD Anderson through April 2021. On October 15, 2019, we entered into another lease agreement for additional office and laboratory space in Houston through February 2027. On</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 7, 2020, we entered into amendments to our existing lease to lease additional office and laboratory space in Houston through February 2027. In June and September 2020, we entered into short-term leases in Houston for additional office and laboratory space. On December 15, 2020, we entered into a second lease in Houston with MD Anderson which provided us additional office and laboratory space through April 2028.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the second quarter of 2022, the Company modified its real estate lease agreement executed on December 15, 2020 with MD Anderson. The modification reduced the Company's leased space from 18,111 square feet to 3,228 square feet. As a result, the associated lease liability and right-of-use asset were remeasured to $0.4 million based on revised lease payments. A gain of $0.1 million was also recorded on the lease modification in the second quarter of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalty and License Fees</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 28, 2019, we entered into a patent license agreement, or the Patent License, with the National Cancer Institute, or the NCI. The terms of the Patent License require us to pay the NCI minimum annual royalties in the amount of $0.3 million, which will be reduced to $0.1 million once the aggregate minimum annual royalties paid by us equals $1.5 million. For the three months ended September 30, 2022 and 2021, we recognized $0 related to royalty payments under this agreement, and we recognized $0.3 million in royalty payments under this agreement for the nine months ended September 30, 2022 and 2021. As of September 30, 2022, we have paid a total of $0.5 million in minimum annual royalty payments under this agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Patent License, we are also required to make performance-based payments contingent upon the successful completion of clinical and regulatory benchmarks relating to the licensed products. Of such payments, the aggregate potential benchmark payments are $4.3 million, of which aggregate payments of $3.0 million are due only after marketing approval in the United States or in Europe, Japan, Australia, China or India. The first benchmark payment of $0.1 million was due upon the initiation of our first sponsored Phase 1 clinical trial of a licensed product or licensed process in the field of use licensed under the Patent License. In addition, we are required to pay the NCI one-time benchmark payments following aggregate net sales of licensed products at certain aggregate net sales ranging from $250.0 million to $1.0 billion. The aggregate potential amount of these benchmark payments is $12.0 million. Payments totaling $0 and $0.1 million were made during the three and nine months ended September 30, 2022 related to the first benchmark payment, as compared to $0 during the three and nine months ended September 30, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 5, 2018, we entered into an exclusive license agreement, or the License Agreement, with PGEN Therapeutics, Inc., or PGEN, a wholly owned subsidiary of Precigen Inc., or Precigen. Under the License Agreement, we are obligated to pay PGEN an annual licensing fee of $0.1 million expected to be paid through the term of the License Agreement and we have also agreed to reimburse certain historical costs of PGEN up to $1.0 million. For the three and nine months ended September 30, 2022 and September 30, 2021, we have made licensing fee payments in accordance with the terms of the License Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the terms of the License Agreement, we are responsible for contingent milestone payments totaling up to an additional $52.5 million for each exclusively licensed program upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions. In addition, we will pay PGEN tiered royalties ranging from low-single digits to high-single digits on the net sales derived from the sale of any approved IL-12 products and CAR products. We will also pay PGEN royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of any approved TCR products, up to a maximum royalty amount of $100.0 million in the aggregate. We will also pay PGEN twenty percent of any sublicensing income received by us relating to the licensed products. We are responsible for all development costs associated with each of the licensed products. PGEN will pay us royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of PGEN&#x2019;s CAR products, up to a maximum royalty amount of $100.0 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Policies and Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In our Annual Report on Form 10-K for the year ended December 31, 2021, our most critical accounting policies and estimates upon which our financial status depends were identified as those relating to clinical trial expenses and other research and development expenses; collaboration agreements; fair value measurements for stock-based compensation; and income taxes. We reviewed our policies and determined that those policies remain our most critical accounting policies for the three and nine months ended September 30, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 3. Quantitative and Qualitative Disclosures about Market Risk.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a smaller reporting company, as defined by Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, we are not required to provide the information under this item.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 4. Controls and Procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, with the participation of our principal executive officer and principal accounting officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act) as of September 30, 2022. The term &#x201c;disclosure controls and procedures,&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#x2019;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#x2019;s management, including its principal executive and principal accounting officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2022, our principal executive officer and principal accounting officer concluded that, as of such date, our disclosure controls and procedures were effective.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no changes in our internal control over financial reporting (as defined in Rule 13(a)-15(f) of the Exchange Act) that occurred during the quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II&#x2014;OTHER INFORMATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_legal_proceeding_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 1. Legal Proceedings</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of business, we may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities from time to time. The results of litigation and claims cannot be predicted with certainty, and unfavorable resolutions are possible and could materially affect our results of operations, cash flows or financial position. In addition, regardless of the outcome, litigation could have an adverse impact on us because of defense costs, diversion of management attention and resources and other factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of September 30, 2022, based on information readily available, there are no material matters that, in the opinion of management, are likely to result in a material adverse effect on our financial position, results of operations or cash flows.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factor_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Item 1A. Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following important factors could cause our actual business and financial results to differ materially from those contained in forward-looking statements made in this Quarterly Report on Form 10-Q or elsewhere by management from time to time. The risk factors in this Quarterly Report have been revised to incorporate changes to our risk factors from those included in our Annual Report. The risk factors set forth below with an asterisk (*) before the title are new risk factors or ones containing substantive changes from the risk factors previously disclosed in Item 1A of our Annual Report, as filed with the SEC. The market price of our common stock could decline if one or more of these risks or uncertainties actually occur, causing you to lose all or part of your investment. This situation is changing rapidly and additional impacts may arise. Additional risks that we currently do not know about, or that we currently believe to be immaterial, may also impair our business. Certain statements below are forward-looking statements. See &#x201c;Special Note Regarding Forward-Looking Statements&#x201d; in this Quarterly Report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RISKS RELATED TO OUR BUSINESS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">*We will require substantial additional financial resources to continue as a going concern and to continue ongoing development of our product candidates and pursue our business objectives; if we are unable to obtain these additional resources when needed, we may be forced to delay or discontinue our planned operations, including clinical testing of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not generated significant revenue and have incurred significant net losses in each year since our inception. For the nine months ended September 30, 2022, we had a net loss of $28.6 million, and, as of September 30, 2022, our accumulated deficit since inception in 2003 was $871.5 million. We expect our operating expenditures and net losses to increase significantly in connection with our ongoing clinical trial and our internal research and development capabilities. Further development of our product candidates will require substantial increases in our expenses as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to undertake clinical trials for product candidates; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">scale-up and scale-out the manufacturing of our TCR-T product candidates; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek regulatory approvals for product candidates; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">work with regulatory authorities to identify and address program-related inquiries; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">implement additional internal systems and infrastructure; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hire additional personnel, including highly-skilled and experienced scientific staff. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of September 30, 2022, we have approximately $37.8&#x202f;million of cash and cash equivalents and $13.9 million of restricted cash related to the Amended Loan and Security Agreement.&#x202f;Given our current development plans and cash management efforts, we anticipate cash resources will be sufficient to fund operations into the second quarter of 2023. We have no committed sources of additional capital at this time. We follow the guidance of Accounting Standards Codification (&#34;ASC&#34;) Topic 205-40, Presentation of Financial Statements - Going Concern, in order to determine whether there is substantial doubt about our ability to continue as a going concern for one year after the date our financial statements are issued. Based on the current cash forecast, management has determined that our present capital resources will not be sufficient to fund our planned operations for at least one year from the issuance date of the financial statements, which raises substantial doubt as to our ability to continue as a going concern.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The forecast of cash resources is forward-looking information that involves risks and uncertainties, and our actual cash requirements may vary materially from our current expectations for a number of other factors that may include, but are not limited to, changes in the focus and direction of our development programs, slower and/or faster than expected progress of our research and development efforts, changes in governmental regulation, competitive and technical advances, rising costs associated with the development of our product candidates, our ability to secure partnering arrangements, and costs of filing, prosecuting, defending and enforcing our intellectual property rights. Global political and economic events, including the COVID-19 pandemic and increased inflation, have already resulted in a significant disruption of global financial markets. If the disruption persists and deepens, we could experience an</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability to access additional capital or make the terms of any available financing less attractive, which could in the future negatively affect our operations. If we exhaust our capital reserves more quickly than anticipated, regardless of the reason, and we are unable to obtain additional financing on terms acceptable to us or at all, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">*We need to raise additional capital to fund our operations. The manner in which we raise any additional funds may affect the value of your investment in our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings and license and collaboration agreements. We do not have any committed external source of funds. The unpredictability of the capital markets may severely hinder our ability to raise capital within the time periods needed or on terms we consider acceptable, if at all. In particular, a decline in the market price of our common stock could make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate. Moreover, if we fail to advance one or more of our current product candidates into early or later-stage clinical trials, successfully commercialize one or more of our product candidates, or acquire new product candidates for development, we may have difficulty attracting investors that might otherwise be a source of additional financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2021, we entered into the Loan and Security Agreement with SVB. The Loan and Security Agreement provided for an initial term loan of $25.0 million funded at the closing, with an additional tranche of $25.0 million available if certain funding and clinical milestones were met by August 31, 2022. In connection with the initial borrowing, we also issued warrants to SVB and certain of its affiliates for the purchase of up to 432,844 shares of our common stock, in the aggregate, at an exercise price of $2.22 per share. The Loan and Security Agreement was subsequently amended, effective December 28, 2021, to, among other things, eliminate the additional tranche so that the $25.0 million we have drawn down is the full amount available under the SVB Facility. As a result, we do not have any other borrowings available under the SVB Facility. In connection with entering into the Amendment we also amended and restated the warrants. These amended and restated warrants provide for the purchase of up to 649,615 shares of our common stock, in the aggregate, at an exercise price of $1.16 per share. The Amended Loan and Security Agreement also required us to cash collateralize half of the sum of the then-outstanding principal amount of the SVB Facility, plus an amount equal to 5.75% of the original principal amount of the SVB Facility in the event we failed to achieve the Amended Milestones. We did not achieve the Amended Milestones and as of September 30, 2022, are required to hold $13.9 million in a restricted cash collateral account with SVB. The collateralized cash represents a significant portion of our cash and cash equivalents that we are not able to access to fund our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that we raise additional capital by issuing equity securities, our existing stockholders&#x2019; ownership will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, creating liens, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">*We have incurred indebtedness that could adversely affect our business and place restrictions on our operating and financial flexibility.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Amended Loan and Security Agreement contains customary affirmative and negative covenants and events of default applicable to us and any subsidiaries. The affirmative covenants require us (and us to cause our subsidiaries, if any) to maintain governmental approvals, deliver certain financial reports, maintain insurance coverage, and protect material intellectual property, among other things. The negative covenants restrict our and our subsidiaries&#x2019; ability to, among other things, transfer collateral, change our business, engage in mergers or acquisitions, incur additional indebtedness, pay cash dividends or make other distributions, make investments, create liens, sell assets and make any payment on subordinated debt. The restrictive covenants of the Amended Loan and Security Agreement could cause us to be unable to pursue business opportunities that we or our stockholders may consider beneficial, including entering into certain licensing arrangements, maintaining flexible cash management arrangements and engaging in certain change in control transactions, among others.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our debt combined with our other financial obligations and contractual commitments could have significant adverse consequences for our business, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Requiring us to dedicate a substantial portion of cash flows to payment on our debt, which would reduce available funds for further research and development;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increasing the amount of interest that we must pay on debt with variable interest rates, if market rates of interest increase;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subjecting us to restrictive covenants that reduce our ability to take certain corporate actions, acquire companies, products or technology, or obtain further debt financing; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Requiring us to pledge our non-intellectual property assets as collateral, which could limit our ability to obtain additional debt financing.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to satisfy our debt service obligations with our existing cash and cash equivalents and any additional amounts we may raise through future debt and equity financings. Our ability to make payments due under the SVB Facility depends on our future performance, which is subject to economic, financial, competitive conditions and other factors beyond our control. We may not have sufficient funds or may be unable to arrange for additional financing to pay the amounts due under our existing debt. In addition, the Amended Loan and Security Agreement requires us to deposit unrestricted and unencumbered cash equal to 50% of the principal amount of the SVB Facility then outstanding and an amount equal to 5.75% of the original principal amount in a cash collateral account with SVB. As of September 30, 2022 we deposited $13.9 million in cash into the cash collateral account pursuant to the terms of the Amended Loan and Security Agreement. Failure to pay any amount due under the SVB Facility, to comply with covenants under the Amended Loan and Security Agreement, or the occurrence of an event that would reasonably be expected to have a material adverse effect on our business, operations, or condition (financial or otherwise), would result in an event of default. The occurrence and continuation of an event of default could cause interest to be charged at the rate that is otherwise applicable plus 3.00% (unless SVB elects to impose a smaller increase) and would provide SVB with the right to accelerate all obligations under the SVB Facility and exercise remedies against us and the collateral securing the SVB Facility and other obligations under the Amended Loan and Security Agreement, including foreclosure against assets securing the SVB Facility. In addition, the covenants under the Amended Loan and Security Agreement and the pledge of substantially all of our assets, excluding our intellectual property (which is subject to a negative pledge under the Amended Loan and Security Agreement), as collateral on the loan may limit our ability to obtain additional debt financing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">*We have previously identified material weaknesses in our internal control, all of which have been remediated. We may identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of our financial statements or could have a material adverse effect on our business and trading price of our securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and the rules and regulations of the Nasdaq Global Select Market. Pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to perform system and process evaluation and testing of our internal control over financial reporting to allow our management to report on the effectiveness of our internal control over financial reporting. We may also be required to have our independent registered public accounting firm issue an opinion on the effectiveness of our internal control over financial reporting on an annual basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have identified material weaknesses in our internal control over financial reporting in the past. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although the material weaknesses identified in the past have been remediated, we cannot assure you that any measures we have taken or may take in the future will be sufficient to avoid potential future material weaknesses. If we are unable to successfully remediate any future material weakness and maintain effective internal controls, we may not have adequate, accurate or timely financial information, and we may be unable to meet our reporting obligations as a public company, including the requirements of the Sarbanes-Oxley Act, we may be unable to accurately report our financial results in future periods, or report them within the timeframes required by the requirements of the SEC, Nasdaq or the Sarbanes-Oxley Act. Failure to comply with the Sarbanes-Oxley Act, when and as applicable, could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in the identification of additional material weaknesses or significant deficiencies, cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. Furthermore, if we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed and investors could lose confidence in our reported financial information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our plans to develop and commercialize non-viral adoptive TCR-T cell therapies can be considered a new approach to cancer treatment, the successful development of which is subject to significant challenges.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to employ technologies such as the technology licensed from MD Anderson pursuant to that certain license agreement between us, Precigen, and MD Anderson, with an effective date of January 13, 2015, or the MD Anderson License, which was subsequently assigned by Precigen and assumed by PGEN effective as of January 1, 2018, from PGEN, pursuant to the License Agreement, and from NCI, pursuant to the Patent License described above, to pursue the development and commercialization of non-viral cellular therapies based on T-cells and TCRs, targeting solid tumor malignancy. Because this is a new approach to cancer immunotherapy and cancer treatment generally, developing and commercializing product candidates subjects us to a number of challenges, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining regulatory approval from the FDA and other regulatory authorities that have very limited experience with the commercial development of genetically modified T-cell therapies for cancer; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">designing and conducting our clinical trials using this new approach or selecting the appropriate TCRs in a way that may lead to optimal results; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identifying and manufacturing appropriate TCRs from either the patient or third parties that can be administered to a patient; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing and deploying consistent and reliable processes for engineering a patient&#x2019;s and/or donor&#x2019;s T-cells ex vivo and infusing the T cells back into the patient; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">conditioning patients with chemotherapy in conjunction with delivering each of the potential products, which may increase the risk of adverse side effects of the potential products; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">educating medical personnel regarding the potential side effect profile of each of the potential products, such as the potential adverse side effects related to cytokine release; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addressing any competing technological and market developments; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing processes for the safe administration of these potential products, including long-term follow-up for all patients who receive the potential products; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sourcing additional clinical and, if approved, commercial supplies for the materials used to manufacture and process the potential products; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing a manufacturing process with a cost of goods that allows for an attractive return on investment; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing sales and marketing capabilities after obtaining any regulatory approval to gain market acceptance; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing therapies for types of cancers beyond those addressed by the current potential products; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintaining and defending the intellectual property rights relating to any products we develop; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not infringing the intellectual property rights, in particular, the patent rights, of third parties, including competitors, such as those developing T-cell therapies. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot assure you that we will be able to successfully address these challenges, which could prevent us from achieving our research, development and commercialization goals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our current product candidates are based on novel technologies and are supported by limited clinical data and we cannot assure you that our current and planned clinical trials will produce data that supports regulatory approval of one or more of these product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our genetically modified TCR-T cell product candidates are supported by limited clinical data, all of which has been generated through trials conducted by MD Anderson and the NCI, not by us. We have assumed control of the overall clinical and regulatory development of our TCR-T cell product candidates, and any failure to obtain, or delays in obtaining, sponsorship of new INDs, or in filing INDs sponsored by us for these or any other product candidates we determine to advance could negatively affect the timing of our potential future clinical trials. Such an impact on timing could increase research and development costs and could delay or prevent obtaining regulatory approval for our product candidates, either of which could have a material adverse effect on our business. We began enrolling patients in our TCR-T Library Phase 1/2 Trial in January 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, we did not control the design or conduct of the previous trials. It is possible that the FDA will not accept these previous trials as providing adequate support for future clinical trials, whether controlled by us or third parties, for any of one or more reasons, including the safety, purity and potency of the product candidate, the degree of product characterization, elements of the design or execution of the previous trials or safety concerns or other trial results. We may also be subject to liabilities arising from any treatment-related injuries or adverse effects in patients enrolled in these previous trials. As a result, we may be subject to unforeseen third-party claims and delays in our potential future clinical trials. We may also be required to repeat in whole or in part clinical trials previously conducted by MD Anderson or other entities, which will be expensive and delay the submission and licensure or other regulatory approvals with respect to any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, there are a number of regulatory requirements that we must continue to satisfy as we conduct our clinical trials of TCR-T cell product candidates in the United States. The criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products and change frequently. Satisfaction of these requirements will entail substantial time, effort and financial resources. To date, the FDA has approved only a few adoptive cell therapies for commercialization. Because adoptive cell therapies are relatively new and our product candidates employ novel gene expression and cell technologies, regulatory agencies may lack experience in evaluating product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">candidates like our Library TCR-T product candidates. This novelty may heighten regulatory scrutiny of our therapies or lengthen the regulatory review process, including the time it takes for the FDA to review our IND applications if and when submitted, increase our development costs and delay or prevent commercialization of our product candidates. These factors make it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates. Any time, effort and financial resources we expend on our clinical product candidates and other early-stage product development programs, which are ultimately not successful may adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">*We report interim data on certain of our clinical trials and we cannot assure you that interim data will be predictive of either future interim results or final study results. In addition, the results ultimately obtained from our preclinical studies or other earlier clinical trials for our product candidates may not be predictive of future results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of our business, we provide updates related to the development of our product candidates, which may include updates related to interim clinical trial data. We anticipate that our clinical trials will involve small patient populations and because of the small sample size, the interim results of these, and all, clinical trials may be subject to substantial variability and may not be indicative of either future interim results or final results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We commenced enrollment in our TCR-T Library Phase 1/2 Trial in January 2022 and announced early clinical data for the first patient in September 2022. We do not know at this stage whether patient response data from additional patients in this trial will be favorable, and initial success in clinical trials may not be indicative of results obtained when such trials are completed. Our product candidates may fail to show the desired safety and efficacy in clinical development, and we cannot assure you that the results of any future trials will demonstrate the value and efficacy of our product candidates. Even if our clinical trials are completed as planned, we cannot be certain that their results will support approval of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are no approved engineered TCR-T cell immunotherapies for solid tumors. We believe our product candidates may be effective against solid tumors and plan to develop product candidates for use in solid tumors. We cannot guarantee that our product candidates will be able to access the solid tumor or show any functionality in the solid tumor microenvironment. The cellular environment in which solid tumor cells thrive is generally hostile to T cells due to factors such as the presence of immunosuppressive cells, humoral factors and limited access to nutrients. In addition, the safety profile of our product candidates may differ in a solid tumor setting. If we are unable to make our product candidates function in solid tumors, our development plans and business will be significantly harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously announced. Negative differences between preliminary or interim data and final data could materially adversely affect the prospects of any product candidate that is impacted by such data updates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the results of any preclinical studies for our product candidates may not be predictive of the results of clinical trials. For example, preclinical models as applied to cell therapy in oncology do not adequately represent the clinical setting, and thus cannot predict clinical activity nor all potential risks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">*We will need to attract, recruit and retain qualified personnel and we will continue to rely on key scientific and medical advisors, and their knowledge of our business and technical expertise would be difficult to replace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2021, we experienced transitions in our senior management including the appointment of Kevin S. Boyle, Sr. as Chief Executive Officer and a member of the board of directors in August 2021 and the hiring of Michael Wong as our Vice President, Finance in September 2021 and his appointment as principal accounting officer in November 2021. In November 2021, we hired Melinda Lackey as our Senior Vice President, Legal, and in August 2022, we hired Abhishek Srivastava as our Vice President, Technical Operations. Management transition is often difficult and inherently causes some loss of institutional knowledge.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may not be able to attract or retain qualified management and commercial, scientific and clinical personnel due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are highly dependent on our principal scientific, regulatory and medical advisors. The loss of any of our key personnel, could result in delays in product development, loss of key personnel or partnerships and diversion of management resources, which could adversely affect our operating results. We do not carry &#x201c;key person&#x201d; life insurance policies on any of our officers or key employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">*We face substantial competition from other biopharmaceutical companies, which may result in others discovering, developing or commercializing products before, or more successfully than, we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our TCR-T cell therapies targeting solid tumors face significant competition from multiple companies, and their collaborators, in the TCR and CAR technology space. We face competition from several companies, including 2Seventy Bio, Achilles Therapeutics, Annoca, Adaptimmune Therapeutics, Affini-T Therapeutics, ArsenalBio, BioNTech, Bristol-Myers Squibb, Immatics, Iovance</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biotherapeutics, Lion TCR, Lyell Immunopharma, Medigene, Nurix Therapeutics, Neogene Therapeutics, NexImmune, PACT Pharma, Precigen, Tactiva Therapeutics, Takara Bio, TCR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Therapeutics, T-Cure BioScience, T-knife Therapeutics, Tmunity Therapeutics, Triumvira Immunologics, TScan Therapeutics, Turnstone Biologics, Zelluna Immunotherapy and others. Many of these companies are either investigating TCR-T cells against germline antigens or are utilizing tumor infiltrating lymphocytes. Some are pursuing CAR-T cells for solid tumors. In contrast, we are focused on developing TCR-T cell products against neoantigens arising from somatic mutations in solid tumors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Companies in the T-cell therapy segment that we believe to have target discovery platforms like ours include Adaptive Biotechnologies, Affini-T Therapeutics, Enara Bio, Immatics, Neogene, T-knife Therapeutics, TScan Therapeutics and 3T Biosciences. Several companies, including Advaxis, Amgen, BioNTech, Geneos Therapeutics, and Gritstone, are pursuing vaccine platforms to target neoantigens for solid tumors. Other companies are developing non-viral gene therapies, including Poseida Therapeutics and several companies developing CRISPR technology, including Crispr Therapeutics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Several companies are pursuing the development of allogeneic CAR-T therapies, including Allogene Therapeutics, Atara Biotherapeutics and Precision Biosciences, which may compete with our product candidates. We also face competition from companies developing therapies using cells other than T cells such as Athenex, Fate Therapeutics, ImmunityBio, IN8bio, Nkarta Therapeutics, and Takeda Pharmaceutical. Other competitors are developing T cells with cytokines such as Fate Therapeutics and Obsidian Therapeutics. Finally, we also face competition from non-cellular treatments offered by other companies such as Amgen, AstraZeneca, Bristol-Myers Squibb, Incyte, Merck, and Roche. Additionally, our ability to pursue partnerships relating to our IL-12 and CAR-T programs may be impacted by substantial competition from these and other biopharmaceutical companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we obtain regulatory approval of potential TCR products, we may not be the first to market and that may affect the price or demand for our potential products. Existing or future competing products may provide greater therapeutic convenience or clinical or other benefits for a specific indication, or fewer side effects, than our potential products or may offer comparable performance at a lower cost. Additionally, the availability and price of our competitors&#x2019; products could limit the demand and the price we are able to charge for our potential products thereby reducing or eliminating our commercial opportunity. We may not be able to implement our business plan if the acceptance of our potential products is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our potential products, or if physicians switch to other new drug or biologic products or choose to reserve our potential products. Additionally, a competitor could obtain orphan product exclusivity from the FDA with respect to such competitor&#x2019;s product. If such competitor product is determined to be the same product as one of our potential products, that may prevent us from obtaining approval from the FDA for such potential products for the same indication for seven years, except in limited circumstances. If our potential products fail to capture and maintain market share, we may not achieve sufficient product revenues and our business will suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We compete against fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies and other public and private research organizations. Many of these competitors have products already approved or in development. In addition, many of these competitors, either alone or together with their collaborative partners, operate larger research and development programs or have substantially greater financial resources than we do, as well as significantly greater experience in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing drugs and biopharmaceuticals; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">undertaking preclinical testing and human clinical trials; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining FDA and other regulatory approvals of drugs and biopharmaceuticals; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">formulating and manufacturing drugs and biopharmaceuticals; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">launching, marketing and selling drugs and biopharmaceuticals. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any termination of our licenses with PGEN, MD Anderson or the National Cancer Institute or our research and development agreements with MD Anderson and the National Cancer Institute could result in the loss of significant rights and could harm our ability to develop and commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are dependent on patents, know-how, and proprietary technology that are licensed from others, particularly MD Anderson, PGEN, and the NCI, as well as the contributions by MD Anderson under our research and development agreements. Any termination of these licenses or research and development agreements could result in the loss of significant rights and could harm our ability to commercialize our product candidates. Disputes may also arise between us and these licensors regarding intellectual property subject to a license agreement, including those relating to:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of rights granted under the applicable license agreement and other interpretation-related issues; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether and the extent to which our technology and processes, and the technology and processes of PGEN, MD Anderson, the NCI and our other licensors, infringe intellectual property of the licensor that is not subject to the applicable license agreement; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our right to sublicense patent and other rights to third parties pursuant to our relationships with our licensors and partners; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether we are complying with our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our potential products under the MD Anderson License, the License Agreement with PGEN and our patent license agreement with the NCI; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether or not our partners are complying with all of their obligations to support our programs under licenses and research and development agreements; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the allocation of ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and by us. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements, particularly with MD Anderson, PGEN and the NCI, on acceptable terms, we may be unable to successfully develop and commercialize the affected potential products. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize potential products under our applicable licenses could suffer. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, and reexamination proceedings before the United States Patent and Trademark Office, or USPTO, or oppositions and other comparable proceedings in foreign jurisdictions. Recently, due to changes in U.S. law referred to as patent reform, new procedures including </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review and post-grant review have been implemented, which adds uncertainty to the possibility of challenge to our or our licensors&#x2019; patents in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to retain the rights licensed to us and PGEN by MD Anderson or the rights licensed to us by the National Cancer Institute to technologies relating to TCR-T cell therapies and other related technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the MD Anderson License, we, together with PGEN, received an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR-T cell and TCR-T cell therapies as well as either co-exclusive or non-exclusive licenses under certain related technologies. These proprietary methods and technologies, along with others within PGEN&#x2019;s technology suite and licensed to us by PGEN, may help realize the promise of genetically modified TCR-T cell therapies by controlling cell expansion and activation in the body, minimizing off-target and unwanted on-target effects and toxicity while maximizing therapeutic efficacy. The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term, we and PGEN shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After 10 years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if we and PGEN are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if we and PGEN are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by us or PGEN, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both us or PGEN and may be terminated by the mutual written agreement of us, PGEN and MD Anderson.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Patent License, we received an exclusive, worldwide license to certain intellectual property and patents from NCI for TCRs we can introduce into T cells using transposon-based genetic engineering. These T cells may be used in our TCR-T Library Phase 1/2 Trial or in subsequent clinical trials, if initiated. The term of the Patent License shall expire with the last of the licensed patents. The NCI could terminate or modify the Patent License if it believes we have materially breached, by failing to meet the defined milestones by the required dates, or upon certain insolvency events that are not cured within the 90-day time limit once we are notified of such alleged breach. The Patent License is also subject to certain public use requirements wherein the NCI could require us to sublicense certain product candidates or terminate or modify the Patent License if we do not meet these public use requirements. The Patent License could also be terminated by the NCI if we are unable to pay the required benchmark payments or the annual minimum royalty payments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There can be no assurance that we will be able to successfully perform under the MD Anderson License or the Patent License and if the MD Anderson License or the Patent License is terminated it may prevent us from achieving our business objectives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">*We are partly reliant on the National Cancer Institute for research and development and early clinical testing of certain of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A portion of our research and development is being conducted by the NCI under the CRADA entered into in January 2017 and which was amended in March 2018, February 2019, March 2022 and June 2022. Under the CRADA, the NCI, with Dr. Steven A. Rosenberg as the principal investigator, is responsible for conducting a clinical trial using the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">system to express TCRs for the treatment of solid tumors. We have limited control over the nature or timing of the NCI&#x2019;s clinical trial and limited visibility into their day-to-day activities, including with respect to how they are providing and administering T-cell therapy. For example, the research we are funding constitutes only a small portion of the NCI&#x2019;s overall research. Additionally, other research being conducted by Dr. Rosenberg may at times receive higher priority than research on our program. The progress and timeline, including the timeline for dosing patients, for this trial are under the control of the NCI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The CRADA expired by its terms on January 9, 2022. In March 2022, we entered into an amendment to the CRADA that is retroactive, effective January 9, 2022 to extend the term of the CRADA until January 9, 2023. In June 2022, we entered into the Fourth Amendment to the CRADA (the &#34;CRADA Fourth Amendment&#34;) which, among other things, extended the term of the CRADA until January 9, 2025.  In connection with the CRADA Fourth Amendment, the Company agreed to contribute $1.0 million per year, payable on a quarterly basis, beginning in the first quarter of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to commercialize any products, generate significant revenues, or attain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, none of our product candidates have been approved for commercial sale in any country. The process to develop, obtain regulatory approval for, and commercialize potential product candidates is long, complex and costly. Unless and until we receive approval from the FDA and/or other foreign regulatory authorities for our product candidates, we cannot sell our products and will not have product revenues. Even if we obtain regulatory approval for one or more of our product candidates, if we are unable to successfully commercialize our products, we may not be able to generate sufficient revenues to achieve or maintain profitability or to continue our business without raising significant additional capital, which may not be available. Our failure to achieve or maintain profitability could negatively impact the trading price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our operating history makes it difficult to evaluate our business and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not previously completed any pivotal clinical trials, submitted a BLA or demonstrated an ability to perform the functions necessary for the successful commercialization of any product candidates. The successful commercialization of any product candidates will require us to perform a variety of functions, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Continuing to undertake preclinical development and clinical trials; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Participating in regulatory approval processes; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Formulating and manufacturing products; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conducting sales and marketing activities. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations have been limited to organizing and staffing our company, acquiring, developing and securing our proprietary product candidates and undertaking preclinical and clinical trials of our product candidates. These operations provide a limited basis for you to assess our ability to commercialize our product candidates and the advisability of investing in our securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in establishing development and commercialization collaborations, which failure could adversely affect, and potentially prohibit, our ability to develop our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Developing biopharmaceutical products and complementary technologies, conducting clinical trials, obtaining marketing approval, establishing manufacturing capabilities and marketing approved products is expensive, and therefore, we anticipate exploring collaborations with third parties that have alternative technologies, more resources and more experience than we do. In situations where we enter into a development and commercial collaboration arrangement for a product candidate or complementary technology, we may also seek to establish additional collaborations for development and commercialization in territories outside of those addressed by the first collaboration arrangement for such product candidate or technology. There are a limited number of potential partners, and we expect to face competition in seeking appropriate partners. If we are unable to enter into any development and commercial collaborations and/or sales and marketing arrangements on reasonable and acceptable terms, if at all, we may be unable to successfully develop and seek regulatory approval for our product candidates and/or effectively market and sell future approved products, if any, in some or all of the territories outside of the United States where it may otherwise be valuable to do so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to successfully manage our growth as we expand our development and regulatory capabilities, which could disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we advance our product candidates to the point of, and through, clinical trials, we will need to expand our development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide for these capabilities. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To manage this growth, we must expand our facilities, augment our operational, financial and management systems and hire and train additional qualified personnel with expertise in preclinical and clinical research and testing, manufacturing, government regulation and eventually sales and marketing. Competition for qualified individuals is intense among numerous biopharmaceutical companies, universities, and other research institutions and we cannot be certain that our search will be successful. If we are unable to manage our growth effectively, including attracting and retaining qualified personnel, our business may be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restructuring activities could disrupt our business and effect our results of operations. In addition, we may not achieve anticipated benefits and saving from such restructuring activities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2021, we announced a restructuring enabling us to focus on and enhance our TCR program. We eliminated approximately 60 positions, representing more than 50% of our workforce. The restructuring resulted in the loss of institutional knowledge and expertise and the reallocation of and combination of certain roles and responsibilities across the organization, all of which could adversely affect our operations. Further, the restructuring and possible additional cost-containment measures may yield unintended consequences, such as attrition beyond our intended workforce reduction and reduced employee morale. In addition, we may not achieve anticipated benefits from the restructuring. Due to our limited resources, we may not be able to effectively manage our operations or retain qualified personnel, which may result in weaknesses to our infrastructure and operations, risks that we may be unable to comply with legal and regulatory requirements, and loss of employees and reduced productivity among remaining employees. For example, the workforce reduction may negatively impact our clinical, manufacturing and regulatory functions, which would have a negative impact on our ability to successfully develop and, ultimately, commercialize our product candidates. If our management is unable to successfully manage this transition and restructuring activities, our expenses may be more than expected and we may be unable to implement our business strategy. As a result, our future financial performance and our ability to commercialize our product candidates successfully would be negatively affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business will subject us to the risk of liability claims associated with the use of hazardous materials and chemicals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our contract research and development activities may involve the controlled use of hazardous materials and chemicals. Although we believe that our safety procedures for using, storing, handling and disposing of these materials comply with federal, state and local laws and regulations, we cannot completely eliminate the risk of accidental injury or contamination from these materials. In the event of such an accident, we could be held liable for any resulting damages, and any liability could have a materially adverse effect on our business, financial condition, and results of operations. In addition, the federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous or radioactive materials and waste products may require our contractors to incur substantial compliance costs that could materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The testing and marketing of medical products entail an inherent risk of product liability, and we will face an even greater risk if we commercially sell any medicines that we may develop. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products, if approved. Even a successful defense would require significant financial and management resources. Regardless of the merit or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Decreased demand for our product candidates; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Injury to our reputation; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initiation of investigations by regulators;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Withdrawal of prior governmental approvals; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs of related litigation; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantial monetary awards to patients; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product recalls; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss of revenue; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The inability to commercialize our product candidates; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A decline in our share price. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we currently carry clinical trial insurance and product liability insurance which we believe to be reasonable, it may not be adequate to cover all liability that we may incur. An inability to renew our policies or to obtain sufficient insurance at an acceptable cost could prevent or inhibit the commercialization of pharmaceutical products that we develop, alone or with collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations, and those of our clinical investigators, contractors and consultants, are based primarily in Houston, Texas. These operations could be subject to power shortages, telecommunications failures, water shortages, hurricanes, floods, earthquakes, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we maintain customary insurance policies that we believe are appropriate. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. Our ability to manufacture clinical supplies of our product candidates could be disrupted if our own operations or those of our suppliers are affected by a man-made or natural disaster or other business interruption. We may have limited recourse against third parties if the non-compliance is due to factors outside of the manufacturer&#x2019;s control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be unable to find appropriate partners to continue the development of the product candidates we de-prioritized in 2021 which may prevent us from ever deriving meaningful revenue from them.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2021, we elected to prioritize our Library TCR-T program and significantly reduced our activities in connection with our Controlled IL-12 and CAR-T programs to preserve our capital resources. The decision to significantly reduce activities for our Controlled IL-12 and CAR-T programs may negatively impact the potential for these programs, which could have a material adverse effect on our business. We are actively exploring partnership opportunities for our Controlled IL-12 and CAR-T programs to support their continued development. If we are unable to identify an appropriate strategic partner or to negotiate and consummate a license or sale agreement with such a partner, it will be difficult to advance the development of these two programs, increasing the likelihood that we may be unable to derive any meaningful revenue from these assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have also mutually agreed with TriArm Therapeutics Ltd., or TriArm, to dissolve the Eden BioCell joint venture.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business, operations and clinical development plans and timelines could be adversely affected by the effects of health epidemics, including the COVID-19 pandemic, on the manufacturing, clinical trial and other business activities performed by us or by third parties with whom we conduct business, including our contract manufacturers, CROs, shippers and others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business could be adversely affected by health epidemics wherever we have clinical trial sites or other business operations. In addition, health epidemics could cause significant disruption in our manufacturing operations or the operations of third-party manufacturers, CROs and other third parties upon whom we rely or may rely on in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We depend on a worldwide supply chain to manufacture products used in our preclinical studies and clinical trials. Quarantines, shelter-in-place and similar government orders, or the expectation that such orders, shutdowns or other restrictions could occur, whether related to COVID-19 or other infectious diseases, could impact personnel at our own manufacturing facilities or third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which could disrupt our supply chain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our relationships with our suppliers or other vendors are terminated or scaled back as a result of the COVID-19 pandemic or other health epidemics, we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner. Switching or adding additional suppliers or vendors involves substantial cost and requires management&#x2019;s time and focus. In addition, there is a natural transition period when a new supplier or vendor commences work. As a result, delays may occur, which could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. Although we carefully manage our relationships with our suppliers and vendors, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our preclinical studies and our ongoing TCR-T Library Phase 1/2 Trial at MD Anderson have been and may continue to be affected by the COVID-19 pandemic. Patient enrollment and study visits have been and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic or concerns among patients about participating in clinical trials during a pandemic. Some patients may have difficulty following certain aspects of clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, if we are unable to successfully recruit and retain patients, principal investigators, and site staff who, as healthcare providers, may have heightened exposure to COVID-19 or experience additional restrictions by their institutions, city, or state, our clinical trial operations could be adversely impacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RISKS RELATED TO THE CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">*If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may experience difficulties in patient enrollment in our clinical trials, including our ongoing TCR-T Library Phase 1/2 Trial, for a variety of reasons, including impacts that have resulted or may result from the COVID-19 pandemic. The timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of patients who remain in the clinical trial until its conclusion. The enrollment of patients depends on many factors, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patient eligibility criteria defined in the clinical trial protocol;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The size of the patient population required for analysis of the clinical trial&#x2019;s primary endpoints;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The proximity of patients to clinical trial sites;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of clinical trial sites;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The design of the clinical trial;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to recruit and retain clinical trial investigators with the appropriate competencies and experience;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to obtain and maintain patient consents;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reporting of the preliminary results of any of our clinical trials; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The risk that patients enrolled in clinical trials will drop out of the clinical trials before the manufacturing and infusion of our product candidates or clinical trial completion.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some of our potential patients may instead opt to enroll in a clinical trial being conducted by one of our competitors. In addition, patients may be unwilling to participate in our studies because of negative publicity from adverse events in the biotechnology industry or for other reasons. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and hematopoietic stem cell transplantation, rather than enroll patients in any future clinical trial. Additionally, because some of our clinical trials are in patients with relapsed/refractory cancer, the patients are typically in the late stages of their disease and may experience disease progression independent from our product candidates, making them unevaluable for purposes of the clinical trial and requiring additional patient enrollment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delays in completing patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing and planned clinical trials, which could prevent completion or commencement of these clinical trials and adversely affect our ability to advance the development of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The clinical development, manufacturing, labeling, packaging, storage, record-keeping, advertising, promotion, import, export, marketing, distribution and adverse event reporting, including the submission of safety and other information, of our product candidates are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in foreign markets. The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials. Approval policies or regulations may change, and the FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Regulatory approval is never guaranteed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective, or with respect to a biological product candidate, safe, pure and potent, for their intended uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such authorities may disagree with the design or implementation of our or our current or future collaborators&#x2019; clinical trials;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs or biologics similar to our therapeutic product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We, or any of our current or future collaborators, may be unable to demonstrate that a product candidate is safe and effective, and that the therapeutic product candidate&#x2019;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be unable to demonstrate to the satisfaction of such authorities that our companion diagnostics are suitable to identify appropriate patient populations;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of a BLA, NDA, premarket approval, or PMA, or other submission or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such authorities may find deficiencies in the manufacturing processes, test procedures and specifications or facilities of our third-party manufacturers with which we or any of our current or future collaborators contract for clinical and commercial supplies;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulations and approval policies of such authorities may significantly change in a manner rendering our or any of our potential future collaborators&#x2019; clinical data insufficient for approval; or</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. In addition, even if we obtain approval of our product candidates, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a Risk Evaluation and Mitigation Strategy, or REMS.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Events raising questions about the safety of certain marketed biopharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new drugs or biologics based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are very early in our development efforts. Our most advanced product candidates are only in an early-stage clinical trial, which is very expensive and time-consuming. We cannot be certain when we will be able to submit a BLA to the FDA and any failure or delay in completing clinical trials for our product candidates could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates are in various stages of development and require extensive clinical testing. Our most advanced product candidates are in our TCR-T Library Phase 1/2 Trial, which is currently enrolling and treating patients. Human clinical trials are very expensive and difficult to design, initiate and implement, in part because they are subject to rigorous regulatory requirements. Notwithstanding our current clinical trial plans for each of our existing product candidates, which we estimate will take several years to complete, we may not be able to commence additional trials or see results from these trials within our anticipated timelines. Failure can occur at any stage of a clinical trial, and we can encounter problems that cause us to delay the start of, abandon or repeat clinical trials. Some factors which may lead to a delay in the commencement or completion of our clinical trials include: requests for additional nonclinical data from regulators, unforeseen safety issues, dosing issues, lack of effectiveness during clinical trials, difficulty recruiting or monitoring patients, difficulty manufacturing clinical products, among other factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As they enter later stages of development, our product candidates generally will become subject to more stringent regulatory requirements, including the FDA&#x2019;s requirements for chemistry, manufacturing and controls for product candidates entering Phase 3</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trials. There is no guarantee the FDA will allow us to commence Phase 3 clinical trials for product candidates studied in earlier clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the FDA does not allow our product candidates to enter later stage clinical trials or requires changes to the formulation or manufacture of our product candidates before commencing Phase 3 clinical trials, our ability to further develop, or seek approval for, such product candidates may be materially impacted. As such, we cannot predict with any certainty if or when we might submit a BLA for regulatory approval of our product candidates or whether such a BLA will be accepted. Because we do not anticipate generating revenues unless and until we submit one or more BLAs and thereafter obtain requisite FDA approvals, the timing of our BLA submissions and FDA determinations regarding approval thereof will directly affect if and when we are able to generate revenues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any potential marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As with many pharmaceutical and biological products, treatment with our product candidates may produce undesirable side effects or adverse reactions or events, including potential adverse side effects related to cytokine release. If our product candidates or similar products or product candidates under development by third parties demonstrate unacceptable adverse events, we may be required to halt or delay further clinical development of our product candidates. The FDA or other foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. If a serious adverse event was to occur in our TCR-T Library Phase 1/2 Trial, the FDA may place a hold on the clinical trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The product-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately or timely recognized or managed by the treating medical staff, particularly outside of the institutions that collaborate with us, as toxicities resulting from our novel technologies may not be normally encountered in the general patient population and by medical personnel. We expect to have to train medical personnel using our product candidates to understand their side effect profiles, both for our planned clinical trials and upon any commercialization of any product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in adverse effects to patients, including death. Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our products candidates, a number of potentially significant negative consequences could result, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may withdraw approvals of such product; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require additional warnings on the product&#x2019;s label; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to create a risk evaluation and mitigation strategy plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of the foregoing could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved. Furthermore, any of these occurrences may harm our business, financial condition and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our cellular therapy immuno-oncology product candidates rely on the availability of reagents, specialized equipment and other specialty materials and infrastructure, which may not be available to us on acceptable terms or at all. For some of these reagents, equipment and materials, we rely or may rely on sole source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing our product candidates will require many reagents, which are substances used in our manufacturing processes to bring about chemical or biological reactions, and other specialty materials and equipment, some of which are manufactured or supplied by small companies with limited resources and experience to support commercial biologics production. We currently depend on a limited number of vendors for certain materials and equipment used in the manufacture of our product candidates, including the DNA plasmids used, which are used as the vector to insert our TCRs into human T cells. Some of these suppliers may not have the capacity to support commercial products manufactured under current good manufacturing practices by biopharmaceutical firms or may otherwise be ill-equipped to support our needs. We also do not have supply contracts with many of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key materials and equipment to support clinical or commercial manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For some of these reagents, equipment, infrastructure, and materials, we rely and may in the future rely on sole source vendors or a limited number of vendors. An inability to continue to source product from any of these suppliers, which could be due to regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands, or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, some of the reagents and products used by us, including in our clinical trials, may be stored at a single vendor. The loss of materials located at a single vendor, or the failure of such a vendor to manufacture clinical product in accordance with our specifications, would impact our ability to conduct ongoing or planned clinical trials and continue the development of our products. Further, manufacturing replacement material may be expensive and require a significant amount of time, which may further impact our clinical programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we continue to develop and scale our manufacturing process, we expect that we will need to obtain additional rights to and supplies of certain materials and equipment to be used as part of that process. We may not be able to maintain rights to such materials on commercially reasonable terms, or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such materials or find a suitable substitute, it would have a material adverse effect on our business. Even if we are able to alter our process so as to use other materials or equipment, such a change may lead to a delay in our clinical development and/or commercialization plans. If such a change occurs for a product candidate that is already in clinical trials, the change may require us to perform both ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Because we are dependent, at least in part, upon clinical research institutions and other CROs for clinical testing and/or for research and development activities, the results of our clinical trials and such research activities are, to a certain extent, beyond our control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We materially rely upon independent investigators and collaborators, such as universities and medical institutions, to conduct our clinical trials under agreements with us. In addition, we hire CROs to help us manage clinical trials, collect data and analyze clinical samples. These collaborators are not our employees, and we cannot control the amount or timing of resources that they devote to our programs. These investigators may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves. If outside collaborators fail to devote sufficient time and resources to our product development programs, or if their performance is substandard, the approval of our FDA applications, if any, and our introduction of new products, if any, will be delayed. These institutions may also have, or implement in the future, policies and procedures that limit their ability to advance our programs. These collaborators may also have relationships with other commercial entities, some of whom may compete with us. If our collaborators assist our competitors to our detriment, our competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have limited experience producing and supplying our product candidates. We may be unable to consistently manufacture our product candidates to the necessary specifications or in quantities necessary to treat patients in our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have limited experience in biopharmaceutical manufacturing. We recently began manufacturing our product candidates at our in-house cGMP manufacturing facility at our leased headquarters in Houston, Texas. Our ability to manufacture our product candidates depends on our finding and retaining personnel with the appropriate background and training to staff and operate the facility on a daily basis. Should we be unable to find or retain these individuals, we may need to train additional personnel to fill the needed roles or engage with external contractors. There are a small number of individuals with experience in cell therapy and the competition for these individuals is high.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specifically, the operation of a cell-therapy manufacturing facility is a complex endeavor requiring knowledgeable individuals who have successful previous experience in cleanroom environments. Cell therapy facilities, like other biological agent manufacturing facilities, require appropriate commissioning and validation activities to demonstrate that they operate as designed. Additionally, each manufacturing process must be proven through the performance of process validation runs to guarantee that the facility, personnel, equipment, and process work as designed. While we have developed our own manufacturing processes using an in-house team, there is timing risk associated with increased in-house product manufacture.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The manufacture of our product candidates is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of product candidates or in our manufacturing facilities, the manufacturing facilities may need to be closed for an extended period to investigate and remedy the contamination. It is possible that stability or other issues relating to the manufacture of our product candidates could occur in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates currently are and will continue to be manufactured on a patient-by-patient basis. Delays in manufacturing could adversely impact the treatment of each patient and may discourage participation in our current or future clinical trials. We have not yet manufactured our clinical trial product candidates on a large scale and may not be able to achieve large scale clinical trial or commercial manufacturing and processing on our own to satisfy expected clinical trial or commercial demands for any of our product candidates. While we believe that our current manufacturing and processing approaches are appropriate to support our early-stage clinical product development, we have limited experience in managing the T cell engineering process, and our processes may be more difficult or more expensive than anticipated. The manufacturing processes employed by us may not result in product candidates that will be safe and effective. If we are unable to manufacture sufficient number of TCR-T cells for our product candidates, our development efforts would be delayed, which would adversely affect our business and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our manufacturing operations will be subject to review and oversight by the FDA upon commencement of the manufacturing of our product candidates for our TCR-T Library Phase 1/2 Trial. We will be subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with current good manufacturing practices, or cGMP, and other government regulations. Our license to manufacture product candidates will be subject to continued regulatory review.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not yet have sufficient information to reliably estimate the cost of commercial manufacturing and processing of our product candidates. The actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also may fail to manage the logistics of collecting and shipping patient material to our manufacturing site and shipping the product candidate back to the patient. Logistical and shipment delays and problems, whether or not caused by us or our vendors, could prevent or delay the delivery of product candidates to patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, it is possible that we could experience manufacturing difficulties in the future due to resource constraints or because of labor disputes. If we were to encounter any of these difficulties, our ability to provide our product candidates to patients could be materially adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may have difficulty validating our manufacturing process as we manufacture our product candidates from an increasingly diverse patient population for our clinical trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During our development of the manufacturing process, our TCR-T cell product candidates have demonstrated consistency from lot to lot and from donor to donor. However, our sample size is small and the starting material used during our development work came from healthy donors. Once we have experience with working with white blood cells taken from our patient population, we may encounter unforeseen difficulties due to starting with material from donors who are not healthy, including challenges inherent in harvesting white blood cells from unhealthy patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we believe our current manufacturing process is scalable for our clinical trials, and if our any of our product candidates are approved or commercialized, we may encounter challenges in validating our process due to the heterogeneity of the product starting material. However, we anticipate that during the early phases of our clinical trials we will be able to adapt our process to account for these differences resulting in a more robust process. We cannot guarantee that any other issues relating to the heterogeneity of the starting material will not impact our ability to commercially manufacturing our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The gene transfer vectors from our Sleeping Beauty system used to manufacture our product candidates may incorrectly modify the genetic material of a patient&#x2019;s T cells, potentially triggering the development of a new cancer or other adverse events.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our TCR-T cells are manufactured using our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> system, a non-viral vector to insert genetic information encoding the TCR construct into the patient&#x2019;s T cells. The TCR construct is then primarily integrated at thymine-adenine, or TA, dinucleotide sites throughout the patient&#x2019;s genome and, once expressed as protein, is transported to the surface of the patient&#x2019;s T cells. Because the gene transfer vector modifies the genetic information of the T cell, there is a theoretical risk that modification will occur in the wrong place in the T cell&#x2019;s genetic code, leading to vector-related insertional oncogenesis, and causing the T cell to become cancerous. If the cancerous T cell is then administered to the patient, the cancerous T cell could trigger the development of a new cancer in the patient. We use non-viral vectors to insert genetic information into T cells, which we believe have a lower risk of insertional oncogenesis as opposed to viral vectors. However, the risk of insertional oncogenesis remains a concern for gene therapy, and we cannot assure that it will not occur in any of our ongoing or planned clinical trials. There is also the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of the vectors used to carry the genetic material. Although we use non-viral vectors, the FDA has stated that lentiviral vectors possess characteristics that may pose high risks of delayed adverse events. If any such adverse events occur from our non-viral vector, further advancement of our preclinical studies or clinical trials could be halted or delayed, which would have a material adverse effect on our business and operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any product candidate for which we obtain marketing approval could be subject to post-marketing restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include, among other things, submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS, which could include requirements for a restricted distribution system. If any of our product candidates receives marketing approval, the accompanying label may limit the approved uses, which could limit sales of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of our approved products. The FDA closely regulates the post-approval marketing and promotion of products to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. However, companies may share truthful and not misleading information that is otherwise consistent with the labeling. The FDA imposes stringent restrictions on manufacturers&#x2019; communications regarding off-label use and if we market our products outside of their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug and Cosmetic Act relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Litigation involving patients taking our product; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictions on such products, manufacturers or manufacturing processes; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictions on the labeling or marketing of a product; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictions on product distribution or use; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Requirements to conduct post-marketing studies or clinical trials; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warning letters; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Withdrawal of the products from the market; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recall of products; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fines, restitution or disgorgement of profits or revenues; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suspension or withdrawal of marketing approvals; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Damage to relationships with existing and potential collaborators; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unfavorable press coverage and damage to our reputation; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refusal to permit the import or export of our products; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product seizure; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncompliance with requirements regarding safety monitoring or pharmacovigilance can also result in significant financial penalties. Similarly, failure to comply with U.S. and foreign regulatory requirements regarding the development of products for pediatric populations and the protection of personal health information can also lead to significant penalties and sanctions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RISKS RELATED TO OUR ABILITY TO COMMERCIALIZE OUR PRODUCT CANDIDATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to obtain the necessary U.S. or worldwide regulatory approvals to commercialize any product candidate, our business will suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to obtain the approvals necessary to commercialize our product candidates, or any product candidate that we may acquire or develop in the future for commercial sale. We will need FDA approval to commercialize our product candidates in the United States and approvals from regulatory authorities in foreign jurisdictions equivalent to the FDA to commercialize our product candidates in those jurisdictions. In order to obtain FDA approval of any product candidate, we must submit to the FDA a BLA demonstrating that the product candidate is safe for humans and effective for its intended use. This demonstration requires significant research and animal tests, which are referred to as preclinical studies, as well as human tests, which are referred to as clinical trials. Satisfaction of the FDA&#x2019;s regulatory requirements typically takes many years, depending upon the type, complexity and novelty of the product candidate, and will require substantial resources for research, development and testing. We cannot predict whether our research, development, and clinical approaches will result in products that the FDA will consider safe for humans and effective for their intended uses. The FDA has substantial discretion in the approval process and may require us to conduct additional preclinical and clinical testing or to perform post-marketing studies. The approval process may also be delayed by changes in government regulation, future legislation or administrative action or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delay commercialization of, and our ability to derive product revenues from, our product candidates; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impose costly procedures on us; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diminish any competitive advantages that we may otherwise enjoy. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we comply with all FDA requests, the FDA may ultimately reject one or more of our BLAs. We cannot be sure that we will ever obtain regulatory approval for any of our product candidates. Failure to obtain FDA approval for our product candidates will severely undermine our business by leaving us without a marketable product, and therefore without any potential revenue source, until another product candidate can be developed. There is no guarantee that we will ever be able to develop or acquire another product candidate or that we will obtain FDA approval if we are able to do so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In foreign jurisdictions, we similarly must receive approval from applicable regulatory authorities before we can commercialize any of our product candidates. Foreign regulatory approval processes generally include all of the risks associated with the FDA approval procedures described above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable either to create sales, marketing and distribution capabilities or enter into agreements with third parties to perform these functions, we will be unable to commercialize our product candidates successfully.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have no marketing, sales, or distribution capabilities. If, and when we become reasonably certain that we will be able to commercialize our current or future product candidates, we anticipate allocating resources to the marketing, sales and distribution of our proposed products in North America and in certain other countries; however, we cannot assure that we will be able to market, sell, and distribute our products successfully. Our future success also may depend, in part, on our ability to enter into and maintain collaborative relationships for such capabilities and to encourage the collaborator&#x2019;s strategic interest in the products under development, and such collaborator&#x2019;s ability to successfully market and sell any such products. Although we intend to pursue certain collaborative arrangements regarding the sale and marketing of certain of our product candidates, there are no assurances that we will be able to establish or maintain collaborative arrangements or, if we are able to do so, whether we would be able to conduct our own sales efforts. There can also be no assurance that we will be able to establish or maintain relationships with third-party collaborators or develop in-house sales and distribution capabilities. To the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful. In addition, there can also be no assurance that we will be able to market and sell our product candidates in the United States or overseas.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are not able to partner with a third party and are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty commercializing our product candidates, which would harm our business. If we rely on pharmaceutical or biotechnology companies with established distribution systems to market our products, we will need to establish and maintain partnership arrangements, and we may not be able to enter into these arrangements on acceptable terms or at all. To the extent that we enter into co-promotion or other arrangements, any revenues we receive will depend upon the efforts of third parties that may not be successful and that will be only partially in our control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If physicians and patients do not accept and use our product candidates, once approved, our ability to generate revenue from sales of our products will be materially impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if the FDA and/or foreign equivalents thereof approve our product candidates, physicians and patients may not accept and use them. The use of engineered T cells as potential cancer treatments is a relatively recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community. Acceptance and use of our products will depend upon a number of factors including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The clinical indications for which our product candidates are approved;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our products; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The prevalence and severity of any side effects;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pharmacological benefit and cost-effectiveness of our products relative to competing products; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Availability of coverage and adequate reimbursement for our products from government or other third-party payors; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The price at which we sell our products. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we expect sales of our current product candidates, if approved, to generate substantially all of our product revenues for the foreseeable future, the failure of a product to find market acceptance would harm our business and could require us to seek additional financing in order to fund the development of future product candidates. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to generate product revenues will be diminished if our products do not obtain coverage and adequate reimbursement from payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to commercialize our product candidates, if approved, alone or with collaborators, will depend in part on the extent to which coverage and reimbursement will be available from third-party payors, including government and health administration authorities, private health maintenance organizations and health insurers and other payors. Patients who are prescribed medicine for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Sufficient coverage and adequate reimbursement from third-party payors are critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. It is difficult to predict the coverage and reimbursement decisions that will be made by third-party payors for novel gene and cell therapy products such as ours. Even if we obtain coverage for our product candidates, the resulting reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the market for our product candidates for which we may receive regulatory approval will depend significantly on access to third-party payors&#x2019; drug formularies or lists of medications for which third-party payors provide coverage and reimbursement, which might not include all of the FDA-approved drugs for a particular indication. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded drug in their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In addition, in the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that requires us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that approval will be obtained. If we are unable to obtain coverage of and adequate payment levels for our product candidates from third-party payors, physicians may limit how much or under what circumstances they will prescribe or administer our products and patients may decline to purchase them. This in turn could affect our ability to successfully commercialize our products and impact our profitability, results of operations, financial condition, and future success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in many foreign countries, particularly the countries of the European Union, or EU, the pricing of prescription drugs is subject to government control. In some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. We may face competition for our product candidates from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition, there may be importation of foreign products that compete with our own products, which could negatively impact our profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancer therapies are sometimes characterized as first line, second line or third line, and the FDA often approves new therapies initially only for third line use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, usually chemotherapy, hormone therapy, surgery, or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor targeted small molecules, or a combination of these. Third line therapies can include bone marrow transplantation, antibody and small molecule targeted therapies, more invasive forms of surgery and new technologies. We expect to initially seek approval of our product candidates as a third line therapy for patients who have failed other approved treatments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval as a second line therapy and potentially as a first line therapy, but there is no guarantee that our product candidates, even if approved, would be approved for second line or first line therapy. In addition, we may have to conduct additional clinical trials prior to gaining approval for second line or first line therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Our market opportunities may also be limited by competitor treatments that may enter the market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory enactments in recent years that change the healthcare system in ways that could impact our future ability to sell our product candidates profitably.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, there have been and continue to be a number of initiatives at the federal and state level that seek to reduce healthcare costs. Most significantly, in March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, which included measures that have significantly changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA of importance to the pharmaceutical industry are the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Created an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Created a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Extended manufacturers&#x2019; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Created new methodologies by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and for drugs that are line extensions; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals with income at or below 133% of the Federal Poverty Level, thereby potentially increasing both the volume of sales and manufacturers&#x2019; Medicaid rebate liability; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expanded the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Created a new requirement to annually report drug samples that certain manufacturers and authorized distributors provide to physicians; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expanded healthcare fraud and abuse laws, including the False Claims Act and the federal Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Created a licensure framework for follow-on biologic products; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Created new requirements under the federal Physician Payments Sunshine Act for certain drug manufacturers to annually report information related to payments and other transfers of value made to physicians, as defined by such law, and teaching hospitals as well as ownership or investment interests held by physicians and their immediate family members; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Created a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been executive, legal and political challenges to certain aspects of the ACA. For example, President Trump signed several executive orders and other directives designed to delay, circumvent or loosen certain requirements mandated by the ACA. Concurrently, Congress considered legislation to repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. In December 2017, Congress repealed the tax penalty, effective January 1, 2019, for an individual&#x2019;s failure to maintain ACA-mandated health insurance as part of the Tax Cuts and Jobs Act of 2017, or the Tax Act. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued that ACA is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health care coverage through the ACA marketplace, which began on February 21, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact ACA and our business. The ultimate content, timing or effect of any healthcare reform measures on the U.S. healthcare industry is unclear.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. As a result, there have been several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#x2019;s proposals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the U.S. Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 2023. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#x2019;s Most Favored Nation, or MFN, executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation, challenging the MFN model on August 10, 2021, CMS published a proposed rule that seeks to rescind the MFN model interim rule. In addition, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate price cap, currently set at 100% of a drug's average manufacturer price for single source and innovator multiple source products, beginning on January 1, 2024. Further, in July 2021, the Biden Administration released an executive order that included multiple provisions aimed at prescription drugs. In response to Biden's executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug price reform. The plan sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions by HHS. No legislative or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of the budget reconciliation process. Individual states in the United States also have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is possible that additional governmental action is taken in response to the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or, if we receive regulatory approval, commercialize our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a pharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#x2019; rights are and will be applicable to our business. For example, we could be subject to healthcare fraud and abuse and patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include, among others:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Anti-Kickback Statute, which regulates our business activities, including our clinical research and relationships with healthcare providers or other entities as well as our future marketing practices, educational programs and pricing policies, and by prohibiting, among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual or the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal civil and criminal false claims laws, including the False Claims Act, which permits a private individual acting as a &#x201c;whistleblower&#x201d; to bring actions on behalf of the federal government alleging violations of the False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal civil and criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on entities and individuals subject to the law including certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as individuals and entities that perform services for them which involve the use, or disclosure of, individually identifiable health information, known as business associates and their subcontractors that use, disclose or otherwise process individually identifiable health information; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Requirements under the Physician Payments Sunshine Act to report annually to CMS certain financial arrangements with physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as defined in the ACA and its implementing regulations, including reporting any &#x201c;transfer of value&#x201d; made or distributed to teaching hospitals, and physicians, as defined by such law and reporting any ownership and investment interests held by physicians and their immediate family members and applicable group purchasing organizations during the preceding calendar year, which will be expanded beginning in 2022, to require applicable manufacturers to report such information regarding its payments and other transfers of value made to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the industry&#x2019;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government that otherwise restricts certain payments that may be made to healthcare providers and entities; state laws that require drug manufacturers to report information related to payments and other transfer of value to physicians and other healthcare providers and entities; state laws that require the reporting of information related to drug pricing; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities, including our consulting agreements with physicians, some of whom receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has further strengthened these laws. For example, the ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal healthcare fraud statutes. A person or entity no longer needs to have actual</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">knowledge of this statute or specific intent to violate it. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that any of our product candidates is ultimately sold in a foreign country, we may be subject to similar foreign laws and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efforts to ensure that our business arrangements comply with applicable healthcare laws involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, exclusion from participation in United States federal or state health care programs, such as Medicare and Medicaid, disgorgement, imprisonment, integrity oversight and reporting obligations, and the curtailment or restructuring of our operations any of which could materially adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#x2019;s attention from the operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security and fraud laws may prove costly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our immuno-oncology product candidates may face competition in the future from biosimilars and/or new technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, provides an abbreviated pathway for the approval of follow-on biological products. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA. However, there is a risk that the U.S. Congress could amend the BPCIA to significantly shorten this exclusivity period, potentially creating the opportunity for generic competition sooner than anticipated. Further, this data exclusivity does not prevent another company from developing a product that is highly similar to the original branded product, generating its own data and seeking approval. Data exclusivity only assures that another company cannot rely upon the data within the innovator&#x2019;s application to support the biosimilar product&#x2019;s approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology or loss of data, including any cyber security incidents, could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability which could harm our ability to operate our business effectively and adversely affect our business and reputation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of our business, we, our contract research organizations and other third parties on which we rely collect and store sensitive data, including legally protected patient health information, personally identifiable information about our employees, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing on-site systems. These applications and data encompass a wide variety of business-critical information including research and development information and business and financial information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy. Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, breaches, unauthorized access, interruptions due to employee error or malfeasance or other disruptions, or damage from natural disasters, terrorism, war and telecommunication and electrical failures. Any such event could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Although we have measures in place that are designed to detect and respond to such security incidents and breaches of privacy and security mandates, we cannot guarantee that those measures will be successful in preventing any such security incident. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, government enforcement actions and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to conduct research, development and commercialization activities, process and prepare Company financial information, manage various general and administrative aspects of our business and damage our reputation, in addition to possibly requiring substantial expenditures of resources to remedy, any of which could adversely affect our business. The loss of clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, there can be no assurance that we will promptly detect any such disruption or security breach, if at all. If the technology supporting our hunTR discovery engine were to experience a cyber-incident resulting in the disclosure or theft of our proprietary screening software or library of TCRs, our business may be materially and negatively impacted. While we are not aware of any such material system failure, accident or security breach to date, to the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our research, development and commercialization efforts could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RISKS RELATED TO OUR INTELLECTUAL PROPERTY</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we or our licensors fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish and our ability to successfully commercialize our products may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success, competitive position, and future revenues will depend in part on our ability and the abilities of our licensors to obtain and maintain patent protection for our products, methods, processes and other technologies, to preserve confidential information, including trade secrets, to prevent third parties from infringing our proprietary rights, and to operate without infringing the proprietary rights of third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have exclusive rights in the field of cancer treatment to certain U.S. and foreign intellectual property with respect to certain cell therapy and related technologies from MD Anderson and NCI, as well as with respect to the PGEN technology, including </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Under the MD Anderson License, future patent applications require the agreement of each of MD Anderson, PGEN and us, and MD Anderson has the right to control the preparation, filing, and prosecution of such patent applications unless the parties agree that we or PGEN instead may control such activities. Although under the agreement MD Anderson has agreed to review and incorporate any reasonable comments that we or PGEN may have regarding licensed patents and patent applications, we cannot guarantee that our comments will be solicited or followed. Under the Patent License with the NCI for certain TCRs, the NCI is responsible for the preparation, filing, prosecution, and maintenance of patent applications and patents licensed to us. Although under the Patent License, the NCI is required to consult with us in the preparation, filing, prosecution, and maintenance of all its patent applications and patents licensed to us, we cannot guarantee that our comments will be solicited or followed. Under our License Agreement with PGEN, PGEN has the right, but not the obligation, to prepare, file, prosecute, and maintain the patents and patent applications licensed to us and shall bear all related costs incurred by it in regard to those actions. PGEN is required to consult with us and keep us reasonably informed of the status of the patents and patent applications licensed to us, and to confer with us prior to submitting any related filings and correspondence. Although under the License Agreement PGEN has agreed to consider in good faith and consult with us regarding any comments we may have regarding these patents and patent applications, we cannot guarantee that our comments will be solicited or followed. Without direct control of the in-licensed patents and patent applications, we are dependent on MD Anderson, the NCI or PGEN, as applicable, to keep us advised of prosecution, particularly in foreign jurisdictions where prosecution information may not be publicly available. We anticipate that we, MD Anderson, the NCI and PGEN will file additional patent applications both in the United States and in other jurisdictions. However, we cannot predict or guarantee for either our in-licensed patent portfolios or for Alaunos&#x2019; patent portfolio:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When, if at all, any patents will be granted on such applications;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The scope of protection that any patents, if obtained, will afford us against competitors; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">That third parties will not find ways to invalidate and/or circumvent our patents, if obtained; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">That others will not obtain patents claiming subject matter related to or relevant to our product candidates; or </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">That we will not need to initiate litigation and/or administrative proceedings that may be costly whether we win or lose. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost, in a timely manner or at all. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. We may also require the cooperation of our licensors in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of other jurisdictions may not protect our rights to the same extent as the laws of the United States. For example, methods of therapeutic treatment, which are patent-eligible in the United States, may not be claimed in many other jurisdictions; some patent offices (such as the European Patent Office) may permit the redrafting of method of treatment claims into a &#34;medical use&#34; format that is patent-eligible, while other patent offices (such as the Indian Patent Office) may not accept any redrafted claiming format for such claims.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in patent laws or in interpretations of patent laws in the United States and other jurisdictions may diminish the value of our intellectual property or narrow the scope of our patent protection. In September 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law, resulting in a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. In addition, the United States Supreme Court has ruled on several patent cases in recent years, narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the value of patents, once obtained, and with regard to our ability to obtain patents in the future. As the USPTO continues to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">implement the Leahy-Smith Act, and as the federal courts have the opportunity to interpret the Leahy-Smith Act, the laws and regulations governing patents, and the rules regarding patent procurement could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain technologies utilized in our research and development programs are already in the public domain. Moreover, a number of our competitors have developed technologies, or filed patent applications or obtained patents on technologies, compositions and methods of use that are relevant to our business and may cover or conflict with our owned or licensed patent applications, technologies or product candidates. Such conflicts could limit the scope of the patents, if any, that we may be able to obtain. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases at all, and because publications of discoveries in the scientific literature lag behind actual discoveries per se, neither we nor our licensors can be certain that others have not filed patent applications for technology used by us or covered by our pending patent applications. We cannot know with certainty whether we were the first to make and file for the inventions claimed in our owned patent portfolio, or whether our licensors were the first to make and file for the inventions claimed in our in-licensed patent portfolio. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in the issuance of patents that protect our technology or products, in whole or in part, or that effectively prevent others from commercializing competitive technologies and products. In addition, our own earlier filed patents and applications or those of MD Anderson, NCI or PGEN may limit the scope of later patents we obtain, if any. If third parties file or have filed patent applications or obtained patents on technologies, compositions and methods of use that are relevant to our business and that cover or conflict with our owned or licensed patent applications, technologies or product candidates, we may be required to challenge such protection, terminate or modify our programs impacted by such protection, or obtain licenses from such third parties, which might not be available on acceptable terms, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if our owned and licensed patent applications were to be issued as patents, they may not issue in a form that would provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity due to our patents being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or even after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our confidential information, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success also depends upon the skills, knowledge, and experience of our scientific and technical personnel, our consultants and advisors, as well as our licensors and contractors. To help protect our proprietary know-how and our inventions for which patents may be unobtainable or difficult to obtain, and to maintain our competitive position, we rely on trade secret protection and confidentiality agreements. To this end, it is our general policy to require our employees, consultants, advisors, and contractors to enter into agreements that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries, and inventions important to our business. These agreements may not provide adequate protection for our trade secrets, know-how, confidential information or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information. Moreover, we may not be able to obtain adequate remedies for any breaches of these agreements. Our trade secrets or other confidential information may also be obtained by third parties by other means, such as breaches of our physical or computer security systems. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret or other confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets or other confidential information were to be lawfully obtained or independently developed by competitors, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets, know-how or other proprietary information is disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and competitive position would suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third-party claims of intellectual property infringement would require us to spend significant time and money and could prevent us from developing or commercializing our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to protect or enforce patent rights, we may initiate patent infringement litigation against third parties. Similarly, we may be sued by others for patent infringement. We also may become subject to pre- and post-grant proceedings conducted in the USPTO, including interferences, derivations, post-grant review, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">review, or reexamination. In other jurisdictions, our patent estate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">may be subject to pre- and post-grant opposition, nullity, revocation proceedings, and the like. Asserting and defending against intellectual property actions are costly and divert technical and management personnel away from their normal responsibilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our product candidates without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. While no such litigation has been brought against us and we have not been held by any court to have infringed a third party&#x2019;s intellectual property rights, we cannot guarantee that our products or use of our products do not infringe or will not be asserted to infringe third-party patents. It is also possible that we have failed to identify relevant third-party patents or applications, or that as-yet unpublished third-party patent applications will later result in the grant of patents relevant to our business. Another possibility is for a third-party patent or patent application to first contain claims not relevant to our business but then to be reissued or amended in such a way that it does become relevant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research, development and commercialization activities, as well as any product candidates or products resulting from these activities, may infringe or be asserted to infringe patents or patent applications under which we do not hold licenses or other rights. Owning a patent does not confer on the patentee the right to practice the claimed invention and does not protect the patentee from being sued for infringement of another owner&#x2019;s patent. Our patent position cannot and does not provide any assurance that we are not infringing or will not be asserted to infringe the patent rights of another.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent landscape in the field of immuno-oncology is particularly complex. We are aware of numerous United States and foreign patents and pending patent applications of third parties directed to compositions, methods of use and methods of manufacture of immuno-oncology products. In addition, there may be patents and patent applications in the field of which we are not aware. The technology we license from MD Anderson, NCI and PGEN is early-stage technology, and we are in the process of designing and developing products using this technology. Although we will seek to avoid pursuing the development of products that may infringe any third-party patent claims that we believe to be valid and enforceable, we may fail to do so. Moreover, given the breadth and number of claims in patents and pending patent applications in the field of immuno-oncology and the complexities and uncertainties associated with them, third parties may allege that we are infringing patent claims even if we do not believe such claims have merit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a claim for patent infringement is asserted, there can be no assurance that the resolution of the claim would permit us to continue marketing the relevant product on commercially reasonable terms, if at all. We may not have sufficient resources to bring these actions to a successful conclusion. If we do not successfully defend any infringement actions to which we become a party or if we are unable to have any asserted third-party patents declared invalid or unenforceable, we may have to pay substantial monetary damages, which can be tripled if the infringement is deemed willful, and/or we may be required to discontinue or significantly delay commercialization and development of the affected products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any legal action against us or our collaborators claiming damages and seeking to enjoin developmental or marketing activities relating to affected products could, in addition to subjecting us to potential liability for damages, require us or our collaborators to obtain licenses to continue to develop, manufacture, or market the affected products. Such licenses may not be available to us on commercially reasonable terms, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An adverse determination in a proceeding involving our owned or licensed intellectual property may allow entry in the market of substitutes, including biosimilar or generic substitutes, for our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annuities and other similar fees must be paid to the respective patent authority to maintain patents (or patents and patent applications) in most jurisdictions worldwide. Further, patent authorities in jurisdictions worldwide require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to submit documents with the necessary formal requirements such as notarization and legalization. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We license rights to products and technology that are important to our business, and we expect to enter into additional licenses in the future. For instance, we have in-licensed patents and patent applications under our MD Anderson License, our license agreement with the NCI, and our license agreement with PGEN. Under these agreements, we are subject to a range of obligations pertaining to commercialization and development, sublicensing, royalty, patent prosecution and maintenance, and insurance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any failure by us to obtain a needed license, comply with any of these obligations or any other breach by us of our license agreements could give the licensor the right to terminate the license in whole, terminate the exclusive nature of the license or bring a claim against</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">us for damages. Any such termination or claim could have a material adverse effect on our financial condition, results of operations, liquidity or business. Even if we contest any such termination or claim and are ultimately successful, such dispute could lead to delays in the development or commercialization of potential products and result in time-consuming and expensive litigation or arbitration. On termination we may be required to license to the licensor any related intellectual property that we developed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in certain cases, the rights licensed to us are rights of a third party licensed to our licensor. In such instances, if our licensors do not comply with their obligations under such licenses, our rights under our license agreements with our licensor may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the licensing or acquisition of third-party intellectual property rights is a highly competitive area, and a number of more established companies are also pursuing strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our employees were previously employed at universities or at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#x2019;s former employer. Litigation may be necessary to defend against these claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OTHER RISKS RELATED TO OUR COMPANY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">*Our stock price has been, and may continue to be, volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The market price for our common stock is volatile and may fluctuate significantly in response to a number of factors, most of which we cannot control, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Price and volume fluctuations in the overall stock market; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating results and performance and stock market valuations of other biopharmaceutical companies generally, or those that develop and commercialize cancer drugs in particular; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market conditions or trends in our industry or the economy as a whole; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preclinical studies or clinical trial results; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The commencement, enrollment or results of the planned clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Public statements by third parties like trial participants and clinical investigators regarding our current or future clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Public concern as to the safety of drugs developed by us or others; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The financial or operational projections we may provide to the public, any changes in these projections or our failure to meet these projections; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comments by securities analysts or changes in financial estimates or ratings by any securities analysts who follow our common stock, our failure to meet these estimates or failure of those analysts to initiate or maintain coverage of our common stock; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The public&#x2019;s response to press releases or other public announcements by us or third parties, including our filings with the SEC, as well as announcements of the status of development of our products, announcements of technological innovations or new therapeutic products by us or our competitors, announcements regarding collaborative agreements and other announcements relating to product development, litigation and intellectual property impacting us or our business; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government regulation; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA determinations on the approval of a product candidate BLA submission; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The sustainability of an active trading market for our common stock; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future sales of our common stock by us, our executive officers, directors and significant stockholders; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Announcements of mergers or acquisition transactions; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our inclusion or deletion from certain stock indices; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Developments in patent or other proprietary rights; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in reimbursement policies; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Announcements of medical innovations or new products by our competitors; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Announcements of changes in our senior management or directors; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General economic, industry, political and market conditions, including, but not limited to, the ongoing impact of global economic conditions; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other events or factors, including those resulting from war, incidents of terrorism, natural disasters, pandemics or responses to these events; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in accounting principles.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the stock market in general and our stock in particular from time to time experiences significant price and volume fluctuations unrelated to the operating performance of particular companies, including in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Public debt and equity markets, and in particular the Nasdaq Global Select Market, have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many biopharmaceutical companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock prices of many biopharmaceutical companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were involved in securities litigation, we could incur substantial costs and our resources, and the attention of management could be diverted from our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Public statements made by third parties such as trial participants and clinical investigators about our current or future clinical trials without our consent may adversely impact our stock price. We may not be aware of these third-party statements when made, may not be able to respond to these third-party statements and may not be able to defend our business or the public&#x2019;s legitimate interests due to restrictions on what we may say about our product candidates which may cause the price of our stock to fluctuate. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions of our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even if doing so would benefit our stockholders. These provisions authorize the issuance of &#x201c;blank check&#x201d; preferred stock that could be issued by our board of directors to increase the number of outstanding shares and hinder a takeover attempt, and limit who may call a special meeting of stockholders. In addition, Section 203 of the Delaware General Corporation Law, or Section 203, generally prohibits a publicly held Delaware corporation from engaging in a business combination with a party that owns at least 15% of its common stock unless the business combination is approved by our board of directors before the person acquires the 15% ownership stake or later by its board of directors and two-thirds of its stockholders. Section 203 could</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have the effect of delaying, deferring or preventing a change in control that our stockholders might consider to be in their best interests.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders; (iii) any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; (iv) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the amended and restated certificate of incorporation or our bylaws; (v) any claim or cause of action as to which the General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware; or (vi) any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These exclusive forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Because we do not expect to pay dividends, you will not realize any income from an investment in our common stock unless and until you sell your shares at a profit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never paid dividends on our common stock, and we do not anticipate that we will pay any dividends for the foreseeable future. Accordingly, any return on an investment in us will be realized, if at all, only when you sell shares of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to use net operating loss carryforwards and research tax credits to reduce future tax payments may be limited or restricted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have generated significant net operating loss carryforwards, or NOLs, and research and development tax credits, or R&amp;D credits, as a result of our incurrence of losses and our conduct of research activities since inception. We generally are able to carry NOLs and R&amp;D credits forward to reduce our tax liability in future years. However, our ability to utilize the NOLs and R&amp;D credits is subject to the rules of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, respectively. Those sections generally restrict the use of NOLs and R&amp;D credits after an &#x201c;ownership change.&#x201d; An ownership change occurs if, among other things, the stockholders (or specified groups of stockholders) who own or have owned, directly or indirectly, 5% or more of a corporation&#x2019;s common stock or are otherwise treated as 5% stockholders under Section 382 of the Code and the U.S. Treasury Department regulations promulgated thereunder increase their aggregate percentage ownership of that corporation&#x2019;s stock by more than 50 percentage points over the lowest percentage of the stock owned by these stockholders over the applicable testing period. In the event of an ownership change, Section 382 of the Code imposes an annual limitation on the amount of taxable income a corporation may offset with NOL carry forwards and Section 383 of the Code imposes an annual limitation on the amount of tax a corporation may offset with business credit (including R&amp;D credits) carryforwards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may have experienced an &#x201c;ownership change&#x201d; within the meaning of Section 382 of the Code in the past and there can be no assurance that we will not experience additional ownership changes in the future. As a result, our NOLs and business credits (including R&amp;D credits) may be subject to limitations, and we may be required to pay taxes earlier and in larger amounts than would be the case if our NOLs or R&amp;D credits were freely usable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If securities and/or industry analysts fail to continue publishing research about our business, if they change their recommendations adversely or if our results of operations do not meet their expectations, our stock price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of these analysts cease coverage of our Company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. In addition, it is likely that in some future period our operating results will be below the expectations of securities analysts or investors. If one or more</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the analysts who cover us downgrade our stock, or if our results of operations do not meet their expectations, our stock price could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business could be negatively affected as a result of the actions of activist stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2021, we were engaged in a consent solicitation led by WaterMill Asset Management Corp., or WaterMill, where three new directors were added to our board of directors. We could experience other stockholder activism in the future, including another consent solicitation or a proxy contest. Activist shareholders may advocate for certain governance and strategic changes at our company. In the event of stockholder activism, particularly with respect to matters which our board of directors, in exercising their fiduciary duties, disagree with or have determined not to pursue, our business could be adversely affected because responding to actions by activist stockholders can be costly and time-consuming, disrupting our operations and diverting the attention of management, and perceived uncertainties as to our future direction may result in the loss of potential business opportunities and may make it more difficult to attract and retain qualified personnel, business partners, and customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if faced with a consent solicitation or proxy contest, we may not be able to respond successfully to the contest or dispute, which would be disruptive to our business. If individuals are elected to our board of directors with a differing agenda, our ability to effectively and timely implement our strategic plan and create additional value for our stockholders may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">*The exercise of outstanding warrants, and issuance of equity awards may have a dilutive effect on our stock, and negatively impact the price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of September 30, 2022, we had warrants for 22,922,342 shares of our common stock outstanding at a weighted average exercise price of $5.62 per share. We are able to grant stock options, restricted stock, restricted stock units, stock appreciation rights, bonus stocks, and performance awards under the 2020 Equity Incentive Plan. Under the 2020 Equity Incentive Plan and our 2012 Equity Incentive Plan, 10,623,215 shares were issuable upon the exercise of outstanding options at a weighted average exercise price of $1.85 per share.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">*Our principal stockholders, executive officers and directors have substantial control over the Company, which may prevent you and other stockholders from influencing significant corporate decisions and may harm the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of September 30, 2022, our executive officers, directors and holders of five percent or more of our outstanding common stock beneficially owned, in the aggregate, 44.4% of our outstanding common stock. These stockholders may have interests that conflict with our other stockholders and, if acting together, have the ability to influence the outcome of matters submitted to our stockholders for approval, including the election and removal of directors and any merger, consolidation or sale of all or substantially all of our assets. Accordingly, this concentration of ownership may harm the market price of our common stock by:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaying, deferring or preventing a change in control; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impeding a merger, consolidation, takeover or other business combination involving us; or </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, this significant concentration of stock ownership may adversely affect the trading price of our common stock should investors perceive disadvantages in owning shares of common stock in a company that has such concentrated ownership.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes to corporate tax legislation, including the Tax Cuts and Jobs Act, signed into law in 2017, could adversely affect our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Tax Act contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for NOLs to 80% of current year taxable income and elimination of NOL carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time and modifying or repealing many business deductions and credits. The Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, enacted in 2020, modified certain of these tax changes, and enacted other tax changes applicable to corporations. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the Tax Act and the CARES Act is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or the CARES Act. Currently, bills introduced in Congress, including the Build Back Better Act, contain additional changes to the taxation of corporations, which could adversely affect our business and financial condition. The impact of the Tax Act, the CARES Act and any other tax legislation on holders of our common stock is also uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to this legislation and the potential tax consequences of investing in or holding our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are a &#x201c;smaller reporting company,&#x201d; and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are considered a &#x201c;smaller reporting company&#x201d; under Rule 12b-2 of the Exchange Act. We are therefore entitled to rely on certain reduced disclosure requirements, such as an exemption from providing selected financial data and executive compensation information. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company also mean our auditors are not required to review our internal control over financial reporting and may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our common stock prices may be more volatile. We will remain a smaller reporting company until our public float exceeds $250 million if our annual revenues are $100 million or more, or until our public float exceeds $700 million if our annual revenues are less than $100 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_unregistered_sale_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. Unregistered Sale of Equity Securities and Use of Proceeds</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ISSUER PURCHASES OF EQUITY SECURITIES<br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:22.806%;"></td>
    <td style="width:17.183%;"></td>
    <td style="width:20.004%;"></td>
    <td style="width:20.004%;"></td>
    <td style="width:20.004%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Period</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a) Total number of shares purchased</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b) Average price paid per share</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c) Total number of shares (or units) purchased as part of publicly announced plans or programs</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d) Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 1, 2022 - July 31, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 1, 2022 - August 31, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,750</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$2.41</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 1, 2022 - September 30, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,750</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$2.41</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) Included in this table are shares withheld during the 3-month period ended September 30, 2022 to satisfy a portion of the tax withholding obligations in connection with the vesting of shares of restricted stock granted under the 2020 Equity Incentive Plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_default_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3. Defaults upon Senior Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4. Mine Safety Disclosures</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_other_information_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5. Other Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_exhibit_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6. Exhibits</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.996%;"></td>
    <td style="width:87.004%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p><p style="border-top:1pt solid rgba(0,0,0,1);padding-top:1.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p><p style="border-top:1pt solid rgba(0,0,0,1);padding-top:1.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tcrt-ex3_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Registrant, and all amendments thereto.</span></a></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520250711/d42031dex31.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws of the Registrant, dated as of September 21, 2020 (incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s Current Report on Form 8-K, SEC File No. 001-33038, filed September 22, 2020).</span></a></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tcrt-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Exchange Act Rule 13a-14(a) or 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.1++</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tcrt-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certifications of Principal Executive Officer and Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File&#x2014;the cover page interactive data is embedded within the Inline XBRL document or included within the Exhibit 101 attachments</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filed herewith.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">++</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALAUNOS THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:53.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:15.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Kevin S. Boyle, Sr.</span></p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kevin S. Boyle, Sr.</span></p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(On Behalf of the Registrant and as Principal Executive Officer and Principal Financial Officer)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dated: November 14, 2022</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:53.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:18.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:18.0pt;margin-top:0.0pt;line-height:23.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Michael Wong</span></p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Wong</span></p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vice President, Finance</span></p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Accounting Officer)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dated: November 14, 2022</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>tcrt-ex3_1.htm
<DESCRIPTION>EX-3.1
<TEXT>
<html>
 <head>
  <title>EX-3.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 3.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATE OF INCORPORATION OF ALAUNOS THERAPEUTICS, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Pursuant to Section 242 of the</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Corporation Law of the State of Delaware)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc. (the &#x201c;Corporation&#x201d;), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &#x201c;General Corporation Law&#x201d;),</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOES HEREBY CERTIFY:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. A resolution was duly adopted by the Board of Directors of the Corporation pursuant to Section 242 of the General Corporation Law proposing this Amendment of the Amended and Restated Certificate of Incorporation and declaring the advisability of this Amendment of the Amended and Restated Certificate of Incorporation, and authorizing the appropriate officers of the Corporation to solicit the approval of the stockholders therefor, which resolution setting forth the proposed amendment is as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RESOLVED: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that the first paragraph of section four of the Amended and Restated Certificate of Incorporation of the Corporation, as amended, be and it hereby is, deleted in its entirety and the following paragraph is inserted in lieu thereof:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;4. Number of Shares. The total number of shares of all classes of stock that the Corporation shall have authority to issue is Four Hundred Fifty Million (450,000,000) shares consisting of: Four Hundred Twenty Million (420,000,000) shares of common stock, $0.001 par value per share (&#x201c;Common Stock&#x201d;); and Thirty Million (30,000,000) shares of preferred stock, $0.001 par value per share (&#x201c;Preferred Stock&#x201d;).&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. This Certificate of Amendment of the Amended and Restated Certificate of Incorporation has been duly adopted by the stockholders of the Corporation in accordance with the provisions of Section 242 of the General Corporation Law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Remainder of page intentionally blank]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">this Corporation has caused this Certificate of Amendment of the Amended and Restated Certificate of Incorporation to be signed by its Chief Executive Officer this 16th day of June, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:45.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.658%;"></td>
    <td style="width:79.342%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Kevin S. Boyle, Sr.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kevin S. Boyle, Sr.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATE OF AMENDMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OF THE</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OF</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZIOPHARM ONCOLOGY, INC.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZIOPHARM Oncology, Inc. (the &#x201c;Corporation&#x201d;), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &#x201c;General Corporation Law&#x201d;),</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOES HEREBY CERTIFY:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. The name of the Corporation is ZIOPHARM Oncology, Inc., formerly known as EasyWeb, Inc. The date of filing of its original Certificate of Incorporation with the Secretary of State was May 16, 2005.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. This Certificate of Amendment amends the provisions of the Corporation&#x2019;s Amended and Restated Certificate of Incorporation filed with the Secretary of State on April 26, 2006, as amended (the &#x201c;Certificate of Incorporation&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Article 1 of the Certificate of Incorporation is hereby amended and restated to read as follows:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.997%;"></td>
    <td style="width:5.996%;"></td>
    <td style="width:78.006%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;1.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Name.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;The name of the corporation is Alaunos Therapeutics, Inc. (the &#x201c;Corporation&#x201d;).&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Certificate of Amendment has been duly adopted in accordance with the provisions of Section 242 of the General Corporation Law.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. All other provisions of the Certificate of Incorporation shall remain in full force and effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Remainder of page intentionally blank]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, this Corporation has caused this Certificate of Amendment to be signed by its Chief Executive Officer this 25th day of January, 2022.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:45.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.658%;"></td>
    <td style="width:79.342%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Kevin S. Boyle, Sr.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kevin S. Boyle, Sr.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATE OF AMENDMENT OF THE RESTATED</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATE OF INCORPORATION OF ZIOPHARM ONCOLOGY, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Pursuant to Section 242 of the</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Corporation Law of the State of Delaware)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ziopharm Oncology, Inc. (the &#x201c;Corporation&#x201d;), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &#x201c;General Corporation Law&#x201d;),</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOES HEREBY CERTIFY:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. A resolution was duly adopted by the Board of Directors of the Corporation pursuant to Section 242 of the General Corporation Law proposing this Amendment of the Restated Certificate of Incorporation and declaring the advisability of this Amendment of the Restated Certificate of Incorporation, and authorizing the appropriate officers of the Corporation to solicit the consent of the shareholders therefor, which resolution setting forth the proposed amendment is as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RESOLVED, that the first paragraph of section four of the Restated Certificate of Incorporation of the Corporation, as amended, be and it hereby is, deleted in its entirety and the following paragraph is inserted in lieu thereof:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;4.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Number of Shares.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The total number of shares of all classes of stock that the Corporation shall have authority to issue is Three Hundred Eighty Million (380,000,000) shares consisting of: Three Hundred Fifty Million (350,000,000) shares of common stock, $.001 par value per share (&#x201c;Common Stock&#x201d;); and Thirty Million (30,000,000) shares of preferred stock, $.001 par value per share (&#x201c;Preferred Stock&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shareholders of the Corporation in accordance with the provisions of Section 242 of the General Corporation Law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Remainder of page intentionally blank]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, this Corporation has caused this Certificate of Amendment of the Restated Certificate of Incorporation to be signed by its Chief Executive Officer this 19</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> day of May, 2021.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Heidi Hagen</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Heidi Hagen</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interim Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDED AND RESTATED</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATE OF INCORPORATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZIOPHARM Oncology, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZIOPHARM Oncology, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. The name of the corporation is ZIOPHARM Oncology, Inc., formerly known as EasyWeb, Inc. The date of filing of its original Certificate of Incorporation with the Secretary of State was May 16, 2005.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. That the Board of Directors of the corporation adopted resolutions, in accordance with Sections 242 and 245 of the General Corporation Law of the State of Delaware, setting forth a proposed Amended and Restated Certificate of Incorporation (the &#x201c;Amended and Restated Certificate&#x201d;), declaring the Amended and Restated Certificate to be advisable. The resolution setting forth the proposed Amended and Restated Certificate is as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:8.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:7.019%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;RESOLVED, that, subject to the approval of the holders of a majority of the outstanding shares of the Corporation&#x2019;s common stock, par value $.001 per share (the &#x201c;Common Stock&#x201d;), the Corporation&#x2019;s Amended Certificate of Incorporation shall be amended and restated in the manner set forth on the attached Exhibit A.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Please see Exhibit A attached hereto.]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. This Amended and Restated Certificate was duly adopted by vote of the stockholders of the Corporation in accordance with the provisions of Sections 222, 242 and 245 of the General Corporation Law of the State of Delaware.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. That the Amended and Restated Certificate was duly adopted in accordance with the applicable provisions of Sections 222, 242 and 245 of the General Corporation Law of the State of Delaware.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, the Corporation has caused this document to be executed in its corporate name as of this 26</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.375pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> day of April, 2006.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:2.444%;"></td>
    <td style="width:16.492%;"></td>
    <td style="width:81.064%;"></td>
   </tr>
   <tr>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZIOPHARM Oncology, Inc.</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jonathan Lewis</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jonathan Lewis, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT A</font></p>
  <div style="text-indent:4.533%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Name.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The name of the corporation is ZIOPHARM Oncology, Inc. (the &#x201c;Corporation&#x201d;).</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Address; Registered Office and Agent.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The address of the Corporation&#x2019;s registered office is 2711 Centerville Road Suite 400, Wilmington, Delaware 19808. The Corporation may from time to time, in the manner provided by law, change the registered agent and the registered office within the State of Delaware. The Corporation may also maintain offices for the conduct of its business, either within or without the State of Delaware.</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Purposes. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the Delaware General Corporation Law.</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Number of Shares.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The total number of shares of all classes of stock that the Corporation shall have authority to issue is Two Hundred Eighty Million (280,000,000) shares consisting of: Two Hundred Fifty Million (250,000,000) shares of common stock, $.001 par value per share (&#x201c;Common Stock&#x201d;); and Thirty Million (30,000,000) shares of preferred stock, $.001 par value per share (&#x201c;Preferred Stock&#x201d;).</font></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Preferred Stock may be divided into, and may be issued from time to time in one or more series. The Board of Directors of the Corporation (the &#x201c;Board&#x201d;) is authorized from time to time to establish and designate any such series of Preferred Stock, to fix and determine the variations in the relative rights, preferences, privileges and restrictions as between and among such series and any other class of capital stock of the Corporation and any series thereof, and to fix or alter the number of shares comprising any such series and the designation thereof. The authority of the Board from time to time with respect to each such series shall include, but not be limited to, determination of the following:</font></p>
  <div style="margin-left:9.065%;text-indent:4.985%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.246527777777779%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The designation of the series;</font></div></div>
  <div style="margin-left:9.065%;text-indent:4.985%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.246527777777779%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of the series and (except where otherwise provided in the creation of the series) any subsequent increase or decrease therein;</font></div></div>
  <div style="margin-left:9.065%;text-indent:4.985%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.246527777777779%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The dividends, if any, for shares of the series and the rates, conditions, times and relative preferences thereof;</font></div></div>
  <div style="margin-left:9.065%;text-indent:4.985%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.246527777777779%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The redemption rights, if any, and price or prices for shares of the series;</font></div></div>
  <div style="margin-left:9.065%;text-indent:4.985%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.246527777777779%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms and amounts of any sinking fund provided for the purchase or redemption of the series;</font></div></div>
  <div style="margin-left:9.065%;text-indent:4.985%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.246527777777779%;">f.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The relative rights of shares of the series in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Corporation;</font></div></div>
  <div style="margin-left:9.065%;text-indent:4.985%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.246527777777779%;">g.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whether the shares of the series shall be convertible into shares of any other class or series of shares of the Corporation, and, if so, the specification of such other class or series, the conversion prices or rate or rates, any adjustments thereof, the date or dates as of which such shares shall be convertible and all other terms and conditions upon which such conversion may be made;</font></div></div>
  <div style="margin-left:9.065%;text-indent:4.985%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.246527777777779%;">h.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The voting rights, if any, of the holders of such series; and</font></div></div>
  <div style="margin-left:9.065%;text-indent:4.985%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.246527777777779%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such other designations, powers, preference and relative, participating, optional or other special rights and qualifications, limitations or restrictions thereof.</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Election of Directors.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Unless and except to the extent that the by-laws of the Corporation (the &#x201c;By-laws&#x201d;) shall so require, the election of directors of the Corporation need not be by written ballot.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="text-indent:4.533%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Limitation of Liability.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> To the fullest extent permitted under the General Corporation Law, as amended from time to time, no director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. Any amendment, repeal or modification of the foregoing provision shall not adversely affect any right or protection of a director of the Corporation hereunder in respect of any act or omission occurring prior to the time of such amendment, repeal or modification.</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">7.</font><div style="display:inline;" id="article_7"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indemn</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ification.</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.246527777777779%;">7.1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Right to Indemnification.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Corporation shall indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any person (a &#x201c;Covered Person&#x201d;) who was or is made or is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#x201c;Proceeding&#x201d;), by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or nonprofit entity (an &#x201c;Other Entity&#x201d;), including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys&#x2019; fees) reasonably incurred by such Covered Person. Notwithstanding the preceding sentence, except as otherwise provided in </font><a href="#section_7_3"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 7.3</font></a><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Corporation shall be required to indemnify a Covered Person in connection with a Proceeding (or part thereof) commenced by such Covered Person only if the commencement of such Proceeding (or part thereof) by the Covered Person was authorized by the Board.</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.246527777777779%;">7.2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prepayment of Expenses.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Corporation shall pay the expenses (including attorneys&#x2019; fees) incurred by a Covered Person in defending any Proceeding in advance of its final disposition, provided, however, that, to the extent required by applicable law, such payment of expenses in advance of the final disposition of the Proceeding shall be made only upon receipt of an undertaking by the Covered Person to repay all amounts advanced if it should be ultimately determined that the Covered Person is not entitled to be indemnified under this </font><a href="#article_7"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Article 7</font><font style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></a><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or otherwise.</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.246527777777779%;">7.3.</font><div style="display:inline;" id="section_7_3"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clai</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ms.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> If a claim for indemnification or advancement of expenses under this </font><a href="#article_7"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Article 7</font></a><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is not paid in full within 30 days after a written claim therefor by the Covered Person has been received by the Corporation, the Covered Person may file suit to recover the unpaid amount of such claim and, if successful in whole or in part, shall be entitled to be paid the expense of prosecuting such claim. In any such action the Corporation shall have the burden of proving that the Covered Person is not entitled to the requested indemnification or advancement of expenses under applicable law.</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.246527777777779%;">7.4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nonexclusivity of Rights.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The rights conferred on any Covered Person by this </font><a href="#article_7"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Article 7</font></a><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shall not be exclusive of any other rights that such Covered Person may have or hereafter acquire under any statute, provision of this Certificate of Incorporation, the By-laws, agreement, vote of stockholders or disinterested directors or otherwise.</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.246527777777779%;">7.5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Sources.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Corporation&#x2019;s obligation, if any, to indemnify or to advance expenses to any Covered Person who was or is serving at its request as a director, officer, employee or agent of an Other Entity shall be reduced by any amount such Covered Person may collect as indemnification or advancement of expenses from such Other Entity.</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.246527777777779%;">7.6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amendment or Repeal.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Any repeal or modification of the foregoing provisions of this </font><a href="#article_7"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Article 7</font></a><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shall not adversely affect any right or protection hereunder of any Covered Person in respect of any act or omission occurring prior to the time of such repeal or modification.</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.246527777777779%;">7.7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Indemnification and Prepayment of Expenses.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> This </font><a href="#article_7"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Article 7</font><font style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></a><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall not limit the right of the Corporation, to the extent and in the manner permitted by applicable law, to indemnify and to advance expenses to persons other than Covered Persons when and as authorized by appropriate corporate action.</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Adoption, Amendment and/or Repeal of By-Laws.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the Board is expressly authorized to make, alter and repeal the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="text-indent:0;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By-laws, subject to the power of the stockholders of the Corporation to alter or repeal any By-law whether adopted by them or otherwise.</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Certificate Amendments.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Corporation reserves the right at any time, and from time to time, to amend, alter, change or repeal any provision contained in this Amended and Restated Certificate of Incorporation, and other provisions authorized by the laws of the State of Delaware at the time in force may be added or inserted, in the manner now or hereafter prescribed by applicable law; and all rights, preferences and privileges of whatsoever nature conferred upon stockholders, directors or any other persons whomsoever by and pursuant to this Amended and Restated Certificate of Incorporation in its present form or as hereafter amended are granted subject to the rights reserved in this article.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZIOPHARM ONCOLOGY, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDED AND RESTATED CERTIFICATE OF DESIGNATION,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PREFERENCES AND RIGHTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OF THE SERIES 1 PREFERRED STOCK</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Caesar J. Belbel, Chief Operating Officer, Executive Vice President and Chief Legal Officer of ZIOPHARM Oncology, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Corporation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), organized and existing under the General Corporation Law of the State of Delaware, hereby certify that the following recitals and resolution were adopted by the Board of Directors of the Corporation as required by Section 151 of the General Corporation Law by unanimous written consent on July 1, 2016:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, pursuant to the Certificate of Incorporation (which authorizes 30,000,000 shares of preferred stock, $.001 par value per share (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preferred Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;)), the Board of Directors fixed the voting powers, preferences and relative, participating, optional and other special rights of the Corporation&#x2019;s Series 1 Preferred Stock&#x37e; and</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, no shares of Series 1 Preferred Stock have been issued.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RESOLVED</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that, pursuant to the authority vested in the Board of Directors of this Corporation and in accordance with the provisions of the Certificate of Incorporation of this Corporation, the Certificate of Designations, Preferences and Rights of the Series 1 Preferred Stock filed with the office of the Secretary of State of Delaware on June 29, 2016, creating a class of authorized Preferred Stock of this Corporation designated as Series 1 Preferred Stock is hereby amended and restated in its entirety and that the designation and number of shares thereof and the relative rights, powers and preferences, and qualifications, limitations and restrictions thereof, as amended and restated, are as follows:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A) 250,000 of the authorized shares of the Corporation&#x2019;s preferred stock, par value $0.001 per share (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preferred Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) are hereby designated &#x201c;Series 1 Preferred Stock&#x201d; (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Series 1 Preferred</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Each share of Series 1 Preferred shall have a stated value equal to $1,200 (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the Series 1 Preferred) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stated Value</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">B) The rights, preferences, privileges, restrictions and other matters relating to the Series 1 Preferred are as follows:</font></p>
  <p style="margin-left:0.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Rights.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From and after the date of the issuance of any shares of Series 1 Preferred, dividends at the rate per month of the Series 1 Dividend Rate (as defined below) shall accrue on such shares of Series 1 Preferred (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Series 1 PIK Dividends</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). The Series 1 PIK Dividends shall accrue on each share of Series 1 Preferred from day to day and shall be paid monthly in the form of a number of additional shares of Series 1 Preferred equal to the cash value of the Series 1 PIK Dividend on such share that accrued during the preceding month, divided by the Stated Value of such share of Series 1 Preferred, within 10 days following the end of the preceding calendar month&#x37e; provided, however, that the Series 1 PIK Dividend on any shares of Series 1 Preferred issued on or about July 1, 2016 shall commence accruing on June 30, 2016 (but for the purposes of clarity, shall be due and paid on July 31, 2016). The payment of the Series 1 PIK Dividend each calendar month shall be mandatory for so long as the Corporation has funds legally available therefor. The &#x201c;Series 1 Dividend Rate&#x201d; for each share of Series 1 Preferred shall equal: (i) in the event that such share is not Unconverted Series 1 Preferred (as defined below), (A) $12.00 per month (subject to appropriate adjustment in the event of any stock dividend, stock split, combination, adjustment in the Stated Value or other recapitalization with respect to the Series 1 Preferred) or (ii) in the event that such share is Unconverted Series 1 Preferred, (A) </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$24.00 per month (subject to appropriate adjustment in the event of any stock dividend, stock split, combination, adjustment in the Stated Value or other recapitalization with respect to the Series 1 Preferred). For the avoidance of doubt, Series 1 PIK Dividends shall be paid only in the form of shares of Series 1 Preferred and not in the form of cash. No fractional shares of Series 1 Preferred shall be issued as a Series 1 PIK Dividend. Whether or not fractional shares would be issuable as Series 1 PIK Dividends shall be determined on the basis of the total number of shares of Series 1 Preferred to be issued as a Series 1 PIK Dividend to any single holder of Series 1 Preferred based on the total shares of Series 1 Preferred held by such holder immediately prior to the payment of such Series 1 PIK Dividend. Any fractional shares not paid pursuant to this Section 1(a) shall be forfeited.</font></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Voting Rights. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of Series 1 Preferred have no voting power whatsoever, other than as set forth in Section 2(a) below.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At any time when shares of Series 1 Preferred are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote of the holders of at least a majority of the then outstanding shares of Series 1 Preferred (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Requisite Holders</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such act or transaction entered into without such consent or vote shall be null and void ab initio, and of no force or effect:</font></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">amend, alter or repeal any provision of the Certificate of Incorporation in a manner that adversely affects the powers, preferences or rights of the Series 1 Preferred in a manner that is more adverse than the effect on any other class or series of the Corporation&#x2019;s capital stock&#x37e;</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">create, or authorize the creation of, or issue or obligate itself to issue shares of, any additional class or series of capital stock unless the same ranks junior or pari passu to the Series 1 Preferred with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends and rights of redemption, or (B) reclassify, alter or amend any existing security of the Corporation that is junior or pari passu to the Series 1 Preferred with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to the Series 1 Preferred in respect of any such right, preference or privilege&#x37e; or</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">enter into any transaction (or series of related transactions) the effect of which would adversely affect the holders of the Series 1 Preferred in a manner that is more adverse than the effect on any other class or series of the Corporation&#x2019;s capital stock&#x37e; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">provided&#x37e; however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that any issuances of the Corporation&#x2019;s capital stock in connection with any transaction (or series of related transactions) would not require approval of the Requisite Holders, unless the special rights, preferences, privileges and obligations of the Series 1 Preferred are adversely affected.</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">3)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conversion Of Series 1 Preferred Shares Into Common Stock.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to Section 3(f) and 3(g), upon the close of business on the second (2nd) business day following the Conversion Event Date (as defined below) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Mandatory Conversion Time</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), each outstanding share of Series 1 Preferred shall automatically be converted into shares of Common Stock, without the payment of additional consideration by the holder thereof, into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing the Stated Value of such share of Series 1 Preferred by the Series 1 Conversion Price (as defined below). The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Series 1 Conversion Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall be equal to the greater of: (x) the volume weighted average closing price of the Corporation&#x2019;s Common Stock as reported by the Nasdaq Stock Market, LLC over the 20 trading days ending on the Conversion Event Date or (y) $1.00 per share. The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Conversion Event Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall be the date that the first approval in the United States of (i) a ZIOPHARM Product, as defined in and </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developed under the Exclusive Channel Partner Agreement dated as of January 6, 2011 and as amended from time to time, by and between the Corporation and Intrexon Corporation, or (ii) a Product, as defined in and developed under the Exclusive Channel Collaboration Agreement dated September 28, 2015 and as amended from time to time, by and between the Corporation and Intrexon Corporation, or (iii) a Product, as defined in and developed under the License and Collaboration Agreement dated March 27, 2015 and as amended from time to time, by and among Intrexon Corporation, ARES TRADING Trading, S.A. and the Corporation, is publicly announced.</font></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No fractional shares of Common Stock shall be issued upon conversion of the Series 1 Preferred. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Series 1 Preferred the holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion.</font></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All holders of record of shares of Series 1 Preferred shall be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Series 1 Preferred pursuant to this Section 3. Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such notice, each holder of shares of Series 1 Preferred in certificated form shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Series 1 Preferred converted pursuant to Section 3(a), including the rights, if any, to receive the Series 1 PIK Dividends, notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this Section 3(c) (though for the avoidance of doubt this sentence shall not apply to Unconverted Series 1 Preferred unless and until such Unconverted Series 1 Preferred is converted). As soon as practicable after the Mandatory Conversion Time and, if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Series 1 Preferred, the Corporation shall (i) deliver, or cause to be delivered, to the converting holder a certificate or book-entry statement representing the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof and (ii) pay cash as provided in Section 3(b) in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion. Such converted Series 1 Preferred shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Series 1 Preferred accordingly.</font></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Corporation shall at all times when the Series 1 Preferred shall be outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Series 1 Preferred, such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding Series 1 Preferred&#x37e; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Series 1 Preferred, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">engaging in commercially reasonable efforts to obtain the requisite stockholder approval of any necessary amendment to the Certificate of Incorporation.</font></div></div>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or delivery of shares of Common Stock upon conversion of shares of Series 1 Preferred pursuant to this Section 3. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Series 1 Preferred so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid.</font></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Corporation shall not effect any conversion of the Series 1 Preferred into Common Stock to the extent that the number of shares of Common Stock issued in such conversion would represent a number of shares in excess of the Conversion Limitation (as defined below), unless prior to such conversion, stockholder approval for such issuances have been obtained in accordance with and to the extent required by the NASDAQ Stock Market Listing Rules (such approval, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Conversion Approval</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). In the event that the limitation provided in the preceding sentence applies, then on the Mandatory Conversion Date, the Corporation shall convert the maximum number of shares of Series 1 Preferred into Common Stock as is possible without exceeding the Conversion Limitation. Any shares of Series 1 Preferred that are not converted on the Mandatory Conversion Date (such shares of Series 1 Preferred remaining outstanding after the Mandatory Conversion Time are referred to as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Unconverted Series 1 Preferred</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) shall remain outstanding until the Conversion Approval is obtained, at which point all Unconverted Series 1 Preferred shall be converted into Common Stock at the Series 1 Conversion Price as provided in this Section 3. The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Conversion Limitation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall be 19.9% of the lesser of (i) the number of outstanding shares of the Corporation&#x2019;s Common Stock immediately prior to the closing of the transactions contemplated by that certain Share Issuance Agreement by and between the Corporation and Intrexon corporation dated on or about the date hereof or (ii) the number of outstanding shares of Corporation&#x2019;s Common Stock at the time of conversion. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 3(f) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Conversion Limitation contained herein or to make changes or supplements necessary or desirable to properly give effect to such limitation.</font></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notwithstanding any provision to the contrary in this Section 3, without stockholder approval in accordance with the NASDAQ Stock Market Listing Rules, the Corporation shall not effect any conversion of the Series 1 Preferred into Common Stock to the extent that the number of shares of Common Stock issued in such conversion should constitute a change of control under the NASDAQ Stock Market Listing Rules, taking into account for these purposes, the NASDAQ Stock Market&#x2019;s policy of calculating of beneficial ownership in accordance with Section 13 of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. Any shares of Series 1 Preferred that are not converted into Common Stock on or after the Mandatory Conversion Date as a result of the limitation in this Section 3(g) shall be Unconverted Series 1 Preferred, and shall remain outstanding until such time as stockholder approval in accordance with the NASDAQ Stock Market Listing Rules is obtained such that such shares of Series 1 Preferred may be converted into Common Stock in accordance with the NASDAQ Stock Market Listing Rules, at which point such shares of Series 1 Preferred shall be converted into Common Stock at the Series 1 Conversion Price as provided in this Section 3. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 3(g) to correct this paragraph (or any portion hereof) to the extent necessary to ensure compliance with the NASDAQ Stock Market Listing Rules.</font></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">4)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidation.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each of the following events shall be considered a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deemed Liquidation Event</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;:</font></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a merger or consolidation in which (A) the Corporation is a constituent party or (B) a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such merger or consolidation, except any such merger or consolidation involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (1) the surviving or resulting entity&#x37e; or (2) if the surviving or resulting entity is a wholly owned subsidiary of another entity immediately following such merger or consolidation, the parent entity of such surviving or resulting entity&#x37e; or</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole, or the sale or disposition (whether by merger, consolidation or otherwise) of one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation&#x37e; or</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the closing of the transfer of this Corporation&#x2019;s capital stock (whether by merger, consolidation or otherwise), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than an underwriter of this Corporation&#x2019;s securities), if, after such closing, such person or group of affiliated persons would hold at least a majority, by voting power, of the capital stock of (1) the surviving or resulting entity&#x37e; or (2) if the surviving or resulting entity is a wholly owned subsidiary of another entity immediately following such merger or consolidation, the parent entity of such surviving or resulting entity.</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be distributed among the holders of the shares of Series 1 Preferred and Common Stock, pro rata based on the number of shares held by each such holder, treating for this purpose all shares of Series 1 Preferred as if they had been converted into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing the Stated Value of such share of Series 1 Preferred by the Series 1 Liquidation Assumed Conversion Price (as defined below), rounded down to the nearest whole share. The amount per share payable to the Series 1 Preferred pursuant to the preceding sentence is referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Series 1 Liquidation Amount</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d; The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Series 1 Liquidation Assumed Conversion Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall be equal to either (i) if such shares of Series 1 Preferred are </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Unconverted Series 1 Preferred, the volume weighted average closing price of the Corporation&#x2019;s Common Stock as reported by the Nasdaq Stock Market, LLC over the 20 trading days ending on the public announcement of such voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event or (ii) if such shares of Series 1 Preferred are Unconverted Series 1 Preferred, the Series 1 Conversion Price.</font></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with or following a Deemed Liquidation Event, the Corporation may, in lieu of distributing the proceeds of such Deemed Liquidation Event pro rata among the holders of Series 1 Preferred and Common Stock as contemplated by Section 4(b), elect to redeem all, but not less than all of the Series 1 Preferred then outstanding at a price per share of Series 1 Preferred equal to the Series 1 Liquidation Amount. A redemption of the Series 1 Preferred pursuant to this Section 4(c) shall occur upon the closing of such Deemed Liquidation Event or on such other date determined by the Corporation during the period commencing on the date of the closing of such Deemed Liquidation </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Event and ending on the 20th day following such Deemed Liquidation Event (such date, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Redemption Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and shall be effected in accordance with Subsections 4(c)(i) through 4(c)(iii):</font></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Corporation shall send written notice of the redemption (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Redemption Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) to each holder of record of Series 1 Preferred not less than 5 days prior to the Redemption Date. Each Redemption Notice shall state: (A) the number of shares of Series 1 Preferred held by such holder that the Corporation shall redeem on the Redemption Date specified in the Redemption Notice&#x37e; (B) the Redemption Date and the Series 1 Liquidation Amount payable for such holder&#x2019;s shares of Series 1 Preferred&#x37e; and (C) that the holder is to surrender to the Corporation, in the manner and at the place designated in the Redemption Notice, his, her or its certificate or certificates, if any, representing the shares of Series 1 Preferred to be redeemed.</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On or before the Redemption Date, each holder of shares of Series 1 Preferred to be redeemed on the Redemption Date shall surrender the certificate or certificates, if any, representing such shares (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation, in the manner and at the place designated in the Redemption Notice, and thereupon the Series 1 Liquidation Amount, for such shares shall be payable to the order of the person whose name appears on such certificate or certificates as the owner thereof.</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the Redemption Notice shall have been duly given, and if on the Redemption Date the Series 1 Liquidation Amount, payable upon redemption of the shares of Series 1 Preferred to be redeemed on the Redemption Date is paid or tendered for payment or deposited with an independent payment agent so as to be available therefor in a timely manner, then notwithstanding that the certificates, if any, evidencing any of the shares of Series 1 Preferred so called for redemption shall not have been surrendered, all rights with respect to such shares of Series 1 Preferred shall forthwith after the Redemption Date terminate, except only the right of the holders to receive the Series 1 Liquidation Amount, without interest, upon surrender of their certificate or certificates therefor.</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">5)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Redeemed Or Otherwise Acquired Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Any shares of Series 1 Preferred that are redeemed or otherwise acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Series 1 Preferred following redemption.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">6)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Waiver</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Any of the rights, powers, preferences and other terms of the Series 1 Preferred set forth herein may be waived on behalf of all holders of Series 1 Preferred by the affirmative written consent or vote of the Requisite Holders.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">7)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Next Business Day</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Whenever any payment or other obligation hereunder shall be due on a day other than a business day, such payment shall be made on the next succeeding business day.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, ZIOPHARM Oncology, Inc. has caused this Amended and Restated Certificate of Designation, Preferences and Rights of the Terms of the Series 1 Preferred Stock to be executed by its Chief Operating Officer, Executive Vice President and Chief Legal Officer this 1st day of July, 2016.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:31.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/ s/ Caesar J. Belbel</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Caesar J. Belbel</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Operating Officer, Executive Vice President and Chief</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Officer</font></p></td>
   </tr>
  </table>
  <p style="margin-left:31.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZIOPHARM ONCOLOGY, INC.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURE PAGE TO CERTIFICATE OF DESIGNATION</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>tcrt-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Kevin S. Boyle, Sr., certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Alaunos Therapeutics, Inc.&#x37e;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#x37e;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#x37e;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#x37e;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#x37e;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#x37e; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting&#x37e; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information&#x37e; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: November 14, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Kevin S. Boyle, Sr.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">      	 </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kevin S. Boyle, Sr.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and Director</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principal Executive Officer and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principal Financial Officer</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>tcrt-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Quarterly Report of Alaunos Therapeutics, Inc. (the &#x201c;Company&#x201d;) on Form 10-Q for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Kevin S. Boyle, Sr., Principal Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#x37e; and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Kevin S. Boyle, Sr.      	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kevin S. Boyle, Sr.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and Director</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principal Executive Officer and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principal Financial Officer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 14, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img159889792_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img159889792_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -4#!4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P!/C)\0/$_A
M3Q?:6.BZG]EMI+!)F3[/$^7,D@)RRD]%'Y5YY_PN;Q__ -!__P DX/\ XBM[
M]H7_ )'ZP_[!<?\ Z-EKR6F!WG_"YO'_ /T'_P#R3@_^(I5^,GQ =@JZ]DG_
M *<X/_B*X*M"S@*#<W4]J0'?1?%GQR$_>:[N)[_9(./_ !RC_A;7CK_H-Y_[
M=(/_ (BN+4D9Q^(-*IZB@#M?^%M^-S_S&\'T^R0?_$4#XL^.<_\ (;X_Z](/
M_B*XD\-SQ[T[IRP./8T =I_PMSQMP?[;_#[)#_\ $4-\6O' _P"8W_Y*0?\
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M%SG_ ( O^%-.MZF#Q<#Z;%_PJC@,GR]12 L7 93CUH OG6]2"Y^T_P#D-?\
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M4@_^(I?^%M>.B.-: _[=8?\ XBN*(YYQTHY91@=.] ':CXM^-^,ZY^5I!_\
M$4'XN^-CG&M8_P"W2'_XBN*V[3DC%(>3D#Z4 =M_PMKQSR/[;R?^O2#C_P <
MI/\ A;7CG!']N<XZ_9(./_'*XOH#N_2DZY_E0!TTOQA^(,38.O<=C]C@_P#B
M*9_PN;Q__P!!_P#\DX/_ (BN9FC$D908!]364RE&((P10!W?_"YO'_\ T'__
M "3@_P#B*!\9_'X((U_D?].<'_Q%<'10!]_UX?X\^*^O>&O&>I:38VFFR6]L
M4VF:-RYW(K')#@=6/:O<*^4_B]Q\4=9((!!A_P#1*4 ;'_"]O$^1BQT?&?\
MGC+_ /'*4?';Q-C)T_2,#J?)D_\ CE>8#:S'YE&>U)CY@,C- 'IX^.WB?/\
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M1\_]<9?_ (Y7!3>?'CSM,5,>H-5FO(_NM9QC!]Z /1C\>/$^,BPT?_OS+_\
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MJMKH>IL 8[21P1G*B@#TE?CQKA(SIVG#/_3-_P#XNGCXZZVQ &GZ=D]_+?\
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M7_XY7F(XY4\^E)V)_,&@#U#_ (7MXH[6.CG_ +8R_P#QRD'QW\4;2?L&C_\
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M.1V_<R__ !RF?\+W\4?\^&C_ /?F7_XY7FCKAC@U&W7!% 'IX^/'BCO8:/\
M]^9?_CE!^/'B?M8:/_WYE_\ CE>7GI]*5(GE($:EC["@#U _'?Q.#C[!H_\
MWYE_^.4@^._BDG T_2"?:&7_ ..5P$.DRR,#,P '8'DU?%M% @2,*I/5FX-
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M.0['';-2&67"[964GJ,T $]_\2XC^[L-#E'^S%+_ /'*RYO$?Q6B)V^&=,D
M[K&__P <K6CN[B,@+*V<],U(NI7R2$+.V%]: .:E\<?$RV_U_A:R7/3$;_\
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M\\ZY_P"2D'_Q%'_"W_'8_P"8[_Y*0?\ Q%<1G(P12'- '<?\+@\=_P#0<_\
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MY[D5N6WP]O)/];,J?A0!$OQ3\==]>_\ )2#_ .(IP^*GC?/_ "&V/M]D@_\
MB*VK?X>V\9!FN 3["M&'P?ID# D[B/:@#F!\4/'C?=U9V_[=(?\ XBI8_B1\
M07!QJ3_^ </_ ,179Q:/IL'W8AFIQ%;)]V%10!QB>//B/(,KJ3_^ </_ ,15
MF/QA\29,?\3-A_VYP_\ Q%=:)%3($:C-.\X\8 H YJ/Q+\27ZZJP/_7I#_\
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MI)_=)]>*-IX!!%6S=(R8 ([TWS4V]1SU- %4' (QR:0#/;FK@E@4<+D^M&^
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MK0$&TC) W</VIC_"SQ6CD-8@X'8U[6+RZ,; 7$@(3.2WZ4X:A?;/FN&'IDT
M>'?\*N\5@X_L]LXS3T^%OBYERMDP&,_>->V#5-1QM^TL>YI1JU\-P,[C;QU[
MT >(_P#"M?%Z8_T.7'IDTV3P+XOM\9L)6SZ*37N3:K?<$3N,#^]3AK-^$ $^
M<C- '@T_ASQ7;CYM*G..A6$U$^F^(TP9='U#@<X1AFO?1K%]CB8L00<&K \0
M7C(R2F-@3G[O;TH ^<&@U",_O=.O4&#N+;J@,Z* 99)(\=BO6OI.354=@)+*
MWDR.<Q@U SZ+*&,N@6;L?^F2X% 'S>;F/YEBN=R@<$KR33UCF:)G+PDL!SO
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M9+<GIV%(XRA(ZMZ4\*0 ZG! P: &<%OF^[3@3SD].!2D*#N;H.U&589P<YH
M;@XSU7O3E&<!3\N>E("Q&  ,&E#;&  R#0 TCDX')/%.4!<9Y;^5)\P7;G![
M^U (XP3NZ$F@ 7!D^4$'N303N(4<\\TH)\ME X'0F@C;SVH :3M&,=30W)"A
M<CI2\%22<>@H&[=R<>]  -N_:!QCG-)PN[(X%*S[N1@<<TC_ "A2HX([4 (
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M\T -)=ATR1UI<\C&2?3%*#D';Q[TA+<GL.XH  [9);C':EW#&X'GWI&;8XW
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M#WI"06+9QB@!N1W'2F\%>,@_2GLI'3G/4T!@.!^M #2JHN223["A6] <4N"
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M("<9]* %&#WIN >_2@=NQIP*DGC:?:@!."<=/>EX;C/-'1AR#GUH*[CG&#0
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M2UG/_3#_ -$1T <.>#S1FCD#U%)G'TH 7CK12^XZ4G3D=/2@ '%)_*EH'UH
M/K1[4I!'!Z4@]* %4T$^U)P1CH:#G%  .N<5/%;[_F;A:=;PKMWO]VG>:99
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M:7;^5'7IQ0 WJ:<!Q[TW-+S@&@ .*8>33QSVI-N* $ .[D4-B@Y/3I2#@^U
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MFR,FD;)P31M &.IH ^YJ^4OB^!_PM+6L^L/_ *)2OJVOE+XO9'Q3UHCL8?\
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MY-: /F:-\I^>-A0!7O(S#=RJQX)R/H:@ !S\O%7]2_?0P7(ZE=I_"J!R!WH
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MR%2X4X+$=:OZ9<V<$TDMS$QD ^3"YX[UEQ31[L @Y/.>U7HC)'(<?, .".U
M&;?M))<O<+N5-Q95(QQ3X[B20JR@#C!R<5>G\IXR7+9QU-9!=-N=I.#R: +H
MN_D=&PI['-36"?,6V@9[DU1@\IWW,NX <!JVH[5TMA=$H$)P%H F91MW%@ *
M:6);"@<>].4F90IC1E[T*,\!" /2@!<G'UZ@<TA7<.>AI55<_*WS"HI)@H/(
MW=J *LS+WW @X!VTD8:0E5^7/0^M1LTLV8U;<3_"*FMX7A"HX8D<Y/:@"S%
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MC'.JX96/:@"\0IE)9B<\8]*@N"Q;:#E1Z4RT6;RW#9ZYW&K!5;96=@74C\J
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MFM8F('EJ<CH14,^GPR'<R;!V"\4 81/1!T[TA"#DYVCBK4]DT9P.A/%5YD$
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MVR:3GO2@=S0 G)[T48S10!Z9\=\GQQ98_P"@;'_Z,EKS *0>4S^->G_'<?\
M%<67('_$M3K_ -=):\PW,5SNSCTH ,Y( P?:DS\V ,>U+N!.2.?YTJQM*X5
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M6DG#8!!'&.U 'HB>)8)E#*G&:E-^TXR&VK["N<TZQ,*,'Z'IFM>'"IQ@X[4
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MR&!S0!HJT6H1B.1MLRC ;UJ&.22SD,,X_=^XJI\P8$<$5?AN5N1Y%SCG[KT
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M0!4\,>$Y=8F\V4LD2\DXZUZC86EOI%M]GME&>[5)%%;V$(@M5"H.M-)Y]S0
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M(VL_&?2@!H@C*J7_ '8/4$4LC1@;$Z#UJUKCI_:KQ@ )&H Q]*H?(%W$,X%
M$SQ>:HF(VKCC/>HL[%)W$BM+6[J"Y2T%J@157#CWJK&;=(,/EY,].U $4;2S
M8D R 0<[:U-7U:*[LX;:WA$>U1O(XR:K2W["U6UAB6$=V7O56&,-)N9N.F*
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MU6*X@,RR"-%ZKCDFL<LPR>O'5NU.W;3A)!M(SCM0!O0NLJDH6R>@J5D /RG
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M.O6NLU_PY/H]T1M)C[&N=FAS\R_>[T 1PK@')XJ*5E#87FIHP6!6H&^5B!0
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MC1\O?=GTH4@@8! ]Z '(O//3'//2D D RJY)[YI3'\W!P#3F?8" 1CIB@!
M!R/F^M(S*6W=/6@G>1\O&.HJ2UM#<2@@!5')H L6EL"1+W^E7S+M'RKC-( B
M#8.,=Q3HEWR# SVQ0!$99<A@VT>M8WC'QC<>'/#[/8X:Z<[0Q'2JGBSQUI/A
MN-[5'2>\/_+-3G;]:\HUWQ5>>(8%1X@H5LX% &7>7NHZU<?:=3N7F9SD@M\H
M_"FK]GWE'7 '0@8IL,J2#&W!'8TY[F.1O+>+8?>@"SIW]EV\LKWC,5884<]:
MA:VB+*]O, JOG!&*B1(I'QO7Y>M,D53(K9^4'B@"?5;B*ZGW1+@JH!-4"[11
MAP<%>0:F>$[]P).['2FS#,FW:"HXYH T+@V=UI\=RZDW&.0.]9FZ-T.U=HZ;
M<U*C3I(52-2F.F*DAMRQ!,6!GTH A6)VA[$TX6S.JF,]/O<5T-CX<EFC\Q0.
M>QKI['PF@4%EQQR* //X["3)WDEL<<5']CF4DM&V1V%>MQ^%$V@  GTI\GA1
M%8,R$#OQ0!Y +60Y*[E<=%-(T-QN&Y?F'(Q7JLW@X2$.L9;'<"H&\)MD;XN
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MD  S@8-+4,\P@0G')H 5I8E8*Q!/O3U*]!Q56"13@E=S$]<4ZZNEM]O')]*
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M3BQS\HQGO2JZA?E&<=<T,F\*RCWZT 1]1\K<]Z4L, <8I2CKP!BD!^7H?Q%
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MDC;5'- #S)LR>PJEJ'B*/3X,EP3VKDM?\8P1QF*V8E_45PE[JD]^QW.V/<T
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M"?KCI6=+&8WPQ'/4]Z .!^)FBR311ZQ;G?LX<8KSJSO H\F0%XG.!GL?45]
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MQJ^_!=1D=Z  ;USESL]*0KM4@/GODTI"JX'F*/4YH4@<MSR<4 +AV7&" >]
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M %)A0<CK2]N>M*JG&: &L?:F%>2:E/.0:9CL: (@,#.,8I^?FXXH..F#F@@
M\T 3QMAUXK6@DW$#I60G')QBKT$@)'- &LC<T2R,O0X%01S #MFG,2V3GF@
M5F8]?QI#)SC.?I4;!R<<T$8X% #99/+4G-9C.78D]ZLW4O.W-503D#% $JID
MCM5M4.W@5%!][D<5=5"<8H 2& L<YQ5C[*3[FIH4"KS4@8"@"+84CQTK'U%
MW-:\LIY%9-^=W2@#"N(5DC/K7-ZM8"ZMWB8?0UUKH!SQ63=H-^: /$=8TYM/
MOFB(XZBJ(CW2*#P":]-\3Z1'=0&4* X'6O-7C>*X*$]#0!:O+9;-4*G.X52)
M)%6[V8RQ(.NT8JD'(% "KD'-!.#QP?:@C'3O0HYYH Z'P[XPU'P_-NAD9HSU
M7->LZ+XWM->C3>@2;'//>O!U0L<*,U8M[N>QF#Q.5(/8T ?1_P!K&S;U4U5)
M&X^]<=X6\21ZG (99/WP'<]:Z@$GF@ N+99!D=:SSE3C%:BMD9/6H;B(%=P
MS0!0*GKG@TFX8Q2D-G!I<+VH 801RW2CCKCFCDGFEQCO0 T]3QB@#T-..#S2
M 4 .5E8&.4;E/&#7$^+_  B%C^UVYRI/*@=*[/\ 'FID9'4Q2X93V- 'SW<6
M[V\A Z4P7'0,H(KTKQ;X6"2O<VL68VY( Z5YI<P&&4@J0* '9CD_AQ2I$R.&
M7E:K?C4D4Y0\$D4 3,ACDWGD'M45Q&,AQSGM5DOE0>"#05!&WL>E &<?<_A1
MFI)H_+?&,U'U[8H ":* !10!ZK\:4_XKJUE/ 33$P??S):\QU!R52/(P/F/X
MUZC\;?F\86,8&2]E&#]/,DKRB\(DNGQGY0%% #$&]AQD#G-/EE:0!5 "B@@Q
M1!58 L.:APJ@Y.?I0 OER&144?,QP *][\ >&H/"N@?;[Q/]/N1E<_PBN#^%
M_A0ZSJO]HW2?Z';<Y/<CFO6[^X\^;(;Y$^55]!0!7:6*20LV[=ZT[<NT[<GZ
MTI=.=JYXI%Z?,N/YT *4XSCJ?6GC?N "\8]:C" J64FG,K#:,_,: ''<%P0,
MGMUJ[:V607D Y(P*+.U\HK)(N3V!J_)* "Q& /6@!?DVE43;QBC#J,D9%7+&
MRDGC-S+\D?\ "#Z5-?VV;)6C*\G (H R8H][D[05[GTKA/B!X[33()-*TMPU
MPW#R*?NU;\=^,X_#EI_9MHY-Y(/F([5XJI$UXUS<2L[2'+<\T /MO,N+EC-+
MYC2<LS<G-/9A:,UKM*OZD8IC7<-G+OB@#D'(W58U#41JTPF>,(X7^&@"O:WM
MW8,[02-%N'8]:;#:7%X7ERS-G+.1G-)$4G888$*<'-=+H6IQKJ\.GLJ_9I2
MS"@"CHD4=HEY=7.'9%P@/O65;9D+.JX=^2"*] \3>$I;&_1X4 MI0"#ZTMGX
M8RP(11QVH X>/2YIE8N@VCMBK<6ARS0JJI\I[&O2+70%&"Z GVK2&BP[U'EC
M..30!YQ#X?FS&!"0%ZXKJM*T4P#=L^\.1FNIBTV./Y5( ]!5Z&TCC V1@COZ
MT 9]II,.1Y<>&]/6MR&#R,$*5 Z\YJ2-(E4<'CL*DX"YP<>AH %3Y2PX]LT@
M8*><_3-.00L3@X'H:=P%)&UA[=J '1B.6/(&"#W-(7V_,K\], 5$%RWR8 P>
MM2^5(D2R?=3OCO0 F0S9\L%J<%9CG(&/6FA0&!'.:1L+R<Y[4 !+-_%U[ 4@
M D4JORE>I-/S)GY7"CUI-QVEB06SW[T "#=C<N[GM0?-9FQA?:C+J0 %3=Z]
M*5P0P+A<^QZT -X'5B6]!3D7AL 8/>DWLK_*G)&,&A][ 'Y5]: #:Q39G( S
M04\IE8DX_.C#JP>.7:,8(]:< V[#O@4 )N1B68<=N<4N <?-@4V3[,IY99".
MV:"P<;?+V@=,4 ."IM8%R1TXXIC*H7"KDGI2@#:5+DX.:#G:"&R:  !0_/#]
MB1FE4/M;<5.3^5)ERQRW0=/6F;4#[MP&>H% #F,JQ$,5P#\I I"8E(W.=_TH
M^0<A7]<4HWC]X 2<\ T )PH;HP(ZXZ4UXV(&%##KUQ2NT@8@J 7Y%-:,;OWA
M/J!0 Q"[D#:$(.*<S1MD,",>E*R9*D;E]NQJ-P%&!P>^* 'B1@VU7.*N0.P"
M*N0 ?FR:IYD4_<(7 P2*ECE(/4NWI[4 ;<,ZJC;3WZYJ<2@Y;(/RY/%84+J)
M,,"%/.*M/<X 5&&&XQWH 9<$22Y08([YJ ["C,<\4K?+"?7/45'MW%,MCL?>
M@"RA@ 4H2I[YJ87D:$')( Z5G^:QWDHXYPN!Z4N\R3!U&,#!H U!<!QO1L9I
M9;C,*AE!-9@\_!PY [>E/5PS;&YXH G:Y,G 8H1VJ(MR"Z$>^<TU2X;[WX4A
M9E;YC\M $5P^UA(/NUG73R&1E9P-_(XK2N8A-$5\P CGBLRX598E##YDXR.]
M %+YP,'C/2I92(PB-C<1UQ3D5=R_,2">*DOVQ,N=C;1T[B@"F0&#+G@\$8K@
M_'6B-,BO'"& '# 5Z KX!;;Q_LU@^)+F:"S:1 3CUH \4$GD$QRP,''7FDW*
M!T)!Z9-7M1G^T7)E91O)QD56DFCAMO)9 TK<AAVH A4@G,@XS5K3]6GTR]6>
MS^5AD U4 3DLI#'H: @0;B>1R#0 MQ<7=Y>2W-V[/,QR=S5<M=UO8S3KAMW!
MSVJ@9Q,_!7S#Q]:W;C0GTWP^)YY1YDQRL>: ,5Y1*BH!T&/K5W2-8O\ PY?I
M?6;% I^< \$51.PA59,-CG%2)*/)*;0PZ<T ?06AZ_;>)])%Y;NOG ?O$[@U
MWL0B33(U<C! KY-T#Q!=>%]26ZM\F$G$D?8BOI3PUK-KXK\-;[=B'4;F"]CZ
M4 :-UI1=!+:X8]UK*&&^22,@@X*GM5FPO);*ZP['RR<.I_A-6M;LR4^W6X+=
M-P'IZT <_=V0B9GB&5(Y6J0S)]W'3\JVE=955QR/YBLV]MEAD#Q [6ZB@"IP
M@RWS'TH7:Q/8=>E)RC9SN!_2I"V^/#<F@",N 04ZCOBIM2T^U\6:0^EWX'G!
M3Y,A'0U&,HJ@,I%(C.CK(A;<#D8H ^>M:T>YT#5Y["[1E9&PI]1ZU41@IVN,
MJ>PKWWQWX6C\7:&]Y;H/[1@7. .6KY_:-H)VBE4JR'!!H E:"$_,K[1Z4V7D
M>7&2P!]:CZ.<884Z$!G+,  !F@!\_F1QHG''-7H9=PAN>/[DG%9;'+ELC!]:
MM6!RSP,3M=>![T ?;=?*?Q=8#XIZT#GK#C_ORE?5E?*?Q>_Y*GK.<=8>O_7%
M* .)Y; (![=:0AE /]:3;\N 0?I2;2<!<GVH MQX2Q.X'#-Q57;EL!NOM5FX
M.V*./:XPN2,TRW2-I"S;@J@DDGO0 LW[B)$S\QY-=!X0\-7GBW58+"'<MM'S
M,W3"]ZYZVMYM2U".")7D:1MJ@=:^CM#T2W\%^'HK) 3?S -/*.H/I0!=G>VL
M;"+2=/41V]LH7<!C<>A_E5(#&2F0P.=I/6DW+\P=LD\[J5CV=>W##K0 UG!+
M':1C'%2!ESG!/&1\N*15?)&X$C&&IZYSM)SDXXH ;DE5,;<Y&5*]:4@+N*A2
MQ/0FC 49(+,.X-)'&99-@V!CS@B@!&4C:@7)]N<5;AL&(!=AM/(^6K$-JEOR
MQ)8]3Z5--,5*D$9/8#@T -*J@550>HJ6.-I_EYY. U1QJTS@1XW8Z$5R?C_Q
MTOANS33]+99;Z8'?)U$?_P!>@"_XN\>Z;X/C$,:B[OR-OE@X"^YKPC5]4O=;
MUF74-2D,DDQW#G  ] .U13O+=O+=7<YFG8Y+/DYK2T2P2[TN^N=AEDMSE%/0
M#&>E !I-O$-.OI)R51\",'^(YJSH^FW-U:WEA!&<[2X+#'ZUBO//); L_&<J
M@Z UT5CXSNK'2I+7[+$TK#9YVWG% &+<6\EG-Y4B@NG4JU*UK#+9M<I(00?]
M41D_7-1A)9"TC N#EB0:TFL77P\FH$%4DD,0Y]!F@"'1]9;1A<;8P[R*5"D9
M&"*IR:A=70.;@P+W6(;1^.*(T4IB3YCU!7BB"UEFD(C7@G[I')H 9'++L$32
M.^[D?,16OI6A27UPBLC=:V=%\+/=31&2/"IUXKTS2="AMGW[.,8% $'A_0(K
M)% A0*!R2>M=/M"J$VJF..#FF+&L:[/E/;IVIX!/*E<9XXH %)X08)!YRO6C
M:<DF,X'^W2M@8SNQGOWH SC@\<<T *H7^$Y/H:1L,V& R.?E/44N !N+*,=>
M*$SY8R8\8Y*+@CVH "!UP<>E+N(!PX8GCD=*3:5.23M]:4*'4[<<'GW% !DE
M<,ZLO7 3!I,%L;<''/3I32!\H+G*\XIQ& 2055O>@!'4EP!Q].*4!BNY5R.A
MSWI$Y^49Y&!GI3COX7C'H.M "< C"%0PYSZT#$:@$$GMFE&X9^\WS< FE09/
MS@X//- #&QU*MN/HW%'RGH<,IZ__ %J7<1\JCH<X% C#$G@>YZT 1L6QEF!)
M/W=F,4IZ$[01UX-/'RDD,#GCYN13=OS,53< , KQ0 C,/E8908(^[DF@;E&5
MQC&#GK3LG!(89XZ]*.-[99=W4$B@!5 (R'##<!C;3PSJ&'RKSC!6HU5C(?D;
MJ#D' J7&1A\M\V<9H -Y5BV!@#G%*I#* <'//"TY<!V*E<8Z$5(I+L0A49'&
M* &Q,0_3^'CTJ5)!A2!@@X(Q46"C*7YXQ\OK4XD7RP!@LO84 3[@=V#MRV.G
M7Z5;MRR2,#T/Z53CD&UL*#(!T/3/K5G=NE8L^..<4 7#( 1NXIDDZIU.#G X
MS4(D&=BJ3D<%CFHI6_>J@D!/?ZT 6$G) ^4Y.>O%-DN,\!P .",5""SML(95
M!X8G@TV9HP6 C9R!C(- $;3H7SD8/JM0/>@[@$P1QNS_ $IDKEOD9 6/0#C%
M, <_*RJ5[GOF@"+$KJ6(QN; YS4RPQCY&)W=\"I,;"6087MGK3AP/,=PH/&>
MYH ;&FWC<1AN>.HH*/*XP>?7&*F"MY:JLBDYW'CG%6(T:-,B,_0]J *=S9(E
MN-ZG?UR#6#/ !E6!!'KWKI[A&E!.X+Q6)?;MWS;6YR,#M0!C $<8P!U/6O/O
MB?H"R00ZS;KDH-LJA?QR37HLR*9 03ZD"F.D<\+07"+)%+PRL,Y'I0!\YJ#,
M@8 8'09Z4Y_,@&[# '^+&16[XP\-2^'M58QQM]DD),97MZBJ&DZU)907=JUJ
MEQ#/'M/F+N,?/4>AH JJFVW!*-\QSG%1LB;C@<8Z&I$N)FR'E5%.=JD=*8[/
MP2491W ZT 0^4N\S1[HW7E2K8(/K[5V?A7XJ^(?#:1VLS?;K%"28Y.6/_ CS
M7,I$OV<N_ ?D"JS;"5 ! SA@* /IGPYXY\.^*[>+RIDM[MQ\T#\8/H/6M.\G
M9+<P!/DSR"/UKY48-;7J2V<S121_,K*<$5Z]X)^)L.L;-)U^14N -D5P. WL
M: .^1E=2"&X'4<9J1D$J[7!)/J.E#QF$8!.1]TYX(J--S$Y=@<>O- &=-;"-
MB6W8!Z@XJ%F##A#DC ]ZV)%4J202,8^8YK.N(6A(8.NTGKB@"LA(^4C&.^:4
MKD''S=QDXH<*?FW9YZ"E'S'A#MSW- #64,Q*_CCI4?EX*#U/7-2X7"!F"J?X
M5XIK$*5Q@<G (Z4 /@N);:;=$X!]<5!XP\(6/CK2?.C"0ZI"I*N!]_V/K3@3
MQG&/6I[:Y>VD#J#\ISD&@#YMN[.\T?47M[F-HIXFP0PIUS$LJ"X1\Y^\H'W:
M^@?''@RT\<Z6U]8JL>K0KG:!_K!7S^HFTR[EM;E"A!*.K#I0 BD7%NR@9=!Q
M[U5!]03CTJSL>TN5<#,9Z'U%-N8Q#)E22K\KS0!)$6-C,.W'%502H.!GCTJU
M; M#,C$DE1@"J@RPP,Y'OVH >=V,G'X4W.,@#GN:7"@$;A]:.HX&!CO0!VOP
ME)'Q.T<=OWW;_IB]?5U?*'PD(/Q-T?&[/[[J?^F+U]7T ?'7CD*/&NMMCG[?
M<?\ HQJP.P.T5T/C@ ^,]:_Z_P"XZ_\ 71JYX# P2* %4 L<#\*E1!]DD['T
MJ \#. ?I5^SM6E6/'\38QZT =/X$\,OJNIPQLO[O(:1O05[3?RQQQ1V5MCRH
M0%P!69X3T@>'?"ZS/$!<SC)/<"K(=V.[;C/.: $PV  <>U&.I)_*@EBH+#I2
M9'S8X[\T *3@=\T!]@RK9/I3LG&[(((Z4L49G954'/>@"Q86_P!I=99%(4&M
M&9B'2*+EV( '6G#; BJ -H'-7] M Q?49E '(C'H.] %Z&"'2;4RN 9B,GZU
M%I=[]ICN+V92@3(Y]*HWL\E_?BWCW<GKZ"N7^*?BP>$O#\.EV<F+R<=/]GUH
M SO&GC2#2-,FCLI UX['H<D5XO=75UJ,WFW<C.S<G)J(33RSM<W+-)*YR2U6
M) +E!Y?R2#MZT :N@I)<07"JJE(/G.X9X%9>H%9KJ27(RV ".V*ETZZGM3=P
MXP98RIK,*.V%C##GG% %V(2SH [;BIP&/7%=#H^@R7DP#]SUJWX.T);N0M=C
M$6*]&M-+M[10(0IXX:@#GH-(%FGD#YF]:THM,DCVMA3^%;\=DI.2"3W.*MI:
M'UVK0!SHTZ65N%W>M6K33C$I&P 'VK=%NZKA><]&%2; J\\'L: ,^WLR$Y4<
M&KT6",,,$=*?A' #*Q([BC!QM5. >] "@(V0<@TP$,2N&('J:<P.T;EY!I1U
M)R>.U "#! QQ1\RCD XI-J^8)-H#8P:4;U;G/L30 JL<$J.,=#VI&C#KN&>.
MIH8,[=<$]QTI61@NQ&_$=#0 PI'M  #$]\4_"<;^@&,"@!NR?,>A%&&9L2 ]
M._K0 GREE\L;?]GUI"TDO*\X.".E.^?.Y6( ]*0MO!5L@]J #YD8C:H:G'YN
M.,]Z15PN !D]^]!7=CC('.30 [Y%.,Y)ZTT8)VJ.I_*@-&J\*!CO1YB< ,3G
M\Q0 \CY@<@XZT J<'JHX.*C*!B,%L=Z?@':8@0.AW4 ,8K&QPS8;H,TC 'MN
M([^E/^7.-J[O0]Z"452"@4D]: (B&SN#$YZYIDJ, -XSC^[4H4LS9QM/44Q@
M%5Q!WQDT #Y0;EZ="#3ED?&WD,!U/2D"M(5. ..M*R.VT.>GI0!/;S!(M_WF
M!Z$5;2:21@RE5Q[51B9HP0RCY3G)IQOOF)R .PH UK:9)1\WK@U-YB]02<G&
M/2LB*6ZF./EC5>A]:U((3M!)R3W% %Q%)"AL@ \<U-WQ42D0H2S9%.C<ODXX
MSQF@!MPY2,L.GI4%O)),&0K@ <$U<P#2X% %?:(@SL20OJ:R;N=II2<@"K6I
MSJHV;C[BLI=TA^0%6ST/>@">U#229C_AXK526.)-KGE>>!4%M;  ASU'4=J=
M\SW)C4-C/W@* )[?+ S$GYN@JQVQR,T@;:-NT\=\4H?()VGB@ VJV!UQ3NE,
M+X<+CK3Q0 @8;B/;-8VIM'+,""!MZFMAG 4USMT#]J=<#':@#-OU183\P8_2
ML?<DL4D#KF-Q@BMNY#< 1\8Y-9#1MYAX&!0!X]XKT!=!G>=007;*"L.2]NKR
MTB:Y=RHX5C7MVNZ=9ZKIK)<1'<@X;'2O*?$/V6 V]G9.<Q9W ]Z ,?SF( $I
M...: OG. 6"J.N!39>$/SC<>U=#J/AB_TOP/8:Y(L9BNW PI^;!S_A0!@.R\
M[02.F:2:P)M 2 H<X!IJ, A"E@3STJY%)]JTUXI Q>,Y4CK0!M>"?&U]X,U)
M+9[@OI[G#!LD+]*]^AUO[;9PWUJR20N,AE-?+;9N(O+()'OUKN_AGXE&E7,F
MCZ@_^CRG]T6/W30![#<S^?+YC8'K3&167:"2II7@50 ^<,.".A%1J&C/ELQV
MY^7% &?=VI3E>E5PJ[,,_7IBMLHK(5;DUC2Q>3(<G;D\"@",A>59#[<TF]5(
MS].E/&-OSX9Z0JR9.5 S^5 #3&N>^#1A\%<8&[UIY;<"&?=32 5.XG'I0 S:
M2<<$U:L[N2WD()!C/#+[5  23R<4W9@E1SF@#C?B/X)B)&NZ3'[RQK7F5PGV
MB)HV&'097^M?15E,BJT%PF^&48*FO+_B+X+.C3C4[)&-N3DJ!T% 'F '&,<C
MUIR2&-L@Y4]14MU  1*I C?GBH N=OI0!.T!>/S(>AZCO5?;M&3G=3T9E)9)
M-ISBI3)#(0''S=VH 2&ZN8B-LC8],U<2_@E!^TPCTW"J30*>4=2/K36@?[HQ
M0!J(&2+?;L)H2>4;M77_  J@MV^)NCSH=CAI?DQ_TR>O/XC<PDF-R,5W?PEN
MY9/B;H\<@R29>?\ MD] 'U)7RO\ & X^*6M>G[C_ -$1U]45\K_&#/\ PM+6
M<<_ZCC_MA'0!QUK'EMW85,A+S,W84U,16OH6I;=1Y;-D\T */W89B.3521MS
M'(JS<L5C [5%"AD< #- %S2K%[B9549W'@5[9H&DQZ1IZM@>:RC-<SX)\.H8
MEO)>@&0,5VTLFXX' % #&)9B: !BD[YI<T +WQ2@>M(#DT\]@#0 *C.X"UMZ
M;IK3NH _&JEC:[G4<[B>*[2&&/3[3W Y- %0P1V>% !?O4>KRI;:=N? )YJ>
MS0W4S32?=7I7F/Q0\8>3>"QM7&$7DCUH I:]XQAM'>")26QC(->=W=^UW<EY
M=V":H3W,EQ*9G;+9S5M/*N;9G)PRT 6$M8PGG;@1Z53 S.2HR":6V9G&T$XK
M:TW3R\BDKG)H I):-,V%7!-:VG:*YD&X<?2NILM!0[6VX-;MKI:(>10!SJZ,
M)80 H!Q5JVT'! ./RKITM4!Z<"IQ$HYH R;;24AYX(K3BA"+M J54[BE'';B
M@   [4H.>12YXS1T.<4 '.:=F@'G(HSSP* #/J*7/M0<TY1D$4 -YQQS0O!R
M:7&#2<GDT *V <8I, ]>E*1D4F: %QQQ0,Y^;FEHQSQ0 G&*4 TO?GK2D'H*
M $.<4F,#'2G#D4TC- "GH"3F@8_&C QQ2X&:  KWZ4T<<&GD\<TS[WL* #O3
MLG!I/E QCFA><T - R">E* "N>] !.>: .U ##G' YII''/6I"/6D*CUS0 W
M.,9JQ$<'K5?&*>N<Y- &@DN,9/%7(7SR!61&WI5J*0@?>H V"ZXSQFJ=U)\N
M1P:42@+D^E4KF3?TZ4 5W)8\FG*.:C%.1LL!0!<B'9C5V)EB3GGTJDO!&:F+
M<@=J +ZMNY[5"\Q+XIGFD)C-0J>_I0 ^9CZU1F(?J:FD?@U6D))H K2A0,8Y
MK*O!N/3D5KR8QS65=@YXH R+N#SH63'45Y9X@TY[6\<]MU>ND8X/>N8\4Z,M
MQ:O*A^8#- 'F*DQGGFD4&60<@<U)<0/#)M:H>5X% &MJ-@MK:PRHX;>N36<C
M?,,CBEDGE>-49BRCI4!9L\4 64G\ESCFF/()')QUJ2&PDFC:0\ 5$4V=3S0!
M8L+N2QNTGC8C!KV'PYK\.K6H7.)%'(->)9YZUK:+K,ND78DC.5/4&@#W0#;S
MUI"V<X&*S="U>/6+$2J0&Z$5I\"@"F\+,V:C9"AZ5HJH)R*5X W6@#+.6Z<4
MW;[U:EM2F2IJMCGO0 F<#I0#D9H/'3K2 GG- !UZ"FFG$X&:3/'% $B.IC,<
MBY4UYWXQ\*M 'NH #&QS@#I7H )Z4LL,=];M:S<JPZT ?/,L+0N0U1XX]J[3
MQ=X:;39R4!*,>":XQU",5).10!/;."/+QGWJ4'<IC/!%5H&(D&VI))&2;(QB
M@!Y02(0/O"J1&&(K0W9 =?QJ&>+Y=ZCK0!5Y[44"B@#U?XWXC\6VLQ?!&G(
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MU%[^_E+/*<X/:FSP21W018CL<_*:C:1&8@*JD=*V_#\%W?O<-AI4MXF8C'3
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M:,X*^N*858(>E:%_&& 8=<50C&,C!S[T -VC()Y(%#$JN,\$TK*V#DH!]:8
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M2AMF2!DGOUZ4 +)*<;C\H[-5"[PZ@R/M+#//\JLRLLA#,<(.QXJG<Y$>%8$
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MBIKD>=;I,H&]>#0!4&2> ,>E*<DC/&>U +''S*,TGKW]Z .V^$N[_A9VCG&
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M.W1G@@9/?O32T>P!@Y4=Z &@$(-V, Y^M*'5^D87U:D8H/NH&SVIV]6(&PC
MZ+0 '9&>"78],<<4NYW41JHP.^:;N=%)R!CL>](Y"IDAAGKM[4 /?S< NJ^G
M':FQ+M+!9-Z]PR]/QI4V1QG,F\'D>M-#R2 E5& .%]: %4Y=E1,'U)IK;AQP
M$'H.M//F,#A0@ YI#$VT?O0.AXH A8@+G#+GM1O7 4AFXSD5.2[*3(&QT!%
M$B#.4 (_$4 1*RRILP<=1DXH* KN9,-G@U(6"#YHR0>A/6C$A7 ^X3GGK0!9
MBCDD)^88Z5=AE,0*&4 #@_+FLU3+N."NWL!UJS'=",;6C"Y^]^% &BABE9$#
M$@'J?6K7 *C?\V.PK+1DG+&-QTSQZU?@W+DJGWNYH L;9?[X_*B5F2(G//K3
M@V$RW'K69>Z@K QQ$MZE: *=P_G7!#$ ?WJ;#EGW,=P' P,5 XW,6.\]P?2I
M8YTQY89LGN* ->W<B)GV=> ":DAC$;&1\[V["H$*N8XBY8*,D^E7!Y:+G/XT
M (S9V@$Y)J3'.:B;YI4*DD#TILLCK(%51L[F@"1LD_*.?[WI1ENY!QZ=Z:Q=
M$P.F.OI5=W-NH=FY- #+R=H3B-L>N1FLJ21V.20>V<=*L7$OF8<OOQVJMN!R
M%0CN2>E %.\/RY$F/6L>3&[()Q_.M*Z,;KAU)'8BJ,C!XP$"#;Q\W6@",I%/
M&RL"%88ZUY#XLT>6RO&N@/W8;[V.M>NJQ'RK&#]*P?&.DIJ6D[%N%@D4Y^8X
M!H \<\II\L%.&[U>O-8U.]TJUTF68FSML;!G_/K4$T%W:3F$R1N ?X#UI[PR
M>6)# PB/&\#C- # ZA2A8$ =A6KX7TF]U?6U2&%C;A"7..V*R!Y:9)8D>G>N
MA\.^,;O1M-U"*V+AY$VH>X% &+J+QVVHS6\2\(V U46+']ZI?<.C#/!H1Y'W
M/+O)<]6[FK\MPMO;QP[!GO0!ZG\-/&RZQ:#1-1?_ $N+B)V/WAZ?I7>21>6[
M+(3G^5?,D=S/:7T5]9;HIHFR&6OH7PGXEB\5Z$ER#F^1<3*.N: -$1$*&5CG
MWJ"2,R,2RY]ZL#>LA)R >QI(MV7W >U %.6P=4#@C\JJG*@ASWZ8K=*' WL#
MSQ5:XMHY48@$'^= &45$;<C@CC%(!\N6&6/09I[ QMLD#8'0&HW0@?+C%  7
M^4'ISC%*1\S%>>*3/0#&:%)SC(YZF@!"?F7/4>G%:.+;5K"33[O#!Q@;JS_O
M,V"#@4A4HRL"H;KD4 >-^+?"TOA_4YK61#Y#_-$V>*Y';M.-V".H-?2/B31[
M?Q5H+1N,W<2Y0_2OGW5=/:TG=7#&1&PP]* *&>>%'XT=.H!/H*0A01US1D;L
MJ<?2@ 5@I)Q@^E+Y[G_]5-)8#).:4L5X"\T /$[@C&,5VWPBE9_BEHV['+3?
M^B7KAB2< *2>]=M\(/\ DJ>B\'K-S_VQ>@#ZNKY:^+2[OBOK '7]Q_Z(CKZE
MKY?^+'R_%'6F(Z>1S_VPCH X>Y<&0*.PJS& D*@_4U!#&9',CCBIYW B.* *
MT[AWP!Q70>&-&>_N$ 0D9YKG[6)I9P%YKV7P5I8L],6XD4!VZ"@#=MX8K&SC
MMXQMVJ :,Y-.=MSDL*3'&10 N.] 'I2 'UIP [T &".:FMXQ(_*G J#/.*T;
M5,1DT ;V@VRO*TA7*ITK0NG>ZN%B3)0'G%5=%E6*VD7NQJW+>VNF6<MS*P&U
M2?K0!@>.O$\/A;1?+@D5;B4$(,\CWKYTO;V;4KUYYW+LYR2:WO'>O/XBUDRA
MCL4G:.U<I\R&@"PT6R,C:<4V)RIV#@-4K7:/ $Q\U+96[R7*_+D9H V-,TXR
M8^0XS7?:/I("(2G-5/#^GJT"DKWKM+:!8HE % #(K=8\ "K 3'05(%7UIP%
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MU%>NW5PUS=2-N.!P/84 5RA*@#TZBG_)Y>W=EO>F #CG)]:E50'R?PH 8'5
M %R<YIW[UI/E 44C'.[(Y/3%+@M(1M/2@"U80;Y&D<$[36HP5^< <BJUG'Y4
M."<9["K/RX#9)^M $^DVJSZPTK@E(5W)ST-3:F?[2N%MT8_-QQV'>I]$\M+>
M:3C<6/UQ4R>1I]E-?R@#:I;/H* ///B[XF'AWPQ%H5C(1<W(\MBIPRKC.?TK
MP:"(#Y?F#DY//>M;Q3K-UXF\67=]/(75'*1>R@\"LT%@^2V* (VC'F8*_-GK
M6UX?\07'A^YG=(P89T*L#SUXK(E ?:Y;@FG1J'78I#=\T 3WBQW1DN(%56+$
ME:CLK6.[NUCN)Q#V^M5R')*C('>I4CR\>\*,'UH ]'\+Z9]B:58WW(0,'->C
M:5!L@RS9/7D5P?@M-T!6-=Q->D6ZLD*AD([' H F)4 "0DCMBE&YCA/NT+Y8
M/ (;U-*2Q4'B@ !P.<8'M0K1\]<$=J7@*-S GTI &;)."!TQ0 87:,@D?6E+
M*W 7:PXI"')W'I00/+SN*YZ8H 0KMP0V!WR*:QP0<[AVS3@&8 JV%'7/>@LH
M!!3*=\T  *[N<DT,1_"K#UYHP6P  H'3%-X4D)A\'F@!V#D$)N Y))IS2'<=
MRA5/84UP<#<VU#VI1&S<@\#D4  \IE/RG)Z&G%L@;>&'KSFF,5;DJP(Z@"A=
MNX';_P!]< 4 .VRY&$!1OXLT@!5F.Y?H*0Q-CF0;?8TU!$0RQX!_O$\T (8I
M""%#X^M+M QGCZTI:<,JL^&'0GO4C;L,7R[#H,<4 -$@(&,[?6A6>3)3)(ZD
MTA98E5BN#GH*D:3<.R]\F@".0X<!SE".JCI06S'D JO<^M.W[U)3KVI=SG&]
MMS$4 1DJ22"".U.&[<?W8.?XLTTLFWE!G' IQXX^49'0&@!S+M)(< D?=I",
MQCHP^E,9,?.8\@=C4N,)N3(/=: &[TW+CY<=P*!]X]CUS3GGXVA$!]":8T<<
MCI\G&.=M "$[D8J"<CFG*4#!O+&[IS2J1'F,;A_=.*:0O 9SNSU- "R2* 5P
M&/TIK2;BN4 P/3BE^Z3CGU)II):,$-D@XQ0 W.&)+(N?]GK3';D< J.N!3C&
MYDW# J3)W9*#!XH 8+>-D ()SW%786C@4@*"".YJK+.(L ,?PJN_[W+D,2.E
M "W;74K@ERJ9^[2K&5?._(ST%"M)+%AB0!_">](BJN0KJ".@S0!,JY^=7*Y)
M&#068)MWC!-1%V?*E^5%+@*ZYR^* )/D"-@D^U1F1-^1D'TI[8C(_E3'R_)'
M:@!'9MF]#AR:1F<H2XX8]5'2E+/M&,@+VIRB:,;P6YX Q0 S:LC9\P\< U,(
M@H^9-WTJ/RMQ)WA<]13T\R)PRN3G@"@!K2(5X;:?2IE @T^260<-PM5IU^?S
M(XD);A@33;V<I%&BCY%'('K0 L4F%WJVXCM31/AR7ZGM5$7&2-HQ]:)96 !(
MY!ZB@"ZMQGGC!X%/4C!WGFLX2[AD#WJ19BQRW..U %N1(Y(]NPMCK[UR6N:)
MIUX[2X9'7C':NJ2=7VJ05856O[6.5&!7@CDB@#P_7M$%B[36IW*>N.U88WF/
M=C+>GK7H_B+3?LX(@E;GMBN"D1EN':8<+UQ0!2A9,.S^G2HQ*COMP2>V*M36
MUM,5>VF"J?O#-=9HTOA;1+(S7D0FNR.#UH XN%9Y)E586VEL9(JU,620HL?3
MK@<UK:AK27BM+8 19/"8K$2>Y%P6:0[R.>* (2X,H8KP1R"*>&0*1&>M2PWR
M LLT:EFX!IC++DDQC9V- $1$L$D=S%(4F1LJP.#7TM\/?&B^(?"R&Z.+J)-K
M^]?-@B\Y6 ;#>E>D?!F:6*[O[5G&PC(!/M0![+<W\5U8K$6&15,#;P!P15<!
M5D#%"H/7%3[]P!SN6@!LZAH,,/QK')D5V Q@"MF3[I(ZUD7 (DR30!'@L@Y
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MYIQ4[_F;:2,X'0T *^TJ<* ,9P!TH0;AT!X_&A?E')QN^;'?Z4N1N.\.?I0
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M#;!QD?> H GC^9 2H#'M[>E/R,8)8'L%/2H?,WJ0SDY(;!ZC%2;I2,@*%]:
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M 7KFQ>WCCE(!CE&48>E0%41-Q8Y'3FENI9!;VT!D8PA<A1]:K*F 612">[4
M=5H_B6QM?"VJV=Y CWLR'RI2O(KFHMJQ#)#%N_I4+%-F"!\HXS3(69B5VEAU
MP10!;,&0&3:V.HJO+$Y!9PHSQTJ1&$3DKN&X<YI-X],\_E0!ZA\-/'[C&@ZS
M*IB(Q;RMU'L3Z5Z<(E?488)"#O;'MBOEUUD5C(@"NI!##J*]O^&/C!-<CM["
M_E O[5QAR?\ 6(/ZT >E3Z'Y0/DN".R5DR0#S!%,N'' #=JUM0NKF#4'"!@I
M *GL<5+/!'J^G^>H*3@<X]: .1FA:&4C!*L":C; "MEO;GI6QM%PACDWY'#
MCFLJ6%H'*DN5/ QVH B)"_>8MZ^E)OY'0>P&*> RN0&/OGTJ,@<DR98=*  D
M$_?/6F@?,,$MZYIX<L3M0@>AI6#EC\X''0=J -'3KVW\J2QOU62UFRIC89!K
MQ3Q[X.;PGJ\ENF]M-N27MV/.#]:]74Y;Y0=XZGTJY?:;%XM\/W&BWBAYPI,#
MO_"W:@#YKD_?6NT\R1$Y(Z8J.TF$;E6(*L,'-7+ZTN-&U>>RNX]KQL8V'KC@
M&L^2,Q.<D<<B@!UQ 8)>@*MT-1?+VR*MQ,ES;%"2)%Y%506S@9S0!VOPD/\
MQ<W1Q_UV_P#1,E?5]?*/PE#?\+.T<L>?WW'_ &QDKZNH ^-O& SXXU_ Y&HW
M'_HQJQ"<#[V,]L5M^,#GQSKX+?\ ,2N/_1C5D6\:RS 'D \T =I\/-$35-7A
M1B=JG>QQZ<U[-J%S&;D1(#Y<0VK@XKG?ASI4.FZ!-J$FU7E^5>*V %9B2PS[
MT "L<\#Z4N_'##DT*,8QDC-!Y;+*?;- !NYQP!0A#*<CK[T 9&< ?6GK&"I8
MCGVH L6<:EU.[ ![UK,=S<D=..*S;( (Q('XU>4ICYL@D=J )?-*1EV P. :
M9)J+1VLS@D*$+$Y]!56ZF(C2/:<=ZJ:Q*MIX:OYR3Q$PQ]10!\_:A<'4/$5]
M=NQ8-*VTD]JAE9N) /E'&<=ZB@$<B%P223DBM.QNK8I):74>R-Q\I(Z&@ TV
M]LH(KA;F#+2*0I!JA%_HS[E VGI3I++R78E@T8^Z1WIC*[,F!Q0!=T>V>6Z^
M3))/]VO9?"EAY48+ <#G(KSKP;"7OD+*<FO7]*MS#$2W.: -(+M!/4'H*7>,
MY5,$>IH^5<'G;[4TE6&5.1GI0 I*J=KR_*W8"GC !.05'2F @G_5 ?6D"QNW
M(('IVH D;:3@-G/7BF\\X8X]Q0^P';R#V(I WRX 8_6@!-JY()/UI1M!S&W.
M>]."R-R  M#J!D$!<=#0 -O)PQ"D]\4F'9=W##I2!2O$ARW:A5";CO/X=J %
M*$XXY6@$;@Y.T=/6@NZ@$$G/.: =RY=<9H =)RORH"<]<XXJ,Y<<'=[ 8H(R
M<L6'H:78 ,1R94]J %VX&4&,]5I-RQ\8/TH/F(VT@^S"GH[L3E03[T (-@;+
M,"2.!2%R#PN$I7B5><#)]>U"_>VEU89R!Z4 -#*7&$.3WI=C)@QL"3P0:<2S
M+G=A0>13/W>/E<[NI H E8L8<R*"1T"BD147$A<@CK@9IJN!"$WL#G\Z8/,)
M^4* >XH =PW ?=ST(QFC:Y$F4 '^]3FB;:-VW?C()H)D&/,*8]!0 B2( -J@
M'H.]'DNX+EP,]AQBE5Q]W"*?I2-!*@SYBLIX/K0 H&%(ST]\YID8E/+ =^#Q
M3A'MR0!N_AQ2'>Q(D8@\8H "G[MLMC _O4NT'"F3^'IBD<(I;<JD8ZCK2[R^
MTKM&10 W*)PRL>.#3E<%@S*0,>M.D>1AP4 0=#36<E$R %ZG'>@!1MD .3R>
M!Z4OV,E< Y!.<[JBRN_<'VCI@T[S2I P1Z#UH E2WCCD^>1MI["KJ.T(&"=O
M0 FLV:Y.PX4Y(Q[BH@\K.-YDV@8()H TKB^ED&S/R#KBJF4"KL!QU/-1 ,C8
M$JE?0]:EPB L2#CCB@"2-XXSE1M&.&)S4BR , 5!'7.*A\M#'\HZ<D4Z/H%+
MC ZK0!?MV( (^5G/7KFM!N(E!;IZ5C)(0P"'Y!TS2^=*Q5 ^&)H V$V*6/F<
MXR:@2X4EV#;LG'-49)I%'DL%R?XZ%D9/EVK@=#VH O37*QI@YS_$:I2W0E!8
M-STP14+L\AY?8W?TIF WS.ORC@>] #"BKB4@X]!2,PVE0_&>A%*S@$EBX^AZ
M55GN8^2RL"!\I]: *M\2,+&?J*KK%.RDA 5 [BIE*RL-K9)/-.OI&0+&C$ \
M';0!4#,K@8 />N>\80SOI4C0N.!S6^,JX R<BJNI6YN--GB"Y&/QH \&>24.
M49\L3R:GEO+LVZV*R#R5Y.1S6O>:"L<[2O*$"\X/6L:X8RDE%  ]>] $08A=
MN<GZ4]_,MXPR\ ]3C-.A*KUP1CI5[1M6AM]6@^W6BSV0/SH1GB@"A8V\^J2E
M(HG*KR6 X%/FVF[=).53C/O73ZMXJM+.[FCT"T6&VDZ\=*Y:64W!,FT9)R:
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M58,!TS3&D*H (VP.Y-(3,"PF\L,/[IS0Y)"Y'!Y)H B+$AB$/ %*L;-DF.0
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M4=R3Y:MN[X-<'JWA_P FTFED*C'KWKUJXRMNSQJ"2.?6O,O$23O+('^XWZ4
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MXH$@V_(I*YZF@!1@[RJ8QW8\4':$QN48.#M.:3)<.I^Z.QI55""%**&'/RT
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M*C-P@.372>(_%D6OI:P66E061A3;(R_QX&,USQ!;E6^J]J:L9$@5\H?7'6@
M;<%&<=>HYJ6*%7C9@XWJ,E3WIJ[,&-B,ENN*:_[N3Y069NE $;/A,MG.:M:3
M>R:7K$5_EPL;!N.,BBVC".)+@ IW%,N9%FD^0$(!P<]J /J#PUX@MO&?AF.]
MME7[1$,-'NY7Z_6K.F73QWNTY7)PZU\\_#[QA)X-\1QL=SV,Y"S(#CD\ _A7
MT1>1"Y$.JZ>^^WD&X[.X]: #6K;R+E;R'!CDX?GOVJA<P&>$@%00,@@]ZVE
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M "C[IPU("JDKC\#2$*H)P2WH* '$N(]H8L">U($=SL8]\@FDQD%UW(![]:<
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M=L@%0">S<TTR[/FV[@#T%  A!1MB]1SFF8B"*"IW=\5()6=&VQA6)SB@"5)
MC(-V.U #"0C':,J?7K2-* R[N<?E33(%W$H20<8S4,D@VG$;=>A- %@2K,=I
M5?J3BF-YI<( ,#TI;6S,[$CY57L:U+=!'D83Y1R6H J1VN5!;+D<X%+( F2%
M*R$=#4=YJ+C]U; %S_$HJHXN(D"O-YKGYB_I[4 2JH9OE*E^IR:G4,@8.J9/
M3!SFJ4,H\PJ5RW4FKJJK '.' R 10 XEU&U(AO[D&@L?,VLA!QGI2AQN.XX*
MCDCN:-[9QN^7KN-  &49)0@FD#*I>3D^@I2XRS-\P ^7'&32C87_ -6>.>M
M"!MZ<[BQ^Z<=*=L8%20<CO2AE8G;E?6H\[OD9RJ]N: ) @&6:0@GU%,E.]CG
M! Z<TTL N&^;GUJ%F8Y"KG':@!))L)L*L2?;BJDN2F !O4_+5A7F7<=N[ Z&
MH%8OD@ $'G- "0APN2JAOK0Z'G!#'OCFK+A5P2N..<4@1/X> >OO0!46$J#@
MG=ZXH8':=_(Z=*MG(PL8_.D\K&2Q&1VH \\\6>'[Z\5YXD A09.!R:\NF&V3
M+$I_L'BO9O$TFI!@$9E@/!QZ5YUJ<,=S.XEA 4_\M ,4 <Z%0YSP.QIS*[C9
M"PIAA$,QY)CSZU(&@C<$,5[\T 1"-X_]8PX["I=B.A;H:1;FWEN<!2^XXX'2
MGSP.DYC3GT]J (_.8Q+&BG )X(ZT]$0,K.FSV]:=*_V?8C#,F,YJ!GD/S,P8
MGVZ4 -=YDO%G@<J\9W+M/I7T)\,O$4?BOPO/93C=<0C+C/?M7@2QL(WV*"?4
M5T'PZU]_"WC&W>9RMK<G9* >I[?K0![SH\]Q97+QR$$(=KC-6]?MO+>.\C 6
M-N'^IZ4FJVZP74=U']R?[QSWJ]\E]I$L;+N*KP?>@#$V[F4J_:E$0QM+#:1S
MDU%$P,80 @KP:D3Y5P5SGIF@#(N(6CG(!S40X();G-:E]%YEN'4 $=ZR,XX8
MCB@"9HPP!1A[BHFP3A3R*%D_> $<4N[<[=%YXXH 1L(.Q]J=!(8)DE&02<TP
ML0I.!UZT KMR6R.E '(?%K0Q<06^M0'D<-@5Y/*AN8?.!_>)U&*^C+RTCU7P
MY<V3@$J-RYYKYYO8VT_6I;=SM .#GTH S<DDY/UH'(X!)J6[A\J<@'*MR"*B
M4XY&0/8T !4%@HXQUKOOA)^[^)FB)GEC*>G_ $Q>N! RZ@ G)KO/A3G_ (6S
MHV>QF '_ &Q>@#ZHKYA^+39^)VK*>@\G_P!$I7T]7S!\7/E^)6LGN?)_]$QT
M <)*07)&<5K^';$W>HP)C(9A6-D,<=Z]#^'^G;[J.<KPG.: /1(+=+2RCA7L
M.11D=<8ITS[GYXQ3.#UH =SUR*4FF]NO%+UZ4 *>10,8X-"@YH8 ]: %!R0*
ML D8S4*+\V?2K"#<>G2@!MW)Y-C(_HIKPR^<R7TLF#RQKV?Q#,(=%F(]*\4;
M<S,P&1G- #"7)YR*(T#DYZT[S=Q (Z5-;1"27B@#0TJT9I4&,\UZ/H]IL &*
MYW0K DHQ_E7?V5NJ(#0!<ACVH*FY'>F@X& *>.>M  % &3S2X)Y'2C''6C=M
MZ4 *./QH*\T8).<XH()XSQ0 F<'ID4N,_6C&UNN10.#F@ VTA8G@4N<&@ 9X
MH :,TIQFE84TKB@!Q.Z@9!XH&#QTH;I0 =N31G Z4@&:=TH !@\$4I! Z4''
M%2'&/:@"+.?:C.#ZTO4$8_&DXVX% "Y/XTJDTT<')/-.Y(H ,X//2EP2,K0W
MW>G-(K';C% "$C'K0>>G H/?BA3B@!",'I1SBE)R*"/E'- "<YH))&,\BDP<
M\4'@T +G+#(I2><&FDY88H;CK0 ,/<4W'3-&>,T$]#0 \, ,4TR_*:8Q)Z"F
M,V<+0 UR7-'0XH"X-.#?-C% #TQ4I.,8I@P/K3]V><<T .W+CD&ER,4@.>,"
MD&0: '=J48 YI@;)HS0 _( XIA/%#>W>HFR>* !^3Q3%4D,.U)R/>IH1D-ZX
MH J8.3S3@HQS3U&<YZ4$CIVH C;KTXIK+E>E3X!&<TQACF@# U2R\V-B&KSC
M6;1(;AB!DUZG?MA",<&O/M;B'VISU6@#D)U$A^0 >M5F&T_-5J["I*2AXS51
MOF89- #HHS.V(QS2R121G##!KHM%;3[2%Y;A06QP*R]0NH[N=VB0 9XH SXP
M2<$\59DD3R@BG%5#D'!-)G#4 .V\U(IR-N,FF!>,YS3P0AS0!>TG4)-)U.&Z
MC8@HP/!KZ7TJ^A\1^'(;J(X.W!SR<BOEHMO.:]K^$>NJM@]A(1@MD$]J /1M
M,G#1^0V<]*Q+^/R[V51TS6W&BQ7>Y>F:R-4(-ZQ!R": */!]:7 Z 49 [4AY
MH HWD'\>:I%,&M>X0M :RSD$Y% #>#QCFD(I,@-T-2=0 !S0 P@^F*;U..E.
M/RGKFC(QTH DA?@H0"K#%>4^-=&-A>EP!M<Y&*]1&<Y':L+QOIZWFDI*H^9#
MR: /'702)[K5,J>PK4EA,,NT]#6?(I20@4 1\]R**",>]% 'I?QV_P"1WLCD
M<::G!_ZZ2TOP7TKSM3O=3D0%;=05/N<BD^/#$>-K/'?34'_D26NN^'=BND^
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MCG IB^60"Q)-/PN.!R: %R%!W,I]@*3_ %F0H(]Z "< 8W9[TYA\P!4''H:
M&KC;AERP[TH+.3^HH!!RQ3!'&!WIH.1\HPW?- "L6/!.".@H$+E2P(/<BDP,
M$# /UI!Y8R[!R^.PXH 7 7^+@CD"E&T+\I^7'6F@1JWR[O<$4! <E1\@Y.:
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M@J1R33?-<':I ST]Z %=@Q"D@';R:CW @$2 $5')E6.&"L>M(-H<@LNUNX-
M$K,#RQ4#'/O060,-H&.Q%5T$3%U;+4Y BYVKCO0!,#YC'(&>E2 ?-@GIVJ*.
M1"ID *E>O%)YA\M9%DW'K]* )U8/]T# .,@4C1A6X.!0'&!@\GG\:(B!D.,@
M\?2@!Q0A3M#$_6ABRE0J@XX(-!**X0.3CO3MK,Q#."1R.: (R#YF3&,GH *
M8RVT,5(&X9J3,B!3\NY>>M ?<"S@!B.U $8+9Y?/J*?^[!)(.2,#%($)C"[L
M'J:%\Q>8Y01W% #40+RQR,]3VI[>7YA(;:IZ8I,$C*N,GK2A6 '"G'4 T .V
M_(09"2.FXTW8W4N!GJ*"5)RT1'TH*(V" <]2* &E$ ^<Y4G -*591@.&5>E.
M7Y0>..PIA)9.7^7N?>@!A8$$XQGMZU4=8F9MH"@=>*N,K$[E(('6HI0K'(_.
M@#.F5"^Z,?*!^=1<[=WZ5;D0)R"&!JJP,;DKG![XH :"3R<*P[5-$Q!^Z#GK
M5<DL X)8G[V:G3;@;#F@"V1NCRH(..17$>)+0;6=WVCO7<"/,>XJ3GD8KDO$
M:91B&8_[)% 'D>I.RW+@$F+..*SR!$NY6<>^:V-741R.=HP>"!6,L_R%"IV>
MA% $P_? >6<..I/>IGNGM[?9+^]4]0:J(75LQC\#UIZ^8ZLDB9]_2@#L/#?P
M^N/$^ER:K%<)!:1<,C5RVH01Q:A+;0-O6(XSV)J[8^)M;TO29=-L;DI:S#YP
M.]991HP,KEG.21S0 Y%.S#DAE/ I))#E)T',;J>>O!J:*%GN5B1]C-TW5:UB
MQ>R_=/@%ER3ZT ?0NC78O_#>FW+8;= N?K44T9,X<)\F:POA??O=^"?*."T#
M;1CGC%=.D:L&4DY]#0 Y8@K@'IC-1R0))&ORG?[5/L8I@\[1BE^90AVC&#0!
MDM@[E8$$'O4'&XD,/QK6FC$JDX /7-9;0A7)4<-UH :KMG P?:E=65\$ 9Z4
MW";2 OS#O00#RV2,4 *\F0%="#Z@T1RB&Y21 <J><TTJO8GI0RXW$9SU.* /
M-_C/H_V?6K;5HUQ%=( 2/4#FO,]RCI7T!X^TU=8^'<TJ$M/:G< 1SR:\ #$@
M*3G':@#[CKY=^+C^1\1M:8;27:+(/7_4I7U%7RI\7W4_%#658D;3%@_]L4H
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MR"'&>W:D.U0 %8\X&1UH 4+SNV*@P<ENII000HVGI@L?YTF 6;Y3VZT@"EB
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M#\F<T[>&^55(/KVI3O(R&&?0T ,)B7&W**.E.WF0G(W*:%C .6(SW%+C R&
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M %67<!D $=P*J/OW;=VT$9YJ],<MCH/4U2E(92#U!XH CW/&>%!]>.M36X#
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M(VUE#(2MM$L9';@8KR7X/Z;'>^,6N9D+I:0^8I _B!KT^YE>:ZD?;GYCUZT
M1H0,CG)..33OEY& 22*9GN5B91V;K4FU=PRVT#[H% #6Y+[3TXP13B3G(&%
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MX.[,8/'7OB@!S@@H@4[CSE3P:1C(KG"CVYZ"F [&/., <#TI^(P-Q/RGMZ4
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M+C[O&::5(/' IV>X?CTQ0 OW68@9!Z@4'][_  D&FL&.U@< ]>*> V<@9]*
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M=RC'!SVH 1@@(Z^^:Y+XT+C1-*<%=N!@=ZZYAE0=V#GTKD?C1G^PM*&1T'%
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MO'VCZMXA.DHX60\1R]F/I73WUNUL2 PWY]>M &5(Q1CD,NXY))ZBES'O^8E
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M_HF.OIJOF_XB1,_Q;U=ATS!_Z)CH [#1D$>AP*.XJSFHK#Y=)@!':I1@<XH
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M,B@3.V<FF!0/F)_"HY)L?*!@4 .D<] U0,26YII;J:* $8\TG;.:49%&3WH
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MGE35;:"I89<#J10 OS$\D8QC(%+AB5*G..N:%VKSG 8?Q49'E[RK'G *GB@
M!5I%&#C=R>E79U\NU1& #-U8>E4U#N4V['(/0BK]R%DO$C!*,5Y]* +2?ZM"
M,8 QNHYP0@[XR>]*J%5/F(0%& PZ4FU@"-^?=* 'Z6Q76P2,$(<'KVIP<R:[
M:-M7!ER3CDFH+ J-=C"MD^6_\JT],A3[<\CQG<B;PQ]: /G[XHS*WQ-U-0C9
M3 )#=?E%<F\F5 RY/3'-;OC>^&I>.]6NU P9!\P[8&*RX+^.- /*5I,G#$4
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M@0#\_;BI)9/+0GOVJI.JLMN_()4EO?FJP>&53WY;'9Q%G<L&EAZ#]][OLO\
M,AD>X=T#OMSV[$4-#MB7 (/49J2:1I[I"5C.T 8 [4L[O+@  *G'_P!:O722
M5D?G4YRJ2<IN[?5E=DSU!/<>U7K>0^4&8 *1QCM5=75I<'@XY7UHB? <+CCB
ME*,9*TD71KU*$U4I2::ZHNQ3+,FY?RJ2J:R",<*!@@9[&K8((!'0UXN*P_LI
M:;,_3LASC^T*+53XX[^?G_F>J_##4DN='O=*DP&M\2Q@<':>OY'^8KKW@V6L
MY<!@8V;/?@9KQ'PWJKZ-K]I=A]L8<)+[H>&_3G\*]!^*>L7>C:%$;*?RVGRC
M$=<5Z&#K.I3L]T?'<2Y?'"8OG@K1GK\^O^?S+_@W6%UK39H^0\+D*2<[EK:G
MV6\H,FP(>/F('-<7\+;1ETY[A69HO+Y(Z;JK_&2[NK;3+!H3LC)^=EX.<\5V
M'SIW%S"&42)P.QSG-1Q$NJJW&#R*\N\&_$?[.(;'4Y/-MRVW+?>4=J]59XKV
M!+VTEC*,1LQV% #@V9<D?+TQCI2A5XP<!N!GUI&ESB-CDGJPHE4A,8P5'% $
M9D+C.1@9&<8Z56,[QLC$ $_E3Y0S G. ._8U6:1O0%??^E %E;TH !\P)H:[
M9CU'7CBJC@ <9P.PI,@IGE2>@- $\LK.Q96QC^'%-#*67(P.N:;@_?)VYX..
MU,+-N(QP<8S0!,#N!SC:>I''%1.5.0-Q!I&P.0F5]O2E 9>02,>O2@!@9EX.
M!WH+C<=K$G'7M2J,$X&X'J?2E ;YB,!1U!ZT -!)Y5AG'I2X##E3G'7-*%RI
M/'KQ52_O8K:)LMB7JOH: 'WUV(K=U##> *\X\6W/EP*ZG&>'0'BI]:\1S(S*
M#UY/J*XJ^OY[B8M*_F(W;TH J2!FYSD#G@TV/;PR,=PYVGO3F6-AA<ENV*<$
MC*9<.'Z=: &,9 =RJO'J,U;@TZX;1;C5F*B)&"A2>22<<"J,C!,?,V>F<]*D
M8R_81$TC!,Y"D]: (T^8!CSCMCFD=&W$8R![8J5&="K# P.I[U8G9+BR$N&6
M5#A\]_I0!0,*<D9Y'3TIRQ(L1<#KQUI4C9V7;DYJ5BD>(]OS+U^M #(R0 5/
M3^'%2@.2>, C(]ZCSA [9!SC/>GG#J5#G ; ^E "B5UBVK_$><FHF+$D[3D=
M<]/RI<)C#'G/4=:FN')V! 0H&6+>M ':?!>18?B.H9QM:W< ^]>ZO;I9ZA)#
MG(W>;D],L:^:_!=S]B\;Z6X?#/*J';QU-?3&K+)_:9;9E=@P1US0 [6XTD6W
MN@W&0HQ68@!P0QWC/&.U7=3,@TZR52N"XZCJ:J8.\9R,4 (P.$).%*]0:JW4
M<;JS $_0U;*E"VWDKTSUJ*X53$>?+('WNQH QU9E. .,]^:4?W@,>WK29&2/
M-&XGJ*=#NZD'/0,: &;0> I))ZDXQ28R^!C']VG'<W7:6S@ TUACEPO(Z8Y%
M "=224(!_P!JD\0Q?:/AOJ\8 +*I9<\TIP -K +CH_)-:%K;0WFB:A:,"(WA
M)/O]* /%OA,Q'Q*T=3CGSNW_ $Q>OJJOECX71[?BGI@'W4DN%'M^ZDKZGH \
MUT1E:+Q#DY(U*X&/^VAJLK)SQ\Q-'AB0R7/BE,XVZG<8'_;0T .&X7YF/)/8
M4 .P&R-H QUHW JO) '0>M(47J&R <4[+ 9 R!TH %+"49_ 5JS<-!S\W>LM
M<-(IZGN36K-D"/D;>.: +$NX$C:0.](GW!N;CH,4Z0C:&Z^WK1GY<@8P.* (
MQ$AC=,%RP.*MQW^SP]+ Q_>QX4*/3-5XV 8,WTK-GW1W!4G <\@T <7\9;7;
M::3< 9&1D_B:\W'D"U:57 ;H%KU?XLKYOA*RE''E3*O\S7D92%(QN8[CSCM0
M ^WO943")SZXKI[CQK=3^'_[(O8$DA ^0@#(KFU?]UL2/!ZTT+E=S'##L* &
M(1QA0,'H14D=OY\Y#2[(QR:<J2%@50L#Z"IKWRH(DM5C*RL-S''K0!!\OVA(
MX^03@$U*\LMK<9!QBGPR0M$8UMB9XAN#8IEI!+J3%22TA8*J#N: 2OHCJO#E
MS<W]RJ197;\SL>BBNVK/T;2X])T]+=<%^LCC^)JOLP52S$!0,DD\ 5XN)KNK
M*RV1]-@L(J$+OXGO_D+T%4Y-05&^4X KE[_Q-)=W4@LGQ;1\#U<^OTJBGB&1
ME.4!85UX;"**YY[GG8W'N;=.D]._<[%=19V*QOM0<DGO5"ZU@M(8E)*D@=:Y
M:?6);B+(S&O\1JHEZ[,%5B<]^]=YY1UCZF]O)L !]#4,VMJ9#O/7TKEYI61M
MS2%B*A:X)8#=]_UH Z5M7*L7ED  Z>]5_P#A(9DG656_=YP8_45B[DCA#RME
M@?NFH&F\Z0L 0M &_?:P3<?(2D3CA151KX*02QQV!K+DF+@ MG;P!31^["F3
M.>H]Z +[WYR5W9)/!%7+'Q'>VEPJ1NOECJC#AJH6UE!/-'NN4C+Y.&.,55F
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MZWH^K0:_IR:@AVRNN7C]#0!J0MM0AAEO45,JAU"<@-RP-11+N([$]JGW>9N
M;GL* &2,,,H7('>J4B11N')SCICM4DESY8\O9@XY-4@692RD-Z@]: )993(I
M.\R*#SSS3 T0+,PZG..XJ+S%B(<(P)Z9%,EQ(W!8-C)(H E&6.!S_2GI&<8)
M!_"F*JJ0K9S_ 'Q3UD.[:6./[U "-EON.% ZY'6D?YP%7!;VXI7)1MKE2O\
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MVAO) O\ >-."_:4+R/R*FU6$)>RKWW5GX;C'2@"1(#(.,FFM:7".NV)F+'
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MG2Q?+N-5_N],B@!&&.!C- )QB@\C=WI!GO0 H.,9I=Q+@#UII(SFEWL#D=:
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MDA*A5.>E:VHR:?'+"EO&1(B[6;.<FLYEQO8XW=C0 ^W@>YCD:)<,@^8U"09
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M1>^>E)XBU2Y8R1F0'M@&N6@N_/AN8I <E"1]: %N-42>-QY8)/&X&J(=,98
M8. ?>HX\A><9[BKB63RZ<T[LJ[#P!R30!&J12J<.4?MD=::]N;>5?M&XH1GB
MF':KX8'"CCZU(&ENAB09*].: &*5/_+-< ]S07^;&0/2D8D':0-O]:56!!##
MYN@- #ESM.UCM'.,5-8W,<5T(2@V2?(2WOWJ [AE2 3C! ..*DLS;6NIVTMV
M/]'213(,Y.W/- "S7,=C=S00;2%)4M5&27?\N-[D]JWO%1\.SZXTOAYY/LDB
M L),YW]^M2^'O%$.@3+*VF17##J9$!_0B@#-@TB]$0DNH9((<9W., U$LP(9
M$(4$9'O6EX@\17VO7+33JL41^[&G  [<"LT,KLJA #MP#TS0 T C!SD'J*EF
M@:(JP8LKC--2$DN&'*CUZTP,Y54PW'(R: +&@^:GBK3G1=S),K?+ST-?6VU=
M6T^&16!.,GZU\W_"S33>^.=S0DQQ1DDGD ]J][L[S[!>F+_EEG)YZ4 .UB8P
M3V]HY^7R]V.V:J@ ("A.#Z<TZZG:[N6D8KSPH//'I49R%"@].P[4 ."XX;Y@
M6Q\O-12 _>C"C! )8U(5.PA'&5_E4<A Y8T 94X(GE*A!SWI/O$'<<]@>AJ2
MY*F9@H/3@$=JB4C.?+.-P[]* %;/). 3Z4U0=H.W(/4#FD)(?K@$].M*2 #@
ME..O6@"/(1>2HR>B\FMC0UP]PI(V&$Y#?2LENS*RX/M6GH07[1-U.8CR?7%
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M =L4TX]<&@":W& Y/'%>(:U<G_A()LCCS#S^->ULQCLY9#V%>$:DQEU2=_\
M;/\ .@">Z5'<,#UHK.G=PPP]% '?_'?)\;60 _YAR<_]M)*W/@]J*W/AZ_TQ
MV)>/Y@/J:P_CMG_A-[+G _LU/_1DM4?@_?\ V/Q:;96XN%QS]#0!ZF"F277)
M%.&YLE< ^C4Z[C,%S(O?=TJ/)8[0.E   #R?O=P*N6;8F XY]:JD[6R%Z=:?
M"27#$XQ0!H7 :&97YVGAJMO@ DOE2!C%5ISYMDPR<GH<4EM<(ZA&.6% $Z %
ME"C"]R:20AK20,O(SS4A5W)##:,<4T$>4Z'T- $>E3N'3: -RX/O7@?BFU^S
M>.M3AQM3<"0/<5[MI[<-V*M@8KR'XH6IL?&WVE$/^DKG)[X% ')Y6&5@AW C
MO4UO;B7)>55!]3TJS'9M<V4L^%4(/F]:J06<EQ&TRGRXEXR>] %TP'R?)M;E
M"#][)KI-*T^&]TV(0,FY)51RI_.N/2W>5&,)Y0\X/6ND\$6K+JYP[>6L;2,N
M>,]/ZUG5ER0<C6A#VE6,>[/0^E<]XSNS;>'Y(U.&G81_AU/\L?C70UQWCR.*
MXM(AYN)(<L$'O_\ JKQ\+#FJH^CQU3DH2??0XB%SN '"GN::!M;IN ZYHQ(%
M0M@J.F*F1EEN5VH=@YQVKW#Y<=+((''V;(+ ;A48CE:14Z,PXS232!I78C;C
M@ 5)%(J31,,LP.<F@"Y_PCVKQP?:39R&+^]BLN:.38P<E>>@K3DU[5[AGC:\
M8P8QL' Q6:97 W#+9.3F@"W<R6J6L*PPL9,?,V*M>'[F'3;Z=K@%XYD/R'IF
MBVL9I]+>1$ R1U/2LD1B*\9)V9\<#:,T +-*T]W(ZQH@9L #TJ:W,UE(Y<'R
MB.<T*;=H"8Y,R;N,C&*@O;IFX)) ."/6@! RR38+YR> .M6#Y5O,P)93MZ5M
M:SJ.C:P^GR:=IWV:6#:)/F^\>*9XBA@FN[:;"Q': RCG- &396$M](Y@(. 6
M(/4XJK(1%-L=6# \J:TIK._TR:"XB(",05*GK[5)K=X9[J&:2W5) OS8'6@#
M-29HE+QH,^]6;S5+>\LD7[(D,R<%XQ][ZU5&)3N;@'M4UVEK&D!M8B WWMQ[
MT +I=Q9V5^EW?0M+"!CRR.,UU]Y8#Q7!"]OY=ND.6$1XR.U<0&.&5ER/>NL\
M)WH_M6WA\S"'AJ .=U.]O[B807EW)+!;'9%&QX45>N;E;G2[=XY-S19##T%;
M/Q TVPL=0::UC8O_ !8& :YGPK:MJFOQV84A)/O^PH J/,TA4)SCFD!FEE6%
MS\S=#Z5KZ_!IUIJ)TRQ_UD+?-)G[U4(IDANW,O)11M% ';>"9I8!<Z=*V53$
MD?\ (C^7ZUUU>7:+?RKJEO>*WEHK@29/!0]:]1KQ\;3Y:G,NI]%EE7GH\KZ'
M ^,;#R-0,J<)<+NX_O#K_0_C7+6NI/;S@_,51AD#O7I/BVT^T:/YH&6A8-^!
MX/\ 3\J\ODDD@8Q[!P<@XZBM\OFK.'S-,^IRJTJ6)[+E?RU7WI_@?0GA36(]
M?T-4BA:*.-<' Q6B+)XDW?*4W9PW>OG:#Q'J]K&$L;MH8VZJ!79>$OB3J=C?
M?V?KF)[8KD/Z5Z)\R>D7+?:=/U&":'RCDM&RUX'KFXZA(LG49&37T#8ZQI'B
M&RE>QN4=E4@QG@UXUXTTQ[68NC#$A)P1TH Y>UYDB7/.1CWK7K-T^S=7%S+D
M';M1?;UK2KQL=-2J670_2N%,-*C@G4E]MW^6QZ%\)-/%[KM\[?<2VVM^+#_X
MFO88]'M4C* $BN&^#NE_9]!N]2=<-=S;$/\ L)_]<M^5>DUZ&#CRT5<^1XCK
M*KF-2W2R^Y:_B8ESX?C:,^2YW]0&Z5@?99K#45+(.& R>E=U6?JMH)X1(H&]
M#FND\,^6?&R20^-[U <[\,2/<FJFESLVHQVK!!&XVDFND^+-B]GXK2[08CN(
MU7\0.:Y" ;5+[L$?=/>@!;RT-O>RP*ZLNX_=[UI:)K3Z8P!3!SP?05DJ[R2%
M]WS\CFE 9@1N&5ZT >W>'O%5OJ/^CS/C@;2>F:Z?[(LC[U"].OK7SOINHM9S
M1N&*C/%>N^'O%J7=LL<P/F=.N* .F%H4SN)R.F*582#OS\^><U9@G6YVL"-Q
M'3-.8(V01ACQ0!2<E> ,#N1UJ/S 1M!(8]">E3E&!;C)'%5]H!^9?EZF@"+>
M['E>>_I2M&6CY4#!X-2,C1MZIV-.<E5+#G':@"I(=O //]TU3GN%B;[V#UVF
MH]0O%4;LX(KE[W7#*CQ-RP/#=Z -RYU-UR5("=P*Q6U17N5CVELG@GM6,VKP
M[ 9I"7'1?6LW^W(TN2WED_CTH T=4U)S,Q5V5EZ5@S7TF[@\M][%0W%X\C$Q
MN&0]B.:HG=R3G!H >[GS6(8*?0]#0J,T1$IQZ'M3/D"CS02OJ*L6R]I2&MP<
MYH 17%C;'S"&+\<]JK^6DJ;@"/<5JF^L)A-%+;;B!^[;-9YF+C#(%'H/2@"6
MPN1;B4R_,A&!558F:1C"2PSD@]J,[\K&>.X(J47'DKL@ W$?,: ':?;276I)
M;1G!F.%%175M>:=?26MQ"V]#T([4EM<2VUU#<QMMDA8.M7+S5KS4=0>]N&5Y
M' '3TH FTC1?[4OX?,N%MX]V6#G%;7BG35NM0C%FT0@"A05/4@8KDI9))"/W
MAC?/&#1-)=0[%$S$#IS0!:O=-NM/81NNY6Y#>U0P@IE1Q5BWU*:X'EW3$HB]
M>M5FE#OF/D=L\4 +:(;K5[2UQRTHKZ.OY$\BUM0,NL2CCZ"O%O 2V,WBJV%P
MFZ4,-H->WWZ([F;;L9 ,4 ):+_H^#\K XJ<!D49Z"JUAN:%W+>_-6=K$@]>*
M *5]<?N]@4G/K3--!$CY"X%-OY"90K#V&*NV\,<49 ^\>IH JZ@R.ZJAP151
M@RJJ@@FIKF+$Y7.>]0LY5QTQC% #<<'@;J9D@D,20/2I#@9P<]\TQOE!8G'T
M% &EI.(;>[N]Q BB8G/TKYBU*X-[J5S<GG?(3S7T5K]W_97@#4KY6VEE"_7F
MOFP#DMW))H ^Y*\$U#:/VE"3_P ]8^G7_4+7O=?/VN,8OVB7E!!Q-&,>G[A*
M .[U($ZA,Q+#G .><U4&.X(7^]WS5_5P%U)@ ,GD@=ZI!MN%8XSV[4 /'  W
M+D\<]::RE<;B$SUS0"#@D*!WIN%&&R#[=S0!?LF8NP"D_+UJS;*OVB1#DGK@
M^E06)57W!PBCM5C:PG5B0Q92#NXQ0!*<%3M !Z?)Q3=P50"@((P:=G@'&W/'
M';%,<[@ IZG&1VH ;.K&!OX!Z4RPWQ,I.W)[CKBI=J%&4'Y@#DFHK!0T1X^8
M'ENU '@OC>)H?B!JD>T.=W]!5"UN/L]A/;-#F.7NW45L_$B(P_$2]E8964@C
M'?@5@$27(VJ-J@X(H KMM"85@1G(';%"$*R !_,8_+SUI98L%ER"5Z&O0O ]
MGX2U/PPL-U"!K]O/YJL3RX# @#VP.:F4N6+D^A=.#G)174ZG3+-=/TRVM5 _
M=H <=SW/YYINK7ZZ9I5S>-_RR0E1ZMT _/%7:Y'Q[=A-/MK/_GM)O8?[*_\
MUR/RKPZ4?:5$GU/J:\U1H-KHM/T//9)9)F#2G>&[G[U,.8T^12Q(XP.:EG:-
M+@%@67:"HJUI.O?V1J<5U-;+/ #\T9'2O>/DS/@E E G 4GLZX-2[@)R0XP#
MP/6O<+G0/"WQ/T>*\TYHK>_10"JX##V(KQ[Q+HT_AC7I=.N83@'Y6/W6]P:
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M'M4R6T<3-G R>I]:=).D,;AL!0,@T /"1I]_@XYV\5E:Q=O;Q-R.F015"_\
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M%?/5S!%:^(;Z*52RQRD@9]S7T)92$/&P5<XR<CH*\-\7VWV'QG?+C(DPWYT
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M9D/^LE8NQ/OS5H29;YO3TIH8%N^T4X$D_*,G&,&@ (3@>OO3'!SM4D+Z8I2
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M@5GAND9B)4# GH:IY)5LL$QU)[U'H%[_ &UX%T^Y_P"6D*A#]:?A&^\"3Z4
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MU:8TR2YT91=7Z1R$[EX]*@\/V-E>^);:UU>7;9AOG<';N% #F0*YMOM>_C<
MQ^[]*S;A9KB=4FF# < M6GX@@TVP\77":=(9-./"/DL1QZU2NK1,,;>3>I&5
M)]: *TEK-%:^<5W(&VBHG=G5 QRRGC':MFXBFB\,6BW*[6E?[WH,UCFW?,K0
MJ9$3JPH E$7F-Y>_Y\?G6MX9M9+?6(GE  W#&:R;=3&\<KJ>> <U+J<[Q7*"
MV=T; (.2>: /0?B3>V-O/ JX:1HN0/6N*T*\.DVUQ?JNV9N WI6IIUC)XP\.
M70G?&J6?S(#U=0,FN4B>9HG@*,'0X9#ZT .A3[1>^;(2S.^3)W%;;>&-0:X:
M6=%6T"[O-;N*RK%LR,6PI4=#6E+<7^H[3)*YBC& BO@$4 4;N\M'A6&'("G&
MZO3] O!?Z%:3[MQ*;6/J5X/\J\MM(H_-=9(#&O10W/-=UX#DD_LNYMY!CRIR
M4/;:0/Z@UQ8Z-Z=^QZ>5SY:SCW1TEW +FSF@(XD0K^8KRB> 2#!X85Z[7F>K
MP?9]7NHL8 D)'T/(_G7DJ3@U*.Y]QEE.GB(5,/55XOI_7R,>UL7EN'CR%55W
M?-TJFV)28I"5P>&'>M>DC1(B2B*">N0#7HPS!6]]?<>3B>#ZG-?#U%;^]_FK
MW^Y%"WN+K3'$UC(UM)NY8'&:VTUV758"VIVXF:,8B)_B]S[52$:#^$?C3JBK
MCVU:"L=& X1C":GBI\UNBV^;%)+')JYI&EW.M:K;:=:(6EG<+G&0H[L?8#FJ
MT$$MU.D$$;22N<*JCDFO<_AMX7@T.PEN)0KZE*,._4(O]T?U]?PKFP]"5:?E
MU/;S?-*66T-/B?PK]?1?\ ['2].@TC2[;3[5=L-O&$7W]2?<GG\:MT#ISUHK
MW4DE9'Y3*3G)RD[MA37 *,&Z$<TZH;IPEM(<@<<4R3P?XTVDC1V-Q&/D$KC'
MX5Y<Q'EHGS!QVKUGXPM(VA6DH/R&5A^/%>4PDB"7(#-C(8T -(#C)7)'>IY8
MX/[.BECE43Y"NI/-58VW;2H; Y-6)4#!I?EW8R /6@" A@F78]>/:M*RU26%
MP5E(*_Q UG')0EB#P.,4GELZJR\@\GB@#T_0?%KK$C,Y*DX)KT.SU6UNU4AA
MR,_2OG.*\GM2K)R ?NUV-GXC,$$$N2JE0&'O0![*VTN>A![TR4)Y3,?N@5A^
M&_$MKJ82(L P'0GFM?4';#!,+"!EB: (7N$1<( 5[UEW=\WER*&"D]"*SM0U
M*.VP2_#9P0:Y?5=:B^8B0AP.F>M ":MJ[J=Q?//;K7*7>I/.[%&^;L:AO+WS
MWQ)D$YP :SQL#?/D+CDYZ&@"?>&P96 /ZTP.1)D/GT/K3H85N 0I^8#(SWJ)
M5,4FUQGVH ?L/WCPWM37D(78[96IKE6CC4LI /2H%=2R XVDCDT 64M6:RWN
MP0$YPW>JS!F0QY_=UI^)#&;ZW1#^Y$1QMZ9K/5(\#!.?>@!D;>4%/#!N"*D2
M 2.6.8P.::IRP^7GH!3L,X*,^#]* &/*,%$4 ?WAWIZVXDMM\1W'."!VI'VQ
MA493D<ANU3V\133Y[H9!8@* >#0!7FC-N@5B":#%MMT?A<]*8J@C+N2W<&IK
M^6.3RHXP=JCD4 1R1@(IS@GD4X#SI55N3V-2W* 00&$YX^;/:H"0K@Y Z4 !
MW122J< GCBD,06$3,I'/%2RQDRB1P0K<YIMS<,\2H"-J>U '3_#2S>Z\9PS*
MH98L,U>WWI5HYF!QGMZ5YE\'M-:!;[5I5.QEV)CN<UZ9*&2!VD7[PXH ;IP(
MM%XSDXS4Z-M5F<D@ U#9/F $< 5+,R16LCYX/&* ,Z(^==[NJJ:TE9/,((P?
M6J=A%Y<)E;D-TJR&W,[8Z4 9URP6=V4YYQFH& +;B<\=Z?*1O8CD9IAY &,8
MH ;C))(Y/&*1CD8!'X4\\GKVI8,-<1QH.2>1B@#GOBW="R\#6MF2 ]RQR![<
MUX5T4%200> :]3^-U^D^KV6GH?\ 4("0/<5Y9@;<#J* /N.OFGX@W@LOC1<S
MC.5N(>G'6&.OI:OEWXI.5^+&JGC"2V[<_P#7*.@#V76/^/A648W*I)(]JSN2
MN" <]ZN:C*9[:RN004>)3D\CI5+*]CQVQ0 X*B]21GVINW<A13N.<YQBE4 G
MDD<Y&32C?G!]"1B@"U8<N5"@^I/:K,N])TE/=ADC_"JM@P60,Y^]P:O3HQ@
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M=^&7A-]'TE]1O8RMY> $*1@QQ]0#[GJ?PKNFC5V8$$'BI&[@'DBD_P"6G4Y
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MXS&58,-H)/2@"8*'9MASVY..:;YA4*L@QU' S0NU]C$,#NS^-*<&7;DCODT
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MB6&];&=K_,OTH J_,7'.2.IIV%.=W?OZ4 ,!A5XQ2D';LXQUH L6LVV4 #(
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MO <\PG_R#'7U/7RS\6TQ\4-7;L3$#@_],4H ]4T2Z^V> =)F+ L$VG%2$GD
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M)8P)#%$/WK8P7..>: .="$H&S@TIPK<9)QVID8 3&XD^G8_C4JJQBW("!]*
M(E7!R4 ST)ZTFP*P<?( >M2J YV[3[YZ?G3)" RQJQ*_3- &O!XW\0Z:(TL[
MIH8HA\H3'^%5[Q=1U]Y-3>X>ZG/+YZUG.H(VX(6I]-NI["Y66V8ACQC''Y4
M5"[QG:R$?W@:D08 8$C(R,UJWNO-<D[K6,N.'8+BJ<\XG"G:HP.@H B<Q[<
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MZO\ #EZ,UH?Q8^J_,](K*UC2H=3EM6NFVVUN6DD]^!BM6N;\9W\]KI2P0?\
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M*I]TGDTB-_K&8\8QQ21LP7;R4SU- %[2;HQ:S:JZ[@SBOH#=NM8&5LD(.*\
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M-JCKTKH_&@/]K0$=H!_Z$U5/"^G?VGK"(X)5>3BO1PW\*)X^-_WB7J=MX%T
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MJ$I# ;>2* &$'8"P&0.*T=#:.:X^RJ,MU K,&\L,U/IUQ]GU>V<8'.TD=\T
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M;^('A&P\,VVGG3IO/,@S*..??BL*PF6WNXKF"%XP>"2, U6FO;_4B6D,C..
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M/BWJUI9#3HHT+!=I?)Y%<!?:G)J=VT\Z 2$5 S*SY)W,1WYIJ%&9HI!R>AH
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M%IFK6UXD)>"(?O#CO7'>"KJ&26:'4%1$P0A(Q\W:NU@MVTV-ED!\A^=P.>M
M'I?B3QS9:#X:353%(_G#$*!>23TS7A+:E'XDNY;Z[M]DS,3R,8%>A:@J:KX9
MM+)V65;8@@GJ>IK@=7E^Q.S+ JJW Q@=* *,]C"&DF,RH .F:R((MNH0&61A
M#Y@Y/3K4\MR+F$[Q@D8(JM-;7EPJ[(R8T(SST% '3^*KBTM]8CAF"RP/%NB"
M\U?\$^5)>W+PI@)& 2?<]/TK/\8V]H]AH=S"A\PVX5B#WS6SX#M_+TVYG((\
MR7;SWVC_ .N:YL7*U%G;E\>;$1\CK*\T\<7"G7)EQS'$J;O<C/\ 6O2Z\EUI
MCJ?BYH$^?S+K;CV!Q_2N+ *]1OR/3S65J2CW9ZS\.M-^P>$X(]@\RX;S"?8U
MZ0K)962E <XZ <UC>'K!8%B0KA(4"*/>M.\E>WN4<K\@!'K7K'SXUY5NHA(T
M>V4<A3W%)&5$4DCC#] AH8BZV.K!645(766,-*H613U]: "'<'4$C$@P13 P
M1)=JE,'&*0L(]SYRP.4QVI[!Y)-Q ^;&: %CVI%NX7C.X^M*-_D;VVEVY#9I
M9(8GDV;\ #)![TW*+A>W3!H 7$C-'*NSRAPYSWJ66*.ZM9H"VZ1UR,]JIC<\
MZPC(BSS[U:LU1;D[F^<=/I0!RT,<D,SVY(9@"&!]*^>M>MTL?%&HPE<.LF%!
M[5]&:Q$UIJ_G$X4XW$>E>'_%"SM[3QH;A <72[_QZ4 <LS.8PN<-GK4^FV4N
MHZO;:<DI5;B4*\G]W-5@VSAANST-.6:6%O,A)23L0: .E\>:;;:#J$&DZ=="
M9%0&1T.<G%8.FQQ?VC9,^2@D!/%52\TA:5G9YC]XN<FIXB=@"YWHV00: -;Q
M-K=SK^NK*7(6 *B 'H!Q5:_FBN9@&E+3!<50 ?\ >XXW$<TGE.?F52Q!P6 H
M "K.-O2ESM!7H1TS38GWRL5SN'44V4N9,[<X'6@ 9I'C#''I5NUM;6=4GNGV
M)&?F0]6JFF68G'RCFE:1;IRIZ#IQ0!HZAK-Q.Z1VG[FVB^ZB]ZIG-TIDSLD)
MR1ZTT(8T)CZYY![T8W'<Q*GK@4 2QL;1M[+DCH#76^&OB;J&@. EA%+">H[U
MQ+LS.&9LXXP:DC<(Q/1<<&@#U:^^-R:E:-;FR,6X8W =#7FFHW(U+4&N$/F;
MNN>U4)(XT"L.03THC8Q-YD7 )Q0 ^+]UN1@<G]*:H!DVL,+Z^M1R2.)"TC#V
MXIX<LF<4 321KYI"G//&*B(8')!\P?J*$N-ARHR>]7K/74LI0T]JDH!Y!':@
M"H'!0.0 P&*6%=\@);Y>N:Z/59_#6HP0S1!K:9QG8.E83QV<&[RI2V>"* (-
MRR2$O]T]*0-R5C&[/0&GQV\;QC$N/04^5T@B"!?G]10!6V9(5P0X/:K'E*H^
M9A4<=X5.[:&..].C5[R[B@3&^5@H % '6?#K0&UG7#>E<P6QY/KBOHFS;S]*
M6& X/W3["N-\.:'%X8\-1PPKF>0 OQU-=#/?C0M$1&P;N8<*/?O^% &;XEN%
MEF@TJ)U,4(W.P/X8-9F,CZ=*CB5U+M-AY)#N9J>$9F5.F: )H(O./(P!WK1-
MN$(V9(XIZ)Y40C('W>3BG D@$<*/UH K7DX7;#MZ]Q6=(") P;H*FNI1+*Q
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M?(;ZYN)8"/E#L2!0!R\0.S).&'3VJ8RM&\<L!*S#YMP]:9DEB0HZ4HW&,X4
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MGD4 9T$SWU_<W?EC$C8R3R<<=*N+R2&Z,,$"HK2*.*W1>20!GZU*K-N_U8W
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M_MJU4_#M_P#8-8@GVCY'!JQXS9O^$^\0X/\ S$[G_P!&M65#*$N55C@=,XH
M^F[QTNK"VO5X$D8_E6<  ,8YZYJ#P-?)JW@TVWF[IH/4=JF&%^4\$<''- #@
M-V2^2N>*<BIYFX<#'>D&-F 3UZTX#Y\9YQZ4 7;"8AR@/![BKR[0"NW//-8\
M<KH0<9'Y5K0LCHK+D CF@"M=6L87=&H#9Z&J!5@Q //KV%;*C$9!Y!/4U4NK
M11$60Y)YQ0!0.2> ,D<FBUN9-,OHK^%0VP[9!Z@]Z&5@?E^7)Y!J/+*6&W([
MT >@6"J6-Q#S;SC>/8FO+OB?X8GOYWU&P7;+"V7"]2*ZKP[K'V*Y%E,3Y,A^
M4MT4U?O8_+U<QS#_ $><8SVQ0!\[K/#-!(DF[S%X+4QY0Z1A2#LZ =:Z'QWX
M;F\+:R9H(]]A<-G/I6"\43H)%^7CH* /3M/N/M6G6TYZR1JQ^N.:AUJW-SHM
MW$O+&,E<^HY'ZBJ/A*Y\[1%B)&Z%BGX=1_/]*W2,C!Z5X$TZ=5^3/K*;5:@K
M]4>/2%U(=E)W<?+4\-E?M,I@@E;TXXJY+#_9^O36XBW+#(>">J]1^E=+)\0V
MDMFLK*PCB\M/O[1G^5>\FFKH^4E%Q;B^AQ]S'-]H)O%*2+C@TV4122+B+Y1C
MYO>I+Z\?509I@$E'7'>H]-M[>]U&WMKN7RX68!CFF(T[?5;.WN%DG*LT8ZM7
M;^$?'FCQZE%;S(K&5@JMV4U4\?>#O#>DZ!%>:;<1F5?E91)NW#'6N3\!:<E_
MXE2XD01V4 W$MZB@#Z.O?$.DZ?"[W%[%&%7/)KYZ\9>*1K>J2O:+FV+?*P[U
MG>+)I-4\7SL)7-N3M3#G;BH)X1IQ,)C&W&>#G- %%49U#NQ49Z&I?(9_N@8]
MNM#[6 "J0O49JQ8R26]Y&[)OZ_+0!4G_ '4(=6P5')[UZY\.?!2:MX<74=63
M=+/G86'( XKRJZA74=1,2_*7?[M?0WAC6;"PTFSTUF/FJF  * /*/B-X4M_#
M-Y;RQ2J$F.-I[UR$Q\QQSMC'3%>H_';$NEV$H5OD8D<5Y?#"HTF&>23YWZ+W
MH >GE0,LTRL_E\H!ZUZCX6^,-I#I'EZO T30C:FW@,!TKRMI6,+QL !CK743
M:=ID_P -XKN.0&^BD(( R2,B@"KXU\50>.M4BECC>&&'_4GN?K6 CE7*JQ+"
MF)Y954<%?]K&,5(^5)*C)Z9% %JSMKN6X\Q%SZA.M==X2C*07C%-I,V"/H!_
MC7':7)<G6;9(LKN.#GO7HFDVGV2*Y&<[[AFS^0_I7)C7:D>AEBOB+]DS0KS+
M4V']JWKGG_2)!_X\:]-KRF\:-[^[D1BT<DS/^9S7-EZ]Z3.S-W[L4);P-JNM
MZ?9,NW=* 57N,5]*Z!:"&$D# 10J#VQ7AWPWLUGUZYU @F*V&U6*YP<__7KW
MJQ1H]+A);YLY)]:]0\,GN)7M^?X3550&5F.<@_A3Y'+L3NW _I2PL))#&<;<
M?-]: (<[H@WS*5/0]Z JJ3(#DD<@4Z1N2,9YP/:HXXAN'F.>Y'O0 \!9HU56
M"MUYI5A#/AB>G"U#DD[4Y/>G2$.X55.=OWL]: +!8I*(U8XQSZ4YXRL9D8MG
MIM/0U!:#,<AD'3MFA2]R27;$2B@"R;99[*2+Y?F&/I7#WB,UC?6DBD,L4@R/
MH:[<;EECCC!V=37/:I$?[6GCC'R/&01CN10!\P1L8GD1QPLA6K,D@=,LN OW
M1W-.U.+[-KNI0L,;+AOYU$TBX)5,G'!H Z;1/!=SJWA>\UN>46\47^K!_BQ7
M*[@8@)1_WS5XZSJ0TK[ MP5MB?N9Q5.(G:8V/?TH ]!\(?V?HOPYUK4+I1Y]
MP"D(/7I7/:5J\D>D;9(89#(21YHR15"\NY)=,BL@<)&V0H/6J[M(L"(  H[B
M@"6XECFFW-$-P.,#I4#JI1/*P"#\RTPLC(O/SY_.I63]UO)V@GH>#0 Z:54A
M&.O?-53,[8**"<\ 4LSJV%&2/>FI.('!B/X$=* -^T\BSM7>\=8I91@ ]15"
M>;[*62#A7Z2>M47_ 'DOFRDNQ[=JL128C\MAO'\J (C'<7)5,DMGK7H_A+X<
M+K<&^?Y#C!/K7G,I5<K"Y0XZUL:!XOUOPT6EM+@R ]0W2@#L?$7P?DTR/[1;
M7>81R5[UQ6IWZPVXT^U.T)PY[DUT%[\6=2U2T,%["!D$?*:X^6,7),^<*QR*
M (@'0;D)'M3AALED*,.XH8E@%1@,4Z.(O'A%)8]: ';?D!6XVY[YIA5'8&:3
M>!W%2MIE^ "MO(P/0*I-2)IMQ)O:6/R0/[W% %=H@Y)CPI'0>M.BB9D(P0>X
M-2IILTC@B0#!ZYJQ+$[ML25!M&.HYH SI"58!D^[W%)'@MOY)'K5D6]Q)E"!
MQT-1R6K^9CI@=/>@!),X)0[B>HJG<2X0)$"'8[0!5C9)"03C/?FN^^&G@\:M
MJD>HWT!\H."J,."M '>?#_P]_P (GX*:ZN%9;VZ&23U&>E=3H\4=CIDM_,<.
MP)9F]:778)9KBSM(6VQ8Y 'ITK/\3W0M;*'2H?O/S)STH R;">2YNY;AOO3-
MNK7 7[HC)]6K%@E,87:<8]!5_P"W+L&[DCIVH LF01*<,#Z5F7<IN)E##Y1V
M/0TR1Y)&+9!/;G%,)<J,GD]!0!):0>?<@N"0IX Z"M9@-P^?@=%'2H+.%H82
M21D]:L?)]\#:%'?O0!0O'!D&X  #I5 .F2%X]A4UPQ=\D\L>!4',FX 8 ]:
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M##':J^L?/9 ^E 'B'Q @\NZB<#J>M<9NXYKTWQ_9F?34E5?F1NM>8K0!("5
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M)\H/RL"WOTJU'J<L=NL*891UXH L)I;VMTCOLGB+  9Z9INMV#6-[N-NRQN
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M[CRAZ)$TB,A92QY4BB2,;FV*K%3C&:6%26)W 8; SV%(8S&Q5#G<<L: &A"
MXP!GC H9D$6UI",GE14Y"12*YX[X-0B)69V..10 ^1%*J#Q'C[U11J#*)EC
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M\RC@&F* J[GQ0 GW5)SD#I5^RA.[[0XX[+5:UMFN6)Z1YY%:I81(N & X %
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MP7"00,=B^=GA2.*CD^0E0Y#]<TS<&P7.QCT]Z +MGJEPFJVI:&,?.,X%>G@
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M[U%*)CMP,)WXH 9@QR#!.!U/K3MQW$(?EW"AB2@\H-GON':G$'  VX'?/0T
M!^\P *YX-68K(K& 7RO7%,6VDFC+9&<\5?1-B!>WI0!2@F<RLH0[0>OM6'X@
ME\K45,?!.-QKH3;@NP#[1GH*YO6F!N,-@L. #0!X'\0[%[3Q@[JF$N4#C'0D
MYK%@@1F4"54..0WK7IWQ,T87_A\:HN1<6G4#TZ?UKR>#+IACN[\4 6)H/+/R
M$-D_>-#*#&@+C<.>.]"910=AV=LTT+AB=Q]CB@"3EG+L-H'&*FLSNU*"WVEU
MF;;M/O3"<(,*'-/T\^7K%M.O'EN&)^AH ZK5=&TSP9>Q7>I6TDDC#,46>#Q7
M&7NI-?Z@\[1+$KMD(!PHKN?BEX@LO$EMI:6Q!FAYD8?2N7TCP_>:O%(+6'>Z
MKGB@#-6+S)5#R!0>_I7;0?#W2KC3H[B/Q!;B9EW%&)_*N.^R7%K<F*[C*[3@
MK3M0TIX"EQ;R%X&Z@.<B@"[>Z:-.D:&.9)^VX5GLCINVD\]<5.UO%LCF#-NQ
MR,U-') ?^/CY_15H SBN K?>'H:F1':/'&S^+/:IQ/9"X+O;G Z"EO)(&5?*
M&U&&2HH H/&H?:B<>IIDI(79NQCH>U2L)#\W&WMFJI.6(8$\T "GR_FPQ&>I
MJPE[<1J6CX'8TV5#L7(&S':E2+='EF^0>E &A:>+=9TR42@I(HZ!AG(K6U?Q
M1::W90/+$8+AA\VS@&N5;;O^_P#+VJP!%-;^6V?D/!'>@!K73@E49]H[YIZS
MY.0F3ZU!("N @)'<4C.J >4>>] &HU^D>T[CN[BD^U0RC?N*MU(-9DA);<5Q
M3H+:?4;V*RLXR\\IQ\O:@#IO#&A77B/5T6WCW6JG,KD<5[[X9BBM[E[>%5$<
M*;1@5A>%O#D/A?PVEO)+B0KOE8=<GM70:,\4-K+J,R^3#_ #_$/6@"]=31VC
MS:C.Q 4;8U/<UQD[RW5S)=3#+2=">P]*N:EJTFHW.[:!"A^13WJG^]>3<[8'
M7 Z4 (-JD%.N.@IH'=QR>YIP*DY/Y"A1YC85=P["@!O/7J#T-:5G;"./S7!9
MCTS1;69C(:7/3ICI5O:JA0<CB@ 7(?& 01VJO>R;( F?F8]NHJQE5Y7I67/<
M,TK-MX' H @<CS1\V[ P*8,LW&0Q]:,YPZ\-W%&'<G;\I% "LA9?F ST!HBA
M:2YCC4;B>U, *G#L?Z5H6#PZ=976IW S'"A91ZT <+\7]>2UB@T> CY%S(/>
MO%QSEF?&:V?%&L/J^L7$[ #>^>N:Q0I;H,?6@ 8J0./QI1Z\D>E+N*#!&32H
MK3M[#J: )(?W:&1D&.@KM_A%M'Q4T8ELNWGG_P @25P\CKO&QL!:[GX1B)_B
MIHT@<EOW_!'_ $PDH ^I:^6?B\2GQ4UENW[C_P!$1U]35\K_ !?S_P +3UGG
M_GAQ_P!L(Z .02<'@C%6=X*]*SUW>U6U+>4#Q0!/ _DS+(K88&O9/"FHKJFC
MHC'YTXKQ8 $;AUKJ/"6KO87R*SD(QZ9XH ]49"I(Z8H'N.*>Y$T:3(<JXSQ3
M"<#K0 H]N*D1]O(J+@BE H U(9!*O3FI@HK*AD,+Y!R*TD;S%W9H 5E!!%49
M;8H25.15_/K32P/IB@##888BD!(((ZBM&^@4H)4QD=0*SJ\/$4_9U&D?4X.L
MJU%-[[,U(RMQ;;6'!&#7 >*O#9MBUS!RAZ@"NRMI2CXSP:OS11W4!C=0RD<Y
MKUJ%7VD%(^>Q5!T:KATZ>AX>"J Y'(J+[Q+5U_B;PV;*8S01_NSR<"N76(9.
M>*V.<K.U1C)/(J=E /2C(Q@"@!]O.T*D*.M1E2K98=>:?%&';K5DR1;"K#)Z
M4 4VPQ^48Q0DA3)QFG1Q--,J)W-=%J&F6^G:5&S >8XH Q]-G@\XB>/(-/O'
MBN)3Y8VA>U4%7G(XIP&&/- #UV%3DX(Z4V$.TR <DL*9C+X49-=9X6T1)9?M
M-T0JI\WS4 =E:NUAX<9R/F5,XKC9?'-]'%)!'D;CZUIS>)8;B_:P4CR6^4>E
M<SK>F&RN1(HRC<@B@#*FDEFN#/*26;DYJY87J6TX=DS56X;?M(]*9C"CF@">
M\F-W<M(HP*C5<C@TJ<1L::AP"Q/% $;\' YH!QC)S2RD,,J*8JY^M %JVYFS
MT-=%X3L#+J4UY(/EA^5?]X_X#^=<S;)))=)'&I9W(50.YKU#3K)+"RCMUY(&
M6/JW<UQXRKR0Y5NST<MH>TJ\[VC^9:KFM=#ZEJUMIL7*Q_O)/J>GZ?SKHY)%
MBC9VZ*,G%2^'?#TZQS:G<0$R3'<21TKEP-/FGSOH=^:5N6FJ:W?Y&KHVF%+>
M*-5PJ@ FNBD&Y54=J73%5=.; &ZG*A#&O6/GQJ1!CR*LI"FW&>M"$*!GJ:E&
M.M $;VS1$$<CK46&R21Q5AIO+/S<CWJM+(96 CH :S#=Q3UCRN<TD=N<G+*/
M;-2+PP!/RB@!T<9D;:...M6!;K$G)W&D,RXP@P!WIPRRCF@"I*H8G;5'4ABS
M(-:TB+M([U5FMO/78!G- '!:S9K=Z;+&>XKQ6]A^RWDD><;6(KZ'U"P-O(8R
M.M>1>-]$>VOFNDC(5N3Q0!R;-\H.*:,D\#BD!RN*D1@OX4 2P2B%_F7<*CDP
MSLP& :83S]:0G(ZT 7=*;$LF6P-M217K6UYNC;@&J]J-D,AZ$BJW<^M &YK&
MH_;XE.,$"L-)&0\$BG/(2.M1 \YH F,C/R:<NXG"U&'&*596'"]30!I:5%LU
M"(R-QFNA\0:+YMHMQ"<X'(KET;[-'YA;]YV]JT]/\03-;M#,VX>] &"KF%L8
M/%=%HZZ=?)Y-UB-B.IK)G>VEF).!S3)8E8AX7QCT- %S5-(@LY2890Z5DL #
M[5,\K,,.Y./4U7;!- "$#L::1@T[J.E!P![T "J.#CBI6\HJ O6HES@\4N.F
M* $;@5UO@WPX^IW/GR<1I@CCK5'PUH3ZK>C>A\M>22*];L+2+3K=8H$"@#G
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MCYY2.#Z4 ,6W8P9FC&]/NX]*KSH3*6!'S_P^E7TRL8,C'<1^%,6!0F206]:
M*GEEK*6%CE3GBN3-NLL%Q;]I49,?6NN;<D>X>O0UBZMIS6TB7"CY&8?=XP:
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M0!3\P*3D<9YH"NJ"0QR&,GY7 .#4CDE,8QD?A5VUU6\%D-.C">2GS $<\]:
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MAQVS6M8^%-4U/2I;RWB!6/K5-+>.[DW1W)1R.C<5VW@Z_O\ 1]#O]/W0W*S
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MF]H@?"/D^E %??Q@"F 9(&:G>V:-"S5!MR,YH D9DV;0O([U-::=-<*SJ5
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M]??K4EU%<:?=M9W"%9HSCZTU5#':S!2>F: !=J8 )P_3/:@R*OR'&13Y[>5
MN4)3LU).J)!&WEYD[_2@!TAD$:L%&#T(J/C;@Q_O/6G_ #_9MPR "/PJ)P^6
M(?..M !+&A #$DFGI!/L+1KMVCJ:<EK)=1DQ*=T?.13#-.Q +L&'8'@T ,".
MQ'SC)ZY-*P)_B/'7BD\M2"X)# ]*>"2P;&/4&@!H0OU.[ZUVO@>]@M-,U.UE
M&5ECQM/UKD@<#!7&:FC?[/*3!*Q)'S<T 5)U"%E0?*'//XTU6!RK+D8ZU,Y8
M#YE!W'.:78P^[M&1TH JLB@\IN7-/C/D-N0X!Z$&GDN,J0!ZXI@550H1DDT
M72\$\(EF7D<9 IJ?9(FW%6*D<9%10RHH:.0?*PX^M.Z K-C8>GM0!$(UC)>-
M\CT-1RSHN-ZG<>F*DBAENKD6MI"99#T""O3_  M\-HHME]K WL<%83VH Y_P
M1\/[O7KR._OT,5BA#;6X+"O:SY-O;K#" L,( 113H]L-ND2JL<2CA1Q@5EW5
MPLK^7&VT#]: "ZE$Y$CM@#HHJ2WM9'Q(WRCTQ3[.R1\22GG^Z>]:+.2/+5<8
MZ"@"-<*!'M!7UJ.206J%P0?04Z>5;4!R06(X%9+3&1R6R<]!0 C2M<OYCY#=
MZ>RB&,!3]<4HVK\Q4YQPM1DR2KNP%!/3TH 0E6Y (('I31G'7)-/(<_,<8]:
M:0/O*>E #>0X3/TQ5Z^U.'PIX?GU&X(#E"$![FETNV6XN#)+@*G->0_%7Q=_
M;NLG3;1_]#MN.#PQH X?5-0FUC4I[VX?<96)&3TJF<J<<D?2@+MX&#FE!.T\
MX(H 0#=QCGZTAR&SLQ1M)/'7VI<M@@G\Z #!8!EQ[BF@^G&.M*<9!4\^U!9'
MYZ&@#[EKY5^,+,/BGK6#_P \.H_Z81U]55\J_&''_"T]9^4Y/D<Y_P"F$= '
M#DD_>/ /2K$+K)$T.S+=5YJN$!.0A_%J569''&".X- '4^!];?0_%%I<K^[B
M8B.;/0BO=]2CQ,D\6W9( R^F#7S20NY71B _7)Z&O=?A_K7_  D7A0V<OSW=
ME@9)Y(ZT :>Y/GQ*H]0!WI-J@;001VR:>LI4E#"F[N-HIP7<"S(%P.G7% #&
M. N^0'/&T?XU)@NF%^Z#DD]/SIK1@-E2.@ZKFG\#<KR CKA1B@"6SN!"QC8_
M)G@YK13R]Q.YDR<XQFL>1#\H7&#R!5NWO"K[)5^7&,]: +OR/G<20#P!U/UI
MO[M\JP.>PQ3\.S$B/" =?6@YV+E@/<#D4 9EU;R0C* &,=3W%59@712%W;>?
M2M@;FRK\\;?0?C5"6V\LX0DXY..@H B@D&!LSNSD@UJ6[K/ 4N%W0OPRD<CW
M%8Y+JV> /7%6X+C;+F1@8VX..U ;%*^LVLKDQD[D/*/_ 'A55E#*58 J1@@C
M@BNEGA2ZMO)=@1U1^ZG_  KG9(VBD:-QAE.#7BXF@Z4KK9GTV"Q2KPL_B6_^
M9YIXSTF>UNXYLLUF1MC*C[G^R?Z5RXX3Y'X)]*]KN[6&]M9+:X0/%(,,#7EF
MNZ!/H=WMVM);N?W4O8^Q]Z[<+B>=<DMSS,?@G2?M(?"_P,;)R<$-[FK-IIMQ
MJ4RK#)'&^.LC86HWCD1@"R9//W::\CY&"54\;ATKM/,.V\.Q0>"[6^U*62*>
M^$91/+;(4D5P9EDU"[GO;ARTTSECN/>K6FF1C<(2\@*$D9R.E5T#%1P.O QB
M@"SYCH@"_+D8.WFDD'SJ'7YB.M-;/ELIC((Z$'K3&9F PWY\F@"5)1''((PQ
M##GC--W-OVE@=WK2(\B*P !'2G?(, +D^I- #554+APQ[@TXG'&<#/2GVT?V
MM+@ GS8EW*O][FHF?=$H_CW9(Q0!.LNP,#]T\8Q30JD#<<=Q0488=@0#T.*C
M5@=S??(XP!P* %8JZ+R <\\U)$RNK@.#@9Q3E"2HRM%M7J"#R:N'4P]N+:2V
MBBB1<!E0;C^- %)9#Y>T9 'M38(KF_NDM;&V>YF_NHM(2H?Y0P5N036IX5UR
M7PYX@6]C5?*D!20E<GH>1Z=: *364T-\;&ZQ'(&QR>AKNO">@&S4ZA=*/M#@
MK&/[J^OU/\JS]'\,R7^M3ZK?2&6V:3?&&ZR'_"NYKS<9B/\ EW'YGLY=@_\
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M&'XUH IN 8G'0>U $1BR$W@Y4[@?>F-YD9(Q]X\8Z59G! 9PPR%PH-1^4TB
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MH;?J%/#/_@*BI4C35Y,UI49U9<L$0Z/I,FJJ(^5MU/SR8_0>]=W;6T5I;I!
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M%<_);>0"[-OC)^4BK>JO--;VC!=ZJN,GM5*/&QB93C^Z3P*8BU9R1WEZEO)
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ML9)"SN3SP*?M6*'S&7YCT%$2[079!M49YICDR.&8Y3T]* $,C%A\V#Z4X;6
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M\[%Y:U[]'[O\CDHM2M-'MVCLH7>Y=2KN^"O-9;S>8P8_*_<+5J^TZ:SE,5Q
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MRT<5N#'D*_8BBT7,ZR !AW&::TH.(R1@'\JU=.T&\OE)AB:-#_RT8%1_]?\
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MQG%7[K[)<ZWNMY?L\)/"U6N9%BN94WB92W!H C7'W2.O0FHV:!#ELYICSJ)
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M.F*I7%AC]Y;R?..WK2E%25F5&3B^:+LS,NK*6U.6!*'HV*K5MV]VSD0W1'/
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MX"HBE$3#(8\"KMMX=DC4>9= '/\ "N: +$%S8/(\4$C0L.3Y@V@_G5^$PAW
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M_P \Y^1^!KMY89('V2(5;WIE<L*M2D[+0[JE"CB%=J_F>37FA:A9/BYL9$C
MQO3YE_,5F$Y+!5('09KVRJ=UI.GWH/VBSAD)_B*X/YCFNR&/_F1YU3*?^?<O
MO/,]$UE=&FFS8Q3K,GEDR*"1[C-9,=O,YFD^4(&)QNZ9->H2^#]'D&%@>/\
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M6A4#.>3C&3FNLOOA9XEM+?S(2MSGHL9_QK#NO"_B/3X=]WI<J)W/6@"@[EL
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M:;*\T1<0K!!_"BUSEKI\^K7F]W+JK?.[=O85?UK7H=-0:;9 R71&,+_"/4T
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M ]I0F5C _P!ZJYD+/DKFG;&]02.U, =L@,H]L4 *TS\$8'84A\T9;<"<4!5
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M*?K@?I4]_JMKIJ[7.Z3'$:]?_K5S5WXAO;DD1L($]$Z_G5Q@Y$N21UBP6EL
MPCACQ_$0!^M!O[,'!NX,_P#70?XUY^[O(VYV9F]6.33:T]CYD^T/1HYX9?\
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MC;T=2#7>3:8D3@EW4=F7H/K0[7]L K1QW,!YSC)Q7)/ 1?PNQZ-/-IKXXW_
MX"BN\:#2;]6$UDD#=-VT*?TK.N?"*LH:QG##_II_]:L7@)]&CI6;4NL6<I16
MZ-(6S/\ IT( '&Y2<&I8K:P.3&874>HSBDL!4ZM \VI=$_P_S.= ). ,FK,5
MA<RC(C*KZMQ70(T2DB-$QV.*"6#;>N:VC@%]IG//-I/X(V,ZWTA%.ZX9F']U
M./UK3B$-O$1;P*K>N/ZTI#LY!. *"AQ@/FNNG1A3^%'GUL35K?&QAEPN2AWC
MOFG!LE2%.XTA+1G<=ISZ]J4M\V"2,CC;6I@/2ZDB(';/.13Y-<G'RQC ^E1
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M0!6BTR:7$L+&(_6M6&_U33Q'YDJW$8&-N,'\ZC"#?A68!N,FE& -H.[_ 'J
M+D/BLN2'LV5AZ'-65\1Q./EA;=C.#Q66RD$2(%4^E*2SX(3!QU% %R?6#=*
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M!H \]1[')+>="WHJY'ZU8>PC90Z3V\F1D O@_E73+XF\*:](JZ[I)M&5,">
MG!/^Z*4_#Q-2C6?PYJEO>H22(I76)@/3DY- '&S64L"!Y(75"<@XJL-QQ@@^
MU;]W9ZMH]S+!?03PHAVY>,NA/L>E4[C37B@%WY<<D;GC9*-W_?(H I12")QN
MB4CN<T]UC4"1%79T()J!T4'@LASPK"I5+P9W!'C/49H ]!^'7CJ;P].-/O)5
MDTR<X )_U1/>O6[G3V:V2\LY(Y;>49#(V017S%+%%M#1YV-U'I7?_#_XA?\
M"/R_V=J4LEQIC' )!RAH ]+/R_+(A//%*6B!.(VZYS6I<6 N[>.]T]EF@DPR
MLK9QFLQQ-$[IM .>YH D!<H=@&5XII$@R PS@&FD_-DRY/? I75%0L)6.1V6
M@!5D93DG<:E\R-L X1O3UJ $!.C$X]*"54D",\ 9SS0 \G;N^12#SFDW# )0
M<<&E$K$!=BC\>U+MBDR4!8GU.* (R!NR _7!)'6GQ,5Y63#'D*32F-P1O3"@
M= U-"98D!<'U.* -""]61@',@/1MHX%6S\R@G#=JQ6B/7(_V@'J2&XG@Z $
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MVS3,KDL&8'ME>HH D,JK\JJ-O3W%1D_,IY) ZTHV[L$Y!&<@4WC<& )7'K0
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M_#WQ=/K'Q.TBVB'EVK>=E/I"Y_I7T+7RO\(%'_"T]%96R/W_ &Q_RPDKZHH
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MVS0!M>7#/&51E96Z@FF037NBY:V>*2#O$[<"LU)1$H:%6 [@FM.UO(98]LB
M'N".M &I:^(K&Y0;H)0_\6%XS[5?2ZL)LCS%&?[V!7-2PF-_.C8"/KL J>-T
M9 \84$]B,T ;DES:6Y#0,CN>H!S6-?S+<2D?9X@I[[!FFKY>X-D*>_%.&_!
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MD<Y9CS0 NH:A)?W337#^9*Q)//6JCAY0-S!1_=ID1\M&DX+>],#M.Z[NN>U
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MSSD4&0X^506/7-.^9LLJ+0 [>."WXFA5BD7Y,Y[YI@=BNUHP33=V,L0<=P*
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M=&<%<9SCO0 W  VA]Q'8=:3+ODO<''3::E+D)S@GJ-W&*J1W1:=HW;&._8T
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M [;X/KCXJ:,1G!\__P!$R5]4U\K_  @7'Q4T?*@$>?\ 7_425]44 ?$'CO\
MY*'XE_["MU_Z-:N?KH/'?_)0_$O_ &%;K_T:U<_0!=L;GR\QLQP>E7N^02#6
M)6K9W"2*JN?F7MZT ;NE>)-:T9U:SO9%4?P9X-=3%\1(-07R=?T>WN5/_+0
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MD^[N)-( 47!X% &C:WJ;0)\8[&K)C+9>$-@],=*PPQQTR/2K4%^\ V_-M]*
M'.LL9/F&16SP15E3N"L-YQ][WJ1)6NT^6,8]2:C$$D,GF#GU&: +02+&X*@'
M=6I L94XV<_I3=WFJ&&!D]Z:7428"#'J#0 X*8S\LA!'=:DW?-EG+>N: I..
M <4TLC# C(;US0 K ;CM ;/Y4@$B [@"HYS3U7"XSNR/I2;BAVJ#CWH :)M[
M N2,],=J%#)D#)'J:>TC%2SJFWT'6D>144?/G/;%  VYAM7YL]Q32-HVEI?P
MI-Z$C:6S],4_?D@DX]30 Q"X;*NQ]CVH&YB?-?('2AS\PPV/H*7*[<;02?>@
M P<-A6(]16YI%H(XOM# [G'R@]A61:0M<721["$=N2#V[UJ>(M4&BZ'/<I@2
M8\N(?[1Z?EU_"IG)1BY/H73IRJ34([LY7QQXFW&31[-B .+AQW_V!_7\O6N"
MI69G<LQ+,QR2>I-)7S=:M*K/FD?=87#0PU-4X_\ #L**N:;I=WJUVMM9Q%W)
MY;^%!ZL>PK4UCPAJ&BV)O+F:V>,,%Q&S$Y/U45,:4Y1<DM$5+$4H35.4O>?0
MY^BBE52S!5!))P .]0;"45TECX&UJ]A64I%;JW($[$''T ./QI]UX"UJVB+J
ML%Q@9VPN<_D0*V^K5K7Y6<KQV&4N7G5_4YBNM\&>)O[,N!87;'['*WRL?^63
M'^A[_GZUR;HR.R.I5E."I&"#25%*I*E-2B:5Z$,13=.>S/<-2LUN82ZJ#*@^
M4^H]*YY2H9A\N"/X:M>"M7.J:&L<K;I[8^6Y/4C^$_EQ^%&HVZV]Z^  C?,M
M?2TYJI!374^%KTI4:CIRW15VY!P-V.YH9HBN2C\#/2F;UR3N/H>.E.4@#:%+
MIZGBK,A&,17Y<CU!IPDC508E&>^:3>$)"IP?QHS@G:F#WH 4OD@*'#^N.*&>
M1B0TNWZ4W<&4;F(8>U!3<?O]!GD4 &5Z!B3ZTDLGRA58D'K[T[Y3&2Q((ZX%
M,A1<$JP&>[4 .#HJ !&'L!1^Z.?EE#'ID4N%&>&;WIC%1]QBQ]">E $,A8$+
MO92O/S=#4JN#&02V['.WO5:2U:Y?,CX ]#5E8TB0;7R%'- !L63&Y JCL>]/
M )7]YL2->E5Y[R-0?+!+=JSY9?./SR'=_=H ORZA CD G/:JLMY+*NU2<FJI
MVY^9AN^E"J"2P<C':@!7RN,MSWH;]X^3*% [9IWE[A\W#'N:>HACP/*W^IS0
M!&L9;),A*^@IP  (4_-[4TR#=Q'M_&FLV5RP//I0 CHP R>?44BQDG>64CT-
M"HF[ <^IS2LBEMP;(]* $( . !SW%)G:Q 'R].:3E22.,T*_!7!(]Z '[B^2
M0,#TIJ[F^[U/3-26\4DS; A&3U%6KN73/#UMY^H3#?U"=Z "VTN0H)KB79$.
M2?:N-\;_ !&338)-.T=QSPT@Z_A7,>+_ (C7FK-):V;-%;= %XKSYXWD(>>3
M.3TSS0!)+<SWDS7$Q=V)SD]ZB$!<L[*X]#5E-J)TX[#-)(T2+ND8EO[H- #8
MH$'RL<GKFI#:D#=",L>]+:1WFI2K'86;NQX!49KK].^'.HNHN-9O8K"'J07&
M?RH XP6=S<$(B;B>RUT^B?#;5M2VRS0F"#N[\#%;?]O>%O":&+3U^V72C[[#
MC-<SJ_C_ %[60\9N/(MSQL3Y?Y4 =9)I'@[PNN+R\^U3CJB$'FL2^^(KQ1M;
MZ%:);0GC?C#5P[QN[[I9=Q/<G)HPJ C=D4 3:EJ=[>,UQ>W+2'/<USLCF1RQ
M[U8O+@3. @(5??K56@ HHHH *] ^"7_)7M"_[>/_ $GDKS^O0/@E_P E>T+_
M +>/_2>2@#Z_KY:^+V?^%HZSQ_SP_P#1,=?4M?+7Q>_Y*EK'/_/#_P!$QT <
M1@GK2TF.YH/- !G'3&:4$G/(II!Z#K2X]: #/'44;N*-H/;BC''3B@ W4O:D
MHH 7D]Z4#WIOUI1].* 'K(Z,"CD$5N:?XKU"QPID$B=U;FL&C /6@#T"UU?2
M-<.R\C6&3L5Z4EWX5Q^^TZX+CK\IK@5RIRN<UI6.NZC8'$-RX7^[0!UEEXDU
M?07$,OSQJ>=PKL-*\::?J6([@"-S7%67B?3[Z,1:I"I8\%\5:DT32[L"33;I
M-_90V#0!Z6(H)T#P.&'L:@:)D)!4UYS#-K^B-B-I6CZ^HK>TWQZH*Q:@FT]"
M2* .E!/IB@YZFG6^J:3J 'DW$>X]LXJ=K7/*-N'M0! ,D4N,FAD=3R"!3?QH
M <%Z4N,&F_C2]^M #N#2D%CP*8#[TX,!T- #<D9&*>KL@R,TN5/&<4%3B@"=
M+PC[X%6HYHV&00*S2A'O2<@Y'% &H^&!YR:C21E.".*II<.G'45:2XB8 -QF
M@"PK C-.#<TP,G\)J3@C@4 &03[TM,P<^U.R1S0 $<T$9ZTAY.>: 2>.<4 &
M,&NCT*W\NT:8CYI#Q]!_DUSHQUKK[8"WT^// 2,$_ES0!RGB*[-QJ1B!^2$;
M1]>_^'X5D4Z1S+*\C?>8EC]31&%,BAVVH2-Q'85UI65C!N[-G2-!-[&+BX8I
M"?N@=6_P%;@\/:8!C[.3[F1O\:9=ZQ9VVG,;6:)G5=L:*>G8<>U<@US.TWG&
M9_-_O[CG\ZS2E+6]B](G0:GX;1(FFLBV5&3$><_2N:KO-'N)+K2H)93ER""?
M7!(S^E<9J,:Q:E<QIC:LC  #@<]*=.3NTQ22W16K5T/2_P"T+@O*I^SQ_>[;
MCZ52LK.2^NT@CZMU..%'<UV,\L.C:='%%]XX2,$9RQ[G^=.<K:+<45U9GZSI
M%C::7+-!!MD4K@[V/<>IKEJ[;Q#_ ,@6;ZK_ .A"N)I4VVM1S6I-:7#6EW%.
MG5&S]1W%=W<QK>V#*O(=-R']17GU=QH,QFT>#/5,I^1X_3%*JM+C@^AS=)CY
MNE3WJ>5?S(. '.*KG=G/6L#0,$\8HY7G%&2>] )YS0 XC(SFDV\\T!LC%)DT
M *3VHZ?>/%,(8]*9M;(#&@!))RIP!FA9B!C;DT/Y8ZD5$US&IRHR: )O,9CR
M,4$@?>-5)+MCRHQ4#3.YY)Q0!;>=5!QS59Y&<\GBH@V?I3ATZ4 !R?>FD$FG
M8-*-O4F@!-M* .QYI"1V.*;G'>@!Q)%-/J.M')/)IRQ.YPHH CR?QH4,_ %6
M3%'$N^=@@]S65?\ BS2M.4K'*CR#TYH UH[7"[Y&PM9FJ>(K#2$^1@[^F:X'
M5O&>HWI9(I6BC)[5SDMQ+,^79I&/<F@#K-3\=ZC<DI;A4C/<#FN5N;Z>X):6
M=F/<9JM*)1W(%,AB>60;49LGGB@!=YQ\HJO),P/W>:WXM(NI.D&Q.[-Q5R*R
MT:R&;^XC9_[HY_E0!S5DES/+\J$CV%:4/AJXNYO,F8QQ]RW%:$_B;3[1"NG6
MJ ] V*P;O7M1N\AYV"'^%>* -X1Z+HRXD<SRCG /%5+KQG<^48;.&.*/H"!S
M7-,2YRQ)/K3<#UH EN+VXNVS,Y;/O5?;@\BG4N?6@!-PQR*;\N>F*4G'TI>#
MP?PH 3&#P<T8[T#:*"/1N* $]B*,'%*#ZFCC^]0 F3Z4$XZCBEP?6@9Z,,T
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MX9-H'H*'#CE?F- &LLL$OW6& ,TDD*, 8LCW%91\W.50!>_-2"XEMQQR#VH
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MF1@W;BFCG*\#'\7K0 OF+(-S,>>F*0\C:K'-2*I X\MOJ<5$5W,6("GU!S0
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MD\O0M+^V3KQYDJD<T <II?A#7-8.ZWLWC0\^8XP *Z&'PAX:\.[9_$.JI<7
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MRZ9'NP. /-EZGM7GO_"*:WC_ (\Q_P!_$_QKV/Q1>2WOB.]:4D^5(T*>RJ2
M/YG\:QZZXX=-7;.>59WT/,SX4UO=D61_[^I_C1_PB6M[O^/3(]?-3_&O3**K
MZM 7MI'F?_"(ZSC_ (\\G_KJG'ZT?\(EK6 /L9]_WJ?XUZ911]6@'MI'F9\*
M:T/NV)_[_)_C0WA/6R!BSQZ_O4_QKTRBCZM /;2/,SX2UG(Q9G_OZG^-'_"(
MZP!_QYDG_KJG^->F44?5H![:1YK_ ,(GK&1BR/U\U/\ &@^%=9Z"R_'S4_QK
MTJBCZM /;2/-?^$5UK=S9\>OFI_C2?\ "*ZS@C^SP<_]-4_QKTNBCZM /;2/
M/]/TKQ7I<HDLA-#@\ 7"X_\ 0J[;3/&7C:!1#J>F07]NHP%=H\G\2:M44?5H
M![:1;,'A?7USJFARZ=*PY>%P0#]%KG-5\!Z249]/U@.>T;PL#^>*V**/JT ]
MM(\\E\%7Z.?*56QT97 _GBMC1;CQOX=<?87>1,Y*22J1^K5U=%'U: >VD;ND
M^.KR[5$U[1"K#@RI*G\@:VI=4\/3$M'=/#_LM$Q_D*XBBCZM /;2.HFOM- !
MCOE8YZ>6X_I47]IV8X\\8S_=;_"N<HH^K0#VTCH_[4LL$&4<_P"P?\*%U:U
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M_P!5N]>@T75KEKJ&=&6&5P"ZN!D9;J00#UR<D<UK?&C2XIM!LM45/W\$XB+
M_P # GGUY _,US/PM\(ZE/XD@UBX@EMK.TW,&D0J96(( 7/IG)/MBNB^-&LP
MQ:19Z,CYN)I1/(HP=L:@@9[C)/'^Z:3^/0/LZGBM%%%;&85O>"83/XWT5%&2
M+N-_P4[OZ5@UZ!\(-+-[XR^V%?W=E"SY[;F^4#\BQ_"ID[(:W/9/$^JVFCZ)
M)=7LPBAW*FXJ6Y)] ":X-O'/AIG5CJ:DCKB"7G_QVG?&O41'H^FZ:#\TTYF/
MT08_F_Z5XK6<8)J[+E)IV/:6\=^&"C?Z=R3QB"3_ .)H_P"$[\,9'_$Q('?$
M$G_Q->+457LT+G9[1_PG7AK'.I \]X)/_B:0^._#(8@7V1U!\F3/_H->,44>
MS0<[/93X\\.<;=0(]_)D_P#B:0^.?#KHRMJA )_YX29_]!KQNBCV:#G9[$/&
M7A@%6_M5]P/7R).G_?-#>/?#Z*%2\1CDG<89/_B:\=HH]F@YV>MR>/='9"HO
M!]?*?)_2H/\ A,M!)S]JYQU\I\_RKRNBCV:#G9ZC_P )=H1 ;^T"K]SY+\C_
M +YI_P#PEVA9R-0"YY/[F3K_ -\UY711[-!SL]5/BW0",'41CJ?W,G_Q-./C
M+0%&5OBS'UA?_P")KRBBCV:#G9ZD/%^AF1F-\ "./W4F?_0:#XNT J ;W)[G
MRG_PKRVBCV:#G9ZC_P )=H1(S?''?]T_3\J7_A+M )_X^\#/>)_\*\MHH]F@
MYV>IGQAH2H52\"ACR!$__P 31_PE?AY@#_:+*P_Z8OS_ ..UY911[-!SL]=M
MO$_A0<RZNRG'0V\A_P#9:GN_B+X;T^(FR$E[,!\O[LJ,_P# @*\;HH]F@YV=
M-KWQ-\4ZNY6V)L8>FV%AS^=</<17UY,9+AI)')R79P?ZUI44>S0<[-'1-!T%
MQYNLZ[Y2@9$,$$C,?;.W'ZULR>+K'08S%X6T*-7V;3=SD"3/KC.*Y6BCV:#G
M97UO5O$OB%XVU2[DN!'G8I< *#]*RUT^Y'2$?BP_QK<HH]F@YV88T^Z)P8\#
M'!W"E.GW1'^K&?4,*VZ*/9H.=F,;*Z)!*MGUW#_&D^P7)89A4C_>%;5%'LT'
M.S$%A=#I&1GT8?XTXV5T>JL?^!"MFBCV:#G9B_8+DG!5L'J=PI/L-WD;H]V.
MAW"MNBCV:#G9B?V?<YSY0_[Z%*+"Z#9V_J*VJ*/9H.=F,+&["X"D9SD9%!LK
MEL Q'IUW#_&MFBCV:#G9K_"2 P_%310ZE3^_Z_\ 7&2OJ6OF/P+=M8^.M%F4
M L;I8N1GB3Y#^C&OI=9PUU)!@Y1%?/KN+#_V6LIKE=C2+<E<^-/%6B:EJWQ#
M\3_8;2295U:Z!88"@^:W&3Q5#_A!_$7_ $#O_(\?_P 57LDS+)=7$ZQA#/,\
M[@=V=BS'\R:;7B3S*?-[J5CZFED5+E7M)._E;_(\=_X0?Q%_T#O_ "/'_P#%
M4?\ "#^(O^@=_P"1X_\ XJO8J*G^TJO9?C_F7_86'_FE]Z_R/'?^$'\1?] [
M_P CQ_\ Q56;;PCXDA.TZ=E#V\Z/C_QZO6:*/[2J]E^/^8?V%A_YI?>O\CS1
M?"6LX.;3'TE3_&E_X1/6 .+/GU,J?XUZ511_:57LOQ_S#^PL/_-+[U_D>:GP
MGK&W'V(^^)4_QH_X175\#_0&R/29/\:]*HH_M*KV7X_YA_86'_FE]Z_R/-?^
M$5UC/_'BWU,R?XTG_"*ZWD$6(X_Z:)_C7I=%']I5>R_'_,/["P_\TOO7^1YL
M/"FM$\V@ ]I$_P :4^%=9VX^R'Z>:G^->D44?VE5[+\?\P_L+#_S2^]?Y'FI
M\(ZNQ&ZSX]I4_P :OZ=8^+]%E#:8;B  _=6Y4 _7YJ[NBC^TJO9?C_F']A8?
M^:7WK_(CL?%_B&9!'K_ANUOEQC>IBW_F6JW/H?A;68/,*SZ7.W5)?W@'_? -
M044?VE5[+\?\P_L+#_S2^]?Y'-7_ (0DL)_,TG4DD8=#"K1G]<5M:)XF\8Z.
M%CEA%W$.TDBG^9JW11_:57LOQ_S#^PL/_-+[U_D=?9^,+2_5?[0L9;1^[!@1
M_P".YJQ-J'AYAF.^.3US$_\ A7$44?VE5[+\?\P_L+#_ ,TOO7^1U1O],7_5
MWJ#_ 'HG/]*B_M*RY)NU)]HV']*YJBC^TJO9?C_F']A8?^:7WK_(Z,ZM:AAB
M<$?[C?X4O]K6HR!,-I_V#G^5<W11_:57LOQ_S#^PL/\ S2^]?Y'2KJ]H%($_
M_?2$_P!*0ZQ;E2OG@ =]AY_2N;HH_M*KV7X_YA_86'_FE]Z_R.G76;5<9GSQ
M_<;_  H_MRTW?,VX#IA3_A7,44?VE5[+\?\ ,/["P_\ -+[U_D=0=:M&.1*%
M![%"?Z4V34K D'[5N]0$8?TKF:*/[2J]E^/^8?V%A_YI?>O\CIGU:QR LIQ[
M*?\ "FC5++<3]H?\0?\ "N;HH_M*KV7X_P"8?V%A_P":7WK_ ".D&K6Q(_TA
M /0QL?Z4[^U+0\M<I]!&W^%<S11_:57LOQ_S#^PL/_-+[U_D=)_:=F3S<KCT
MV-_A2KJMFH&9@<=@C?X5S5%']I5>R_'_ ##^PL/_ #2^]?Y'2-JUJ1\LX'_
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M_P CS;_A%]<8\V>/?S4_QI?^$3ULY_<CVS(O^->D44?VE5[+\?\ ,/["P_\
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M^@;_ .1X_P#XJO;**/91#G9XD? /B8C_ )!G_D>/_P"*I?\ A ?$P'_(,_\
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M_P *IZCHT^I3;I+W9&OW(Q'D#]>M8'_"0:I_S]?^0U_PH_X2#5/^?K_R&O\
MA6?).][E<T;6-+_A$O\ I]_\A?\ UZPKZT-C>R6S,&*8^8#&<C/]:M_\)!JG
M_/U_Y#7_  JC<7$MU.TTS;I&QDX SQCM6D5*^I+MT(JD@_X^(O\ ?'\ZCI58
MJP8'!!R*HD[7Q#_R!9OJO_H0KB:O7&KWUW T,\^Z-L9&Q1_(51J81<59E2=V
M*JEF"J,DG %=_"B:?IJ*Q^6&/YC]!S7,^'+ W%Y]I<?NX3D>[=ORZ_E6IXEO
M?)LA;*?GFZ^RBHG[TE$J.BN<C*3-*TC<LS%C]33-O/%/HI^RB+G8S:?2E(_V
M:=11[*(<[&?-C[M'S'M3Z*/91#G9%A^X_6DV/FIJ*/91#G9"4?\ R:3RW-3T
M4>RB'.R(0\]14JQ1]VHHH]E$.=DH\@#ID_2H)[R6(?N+1W_X$H_F:=11[*(<
M[.=U&[\23$BVT]@O_79!_P"S5S5SHOBN[9B\# -V,Z?_ !5>CT4>RB'.SS"/
MP/K,S?OU5/?S ?ZUJVO@;R@&G!D;N%(_J:[JBCV40YV<FVDRVD>+31/-<="S
MQC/_ (]65>1>,I!MM=(6$?[,\0_]FKT&BCV40YV>077AOQQ>'][;2'V^TQ__
M !543X \3N=SV!)][B/_ .*KVVBCV40YV>)_\(!XE'33?_(\?_Q5._X0+Q-_
MT#?_ "/'_P#%5[511[*(<[/%#X#\3Y_Y!O\ Y'C_ /BJ#X"\38_Y!O\ Y'C_
M /BJ]KHH]E$.=GBG_"!>)<?\@SG_ *[Q_P#Q5)_P@/B7OIG_ )'C_P#BJ]LH
MH]E$.=GB9\!>)NVE_P#D>+_XJ@^ O$W'_$K_ /(\7_Q5>V44>RB'.SQ/_A O
M$W;3/_(\7_Q5'_"!>)\?\@S_ ,CQ_P#Q5>V44>RB'.SQ+_A O$__ $#/_(\?
M_P 52_\ " ^)^^F_^1X__BJ]LHH]E$.=GB?_  @/B;K_ &<?^_\ '_\ %4'P
M!XDZ_P!F'/\ UWB_^*KVRBCV40YV>)_\(%XE_P"@5_Y'B_\ BJ#X"\3=M* _
M[;Q__%5[911[*(<[/$_^$!\3G_F'?E/'_P#%4?\ " >)<<Z<Q_[;Q_\ Q5>V
M44>RB'.SQ/\ X0+Q*.FEY^L\?_Q5(W@/Q,JECIIP!GY9HR?RW5[;11[*(<[/
MG6:TN;:>2":)TEC;:ZL.0:*]_N=(TV_E\V\M@\@& P'./>BLW2=]"E-&1KG_
M ",&I?\ 7U+_ .AFJ%7]<_Y&#4O^OJ7_ -#-4*[X[(Y7N%%%%,04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P B[J?_ %Z2_P#H!I2V8UN?0%G_ ,?6H?\ 7P/_ $4E?)U?6-G_ ,?6H?\
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M_P"PA!_Z,6OIJ/\ Y#%S_P!>\7_H4E<U;XHG11^&7]=4>&T445\B?HH4444
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M47N\H_IFM/:0[D\DNQS=/AAEN)EBAC:21SA449)/TKNK'X<'(:_OACND"_\
MLQ_PKJ[+2M*T"W9X8HH% ^>:0\_BQK*5>*VU+C2;W.>\,>"EM#'?:FH:X!W)
M#U">A/J?Y5=\5^*(M(MGM;60-?N, #GRAZGW]!67X@\>($>UTC+.>#<D<#_=
M'?ZUP#NTCL[L69CDL3DDU,:<IOFF.4U%<L09F=BS$LQ.22<DFDHHKI,0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO/J]!U'_ )!EW_UQ?_T$UY]7V%+9GYU4"BBBM3,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "I()Y;:5987*.O0BHZ* .JL/$T4@"7B^6_\ ?4?*
M?KZ5K2066HQ!G2*=>S#G]17G]213RP-NBD>-O56Q6;IK=%J?<ZJ;PO9N<QR2
MQ^V015<^$USQ>G'_ %S_ /KUFQ>(-1B !F#@?WU!J<>*+['^K@/_  $_XTK5
M%U"\30C\*VZG][<2O_N@+_C6E;:78V7S1P("/XWY(_$]*YF3Q)J+CY7C3_=3
M_'-9\][<W7^OGD<>A;C\J.2;W8^:*V1UM]X@L[4%8V\^7T0\#ZFN6OM1N-0E
MWS/P/NH.BU4HJXP427)L****HD**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** .=US_ )&#4O\ KZE_]#-4*OZY_P C!J7_ %]2
M_P#H9JA6\=D9/<****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** -73?$FJZ4%6VNV\H?\LI/F7\CT_"NEM?B1,H N]/1SW:)ROZ'/\ZX6
MBHE3C+=%*<ELSTI/B-IA'SVEV#[!3_6FR?$>P _=65RQ_P!HJO\ 4UYO14>P
M@5[61V=Y\1;Z4$6EI# #W<ES_0?I7,7^JWVIOOO;J28CD!CP/H!P*IT5I&$8
M[(ER;W"BBBJ)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "K^A_P#(P:;_ -?47_H8JA5_0_\ D8--_P"OJ+_T,4I;,:W/8;/_ (^M
M0_Z^!_Z*2ODZOK&S_P"/K4/^O@?^BDKY.KSZ&S_KJ=E?=>B_)!111708!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCH?_ &$(/_1BU]-1_P#(8N?^O>+_ -"DKYE\*?\ (XZ'_P!A"#_T8M?34?\
MR&+G_KWB_P#0I*YJWQ1.BC\,OZZH\-HHHKY$_10HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@"_I^M:CI3?Z'=R1KG)3.5/X'BNGM/B
M/>1@"[LH9O>-BA_K7$T5M3Q%6G\,CFK8*A6UJ139Z5'\1].('F65TI_V=K?U
M%*_Q'TP [+.[8_[04?U->:45O_:%?N<G]C82^S^\[FZ^),[ BTT^.,_WI7+?
MH,5S6I>(M5U7*W5VYC/_ "R3Y5_(=?QK+HK&IB:M324CJHX'#T7>$%?[_P P
MHHHK Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M0T+_ )&'3?\ KZB_]#%9]:&A?\C#IO\ U]1?^ABKI_&O4SK?PY>C/9-1_P"0
M9=_]<7_]!->?5Z#J/_(,N_\ KB__ *":\^K["ELS\ZJ!1116IF%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!SNN?\C!J7_7U+_Z&:H5?US_ )&#4O\ KZE_]#-4*WCLC)[A1113$%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7]#_Y&
M#3?^OJ+_ -#%4*OZ'_R,&F_]?47_ *&*4MF-;GL-G_Q]:A_U\#_T4E?)U?6-
MG_Q]:A_U\#_T4E?)U>?0V?\ 74[*^Z]%^2"BBBN@P"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K0T+_D8=-_Z^HO\ T,5GUH:%
M_P C#IO_ %]1?^ABKI_&O4SK?PY>C/9-1_Y!EW_UQ?\ ]!->?5Z#J/\ R#+O
M_KB__H)KSZOL*6S/SJH%%%%:F84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '.ZY_P C!J7_ %]2_P#H9JA5
M_7/^1@U+_KZE_P#0S5"MX[(R>X4444Q!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !5_0_^1@TW_KZB_\ 0Q5"K^A_\C!I
MO_7U%_Z&*4MF-;GLT$!BEN7+ ^;(''M\JK_[+7R37UY7@/C_ .'<WAN5]0TY
M7ETICR.K0$]CZKZ'\#[\%*RT.NI=ZG T445N8A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!K^%/^1QT/_L(0?^C%
MKZ<2-QJ<\A7Y&AC4'U(+Y_F/SKYC\*?\CCH?_80@_P#1BU]2UA55VC:F[)KN
M>!45O>)/#-QH-QN&9;-S^[EQT]F]_P"=8-?)3A*$N62U/T.E5A5@IP=TPHHH
MJ#0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH&ZJ"2,9[]*Q*N+35T2U9V"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *OZ'_P C!IO_ %]1?^ABJ%7]#_Y&#3?^OJ+_
M -#%*6S&MSV6SO;?4+2.YM9!)$XR&'\OK4LD:31/%*BO&X*LK#(8'J"*\?\
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M/P+HOA'2[2:QNKR2YN)BNR>1"-@4DD *#UV\^_O7G="=U<;5@HHHIB"BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &CH%W#8>)-+O+ABL%O=Q2R,!G"JX)./H*^IK>XA
MN[:.XMY4EAD4,CH<A@>X-?)%=MX"\?W'A:Y%I=EYM)D;YDZF$G^)?ZCO]:SG
M&^J+C*Q] W%M#=V[V]Q&LD3C#*PX(KRGQ/X6FT.<S0[I+%S\K]T/]UO\>]>J
MVEW;W]I%=6LR302KN21#D,*=/!%<P/#-&LD3C:RL,@BO/Q.&C6C9[GIX''3P
ML[K6+W1X-172^*?"DNBRFXM@TE@YX;J8SZ'^AKFJ\"I3E3ERRW/LJ-:%:"G3
M=TPHHHK,U"BNA\):)8:[=W%M>33(Z('C$1 R,X.<@^HJ]XK\(V^B6$5W9RW$
MB>9LD$F#C(X.0!CIC\16ZP\W3]JMCDEC:4:ZH/XCD***Z#PIX>37[V99WD2W
MA0%C'C.3T'(/H?RK.G"522C'=F]:K&C!U)[(Y^BNK\6^%(=!MX+FTFE>%W\M
MA*02&QD8P!Z&N4IU:4J<N66Y-"O"O!5*>P45TGA+PW%K\UPUS)+';P@<QX!+
M'H,D'T_E4OB[P[I^@):BUEN'EF+$^:RD #'H!Z_H:OZO/V?M>AF\;2]O]7^U
M_3.6HHHK Z@HHHH **** "BBN[\%^'M*U;1YI[ZU\V5;AD#>8R\;5.."/4UM
M1HRK2Y8G/BL3##4_:3V\CA**U_%%E;Z=XCN[2TC\N"/9M7<3C**3R>>I-9%9
MSBX2<7T-:515(*:V:O\ >%%%%26%%%6]-TVZU6]2TM(]\C=3V4=R3V%-)MV0
MI244Y2=DBI17I,7PZTY+53<75TTP7+F-E"Y]@5)Q7FU;5L/.C;GZG-AL92Q-
M_9O8***[/1? $]Y MQJ,K6RN,K$H^?VSGI]*FE1G5=H(O$8FEAX\U1V.,HKT
MUOASI17Y+J]!]2RG_P!EKCO$'A>[T!E>1UFMG;:DJC'.,X(['K^5:U<)5IKF
MDM###YEAZ\N2#U\S#HHHKE.X**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** .=US_D8-2_Z^I?_ $,U0J_KG_(P:E_U]2_^AFJ%;QV1D]PHHHIB"BBB
M@ KVS0_^1?TW_KUB_P#0!7B=>V:'_P B_IO_ %ZQ?^@"N;$[(VH[L\HN];U9
M;R=5U2] $C  7#\<_6NF\$^(=1N]4^P7=PT\31DJ7Y92/?O^.>U33?#GSIY)
M/[5QO8MC[/TR?]ZMO0_"MGH$LES&\L\[(5W-@8'7 'J<"B=2FXV0XPFI7*'Q
M#AC?089FVB2.<!21R00<@?D#^%>:1QO+($C1G<]%49)KI?&.N7.I7HM)+62U
MA@)Q'*/F8]-Q_IC/UI_@_7M-T;[1]M@Q*V#',J;FQT*^WK^?M5TU*%/:Y$K2
MF4(?".O3QATTYP#_ 'W5#^1(-4M0T?4-+*_;;22$-T8\J?;(XS[5U%S\1[LS
M_P"BV,*P@])268C\" /UKK[*XM?$_A]9)H/W-PI5XVYVD'!P?J,@_2I=2<=9
M+0:A&6D6>-5H:?H>IZHN^SLY)4SC?PJY^IP*GL-)67Q3'I4S;D6Y,;GIN"DY
M^F<5Z7K^J?\ ".Z*LUM:!U5EB5%X5!@X)QVXQ^(JZE1II1W8H0O=L\VN/">N
M6L32RZ=)M7KL97/Y*2:QJ[JQ^(\H;%_8HRD_>MR00/H2<_F*Y74KIM;UR6>"
M (US( D8QUX _$TX2G?WD*2C]EE:UL[F^G$%K \TI_A09_'V'O6M_P (;X@*
M;O[/.,9_UJ9_+->AVUK8>$M =R!B)-TL@'S2-_\ 7/05R9^(]_\ :=PLK;R,
M_<RV['^]G'Z5"J3E\"T*Y(Q^)G(W5I<64QANH)(9!SMD4@X]?I71_#__ )&0
M_P#7!_YBNTO;6U\7>&DD10&D3?"W4QN.HS]00:XSP"I7Q,RL""('!![<BAU.
M>#ON')RR1M?$C_CQL?\ KHW\JR/"EQXEALY3I-M%<VN_!65@ K8!./F!Z8]J
MU_B1_P >-C_UT;^53_#K_D"7/_7R?_05J$[4;E-7J'$>(#J;:O(VKC;=$ [-
MP(5>P&"0!3[GPQK-I9M=S616!0&+!U; ]< YJ]X\_P"1HE_ZYI_*O3XPAL$\
MT IY0W C(QBJE5<8Q:6XE!2;/(K/POK5_;K/;V#M$PRK,RID>HW$9%0ZAH6I
MZ4BO>V;Q(3@-D,/S!.*ZB\^(LZW>+&SB^S*<9ESN<>V#\OZUU^G7=OXBT))Y
M(,17"E7B?G!!(/ZC@T2JSCK): H1EHF>+U8L["[U";RK2WDF?N$&<?4]JF;3
M7;76TR,DO]I, /7^+&:]3*Z?X0T!G2/]W&!G'WI7/J?4_H/I5U*G+:V[(A"^
MYYW_ ,(;X@";O[/.,9_UJ9_+-8T]O/:RF*XADBD'5)%*G\C78+\1[\7(9K*V
M,&?N L&Q_O9Q^E=-KVG0>)?#@N(%!F\KSK=L<],[?QZ?KVJ?:3BUSHKDBU[K
M/):***W,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J_H?_(P:;_U
M]1?^ABJ%7]#_ .1@TW_KZB_]#%*6S&MRA6MH.OW.@WGF1?/ Y_>PD\,/Z'WK
M)HIM)JS$FUJCW#3=2M=5LTNK23?&W4=U/H1V-6B P((!!X(->+Z+K=UH=X)[
M=LH>)(B?E<?X^]>MZ3JUKK-DMU:OD'AD/WD/H:X*M)P=^AU0FI'DWQ#^&AM/
M-UG0H2;?E[BU0<Q^K(/[OJ.WTZ>55]>5Y!\1?AKCS=;T&#CE[BT0?FR#^8_*
MB$^C"4>J/(JU?#.K'0O$NGZEG"P3 O\ [AX;_P =)K*HK4S/JK7M/&M>';^P
M0J3<V[HC=1N(^4_G@U\K,K(Y1U*LIP01@@U]+^ =475_!.F3Y)>.$029.3N3
MY<GZX!_&O#_'FC2Z;XZU"UCC9OM$WG0JHR6$G. ![DC\*SIZ-HTGJKGIGP:T
ME;3PQ<:DP'FWLQ ()^XG '_?1?I[?AV6OZ;%XA\,WU@K*XN86$;=0''*G\&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M [*B#Z--)C^9_0>PK..&]K5G*;M%-FT\<Z&'I4Z:O-I67R/+=2T34-'$?V^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6AH7_(PZ;_U]1?\ H8JZ?QKU,ZW\.7HSV34?^09=_P#7%_\ T$UY]7H.H_\
M(,N_^N+_ /H)KSZOL*6S/SJH%%%%:F84444 %%%% '9>&[DS:7Y;?>A8KR<\
M=1_/'X4^VTX1:]<W6,*R KQW/7^7ZUC>&+GRM0> D8F7CZCG^6:ZUF"J68X
M&2:YY^[)FL=4<CXFN?.U%80?EA7'XGD_TJUX5N?]?:DC_GHO\C_2N?N9C<74
MLQS\[EN?<U:T:X^S:M;N2=I;8<>_%:N/N6(3]ZYU L /$+7>WY?)SG_:Z?R_
MG6?XJN<)!:@]3YC?3H/Z_E71UPVN7(N=6F(QM0[!^'_U\UG3UD7+1$WAH*=7
M7<.0C;?K_P#JS71ZK=6EK#&UY;^<A; &P-@_C7&V5R;.]BN ,[&R1ZCO^E=G
M>VT6L:9M1QAP'C?'0_YXIU%[R;%':QD_VQH?_0-_\@)_C4DGB2Q^RO%%;S#Y
M"JKM 4<>QX%9G_"-ZCYH3RTV_P!_>,?X_I5F[\.?9=-:?SPTR#<PZ+CT%.T.
MX7D7O"N/[-E]?./\A2ZAJ6E6]])%<V7F3+C<WE*<\#')/I6;X:OEM[I[>1L+
M-C:2> W_ -?_  K3US19+]TGMRHE4;65CC(J6DIZC7PZ%=-;T:-PZ6!5AR&6
M% 1^M5-:UFWU&UCBACD4J^XEP!V(['WIEOX:OI7_ 'VR%<\DL&/X 5%K.DC3
M)(S')OC<?Q$;@1UX]*M*%]"6Y6.JTG_D$VO_ %S%/M+BTF,J6I3*,0ZJNW!_
MSWIFD_\ ()M?^N8KD8KU]/UF6=.0)&#+_>7/(K-1YFRF[6)O$-O/%J3/*Y=)
M!F,GL/3\*R:[R\MH=7TW"-D.-\;CL>U<-+$\,K12*5=3@@]C6M.5U8B2LQE%
M%:FCZ2VI2EW.VW0_,1U)]!5MI*[$E<-'T=]1DWOE;=3\S?WO85T.I:E!H]JL
M,*KYNW$<8Z*/4^W\ZO/&\%IY=G'&&4816.%%<W-X;U*>5I9;B!W8Y)+-S^E8
M74G>6QI:RT,.662>5I96+.QR2>]=KH=M%;Z7$T?)E4.[>I_^MTKG;KP]>6EL
M\[-"RH,D(QSC\15".]NH4"17,R(.BK(0!6DESK1D)\KU.FOO#TE]=O/)?<MT
M7RONCL.M6M)TC^RS*?/\WS,?P;<8S[GUKD?[1OO^?RX_[^M_C6_X8N9[A[GS
MII),!<;W)QU]:B49*.Y2:;)M7T/[9-)=_:-F$^YLST'KFN1K<\17-PFI20K/
M*L1090.0#QZ5AU<+VU)E:X44459(4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!SNN?\C!J7_7U+_Z&:H5?US_D8-2_Z^I?_0S5"MX[(R>X4444Q!11
M10 5U%IX\U2SLX+6."S*0QK&I9&R0!@9^;VKEZ*4HJ6XU)K8Z[_A8NK_ //M
M8_\ ?#__ !50W/C[6IXRB&W@)_BBCY_\>)KEZ*GV4.P^>7<DGGENIWGGD:25
MSEG8Y)J_I&OZAHC-]CF'EL<M$XRK'UQV_#'2LRBJ:35F2FT[G53_ ! UF:)D
M5;6$D8WQQG(_,FJ.E>*]2TF2YDC,<[7#!W\_<WS<\C!'K^@K#HI>SC:UBN>6
M]RW=:C<76I27Y;RIY'WYB)7:?;G(K;M?'FMVZ;7>"XYX,L?/T^4BN9HH<(O1
MH2DUL='?>-]9OH3$)([=6X/D*5)_$DD?A7.444XQ4=@;;W+NFZM>Z1.9K*=H
MV/WAU5A[@\&N@'Q#U@+CR+(GU,;9_P#0JY*BDX1EN@4FMF:VJ^)=4UA3'<W&
M(20?)C&U?\3Z\YJ'1]7N-$OOM=LD3R;"F) 2,'Z$>E9]%/E5K6"[O<VM;\37
MNO111W45N@B8LOE*1U]<DT[1?%5]H5J]O:Q6[H[[R958G. .Q'I6'12Y(VM;
M0.9WN7M6U6?6;]KRX2-9&4*1&"!Q]2:W?^$_U7R/)^SV6W;MSL;.,8_O5RE%
M#A%JS0*305T.D^,=0T?3TL[>&U:-22#(K$\G/9A7/44Y14E9@FUL6+^\DU"^
MFNY559)6W,$& #[5/I>M7^CRE[*X9 WWD/*M]0?Y]:H4465K"N[W.M_X6)J^
M,>19?78W_P 56-JOB'4]8^6[N"8@<B)!M4?@.OXYK+HI*G%.Z13G)[L****H
MD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG].L7Q"^(SZZ\FE:3(R:8IQ)*.#<'^B^W?OZ5YS3A"VK%*71!1116IF%%%%
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MB(,!0.P%9SE;1%QC<2TM+>PM(K6UA2&")=J1H,!13IYXK:!YII%CB0;F9C@
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MW_KZB_\ 0Q6?6AH7_(PZ;_U]1?\ H8JZ?QKU,ZW\.7HSV34?^09=_P#7%_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH YW7/^1@U+_KZE_]#-4*OZY_R,&I?]?4O_H9JA6\
M=D9/<****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ J_H?_ ",&F_\ 7U%_Z&*H5?T/_D8--_Z^HO\ T,4I;,:W/;*\
M!\?_ !$F\22OI^G,\6E*>3T:<CN?1?0?B?;WB"<RRW*%0/*D"#W^56_]FKY)
MK@I6>IUU+K0****W,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH U_"G_ "..A_\ 80@_]&+7U+7RUX4_Y''0_P#L
M(0?^C%KZ<21SJ<\9;Y%AC8#T)+Y_D/RK"J[-&U-73?8\I\2>)KC7KC:,Q6:'
M]W%GK[M[_P JP:**^2G.4Y<TGJ?H=*E"E!0@K)!1114&@4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5H:%_R,.F_]?47_
M *&*SZT-"_Y&'3?^OJ+_ -#%73^->IG6_AR]&>R:C_R#+O\ ZXO_ .@FO/J]
M!U'_ )!EW_UQ?_T$UY]7V%+9GYU4"BBBM3,**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1^&7]=4>&T445\B?HH4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %:&A?\C#IO_7U%_Z&*SZT-"_Y&'3?^OJ+_P!#
M%73^->IG6_AR]&>R:C_R#+O_ *XO_P"@FO/J]!U'_D&7?_7%_P#T$UY]7V%+
M9GYU4"BBBM3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#G=<_Y&#4O^OJ7_P!#-4*OZY_R,&I?]?4O_H9J
MA6\=D9/<****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ J_H?\ R,&F_P#7U%_Z&*H5?T/_ )&#3?\ KZB_]#%*6S&M
MSV&S_P"/K4/^O@?^BDKY.KZQL_\ CZU#_KX'_HI*^3J\^AL_ZZG97W7HOR04
M445T& 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 :_A3_ )''0_\ L(0?^C%KZ:C_ .0Q<_\ 7O%_Z%)7S+X4_P"1
MQT/_ +"$'_HQ:^FH_P#D,7/_ %[Q?^A25S5OBB=%'X9?UU1X;1117R)^BA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5H:%_R,.F_P#7U%_Z&*SZT-"_Y&'3?^OJ+_T,5=/XUZF=;^'+T9[)J/\
MR#+O_KB__H)KSZO0=1_Y!EW_ -<7_P#037GU?84MF?G50****U,PHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* .=US_D8-2_Z^I?_0S5"K^N?\C!J7_7U+_Z&:H5O'9&3W"BBBF(**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *OZ'_P C
M!IO_ %]1?^ABJ%7]#_Y&#3?^OJ+_ -#%*6S&MSV&S_X^M0_Z^!_Z*2ODZOK&
MS_X^M0_Z^!_Z*2ODZO/H;/\ KJ=E?=>B_)!111708!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!K^%/^1QT/_L(0
M?^C%KZ:C_P"0Q<_]>\7_ *%)7S+X4_Y''0_^PA!_Z,6OIJ/_ )#%S_U[Q?\
MH4E<U;XHG11^&7]=4>&T445\B?HH4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "K^A_\C!IO_7U%_P"ABJ%7]#_Y
M&#3?^OJ+_P!#%*6S&MSV&S_X^M0_Z^!_Z*2ODZOK&S_X^M0_Z^!_Z*2ODZO/
MH;/^NIV5]UZ+\D%%%%=!@%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &OX4_Y''0_^PA!_P"C%KZ:C_Y#%S_U[Q?^
MA25\R^%/^1QT/_L(0?\ HQ:^FH_^0Q<_]>\7_H4E<U;XHG11^&7]=4>&T445
M\B?HH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %:&A?\C#IO_7U%_P"ABL^M#0O^1ATW_KZB_P#0Q5T_C7J9UOX<
MO1GLFH_\@R[_ .N+_P#H)KSZO0=1_P"09=_]<7_]!->?5]A2V9^=5 HHHK4S
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH E\6^$KPZA+J%A&T\<[;GC099&[\=P?ZXKF/[#U?\ Z!5]_P"
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M+[![%=SQ/^P]7_Z!5]_X#O\ X4?V'J__ $"K[_P'?_"O;**/K+[![%=SQ/\
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M@5??^ [_ .%']AZO_P! J^_\!W_PKVRBCZR^P>Q7<\3_ +#U?_H%7W_@._\
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M_0*OO_ =_P#"O;**/K+[![%=SQ/^P]7_ .@5??\ @._^%']AZO\ ] J^_P#
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MC_Z%_5?_  #D_P */^$4\1_]"_JO_@')_A7U+11[5AR'RU_PBGB/_H7]5_\
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M5_\  .3_  H_X13Q'_T+^J_^ <G^%?4M%'M6'(?+7_"*>(_^A?U7_P  Y/\
M"C_A%/$?_0OZK_X!R?X5]2T4>U8<A\M?\(IXC_Z%_5?_  #D_P */^$4\1_]
M"_JO_@')_A7U+11[5AR'RU_PBGB/_H7]5_\  .3_  H_X13Q'_T+^J_^ <G^
M%?4M%'M6'(?+7_"*>(_^A?U7_P  Y/\ "C_A%/$?_0OZK_X!R?X5]2T4>U8<
MA\M?\(IXC_Z%_5?_  #D_P */^$4\1_]"_JO_@')_A7U+11[5AR'RU_PBGB/
M_H7]5_\  .3_  H_X13Q'_T+^J_^ <G^%?4M%'M6'(?+7_"*>(_^A?U7_P
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MO_ =_P#"O;:*/[,A_,']O5/Y$>)?V%J__0*OO_ =_P#"C^PM7_Z!5]_X#O\
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M+5_^@5??^ [_ .%']A:O_P! J^_\!W_PKVVBC^S(?S!_;U3^1'B7]A:O_P!
MJ^_\!W_PH_L+5_\ H%7W_@._^%>VT4?V9#^8/[>J?R(\2_L+5_\ H%7W_@._
M^%']A:O_ - J^_\  =_\*]MHH_LR'\P?V]4_D1XE_86K_P#0*OO_  '?_"C^
MPM7_ .@5??\ @._^%>VT4?V9#^8/[>J?R(\2_L+5_P#H%7W_ (#O_A1_86K_
M /0*OO\ P'?_  KVVBC^S(?S!_;U3^1'B7]A:O\ ] J^_P# =_\ "C^PM7_Z
M!5]_X#O_ (5[;11_9D/Y@_MZI_(CQ+^PM7_Z!5]_X#O_ (4?V%J__0*OO_ =
M_P#"O;:*/[,A_,']O5/Y$>)?V%J__0*OO_ =_P#"C^PM7_Z!5]_X#O\ X5[;
M11_9D/Y@_MZI_(CQ+^PM7_Z!5]_X#O\ X4?V%J__ $"K[_P'?_"O;:*/[,A_
M,']O5/Y$>)?V%J__ $"K[_P'?_"C^PM7_P"@5??^ [_X5[;11_9D/Y@_MZI_
M(CQ+^PM7_P"@5??^ [_X4?V%J_\ T"K[_P !W_PKVVBC^S(?S!_;U3^1'B7]
MA:O_ - J^_\  =_\*/["U?\ Z!5]_P" [_X5[;11_9D/Y@_MZI_(CQ+^PM7_
M .@5??\ @._^%']A:O\ ] J^_P# =_\ "O;:*/[,A_,']O5/Y$>)?V%J_P#T
M"K[_ ,!W_P */["U?_H%7W_@._\ A7MM%']F0_F#^WJG\B/$O["U?_H%7W_@
M._\ A73^$O"-X-1CO]0A:".!@T:.!N=ATX[ ?X5Z-15T\OIPDI-WL95\ZK58
M."25QLB++&T;?=8%3]#7$WNAWEK,52)YH_X7C4G/U%=Q17I1FXGB.-SS[^SK
M[_GSN/\ OTW^%']G7W_/G<?]^F_PKT&BK]J^Q/(>??V=??\ /G<?]^F_PH_L
MZ^_Y\[C_ +]-_A7H-%'M7V#D//O[.OO^?.X_[]-_A1_9U]_SYW'_ 'Z;_"O0
M:*/:OL'(>??V=??\^=Q_WZ;_  H_LZ^_Y\[C_OTW^%>@T4>U?8.0\^_LZ^_Y
M\[C_ +]-_A1_9U]_SYW'_?IO\*]!HH]J^P<AY]_9U]_SYW'_ 'Z;_"C^SK[_
M )\[C_OTW^%>@T4>U?8.0\^_LZ^_Y\[C_OTW^%']G7W_ #YW'_?IO\*]!HH]
MJ^P<AY]_9U]_SYW'_?IO\*/[.OO^?.X_[]-_A7H-%'M7V#D//O[.OO\ GSN/
M^_3?X4?V=??\^=Q_WZ;_  KT&BCVK[!R'GW]G7W_ #YW'_?IO\*/[.OO^?.X
M_P"_3?X5Z#11[5]@Y#S[^SK[_GSN/^_3?X4?V=??\^=Q_P!^F_PKT&BCVK[!
MR'GW]G7W_/G<?]^F_P */[.OO^?.X_[]-_A7H-%'M7V#D//O[.OO^?.X_P"_
M3?X4?V=??\^=Q_WZ;_"O0:*/:OL'(>??V=??\^=Q_P!^F_PH_LZ^_P"?.X_[
M]-_A7H-%'M7V#D//O[.OO^?.X_[]-_A1_9U]_P ^=Q_WZ;_"O0:*/:OL'(>?
M?V=??\^=Q_WZ;_"C^SK[_GSN/^_3?X5Z#11[5]@Y#S[^SK[_ )\[C_OTW^%'
M]G7W_/G<?]^F_P *]!HH]J^P<AY]_9U]_P ^=Q_WZ;_"C^SK[_GSN/\ OTW^
M%>@T4>U?8.0\^_LZ^_Y\[C_OTW^%']G7W_/G<?\ ?IO\*]!HH]J^P<AY]_9U
M]_SYW'_?IO\ "C^SK[_GSN/^_3?X5Z#11[5]@Y#S[^SK[_GSN/\ OTW^%']G
M7W_/G<?]^F_PKT&BCVK[!R'GW]G7W_/G<?\ ?IO\*/[.OO\ GSN/^_3?X5Z#
M11[5]@Y#S[^SK[_GSN/^_3?X4?V=??\ /G<?]^F_PKT&BCVK[!R'GW]G7W_/
MG<?]^F_PH_LZ^_Y\[C_OTW^%>@T4>U?8.0\^_LZ^_P"?.X_[]-_A1_9U]_SY
MW'_?IO\ "O0:*/:OL'(>??V=??\ /G<?]^F_PH_LZ^_Y\[C_ +]-_A7H-%'M
M7V#D//O[.OO^?.X_[]-_A1_9U]_SYW'_ 'Z;_"O0:*/:OL'(>??V=??\^=Q_
MWZ;_  H_LZ^_Y\[C_OTW^%>@T4>U?8.0\^_LZ^_Y\[C_ +]-_A1_9U]_SYW'
M_?IO\*]!HH]J^P<AY]_9U]_SYW'_ 'Z;_"C^SK[_ )\[C_OTW^%>@T4>U?8.
M0\^_LZ^_Y\[C_OTW^%']G7W_ #YW'_?IO\*]!HH]J^P<AY]_9U]_SYW'_?IO
M\*/[.OO^?.X_[]-_A7H-%'M7V#D//O[.OO\ GSN/^_3?X4?V=??\^=Q_WZ;_
M  KT&BCVK[!R'GW]G7W_ #YW'_?IO\*/[.OO^?.X_P"_3?X5Z#11[5]@Y#S[
M^SK[_GSN/^_3?X4?V=??\^=Q_P!^F_PKT&BCVK[!R'GW]G7W_/G<?]^F_P *
M/[.OO^?.X_[]-_A7H-%'M7V#D//O[.OO^?.X_P"_3?X4?V=??\^=Q_WZ;_"O
M0:*/:OL'(>??V=??\^=Q_P!^F_PH_LZ^_P"?.X_[]-_A7H-%'M7V#D//O[.O
MO^?.X_[]-_A1_9U]_P ^=Q_WZ;_"O0:*/:OL'(>??V=??\^=Q_WZ;_"C^SK[
M_GSN/^_3?X5Z#11[5]@Y#S[^SK[_ )\[C_OTW^%']G7W_/G<?]^F_P *]!HH
M]J^P<AY]_9U]_P ^=Q_WZ;_"C^SK[_GSN/\ OTW^%>@T4>U?8.0\^_LZ^_Y\
M[C_OTW^%']G7W_/G<?\ ?IO\*]!HH]J^P<AY]_9U]_SYW'_?IO\ "C^SK[_G
MSN/^_3?X5Z#11[5]@Y#S[^SK[_GSN/\ OTW^%']G7W_/G<?]^F_PKT&BCVK[
M!R'GW]G7W_/G<?\ ?IO\*/[.OO\ GSN/^_3?X5Z#11[5]@Y#S[^SK[_GSN/^
M_3?X4HTV^)Q]CN/QC->@44>U?8?(CGM+\/*MN7O5_>,>$X.T45T-%0YME**"
MBBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!4L_^/K4/^O@?^BDJW52S_P"/K4/^O@?^BDJW4PV^_P#,
MNIO\E^044451 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %5(_\ D,7/_7O%_P"A25;JI'_R&+G_ *]XO_0I*F6Z
M_KH7#:7I^J+=%%%40%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 5+/_CZU#_KX'_HI*MU4L_\ CZU#_KX'_HI*MU,-OO\ S+J;_)?D%%%%
M40%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !52/_ )#%S_U[Q?\ H4E6ZJ1_\ABY_P"O>+_T*2IENOZZ%PVEZ?JB
MW1115$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %2S_X^
MM0_Z^!_Z*2K=5+/_ (^M0_Z^!_Z*2K=3#;[_ ,RZF_R7Y!1115$!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54C
M_P"0Q<_]>\7_ *%)5NJD?_(8N?\ KWB_]"DJ9;K^NA<-I>GZHMT4451 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4L_^/K4/^O@?^BDJ
MW52S_P"/K4/^O@?^BDJW4PV^_P#,NIO\E^044451 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5(_\ D,7/_7O%
M_P"A25;JI'_R&+G_ *]XO_0I*F6Z_KH7#:7I^J+=%%%40%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 5+/_CZU#_KX'_HI*MU4L_\ CZU#
M_KX'_HI*MU,-OO\ S+J;_)?D%%%%40%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !52/_ )#%S_U[Q?\ H4E6ZJ1_
M\ABY_P"O>+_T*2IENOZZ%PVEZ?JBW1115$!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% $$$82:Y8$Y>0,<_P"XH_I4]%%3'8J>_P!WY!11
M15$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5 L8%]++D[FC13Z<%O\:**E[HJ.S_KJ3T4451(4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img159889792_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img159889792_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,(#$X# 2(  A$! Q$!_\0
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MFF>82.E/.UP#N&:8Y"X&<XH >) (]L@)^E-6&#&_8P-)D,<XY%*5<@,6&#0
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M]+D2!9(F[U3:.8D<XQUH ]0KE_%X8M8A>IW_ /LM=16-KJQL]J7(##=MS^%
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M&..2*H*OR_K0!!'$=Y'3TS4YM 5.\@GVH2&264Y?@=*M&+Y.#\U %9+3. &
M^M2I$D8.5-.V;1NV_,*<QW#D8% #<QA3A2#[TQ#(R':0,>M()DWE7/3H:7='
M@CSAS0 @DDQU!QUQ0K?*2<XIJ%1DB08'ZT%25.) 0: )<HO//-#.53AA[BJO
M*MAVX]::S?,67G- %KS8OEW9R:1YQ&"<@BJ!?+?,O(IP@>1@ #@T 2BY:64
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MCW;54_6@DJN6/!I(G1CMSB@!064'YACTIZ2,0-HP?6D=4W JM.;**"6VY[4
M.9R1@D9[T&;&#N [8JU9Z:98FD=#SR#52^TN=$+KG(H <IS]QAFA4/)+C-9!
MFFA;Y@0?6ITO(]H+MDF@#07D_+\I]3WIQR 0W-5DO(R &8,!^E2B:-N=X H
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M_)NQDYH >?,)SM!%-#\X88-/#!1M)YI<1L/G.!0 PE&D <XI3 F[B0X-*T<
M7[QJ," <;WH =)& O$C'%("Y&5)XI%E6)^#E?>DDN(P P/'?% #B<,&R<^E
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MC^M %<2L>&1:3:2/F  ]128YP<CZTA4C)SQ0 \*&(\L9'O2DQA\R\'IBA 6
MS@#VH/ ^0!CG^*@!-RY94ZTPH0,R#'O2R2QJ09 0W^R*/-$JX'ZT ,6)_OQL
M67T-/P7&'4"D\N3<&/"^U.\\ $$?I0!&]E&XPIJO)I;IGROF)]:LGRVZ,P-.
M&[ &[I[T 9$D1C.)%QCTJ,2*W&W@=\5O$LPVLB%?7'-12VL90[ * ,8KSP,T
M_82O/ J\UHY7:H%5WMV7CGB@"NHR?E.0*4KAMQZ5)]D9ER,BF&)%7#LW7M0
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M!UH =@]12@X%1>:.N::9UH E8@\T;JK&;!]J:926H N;@12 \U5\SWJ1')H
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M!!]J4''2@ Q@<T#/0"D/O2A@.E &AJ3EM2O 6SB9\#_@1JJ(G<IG.,UO7-A
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MJE'XVECDR/G4>IKBBLF-Q%*9&6, *.: /6M(\>V-Q-'"R(2>OM77FX@=0R,
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M!TIPCW',@V58")'RV"G8B@"!7) +#;4;M)\S<[1WJZ"K\!1[4-&C?*>&].U
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MC I,<9H &]J7F@=*>B[CTH CY/ %3) S=JM0VX')JXB =J *D5OM7D5:7:.
M*<>N*3&!0 -C( H!IBME_I3F8 ]* %SSR*,TU7!-&[YJ '#I0O6@MVQ3-Q%
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M7)H <I'(Q]ZFLH!&&VGUI%D#LG&-O6G/M<GC- $3)M;(F!)J-UD"G:QYJ81
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M H+KM *\9H>UAE&!@&@"O]K2XN?D&!5[Y2>#@U1^RI;'<JYH^T/"Y9DRK<4
M=U61KG2#_@7]*UZR-<)!MR#C[W]* ,4GY< ].H-(5+2+MZ8YI#&3,#G#'I3\
MXRH.#W- $*( IZYS4A,:8#*Y;U'2E&3U7(]:7=GHX H 0E0&8#Z9IK?.\93T
M^:GGYRHQGU--& 6"<$?K0 I!,FV,X&.<TI 6/WS348%^4.<=:3=GZYZT *$<
M?<8 'KFE(4 [CN(Z8H8!B0IR*0!(\?+@^]  Q0[2 >E)F0Y((%133HN0HY-0
M>;(S87N* )5G&X+ABP/4=*6:0ECDC)IL2LD>.A]:%C\YP@/S'J: %M;*XO9O
M+1@5[FNML["*PM]D:_,>I]ZJZ=%!8VQ5& <]33-3\16>F0,\LJY SC- %Z2&
M,-YUPX'U/%<WKWCO3-%C<*0T@'5#FO*O&'Q4NKX/:V#E5!ZBO.KG5+R[0F>0
ML30!Z#K_ ,6;N^<Q0EE7H,"N3G\4:A/EO.;\36.B1&'<3EA4BA#'DK0!<;5K
MV6',DP_ U6WS7"&3S<$=B:AV=]I(I!C/(.* %#.V"6R1UJ6&%IR5#J#[U&BA
M2YSP>@IL)VN2J'=ZT .9&1BC,-PJ1;5Y;;*LN0:62-)1NW /4=O,T;,%!^M
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MEW8 -/2)W.YC^%32QD'BE0'@=Z  0EE!3C%(P8Y5J5ED\S:C$8YI=SC!9>E
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M0,8I-O(%')/%6[>WW$$T ,AM]YJ]%;QJ.1S4B1*O04IQ0 !5SBG4S@4XX H
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MWV!2G>@"[H.FFRM\R+M=AR*OFZMHW959=XZBFP7ZS2N. J]#6'=3PVUS/*S
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MZMV_B":,89/F],US\NG7"QA_-(!]Z@"/"^YI2Q- '7KXEE'W\Q_C5RW\43!
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MMU:_Z,=I X [UKR;>A[TB[8\+ZT <1_9-XH/FVQ '\559D>'Y"2H->A;ED#
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MC9!'SVH GDR%!+;@>]=-IBA=/B Z<_S-<M$\9.UV/3(KI=&??I4+'_:_]"-
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MP  XZ4H&WI1@9H 4=: ,YI!Z4N2M #'^6HRQ;H*D(+=:4# H 100!3AS2&G
M =* # I&;'04C'GK2C@4 (!DY-&<4I.::1GB@ W<9H([TF"*&;'2@!=W&.E-
MP6.!UII+/P.IK1LK(CYVH BM[%I&&ZM2"S2$YZFI4"H,GBJ-_JL-FI;</SH
MO.53D\"J<VH0Q<[A7'ZIXQ^5E0C\ZY>Y\32OGF@#T6?Q(B9Z<5CW?BX;2J_S
MKSJ?7)6SEJH/J;D]: .QN=?+%CG)K)EUYVS7.-=R-D]JB,[&@#;DUQSU%5GU
M)I#GI66T@(&:7'R9H N/?-GKQ3!>%SC)%4U(-#'!XH M&8DX)J-Y/>JS%NM
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MFJ>(KFZ;9YA1?0&L=M59(SM //6N4?4G:7!8]*A:Y8QE1(<Y]: .BNM:=UX
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M]ZZ1K,+$$5 JXZT 9,4112D*Y&.M/CB<1#Y,L3TJQM\LE$_.IHU6.,,<DYH
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MI%6&MHB-QY]:58\*0.E %*>:XBD^3!!]:7[7*%&\#\*LLB':#U%,:T5NX]:
M!9Q)UXJ=,=,C)JGY2D$!3QWIR188<T 7%C())(Q]:0;<''6H%#@[=PJ0@QJW
MK0 \+E=IZ]:54;;DXP*14R<AADBB-2H*L: !7 8GO2[@S'CBB-%)((I\6%SR
M,"@"G+9PS$D9!JC<P/$V,<8K7=?F+C\J&82<%#^5 &[X<&-!M@?]K_T(U:U/
M_D$WG_7!_P#T$TS25V:9"OIN_P#0C3]2YTN[_P"N+_\ H)H \^@BWD&M(<
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M1\M %*&%Y#G'%6U8P\#K6_#I<<7I4RV$ ))0&@#G9IVE3'-9[,5)KM/L-OC
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M[I*6MY/LE95)]: *:L\Q^3KZT/&[<M(.*N:@T-K=^1:H#ZD57N<%%"I\QZT
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M6ZCN:H)M4@#-.F?;*'&[% #)743'>#NSVIQ+$#&,&K#20/\ -M.[%4I96#9
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MUH)HDL*YW9;ZT 7;R(:A:B6 <@YYK,$DAQ$_&#S5B.2^MV,8 V#VI#(KL2X
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MAGQ9+;;5E?O7K6F:Q%J,"LK#.* +3,ZDXQBF0H\L1.,G-#X4_-6MI/E.,#%
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M !;8P1R;;26,L.< T >CT51O]4L[&W\R>=55CM!!SR:IG7].L%$<UT23SG%
M&U6/J.OV]G*((\2S'H@/-8]_XHFN!)'91[HCP).XJEI=HJR&^N6WR#D%NHH
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M/#*6MB]U=28P,C!J;PMI-K?I<3-*1LS@9K$NM0N;B);=W.P5'IUQ/I\_R/\
MNVZ@&@!]VS+=R0Q\!3Q3HD6;"LWS5+?I'+/YL8()ZU29'E<>62K#O0!TVE^$
M9?*>]F=0F#@9K%GAD2^^<?+FGQZO>L\=N7.T$=.E=)<Z4;FR$_!8#)Q0!SU\
M$G1/+.=HJM'"6!;(..QILLRQ2-$H.[-)"N9!@D#O0 W<$D)8?E3F7S<;>6/0
M5/-&%!(P:;#&83YK$>PH DN+-X[13)C=CI6>L9SSTJ:>66>3+.,=AFF1J<'Y
MA0 V4+L&WK48!)P<4-UVT[Y,@-F@!<*JD,.:8,$YVC%.<K*X5,XJ2;RHHP ?
MFQ0!%D.I"TQ-V0N,?2F^>0<*.*<DZ[ONF@!S\' )I5DD3"ACCUI6S[<T\1L\
M)VXW4 :FE:M)9OD-DY[UZ#HGBA9SAGP0*\E)>%-P^]5FUU*:WDW$X)]* /H"
MVOA<("A!/:K!!V$L3FO*] \3LCH&?BO1M.U2&^A!)YH L+"70CUJ)H&2,A@#
M5TQCAE.*9*-^ >1[4 9821&#=%J0,2<*>M69H%)Q'FJ<D;1=.M $PN&63:>H
M%78;G> K$<UD-*^T$BCYWP0<4 = "O.,=*(U_=Y)K,MI"K %JMR.O16X[T 3
MKRIRW&:>6.W&!4 *&/Y3S3S\P5L\B@!R[1P3R:&7:^&]*0C>_'6@!6)W9R*
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M(F<D?\"--L0 SLHZBI6AA&LZFSIN9I7Q_P!]&I+<+'&H*XH E@!!8[33W(;
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M1ZT :.JV\#B)%8948/-8[[E< ' %,EDF\PNS[B:<&>3!:@!#*3\I!IT3M&A
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M+TIR0JK!QUQBJVK78L]*N+@, 40D$T >*?&KQ )YXK"-\&/(('>O)[:'?'N
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M0,FKZV2G((H Y:2-UF5R>O.*>C#=R._:MB\TX %]I./2L=E, ED7C:C'GZ4
M>._%W6&FUU=,7F%55OQKATW1C" ;?>KOB;47UGQ++</U4E?R-5Y67:JCD>U
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MFH&7]V03DTKJ?O>E"C<N_&* )(98EM]KJ2:$B4MN ^4TW:#@[>/6KBR1K;;
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ME )D7GB@#O\ 1I!+I,#KT.[_ -"-2ZGSI5X/^F#_ /H)JKX>&-"M@/\ :_\
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MYA#]* ()D#-A(CDUT?A.:_T?58))$86[, V1QBLR.:.*0':#3+[4[J7Y4F9
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M]\0'2=;CA+?NW:O><1S0K,BY#C<:^7F+6UXDT0V[3GBOH?P7JC:KX?1L?-&
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M$J2*,KQ0!12Y:W=?+7Y?45VGAWQ0T#I$\F5/O7'B3*A%A5O>A7CB<'?M;T%
M'OUK=I=VPD0[N*Z;PRZ3V\WR\J<5XUX,UIW86[2':>,YKU_P@ B7*[L[VR*
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M@!CR*B'O4APQR:FAA$I % $&.*=%%(S<*<5HW%D+>%6(YJJETL8P!S0 D\3
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M50 ,8I'+(!\H)':I'?YSMX6FELC<>5[T "1Q-*AD)7)S@5I:R([ETDMV+E4
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MC$X%GQG[_P#[+7,LS+L*@8Q74^+%#_8P?]O_ -EKEBQ<F/'"\4 +&9+A=SG
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M$K)O% %*</(IR,#':N]^$VKO%<SZ>[G:Q  KD&C2/+D@\=*G\(WKV7B^TD3
M61^<T >_W&?, 4 <=15(22^<RH2&'I6E-;!S"Q;[Z!N#3EM;;3HVU"Z?;$@W
M')ZT $%G<ZA&$=FP!R2:?_PCMNH*O.!CGJ*\R\7?&9UE>UT-$V#@L1@UYK=>
M,-:OI6=KF12>P<T ?21TM"NR&13MZ<U$T5Q;$HXRI&*^=['QQK6F,&29G_WF
M)KOO#/Q<\\B'6%4$G *B@#T<VI\@FH8K4*"3(Q/H:MVMW!J=D)H'#!AD &H(
MC(CD,.] $D6Q#G/%1!MUWA1\M3S , .!]*LZ=:*S]"<F@!L=H\@W9/M4Q@>!
M0,G)ZUT45K'$@XJ3R8V!.T<^U ').Y.1C\:IEGSD#/UKK+NRB5&91VKDKV7[
M':W$V.$&: /&?B'?R7VMI 6("C& :QOLTD5LCNO![U%J-R]]KMS<L<X<@"K]
MM?QM;F&4?,/:@"FJ(?F4].M31I"V?G(-1OA&.WH::+2:9=T.30 I9-Y0N2?6
MD1F1]\?.*B\B[+!?LTA/J%-/$1B?YPRMZ&@"Q)))< &0G=32QB&.W>A',AP
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MNT .$NWI37N,]Z9D8JNS  YH XKQC=,967=Q7 L2&..]=7XNFW7C@&N6V\4
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MOVJJK-N_>#/UH D!!PY4!12-F0$QBD\U)#R=JBHY'V@[#Q0!/!<R0]<DU5O
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MC8,RK(-H]: '&>8* &X]*1<R*2$(>G-L\QA&=V.]$;/N^4<T )G:,.,TPX1
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MQ_\  _\ V6N<ABWMLSC=ZT ,=HVC '6D$AB5=O0^M)+%Y+;,YYHPI8*1C;0
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M#;A: .^A\7V]];EO*42#U45BMXSG@O2$BC !_N"L. ")B%/)J"5 TI9B![4
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M4^82"-I&*\;^)D1AUQMJG!QS0!Q"L(\KU [T[(<9Q]*CW8W8&2:D4*^TGC%
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MW#!'O4EJT\UQB*!W7N0N: (;]GG2( EO+7;@U(TR#3!;!0K[LY%,5B)Y%(
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M,Q9B0U6K/6[159&0-(_.:CMM#-Z_EM*4)KU?PO\ #S0+'3UN;R5)6(!)8=*
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M5X"I8J*]J^*LAD\#Z<1]WRHJ\4&0%([T 2G P3UI'8=/2E8JV,GFC>N[ 7-
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MXJ"*<P[E4[B<T 2-&S$?,U #MC;TP,#%*JK)<HA..:2#S&(SU IO4^8#@@T
M+K%DZ$$/\M8Z*K9!;)%:-S=/(I1V.#TJC+&L2 @_,30!VWA[/]A6V?\ :_\
M0C5K4O\ D%7G_7!__035;P\,:%;?\"_]"-6=2_Y!5Y_UP?\ ]!- 'G@.,9JW
M'@#(-4\9JU$ !0!)G)I2.*DBB+<BI'MF(R!0!6P"*PM><);MSVK='R,0>M<M
MXFD_=.* /-[YP]TY]Z@(S3K@$S,?>F*#F@!23C!J(@]:T8;<2)N;BJLZJK86
M@"-,D4;.<XJ>U$;<,>:OK9*PR"* ,K:Q['%* Q^45T-MI@FCXQFI5\.S^:&"
M\4 <ZUM+&OF$'%1 L[8)KO7TF*2T\IP U8LWAN4-F(@B@#G9(BHZU":W;O1;
MJ*+)7.*R6MY(\^8,4 1C.*L6UU) _'(J)5+'"C-+(&C&".: -8:A%<)LE4#/
M>FMI"2?/"^?:L7YLYJ_::FUL0,YH )+&:+.Y355T9.2*ZJUU6PNBJS<$U=OM
M M[J#?;%30!P;LQ-2+(5')JY=:3=P,08C@53:VEQ@H:  OOZ4C1^IIR6\B\E
M<4UR<X- #1CI1(H&"#4J1*J[W( I\=J;K_5?,/:@".VU":V8%'/%=MX4U=[Z
M[6.=<C-<4VG3QR;2AKU7X=>%1+$+J8 $'@&@"SXQL]/BTP2,H#$5X](D3R,5
M/>O;_B%HWF6)V$  >M>%S0M;S,I]: 'LB;<9YIFT \4PMR#2E\8H 4KS2D$X
MH'(S0 <\4 '*UM^&6*ZD#60Z\ UI:#,$U!>U &[X^FW6*#/>O-1_.N_\;$M:
M(_;-< *  9''I2'GFESDY-!X/L: $Q0>:#P*3J.* );3/VE,=,U[YH>1HUOG
M^Z*\.T:U>ZOD1%SS7O>G6K1:7 A'(44 2KUS3G;"$]J804X/6H+R816[?2@#
MG-<U4H2BFN)N;YI9&S6AJUQYDK9/>L1\9SUH &/.2*3S"#Q4@*NHP>E-=%"\
M=: '+=LHQ@9J9-2E"[<#%4E1B,XS2>7*3D*<4 6UU!]Y) JO/.9I2>E1,CKU
M4TWW[T 2B,$9+4AA 7.:B+-TS2AVQB@!K*172>#M<BTC4U>9 RXQS7-DDTW^
M= '7^-;ZWU259K=0.YQ7' X.*MQW&(2&R:K%5;YEH D!&W-,;%6K)(Y%<.?I
M5608D('K0 J],"K"V;,N[-5@:L+=M&F#TH 06;LP [UN?V<\%@6.>E1Z##)?
MWBX&1FNB\2RQV=H81PV,4 <!(#N.:@P<U,6W'DT,!V% $.T9IRGG %&,4]1M
M.: )&B"QAL\U 1FII&W 5"010 F#3X[=GY%$:LYP!D5-'<"W.T]J 'C39BN0
M"1]*JR6\D3$,I%=)INL6B*%FJ'4[FSN&+1\"@#GN<TC#O4[",GBI5LVD3<*
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MFG.(YE,C$X% '3G4-(U?3Y R[9^W&*Y=VE,Q2,#:IP,T;!YB>1PO>I;EMNT
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MRV@C^NVL27Q7<:E*WVE0,^@KG(I #M=<$>HJU$RR/MQR* );EH3(SU$DUM(
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M1M(/J:%Y(&,4IYEVD9S0 _RV(W9! ["B.*,D[A4;DJ=JR;3Z5+9G>&#CGUH
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MR%\1$HXQ0!5&67(X Z58<H(0Q/..:AE1EEV_= ZBNF\*:7IE[*RZE<K&A/\
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M(^]U_P!XUS,$<@MR&4IZ9KIM&8MI,)8Y/S<_\"- &3XMB$JVF>@W_P#LM<R
M!$P4DD5UGB:%I5M@O4!_Z5RC2I!(L; Y[\4 1N/E!VC(IZ?,-Y)X[4I.7W+^
MM(3YB[6^7Z4 6[:0E^1\N*+<AKF7:!STJ&V4DE5/:K6EVI-XJMU)H M2!O+
MQ4$A7)SQ@5MW.G/&<H,_6L>_(MI!O4C=QTH K:G,JZ-*0>B\5\]WDC7&IS;^
MH<_SKZ&U6W2317DS@*M?/^M.#JDGD*."<\4 5R&C=B5RIII/'7:.O%7+>^1+
M=HY$!?'I5.5S+R0 /:@"3*S*/FR:>OR8 .:@@*JS'M3T==^[G% %CS2T>S&*
M>LS)'Y:G)J+*N01TI<^2Q=.?K0!,EU)'\K 8-+YJ[6(49Q5-V>9MS8'TIZC
MZGB@"6"U>>7>_P J5L)>6MM9F&( N>"<5ER7 :$*F00.<57&W<&R: $>;R9C
M)U&><U.TL%Q'OC.UL<@4LGV<PEB?F]*I[1ORG Q0!*BHQ^;[PH,KL3&$"^XH
M2,8WDG(J52C#!SGMB@!UO/+;1DAR7IMUK6JSQ>2EW*@/8-3&+KP5_2HI8)I
M/+7DT 1Q-*,K<3N['U.:MP0,1N9V"CO5RUTD0(MQ>''L#2S7<,[F.,84>@H
MB@6!Y2K2'&.#4,]JH;[QQVI)%!Y&1@]J4RL4PWYF@"&00J0KJ&(]13Y[MY;,
M6R?+$.PJ!L;O6G;8RJMD@^E $V@0SH\QBE:(#/*G':H=*;6;F:Y6*XD,0W;O
MG[9J1I_(PJ9&X=J+,-9I(=Q&\'H?6@"M#<ZA:W#B&]F09Y :IKBYFFPTLKR'
MU8YJ/Y5;<V:LQO $SU_"@"F"(9-S9.?:K:R1.P+* IZG%3G4;..,$IDCU6HK
MJ]MKV,>2NTCKQB@#8CLM*-BSQ2_O2/2N?FA97/H*7+) J1L=V><TUY)%VAQG
MCMS0 UPQ4#&*K7,P$>T#)%65@NG3>B?+GG-0W2IY/^T>M 'IOC*-M4^%UM,O
M+1^6O'L*\74\J.X->V>$G_MWP)=:>2&9&) ^@->,WML]E>R03 JRL?YT )A/
M,W-Q2/M(&SUI%(-'(.T4 .VCIG)J+L12_*"<$[J=#')<2K%$A9V.  ,T 6--
MLI-7U*"RA3+R-@8KZ;L=)72?#=M90DABBEQ[UROPQ\ +H\":MJ*#SV :-3S@
MUWMQ,SLV N* ,AHC% "2213(E9@6VCFK8C=XG.!P*J0LJ;F<GY>U &5XBUH:
M59N(F_>$5Y%>:C<ZK<,TQQ@^M;_B^\EN-08*<KTKEU0*2Q)!H ?!'(\VP=J>
MQ=)"B\L*;!,QF!7''6K,CB28,@&!UH A$+1L'<Y)[42$.Q8]!3BVYCOSC/&*
MD(B(('0T 0%?,B^60X]*:A>*U9?,;!)XK03P[?7<7FV90@=B^*J/H.O(Q#6Z
ME1UV\T 0VTD"1C<>?I5I;BWD91L7'KBJ?V:2,E94VL.H(I&)C[<4 7KDVSRA
M2<+6==VH=LPL?E.13S%D;\G%3HZQQY')H [[P?\ $Q-.T0Z5J"*& (!/.:\[
MUJ87.NW%U&OR2/D#M3)6,LZD(HYZU+=W9C\NW2-2S#KB@"M'\S RD@5,\^UF
M2+YE]ZCD/DR()QC<1TKI-1TK3;/0(+ZWD<RR@DANU '/HQ0AG4 >E6A9R7S#
MR5%48YCP6'!JS',(I@R.P]J &S:>T,ACE/-5S "_S'&/2IY[N1Y3(.?K4]GI
M\\L)NI1A* ,Y8<3[^H]ZL-M<^_I4K_,_R@8%0F-9"2#AA0 Y94B;;**<HC+[
MU;%5^=Q\T?*.XH1L9\K)&>] $\C2"5(PNX$TZYB"$+T/I6AX?F;^T#+)&K*!
MP&%.U'3FU#5I9V(1"V0%.* ,-B8SGK5>2=7DP <GT%=0FD:?&0LDS9/O74:3
MIOAZR,+7C94]\ T >?Q6_E('E& ?6E:[BA(=5&1TKNO%NE:/<E7T^9MFW/4"
MO/)+<0SE<Y ]: +$NK7,X&% 'K4(NY<$&1LU&9.<(/TJ: @RMY@ RO% %;:\
MC9R21ZT?+#RSGZ5*49)&5>AJ,)'O^<F@!"ZL 4-/>*4()"2/2IK8 WD*!1M)
M]*N^(/-:6*&)4"A>>U %$32B+&XG(Z9IBR!ODE4#WIOER87=T]JE*Q#'//O0
M!!=%$5@IR,5Z1\)Y_.5X2<#@5YI,"H/<&O0?A(O^GR!B1EA0!ZJZ[6.!P#UI
M^)/*##H:+@;"3VSBD1OW8VG..QH 9'*T3EC4Z[9$XXS4:SK(I#* <^E/(W;0
MO!H SKXF-U4CCUJOM;;D\BKMVSJ^'4'%4VDRF .O% ';^'N="MO^!?\ H1JW
MJ(SI=V/6%_\ T$U4\.#&@VP_WO\ T(U=O?\ CPN/^N3?R- 'G?ED<580;1@T
ML\>TYH1AB@#5LH=R#%7O*&=M+IT6;56Q4NX"0&@#"U"W,,A..*X7Q2_[HUZ?
MK<!, D5<Y%>=>([426Y;T% 'F#G,I/O29"D&I)0%N67WID@5>] $QD8IA354
MH[,:D$@"]:FLG5IL,.* *\4$@D]*UXXI3%P:DN!$@!&!207T<8Y(H T--2:,
M9;.,UV%AMD@.>3BN8T^_ADB(. :G;619-@'@T :.HQ,J%@<5B37DMLNXL2*G
MGU@7T>Q""?:H&MS/$0W6@"B^O;CMD!(INV'4%P@ -9=]:F&4BI[+?$A89S0!
MHPZ=! C.Y&16%J+J93M'%699YR"3G%4)#YAYH KY- 3=WI[)@4F,#B@ B1_-
M4] #7=:/J4,$:K*^:X?S,+[TY;F0#@F@#TF74],EX?'-0_8].N3F/;7G0GF9
MN&)KH--EF@CWNY ]Z +6L6L40*PXR*YAXFSS5^YO6EE;Y\Y-496.>M #;H>9
M$$4\UH:'BR7=*<C/2LHDGG-+YKCY<F@#:O=<M_/SLZ&NFTCQZME8@1 C':N
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MY/975@V98V7ZBH /.8#UH A"ES@#FI&AD5<,IYKK/#_AZ.ZD0R, ,]ZZN_\
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MQ&&0@9KYW\4:7_9'B.:&0,$W<$=*^AV5HD4C.[/-<GXV\'+X@LFN(HSYZ#-
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M?Y4 7UG,VD"7;R5Z5D7NJ"V,<Y0#9\M:6FJTVA1*""Y6L+4K<RQM&^/E.>*
M(?%%OY4T.L;R X"X%>??$Y5N?#UO.)"3OKU.+R];\.2"=3B$' QZ"O*?%32Z
MAX65$3F-VR".U 'D]LZAU;.,&KSW/FJ5//I51&CC0H5._P"E2*NY<DB@!-N
M00,5)$X2,JP'M5:8.T84'DN!^M:.L:%/IL$<TC JP!^4Y[4 4G4[,E0/>FQO
M<=?,8(.@I%*^6"I<D]<T$X3&>: '!1*K$GG-.B0(W#$BD2%\ DK@^]/ *C!Q
MU[4 /W!1@CD5-;1I-NW':W:HXVC>1@0<@4[;A<J>G3% $+A1(0><=Z="^&*C
MIZTX;0C-CD]<TW"D93@T  0%MR_-[&I99 51 .5/2JYW!P1P.]3.R[@4Z]Z
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MZTX EOE7BD:/YQNS[4 )O&=O2D9W"D#D>M/,9AB+$ FC2X1?ZM;VKDA7D -
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MM1D<L,;A0!ZK*P!8,1C-11JF-X-27$*)*P///:@1QF("-6SWH :,L> ,5(
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M)@EW"P)&<$57B ,VYQ@ ]#0!,6V$[AU%-1RIP./K4UQ-#*ZXQD5#(F]NN!0
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MYW#IBI=O ^; I\84$LQZ=* .I\&?$+4O"4?DS%GM&.64\FO2=1US0/B/X;:
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MR#-6)HXF@!CP&[U R;%!SCWH 4#<I.?PI2ZKM[&FQ;""<Y-2LD*1EVP6/04
M-:W<LLBMD4LKI,,8PPJU$Z)9DMUYP*H$@C=C!- "BRAE3#R+DU] _#+2]*LO
M#D+6H0W##]X1S7SLRF3A?E-=CX2\8W'AFWFW9DXX&: /6/B/X8AUC2#(H59
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MY<Y,P ':FW&I2HF$X([TP ,-SKR:DC@60$M]T=J /7?A]XB5?"5Y]MD#!4&
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MS9V1N+@WUW]U#A$/<=J6XD:>\"L2(QT'I5^=LA;>/[H'6JPP\@#KAAZ"@!S
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MJRZ;$& !YZ?4T 5-<56$&>HW8_2L01\D,.#6SK[%/L[#MN_I61'(7R7& >E
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MN,T 6[LQRC..:S64(:M7C(JC:U5E0OR>E #" PZ4@7G%7/LX\O(J!4)? ZT
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M]: $S@<4%RW:E ]Z!]* $";JEBMQN!S3,_A2&8@8'% '?:3;I/HQ0')KA[Z
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M#;@>M4K1&O;Z2^D'S-Q@U>=9' &2%6@#L:QM>R#;'(QELY_"MFL?74#^1QG
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M<J=HY-,"KYA#-\QJ:-5F<;?W9/K5B*V@6?\ >88XZT 4BB(VWDCK4\+"160
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M94:,^8Q ;CC-3)*D0?(8L1P>U>@?%_PTUOJ*:W$P\EPJ;0.^*\]CVN@R00M
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M/*=AVD9- &AX7M%N]=4("0,5]/\ ABS-IIJY'WA7B'PYT-TC^W2+][IQ7O\
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MN9?DZ4 9;%F/)J1)2!@4QE/7M3>HH TH+@;"K=Z2'"W*L>F:H*V.AJ>)F8T
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M)!QUH '**[!0,#O2?9C*H96(%1I;.JG>3CN:O6H$T9CB^8B@"JR[%QNSBG1
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M_I6S63K04F '@_-C]* ,,K(I;/(/7VIQ5BRKNQQTI!%(2Z[N#W)IJQ.BDNW
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MZ/X0@TE;J58WG SP]3>'?%VV>:UM?W-MM*\UYK);](_, 7TJ>WE>T&U#U]*
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MIB;57Y_E'H: .GTMBVFQ$^_\S4M[_P >-Q_UR;^51:4RMIL)7IS_ #-2WO\
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MW"QJV[GB@"(+EL1KDT-(\.0R%<]\5=LKT0SAC$A7/<5T5OJ&AW;;;TK'[A:
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MYSU% #P,L"[#..U=)I0 TV( Y^]_,UR_EQ^6"/OYKJ=, 73H@.G/\S0!1UT
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MI7.*Y.W0V\Q4R%P#78P9>ZYZ%>16%J$*17<J[0OI0!Y)\4O#DEC)'JMJ"L;
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M 3Y:\"@!L2,5,GE[2:NZ<TC7*#<1SR:KJI\M5W'K4SW"PQF- -_K0!>U._\
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M@U"T+)YH%6XDS(!5ZXB7[-M:@#BG@6>-XV4'/'->2>+-/^Q:I)A< \U[>UN
MY*^M<)XYTE95,H7YL4 >5(^#5E;A@N*KN/+E*D=#4L87'- #68L<FG J4YH(
MW' %,E0QX% #& SP:GLH#-.HQP*A12[A1WK;$8L+ RX <T 7CJ0M[8V^[C%<
MU=,K3%A36FDF<L32M'D9H @+]J8,D\U(56@@ <=:  #%2@C;BH%)[TX9S[4
M2#*=#2-ZGDTT')IV0>: +NE6L=S<!7. :U->T:WM80T1!..U8$=P\3YC.#[5
M8EU&XG3;(Y/UH H!2!S001S4^X=Q5V%+9U :@#-5=YQ5ZWB6$Y?I6C#86Q.Y
M:BN;%V8]EH H7<D;-\N*J$59ELS&QS4!^]B@",@DT\8'6GRQE ".]1A"PH '
M(SQ30PSTJ4*HX--(7M0!()24*@57(8MBGEO2MOP]H[:E=@.ORB@#6\&Z)Y\I
MFE7@=,UZ2(5BC5$  'I5/3].CT^W"1KCCFKJ[CUH 4  @8J4# IH7FE([9H
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M0SC:.%-+);*@#+(Q([4Z2"2-5QC&.U, =@5&.: '?*\6.K5$7$2$E%&*C/\
MHK%V;\*U/#WAC4?%=\HBCQ#G!/2@"#1-(G\0ZG'"B-MSS@5]!^']$B\/Z2L4
M2 /QD]ZB\+^&=.\,6855W3XY)&>:V'FW*3VS0!&<J,XR34J+L3>0,TQ=P&2.
M*8H>1B?X: )&F\J(D\L:BMT)_?2TW8CR<$DBK)V>5@GD=J &)(TLY"\*!UI%
M0M*VPDG%+ AD8D8"THF$;LD?)Q0 X)Y<0W'G-(S[E.PX]::K,4)E_2G>4/*#
M#O0!V-9&MJI-N6?:06(]^E:]8^N\+#\H/#<GMTH RW5/,#-]T]347[M"Q4YR
M>&]*103$TBG>5_A/2I%)*#;&ISR10!%G<N&X&>M#1QY8AOF ZT]E!3;,=K=0
M!1LW1;E S0!$</'&&^8TP%-^P#:?6IEC9R#C&.U-GBB<$AB''7% #6$D;;A)
M[8ICB0MQSZTL4\;QE6/(XS0L@B;))(- !$8EES]UC6-XM\'V?B*S,L5NJW48
M)W]R:VR87<?H:FCC>&4,DA8'L30!\QZC8W.EZF]K=QG()"Y]*G"+)!MQ@YZU
M[#X^\!-K,!U"Q!-TH^X.AKQ9FNK*=K2>+:ZDCF@"R5=$Y7>M+%+%N7<@7':F
M1JKN5DE93Z"ED0+N4CC^%J +ESKT\<7DVV57VJLVH7$^/,<@XZU  ZQD[ <4
MD)>=]D:;C0 C*R-D\Y[UH68_=%B,$FJLB3 ;&4 CFKEK_P >ZYZ\_P ZXL>[
M4OF?3<)P4L>V^D6_R7ZDU4]7MKBQNH?,.T2H&7V%7*;K-\=0:W+*"8TQ7/ET
M4Y2D>QQC6E&E2I+9MO[K?YE!'(;/WCBKD%V\!&U:JQRH/O "F2@C+(YYKU3X
M$[[PGJ,LTDSABNW&:Z(:C"7=WG&\&O//#,SV<-Q\Q+2C S6Q(SQ0?./F?G-
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M[B3M.3VS3MKH5+(.>M $GS,O3=3-H'SCY>U)O4MG>5/H*:Q1%PSDJ30 Z8L
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MTT:!(+>5E<<L!6'=WZS7 FV[G/).*8Q:^N7F8\DU8AMFC)" $GUH JM/,Y!
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M&Q5A7MMS;I<1%6%>=>)]$^S2>9&.#0!RBH">E7DVQP''!JHHVYSP:7+-P.E
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M'6G(N1DTAR>>U ;O0!)M Z4P\GFG9R,8I#P* $\S"D4B%B>.E*J@FI!@#@4
M-;.0*>(N*7CK0K<T -P>1Z4JJ2.:=P#2<]J +=PI:^N#G_EHW\Z@+.696/':
MI[H*+Z8G/,K#]:BD1%.YLX]J $R&0*W:ETZ\-E>L/^6;&A"C L,_C4=RBF(9
MZGTH ZN4"[LV"?QCBN257M[UHG)&TX%:GA_4R^ZUE.-G"Y[T>([%S;FZA W)
MR: -:RE6:#:><#G-<YXD\,Q743RH@((^88J]X<O#/!A_O]ZWR 1@C(H ^5O%
M?A<V-Q)<1(P ))%<['<M* C#&WBOIWQ3X4AU&!WC09QR*^>/$GAO4-&U%SL'
MEL<C H SMJ1\XYI]RF(@R@]*K++*I ?%:+R+]EPJDDT 5K:%IR%&!]:EFTX6
M_P SL"/8U5&\@@'!]J#(S#8X<F@!(8H)[I4?(7(K?\1S6*VL5O9*-^P9..]<
M^ BKN(.?:I4\B5<G=O'K0!7AM[@N!)C;4TVV)=K%BOM4KRL!C:2/85,MK)):
M^8J\9[B@#/Q%*\3H6SO&/SK;JA%821[9), !@:OUY68[Q/O>#4O9U7UNOU(K
MB3RXL^IQ3[:^SA=JBH;U28..QJ@@FQ\@)/TKHP"7LOF>3Q9*3QZ3V45;\3K+
M6QM[B0&0C)KI++1+>S03+SNKAM),IE^<G<.:]%TRYAGTU4E;# >M=I\P5+BP
MM)3E\#/I6A:^ %O+=;J+A>O6H%L;>:0$MGGL:]$TUDM="BC7.,&@#)T_28["
MT2,G+#UJP\"CAN0U+*7D4X/ IL)DVLTI&Q!F@#DO$V@[HY)$3(/H*\]ETK9N
MW*1CVKW""\MK\O"JGCUKS_Q4$BN)(E4#G% '#26END#$D[JRHTVW2NK' />M
MUM-:4@@\=ZI7=D]L0=N1[4I)--,TI2E&I&4-TU;U):BN(5F0*QP V<U+45SG
MR2 >3BOG\/\ Q8^I^N9ND\!63_E?Y&?*[PS Q,Y"^M:*ZH)[-HG1 WKBH/-\
MH 2 %3UQ5:XBBD<,F0M?0GX^#D '/-5H(I=5OTMH%;GT%,;S&D$$/S,QP!UK
MU[X=>")+2)=1O$7?U'TH Z;P9I=CH-C'A&\YER21WKH'U%=Q<<GMFJ<LR^9L
M"XQP.*@(09!SF@"[]L=LC.#[55*^;/OE9BWK49$LK!(^![U=*Q0IA_O8H M:
M/>!=;%IDGY,YKI)8V\S>H&:YWP[:&6[-\<<96NI!!Z4 56A6)WNF^^%KBKFX
M:]U*2X!&T\5W=RNZVD7U4UP4%L(99%;U)H M1[(XQO!+9I61&DW FFQLVW<0
M"#4ODYPPX- #'52.2:0.#\BKT[T\']XRXZ"CSUC& !N- $30(Y_>' J71;H6
M>IM"I)5S@9J'!D?DXI((W358-F"-W.* .UE@#G('UI88%AR1U/6IJ* . U*)
M[36I97Y61N*DRMV=JJ!6QX@LXOEEP=W6L>W5F7Y&48]: (VAC@;#DD]J%NG#
M 6X&X>M6;FV21 0<L*HG=!RH.?I0!5\3Z--XET:6"2-!*%PI KP/4-*N/#]^
MUO<K\N<"OHJ#4;@Y"XR*YSQ=X.3Q#:-<87SU'&* /%Y)C(%6' )'6G1V:J<O
M(2Q]ZKZEI][H]VT$R%0#P2#2*P\OJ2Q]Z +<=Q!9R[F!;'XU<BEBU.X#;< "
MLM('"\X(-:^E000H[G(?F@"C>BT2;:A)(JS8ZK<I;/:P1IL/.2*S'CQ<.QY.
MXU9M6D23(*@4 0(S1,Q?.XFI8W5L[S3K@/YF3MYJ%8E)Z\_6@".39&ZR1[MZ
MG(KK8O'.LR:(;.4CRP,>]<RTL<"X(S].:#>6^S[K\^U $4<IE9G8#D]J?YTB
M#"#%,+P_\L58'WIXW$9.* )%$T@R[?K48BVN><@5+;Q/,WSL OUJ.[\R*<P6
MXW;N!@9H CFE+_ND&2>!BN\\(^$%UBP$=[((U"\;CBK?A3P?I>F:2VL:\<$K
MN10P!S]#7):]XKEGU&3^S&9+;/RCH<4 6O$WA]M'N#;66V1 <$CFN>*2Q  \
M'O5NVUV]CR\AW@]<C-:L<5IK,(;(24CG)Q0!@;6899OUI@)=BN!@=ZMWFDO9
M.PW CM@TR.%!%QG<: +VD>)KG19#"P#0MU!YJ34;6SU#-XAVEOF('%93PJBY
M;G-7'@+6!>)L8'3- %)DV+A <"ED^>,%LC I([B54 ;&:D-RDXPPQCK0!#$2
M,DGY?>JTTQ!)CY/I2SSAF\J)69N@P,UW7@;X>3:C(M[?(1"#G!X- &5X0\#W
MOB6Z669&6W!YSQ7NVFZ1I_AW31;6R 28&3CFIK86^E68M;&,+@8R14,@DF<,
M_)]J )HD4DDD\\\TGF!GVH/E]Z003OC!&*'@94P2 O>@!3=,K?=&T5"+B>9R
ML:@+4QV;-JCCWIZ1[8LI@4 1HGE1GN]" LI+]*<JC.&-2,$#;4!H C4*L>U"
M<YI\<<:$D\G%((6:0DD8IZ^4,]2: &)M.2PX%-<R3$>2/E'K3@2Y*I^M*TCP
MQ^6F-QH ["LG6]N(=V>C=/PK6K(UP,1#M('#=?PH QLE0#".O8TSKD$D9ZU)
MDH44CD_Q=J:9&D#8&2#C(H C79$Q W-D=33TP8QA@">E.5W)*L,C%1+' T8_
M=L) <YH ?F5'57QCVH4*'8\]:/,3!#(=W:F/(Q*D#:!US0 R:()\Z ^]+!<Q
M2@[5]N14OFNF#U4BJT@V-D8"]<4 6HHDD)7!^;C-+-8O;IE=[+1:72*RY(QZ
M5T4<R&$,@#+CD4 <HEYY;[6#8]#7->,O!%GKUDUY8+MN%'('&:]$O]'2]A+V
MQ5)#W/:L/['J&DR^6Y\V/J2HXH ^;+FRN[&\>"="K)US2%B^ IS7T!JOA;2/
M$9>8!(YR.=QQ7CWBGP;?Z#>.\4;/;D_>49&* ,$N0NQNOM6II5W;V*,Y4%SZ
MBLE;A$(R/F':G!X]^1\OUH ?<R>;=-*F03V/2K=FY,;*W534+@R1;D=:2TE9
M9-K$;3P*YL73YZ32/:X?Q:PV/A*6ST?S_P"#8OU1EBP[C.,\BKU13PB1<[<L
MO2O,PE94ZFNS/N>(<NEC<+^[7O1U7GW7]=C.A!)*8R14D4#2D G S3X)1'-D
M0LO'.:E>ZB68,L39KW#\L:MHRY;N(%*)G(]:VK2X$JJ"<L/6L!I=\;2!3G'%
M2V5X(D+RY)[4 :&M;ECPP7'7-5=+NUU6TDTR;&%!9#WS6=>WT^H1,G.T'BJ5
ME*]M<K.H*LIS0 31O873VLH(9>M.C968C)Q[U<O[H:Q.\[+B7N?6J'DM&020
M?I0!9A2+SP 3COFJMP%6;"GBGP@++\P(S4T-F?M!=Q\HZ ]ZSJ5(TXN4CKP6
M#JXRO&C26K_!=RW GEPJOX\T\D*I)Z#FEJO>175S%]FLX))II.,(,D"O"BG6
MJ6[L_5ZU2GEV"<ND(Z?+1?>9%U=&-@1@LU='X6^'VL^*V681F.WW<[N.*[[P
M7\&K=;)+[Q"RR"0!U3."@]#7I=SJ-MI=O'8:9$#M7:K(,@5]"?CS;;NRKHN@
MZ1X&T)+6"-9)!SO8 MFD4MJ<OG2[O]WM3[73+J[E$]R^YR>3VQ70QV=K9KO.
M% '))XH$06MD6B7< J8XQ3;K4;+35VN=Q]N:S-2\2[Y6MM/!=QQE>146F:#)
M=RFXO23DY*F@"CJ&O7NHY@LHF6)CC<!@U-I/A*.UF^VW\K.X^;YCFNMAMK:U
M01HJ@>]4]1MIY\LK@QKR%% %>6_6295&5C4\8XK0@;8-ZME#[\UB%XGC"F-H
MY4[MWJUID,ID,A<;.ZT 8/CVQ<-%J8&8TPIJ.WDAE@C="QX&?2NIG@34K:6R
MN\-NSM'I7"0+<:!J,FG7)WQYW*P'% &PA8EV3&".]* Z@,3FH@Y;/S#;VIH=
MB2I4X% %EO+;!;CZ4QMBKM!R/>FAEV_,0?:F336\4.]P<9XYH BNYECM5VXQ
MGG-;OA2S\N.2Z;[DG*Y[5GZ;H;:NJWDK 6Y/"'K722>586T=M"IV'CCM0!9E
MOH8;B.%CR_0]JX_Q?I\\NJQ7BY,*J!@>M:MUN>6.$*5#?Q'M6J!$\2VT^&&W
M[U &!HVLK-"+6Z(XZ&M5[79AT.Y>V*R-6\-E8VET]@%'.!R<U2T+Q'-8W"V.
MH!BI.T$C&WZT :=Y9>>K%I"I/H:FT[48I4_LV^"G(VJ6'!%7[NUAFB-Q 0ZG
MD[3G-8UY:VEV@\L&.=1P2: /&_BA\-I=!N7U;3 SV3G+ <D,>?RKSF)PRKNS
MD&OK"RN8M9LI-,OTRV"HW>E>$?$'X?77AB^>\LXS)9R-]U!G;[T <C@-D@C-
M1Y._'>H(YX6^5%8$]Z>Y*#&1GM0!8@)=RIJN7"N0V34]CD3[G&5QVJ%Y,2ML
M4XH ?&1(W!;/O3\(7PX%1).4&3&W/?%6+98VF5YB"G<4 1!8RQ Z5#*BLAX;
MK5V2*%Y&^S#;SWJ!C,H^9U';% '2_#WQ/<:'JZPLY:%R!M)XKOO%V@Z9XG#7
M,6U)P,X7C)KRKPUIDU[JOF*I<0_.2HJ]?^)KZUU\M S".%ON^M &3?9LKA[.
M:,J(SM!QUJJ6*_=Z'FM?4=336Y3/+$5D[DC%9TD:KQUH 72K:75]2AL@0J,X
M#$\<5VGC[P-H_A;1[*:UNFDNIFPX#9Q7$0M+;S":W;:X/%27MU>ZA,LEY,7(
M.0#0!'!"?*5\G(ZYJ0,Z@C:#4R+N0$.JCOFFMB,'Y@0?2@!('E20E6P<5'(K
MO*7]:>DT<C;?*;ZT^=)8R,L-AZ4 1^:R*HP#BEBCW,68\&DP%!)(--4!P6W@
M =10 YE+/\N-HI#L!PV=WM0@4CAJ<8_F\QSU&!0!"SY. .G>HR^-V2<U*YV_
M?((/2H99DRBH.: &M<;2..,?C6QX<\+76N78)1U@)ZFK_A;P5?:[=+++\D .
M?F&,U[7IFG1:;;K#&BJ%7&<=Z *WA[0;;0K6.&%06/4D<UZ#IL;) ,^E<>)
MI4N"S9X(KJM(F>6+!!  [T :E4[P>8PB1 7/.2.U6SR.#S5'4=0CT^ N5+R=
MD7K0!#J=]#IEB5(.YQM 7UKEX4VA)9]S.QZU.UW+<G[1/&Y.?NXJ19))<,%P
MG]TCF@".0"0XY /I4PC9=NT[E YSUH\S:6;;S35RV2F58]S0!() L?&,Y[T$
MHQ 888<G%-DC& CJ7[Y6G@Q@DA2,C!'>@!&8!3P,=J9@ !H\D]\T]C"FP+$Y
M+4?+GY?EQZT 1NV2"ZD>X%=-I>/[.BQ[_P S7/&>>-"''F)_LBNATI@^FPLJ
ME0<\'ZF@"KK6/W"D\'=_2LG:@8*3SV-7/$SLC6A'W3O!/_?-9:KD*=V30!:\
MI6!#G/I41@/.UAQ3?F0@L<BG!AO)!Q0 $1M\K*=P'6HW640*\>>*E63,N&&>
M*>+C)VJO ZB@"LURYV;T)..M/97+ [AM/K4DLH49,>?:HN9OF"D 4 ,D,B2+
M@@BI ZMRZFF[264!L&D6.02$L^X8Z4 $L:%A)%P.XIC&)A\HY[T]75OE5?J*
M@.V&7.WCO0 ]85VX!Y%(2R [AD5+O1V^7Y<U*$1AY;.,F@"+RXW3:1N1Q@BO
M*?B!X,N=-D.I:>FZ-OF95&:]6\B2'CG%.\V.2)K>X4.C\$&@#YKMY?M.1("K
MC@@]:5H5!Z,*[OQQX'ET^X;4-.0^6>2%%<-%.TAQ(-K#J#0!9D@46P9#@CKF
MJX?8N<YJ625=FW< *8I@'& 30!"L3W4P2'>&-:9!4X/4<&I-"B+:JF#@4^]7
M9>S#_:)KSLQC>,9'V7!U91K5:3ZI/[O^'*EP"8'"]<5N^%[J&73+BTNU^?#%
M2:QJKH\T4Q*O@]*67S5G#YE<8X:7M*>(6UN7[M5^;^XA=6BG>/\ A!J8%7 7
M=M%$IWL"3R>M,*QL"F0#ZUZ1\6;UA-*'2%9-PK>\QMPC=N17#V$T\-X"K9%=
M3YKJIF<;BW- #A<22W8A+97-.U^ZNM/A@$! 0]:RFEDB1KCE<&I]2NY-0T.-
MU4DJ.M #6U5;BUQ.F6QUQ6+-$)W+(<>U-CE=HP#VZT2#^-3M% !!I@N;A%D)
M*9!-;WBVZTPV4%E8A@5P6.?:LVUG6*!F,H)-9V$EG.\[B3Q2;25V5"$JDE"*
MNWHB:W01VZ*.@%2$X!-*   !T%-<$H0#@D5\]_$J>K/V+3!8+7:$?R151(V4
M. <BEC<(3D9S2P*R-M)SFH+N00AL. :^B/QL)YEA!,HR/:MGP5X.N/%NK(QC
M9;5&Y+=*V?AYX.E\3S>;J%LQM!R&(X->[V&F:9X8L?*M(EC'IZT 6-,TZUT+
M3H[:! JJ .*;=WV2%3FJ\MQ/. 51F&>U0EG)*I$=] #]-,LU]DCY #S3/$=^
M86BBBR9,\XJ^)8](TYY9W"Y^;GUKDK"\GU[53.L#!"<9/2@"23?@/*A.>M20
MQ1E^!C/K703Z6Y3:2&'TK%FA,,K*1M('>@"-V43A$(R/2EW$ CJ<U1MMANW*
MR@MGI5L%E<C:23WH E67D+MXI4/S%>@]Z7("+Q\WK2O/$H 9<F@!I(C7Y5)-
M-S.KB1<8]*4R$ME1A:C<3LV5;% $LL5O<*&? DJL]A%(R[>#WHC0^9ED+'UJ
MW/B*$E4.XT 94Q13Y88\>];6B6J74;.PSBN=N%,;9="-W<UUGAAX?LYC5@6
MYH E60-*8<8 K/N8?(O?-9OW9ZBM2X,4=SDX!S3Y;6WO8RK.N6&!0!XI\4/#
M0##5]. Q@LP%>=VMR)(_G!+=*^B-1TT+%-8SPEHFX#'I7@7B+1[GP]J[@QL(
M7;(...30!&D3 [F!*TK%68;0<TU;F3R\ Y!I5E\OYL9]J )[=(VN8TN/FR>
M*T?$NJ>?!!8Q I&BX(K,L)XWOED:$AL\&FZE(WVQF=">>* ([?Y5R3@"I1J
MC<; ?K4#9<#]V=M3Z=I<VK78MX$*<X+4 3O<07;JI0E_44E]*8XQ%#'CU.*W
M=4T[3?#=LJ--'-<D G!Y%<K<ZBS@E1DGM0!"8[AN55G/^S4T5JHB$DH*MZ&O
M2/A1I.FW=A=3ZH\9<.=JMUQBN/\ '36J>)Y(+ C[.N,!: ,=)5DW*JGBFA22
M<*0:=$P@/W>33@99 64$4 .C4,I# 9%0NB9P>I/:K:6TAA+D'-5PJAMS#D4
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MI6W>2P6EGY2\R8Q0!(D5EY.6Y;ZUA74&Z0E1QFHA+(>]31SD'YZ *3(5;::
MA!R!6C)$LB;P*J8(..E %P7)>Q\INU4A&M2=%QFHR<G H ",+48)+;0*D^9G
MV@9-=#HOAV:Z=9'7"F@"+0_#K7\@DDSM!KTO2M*BLHPL:\XJ;1=%,<02*/-=
M=8:.(OFE ^E &9;:8TBYP:MFR6,<UM#RT&U!5.Y1^6/ H Q+I4AZ"J)<-5B^
MD#28'-5@  "10 [( XH/(XI0I;MQ3EPIH %!/6D) &*>>1Q3=OKUH %Q]*4X
M''6FGBEV\XH =D 4@.3UH" 'YC2X4&@!#R>32A@.* O.:8Y7/6@"_>JRW4K#
MG]ZW\ZB8R\LV-IJQ=%OMDZ@_\M&_G39<B# ()H K*V =P.&Z4]8EV J>1ZTB
M3*ZA&'S"F%6#'!'% %299XYQ<J"#&<\5U.FZC#J=H%D8%R/F%8OG%X7B<9##
M'%4H5&ESK.BMM!R0* -EK*XTZ^\R+'E,<FMVWF\Y-U16T\.HV888(8<CN*GC
MA6%-J< 4 2$ C!%<5XN\.1WT+,$!R/2NUJ*>-9(BK#(H ^3?$>@W6FW4C;?W
M8)YK.AU D",#C&#7T1X@T"QU59+9HL%NYKQGQ#X(O-+N&>V&Z+/\(S0!BHL9
MRYZU()@J$@#CVJBT<Z-M9@".QJRD+-'PXH KQ2QR,V1WJ7RACJ,4IM8E7&X;
MOK4Z6H^S%RPX]Z -&PEL+6#=<C<?:H)==@$ICAC.SZ5BR;%/*LWTIVT;<JI'
MUH LR7$UW(50@+UJZ,[1GK5*T5W+>6C,0.PIUI<LTK12*5/5<BN''4G*GS+H
M?4<*XZ-#%.C-Z3T^:V_4M.N]"I[BK/A()<ZNUK<1GICI4%:.BWT6G7XFD3(/
M\0ZBN3!XA4Y<LMF?1<2Y3+&4E6HJ\X].Z_S7^9MW&BI9:S(J#";137MDC9OF
M.,=C5[4-9M]1A$D2D2=R:S83YT94N,X]:]D_-FFG9D^FW2)=)&"3SZUZ1-?^
M3I,*A3FO*(PUI>PL 2 V3BO2;?4[>\MH8]A!]30(L6MT)8MLBL,TZ?.P1@$*
M>*G\E%V#>F>W-1W\PM+9Y9W4*HR* *RM;Z=$\AD56/3)KA-9G^TW3RNP9,YX
MKF_%7BF>ZO&6W<A%/%16&HR/I\C3Y)V\&@!]]JT=L-L2G\:KC5#?1[0N HY)
M%5956\CRK 'UJ6*-8HPB]!^M<6,Q"A'D6[/I^',HGB:RQ%16A'7U:_K7[A]5
M;W<40*0,')JRS!5+,< #)-9+W'GS%\X0= ?2N/ TG*IS=$?2<48Z-#!^Q3]Z
M>GRZ_P"7S$N9&VKCTJO+>.Z"&-27/I3R\MU)Y5M$[L3@%1FO5? /PR&$U/5B
MAQR%/!Q7LGYH4_AQX -Q<IJ&H(0HY ->J3W$<#BW@ "+QQ4CW45K&(8%Q&HQ
M@5GH\<]Q\L3C/7- "[GE)P13F6.*+).6IWV%B"5E15]":6'399CE>10 R)W"
M%L<T+!<7DX3!VYZUMVVCRM%AB!6A8VOV638P!/K0!+864=G;B- >1DU:1 @P
M*=0/>@".=6:)@O4BN)O8I8+EMZD#UKNJK7EE%>0E)%SZ4 <6LQ\L*".*>)9"
MV6Z=J;?VQT:7YX))E)P/+&<46]Q!)DL0HQ]TGF@!S22$@C&":40!W9F[#-*)
M[<9[8[YJHL\]].(+0YR<$CD4 3/EUVA@*VM TPQDS2G=GI1#X9&R/SV#,#\Q
M'>M^"!+>(1QC"B@"2FY).!2Y&<9H&,G!YH SM2M&GA8D]!7)36SVTF<\5WDB
M;XROK6?<Z1'.BC R.M ')QW#9(4$U,TFZ,AE_2MR/14MR=S*/3)JE<P(LFW>
MF/K0!A[HXI,A3FK4=W$2-J-N]^E3RV\'EMY:[G]JH"22&3E"OU% %+Q3X5M_
M$MKG8JRA<# Q7BNM^%+[P].WF(QBSQ@5]!12R!@Z2+4UWHUKK]JT5UL)(QUH
M ^88KZ-G"@$'WJRLDF[.>*[OQA\*;C3]]UI^UEZX7DUYUMGLI3%<HRD<<C%
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M =O- ]K:0Q6B[5XW 5:2W1XEW#)J&POQ<QXD 5P.15Q)$;A2.* *DM@93R_
MZ>U2/:HL0&W)Z5:HH RF:>QF 5"\)ZCTK)U_08-7A:XLR!.!EL?Q>U:&J,PF
M8)*PX^[6=;7%Q;MF)=WMGK0!SUEKNH>''2&^B=8!P,^E=?:+IVL0BYM67>W)
M([5']HM-0++JEK&-O3(S5";P_P"7&]QH]TZD'(B7@4 7Y]$E6?S87PX'WA5W
M['%J6E_9]3B#!LJ5;O7.Z;XJNX)?LVH0!"#C<376Q7,-W'F(AN,B@#Y]^(GP
MJN-'O)-0T6(M:.<^4@_U8KR]R1(8YU*R+P<]J^R;B\AC5H;]0(VX&><UY]XM
M^&&B^((VNK&002XR%C7[U 'S]$[+]U^*3>W;@U:UWP[J7AV\:&YB94!^4^HJ
MBD^5&!DT :5I$'@D>5QC'RBJZ!2Q79NS0KXB4,=N>U*[*BC:<$]Z ',DL9^1
M2M,\AIP3(<>].:28H GSCU-1.DK<;B#Z4 =UX9U73O#WARX9=LEU,A3(ZUPK
MM//<R3%CECFG>254(SE13PQ3"J-V: (#YJG)/%2JX/++@>M3SNFU% !..14,
M/[V;RE7/?% ",X7&.I/6M7[%:BPCGEN5:1OX/2L^<^1(%:,4QO*D^;S&R.=N
M* )'V'Y=N5'ZTT^6%VA<^U"O&P'S8JQ-9>7$)F.U<=: (I%9%'EG'?%3-<1O
M J2#YJB,JK%D'<>E*(X6AWN^&]* !-@&&BW>AI\D=IM&$ 8]:JI.A^5G(QT]
MZD!R/N@@]Z $(@1>,#WIC2CRMK'<N>*CED"_ZQ0!VJ33=(O=;NE@LXBP)YQV
M% %8DSRB)1G/05Z%X-^'INY!>W\?[E>0C#J*ZSPG\.++2HTNK_\ >2==KKTK
MM96C2(10H(HN@*T 4K6QBMH?*MB(D7@+4LF($VR2!SUVTC%(T^5]WN:KB">X
M/RKN)X!H %_TF<)%+LP?NUV6CVTT$.96SD<#TK)TS28[%5FO %:K.IZ\L*;+
M<!L\$^E &AJ6JP:=&=S R'[J^M<S&TU].;J:;8XX4'TJLJ7%[-YUTOR#[K&K
MK+&$"QMN:@!P,F"3)FE".8PPDVYJ/:Y&.U2>2VWY3NQV-  @95;<N\>M+C./
M3TI 2H)W''<4H0E<9Z\T  +%L*V,4I.?GQACQF@ MGC QC-,*RK"HVY&>3Z4
M .8S1C(!:H]KNI)0D'J*7"M(BBX;'<42RP9V?:&7;QP.M #Y&:-0J/M&*Z'2
M?^09#DY^]S_P(US+-%&OWRYZ\UTFBN)-)@8=#N_]"- $FHVB7EHZ,N6 ^7V-
M<?$S6TQ@F7# X&>]=1JFH_V?<6K,/W;[@Y/;IS575M*CU:V6XMGVN1E67O0!
MG$;CM)]Z1HPB[E&ZJ1GEM'\FY&R4=CW%6U92@;?PW:@!QP2'SCVIYBC<AXY@
MK=Q4)C'ED[N<\"F*P2;G[WI0!,X;.&-1A9H5#!24)J64EE#8P:9]H_< .V.:
M !PS .B'CK3<2,^1GIR*<K';N5B5IQC8/N5B>.E $8(W[U&#W%.>))E..#Z5
M',DH4NJU$EQ_>^4T 1/')$<%3CUJQ!&78$]?6AMS*03GTJ"*Y>*8*1QF@#HE
MMI&@'R%L]ZS+VSFA7=Y1'O6Q871)"GIBM Q"4,)%RI]: .,5OM4307!^0C&#
M7FGC/P#)%(]YIN2O4JHKV+4O#[,#+;,=_P#=%8IE:'-I>KM<\;30!\[M 8G\
MNX7:PX(-3O;I"H<<YKUG7_ L>HHT]JGSXSP*\NU+3+[2+@QW41V*>IH ALOM
M"7B31N5 [5:N9F:\(?\ B'7WJ!;@3*OD\8]*?)%),0<=.<UG5IJI!Q9V8#&3
MP>(C7CT_%=4/J&>-F7=&<,/UJ1&SD=QUIU>$G.A4\T?JLX8;-,);>$E]W_!1
MGB39M5SR>YJ\+*-HPXD!)H,<;GYE!I[)&D>4D.?3%>S1Q,*JTW['YKF>38G
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MG*QQ467[CBE!.>* 'EG8;2:8(2O.:4DYJ8)B/+4 0$@C&*:&QVIX&32%/FH
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M)?O82B_*S_R_(\!HKW!OA!X;/S"ZU(#T$J?_ !%,;X6>&H8]R-=RMZ2S#'Z
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MMCWZUGB"X4#)4Y]Z&\[;A3S4L<+NN6#;A0 P1,'^51GO5@*KKL<8'<BI$AV
M.Q!'<#K5Z"UB6,N_RH>?FH 33HX^J9*CCFK%W>PV<>689["LV^URUTU3'"ID
M)'!3D9KF'N)KVY,UP_)[4 7=0U:XFF)X"9[5GBZ7>6$LH;VJR4@7!8[L^AJ'
M]SYA;RVP.U %NWU-PP9';CCFM(NUP 0V3[UD62I<2&-4()/>MV*R,<70@^]
M%5[9F!9LC_=J&2PCD5,!LGKFM&V\Q+H*65ESVJ^7CN9S$5P!QQ0!AI:"%E58
MPQ/J*E 8]8U ^E:\ZK$,1(=P'!(JBL5S)G*G)_V: *#R/#+A#CUIKSNH9C(P
M],&I)[&XB)DE1F'^RIK+)DEE"8(3/>@#8M==D1TC8@KZUTL4BRQAE(.17GS6
MB(6<.,@\<UHZ9KWV%Q#,KLA/6@#>U*/,H) "GC-5/LT<1 !.:U7$%_"-KJQZ
MC!Z5F2*4F,<H.[H#V- $+PF23<H&!US42&:"?SH&SC@J3Q4[PR1M@_=-1_NU
M?[K4 3W^DV>L0X;]W+C.5]:SK*PNM"P9&9HR<#G-:-KC?T;UK49UEMV5T+<>
ME $.(=6LRCCDCKZ5Q^J6M_X>9I(F:2WZDDYQ71VE\MK,8?+<)T&16I<6\&I6
MC12KN1AR* .,F72_$EAY5[#'O*XW8YKQ_P 6_#:YTN=[K3 9+;KSUKTYH?[/
MO9(S%(!N.WCM6G:WT@'ER1[E/J* /F-YIHVV3Q%,=<C%3"XBVJ5YQZU[_KG@
M;1-?#22VY6X/\0.!7D?B3X?ZIH,SO"GG0'E1&N2!0!SN8W.<L/I5F';(<#KC
MO5,2^3\DL$BL.H(Q4L;;OG_2@"0P2YSUQ3H[>21MRXW#L:?!<D$EU)%122R>
M:2O"GI0 R1Y49A(JY]JU_"[VL5^UU>#Y C #'>LO'0MR:EBE(.U1\G<"@"0K
M]HEENB!LW$*#5VQUU8[=[22TA.X;=VWFLVZE+X0*=GH*9%%N&$4[Q0!8FL2<
MR0X(]*@F9V4*Q;CL>E21FYB8[CC'7-,GN99> !QWQ0!+;E6BP5&/>H9&9)#M
M (I#<CR-C\MG^&B"VO+U@EM&QW<=,T 02NHZ ;Z(X;RZ81PH6)]!7=:!\*-2
MU K+=W$*Q'DJ>#7IVD^#/#^@Q*T<6ZX4?>)R,T >7>&OAG/?NLVH%EBZD5ZQ
MH^BZ/H5LJ6T69!QN*\U=%TNPK$ K#IZ8I@$LPZJ .N: )9+UB-JJ#58L2P+
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MV/TK&AUJ?2@%VAHCUS_#6YKS;?L_&?O?TK#N(OM";=HH W&BL=>M!(I 8_Q
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M-UI<9MMD2+D>U '!1K(J$+&I-->*3N[*3V%=9:>'<S"67(&>E6;S1(V8>6*
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M#MDPO]VJ<PTV[W+=VB$G^(T ?.0U&1$V21$8]:?%>AQA6Q[5[)JG@33+Q&:
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M^.M)K8)G:NY3SGTH R4GD4X7D5?L[]0_ER<'WJJZ1_, VSGJ*K$;?F4[SZT
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MU"DY->>&>XM;GRKZ%HSGNN*^P[>=;I.4R/<5S'B3X=:)XBW2SVX$_P#"R\4
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MM,CGD^M9D\A+8[5>U*7>P13@"J(0D^M $:@L>:L)&01BG)%R!BK]O;H@WS'
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MW.<_6E5.,DY)IVT=SQ0 W(7H*7.>U&  :%R#G% $BC I3TXI%);M3PK') H
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MA%]F.34TUI,4CVR,<8R*M,L<:^8X&0.M &><?:Q^YS)W-:HZ"JD+Q2;KI2,
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MH8]:/-;<0%^;N2.* %5< LS-CM2-N8;V.4'?O2^:XZXP>U0F:,9:%L>JL>]
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M.TQ;AV- 'H(\JX7((85"=.MS_!7,V5_<Q= <>E;-OKT#<3$(: )+FRMHP-X
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M@Y/'6@#9<;7$L9X/WO>G7$/VB''0FL[3YI@_E2 E3P":?=7;Z7EY3NB/<]J
M*L^GR1+G?UJF+&260*R$#/!K1L]>LK]RA9<CI6I&T,H^0@XH ;:P^3 J]ZF9
M@BY8X%"C;U.:22,2=>GI0 +)')P"#5&_T/3]2&+FW5_PJ;R6\SY!L J4R% =
MW0=Z .+O_A;H-VQ*VRKGWK G^$%E"S-;@#TKU-;J%AP]/,J;<YXH \-N/AI=
M)(0L98>H%(GPUNR>05^HKW48(R.E,<?[&: /&K?X:S@YW9Q[5T%CX#DV;&.T
M?2O1E547.,4XG &!F@#D+/P/!;1[25/X5K6WAJQ@',2EO6MJB@"O%90Q* J
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M:<J,S4 3J@4<**>I8BE1<  T_@4 0-&SCDFFI;;34DEQ'&.6%4)]:BC.%!-
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MT/XUTD_BF".?9% TJ X+[L?D.]:=O<6VJV6]5#Q/E65NH/H:CGDM6B^5/9G
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M%(RAA@C(H XC,C,!(2IJ0)N.%.XUN:MHXN8&,&1)V KEO)O[6X"2QE3VYZT
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MD?*?:I=N'R&(&*8K+C .3F@"O<QS(@P2U/BX0+CYJLF5$'S<GT-(LSR+E8%
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M]D:.W;;U(JP!C-4-74M:D9(^E ',SJSODN:0^8<+C ]:=&3$-S\@4[S&E.<
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M+"FM==L4OV=A4;Q;>0* &F1FZTO/K2=:3[K<T 64D*BGER1D&H 1UI=X&,4
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MOQ&NTDU"SM5.6AC9V]MQ''_COZUQ5*BK005/B84445J0=A\.L_V[<^GV8_\
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M54X8^E7\55DTZTF;=)$6/^^W^- '-3;I"6,S'/;-110D-C))KJ/[*LO^>/\
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M,&VX_P"NC?XT'0-,/6V_\B-_C0!Q2HX&2J@=CFE0,7R#D^G8UV7_  CNE?\
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M?^^A_A0!CFVBZDY_&D%O;M\JF3)K=70;5#D239]V'^%2?V/ /^6DOYC_  H
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M .^A_A6U10!DQ^'K.-@P>8D>K#_"I)-$MI3DO*/H1_A6E10!D'PY9G_EI/\
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M@6O_ #TF_P"^A_A2?\(]:9SYD_\ WT/\*UJ* *EMI\-K]PN?]XBK1&1BEHH
MC6$(V0S?G3G19%*L,@TZB@#)?P_:.Y;?,"?0C_"FMX<M&_Y:W ^C#_"MBB@#
MQWQ!XANM:OG8RLMLIQ'$K';CU]R:QJ**]-))61Q-MN["BBBF(**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#T3X=7X>SNK!C\T;^:H]CP?U
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M:KLE%!111708A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX=495->KMO\ B>X:CI5IJT2Q7J/)$ISL$C*"??!&:S?^$*\/?] __P C2?\
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M3YI,?H/Z_E7-TYW:1V=V+,QR2>YIM:1CRJQ+=V%%%%,04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %;>CZX]KNBN&,D6,KD\@Y]:Q**32:LQIV..
MHHHKI, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M >H^%O\ D6]"_P"OB7^4M>:?&G_D<;3_ +!Z?^C)*]+\+?\ (MZ%_P!?$O\
M*6O-/C3_ ,CC:?\ 8/3_ -&25Y\?XLO4[9_PX^GZL\XHHHK<P"BBB@ HHHH
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M2"/Y8T^@_J<FL2BK44B7)L****HD**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *[OX5_\ (:UG_L$3_P#H25PE=W\*_P#D-:S_ -@B
M?_T)*RK?PY>AK1_B1]3V+QK_ ,BC??\ ;/\ ]&+7D->O>-?^11OO^V?_ *,6
MO(:^>S+^*O3]6?79%_NTO\3_ "04445YQ[04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXGD_E^->9$EB2223W-)43S&;5H*QI2R2DGS59.3^[_@_B:6K:[J&M2[[R;*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!QU
M%%%=!B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 >H^%O^1;T+_KXE_E+7FGQI_P"1QM/^P>G_ *,D
MKTOPM_R+>A?]?$O\I:\T^-/_ ".-I_V#T_\ 1DE>?'^++U.V?\./I^K/.***
M*W, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "N[^%?_(:UG_L$3_\ H25PE=W\*_\ D-:S_P!@B?\ ]"2L
MJW\.7H:T?XD?4]B\:_\ (HWW_;/_ -&+7D->O>-?^11OO^V?_HQ:\AKY[,OX
MJ]/U9]=D7^[2_P 3_)!1117G'M!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>Z:C_R#+O_ *XO_P"@FO"Z
M]TU'_D&7?_7%_P#T$UZ^5;R^7ZGSG$'_ "[^?Z'GU%%%?0GRH4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
M'4445T&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!ZCX6_P"1;T+_ *^)?Y2UYI\:?^1QM/\ L'I_
MZ,DKTSPJI/AO0R 2!/*3@=!B6O,_C3_R.-I_V#T_]&25Y\?XLO4[9_PX^GZL
M\XHHHK<P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *[OX5_P#(:UG_ +!$_P#Z$E<)7??":-YM?U:*-=SO
MI,RJ/4EDQ6=7^&S2CI4CZGK_ (U_Y%&^_P"V?_HQ:\AKU[QK_P BC??]L_\
MT8M>0U\[F7\5>GZL^OR+_=I?XG^2"BBBO./:"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]TU'_D&7?_7%
M_P#T$UX77NFH_P#(,N_^N+_^@FO7RK>7R_4^<X@_Y=_/]#SZBBBOH3Y4****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#CJ***Z#$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ]<\%_\BC8_P#;3_T8U>??&3P]J$][
M;Z[!%YEG%;K!+MY,9#,=Q'H=V,^U>@>"F!\)60!!(,@/M\[5O.BR(R.H9&!#
M*PR"/0UY\G:;9UI7BCY%HKTOXA?#=](:35]%B9]//S30+R8/<>J_R^G3S2MD
MTU=&;5@HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH XZBBBN@Q"BBB@ HHHH *ZQ/A[JTD:N+BRPP!&7?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!KZ!X@N=!N]\>7MW/[V$GAO<>A]Z]9T[4K75;-+JTD#QMU]5/H
M1V->'UI:+K=WHEX)[9LJ>)(B?E<?Y[UC5I*>JW-(5.71['M! (((R#U!KQWX
MA_#/R!+K.@PYBY:XM$'W?5D'IZCMVXZ>J:1J]KK-DMS:OGLZ'[R'T-7ZXTW%
MG2TI(^0Z*]C^(?PS\\RZSH,/[WEKBT0?>]60>OJ._;GKXX002",$=0:WC)-&
M+5@I5 9P"P4$X+'.![\4E%4(]%?X,>)%C9A=:8Y )"K*^3[#*8KSME9'*.I5
ME."",$&OIGP+K']M^#=.NV;=,L?DRYZ[T^4D_7 /XUX=\1-,&E>.=2B1-D4S
MB>/T(<9./^!;A^%9QDV[,N44E='+5WB_"/Q,^EB]4V>XQ>8+;S&\WIG;C;C/
MXUA^"='_ +=\7Z=9,FZ'S?-F!3<-B_,0?8XV_C7TY1.;6P1C?<^0Z*Z3Q[H_
M]B>,]1ME7$,DGGQ>FU_FP/H21^%'@+3#JOC?2X-K%(YA/(0,@*GS<^@) 'XU
M=]+DVUL;Z_!OQ&;<327>F1#;N97E?*_7"&O/*^E?B#K']B>"M0G5]LTR?9X<
M/M.Y^,@^H&6_"OFJI@VU=CDDM@HHHJR0HHHH **** -3P[H_]O\ B"STOS_(
M^T,5\W9NVX!/3(ST]:Z_Q9\+O^$7\/S:I_;'VGRV5?*^S;,[CCKO/\JQ/AU_
MR/\ I'_75O\ T!J]>^+'_(@7?_76+_T,5G*34DBTE:Y\\T445H0%%%% !6GH
M.@:AXDU-;#3HP\Q4NQ8X5%'4D^G('XU0MX);JYBMX(S)-*X2-%ZLQ. !^-?1
M?@OPQ:^"O#C/=/&ETZ>;>SLV%7&3C/3"@GGOR:B4K(J,;GE.K_"W5M#TV74-
M0U/28H(QR?-DRQ[ #9R3Z5PU=?X_\9R>*]6VP,ZZ9;DB",\;CW<CU/OT'U-<
MA3C>VHG:^@44450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "I;>XFM+F.XMY7BFC8,DB'!4CN#45% 'O7@'XCP^(533=49(=4 PC=
M%N/IZ-[?EZ#T*OD1':-U=&*NIRK X(/K7MGP_P#B8FI"+2-<E"7O"PW+<";T
M#>C>_?Z]<9PZHTC+HSN-?\/VNO6FR4;)T'[J8#E3Z'U'M7DNIZ7=Z1>-:W<>
MUQR".C#U![BO<:S]8T:TUNR-M=+R.4D'WD/J*\W%8-5ES1^+\SV<NS*6&?)/
M6'Y>AXE16CK.BW>B7IM[E<J>8Y!]UQZC_"LZO"E%Q=I;GUT)QG%2B[IA6]HW
MA.^UVR:ZM9[945S&1(S @@ ]E/J*P:[?X<ZAY=[=:>Q^651*GU'!_,']*VPT
M(3JJ,]F<N/J5*5"52ENCF=9T2[T*[6VN]C,R;U:,DJ1^(%9U>E?$6R\W2K:\
M5<M#+M)]%8?X@?G7FM&*HJE5<5L& Q+Q%!5);]39T3PQ?Z]'+):F%(XR%+2L
M0"?08!_R:J:OI%UHM\;2["[]H960Y5@>X_(_E7JOA33_ .S?#EK$RXDD7S9/
MEP<MSS[@8'X5A_$;3_-L+:_4?-"_EO\ [K=/U'ZUUU,$HX?G^UN>=1S64\8Z
M3^%NR_KS/.*W-$\*W^O6TEQ:O D:/L)E8C)P#Q@'U%8=>S>%[(V'ANRA8$.8
M_,8,,$%OFP?IG%88.@JTVI;(Z\SQDL-23ANV>5:SHUQH=ZMK<R1/(4#YB)(
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M'(/K5.NS\1VWGZ6S@?-"0_X=#_GVKC*(2YD$E9EW3]+GU)I!"4&S&XN2.O\
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M--FTV1$F:-BXR-A)_F*[>"."T2*UBPN%.U>Y ZG]?UKG/%?_ !]V_P#US/\
M.LHS;E8MQ21S]%%%:D!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUV->M:EI]MJED]K=KNA8@G!P1@YZ]J\E\3_\C-J'_78UZMKG_(OZE_UZR_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7X5X:@H/?=A1117,=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M58J1@@X-)6QF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)ZF?I&HKIWCZX>1E6*6XEB=B.F6./U KJO&^BRZKI4<MM&TEQ;,6"+R64_>
M'<\ _A7F=_.MUJ-U<("$EE=U#=0"2>:ZG1/'MQ91+;ZC$;F)0 LBG#J,=^S=
MO3\:4X2NIQW0XR5G%G*)9W,EP;=+>9IAUC5"6_+K6E?^&=4TS34OKJ$)&S8*
M@Y9,]-WI7:'XBZ5MXM;TMZ%5Q_Z%7-:]XTO-7B>V@C%M:MPR@Y9Q[GT]A^M-
M2J-[6$XP2W.8HHHK8S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7NFH_\@R[_P"N+_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#T3P-X>MA9Q:Q-B69RWE*1Q'@D9^O%=O6!X*_Y%*Q_[:?\
MHQJK^,_&EEX1L-SXFOY5_<6P/)_VF]%_GV]O/J-RFSKA911-XM\7V'A+3O/N
M3YES("(+=3\TA_H/4U\[Z]K^H>(]3>_U";?(>$0<+&O]U1V%1:MJ][KFI2W^
MH3F6>0\D]%'8 =@/2J-:1ARD2E<****LD**** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KW34?^09=_]<7_
M /037A=>Z:C_ ,@R[_ZXO_Z":]?*MY?+]3YSB#_EW\_T//J***^A/E0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** ..HHHKH,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#UCP?,(O"VEH0297D08['<[?^RUY9\:
M?^1QM/\ L'I_Z,DKTSPM_P BWH7_ %\2_P I:\T^-/\ R.-I_P!@]/\ T9)7
MGQ=ZLO4[))*G'T/.****W,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>Z
M:C_R#+O_ *XO_P"@FO"Z]TU'_D&7?_7%_P#T$UZ^5;R^7ZGSG$'_ "[^?Z'G
MU%%%?0GRH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% ''4445T&(4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!ZCX6_P"1;T+_ *^)
M?Y2UYI\:?^1QM/\ L'I_Z,DKTOPM_P BWH7_ %\2_P I:\T^-/\ R.-I_P!@
M]/\ T9)7GQ_BR]3MG_#CZ?JSSBBBBMS **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KN_A7_P AK6?^P1/_
M .A)7"5W?PK_ .0UK/\ V")__0DK*M_#EZ&M'^)'U/8O&O\ R*-]_P!L_P#T
M8M>0UZ]XU_Y%&^_[9_\ HQ:\AKY[,OXJ]/U9]=D7^[2_Q/\ )!1117G'M!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>Z:C_R#+O\ ZXO_ .@FO"Z]TU'_ )!EW_UQ?_T$UZ^5;R^7ZGSG
M$'_+OY_H>?4445]"?*A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 <=111708A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'J/A;_D
M6]"_Z^)?Y2UYI\:?^1QM/^P>G_HR2O2_"W_(MZ%_U\2_REKS3XT_\CC:?]@]
M/_1DE>?'^++U.V?\./I^K/.****W, HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N[^%?\ R&M9_P"P1/\
M^A)7"5W?PK_Y#6L_]@B?_P!"2LJW\.7H:T?XD?4]B\:_\BC??]L__1BUY#7K
MWC7_ )%&^_[9_P#HQ:\AKY[,OXJ]/U9]=D7^[2_Q/\D%%%%><>T%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5[IJ/_ "#+O_KB_P#Z":\+KW34?^09=_\ 7%__ $$UZ^5;R^7ZGSG$'_+O
MY_H>?4445]"?*A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 <=111708A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'J/A;_D6]"_Z
M^)?Y2UYI\:?^1QM/^P>G_HR2O2_"W_(MZ%_U\2_REKS3XT_\CC:?]@]/_1DE
M>?'^++U.V?\ #CZ?JSSBBBBMS **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KN_A7_R&M9_[!$__H25PE=W
M\*_^0UK/_8(G_P#0DK*M_#EZ&M'^)'U/8O&O_(HWW_;/_P!&+7D->O>-?^11
MOO\ MG_Z,6O(:^>S+^*O3]6?79%_NTO\3_)!1117G'M!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>Z:C_
M ,@R[_ZXO_Z":\+KW34?^09=_P#7%_\ T$UZ^5;R^7ZGSG$'_+OY_H>?4445
M]"?*A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 <=16AK.DW&CZC);3QE5W$QMCAU[$5GUT)W5T8M6"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG^%']AZ1_P! JQ_\!T_PJ_11S/N%D4/[#TC_ *!5C_X#I_A1_8>D?] JQ_\
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M6/\ X#I_A1_8>D?] JQ_\!T_PJ_11S/N%D4/[#TC_H%6/_@.G^%']AZ1_P!
MJQ_\!T_PJ_11S/N%D4/[#TC_ *!5C_X#I_A1_8>D?] JQ_\  =/\*OT4<S[A
M9%#^P](_Z!5C_P" Z?X4?V'I'_0*L?\ P'3_  J_11S/N%D4/[#TC_H%6/\
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MD4/[#TC_ *!5C_X#I_A1_8>D?] JQ_\  =/\*OT4<S[A9%#^P](_Z!5C_P"
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M_"C^SK'_ )\[?_OTO^%6:*+L+%;^SK'_ )\[?_OTO^%']G6/_/G;_P#?I?\
M"K-%%V%BM_9UC_SYV_\ WZ7_  H_LZQ_Y\[?_OTO^%6:*+L+%;^SK'_GSM_^
M_2_X4?V=8_\ /G;_ /?I?\*LT4786*W]G6/_ #YV_P#WZ7_"C^SK'_GSM_\
MOTO^%6:*+L+%;^SK'_GSM_\ OTO^%']G6/\ SYV__?I?\*LT4786*W]G6/\
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MT4786*W]G6/_ #YV_P#WZ7_"C^SK'_GSM_\ OTO^%6:*+L+%8:=9 Y%G;_\
M?I?\*L*JHH55"J.@ P!2T4KC"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"I>?\?6G_\ 7P?_
M $4]6ZJ7G_'UI_\ U\'_ -%/5NICN_ZZ%SVCZ?JPHHHJB HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JFJ
M_P#('O?^O>3_ -!-6ZJ:K_R![W_KWD_]!-3/X673^->I;HHHJB HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *EY_P ?6G_]
M?!_]%/5NJEY_Q]:?_P!?!_\ 13U;J8[O^NA<]H^GZL****H@**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
MIJO_ "![W_KWD_\ 035NJFJ_\@>]_P"O>3_T$U,_A9=/XUZENBBBJ("BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J7G_'UI
M_P#U\'_T4]6ZJ7G_ !]:?_U\'_T4]6ZF.[_KH7/:/I^K"BBBJ("BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *J:K_R![W_KWD_]!-6ZJ:K_ ,@>]_Z]Y/\ T$U,_A9=/XUZENBBBJ("BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J7G_'U
MI_\ U\'_ -%/5NJEY_Q]:?\ ]?!_]%/5NICN_P"NA<]H^GZL****H@**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ JIJO_('O?\ KWD_]!-6ZJ:K_P @>]_Z]Y/_ $$U,_A9=/XUZENBBBJ(
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J
MW:DW-B0"0)R3CM^[>K5%%2MV7+9?UU844451 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !574U+:3>*H)8
MP. !U/RFBBIE\++I_&BU1115$!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img159889792_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img159889792_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -3#%X# 2(  A$! Q$!_\0
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MFJ$_]?<G^-2B;6@,G7-3_P# N3_&K4?S*2::F6<@]* $6XU?9DZSJ7_@4_\
MC2K>:M_T&-1_\"G_ ,:E?@;0*8% ZT .6^U0==7O_P#P)?\ QJ1=3U$9_P")
MK>GZW#_XU L8W9S0P3:< 9H G_M;4W.%U.\_[_M_C3TU74NAU*[S_P!=V_QJ
MBA SBG@*#N)H O?VOJ0ZZA=_]_V_QI#K&HJ/^0A=G_MLW^-43*K' QBC@_Q4
M 7UUG4",G4+O_O\ -_C3FUG4-H_T^Z'_ &V;_&LML#O3]Z!>6% &D-9OB.-0
MN\_]=F_QH;6-0'_+_=?]_F_QK'DN(XUX(JL+WS)0N[B@#>_MJ_/_ #$;K_O^
MW^-#7NK2K\FH7_/]V=_\:W_#_AV"ZMEGE&<^M=3'I=G$H A3CVH \IN8/$KJ
M3'JNJCTQ=2?XUES0>,5'RZMK'_@7)_C7MY@MD7E% H$5JW1$H \'%OXV+ G6
M-9Q[7<G^-;=GI_BMX@SZKJY^MW)_C7KOE6H/W$IP,"+QM H \PBM/$V1_I^I
MG'K</_C4\I\1P*,W%\??SF_QKT;[1;K_ !+3@T,PQ\K"@#RY=5UE'_>7=Z/K
M,W^-2G6-18C%]=#_ +;-_C7H[Z;:2?>@0_A7!>*+%;*_40C"MZ4 53J^I]KZ
MZ_[_ #?XTW^UM4)_X_[O_O\ -_C415A$ .:6-&'WA0 IU75'? U"[ _Z[-_C
M3CJ>IXXU*\_[_M_C2)&'D(Q5HV\:QYQS0!G_ -JZL'R=2O,>GGM_C3O[5U8O
M_P A&\Q_UW;_ !JW%91GYFIWV1-V10!5.IZKN'_$QO/^_P"W^--.JZN3@:C=
M ?\ 79O\:O"S!.<4?95SC% %,:GJZCG4+L_]MF_QI?[3U7OJ-W_W_;_&K/D#
M. *#;+F@"L^IZFBY.I7?_?\ ;_&H/[7U9CQJ5W_W_;_&K,EH7?':G-8!$Z4
M53JVJ*/^0E>$_P#7=_\ &E_MC4F !U&\!]IW_P :=]D#-R.E$ENF>* (WO\
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MB_Q+G_D8=6_\#9/_ (JG?\)7XFW<^(M6_P# V3_XJL%\@BGACQS0!M/XK\4
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M6/#US+M9>*>^AW 4C;S7;QQA$Y7%/6-7)^4?C0!YPVAS=".:8_A^[8<+Q7I
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MW[F3_P".4 >_T5X'_P +O\2_\^.DY_ZY2?\ QRE;XW>)0%Q9:3N/;RI/_CE
M'O=%>!K\;_$Q.&L=)S_URD_^.5$WQS\3K)M-AI&WU\F3_P".4 ?0-%> K\;_
M !,S8^Q:1G_KC)_\<H?XW^*$_P"7#2/^_,G_ ,<H ]^HKY_7XY^)2<?8=)_[
M\R?_ !RG-\;_ !.N,V.D?]^9/_CE 'OU%>!O\</$:D?Z%I/_ 'ZD_P#CE-/Q
MQ\39P+'2?^_4G_QR@#WZBO"1\:/$FW<;/2<?]<I/_CE0'XY^(0<&RTKV_=2?
M_'* /?:*\ 'QR\3>9M^PZ1C_ *Y2?_'*D7XX>(B<?8M)_P"_4G_QR@#WNBO
M)?CEXE4_)8Z21[Q2?_'*E7XV^)73*V.DY[_NI/\ XY0![U17@H^-/BIB-NGZ
M21_UQE_^.5?MOBKXPN.?[.TG;_UQD_\ CE 'M=%>4P?$/Q/)C=::8/I%)_\
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M?5T'-O9_]\-_\50!Z#17FS>/M;W<6MCM_P!Q_P#XJG?\)YK>W=]FL<?[C_\
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M<!CI0 UFP0">: ,@G)I6P[].E/"[ACI0 Q0-F!UI%&Y^3BG ;/J:63:N,=:
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M-H)S0 YR<;CP.U&=X -6H[&YG  C;\JU+3P[)*FY\AO3% &"0R_*!R:5BP
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M (3712%'_'_ ?_(BU]2U\N>#SCQEHQ;DF^@'_D1:^HZ "OB54^7.ZOMJOB-
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M@#T&PDB@<,0QWCI6-XNT6-T^U1GGTJSI]S-(ZF1"4 ["J?B+4C]F>,G"X[T
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M>>XH ^LO!O\ R(WA_P#[!MM_Z*6MNL3P:<^!_#Y]=-M__12UMT >1_&]%=]
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MT4"L/O;?K6A#9!5.X@FE-F''3% %-XP<*'&!WI?.:'"K\PJ=++!.6S1]F(+
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M!3 X&XGCTIB'#X)JRDP/W^GI39K7>?,0X% $+#@YI@;<14A!*X(Y%-5<]NE
M$@7)QT%"HHW+^M-5]QY[4JLKN0* &N<KA1P.YH4M(I7.,>E/VX!!;C-0/+Y<
M@$8X/>@"Q&"05'ZT)(L+D#):F1N1)P>#3G&TY YH V_"LS'QKH1P.=0MP?\
MOXM?5%?*WA$?\5AH1/\ T$+?_P!&+7U30 5\60()9 !P:^TZ^-XQ'!-G!Z4
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MUZ]B.3*QJ\GBJ=>JDGZUSM% '5?\)>3&0T&6]<U;TWQE%%.GFPD+GDYKBJ*
M/HE-4\/7GA>6X\U1*$SC'->>V'B6P^VD*Q SZ5Y\MW<+&8Q,X0]L\5$&*G()
M!H ]-UCQ-IZQC8Q+'VKG(]?24E=Q KEF=F^\2?K2 D=#0!ZIX7\30:;>QS;^
MA&:^@]!\3Z5XIMUAB8,X7)4U\5+-(O1R*ZOP9X[O?">K)=+F2/HRD]J /J^_
M\*V]V<KA?;%<;J'@>Y6Z8H 5 K'TSX]VUYQ-:[/J:ZS3_BCHMX!YCHI/JPH
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MA0_-=->>&'5B(\'/6L2[\.W-M^\5,T 4IH]OS*<TU&Q\V.:L?99$4,_ ]*8
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M2!</S2/MR<=: (LDM@=*;(".E2H5';FHIV<_*HH I9,L^PGBNC\/I;65SYK
M9'.37-L)PW[BUDGD]N!^9XJI>:9XEOUV036UE&>N]RS?H,?K6<JU./Q,WAAJ
MU36,6=QXO^)\.C:>_P!F(,@&!@UX3J7Q4\17TLG^E%48\ 5T$_PMOKLDW/B+
M.>H^S$_^SU4E^#LH7]SK:,WH]L5'Z,:R^MT?YOS-?[/Q/\OXK_,X&YUW4KN0
MO+=RDG_:-4VN9W^]*Y^IKM+WX4^(+9"\#VEUCHL<A5C_ -] #]:Y/4-'U+2G
MV7]C/;GL9$(!^AZ'\*UA5A/X685*%6G\<6BH78]6)_&FT45H9!1110 4444
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MZ398'L::^0Y/44 77DC+9 X-)Y>Y@W 6J:2-GD<4]97#<]* +$L*J0RCCO4
M $IP.*LI.KC;)T[4U-ADP* &>49$J*2'/R^E:44+>9C'R&EN+$L1L!Q0!CC
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MC;:&+4 *1AB*#& ,DYJ,MNY%2$$0G- "* 4)QQ3'=TQM%2!@+<+TIK.K8 H
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M'%/+*Y"KU%9T,#R3Y)XS6A&GE2"@"S#$<DGK4HVJ3GK4.\DX4YI?,5<!CS0
MVY@60 U7BL&9LYXK190T:^]#(R+Q0!XYXWLS;ZR[X^4UR]>@_$.V?]W+M/)Y
M->?4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 *"5.0<&
MNBT'Q9=Z3*-[F2/N#S7.44 >U:;XNL;^-7$HC8]58UOQS"8!D8$'TKYYCE>)
M@48@BN_\)>+T@"V]XY)/ )[4 >E[FCY'--6\^8!AQ56*]CN8]\3AE/H:5B&'
M2@#0,J2$8(Q4AB1^E88>2)L\[:O17RLHP>1UH M21$#BHAN4\DD5-'+YG7I2
M@#D$4 -64=#5/4-)MK^,L4 :K[0J>1B@';Q0!Y[K'A^:T^>($K[5A!)58AP1
M7KCQI/&R. :Y77=$(0R1)T]!0!QFW!P>:Z+0[A$3:V,UANI23##!JU9.%E_&
M@"WK.UKHG/!K'=1C)K5U1?F#>M8[ GO0 AQL.#7IGP,S_P )E>?]@]__ $9'
M7F*\'!KT[X&G_BM+P?\ 4.?_ -&1T >_UROQ(_Y$#4_^V7_HU*ZJN4^)1"_#
M_4R>G[K_ -&I0!\UWHVGKWJ$ @!Q^5:%[;';O7D50C;+A<<YH -F]]W0^E2?
M9V<[NU6H[0SR C@"K]Q$MO:8XSB@#*0A%)/:HB^\]:4DLF*B@C9G(4<T /(+
MR;0,UNZ-H+7!$KJ0M6M#T,EA-+W[&NNC2.&,1H,&@"M8:?#;*2$Y%7T.3[4S
M.T@#J:=N+=1B@!\C  8JG(C329SQ4X)8\"K<>GS-'Y@4X/M0!G[Q&/+4?C2E
ME48!R:GN;<V\98]?>L1Y'>;*_C0!>,YSM'6GX)7)-$%JY&Y5SGN>E/DTJ2Y7
M;/<,B'JL7!_,_P"%8U,13ANSII82M5UC'0S;_6[.PB+/.@V]LUY?XA\975_<
MRQ6[8A/ QWKUN#PCH4#[SI\<SYR6G)DR?HV1^E:T-K;VXQ!!%$/]A O\JY98
M^/V4=T,IF_BDE_7R/F@V=ZXWFVG8'OY9J)X)HQEXI%'JRD5]0T$ C!&0:G^T
M'_+^)I_9"_G_  _X)\M45])7?AW1;[/VG2K.0G^(PKN_/&:Y;5/A3HMYN>QE
MGL9#T /F)^1Y_6M(8ZF_B5C"IE56.L6F>+45U>O?#W7-$#2K"+RV'/FVX)('
MNO4?J/>N4KLA.,U>+N>=4I3IOEFK!1115$!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !5NQLI+N=5"G:3R:=I^GR7
MTH"@[<\FNVL+&.TVH!SW- $NFV_V*W$4(P.]7RGF #/-31J$&,=::?E?F@!8
M\)\II)0NWCD=Z XWGO4J /&Q% &<R"4';QBJ'V9I92#VK=\C=D*,5%]@89(/
M6@#.DM?+MVP><=*X+4 1?2@]<UZ/?Q&*SD=3\P'>O-KUR]W(S=2: *]%%% !
M1110 4444 %%%% !1110 4444 %213R0N'1B".G-1T4 ;UMXLU* C,FY1VQ7
M3Z5XR@NLK=A8CZYZUYU10![/'/;W<>Z&92/K4,K&/.5X]:\JLM3N;&7?&Y^A
M-=?I/B]+F5(;M "?XNU &\7=>4)!]*MV5U= 8;-7[2VMKF%9$=6!Z8-:,-E'
MMSCI0!06]E4;E7GO4L&J@MLEP :O-9#&5P*IW.D+(N]#\WM0!>@N8G."1CM5
M@,H/RD'VK#%A*HQN.12+<RVCX<$T ;,T$4RX91@U@7WAV*=6 Z]JU;>^$WRM
MP:LY*MCK0!YI?:3-8R$;6*YZXJOL^7!KU.YM8;NWV2+R:Y;4/# 64M&3M- '
M',2K>PIX.Y-PJY>6$D$A5AT]JK)#C.X]:  MA0V:4@@[E.:" !@TT,RG/:@#
M3L+[=*L4@P.F:WEA0MM#94UQOFE7!Q@=:V]/U/;M#\C- %S4]+& T?/%<\UJ
M8WP5.:[;SEDQM&014,NG1S\@8- %3P3!M\5Z0Q'_ "^P_P#H8KZ=KY^\,VJV
M_B32AP3]LB_]#%?0- !7Q9<0EI@N*^TZ^,V.\[L\XH JRQ@$+0(69L8R*<_+
M)[UJZ=;&5N5ROK0!56#$18\ "J<\Q<X'(%:NH2)&C1KP.E83':<9S0 X!GD4
M@=ZZ#2M)DEE$KK\@J+3-.:X",4ZUV,$'V> )VH EL;:*!6<XZ<5-&RR$[N/<
MTUES;@+VJ(R!(2&Y- #KA#@!2,>U.@CD;$8&<T65M/>RA(U)!-=KIGAUX,22
M*#@4 84.E%5#%2*CN%6-&+C '>NR:Q>8$(N%7J:X/Q!J41F:WC'"\$T 93W.
MZ;"G-2&[!."*R6N8;7=*SBH+"\NM:EDATRV>9@<,_1$^K'BDVHJ[*C%R=HJ[
M-AKJ.-268 5EWEQ-??N-,MY;F;TC7('U/0?C72:;X-BC(FU28W4O7RER(Q_4
M_P">*Z:*&*",1PQI&@Z*B@ ?@*X:F.BM(*YZE'*IRUJ.QYU9^"O$5XH-_>VU
MHA_A7,CC^0_6M"W^%NA(=]W)=74A.6+2;1^0&?UKN**XY8NK+K8]&G@,/#[-
M_4YVW\">&+8832(&_P"NA9__ $(FI_\ A#_#G_0%LO\ OT*T+C5=.M,_:;^U
MAQ_SUF5?YFJW_"2Z#_T&]-_\"D_QK/FJO6[->2A'2R_ SKGX?^&+K.[2DC/K
M$[)C\ <5@ZA\(]*F0FPO;FVD]),2+_0_K7>6]]:78S;74$P]8I W\JGIJO5C
MU8I86A-:Q1X1J_PW\0:6CRI"E["O):V.6Q_NGG\LUR3*58JP(8'!![5]25@:
M]X.T?Q"C-=6P2Y(XN(OE<?7U_&NNECWM41Y]?*EO2?R9\\T5T7B;P;J?AF8M
M,GG69.$N4'RGV/\ =/\ GFN=KT8RC)7BSQYTY4Y<LE9A1115$!1110 4444
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MM11((6,<@J.ZLB3YD9QZ4 ::2&-,M@FFF9)>H_2L^ 3XVRM@5=(VQ_(,GUH
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MBRNI'7FOFS4/$XDED,;;Y';@#DDU%XF\2ZEXX\0F.T228S-B.->IKO\ PAX
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M.WJ/QKE:]N$U.*E$^8J4Y4Y.$MT%%%%40%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 444JJSL%49)Z"@!.M:NEZ:\C^=*N(UY&>YJ?3-$FD?S9
MEP@[&N@CC5T*#@ 4 /A8"W"(N,^E,.]7 (YJ6V!0G(X6I59)IE8$<&@ MT5
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MA@J1V(IE>@>2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&:U-+A,EXN] 4'J*U[W1HP#*![U$A,</[M<8'6@#M]/M(6MEV8Z=J@U" QL
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M !1110 4444 %/CD:)MRG!IE% '7Z!XF$">5<L<YX-=Q::E%<6ZE&W ]Q7C
M.#6UI.NRV)"L25^M 'K&Y6CXZU")&0X4YK"TOQ!;W"$&5<^F:U%?</-1L@^E
M %H$K(&/?K5M$R,J,YJ.T03CGEO2M2.SDC3.PT 552-3E^*CFA5SE>E79K-W
MC#$$567$9*DT 5$1E8Y&!4ZMO4J1Q3W(+4UW6%/>@#/U'3%N4Q'@-7$W^G/9
M7I#+U[UZ&<L5<'&:R=>TU[IMT:Y..HH Y:Q+++UK7W[T;)S67';R6]PRR C
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M%[T :D2[8Q3Z** "BBB@ HHHH *YKQW;K<>$[U6_N&NEK(\3PB?P_=QGNAH
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M9U'S>U<]E8U:)^&'K76HPW'GK7)^)(FM[GS44D$=J /J'PE_R)FA?]@^W_\
M1:UL5B>#6W>!_#[>NFVY_P#(:UMT >+?'U69_#@7UN?_ &E7D($D0*]">XKV
M3X[JI?PZ20,?:?\ VE7D\47FRC(X'>@#I/"EMO@=V&3V)KHPK1@D\&LC1F%M
M9@#J36@EX9'*/^% %I9_DYQFN@\)6R7NK*' *@9KG L8CRQY-;WAV]CTVX$A
M8 $>M 'JJ@*H4=A6%XG\5:9X5TR2\OIU3C"@<DFN?O\ QM';EG208 ]:^?\
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MBVD,@SCZ5/<:-;7"%2@&?:O+/@EXPBU'3CI]S,OV@'"*3R0*];N;D6V"W0T
M<'K?@QH";BT3=MY-<->RR0W.UPRG//%>\I)'/'P0P(YKA_%?A3SBUU HXY(
MH XBTN49MN_GWJPUG'*I9R/PK'NK5XF+(""M36.IA,1RG.>,T 1WL;1Q,I3*
M>N*X>^@Q(V!QFO49[831A1@JPKA=>TN:&=L*=N?2@#GW$<;+N Z56GBR<JV!
M]:LLA*G<,D4QX20,@B@#V7XZKN_L ?\ 7Q_[2KS;2)5M6R>37IOQP )T'/\
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MY\'C;X)T$>FG6X_\AK6U67X:79X5TA/[ME"/_'!6I0!XY\=XO,;P\>P^T?\
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MJ0,&@#YWGTR:T=@\;#\*B7>LJKMPOK7N.J^'+6Y@<I& ^#7D6JV,EK=/'M.
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M)8VH5% K47:>,TV+8HVFIXX 02*H@GA0JV!S5I\'Y2.E5(6*-5F1Q(.!^-
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M 6=O\W+GJ:T: "BBB@ HHHH **** "J.KMLTR9LXPM7JQ/%=RMKH%S(QQA:
M/FOXCZ]*)S A!5L@UY?U-='XQOA>:NVPY45SE !1110 4444 %%%% !1110
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MKQ7Q7="#2'"C!- 'F$\K33N['DFHZ5CN8GUI* "BBB@ HHHH **** "BBB@
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M >8I'@]:ZSP0H&MS$?\ /LW_ *$M<G)%)'(5(((-=7X%S_:\V>OV=O\ T):
M._KF?B#%YW@C48_[WE?^C4KIJP_&"AO"UX#_ -,__0UH \CLK9;=%4KSBK$^
M O!.:>QRW'&*5('N)PBG)- $:0&6/@9J6WT[9<)*_P##R![UVVC^&6^S*\BB
MLG6(5MM0>$8^0#-<^*GR4GYG9@*7M*ZOTU*%>6_%W5^+'1XV];B4 _4+_P"S
M?I7J5?.GBW4SJ_BG4+O=N0RE(_\ <7Y1^@S^->?@H<U2_8];,ZO)1Y5U,6BB
MBO8/G0HHHH **** +'V5O(\SL:@((ZBKUK< 0E6&0*=')!.X5UPQ.* ,\#)
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M[=3(L5CY1:]V"ZO]%_PQ>U;QMJ7B71EMF@DD8C&X#C\ZXU/#6HORRQI_O/\
MX9KM**<LPJ/X4D>C1X0PD5^]G*3^27Z_F<?_ ,(K?X_UEO\ ]]'_  J&3PWJ
M2#B-'_W7']:[:BI6/J^1O+A/+VK+F7S_ . ><SV=S;']]!)'[LI _.H:],(R
M,'I67>Z!97F6">3(?XH^/S'2NBGF">DU8\?%\'U(KFPT^;R>GX_\,9/@BPBU
M'Q59VTZ[HW< BOLG0M&M-&T^."TC")@'@5\Z_"7PG'_PE8,]Q&7C^:,9P6^@
MKZ=5=J!?08KOA.,U>+NCY+$8>KAZCIUH\K7<6BBBJ,0HHHH BN!FWD'^R:\A
M6-K35)G#$?,>_O7L$HS$P]J\VO[%?MKECCF@#<TC7F6$*YSBMRWUB*8X[UP\
M%N^[]UDBMG3+*Z>3[A'N: .LDNDC7<:QKG76,GE0KR3BK\>GLR#S7.:DCTNV
M1P^P%O7% %2VTQY9/.NF+'J!VK750B@*,"EZ44 %%%% !1110 4444 %%%%
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#WWX#6S2$3L,@$C)KZ
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M>SE$/BD8OB^Z^R>$-5ES@_9F0'W8;1_.OG2O</BE>"V\'-!GFYG2/'L#N_\
M9:\/K7 1M3;\S+-97K*/9!1117:>6%%%% !2JI9PHZDXI*Z_X;Z)'KGC"UMI
MX3)#G+#% 'N7P1\)/I.C->7<0$TAW(<=C7KU5K&UBLK&*")0B1J% JR#GI0
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MEF.(Y.E;JD, 1T-4M5L_MEDR X8<@UBZ#KR/<'3YVQ*#@;J .HHHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKGM=K*MW;)(#U&35D #I7FO@[QE$EF(;G>S>M=[8ZG#?INCS^-=9\\7:***
M"JU]++#:.\*;G X%6:" 1@T >2Q^'K_7=?FFOF<*,[03P*[31O"=K88:1%<^
MC"NB6&-&+*@!/<"I* (([.WB.4A13["I\8Z444 %%%% !1110 4444 %%%%
M!1110 4V1PB%CT%.K%\17XL[(X;!(H Y75KHW6L[<Y4'BN6\<Q(VDF,ODL#Q
M5R"\:>[>4YPO<UAZ[,M\'CRQ('&: /!;V$07;QCL:KUJ:];/;ZG*K CFLN@
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MZ?)XSQ0![EX].#I__;3_ -EKCFP$.179>/#M_L\X_P">G_LM<A$#/,D8'WF
MH M:=H+ZC$74'%+?>%)H[=F522!7HVD6"65A&@49QS5FY6-;65F485"?TH&E
M=V/*8D\N%$_NJ!3+IMMM(?;%354U$XM"/4@5X-)<U5>I]77?)0E;HC)QAR33
M8U7YVW4V3.WBF1(9057BO>/DS8LBFP9Y-760M@9ZU1LX/+CY/-:,<19,[N:
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M?:7X=L-/C15A1F'\16@#S'POX$O[ZX2>=7@5&!P5ZU[7;)>+:QP*[%4  JQ
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M-U X->64 %%%% !11@^E% !1110 4444 %%%% !1110 4444 %%%% !1110
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M )^8_P#T(5ZY7D.D+C7-./3_ $F+_P!"%>O4 %?.L,T;3_<./>OHJOG"XF"
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MBJ\YKV=&W:,&/>+^E>-:H_\ Q-IUQQF@#V/03N\.Z83WM(C_ .."M"L_0O\
MD7M,_P"O2+_T 5H4 <-\0YA#)I1/K+_[)74:$_F:/;MZK7*?$I-R:;ZCS?\
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M-X@UFP^UBV98V7,9_O5Q^M:1=:'J<MA>(4FC."#7W5;6\-K;I# BI$@PJKT
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MSU="/Y&NAKF;!BEW;N.!NQ^?%=-7D8Z-JB?='T.53O1<>S/'?BY;M'K]G/\
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M]-\"V-TNDG4]0S]IO/F56_@C[#\>OY5S^KV)T_4YH,?)G<G^Z>G^'X5Z6
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M(.1FOE3X-RO#JKL3A#@?K7U/ P>%&!R"* )**** "BBB@ IKH'0JW0C%.HH
MY.[L7L-2#6O )R1736TCR0@N,'%8NKW"QWJ#(R*U[.=9H1@C.* +-%%(2!U.
M* %I&(522< =:PM<\7:/H,#O>7L2.HX4MUKP_P 7_'>[G::STJ)43&!*#G-
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M>J2$?R-;%>#75JLO4^KPCO0AZ'S9K=[)=ZE,68E0V #VK-J_K<!M=>U"W/\
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MK&XJ%[U@05X%6[5]XWODMVJ9244Y,J$'.2C'=EVX892)?NQJ%'U[U 2 "2<
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M[=>?$.TA+"$*Y%8DOQ0N9&*PVJC'O7D]IX[TB5QYD# U8@\;:++<F(0%<]Z
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M)IEWJ%W?$&YG>0C^\<T =EXU\=+K<C0:<A@M0W"@8XKA223DG)I** "BBB@
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M** "M7P[;BYUJ"(C()K*KI/!EJ\^M(Z DIZ4 >FVVE37=S%:VZ\\# KTG2/
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M*I*$_+(!PU>@ Y&13)8HYXVCE171NH89KBP^)E1=MT?3YQDE+,8\R?+-;/\
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M?G"@&@#*HH/7BG1QM*X5!DGM0 VBMJW\*:S=*&AL97![A:F;P5KZ#)TZ<?\
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M'))Z =@!V ]*J445ZJ22LCP&VW=A1113$%%%% !1110 4444 %%%% !1110
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MD/ECK0!U?ACPI#+ );J($8XKLHM,M+6/$4*C'0XJS%$L$0C08 I"[!]GKWH
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M :5I _V*-,D8%%VK16N%Y)JP6886(?+3)/GRK'I0![CX9S_PBFCYZ_88<_\
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MP#X[2(LFW(W%:][N)DMX&E<@*HR2:^2_C%X@&L^+'2-OW</R\'K0!YQ1110
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M?R'YUW^C>'=*T"'R].M$C8C#2'EW^K'G\.E:E>=6QLI:0T1[.&RR,/>JZO\
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MYDO]0#0Z:#E1T:?Z>B^_Y>WM-O;PVEO';V\2Q0QJ%1$& H]J>JJBA54*JC
M& !535-4L]&T^2]OIA%"@ZGJQ[ #N:\>K6G6E^A]'A\/3PT/S8NI:E::182W
MM[*(H(ADD]_0#U)]*\$\5^*KOQ1J/FR9CM8R1!!GA1ZGU)I_BWQ==^*+W<^8
MK*(GR8 >G^TWJW\JYVO1PV&]FN:6YXV.QKK/DA\/YA11178><%%%% !1110
M4444 %%%% !1110 4I8GJ3244 %%%% !1110 4444 >Q?"1XVAN0#RH&:]0F
MD"E6Z@&O'?A!(R75ZI!*D"O7'9?+*D@9Z&@"Q*Y.UP?PK'\46:WVG[HXOWHQ
MTK0M)E5PDG('<U?NIK58\$#D4 >516+B54E!7)Q6K-X<>.,&$G:W6MJ[TR.Y
MD+QM@CD8JH[WL$>TG*@^M '=?#RT^RPNA["N[KS/P7K3+>>2R_?('->F#D4
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MS+MKI? @ UB; _Y=V_\ 0EH ]!K$\7?\BO>8_P!C_P!#6MNL7Q;_ ,BS>?\
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MZQ\#^"%T?3X?/1<[!D#O0 NG>&Y]1 ED/EQ'I6W%X2MT #/N^HKH418U"J
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M>K/ Q>-G7=EI'^MPHHHKI.(**** "BBB@ HHHH **** "BBB@ HHHH ****
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M>6([\8!Q7%?$&_5-,D:)CD]* /)M5NWO-2FF=B26/6J5*Q+,2>II* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** );>(SW$<2C)=@ *^HOA9X%&GZ=#>W48#$953U%>+?"[P;/
MXD\26LQ&+:&0,S8].:^MI#%IUB=H551>!0!(+J+SQ"#\U3.0J$GH!7-Z)-)>
M7C3L.,FM#7M4BTS3W:3.YP0OUH \PUEUFU>?@XW$9JBA%LF!U-2$R7%PTCX&
M233A'O8[@,4 $(^?YN<^E3,R1*57O3?LZKC#FF%,.-V2* '[=T)P":BW[5"G
M.:LR8A V-P>QJ-H1*H?(&: .Z\<<"Q/_ %T_]EKB^2Q/:NO\>D[M.'KYO_LM
M<B6&P@=: ' @=Z:S98KWJN Q?.34S# WCK0!4,0$S;NM<Z[M;:H6' S76*BE
M=S=37/ZS8[W,B\4 =3X:87UU&G!R:]%N]"M;RQ\B2,'CKBO(O =T8=<BA8YR
MU>Y#H* /FGXC?#:Y@N9+FUBS&H)X%>-2Q-#*T;@AE."#7WG>64-[;O%,@8,,
M<BOD_P"+'@\^'=?DFC'[J8EA[4 ><T444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 48HJ1Y-R@8 H CHHHH **** "BBB@ HHHH **** "BB
MB@ K=\(6XN?$EI&1D%JPJ[WX86"7.M^<PYB((H ^D_"5@H19MO 4+^5:^KW8
MC98@<'K3]"A%OIJX[\UF7KBXOV8_PC% $JR&51MX(I0RL<$\TQ1\ORGFF"*0
M/F@"U$TC%E+?**A=W5\*U*)##+\W0T]=AYQ0 W))#=ZB4"7<>0:L@!PQ':FQ
MQ&6-N@^E %:WC,-P'9S@'UK1UNRCUC198\!CM./K5!HG (K;T^+R[;;G.: /
M';"Q@M7GMY0/,1B.:Y'Q]:*^F.%' /45Z)XDL/LWB%BN1YAW5F^,-&B/A5Y0
M/F*YH ^:R,,124^48E<>YIE !1110 4444 %%%% !110!DXH **L2VDL48D9
M#M/?%5Z "BBB@ HHHH **** "BBB@ HHHQF@ HI2K <@TE !1110 4444 %%
M%% !1110 JJ68*.IKUKP+H"V=J+F88=N3GTKCO"_A][N>.YD ,0/2O17O?LJ
M+!&,#&* .BM,:KJL5K'S&I&<5Z-=7=GX4T1B' ?;P">]>::/<?V7:M><>81Q
M7/ZOKM[KVH)$\A* ],T ;*WD^KWTM[.20S?+GTJ_A%B)[U#9P+;VRJ1VI)'R
MVT4 10*SW&YQQVK2\OYUVBJ)E\MU&.*MM-TV]30!+C:>:Z#P(!_PD%Q@YQ;-
MG_OI:YL!\$L:[KP3I:VUO)>-_K)!M_#.: .MK'\5-M\-W9_W/_0UK8K'\4X_
MX1N[ST^3_P!#6@#S7(^\ <T\R*ZC(Q3 ?F(%-VED]\T 3AU"X.,4CK%+;M@<
MBH0N5VGK3ES'&5H HE6'._E3D5Z=X2UM-5L-F 'BPN,]:\TEB)&>.:7P_K4G
MAW607&Z.7Y<9XH ]LJEJ]LMWI5S PR'0BK,$JS0I(I!##/%+*,Q,/:@#XS^(
M&@-I&NR! 2C'/3I7'U]"?$K1X[N[GR!DKP<5X%=VS6L[1MV/% $%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 45(D1="P(XJ.@ HHHH **** "B
MBB@ HHHH **** "BBB@ KI? =E]O\76,14D;P:YJO9?@II"R:G%<R("=V5.*
M /I2 >5:1C^Z@K'O]3P&#+C%;<@_<L!Z5QE]F69DW=#S0 @O1*=K'@T\1[?G
M5L"LN0 D*O!'>IUD(BVDG- &@DBO\Q/S"HIBQ8,:@MR>M7D&_EAQ0!&BL)%?
M!(JXMPP< "H1.%DV 5)YBL<XP10!HP7;H,D5JQR!U!!ZUSL<QD91TP:V[61<
M!<<T 87BVP:6!;F+/F)UKP;XCZI/=Z4T<@X4U]+WZ![&8$9^0U\U^---:ZAN
M4#8VM0!X[13Y4\J5D/\ "<4R@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK?\ #6@2:Q=
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M>5[5XMJ^BWNEZNX*GRB<B@#Q;Q#I4FFZBZLI",>#6/7JWCFS2[TT2+'F5!U
MKRH@@D'M0 E%%% !1110 4444 %7=)MEN]2@A=@JLPR2:I4J.R,&4X(Z&@#Z
MHE^'6@7G@Q?FC#^5GS!CKBOF+5+9+/4[BWC;<D;E0?6M5?&_B!;+[(-1F$&,
M;=W&*P))&ED9W.68Y)H ;1110 4444 %.V-C.#BFUJM>6W]FB$(/-]<4 95%
M%% !3XW\MPV ?8TRB@"Y/>B:+9Y2K[@53HHH **** "BBB@ HHHH *O:5ILV
MI7B0Q*3D\FJT$$ES,L4:EF8XXKUKPOHL>BV"R3(#<./RH TM.LX-)L$A498#
MFHVMFN;A7"_*#5SRQ*^<9S4UY*EE8G) 8B@#(UF_D6-;:$\ <XJ'0;9_M/FR
M#)JE&)+BY+C)R>]=+IL,B8XH V-Q*Y88%+%&'W-3)E8JJ^U20QD1X+&@!IA5
M\>M2$(C GM2KA< =:LZ?ILVJWJQ(IV9^8T )I5O+JE^D**=F>37J5F(K5X[)
M,;EC+$?0@?UJC';Z?X=L3(517"\XZFLCPUJ3ZGXIN9FX7[.P _X$M '9UB^+
M/^19N\?['_H:UM5GZY;?:]&N(!U8 _D0?Z4 >6DE1G%)YJ@ GUZ4^1BCE&'(
M.*9*F$# "@"0QLXW(.*C*-G!%$<KA,$\>U.*L2&!XH K,F> <8JCJ5H9HPR_
M>'>K]R2)!@=>M(2#&0>30!O?#_Q.S3?V7=N<J,)D]:]'N7V6[MUP*^>+HS6%
MY]JMI"C@Y!!KUSPAXFM]7TN.WGE!N,;6!ZF@#DO$[QSW+$KFO(O&GA\,@N;=
M!GOBO8O'-E)8WQDC7]RPS7'SI'>VKQ, <KQ0!X21@D>E)6CK.GRV&H2HZ%5W
M'!]:SJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ R:*** "BBB@ HHH
MH D@B,\RQCJQQ22QF*5D/53BDC=HW#J<$=*'<NY9NIZT -HHHH **** "BBB
M@"WIEH;Z_BMQ_&V*^B?AG9+IU];VW&Y:\8\%:;+)J"W)B)C49#8KUWPW=/;>
M(('Z#=0![H_W#CTKB=25A=,2,9-=JAW1J?45EZEIWGC<JY- ')M$2N%Z^M2"
M D+GDU?^P31.6*' JQ;VY+;V''I0!32)-RCI4ZY1\=15J:T7*NHZ4X('&%7Y
MJ *AC!PU#QDKE%J]-;;4&WK3HH6V#*DB@"K$BY!)P:VK6/@-GI59+'<X;;BM
M)$"+@4 5]0=8["8DX^4UX3K4"3F8CJQ->H>-M2>WMEAB?#-UKR\0S2NP;F@#
MQ+7;%[#5)8W[G-9M>B>.M*(@-P(CY@/)QVKSN@ HHHH **** "BBB@ J:VM9
M;N810J68]JAKH_"FM6>CWR2W46]0?3- &1>Z7=Z><7$16J=>R^+?%GA35?"Y
M6*!?M;#@A1D5XV>IQTH 2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BB@#)P.M $]G:O>74=O']YS@5Z[H&EKI&GI#M"RD98^M8'@_P /
MB!$O)XCYA&1FNS"9;+''UH 5(^2Q;)J&ZD; 11UI\[>2,YX]J2SBDNY1)CY0
M: +^FVGD1;F W-S5]8V)))XJ-RRJ/0>E0M,0, D9H MC)Z-TJPI(B/&35.$9
M48:K0''&30 L:HQ^[@U-YB1CE::&$:_.N":OZ-IHU2^"8)0<M[4 ;/A;1O/N
M$U"3!13E0>Q%=Q4-K;1VEND,:A548XJ:@ KY[,SJ,[<U]"5X ,D;=F/K0 "Z
M65<$8/K4J!E7.[(JL8EC!!SS4D:;D^_@4 38C W(/F[U%,J3(5(PU,Y'?I0S
M%D.\;?>@#,EMBUO(JG+ <5W/PP\:-+(-&O<^;GY6)["N-B)7>N,Y[UF^=<:'
MJD.H0KS&X)]Z /I"^@8H90V O.*P[V5+K39H&;AU(Q4WAGQ'%XFTD-@+(5^8
M"N?U9YM-NRC#*$T ?/?C_P -R:9JDEPO,;GC%<37T#XKMH-6MY%=0"0<5X/?
M6K6EU)$P( 8@9[T 5J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%(^+9^#GH#7J\=Q%<0^9"X=2,@@T <-\1-.2_L9$(!8BOF[Q'X=GMRS  X/
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MI%ANN[% '@=%375N]K</$X(*FH: "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** #-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%% &3@4  &3@5U?ACP^;B83W41*#E0>]-\,^&9=1E\V6-Q&I]*]1LM+$$01
M4*J!B@ M5BBB1!Q@8 JP45^2./6G?8U0;N]5YY"N$09- $+V[S3<#*"M*WC,
M$05%QFH[4,D88C#>E7D8'#/U% "#<%^89S2/;(_W34Y9F7D4P1,V<&@!T,"Q
MIQS3\LOW1Q2 >4FTM06/ 0;LT 3(_F.J,I9CP,"O1O#VD)I]J)2NV60?,*Q_
M#&@ #[5<H0>P-;>IZ];Z=&0A$CKP5!Z4 :Y8#&2!FEKA(M?O+[6+1,@1-.F1
M[;A7=T %>&7O[J9H\8(->YUYOXL\/E$^W0@%&'04 <AY:O%DL"U011&27;G%
M.,;"$%6Y':HX&;S>N#0 KKM.TTVY1W &<K4SL$R&&XGO1(!L!)H I%E3"XY]
M:JZJDDMJ5(S6G,D;HI'!JM/&Q@89!H H>$?&$WAO5XX92PB=@I^E>PZUY6L:
M6;N"16.W(KP?4;)5 F.-XYKIO"/B>X.VSF8[#QR: 'WDK!GC?.17#>*]!^T6
MK7L&"4'(%>GZUI7GQ/- 1G&<5QRS@LUM,GRMP: /(",'!HKI_$^@?8YC<0<Q
MMV Z5S% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3BH
M"@YIM% !1110 4444 %%%% !7<?#WPO?:QJBRP1$[1E37'V5J]]>PVL?WY7"
MC\:^N_AMX,7PQHD/GX-P1R<4 5K'P1-:V0=]OFXS]*Z+0+F2!A92(>.]=#(-
MT;#U%8$[QZ6/M,F<@]A0!ON@="K<@UD_V+#Y[21XJ6QU>"^A+!@OUJS!&-V\
M2Y'I0!A7=O/93[P>",5G!)+ABLA'/>NOO;5;J+:3@^M4K73H;8[I9%;ZT <R
M%D:7R44E5/-:&Z0LMO$I]ZUGN=-BE*#8&;N*DM;6VCD,BS*['WH ;::8BQ[G
M49(J*XTF"13YN#CD"M<9"_+S4%Q THRK8)H P8=-LXIR01GTJ47-C#=+"SXS
MQ5R&RBMI&DDD5F/8UEW=A'<7)E.%"C((H YCQ?X6N+BY2>T42+(>W:N<OOA_
MJ=MI[W1484;B!7KND+YB,KDN%Z9JWJ#P_97AE.%<;: /D#Q=:-Y D/6,X(KB
MZ]\\=^&X897"+NCDR0<5X;J%J]I=O&XQSQ0!5HHHH **** "BBB@ I0"Q '4
MTE.1MCAO0T 6#IUTL?F&([?6JQ!!P>M=1I?B:VA4QW=L&0#BN?OYX[B[DDB0
M(A.0!0!6HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K8T'
M2VOKI69,Q \U7TG29M6N/*BX ZFO1=.TZ+2[9+<8+@?,?6@#<TB(0>6B@*%Q
M7IGANUFO9$=%_=)P37F6CQ7.J:BEO;CN 37LUK)#X4T(+.ZF7&2,T 7-?U^V
MT"P_>/\ O2N% ]:\:U&^FU2^DO9"2S&KFNZM-XBU,.3B)#@#-5)UBA3&[\J
M(5D\M?G4G/:K&SSH@50J/>F1*KX8\BKADRH"J !0!6V/$N%'S5#Y<KRAI'&*
MNO.%CR5S582>><;=M #)=EP?)4':.IJ1((8@J1#..M1;-DAP<"KM@@G.$&6)
MH ]IT+CP_IO_ %ZQ?^@"K]4]*C,6CV,9ZI;QJ?P45<H KWMG#?VS03*"K#%>
M6:_X;DTFZ)# 0N?D&:]'U75ETR[LTD^Y-O!/IC'^-4/$]HFJ:2)(,.R\@CTH
M \VC$BKR?I4L<A9\,:58PX*YP0<5&,0R[3S[T 73YBQ[3]WK5*\"RA=@^85;
MBG60^6YQGI2/%@D#IZT 8=S"7L7#<$=,5M^ _&45C='3KZ4A",*36?Y9W,'Y
M'I7.:C;);78N/N'/!H ]-\<6!OK8W=HP9,9XKSB)R%>&8\UT6A>(EO[%K*24
M%L<9-8VK69MKD.HR#0!S>M:?'/9R?)FO,;R P7#)M( /&:]EB4/+LF'RGUKA
M/'&F):SI)",JQYP* .-H R<"B@'!S0!=ATJZG^[&>:U+;PM=2KN< >U+H/B!
M;*1$N$#KG[Q[5W.GZUI=Y* LJ GM0!YA?:;/8R%95P/6J=>I>,M,MIM-,MNZ
MLWM7EQ&"1Z4 )1110 49HHH **** "BBB@ HHHH **** "BBB@ HH S10 44
M44 %%%% !1110 5Z'\-?!MWX@GDN8XMR(< ^AK@K6%I[J*)5)+,!@5]B_#7P
MS'X=\,Q($ >4!R<>HH 7PQX1?1F%PV/-(Q79#.!GK2T$X&30 8SUH  Z4T.K
M=&!IU !102 ,DXJ&:[@MXS))*JJ.IS0!-162?$>F;@!<J<U,NN:<[!5N5R:
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MMX/N]%UF<+&3&6)! H XVBE92K$,,$4E !1110 4444 %%%% !1110 4444
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MLFMS;O\ GV;_ -"6@#T&L;Q9_P BS=_\ _\ 0UK9K&\5?\BW=_\  /\ T-:
M.$TK5I-,N5D0$KT(KL-7M4UK1A<P*OF8W9%<"OS D]!6MX?UZ33[P12L6MSQ
M@GI0!EOOMG9)%Y!Y%"3$XP!BNXU70X=9C%W:%02.F.M<1=VEQ97#02)@CO0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***U/#^B77B'6(-/LTWRR'@4 =O\(?"3:SX@BU&92;6V;<V!W%?1:>(E>[>
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M\&I_"VHQW6FI"7!E4<@]:IZK!]GF8,2 W.: -2SFAU+3WM91DE2#FOGKXE>
M+^&]DN8H,H,X(]*]EL[I[9@XS@'\ZZ&^L;;7M-\MMI++UH ^&I(VBD9'&&4X
M(IM>A?$7P'>Z'JL]Q' [0,Q.0. *\]Z&@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***559V"J"2>PH $1G<*HRQ. *[GPOX7E
MBD%[>* H'RJ>M5O#7AR02)>W2$!3D(>]=V%>=1M4HH[4 5F>0G"C$:U>TZR7
M4KA8XT)8GFD^SR3)Y*IC/\5;FG1)HT'FA@9 .30!W=O=6'A3P^Q0A9=N>?6O
M+M<\6OK=VJNY*ENU5_$FORWI\H2Y!ZC-4=&LD>8/(N0.>: .A@7RXML"DY%6
M=.MD6=I)S\QZ4*P0_NQ^57(P BL5R30!::0_=X.?2HG=L; *>LBYQBCS@Y(2
M/..IH @$4N<]J#$5;+$"I,$G=YF .U)##<7<X2.)I-QQQ0!);6LM]<*D2EST
MXKT?1]-CTC3O,E 5PN6--T318-*M5DD"B0C))[5S_B7Q*L[2V=M)\J\%E[T
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M[T\<5%X1M[AH'N;AF.]LKDUB:-H=YJ]ZM]=\0$[L'O7H$,,=O$L<:A44<"@
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M-0\-Z@UI?1%7'?M0!D4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 445T_A3P)K'BZ1OL$.8T(#N>,4 8VEZ/>ZS<BWLH&ED]%%?0GPN^#_
M /9$O]IZ[%'+(R@QQGG;]174?#KX8VO@^Q9KHI/=N<[\=/:NXN+Q$!1.HXH
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M?9ED3D'(H ZSPUXADTB=8),O YQS_"*W_$/A2'6(_MU@RA\9VCI7GD+3/'N
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MDX+2A>2I[F@#QNB@@@X-% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5:LK":^E"1C\:2SL9[Z79"A/J?2O0M&T?[)8K'&H,Q^\
M: &^'M#@TT%IL22,.OI6S(_[S$>"M(EF\497.9#4MK:B+_6<MWQ0 Z*%'<,W
M4=JK:OJIB7[.@YQVJW<SPVJ%V8*2. :YQ6-[>LY(VYH LZ?93W+F0G%;BLEH
M!$1ND--M4,<6(R"<=JLV]GF0S3$9[4 206(E/F2$>N*N1ND651!445NX+.7
M7MFK$4:_?;D4 1(LLQ;;E0>])+$\*A Q;UQ4TDLC#9".,\U(KQP+^]!:3VH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBE56=@J@ECT H  "3@#)->]_
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MTD3*<'<M %.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **4*6.
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M:R].UBYTR53%,64?PGI79Z1XLM;T".X=4F)Z=J //+Z">VF"SQLA]Q4<B&0
M@5ZS>Z38:K&6DC5B1PXKB->\.2Z6P>V#R0D<GTH X>^M[F+YX2>>U45A>Y&V
M1<M6Z\N[*=QZU13,5X-PX)H QKG39H&WJA!'0BKNDZLR,8KB0Y[9KHW6"2/#
MC.17/:AI*+*)(@<]>* -1I"YR1D&F':I]JS[74O*/E3<8XR:T@89%W [A[4
M5[FQMM0A,5Q$'0^U>=^)/ LT4KSZ>F8O[G>O2QZ(3BG+'(Y.02* /GN>WEMI
M3',A1QV-15[IJO@O3M64NT6R4CJM>;ZWX'U#39"8H6>+UH Y.BI)8)86VR(R
MGW%1T %%%% !1110 4444 %%%% !115FVT^\O!_HUM++_N*30!6IR(TCJB E
MF. !7?\ A;X2^(=>DMYY;-XK)WP[-PP'T->\^&_@YX:T*(F: 7<F0P>7JIH
M\;\"?![5-7U."?5K9HK'[SAN"PKZ+T+PCHOAN%5L+.-&4??(^;\ZMW6HV]C;
M[(2N5&%457L[Z>_;!& ?2@#7CF$K$ ' [U%?7]OI\!FN) B]L]Z?A;:!CV S
M7"7]X^O7C13@B",\ =#0!2U?7=9UZ9K?2E=8B?O8QQ6CX>\$2(WVC5CYCGD
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MO"DA3 7DU((W@XQDGK0!++('XQA13HUE9?EX7TJ/C>"Y /I4KF61@D*DGT%
M$C6\D:AMP!/09J>RTJZU"\6-!N<_E5O2O"^J:A*&>)@GOQ7H>DZ=9>'K3-PZ
M+(><L>: *6B>%HM+3[3?LK,HS@]JS/$?C:,;K.R4],;QVJMXI\5/>2-:V1)B
M'\0[UQPC=LLV,^] $DS.S^:[;BW-,$3R3!\?*.U!4@ YR?2ID?RQANIH ]GT
M3_D Z=_UZQ?^@BKU4=$(.@Z<1T^RQ?\ H(J]0!QWCK&[3@>_F?\ LM<B55\A
M?O"NL\? _P#$N(Z_O/\ V6N.\N0L,,030!8B9#"4?[U:&A:HFE7O).Q^#65M
M6-"I;+5$!(_^KBW'UH ]/U2PBUG3OW>TOC*D>M>8:KI5S;7>R0;<'K6AHVMZ
MAIMT@EWBWSRI/%=M=PV7B73P$=!)UR.HH \SABRNPM2-"J/GD@UIZGX=O=.N
M#A':+^_6:(G!(,G3M0 21[5X_#-12+(R891^52D@C+')':FB4@DD?A0!RFK6
MQB#EEZUS^3$RLF<K7?7D2W)*;>37+W5FUI.P>/Y30!HZ3K:2LL4V.>*U9(TW
M$KT;I7#SVTG+Q97'(Q6YH>J':+>YDYZ#<: -ET$<.WC=6;?Z9'JELT3J#QBM
M5!%N&_#9[U(T422!HV&#UQ0!X]K/A*ZL TJ+NCST'6N;961B&!!'8U]!/%$2
M2R@K[BN8U[PKI]_&SPJL<N,Y ZF@#R.BM"]T:^L782V[A0>#BL_I0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%:6E:#J>M2>7I]G).W3Y10!G*I8
MX4$D]A7MOP6^&RZI(VMZK"PBB8>2K#&2*Z;X<?!NVTV&+4M=B625QDP2K]PU
MZM<7$=C EO91+TP%0=* +<_^CVVRW4+@8  J#3(KE-[7!')XJQ9AF@5Y1\YZ
MYKFO&WBJ/0K PQ./M,@(7!Y% $WC'Q/'H6G'RI%\]^ ,]*\8O+FYUNZ,DCDD
MGUJH[WFKW3374KR,3GYC5@)+;XV(: /8_ 6EBQTI9"/F<=:Z^O/OA_XC6XC:
MQN6$;H/EW'K7H/6@ HHK+OM>L[,E QFE'\*=!]332;V$W8R=<\ Z7K]VL]S+
M<1D')$)"Y_$@T6WP\\.VX'^C32$=WG;/Z$5#<>)KV4D1!(5[8&3^9JB^K:@Y
MR;R;\&Q_*M%29/.C:?P'X?8';:.F>ZS/_4FL75?A=:7D++8ZG<VKG_GHHD7\
MN#^M(NJ7Z'(O)OQ<G^=7(/$E_$1O9)1_M+@_I0Z3#G1Y9J7PG\4:=>B3$=];
M;N9+=N0/=3S^6:]B\(>'8M"TQ%" 2, 22.:MV7B.TN2$FS Y_O'*_G_C6R""
M 0<@UFTUN4FF%%%%(8R4[8G/H*^??%P>YN[AG(R'.*]RUO4H]/T^5RX#[3@9
MKP3496O+B5G7(9B<T <G"KQ3APY# \$&O3/"7Q)ET^2.WU%B8>F:X*6Q=V(2
M,_+T(IZ0%HC')#\WJ10!].#R-1LEFBVLLBY4BN1U&*6QO1PWKD5YQX*\=7WA
M^]6QO2[69;:NX\(*]S@GL=6MEDC:.5&&>.: ,G3_ !)$VV*<\]*/$'A/1O%5
M@UM=1)M?G* 9J&\\*@R-+"^,\X%9R6^HV4F$,@Q0!X7XV^$&J:#<S7%G'YEG
MGY HR<5YI/;3VS[)HGC;T88K[@LM6BN(Q'=JJL!CYA5/5/!?AK7F,USI]M)*
MPP'*C- 'Q-17NGB?X"3VR376F3-,6)98E'3VKR_4O 7B728S)>:5/&@[[: .
M;HJ:2TN(O]9!(OU4BH: "BBB@ HHHH ***4*3T!- "45(L$KG"QL?PK4TWP_
M=7LF&1D3UQ0!D $G &36AINBW>I3>7'&1CG)%=EIFA65HI\U%=QT)%=#;RI;
M*K)$ .^!0!SND^%DM9 TJY<=<UUT-L5 " *!Z4]KA;A 50+BF&;R^.>: )?L
M^ 3(>>U2QF-8^3\U43=,9!D%A27-Q'%&9,!2.U %X.5;?G@5@Z[J7VEPD9Z'
MFJ=UJ\DBLD;'GCK6>D,I!DE!"GN: +$-P\S@<;!P:T;"W^T705>E8RA=XCB)
M9F/05U^CV8C"@_(W>@#9%L%B6-N..U:$ C6'9TQ6;YOF3K'UQWJPP9_E3.[T
M% %F.:,R=>!4]NC7,X6%&.XXSBM30/!<]TR75T#"H.=I'WA7<G^RM'@+*(8\
M"@#+T7PQ';XN+OF0<CTJ?7/$46F1;(2"YX&*Y#7O%MU=S%+:1HHQQ\IZBN>%
MU(\Q+.7^M &K=WUQ>;I+AR03G -46GP"L?2D\S<A'3-(MLP7Y3F@":!I0@R1
M41F)E^8G@TZ*)@A(Y-$*EF97'2@".:=DE&,XI9;Z8 *@'%3HD>UBS @4W;$3
M\I% &M\8KH6LFAL3U\__ -IUR&D:[!*H1FP:Z+XY, =!S_T\?^TZ\C5F3YD)
M'- 'K)"3;2C \4U8COKB-,U][=T65\C%=#;^(+>24*&&30!LA#&QS4;QL2#2
M++YN'##!J8/N4 4 -*$IMIWW8]IH7<K9[4FTDGF@"'[.Y8-G%=OX7UH "SG;
M! X)KCTDP/F-$I;*RQMM9?2@#U/5+9;W3Y(^#D<5XEK&D3:?>DN, GBNXL?%
MT]O:&*5"Y P#FN9U:\EU27>PZ&@!;&<"+#=Q575-)CO5R,9JU%%M@4XJPL>[
MG- '(V<T^A7@W@[,]:[>/7(KRT + Y%9EW913@I( <USTMO/I5SN3)BSTH V
M[JU$I9E%4/LL@&<=*EMM6AE^5N*NPD2$[2"* *!7,>)$W#WKD_$OA6/4T\RW
M&)!_#BN[92I(VYJ-HE)!*XH \!O]$O=/E*2PM^'-9Y4J<$$&OH>^TNVE0%XU
M8'KQ7/77@G2KG<XC"DT >,45W>I_#V>/<]HV_P!%Q7*7FC7UBV)H&'X4 9]%
M.:-T^\I'U%-H **** "BBB@ HHHH ***M6NGW5Y*(X8F8GVH JU-;VLUS($B
M0L3Z"NXT;X9ZC?F,RJR ]L5[-X6^%-E:1JTL0!P,Y[T >4>$/ 5Y/B5XB6/;
M%>O^&O <T,RRSH$4=J[^STK3])A C14 %9^M^++/2K8E&5G[ 4 ;MM;);0A%
M XI+B^M[6-GEE50!SS7BVK?%#4C*5MB4KGKOQ'JNI_//,W/:@#M?&OCE+T/8
M6ARF>6%<5:7 BZC)-/TW35N#YDW(Z\UHG2X0X8#B@"M(GVA>!@UV?A#Q/_9,
M"VMWD1Y^]6!' BCY12W-N7@RJXH ]HM-0MKV(/#*K ^]6J\'L]1U'3Y/]%E9
M?UKK]%\?31%8=00GGES0!Z32,JL,,,BJ5AJUGJ,>^WE5JO$X&: *%_I4%];-
M$R*,]\5S1\ 6I<G</RKKQ<1DD;NE2 AAD=* .9MO!UK;LI&#CVKH8[6*) JH
M./:IJ* #&***HZHNH-9N-/\ *\TCC>Q']* '7NIVE@A:>55]LUYWXK\1PZLP
MMK=LIW-86N:7XC^TE]425%)X;JOYCBH+?36C0-G+4 ,5%AZ<TK/NX*U*5=<_
M+DBJ-Q/("<C% %346 4@+6%+#*2<+Q6R96GX85?%I ]NI(&: &^!M??0M4'G
M$^4_!YZ5[S9WD-];I-"X96&>*^>+NUAC.Y#@UO>&/&,NBRB*5RT/H: /;);=
M)4(*CFL*XT(ARR#-3:;XITW4(E9)U#'MFMI'21<JP(]J .'O8;FWD!3=@=JM
M6_B"6V3$B&NJEMHI?OJ#5672+612-@H IVWB.SN0$?.X\8Q5T:;ITOS_ &:(
MD\]*B@T.VA)(09J_' L8XH X3QG\,+#Q45((@Q_=%<;_ ,,]67_/X?\ OFO<
M0"#UI: /"Y/V>[0(=EV2?]VLI_@%,'PLA(KZ)HH \#M?V?HW'[ZX*_A5K_AG
MJR_Y_#_WS7N5% 'FWA/X36'AN<2%Q-[%:[U=)L%(*VL8(]JN44 (J*BA5  '
MI2T44 %%,>1(QEV 'N:Y/Q'XZL-(A=4D#2^E '27FH6]FA,L@!QTS7E7BKQ3
M"]RY# @=*XS6O&&IZK<,Z.VTGC%9EI8WFHR@S!L>] "WU\]_*=BGDU<TK09)
M)ED<$#K6[I^BP6Z[B@+"M1 4^ZN!0 ^/9%$(QU%(<$U&6&[.*6-P6Y'% #A\
MA)H0%^U.9\D*HI>,8SB@!JIM?.*1V)!XJ5%*\YXJO).B*S,<4 86KRF)1ZYK
M&&H%&XS4NLWK33$*>!6.9\'F@#HEUH"$ ]:/[:94-<TSEN0::T[],Y% &C=:
M@UQGGFLIR=WJ:4DLW!Q3=X0GN: $9"5KTGX* CQ9=@_\^#_^C(Z\T:3<I[5Z
M-\$B?^$RO ?^@>__ *,CH ]ZK#\7R+#X6O'<@*-F2?\ ?6MRN1^)Y8?#O52I
MP?W//_;9* .&1X9,?O 11E"#&.GK7G]EK,EJRY;=^-=+9ZU;W)"$[21ZT :R
ML(SMJ7)9>*@#QD J<U84'9N7% $?S#ACBCRL?-NS22%F.?TI5W!..E  %#<X
MI7A52K@D$=ZC)P,581\Q8X- '3^'O$S6NRVN2#$3@,>U=S^ZNH>SHPKQV)X\
M[&ZGO72>&?$#6,AM;ABT;'Y23TH S_&/AI]-?[9:JSQLV6 'W:Y.5F> ./O#
MM7O,D<5W;[6 9&'?FO*/$F@3Z1>RS1KN@<YQCIF@#GK6Y>4;&'(JXSD#;C)K
M,\PQW (4]>U;$;B9 =N#0!EW.GPW:L"-KCI6,TE[IK%5R5]Q75R0<YR!4$UL
MDHP^* ,:RUC<_P ^%/O6[:WP<CD8-85_H.1YD3X-48KJ>PE"."0.] 'H]FD<
MI"Y&:V1H<5\H21,^]<'INMP[U+-@Y]:])T+5K:8 %U/XT <WJGP8TK5LL[E6
M/.17)ZC^SN%5Y;743QT3;7OR,KJ"I!%.H ^/M8^$OB.PN-EK8S7"_P!Y5K N
M_!7B&Q_X^-,G3ZJ:^W\#T%12VEO/_K8(W^JT ?!\NGW<)Q);R*?]VH_LL_\
MSQD_[Y-?=+:#I+G+:?;GZH*3_A'M'_Z!MM_W[% 'PO\ 99_^>,G_ 'R:FBTR
M]G8".VE8GIA:^XO^$>T?_H&VW_?L4Y-#TJ,Y2PMP?9!0!\;6WP_\47<0DATB
MX9#W"FNG\*?!G7-;NVBU&&6P0#AW2OJ^.&.)=L<:JOH!3\ =J /$=&_9ZT^T
MN_,U&]-S%_< Q7HN@>!?#_AA2+&W51G)WG-='<+*T9$1 )]:Q)=#NIIB[7!
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MK$''/(IPPPY(H M:.HCUG3PISFYC_P#0A7K=>0Z64.OZ<H)R+J+_ -"%>O4
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MY%4;E23M#?C0!M6,-YJ%]#;:<NZZ=OEQP!ZDGL!7M]K&;'3HTN)]YB0>9*>
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M!@(-K+ZB@#I_CI_S /\ MX_]IUY.X A&*]6^.S$?V !W^T?^TJ\C65E0@\T
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M #Y/*3.,T 2VB&[NS(  F>!7111E(\?EBJ_AS0KN_6,0QD*3RU>EZ5X5M[5
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MV/(!Q7C<LDVGS^=;H5;O6UI'Q*CL7\J\W'- '?7.C&2 "$#)ZYK-?0[B$Y9
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MEC0!(6 (Q29#-GTIAIHR2<4 +)("<8KTOX(9/C.\/;^SG_\ 1D=>>V5A+<S
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M;N;ZU?CB@A0X &.U '/PV.HW/,A;'UJ]!H #9E7@^M:RW''RKBG-.\B\#)H
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M)A?45S+W:EBK9+=ZC$X"OV7L* /K;PJV_P (:*Q.<V$!S_VS6M:L7P<<^"-
M/KIMO_Z+6MJ@#R'XY2>7_8(P#G[1U_[9UY-::C/9S Q 8/6OH?QSX%'C0V!.
MH_8_LGF?\L/,W;]O^T,8V_K7(CX'$9V^(\9_Z<?_ +90!R=CXCMWA7SU'F5O
MPW%A=0*XQ5Q/@:57!\1Y/K]A_P#ME6K?X-SV_P!WQ*2/3[%_]LH S,128$6*
M4+&I*L!FNGMOAG);J =:W$=_LN/_ &>K+?#S<.=4.?7R/_LJ .-*1;?D #FF
MK$Q;;N KLW^'89<#5,>_V?\ ^RIK?#C<H U8@CO]G_\ LJ ./,,D;95ACZTN
MQ6/SMUZUUX^'+!<?VN?K]G_^RI3\.00!_:G3_IW_ /LJ ./\J+<-KG'UJW9Z
ME=:7<*]O(=N>5SP:Z7_A76.FJ\?]>_\ ]E3#\.'R"NLD8_Z=_P#[*@#J-(UN
MWU6$%#A\<@T_5M(M=6M6CGB#-@[6[@USMCX&N;&^CNH];;*GE?L^,_\ CU=B
MBLJ ,VX]SC% '@NLZ?+I5Y);7:'G.U@.,5FV]RMO*H#,%)YQ7NVO^'K?7K)H
M'81.>DFS<1^HKCS\)P0/^)S@CO\ 9?\ [.@#E//B"ATR3[T_SHY1FNRC^&>R
M/:=6R?7[-_\ 95(GPX13G^TO_)?_ .RH \UNH$D)RI/U%<_>::N3((R/I7N(
M\ (!S?@_]L/_ +*AOA[;N,-=J?\ MA_]E0!X/ ]W;KNAED"CMFMO3/%6IV9#
M),XQ7JX^&EF&S]J7'IY'_P!E3C\-K$J0+A1G_IC_ /94 <II_P 4;W 24*?<
MBNSLO'=C) K3MAB.U9$WPFMY#E-3\OZ6W_V5,3X3!3_R&R?^W7_[.@#LK3Q'
M87B@I(!GU-:0N8#TE3\ZX./X921?=UQ@/^O;_P"SK03P-(B@?VLQ([^3_P#9
M4 =>)$;HZG\:4D#J17,1>%+N(_+K+[?3R?\ [*KAT2]90&U9R!_TR_\ LJ -
MK>O]X?G3?/B_YZ+^=83^'+MQC^UV _ZY?_95!_PB$I'.J,3Z^3_]E0!MSZI;
M6Y(9Q^!JB?%%B">3Q63)X'GDSG63@_\ 3O\ _94Y/ Q5<'4LC_KA_P#94 7S
MXOTX=VS6%JGC.X)*V.W&.I%7#X"0MN_M#G_KC_\ 94B^ 8@#F^S_ -L?_LJ
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MES_[/3X_AQ*B;3K1/O\ 9L?^ST <E/'!*-JJ3]:$LX/+ =2,=A79K\/W4?\
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M)_VYJ_\ T%;[_P "'_QH_MS5_P#H*WW_ ($/_C3^K/N+VR['ME%>)_VYJ_\
MT%;[_P "'_QH_MS5_P#H*WW_ ($/_C1]6?</;+L>V45XG_;FK_\ 05OO_ A_
M\:/[<U?_ *"M]_X$/_C1]6?</;+L>V45XG_;FK_]!6^_\"'_ ,:/[<U?_H*W
MW_@0_P#C1]6?</;+L>V45XG_ &YJ_P#T%;[_ ,"'_P :/[<U?_H*WW_@0_\
MC1]6?</;+L>V45XG_;FK_P#05OO_  (?_&C^W-7_ .@K??\ @0_^-'U9]P]L
MNQ[917B?]N:O_P!!6^_\"'_QH_MS5_\ H*WW_@0_^-'U9]P]LNQ[917B?]N:
MO_T%;[_P(?\ QH_MS5_^@K??^!#_ .-'U9]P]LNQ[917B?\ ;FK_ /05OO\
MP(?_ !H_MS5_^@K??^!#_P"-'U9]P]LNQ[917B?]N:O_ -!6^_\  A_\:/[<
MU?\ Z"M]_P"!#_XT?5GW#VR['ME%>)_VYJ__ $%;[_P(?_&C^W-7_P"@K??^
M!#_XT?5GW#VR['ME%>)_VYJ__05OO_ A_P#&C^W-7_Z"M]_X$/\ XT?5GW#V
MR['ME%>)_P!N:O\ ]!6^_P# A_\ &C^W-7_Z"M]_X$/_ (T?5GW#VR['ME%>
M)_VYJ_\ T%;[_P "'_QH_MS5_P#H*WW_ ($/_C1]6?</;+L>V45XG_;FK_\
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M /05OO\ P(?_ !H_MS5_^@K??^!#_P"-'U9]P]LNQ[917B?]N:O_ -!6^_\
M A_\:].\'33W'AFWFN)I)I'9R7D<L3AB.I^E14HN"NV5"HI.QQGCZ]-QXA^S
M@_);1A<>Y^8_S'Y5RM:GB.0R^)-18G.)W7\CC^E9==D%:*1SR=Y,****HD]-
M\#:'':::NI31@W-P,H2.43MCZ]?QK(\0^-K]-2FM=-=88H7V&38&9R.#U& ,
M_P NM=TBI8:.%B&$@@PH'HJ__6KP^N6DE4DY2-YODBDCU/PEXF?74FMKM4%U
M$ WRC =>F<>W&?J*Y#QIHD>D:JLEN@2WN0751T5A]X#VY'YTWP1,T7BJV48Q
M*KHWTVD_S KJ_B' )-!AEXW13CD^A!'\\4_@JV6S%\5.[Z'F5%%%=)B%=S\.
M+TK<WEB3PR"51[@X/\Q^5<-71^!I"GBJW4'[Z.I_[Y)_I455>#*@[21ZQ17*
M>/;FZL](MIK6YF@;SPI,4A4D%2>WTKS[^W-7_P"@K??^!#_XUR0HN:O<Z)5%
M%V/;**\3_MS5_P#H*WW_ ($/_C1_;FK_ /05OO\ P(?_ !J_JS[D^V78]LHK
MQ/\ MS5_^@K??^!#_P"-']N:O_T%;[_P(?\ QH^K/N'MEV/;**\3_MS5_P#H
M*WW_ ($/_C1_;FK_ /05OO\ P(?_ !H^K/N'MEV/;**\3_MS5_\ H*WW_@0_
M^-']N:O_ -!6^_\  A_\:/JS[A[9=CVRBO$_[<U?_H*WW_@0_P#C1_;FK_\
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M_MS5_P#H*WW_ ($/_C1_;FK_ /05OO\ P(?_ !H^K/N'MEV/;**\3_MS5_\
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M$K\1_P#0P:K_ .!DG^-'_"5^(_\ H8-5_P# R3_&CV3#G/J6BOEK_A*_$?\
MT,&J_P#@9)_C1_PE?B/_ *&#5?\ P,D_QH]DPYSZEHKY:_X2OQ'_ -#!JO\
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M$K\1_P#0P:K_ .!DG^-'_"5^(_\ H8-5_P# R3_&CV3#G/J6BOEK_A*_$?\
MT,&J_P#@9)_C1_PE?B/_ *&#5?\ P,D_QH]DPYSZEHKY:_X2OQ'_ -#!JO\
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M ($/_C1_;NK_ /05OO\ P(?_ !H_M.'\H?V#4_G1[;17B7]NZO\ ]!6^_P#
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M?^!#_P"-']NZO_T%;[_P(?\ QH_M.'\H?V#4_G1[;17B7]NZO_T%;[_P(?\
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MQ_79=CM^HQ[G;_;[/_G[@_[^"C[?9_\ /W!_W\%<111]=EV']1CW.W^WV?\
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M$U-!6@AU7[P4445J0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >H^%O\
MD6]"_P"OB7^4M<7\<O\ F _]O'_M.NT\+?\ (MZ%_P!?$O\ *6N+^.7_ # ?
M^WC_ -IUYT?XLO4[9_PX^GZL\AHHHKH, HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /6/@A*!>:S#GEXXF ^A8?^S54^-<)7Q)I\^/E>TV
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6_Y%O0O^OB7^4M<7\<O^8#_V\?\ M.O.C_%EZG;/^''T_5GD-%%%=!@%%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "N[^%?_ "&M9_[!$_\ Z$E<
M)7=_"O\ Y#6L_P#8(G_]"2LJW\.7H:T?XD?4]QUW_D7M2_Z]9?\ T UXE7MN
MN_\ (O:E_P!>LO\ Z :\2KP<S^.)]5D/\.?J%%%%>6>\%%%% !1110 4444
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M<Y.3ZGMT:2I4U3CL@HHHJ#0**** "BBB@ HHHH **** "BBB@ HHHH ****
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M++U.V?\ #CZ?JSR&BBBN@P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *<CM&ZNC%74@JRG!!]13:* /H'X>^/8/$=C'87\RIJ\2X(8X\\#
M^(>_J/QZ=,KQY\+TU$S:KH2!+QB7EM>BRGN5]&]NA]N_BL<CPR+)$[)(A#*R
MG!!'<&O8/!WQ;B:**P\1DI(/E6]49#?[X'0^X_3K63BXN\3123T9Y%<VT]G<
M26]S"\,T9VO'(I5E/N#45?3^J>'_  _XOLDEN8+>[1E_=W,+#<!_LNO;VZ5Y
M[JOP3.YGTC51CM%=IT_X&O\ \3351=1.#Z'D5%=Q<?";Q9"V([6WG'K'<*!_
MX]BHHOA5XOD8!M.CC'J]S'Q^1-5S+N3RLXRBO4=-^"FIRL&U+4[:W3NL"F1O
MUP!^M>@:!\//#WAUEFBMOM%RO/VBY(<J?4#H/P&?>I=1(:@V>:^"/A?=:PZ7
MVMQRVM@,%82-LDW]57WZGMZUZMKNOZ1X*T-6EV1I&FRVM8^"^!PH'IZGM6'X
MJ^*&D:$KV]@R:A?CC;&V8T/^TPZ_0?I7AFKZQ?:YJ,E]J$[33OW/11V '8>U
M2DY.[*NH[#M:UF\U_5I]1OI-\TIZ=D'91Z 5GT45J9A1113 **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "N[^%?_ "&M9_[!$_\ Z$E<)7=_"O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M[^N KOZ[\#]KY'G8_P"S\_T/!****^C/!"BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /4?"W_(MZ%_U\2_REKB_CE_S ?\
MMX_]IUVGA;_D6]"_Z^)?Y2UQ?QR_Y@/_ &\?^TZ\Z/\ %EZG;/\ AQ]/U9Y#
M111708!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!I:3X@U;0I3)IE_-;$G+*C?*WU4\'\17=Z;\:=6@ 74=.MKL#^*-C$Q^O
M4?H*\RHJ7%/<:;1[=!\;-(91Y^EWT;=Q&4<?J13Y/C5H0'[O3M18_P"TJ+_[
M,:\.HI>SB/G9ZQ?_ !NN64KIVC11MV>XE+_^.@#^=<1K?C?Q#X@#1WNH2"!N
ML$/R)CT('7\<USU%-12$Y-A1115""BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /4?"W_(M
MZ%_U\2_REKB_CE_S ?\ MX_]IUW_ (+ /A*QR.GF8_[[:N%^-]M/);:-<I$[
M01-,LD@'"EMFT'TSM/Y5YZ5JK]3L;O32[(\<HHHK<Q"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KVW0O^1>TW_KUB_\ 0!7B5>VZ%_R+
MVF_]>L7_ * *]/+/CEZ'@Y]_#AZFA7(:W_R%Y_\ @/\ Z"*Z^N0UO_D+S_\
M ?\ T$5W8W^&O4\3 _Q'Z&?1117F'JA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5W]<!7?UWX'[7R/.Q_V?G^AX
M)1117T9X(4444 %%%% !115V/1M4EC62/3;QT<!E98&((/0@XH;2W"Q2HJ__
M &'J_P#T"K[_ ,!W_P *@N-/O;-0US:7$"DX!EC*@G\12N@LRO1113 ****
M"BBB@ HHHH **** "BBKFG:7>:M<-!8P^;*J%RNX+QD#/)'J*&[;AN4Z*OZE
MHVH:.8Q?V_DF7.SYU;.,9Z$^HI=.T/4]61WL;1I40X9LA1GTR2,GVI<RM>X[
M.]C/HJ2:&6VF>&9&CD0[65A@@U'3$%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[N- ,EGA8 #\15*,FKI$N<4[-ZE.BBBI*"BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,5]9&YA4&4+O5A_$/3WJW0C)-TY7L0L1.,DJD;7,WPY_R$)/^N1_F*L>)O\
MEU_X'_2J_AS_ )"$G_7(_P Q5CQ-_P NO_ _Z5:_W5_UU,Y?[VOZZ& JL[!5
M4LQZ #)-2O9W,:%WMIE4=24( KHM%TP6L8N)A^^8< _PC_&LW6=3-U*8(6_<
M(>2/XCZ_2LG14*?--ZOH;1KN=3D@M%U,FI(8C-/'$#@NP7/IDU'0"000<$5S
MHZ&=K/+%INGEE7Y(UPJ^OI7.C7[X2[]R%?[FWC_']:SWFED4*\KLHZ!F) I(
MXWED6.-2SL< #O734Q,I-<FAS4\-&"?/JSMHGCOK)7*_)*G(-<5-'Y4\D?\
M<8K^1KLT\O3]/4.PVQ(,GU__ %FN+D<RRO(W5B6./>M<9M&^YE@MY6V".-Y9
M%C12S,< #O76VEO%I%@2^"Y +D?Q-V JKH>F^2@NYEQ(P^0'^$>OU_I5'4M1
M^VWT<<9_<(XQ_M'UI4XJC#GEN]AU9.O/V<=EN:^N?\@F;ZK_ #%<C77:Y_R"
M9OJO\Q7(U.,_B+T*P/\ #?J%%%%<AV!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO\Q:4A2<]_F(KTSPQ:WMEH%O;7ZE9X]RX+!L+DXY!/:N-U'X@W\ERZV$4,4
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M!*S6QV&O6E_?:5):Z=+'%+(0K.[%<+WQ@'GM^)KA?^%=:O\ \_-C_P!]O_\
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M]Y47RVEE"S#<W11ECDFH;LG$O?4\1^+6L?VCXR:T1LPV$8A'IO/S,?U _P"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4&UP>_O6#JU@;*Z.T'RGY4XX'M48J/.E5CL:867(W2EN9]%%.1&D=412S,<
M#O7$=P(C2.J(I9F. !WKJM-TV/3H3-,5\W&68]$%+I6E+8IYDF&G8<G^[["J
MNJQ:E?,8HK<K;@_WU!<^IYZ5WTZ7LH\[5WV//JUO;2Y(NRZLS]6U4WS^5%D0
M*>/5CZTW1;..[O?WI!6,;MO][_ZU)_8FH_\ /O\ ^/K_ (U6CEN+"Y8H3'*N
M5/ -<[<N=3JHZ$H^S<*3.LU&"YN+4PVS(F[ABQ(X]!@5C1^'KM)%8R08!!^\
M?\*J_P!MZC_S\?\ CB_X4Z+6=0:5%-QP6 /R+_A6TZM&I*[3,(4:].-HM'1:
ME;/>6+P1E0S8P6Z<'-<G>V4EC.(I60L5W?*>*ZK59Y+;3I)86VN",' /<>M<
ME<7,UU+YD[[WQC. ./PIXSDOYA@E.WD14445PG>%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5W]<!7?UWX'[7R/.Q_V?G^AX)1117T9X(4444 %%%% !7K
MVC:SI<6AZ?')J5FCI;1JRM.H((49!&:\AHJ*E-36I4)\IZZS>$F8LQT0DG))
M\KFGG7/#NE6Y\FZLHTZ[+;!S^"UX_16?U==67[7R.D\4^*7UR06]N&CLHSD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@HHHJ"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N_K@*[^N_ _:^1YV/^
MS\_T/!****^C/!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*Z^N0UO_ )"\_P#P'_T$5W8W^&O4\3 _Q'Z&?1117F'JA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5W]<!7?UWX
M'[7R/.Q_V?G^AX)1117T9X(4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!ZCX6_Y%O0O^OB7^4M<7\<
MO^8#_P!O'_M.NT\+?\BWH7_7Q+_*6N+^.7_,!_[>/_:=>='^++U.V?\ #CZ?
MJSR&BBBN@P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *[OX5_\AK6?^P1/_P"A)7"5W?PK_P"0UK/_ &")
M_P#T)*RK?PY>AK1_B1]3W'7?^1>U+_KUE_\ 0#7B5>VZ[_R+VI?]>LO_ * :
M\2KP<S^.)]5D/\.?J%%%%>6>\%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5[;H7_(O:;_UZQ?^@"O$J]MT
M+_D7M-_Z]8O_ $ 5Z>6?'+T/!S[^'#U-"N0UO_D+S_\  ?\ T$5U]<AK?_(7
MG_X#_P"@BN[&_P ->IXF!_B/T,^BBBO,/5"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KOZX"N_KOP/VOD>=C_L_
M/]#P2BBBOHSP0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#U'PM_R+>A?]?$O\I:XOXY?\P'_MX_\
M:==IX6_Y%O0O^OB7^4M<7\<O^8#_ -O'_M.O.C_%EZG;/^''T_5GD-%%%=!@
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5W?PK_P"0UK/_ &")_P#T)*X2N[^%?_(:UG_L$3_^A)65;^'+
MT-:/\2/J>XZ[_P B]J7_ %ZR_P#H!KQ*O;==_P"1>U+_ *]9?_0#7B5>#F?Q
MQ/JLA_AS]0HHHKRSW@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "O;="_Y%[3?^O6+_ - %>)5[;H7_ "+V
MF_\ 7K%_Z *]/+/CEZ'@Y]_#AZFA7(:W_P A>?\ X#_Z"*Z^N0UO_D+S_P#
M?_017=C?X:]3Q,#_ !'Z&?1117F'JA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5W]<!7?UWX'[7R/.Q_P!GY_H>
M"4445]&>"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#U'PM_R+>A?]?$O\I:XOXY?\P'_ +>/_:==IX6_Y%O0
MO^OB7^4M<7\<O^8#_P!O'_M.O.C_ !9>IVS_ (<?3]6>0T445T& 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7=_"O_D-:S_V")_\ T)*X2N[^%?\ R&M9_P"P1/\ ^A)65;^'+T-:/\2/
MJ>XZ[_R+VI?]>LO_ * :\2KVW7?^1>U+_KUE_P#0#7B5>#F?QQ/JLA_AS]0H
MHHKRSW@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3Q,#_$?H9]%%%>8>J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBO7/^$*\/_\ 0/\ _(TG_P 51_PA7A__ *!__D:3_P"*H^LP#V,CR.BO7/\
MA"O#_P#T#_\ R-)_\51_PA7A_P#Z!_\ Y&D_^*H^LP#V,CR.BO7/^$*\/_\
M0/\ _(TG_P 51_PA7A__ *!__D:3_P"*H^LP#V,CR.BO7/\ A"O#_P#T#_\
MR-)_\51_PA7A_P#Z!_\ Y&D_^*H^LP#V,CR.BO7/^$*\/_\ 0/\ _(TG_P 5
M1_PA7A__ *!__D:3_P"*H^LP#V,CR.BO7/\ A"O#_P#T#_\ R-)_\51_PA7A
M_P#Z!_\ Y&D_^*H^LP#V,CR.BO7/^$*\/_\ 0/\ _(TG_P 51_PA7A__ *!_
M_D:3_P"*H^LP#V,CR.BO7/\ A"O#_P#T#_\ R-)_\51_PA7A_P#Z!_\ Y&D_
M^*H^LP#V,CR.BO7/^$*\/_\ 0/\ _(TG_P 51_PA7A__ *!__D:3_P"*H^LP
M#V,CR.BO7/\ A"O#_P#T#_\ R-)_\51_PA7A_P#Z!_\ Y&D_^*H^LP#V,CR.
MBO7/^$*\/_\ 0/\ _(TG_P 51_PA7A__ *!__D:3_P"*H^LP#V,CR.BO7/\
MA"O#_P#T#_\ R-)_\51_PA7A_P#Z!_\ Y&D_^*H^LP#V,CR.BO7/^$*\/_\
M0/\ _(TG_P 51_PA7A__ *!__D:3_P"*H^LP#V,CR.BO7/\ A"O#_P#T#_\
MR-)_\51_PA7A_P#Z!_\ Y&D_^*H^LP#V,CR.BO7/^$*\/_\ 0/\ _(TG_P 5
M1_PA7A__ *!__D:3_P"*H^LP#V,CR.BO7/\ A"O#_P#T#_\ R-)_\51_PA7A
M_P#Z!_\ Y&D_^*H^LP#V,CR.BO7/^$*\/_\ 0/\ _(TG_P 51_PA7A__ *!_
M_D:3_P"*H^LP#V,CR.BO7/\ A"O#_P#T#_\ R-)_\51_PA7A_P#Z!_\ Y&D_
M^*H^LP#V,CR.BO7/^$*\/_\ 0/\ _(TG_P 51_PA7A__ *!__D:3_P"*H^LP
M#V,CR.BO7/\ A"O#_P#T#_\ R-)_\51_PA7A_P#Z!_\ Y&D_^*H^LP#V,CR.
MBO7/^$*\/_\ 0/\ _(TG_P 51_PA7A__ *!__D:3_P"*H^LP#V,CR.BO7/\
MA"O#_P#T#_\ R-)_\51_PA7A_P#Z!_\ Y&D_^*H^LP#V,CR.BO7/^$*\/_\
M0/\ _(TG_P 51_PA7A__ *!__D:3_P"*H^LP#V,CR.BO7/\ A"O#_P#T#_\
MR-)_\51_PA7A_P#Z!_\ Y&D_^*H^LP#V,CR.BO7/^$*\/_\ 0/\ _(TG_P 5
M1_PA7A__ *!__D:3_P"*H^LP#V,CR.BO7/\ A"O#_P#T#_\ R-)_\51_PA7A
M_P#Z!_\ Y&D_^*H^LP#V,CR.BO7/^$*\/_\ 0/\ _(TG_P 51_PA7A__ *!_
M_D:3_P"*H^LP#V,CR.BO7/\ A"O#_P#T#_\ R-)_\51_PA7A_P#Z!_\ Y&D_
M^*H^LP#V,CR.BO7/^$*\/_\ 0/\ _(TG_P 51_PA7A__ *!__D:3_P"*H^LP
M#V,CR.BO7/\ A"O#_P#T#_\ R-)_\51_PA7A_P#Z!_\ Y&D_^*H^LP#V,CR.
MBO7/^$*\/_\ 0/\ _(TG_P 51_PA7A__ *!__D:3_P"*H^LP#V,CR.BO7/\
MA"O#_P#T#_\ R-)_\51_PA7A_P#Z!_\ Y&D_^*H^LP#V,CR.BO7/^$*\/_\
M0/\ _(TG_P 51_PA7A__ *!__D:3_P"*H^LP#V,CR.BO7/\ A"O#_P#T#_\
MR-)_\51_PA7A_P#Z!_\ Y&D_^*H^LP#V,CR.BO7/^$*\/_\ 0/\ _(TG_P 5
M1_PA7A__ *!__D:3_P"*H^LP#V,CR.BO7/\ A"O#_P#T#_\ R-)_\51_PA7A
M_P#Z!_\ Y&D_^*H^LP#V,CR.BO7/^$*\/_\ 0/\ _(TG_P 51_PA7A__ *!_
M_D:3_P"*H^LP#V,CR.BO7/\ A"O#_P#T#_\ R-)_\51_PA7A_P#Z!_\ Y&D_
M^*H^LP#V,CR.BO7/^$*\/_\ 0/\ _(TG_P 51_PA7A__ *!__D:3_P"*H^LP
M#V,CR.BO7/\ A"O#_P#T#_\ R-)_\51_PA7A_P#Z!_\ Y&D_^*H^LP#V,CR.
MBO7/^$*\/_\ 0/\ _(TG_P 51_PA7A__ *!__D:3_P"*H^LP#V,CR.BO7/\
MA"O#_P#T#_\ R-)_\51_PA7A_P#Z!_\ Y&D_^*H^LP#V,CR.BO7/^$*\/_\
M0/\ _(TG_P 51_PA7A__ *!__D:3_P"*H^LP#V,CR.BO7/\ A"O#_P#T#_\
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MNC_A5_@W_H#_ /DS-_\ %T>T0<C/G*BOHW_A5_@W_H#_ /DS-_\ %T?\*O\
M!O\ T!__ "9F_P#BZ/:(.1GSE17T;_PJ_P &_P#0'_\ )F;_ .+H_P"%7^#?
M^@/_ .3,W_Q='M$'(SYRHKZ-_P"%7^#?^@/_ .3,W_Q='_"K_!O_ $!__)F;
M_P"+H]H@Y&?.5%?1O_"K_!O_ $!__)F;_P"+H_X5?X-_Z __ ),S?_%T>T0<
MC/G*BOHW_A5_@W_H#_\ DS-_\71_PJ_P;_T!_P#R9F_^+H]H@Y&?.5%?1O\
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M ,*O\&_] ?\ \F9O_BZ/^%7^#?\ H#_^3,W_ ,71[1!R,^<J*^C?^%7^#?\
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M_P"@/_Y,S?\ Q='_  J_P;_T!_\ R9F_^+H]H@Y&?.5%?1O_  J_P;_T!_\
MR9F_^+H_X5?X-_Z _P#Y,S?_ !='M$'(SYRHKZ-_X5?X-_Z _P#Y,S?_ !='
M_"K_  ;_ - ?_P F9O\ XNCVB#D9\Y45]&_\*O\ !O\ T!__ "9F_P#BZ/\
MA5_@W_H#_P#DS-_\71[1!R,^<J*^C?\ A5_@W_H#_P#DS-_\71_PJ_P;_P!
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MZ_'_ "#^W</_ "R^Y?YGD-%>O?\ "%>'O^@?_P"1I/\ XJC_ (0KP]_T#_\
MR-)_\51_9M7NOQ_R#^W</_++[E_F>0T5Z]_PA7A[_H'_ /D:3_XJC_A"O#W_
M $#_ /R-)_\ %4?V;5[K\?\ (/[=P_\ ++[E_F>0T5Z]_P (5X>_Z!__ )&D
M_P#BJ/\ A"O#W_0/_P#(TG_Q5']FU>Z_'_(/[=P_\LON7^9Y#17KW_"%>'O^
M@?\ ^1I/_BJ/^$*\/?\ 0/\ _(TG_P 51_9M7NOQ_P @_MW#_P LON7^9Y#1
M7KW_  A7A[_H'_\ D:3_ .*H_P"$*\/?] __ ,C2?_%4?V;5[K\?\@_MW#_R
MR^Y?YGD-%>O?\(5X>_Z!_P#Y&D_^*H_X0KP]_P! _P#\C2?_ !5']FU>Z_'_
M "#^W</_ "R^Y?YGD-%>O?\ "%>'O^@?_P"1I/\ XJC_ (0KP]_T#_\ R-)_
M\51_9M7NOQ_R#^W</_++[E_F>0T5Z]_PA7A[_H'_ /D:3_XJC_A"O#W_ $#_
M /R-)_\ %4?V;5[K\?\ (/[=P_\ ++[E_F>0T5Z]_P (5X>_Z!__ )&D_P#B
MJ/\ A"O#W_0/_P#(TG_Q5']FU>Z_'_(/[=P_\LON7^9Y#17KW_"%>'O^@?\
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M)_\ %4?V;5[K\?\ (/[=P_\ ++[E_F>0T5Z]_P (5X>_Z!__ )&D_P#BJ/\
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MOQ_R#^W</_++[E_F>0T5Z]_PA7A[_H'_ /D:3_XJC_A"O#W_ $#_ /R-)_\
M%4?V;5[K\?\ (/[=P_\ ++[E_F>0T5Z]_P (5X>_Z!__ )&D_P#BJ/\ A"O#
MW_0/_P#(TG_Q5']FU>Z_'_(/[=P_\LON7^9Y#17KW_"%>'O^@?\ ^1I/_BJ/
M^$*\/?\ 0/\ _(TG_P 51_9M7NOQ_P @_MW#_P LON7^9Y#17KW_  A7A[_H
M'_\ D:3_ .*H_P"$*\/?] __ ,C2?_%4?V;5[K\?\@_MW#_RR^Y?YGD-%>O?
M\(5X>_Z!_P#Y&D_^*H_X0KP]_P! _P#\C2?_ !5']FU>Z_'_ "#^W</_ "R^
MY?YGD-%>O?\ "%>'O^@?_P"1I/\ XJC_ (0KP]_T#_\ R-)_\51_9M7NOQ_R
M#^W</_++[E_F>0T5Z]_PA7A[_H'_ /D:3_XJC_A"O#W_ $#_ /R-)_\ %4?V
M;5[K\?\ (/[=P_\ ++[E_F>0T5Z]_P (5X>_Z!__ )&D_P#BJ/\ A"O#W_0/
M_P#(TG_Q5']FU>Z_'_(/[=P_\LON7^9Y#17KW_"%>'O^@?\ ^1I/_BJ/^$*\
M/?\ 0/\ _(TG_P 51_9M7NOQ_P @_MW#_P LON7^9Y#17KW_  A7A[_H'_\
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MTG_Q5']FU>Z_'_(/[=P_\LON7^9Y#17KW_"%>'O^@?\ ^1I/_BJ/^$*\/?\
M0/\ _(TG_P 51_9M7NOQ_P @_MW#_P LON7^9Y#17KW_  A7A[_H'_\ D:3_
M .*H_P"$*\/?] __ ,C2?_%4?V;5[K\?\@_MW#_RR^Y?YGD-%>O?\(5X>_Z!
M_P#Y&D_^*H_X0KP]_P! _P#\C2?_ !5']FU>Z_'_ "#^W</_ "R^Y?YGD-%>
MO?\ "%>'O^@?_P"1I/\ XJC_ (0KP]_T#_\ R-)_\51_9M7NOQ_R#^W</_++
M[E_F>0T5Z]_PA7A[_H'_ /D:3_XJC_A"O#W_ $#_ /R-)_\ %4?V;5[K\?\
M(/[=P_\ ++[E_F>0T5Z]_P (5X>_Z!__ )&D_P#BJ/\ A"O#W_0/_P#(TG_Q
M5']FU>Z_'_(/[=P_\LON7^9Y#17KW_"%>'O^@?\ ^1I/_BJ/^$*\/?\ 0/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5+S_CZT__
M *^#_P"BGJW52\_X^M/_ .O@_P#HIZMU,=W_ %T+GM'T_5A1115$!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %5-5_Y ][_P!>\G_H)JW535?^0/>_]>\G_H)J9_"RZ?QKU+=%%%40%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M5+S_ (^M/_Z^#_Z*>K=5+S_CZT__ *^#_P"BGJW4QW?]="Y[1]/U844451 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !535?\ D#WO_7O)_P"@FK=5-5_Y ][_ ->\G_H)J9_"RZ?QKU+=
M%%%40%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 5+S_CZT_P#Z^#_Z*>K=5+S_ (^M/_Z^#_Z*>K=3'=_UT+GM'T_5
MA1115$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %5-5_Y ][_U[R?^@FK=5-5_Y ][_P!>\G_H)J9_"RZ?
MQKU+=%%%40%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 5+S_CZT_\ Z^#_ .BGJW52\_X^M/\ ^O@_^BGJW4QW?]="
MY[1]/U844451 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !535?^0/>_P#7O)_Z":MU4U7_ ) ][_U[R?\
MH)J9_"RZ?QKU+=%%%40%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 5+S_CZT__ *^#_P"BGJW52\_X^M/_ .O@_P#H
MIZMU,=W_ %T+GM'T_5A1115$!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %5-5_Y ][_P!>\G_H)JW535?^
M0/>_]>\G_H)J9_"RZ?QKU+=%%%40%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 0S(K2VY89*2$K[':P_D34U%%)=1O
M9!1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5#=HLEG/&XRK1L"/4$444GL..Z)J***8@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
; "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img159889792_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img159889792_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1\"U@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ]M(]8_X3G0?^?I_^_3?X4?\)SH/_/T__?IO\*\GHH^KP#VTCUC_ (3G0?\
MGZ?_ +]-_A1_PG.@_P#/T_\ WZ;_  KR>BCZO /;2/6/^$YT'_GZ?_OTW^%'
M_"<Z#_S]/_WZ;_"O)Z*/J\ ]M(]8_P"$YT'_ )^G_P"_3?X4?\)SH/\ S]/_
M -^F_P *\GHH^KP#VTCUC_A.=!_Y^G_[]-_A1_PG.@_\_3_]^F_PKR>BCZO
M/;2/6/\ A.=!_P"?I_\ OTW^%'_"<Z#_ ,_3_P#?IO\ "O)Z*/J\ ]M(]8_X
M3G0?^?I_^_3?X4?\)SH/_/T__?IO\*\GHH^KP#VTCUC_ (3G0?\ GZ?_ +]-
M_A1_PG.@_P#/T_\ WZ;_  KR>BCZO /;2/6/^$YT'_GZ?_OTW^%'_"<Z#_S]
M/_WZ;_"O)Z*/J\ ]M(]8_P"$YT'_ )^G_P"_3?X4?\)SH/\ S]/_ -^F_P *
M\GHH^KP#VTCUC_A.=!_Y^G_[]-_A1_PG.@_\_3_]^F_PKR>BCZO /;2/6/\
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M (6MX1_Y_P"7_P !W_PKYXHH]F@YV?0__"UO"/\ S_R_^ [_ .%'_"UO"/\
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M-9LHM*AU-I&%K,B.C;3DAAD<=:H?\)AHO_/P_P#WZ;_"LB^_Y)GI/_7M;?\
MH KBZ\/&XVI0J\D;6/<P.!I5Z7/-N]STO_A,-%_Y^'_[]-_A1_PF&B_\_#_]
M^F_PKS2BN3^U:_9?U\SL_LFAW?\ 7R/2_P#A,-%_Y^'_ ._3?X4?\)AHO_/P
M_P#WZ;_"O-**/[5K]E_7S#^R:'=_U\CTO_A,-%_Y^'_[]-_A1_PF&B_\_#_]
M^F_PKS2BC^U:_9?U\P_LFAW?]?(]+_X3#1?^?A_^_3?X4?\ "8:+_P _#_\
M?IO\*\THH_M6OV7]?,/[)H=W_7R/2_\ A,-%_P"?A_\ OTW^%'_"8:+_ ,_#
M_P#?IO\ "O-**/[5K]E_7S#^R:'=_P!?(]+_ .$PT7_GX?\ []-_A1_PF&B_
M\_#_ /?IO\*\THH_M6OV7]?,/[)H=W_7R/2_^$PT7_GX?_OTW^%'_"8:+_S\
M/_WZ;_"O-**/[5K]E_7S#^R:'=_U\CTO_A,-%_Y^'_[]-_A1_P )AHO_ #\/
M_P!^F_PKS2BC^U:_9?U\P_LFAW?]?(]+_P"$PT7_ )^'_P"_3?X4?\)AHO\
MS\/_ -^F_P *\THH_M6OV7]?,/[)H=W_ %\CTO\ X3#1?^?A_P#OTW^%'_"8
M:+_S\/\ ]^F_PKS2BC^U:_9?U\P_LFAW?]?(]+_X3#1?^?A_^_3?X4?\)AHO
M_/P__?IO\*\THH_M6OV7]?,/[)H=W_7R/2_^$PT7_GX?_OTW^%'_  F&B_\
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M4?\ "8:+_P _#_\ ?IO\*\THH_M6OV7]?,/[)H=W_7R/2_\ A,-%_P"?A_\
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M*L 1]#145E_QXV__ %R7^5%=J=T>9)6;1/1113$%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#Z'OO^29Z3_P!>UM_Z *XNNTOO^29Z3_U[6W_H KBZ^3S7^/\
M(^LRG_=_F%%%%>:>F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >EM
M_P BG8_]<(O_ $$5CUL-_P BG8_]<(O_ $$5CU]%4^SZ(\"AM+U84445F;A1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% '7V7_'C;_]<E_E119?\>-O
M_P!<E_E17J1V1X4_B9/1113)"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.5)]LU2KH_'W_(]ZQ_U\'^0KG*I;">X4444Q!117L7PT^'EJ]C'KFM6ZS-,
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M(O\ T$5CUL-_R*=C_P!<(O\ T$5CU]%4^SZ(\"AM+U84445F;A1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>??$G_CXT[_ ''_ )BO0:\^^)/_ !\:=_N/_,5K0^-&=7X3A:***[SE"M'0
M/^1BTW_KYC_]"%9U:.@?\C%IO_7S'_Z$*4MF-;GK>N?\B_J7_7K+_P"@&O%4
M1Y75(U9W8X"J,DFO=9Y8X+>6:8A8D0LY(R H&361#XG\/E\1WUNK'C)4K^I%
M<=*HXIV5SHJ14GJRWHL$UIH=E#<\2QPJ'!/3CI^%>3^(;N.^\07MQ"08VD(4
MCN!QG]*]9U*Q36=.,"7DL44@^_ P^8?U%>1ZSI%QHFH-:3X;C<CCHZ^M7A[<
MS?4FK>R70Z+PKX/M]6LA?WLK^46(2).,XXY/^%=4/#GANWQ$UK;!O223)_4U
MYI:ZOJL=E_9MI<S+"S$^7$.23UY'/X5-'X7UR<;UTV?GGYP%/ZU<X2;NY6)C
M)):([W4? VD7<+?9HS:S8^5D8E<^X/;Z8KS&[M9;*[EMIEVRQ,48>XKUSPM!
M?6N@06^H(R31EE 8@G;GCI7GOC50OBR\P,9"'_QP5-&3YG%NXZD59-&IX5\&
MQ:C:K?ZCO\ES^ZB4XW#U)ZXKI&T;PG;R?9I([%)/[CS?/^IS5SPQ<QW7ANP:
M,@[(EC8#LRC!_E7%:]X)U..[GNK0?:XI'+X!^<9.>0>OX5',YS:D[%648II7
M$\9^'K'2([:YL0R),Q4H6W <9!!/-<YIFFW&K7\=G;+F1^YZ*.Y/M44SW*J+
M:=I0L1.(G)PA[\'I7>_#BS06EY?$ NT@A!]  "?YC\JW;=.&KN9I*<C0L_!>
MB:=;^9> 3LH^:69]JC\,X ^N:F'AOPSJ<#?9H;=P/^6EM+RI^H./SK/\::7K
M6KSV\-C;F2TC7<W[Q5!<GN"1T&/S-9GAGP]K^DZY!/):F.W.5F_>H05(] ?7
M%8*[CS.6IIHG;ET,;Q+X<ET"Y7#F6UESY<A'/T/O6W\-_P#C\O\ _KFG\S70
M>.8!-X6G<@$Q.CC_ +Z _D:Y_P"&_P#Q^7__ %S3^9J^=RHMLGEY:BL6?B3_
M ,>^G?[[_P A6-X*T:QUB[NA?1&5(D!50Q49)]N:V?B3_P >^G?[[_R%5OAO
M_P ?E_\ ]<T_F:(MJC= U>H5_&VA:=H\=F]C 8O,+!AO9@<8]2?6H/!6C6.L
M7=TM]$94B0%5WE>2?8BMCXD_\>^G?[[_ ,A5;X;_ /'Y?_\ 7-/YFFI/V-[@
MTO:6+UWX!MI]:3[.#;:>(P7 <LS/D\#.<<8YK;B\):%%$$&GQMCNY))_'-4O
M&NMW.D:=$EH=DMP2OF=T QG'OS7#^'=8O;77[5C<RLLTJI*'<D,&(!SGO4)5
M)QO<IN$96L:WB[PE#ID']H:?N%N"!)$23LST()[?XUQRJSNJ(I9F.  .2:]I
MU]%D\.ZD&&0+:0_B%)'\J\Y\#6:7?B6-G (MXVFP?48 _4@_A5TJCY&WT(G!
M<R2ZG1Z+X"M(K=)M5W2S,,F)6PJ>Q(Y)_2M./1/"UR[6\4-E)(!@I'+EA^1S
M4_BF#4KK17MM,C+RRL%?#A2$YSR2/8?C7 0^$/$MO,DT5D4D0AE83QY!_P"^
MJSBW-7<K%NT=%$T/%'@Q=-MVOM/9VMU_UD3')0>H/<5QM>YR0FZT]X9U ,L1
M5UZC)&#7AA&#@]16U";DFGT(JQ2>@4445L9!1110 5UGP\_Y&*7_ *]F_P#0
MEKDZZSX>?\C%+_U[-_Z$M15^!E0^)'G?Q'_Y*!J__71?_0%KEJZGXC_\E U?
M_KHO_H"URU<\=D:O<****H04444 %%%% !1110 4444 %%%% !1110 4444
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MEHR5'N.1^H%<AX$MO,U*XN2,B*/:/JQ_P!I8JAS8R'G^G_ 'A,1RX*?E^O\
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MNIKVN4]0L&L9!SNC;[K?T-06UO)=3K%&/F/<] /6NAUE ^FN>ZD$?GC^M5]
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ML?\ KA%_Z"*QZ^BJ?9]$>!0VEZL****S-PHHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=BS,68]23DFDHHH **** "BBB@ KK/AY_P C%+_U[-_Z$M<G76?#S_D8I?\
MKV;_ -"6HJ_ RH?$CSOXC_\ )0-7_P"NB_\ H"URU=3\1_\ DH&K_P#71?\
MT!:Y:N>.R-7N%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M J1)Y8EVQRN@ZX5B*CHH 5G9V+.Q9CU).32444 /2:6($1RN@/4*Q%([M(Q9
MV+,>Y.33:* "BBB@"W;ZKJ-FFRVO[J!?[L4S*/T-,N;^\O#FZNYYS_TUD+?S
MJO12 ****8%NWU74;--EM?W4"_W8IF4?H:9<W]Y>'-U=SSG_ *:R%OYU7HI
M%2)/+$,1RN@ZX5B*CHI@%/262(DQNR$]=IQ3** '.[2,6=BS'N3DTVBB@ I5
M8JP9201R".U)10!>&M:JL7E#4[T1_P!P3MC\LU2)))).2>I-)12 ****8!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'T/??\ ),])_P"O
M:V_] %<77:7W_),])_Z]K;_T 5Q=?)YK_'^1]9E/^[_,****\T],**** "BB
MB@ HHHH **** "BBB@ HHHH **** "E5F4Y4D'U!I** '-([_>=F^IS3:**8
M"ABIRI(/J*5I'<89V8>YS3:* L%%%%(!\<TL+;HI'1O56(J5[Z[D7;)=3L/1
MI":KT52DTK)B<4W=H****D8^.:6%MT4CHWJK$5*]]=R+MDNIV'HTA-5Z*I2:
M5DQ.*;NT%*K%3E20?44E%2,5F9CEF)/J32 D'(X-%%,!S2.XPSLP]SFFT44
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5Y]\2?^/C3O]Q_YBO0:\^^)/\ Q\:=_N/_ #%:T/C1G5^$X6BBBN\Y0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "NL^'G_(Q2_\ 7LW_ *$M<G76?#S_ )&*
M7_KV;_T):BK\#*A\2/._B/\ \E U?_KHO_H"URU=3\1_^2@:O_UT7_T!:Y:N
M>.R-7N%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^A[[_DF>
MD_\ 7M;?^@"N+KM+[_DF>D_]>UM_Z *XNOD\U_C_ "/K,I_W?YA1117FGIA1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'I;?\ (IV/_7"+_P!!%8];
M#?\ (IV/_7"+_P!!%8]?15/L^B/ H;2]6%%%%9FX4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_#->C_\ 0P7W_?E*/^&:]'_Z&"^_[\I0!Z?_ ,)WX0_Z&O0__!C#_P#%4?\
M"=^$/^AKT/\ \&,/_P 57F'_  S7H_\ T,%]_P!^4H_X9KT?_H8+[_ORE 'I
M_P#PG?A#_H:]#_\ !C#_ /%4?\)WX0_Z&O0__!C#_P#%5YA_PS7H_P#T,%]_
MWY2C_AFO1_\ H8+[_ORE 'I__"=^$/\ H:]#_P#!C#_\51_PG?A#_H:]#_\
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M_?E*/^&:]'_Z&"^_[\I0!Z?_ ,)WX0_Z&O0__!C#_P#%4?\ "=^$/^AKT/\
M\&,/_P 57F'_  S7H_\ T,%]_P!^4H_X9KT?_H8+[_ORE 'I_P#PG?A#_H:]
M#_\ !C#_ /%4?\)WX0_Z&O0__!C#_P#%5YA_PS7H_P#T,%]_WY2C_AFO1_\
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M_#->C_\ 0P7W_?E*/^&:]'_Z&"^_[\I0!Z?_ ,)WX0_Z&O0__!C#_P#%4?\
M"=^$/^AKT/\ \&,/_P 57F'_  S7H_\ T,%]_P!^4H_X9KT?_H8+[_ORE 'I
M_P#PG?A#_H:]#_\ !C#_ /%4?\)WX0_Z&O0__!C#_P#%5YA_PS7H_P#T,%]_
MWY2C_AFO1_\ H8+[_ORE 'I__"=^$/\ H:]#_P#!C#_\51_PG?A#_H:]#_\
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M_?E*/^&:]'_Z&"^_[\I0!Z?_ ,)WX0_Z&O0__!C#_P#%4?\ "=^$/^AKT/\
M\&,/_P 57F'_  S7H_\ T,%]_P!^4H_X9KT?_H8+[_ORE 'I_P#PG?A#_H:]
M#_\ !C#_ /%4?\)WX0_Z&O0__!C#_P#%5YA_PS7H_P#T,%]_WY2C_AFO1_\
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M_#->C_\ 0P7W_?E*/^&:]'_Z&"^_[\I0!Z?_ ,)WX0_Z&O0__!C#_P#%4?\
M"=^$/^AKT/\ \&,/_P 57F'_  S7H_\ T,%]_P!^4H_X9KT?_H8+[_ORE 'I
M_P#PG?A#_H:]#_\ !C#_ /%4?\)WX0_Z&O0__!C#_P#%5YA_PS7H_P#T,%]_
MWY2C_AFO1_\ H8+[_ORE 'I__"=^$/\ H:]#_P#!C#_\51_PG?A#_H:]#_\
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M_?E*/^&:]'_Z&"^_[\I0!Z?_ ,)WX0_Z&O0__!C#_P#%4?\ "=^$/^AKT/\
M\&,/_P 57F'_  S7H_\ T,%]_P!^4H_X9KT?_H8+[_ORE 'I_P#PG?A#_H:]
M#_\ !C#_ /%4?\)WX0_Z&O0__!C#_P#%5YA_PS7H_P#T,%]_WY2C_AFO1_\
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ME'_#->C_ /0P7W_?E*/K+[![%=S#_M[1_P#H+6'_ ($I_C1_;VC_ /06L/\
MP)3_ !K<_P"&:]'_ .A@OO\ ORE'_#->C_\ 0P7W_?E*/K+[![%=S#_M[1_^
M@M8?^!*?XT?V]H__ $%K#_P)3_&MS_AFO1_^A@OO^_*4?\,UZ/\ ]#!??]^4
MH^LOL'L5W,/^WM'_ .@M8?\ @2G^-']O:/\ ]!:P_P# E/\ &MS_ (9KT?\
MZ&"^_P"_*4?\,UZ/_P!#!??]^4H^LOL'L5W,/^WM'_Z"UA_X$I_C1_;VC_\
M06L/_ E/\:W/^&:]'_Z&"^_[\I1_PS7H_P#T,%]_WY2CZR^P>Q7<P_[>T?\
MZ"UA_P"!*?XT?V]H_P#T%K#_ ,"4_P :W/\ AFO1_P#H8+[_ +\I1_PS7H__
M $,%]_WY2CZR^P>Q7<P_[>T?_H+6'_@2G^-']O:/_P!!:P_\"4_QK<_X9KT?
M_H8+[_ORE'_#->C_ /0P7W_?E*/K+[![%=S#_M[1_P#H+6'_ ($I_C1_;VC_
M /06L/\ P)3_ !K<_P"&:]'_ .A@OO\ ORE'_#->C_\ 0P7W_?E*/K+[![%=
MS#_M[1_^@M8?^!*?XT?V]H__ $%K#_P)3_&MS_AFO1_^A@OO^_*4?\,UZ/\
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M?\,UZ/\ ]#!??]^4H^LOL'L5W,/^WM'_ .@M8?\ @2G^-']O:/\ ]!:P_P#
ME/\ &MS_ (9KT?\ Z&"^_P"_*4?\,UZ/_P!#!??]^4H^LOL'L5W,/^WM'_Z"
MUA_X$I_C73>!?%/AZSUZ22YUW3($-NP#2W<:C.Y>,DU5_P"&:]'_ .A@OO\
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M .A@OO\ ORE'M6'(>5?;[/\ Y^X/^_@_QH^WV?\ S]P?]_!_C7JO_#->C_\
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M_?E*/^&:]'_Z&"^_[\I1[5AR'E7V^S_Y^X/^_@_QH^WV?_/W!_W\'^->J_\
M#->C_P#0P7W_ 'Y2C_AFO1_^A@OO^_*4>U8<AY5]OL_^?N#_ +^#_&C[?9_\
M_<'_ '\'^->J_P##->C_ /0P7W_?E*/^&:]'_P"A@OO^_*4>U8<AY5]OL_\
MG[@_[^#_ !H^WV?_ #]P?]_!_C7JO_#->C_]#!??]^4H_P"&:]'_ .A@OO\
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M #]P?]_!_C7JO_#->C_]#!??]^4H_P"&:]'_ .A@OO\ ORE'M6'(>5?;[/\
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MO1_^A@OO^_*4?V3#^9A_;$_Y44O^$BT/_H,Z=_X%)_C1_P )%H?_ $&=._\
M I/\:N_\,UZ/_P!#!??]^4H_X9KT?_H8+[_ORE']DP_F8?VQ/^5%+_A(M#_Z
M#.G?^!2?XT?\)%H?_09T[_P*3_&KO_#->C_]#!??]^4H_P"&:]'_ .A@OO\
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M,%]_WY2C_AFO1_\ H8+[_ORE'U9=P^O2['0?\)=X:_Z&+2?_  -C_P#BJ/\
MA+O#7_0Q:3_X&Q__ !5<_P#\,UZ/_P!#!??]^4H_X9KT?_H8+[_ORE'U9=P^
MO2['0?\ "7>&O^ABTG_P-C_^*H_X2[PU_P!#%I/_ (&Q_P#Q5<__ ,,UZ/\
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MZ/\ ]#!??]^4H_X9KT?_ *&"^_[\I1]67</KTNQT'_"7>&O^ABTG_P #8_\
MXJC_ (2[PU_T,6D_^!L?_P 57/\ _#->C_\ 0P7W_?E*/^&:]'_Z&"^_[\I1
M]67</KTNQT'_  EWAK_H8M)_\#8__BJ/^$N\-?\ 0Q:3_P"!L?\ \57/_P##
M->C_ /0P7W_?E*/^&:]'_P"A@OO^_*4?5EW#Z]+L=!_PEWAK_H8M)_\  V/_
M .*H_P"$N\-?]#%I/_@;'_\ %5S_ /PS7H__ $,%]_WY2C_AFO1_^A@OO^_*
M4?5EW#Z]+L=!_P )=X:_Z&+2?_ V/_XJC_A+O#7_ $,6D_\ @;'_ /%5S_\
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M_P##->C_ /0P7W_?E*/^&:]'_P"A@OO^_*4?5EW#Z]+L=!_PEWAK_H8M)_\
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M&"^_[\I1]67</KTNQT'_  EWAK_H8M)_\#8__BJ/^$N\-?\ 0Q:3_P"!L?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_BZ /5Z*PO"7B[2_&FC'5-):4P+*T++*FUE< $@C)[$'\:W: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***X+Q3\7_"_A'7)=(U WKW<2JT@
M@@W!=P##DD=B.E '>T5D>&O$FG>+-$BU?2GD:UE+*/,3:P(.""*UZ "BBB@
MHHHH **** "BBL;Q9XAA\*>%M0UR>%IDM(]PB4X+L2%49[9)'- &S17A7A3]
MH*XUKQ18:7J&B00P7LZ6ZRPS$E&8@*2".1DC/3UKW6@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXW\$?$31KDH);%IPMQ<6,Q*>7@Y#@X.,>HQ^->R_$QF7X9^(BI(/V&3D'VH
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M^-?9?_")^'/^A?TK_P  X_\ "JL$'@VRUV"RMX-#@U<Y:*&*.)9^ 22 !N'
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M\E0\/?\ 7V/Y&OH+X\:5+J?PQGEB4L;&YCNB!_=&4)_ /G\* /&_@)IL-_\
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MFY^A53^%?75 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(26%,XWLC!MOX@$#WQ7RMX8\1ZS\//%7VZ"V\N\B5H9[:ZC*Y4XRK#@CH#^
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M)K@*F/\ @3 5ZU\'/A7K?@O6;K6=:EMHWFM6MDMHGWL,NK$L>G\'8GK7LM%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVA6&")(HE&%2-0JCZ 5)10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1OT75 W<#RR/_0J=_P -(^'/^@-JOY1__%4 >ST5XQ_PTCX<_P"@-JOY1_\
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M'/\ H#:K^4?_ ,51_P -(^'/^@-JOY1__%4 >ST5XQ_PTCX<_P"@-JOY1_\
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M'/\ H#:K^4?_ ,51_P -(^'/^@-JOY1__%4 >ST5XQ_PTCX<_P"@-JOY1_\
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M'/\ H#:K^4?_ ,51_P -(^'/^@-JOY1__%4 >ST5XQ_PTCX<_P"@-JOY1_\
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M-(^'/^@-JOY1_P#Q5 'L]%>,?\-(^'/^@-JOY1__ !5'_#2/AS_H#:K^4?\
M\50![/17C'_#2/AS_H#:K^4?_P 51_PTCX<_Z VJ_E'_ /%4 >ST5XQ_PTCX
M<_Z VJ_E'_\ %4?\-(^'/^@-JOY1_P#Q5 'L]%>,?\-(^'/^@-JOY1__ !5'
M_#2/AS_H#:K^4?\ \50![/17C'_#2/AS_H#:K^4?_P 51_PTCX<_Z VJ_E'_
M /%4 >ST5XQ_PTCX<_Z VJ_E'_\ %4?\-(^'/^@-JOY1_P#Q5 'L]%>,?\-(
M^'/^@-JOY1__ !5'_#2/AS_H#:K^4?\ \50![/17C'_#2/AS_H#:K^4?_P 5
M1_PTCX<_Z VJ_E'_ /%4 >ST5XQ_PTCX<_Z VJ_E'_\ %4?\-(^'/^@-JOY1
M_P#Q5 'L]%>,?\-(^'/^@-JOY1__ !5'_#2/AS_H#:K^4?\ \50![/17C'_#
M2/AS_H#:K^4?_P 51_PTCX<_Z VJ_E'_ /%4 >ST5XQ_PTCX<_Z VJ_E'_\
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M] ;5?RC_ /BJ /9Z*\8_X:1\.?\ 0&U7\H__ (JC_AI'PY_T!M5_*/\ ^*H
M]GHKQC_AI'PY_P! ;5?RC_\ BJ/^&D?#G_0&U7\H_P#XJ@#V>BO&/^&D?#G_
M $!M5_*/_P"*H_X:1\.?] ;5?RC_ /BJ /9Z*\8_X:1\.?\ 0&U7\H__ (JC
M_AI'PY_T!M5_*/\ ^*H ]GHKQC_AI'PY_P! ;5?RC_\ BJ/^&D?#G_0&U7\H
M_P#XJ@#V>BO&/^&D?#G_ $!M5_*/_P"*H_X:1\.?] ;5?RC_ /BJ /9Z*\8_
MX:1\.?\ 0&U7\H__ (JC_AI'PY_T!M5_*/\ ^*H ]GHKQC_AI'PY_P! ;5?R
MC_\ BJ/^&D?#G_0&U7\H_P#XJ@#V>BO&/^&D?#G_ $!M5_*/_P"*H_X:1\.?
M] ;5?RC_ /BJ /9Z*\8_X:1\.?\ 0&U7\H__ (JC_AI'PY_T!M5_*/\ ^*H
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M] ;5?RC_ /BJ /9Z*\8_X:1\.?\ 0&U7\H__ (JC_AI'PY_T!M5_*/\ ^*H
M]GHKQC_AI'PY_P! ;5?RC_\ BJ/^&D?#G_0&U7\H_P#XJ@#V>BO&/^&D?#G_
M $!M5_*/_P"*H_X:1\.?] ;5?RC_ /BJ /9Z*\8_X:1\.?\ 0&U7\H__ (JC
M_AI'PY_T!M5_*/\ ^*H ]GHKQC_AI'PY_P! ;5?RC_\ BJ/^&D?#G_0&U7\H
M_P#XJ@#V>BO&/^&D?#G_ $!M5_*/_P"*H_X:1\.?] ;5?RC_ /BJ .3\ _\
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M_P#0KZ5_X#+_ (5U%% '+_\ "N/!?_0KZ5_X#+_A1_PKCP7_ -"OI7_@,O\
MA7444 <O_P *X\%_]"OI7_@,O^%'_"N/!?\ T*^E?^ R_P"%=110!R__  KC
MP7_T*^E?^ R_X4?\*X\%_P#0KZ5_X#+_ (5U%% '+_\ "N/!?_0KZ5_X#+_A
M1_PKCP7_ -"OI7_@,O\ A7444 <O_P *X\%_]"OI7_@,O^%'_"N/!?\ T*^E
M?^ R_P"%=110!R__  KCP7_T*^E?^ R_X4?\*X\%_P#0KZ5_X#+_ (5U%% '
M+_\ "N/!?_0KZ5_X#+_A1_PKCP7_ -"OI7_@,O\ A7444 <O_P *X\%_]"OI
M7_@,O^%'_"N/!?\ T*^E?^ R_P"%=110!R__  KCP7_T*^E?^ R_X4?\*X\%
M_P#0KZ5_X#+_ (5U%% '+_\ "N/!?_0KZ5_X#+_A1_PKCP7_ -"OI7_@,O\
MA7444 <O_P *X\%_]"OI7_@,O^%'_"N/!?\ T*^E?^ R_P"%=110!R__  KC
MP7_T*^E?^ R_X4?\*X\%_P#0KZ5_X#+_ (5U%% '+_\ "N/!?_0KZ5_X#+_A
M1_PKCP7_ -"OI7_@,O\ A7444 <O_P *X\%_]"OI7_@,O^%'_"N/!?\ T*^E
M?^ R_P"%=110!R__  KCP7_T*^E?^ R_X4?\*X\%_P#0KZ5_X#+_ (5U%% '
M+_\ "N/!?_0KZ5_X#+_A1_PKCP7_ -"OI7_@,O\ A7444 <O_P *X\%_]"OI
M7_@,O^%'_"N/!?\ T*^E?^ R_P"%=110!R__  KCP7_T*^E?^ R_X4?\*X\%
M_P#0KZ5_X#+_ (5U%% '+_\ "N/!?_0KZ5_X#+_A1_PKCP7_ -"OI7_@,O\
MA7444 <O_P *X\%_]"OI7_@,O^%'_"N/!?\ T*^E?^ R_P"%=110!R__  KC
MP7_T*^E?^ R_X4?\*X\%_P#0KZ5_X#+_ (5U%% '+_\ "N/!?_0KZ5_X#+_A
M1_PKCP7_ -"OI7_@,O\ A7444 <O_P *X\%_]"OI7_@,O^%'_"N/!?\ T*^E
M?^ R_P"%=110!R__  KCP7_T*^E?^ R_X4?\*X\%_P#0KZ5_X#+_ (5U%% '
M+_\ "N/!?_0KZ5_X#+_A1_PKCP7_ -"OI7_@,O\ A7444 <O_P *X\%_]"OI
M7_@,O^%'_"N/!?\ T*^E?^ R_P"%=110!R__  KCP7_T*^E?^ R_X4?\*X\%
M_P#0KZ5_X#+_ (5U%% '+_\ "N/!?_0KZ5_X#+_A1_PKCP7_ -"OI7_@,O\
MA7444 <O_P *X\%_]"OI7_@,O^%'_"N/!?\ T*^E?^ R_P"%=110!R__  KC
MP7_T*^E?^ R_X4?\*X\%_P#0KZ5_X#+_ (5U%% '+_\ "N/!?_0KZ5_X#+_A
M1_PKCP7_ -"OI7_@,O\ A7444 <O_P *X\%_]"OI7_@,O^%'_"N/!?\ T*^E
M?^ R_P"%=110!R__  KCP7_T*^E?^ R_X4?\*X\%_P#0KZ5_X#+_ (5U%% '
M+_\ "N/!?_0KZ5_X#+_A1_PKCP7_ -"OI7_@,O\ A7444 <O_P *X\%_]"OI
M7_@,O^%'_"N/!?\ T*^E?^ R_P"%=110!R__  KCP7_T*^E?^ R_X4?\*X\%
M_P#0KZ5_X#+_ (5U%% '+_\ "N/!?_0KZ5_X#+_A1_PKCP7_ -"OI7_@,O\
MA7444 <O_P *X\%_]"OI7_@,O^%'_"N/!?\ T*^E?^ R_P"%=110!R__  KC
MP7_T*^E?^ R_X4?\*X\%_P#0KZ5_X#+_ (5U%% '+_\ "N/!?_0KZ5_X#+_A
M1_PKCP7_ -"OI7_@,O\ A7444 <O_P *X\%_]"OI7_@,O^%'_"N/!?\ T*^E
M?^ R_P"%=110!R__  KCP7_T*^E?^ R_X4?\*X\%_P#0KZ5_X#+_ (5U%% '
M+_\ "N/!?_0KZ5_X#+_A1_PKCP7_ -"OI7_@,O\ A7444 <O_P *X\%_]"OI
M7_@,O^%'_"N/!?\ T*^E?^ R_P"%=110!R__  KCP7_T*^E?^ R_X4?\*X\%
M_P#0KZ5_X#+_ (5U%% '+_\ "N/!?_0KZ5_X#+_A1_PKCP7_ -"OI7_@,O\
MA7444 <O_P *X\%_]"OI7_@,O^%'_"N/!?\ T*^E?^ R_P"%=110!R__  KC
MP7_T*^E?^ R_X4?\*X\%_P#0KZ5_X#+_ (5U%% '+_\ "N/!?_0KZ5_X#+_A
M1_PKCP7_ -"OI7_@,O\ A7444 <O_P *X\%_]"OI7_@,O^%'_"N/!?\ T*^E
M?^ R_P"%=110!R__  KCP7_T*^E?^ R_X4?\*X\%_P#0KZ5_X#+_ (5U%% '
M+_\ "N/!?_0KZ5_X#+_A1_PKCP7_ -"OI7_@,O\ A7444 <O_P *X\%_]"OI
M7_@,O^%'_"N/!?\ T*^E?^ R_P"%=110!R__  KCP7_T*^E?^ R_X4?\*X\%
M_P#0KZ5_X#+_ (5U%% '+_\ "N/!?_0KZ5_X#+_A1_PKCP7_ -"OI7_@,O\
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M\!E_PKJ** .7_P"%<>"_^A7TK_P&7_"C_A7'@O\ Z%?2O_ 9?\*ZBB@#E_\
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M_ 9?\*/^%<>"_P#H5]*_\!E_PKJ** .7_P"%<>"_^A7TK_P&7_"C_A7'@O\
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M '+_ /"N/!?_ $*^E?\ @,O^%'_"N/!?_0KZ5_X#+_A7444 <O\ \*X\%_\
M0KZ5_P" R_X4?\*X\%_]"OI7_@,O^%=110!R_P#PKCP7_P!"OI7_ (#+_A1_
MPKCP7_T*^E?^ R_X5U%% '+_ /"N/!?_ $*^E?\ @,O^%'_"N/!?_0KZ5_X#
M+_A7444 <O\ \*X\%_\ 0KZ5_P" R_X4?\*X\%_]"OI7_@,O^%=110!R_P#P
MKCP7_P!"OI7_ (#+_A1_PKCP7_T*^E?^ R_X5U%% '+_ /"N/!?_ $*^E?\
M@,O^%'_"N/!?_0KZ5_X#+_A7444 <O\ \*X\%_\ 0KZ5_P" R_X4?\*X\%_]
M"OI7_@,O^%=110!R_P#PKCP7_P!"OI7_ (#+_A1_PKCP7_T*^E?^ R_X5U%%
M '+_ /"N/!?_ $*^E?\ @,O^%'_"N/!?_0KZ5_X#+_A7444 <O\ \*X\%_\
M0KZ5_P" R_X4?\*X\%_]"OI7_@,O^%=110!R_P#PKCP7_P!"OI7_ (#+_A1_
MPKCP7_T*^E?^ R_X5U%% '+_ /"N/!?_ $*^E?\ @,O^%'_"N/!?_0KZ5_X#
M+_A7444 <O\ \*X\%_\ 0KZ5_P" R_X4?\*X\%_]"OI7_@,O^%=110!R_P#P
MKCP7_P!"OI7_ (#+_A1_PKCP7_T*^E?^ R_X5U%% '+_ /"N/!?_ $*^E?\
M@,O^%'_"N/!?_0KZ5_X#+_A7444 <O\ \*X\%_\ 0KZ5_P" R_X4?\*X\%_]
M"OI7_@,O^%=110!R_P#PKCP7_P!"OI7_ (#+_A1_PKCP7_T*^E?^ R_X5U%%
M '+_ /"N/!?_ $*^E?\ @,O^%'_"N/!?_0KZ5_X#+_A7444 <O\ \*X\%_\
M0KZ5_P" R_X4?\*X\%_]"OI7_@,O^%=110!R_P#PKCP7_P!"OI7_ (#+_A1_
MPKCP7_T*^E?^ R_X5U%% '+_ /"N/!?_ $*^E?\ @,O^%'_"N/!?_0KZ5_X#
M+_A7444 <O\ \*X\%_\ 0KZ5_P" R_X4?\*X\%_]"OI7_@,O^%=110!R_P#P
MKCP7_P!"OI7_ (#+_A1_PKCP7_T*^E?^ R_X5U%% '+_ /"N/!?_ $*^E?\
M@,O^%'_"N/!?_0KZ5_X#+_A7444 <O\ \*X\%_\ 0KZ5_P" R_X4?\*X\%_]
M"OI7_@,O^%=110!R_P#PKCP7_P!"OI7_ (#+_A1_PKCP7_T*^E?^ R_X5U%%
M '+_ /"N/!?_ $*^E?\ @,O^%'_"N/!?_0KZ5_X#+_A7444 <O\ \*X\%_\
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M_P#1\5?2=?-GP'_Y*WKW_7E<?^CXJ^DZ "BBB@ HHHH **** "BBB@ HHHH
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M@[Q%_P!=8/Y/7K_BS_D3=<_[!\__ *+:O(/V:/\ D'>(O^NL'\GH ]WHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KR3]HK_DG-K_V$XO_ $7)7K=>2?M%
M?\DYM?\ L)Q?^BY* .D^#_\ R2C0/^N3_P#HQZ[>N(^#_P#R2C0/^N3_ /HQ
MZ[>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^;/AK_ ,G%
M:U_U\7__ *,-?2=?-GPU_P"3BM:_Z^+_ /\ 1AKZ3H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /G#X>_\ )R>O_P#7WJ'_ *,:OH^OG#X>
M_P#)R>O_ /7WJ'_HQJ^CZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR-,S1&%@I8NS ;L8^[CO0![/7EOCWXVZ+X6\VQTGR]4U5>"$;]S"?]MAU/\
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MKQ3XP\4WFGZQ)'<VB6AF#I J>6P90!E1W!/!]/K7M<\T=M;R3S-MBC4N[>@
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M_%DXMM+U5#=GI;3J8I#] WWOPS0!UM%%<AHWQ-\*:]XB_L*PU!WU#+J(W@=
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MC.[!44$LS'  ]30 ZBO/=7^-G@;2+AH/[3>\D3(86<1D4'_>X4_@32Z-\:O
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-GPU_Y.*UK_KXO_\
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S9X!_Y.6UG_ *_=0_\
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M+/#_ /U[G_T-J .*^(?P3\.+X4O=0\.V365_9Q&8(LKNLRJ,E2&)YP#@CO\
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M.3\J9^S;K9#:UX?D;!&V\B4_]\/_ .TZY_7%_P"%A?M$K8C]Y9PW:VY'4>5
M,R?@2K_]]4 >X^ =)B\'_#33+>Y_=>1:&YNB1]UF!=\_3)'X5X+H=C?_ !P^
M)MS<ZG<2PZ; ID94/^IA!PD:=@3W/^\:^@OB+))'\-_$;1YW?V?,./0J0?TS
M7S3\+HO'TCZH? LT4;@1?:]XAR1\^S'F _[73\>U 'T.?A'X$:R%K_PCEL$
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M2YHM(NW$MM\UM,R@EXW7@,.A/)!XZC->M^"?@G;W<#:YX[\[4-5O#YK6TDK
M1YY^<@@LWJ,X'3FN&^/H ^*5O@=;*'/_ 'V]?4= 'R[\9_AMI_@F6PU70A)#
M8W+F)H6D+>3(!E=K$YP0#U/!'OQ[U\.==G\2?#W1M4N3NN)8-DK9^\R,4+'W
M)7/XUP_[1P'_  K[3SCG^U8^?^V4M;OP._Y)+I'^_/\ ^CGH \S_ &E/^1AT
M/_KT?_T.MGP'\(CXG3_A*O'LD]Y<WP$L5HTA3Y".&<K@CC&%!  QGT&-^TI_
MR,.A_P#7H_\ Z'7O?AK_ )%;2/\ KRA_] % '@7QH^%>D>&-)@U[P_"UM;^:
M(;BV,C.HW9VNI8DCD8(SW&,<U2\#^&?$7Q=^Q'7]2G'AW1T%NA7@N0!\J^K8
MQECDXQ7JWQU /PHU'(Z308_[^+69^SK_ ,DYNO\ L)R_^BXZ #Q=\#?"LWAB
MZ;0[%[+4K>%GA=9W<2,H)VL&)'/3(P1^&*Y/]F_7KC^T=6\/.Y:W:'[9&"?N
M,&5&Q]=R_P#?-?0Y (((R#U!KY<_9U_Y*-=?]@R7_P!&1T ?4=?,/[15L+?Q
M_874>5:;3T)(_O*[C/Y8KZ>KYL_:2=3XIT9,?,+)B3[%SC^1H ^AM'NVO]$L
M+UL;KBVCE./5E!_K5VL;PBC1^"M!1_O+IUN#]?+6MF@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\6?\B;KG_8/
MG_\ 1;5Y!^S1_P @[Q%_UU@_D]>O^+/^1-US_L'S_P#HMJ\@_9H_Y!WB+_KK
M!_)Z /=Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y<_:*_Y*-:
M_P#8,B_]&25]-V'_ "#K;_KDG\A7S)^T5_R4:U_[!D7_ *,DKZ;L/^0=;?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /FSP#_R<MK/_ %^ZA_Z&]%'@'_DY;6?^OW4/_0WHH /@
M/_R5O7O^O*X_]'Q5])U\V? ?_DK>O?\ 7E<?^CXJ^DZ "BBB@ HHHH ****
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M:5/>R6@BN5N%E1 WS!67!!QQAS5GP1X3A\%>&(-$ANGNEB=W,KJ%)+'/0=*
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M;.TFU"2R-K*9%=(P^<C!!!(_G6YX7T&+PQX:L-%AG>>.TCV"1P 6Y)S@=.M
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M>%_@)X=\/ZC;:C=WEWJ5U;R++&'Q'&&4Y!VCDX('4X]J /5Z^7/A'_R76?\
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MKFVULYI3-;WISM5CP0_MQPW8YSZCW36/&GAW0]&DU2[U:T-NJ%D$<RNTOH$
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M_HN2O6Z\D_:*_P"2<VO_ &$XO_1<E '2?!__ ))1H'_7)_\ T8]=O7$?!_\
MY)1H'_7)_P#T8]=O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH ^;/ /\ R<MK/_7[J'_H;T4> ?\
MDY;6?^OW4/\ T-Z* #X#_P#)6]>_Z\KC_P!'Q5])U\V? ?\ Y*WKW_7E<?\
MH^*OI.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S;XM_#.7Q]86EQI\
M\4.IV6X()<A)4;&5)&<$$9!]SZY'G6F:Y\9O UK'I1T"?4K:W'EPA[1KD*HZ
M /$<X],GCI[5]'44 ?.U]K?QJ\:6KZ='H<NF03C;(4MC:Y4\$%I6R!]#FN_^
M%/PL3P%!-?7TT=SK%R@1VC^Y"F<[%)Y.2 2?8?CZ510 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ^;/AK_R<5K7_7Q?_P#HPU])U\V?#7_DXK6O^OB__P#1AKZ3H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G#X>_P#)R>O_ /7W
MJ'_HQJ^CZ^</A[_R<GK_ /U]ZA_Z,:OH^@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ^;/ /_)RVL_]?NH?^AO11X!_Y.6UG_K]U#_T-Z*
M#X#_ /)6]>_Z\KC_ -'Q5])U\V? ?_DK>O?]>5Q_Z/BKZ3H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YL^&O_)Q6M?\
M7Q?_ /HPU])U\V?#7_DXK6O^OB__ /1AKZ3H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** /G#X>_\G)Z_P#]?>H?^C&KZ/KYP^'O_)R>O_\
M7WJ'_HQJ^CZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR^_\$LG^%'_"POC3_P!"Y??^"63_  KZ/HH ^</^%A?&G_H7+[_P2R?X4?\
M"POC3_T+E]_X)9/\*^CZ* /G#_A87QI_Z%R^_P#!+)_A1_PL+XT_]"Y??^"6
M3_"OH^B@#YP_X6%\:?\ H7+[_P $LG^%'_"POC3_ -"Y??\ @ED_PKZ/HH ^
M</\ A87QI_Z%R^_\$LG^%'_"POC3_P!"Y??^"63_  KZ/HH ^</^%A?&G_H7
M+[_P2R?X4?\ "POC3_T+E]_X)9/\*^CZ* /G#_A87QI_Z%R^_P#!+)_A1_PL
M+XT_]"Y??^"63_"OH^B@#YP_X6%\:?\ H7+[_P $LG^%'_"POC3_ -"Y??\
M@ED_PKZ/HH ^</\ A87QI_Z%R^_\$LG^%'_"POC3_P!"Y??^"63_  KZ/HH
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MR^_\$LG^%'_"POC3_P!"Y??^"63_  KZ/HH ^</^%A?&G_H7+[_P2R?X4?\
M"POC3_T+E]_X)9/\*^CZ* /G#_A87QI_Z%R^_P#!+)_A1_PL+XT_]"Y??^"6
M3_"OH^B@#YP_X6%\:?\ H7+[_P $LG^%'_"POC3_ -"Y??\ @ED_PKZ/HH ^
M</\ A87QI_Z%R^_\$LG^%'_"POC3_P!"Y??^"63_  KZ/HH ^</^%A?&G_H7
M+[_P2R?X4?\ "POC3_T+E]_X)9/\*^CZ* /G#_A87QI_Z%R^_P#!+)_A1_PL
M+XT_]"Y??^"63_"OH^B@#YP_X6%\:?\ H7+[_P $LG^%'_"POC3_ -"Y??\
M@ED_PKZ/HH ^</\ A87QI_Z%R^_\$LG^%'_"POC3_P!"Y??^"63_  KZ/HH
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MR^_\$LG^%'_"POC3_P!"Y??^"63_  KZ/HH ^</^%A?&G_H7+[_P2R?X4?\
M"POC3_T+E]_X)9/\*^CZ* /G#_A87QI_Z%R^_P#!+)_A1_PL+XT_]"Y??^"6
M3_"OH^B@#YP_X6%\:?\ H7+[_P $LG^%'_"POC3_ -"Y??\ @ED_PKZ/HH ^
M</\ A87QI_Z%R^_\$LG^%'_"POC3_P!"Y??^"63_  KZ/HH ^</^%A?&G_H7
M+[_P2R?X4?\ "POC3_T+E]_X)9/\*^CZ* /G#_A87QI_Z%R^_P#!+)_A1_PL
M+XT_]"Y??^"63_"OH^B@#YP_X6%\:?\ H7+[_P $LG^%'_"POC3_ -"Y??\
M@ED_PKZ/HH ^</\ A87QI_Z%R^_\$LG^%'_"POC3_P!"Y??^"63_  KZ/HH
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MED_PKZ/HH ^</^%A?&G_ *%R^_\ !+)_A1_PL+XT_P#0N7W_ ()9/\*^CZ*
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MED_PKZ/HH ^</^%A?&G_ *%R^_\ !+)_A1_PL+XT_P#0N7W_ ()9/\*^CZ*
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M_@ED_P */^%A?&G_ *%R^_\ !+)_A7T?10!\X?\ "POC3_T+E]_X)9/\*/\
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M&G_H7+[_ ,$LG^%?1]% 'SA_PL+XT_\ 0N7W_@ED_P */^%A?&G_ *%R^_\
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M_@ED_P */^%A?&G_ *%R^_\ !+)_A7T?10!\X?\ "POC3_T+E]_X)9/\*/\
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M1]% 'SA_PL+XT_\ 0N7W_@ED_P */^%A?&G_ *%R^_\ !+)_A7T?10!\X?\
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M1]% 'SA_PL+XT_\ 0N7W_@ED_P */^%A?&G_ *%R^_\ !+)_A7T?10!\X?\
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M1110 4444 ?-GPU_Y.*UK_KXO_\ T8:^DZ^;/AK_ ,G%:U_U\7__ *,-?2=
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\X?#W_ ).3U_\
MZ^]0_P#1C5]'U\X?#W_DY/7_ /K[U#_T8U?1] !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!\V> ?^3EM9_Z_=0_]#>BCP#_ ,G+:S_U^ZA_
MZ&]% !\!_P#DK>O?]>5Q_P"CXJ^DZ^;/@/\ \E;U[_KRN/\ T?%7TG0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445\]_#+7-6\0?'+
M6'DU.]DL8S=S+;M.QC">8%4;<XP-PQ]* /H2BN'^+^JSZ/\ ##5[FTGD@N6$
M<4<D;%6!:10<$<CY=U9GP*FO[KX<B[U"\N;J2>\E97N)6D(4;5P"3TRI_,T
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MN/NF@#O**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH P?%/C'1/!MG#=:W=-!'._EQ[8F<L<9/"@]JT=(U:RUW2;;4].
MF\ZTN4WQ2;2N1]#R*\=_:4_Y%[0_^OM__0*[SX2_\DL\/_\ 7N?_ $-J .SH
MHHH **** ,KQ#XCTOPKI#ZIJ]P8+1&"%@C.<DX P 32>'/$NE>*])74]'N#/
M:LY3<49"&'488 UPWQ]_Y)?/_P!?</\ ,U'^S]_R3(?]?LO_ ++0!ZG1110
M4444 %%%% !1110 5Q7C/XHZ#X'U.TT[48;ZXNKE/,6.TC5RJYP"=S#J0<8S
MT-=HS*BEF("@9))X KYD\(EOB;\>I=7N 7LK61KM5(X$<9"Q#\]A/KS0!]-J
M=R@X(R,X/:EHHH **** "BBB@ HHHH **** "BBB@ K&\4^);3PCX>N-:OH+
MF:V@*AUMD#/\S!0<$@8R1WK9JEK&EVVMZ->:7=KNM[N%H7]0&&,CW'6@#/\
M"/BW3/&FA)J^E>:("[1M', 'C8=0P!(Z$'KT(K=KYP^!6KW'ASQ]JO@^]? G
M:10I[3PDYQ]5#?\ ?(KZ/H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH Q_%G_ ")NN?\ 8/G_ /1;5Y!^S1_R#O$7
M_76#^3UZ_P"+/^1-US_L'S_^BVKR#]FC_D'>(O\ KK!_)Z /=Z*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBO./B!\8=%\%F6PMP-0UA1C[/&V$B/\
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M_P G)Z__ -?>H?\ HQJ^CZ^</A[_ ,G)Z_\ ]?>H?^C&KZ/H **** "BBB@
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MDX]AZ5-\!M0NK[X90K=.SBUN9((BQS^[&T@?0;B/PH YW]I3_D7M#_Z^W_\
M0*IZ/\8-)\$_#/0--MH#J6K_ &;)MT?:D66;&]N>>^T#/TR*N?M*?\B]H?\
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MYTG4H1);SK@''*-V93V(- &=X(\<:5X[T7^T-.+1R1D)<6TA&^%O?U!['O\
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MX2_\DL\/_P#7N?\ T-JX/]I3_D7M#_Z^W_\ 0*[SX2_\DL\/_P#7N?\ T-J
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M@[Q%_P!=8/Y/7K_BS_D3=<_[!\__ *+:O(/V:/\ D'>(O^NL'\GH ]WHHHH
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MQ^1$>G4A0&^A)YKU;X(ZIX"CMY=/T(W$.LRC,W]H;?.F &<(5X*CG@<]R.]
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M$E?4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKZKKY4_:!_Y*:?\ KRB_]FKZKH Y?XCZL^A_#K7;^)MLJ6K1HP/W6<A ?P+
MUY%^S;HT4EWK>M2(#)"L=M"3VW99_P#T%?UKO_CHQ7X3ZF!T:6 '_OZI_I7.
M?LW(!X1U=^YO\'\(U_QH ]IKYF_:,TF.T\8:=J<:;3?6I60C^)XSC/UVLH_
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MB]H?_7V__H%=Y\)?^26>'_\ KW/_ *&U '1Z[_R+VI_]>DO_ * :^?/V;?\
MD:=9_P"O)?\ T,5]!Z[_ ,B]J?\ UZ2_^@&OGS]FW_D:=9_Z\E_]#% 'L_Q.
M_P"29>(O^O)Z\P_9G_X]_$O^_;?RDKV3Q5IDFL^$=8TR)0TMU930Q@_WV0A?
MUQ7S)\)?B!;_  ZUG4[;6;6X^S785)?+3,D4D9;&5../F8'OTH ^LJ*X[P1\
M1])\?7&I1Z3;W<:6(CW/<(J[]^[& "?[IZUV- !7RQ\6\1_'0.YPOF6C9]L+
M_A7U/7SM^T3X6N(M4L?%%M&[021BVN&4?ZMU)*,?3(./^ ^] 'T37EG[0/\
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M+K/_ +]W_P"S4 ?4=?+GQ^_Y*E;?]>4/_H;U]1U\N?'[_DJ5M_UY0_\ H;T
M?4=>0?M'?\D]L/\ L*Q_^BI:]?KR#]H[_DGMA_V%8_\ T5+0!N? [_DDND?[
M\_\ Z.>O,_VE/^1AT/\ Z]'_ /0Z],^!W_))=(_WY_\ T<]>9_M*?\C#H?\
MUZ/_ .AT >]^&O\ D5M(_P"O*'_T 5QGQU_Y)1J/_76#_P!&+79^&O\ D5M(
M_P"O*'_T 5QGQU_Y)1J/_76#_P!&+0!E_LZ_\DYNO^PG+_Z+CKUNO)/V=?\
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M_P DHT#_ *Y/_P"C'KMZXCX/_P#)*- _ZY/_ .C'KMZ "BBB@ HHHH ****
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MQ[=J /0J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#YL^&O_ "<5K7_7Q?\ _HPU])U\V?#7_DXK6O\
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M2LD=C$74]0Q4$C\R:Z*@  8 P** "BBB@ HHHH **** "BBB@ HHHH ****
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M'+;L*65<_P"Z#C'MC%4/A1\/;WX?Z;J$%]>V]S)=RJX\@-A0H(ZG&>OI7H5
M$%E96FG6D=I8VT-M;1C"10H$51[ <"IZ** *NH:;8ZK:-::C9P7=L_WHIXPZ
MG\#7*-\(O 3R%SX;MLDYX>0#\@V*[6B@#(T?PMH'A_)TG1[*S<C!>&%5<CW;
MJ?SK7HHH P]/\'>'-*U>35;#1K2WOY-VZ>./#?-UQZ9]JW*** "BBB@#,UOP
M[H_B.VCM]9TZ"]BC;>BRKG:>F1Z5;L;"TTRQALK&WCM[6%=L<4:X51["K%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^*OI.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_%G_(FZY_V#
MY_\ T6U>0?LT?\@[Q%_UU@_D]>O^+/\ D3=<_P"P?/\ ^BVKR#]FC_D'>(O^
MNL'\GH ]WHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR3]HK_ ))S:_\
M83B_]%R5ZW7DG[17_).;7_L)Q?\ HN2@#I/@_P#\DHT#_KD__HQZ[>N(^#__
M "2C0/\ KD__ *,>NWH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /FSX:_\G%:U_P!?%_\ ^C#7TG7S9\-?^3BM:_Z^+_\ ]&&OI.@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^</A[_R<GK_ /U]ZA_Z
M,:OH^OG#X>_\G)Z__P!?>H?^C&KZ/H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&2Q_[^S?_$T ?1]%?.'_  S[XO\ ^ADL?^_LW_Q-'_#/OB__ *&2Q_[^S?\
MQ- 'T?17SA_PS[XO_P"ADL?^_LW_ ,31_P ,^^+_ /H9+'_O[-_\30!]'T5\
MX?\ #/OB_P#Z&2Q_[^S?_$T?\,^^+_\ H9+'_O[-_P#$T ?1]%?.'_#/OB__
M *&2Q_[^S?\ Q-'_  S[XO\ ^ADL?^_LW_Q- 'T?17SA_P ,^^+_ /H9+'_O
M[-_\31_PS[XO_P"ADL?^_LW_ ,30!]'T5\X?\,^^+_\ H9+'_O[-_P#$T?\
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M_P ,^^+_ /H9+'_O[-_\31_PS[XO_P"ADL?^_LW_ ,30!]'T5\X?\,^^+_\
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M\,^^+_\ H9+'_O[-_P#$T?\ #/OB_P#Z&2Q_[^S?_$T ?1]%?.'_  S[XO\
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M_LW_ ,30!]'T5\X?\,^^+_\ H9+'_O[-_P#$T?\ #/OB_P#Z&2Q_[^S?_$T
M?1]%?.'_  S[XO\ ^ADL?^_LW_Q-'_#/OB__ *&2Q_[^S?\ Q- 'T?17SA_P
MS[XO_P"ADL?^_LW_ ,31_P ,^^+_ /H9+'_O[-_\30!]'T5\X?\ #/OB_P#Z
M&2Q_[^S?_$T?\,^^+_\ H9+'_O[-_P#$T ?1]%?.'_#/OB__ *&2Q_[^S?\
MQ-'_  S[XO\ ^ADL?^_LW_Q- 'T?17SA_P ,^^+_ /H9+'_O[-_\31_PS[XO
M_P"ADL?^_LW_ ,30!]'T5\X?\,^^+_\ H9+'_O[-_P#$T?\ #/OB_P#Z&2Q_
M[^S?_$T ?1]%?.'_  S[XO\ ^ADL?^_LW_Q-'_#/OB__ *&2Q_[^S?\ Q- '
MT?17SA_PS[XO_P"ADL?^_LW_ ,31_P ,^^+_ /H9+'_O[-_\30!]'T5\X?\
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M??%__0R6/_?V;_XF@#Z/HKYP_P"&??%__0R6/_?V;_XFC_AGWQ?_ -#)8_\
M?V;_ .)H ^CZ*^</^&??%_\ T,EC_P!_9O\ XFC_ (9]\7_]#)8_]_9O_B:
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MZ/HKYP_X9]\7_P#0R6/_ ']F_P#B:/\ AGWQ?_T,EC_W]F_^)H ^CZ*^</\
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MZ/HKYP_X9]\7_P#0R6/_ ']F_P#B:/\ AGWQ?_T,EC_W]F_^)H ^CZ*^</\
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M/_?V;_XFC_AGWQ?_ -#)8_\ ?V;_ .)H ^CZ*^</^&??%_\ T,EC_P!_9O\
MXFC_ (9]\7_]#)8_]_9O_B: /H^BOG#_ (9]\7_]#)8_]_9O_B:/^&??%_\
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M,^^+_P#H9+'_ +^S?_$T?\,^^+_^ADL?^_LW_P 30!'X!_Y.6UG_ *_=0_\
M0WHK)^$FESZ7\=!I\\RR36$EW#*ZDX=E5T)&>>3SS10!K? ?_DK>O?\ 7E<?
M^CXJ^DZ^;/@/_P E;U[_ *\KC_T?%7TG0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 8_BS_ )$W7/\ L'S_ /HMJ\@_9H_Y!WB+_KK!_)Z]?\6?
M\B;KG_8/G_\ 1;5Y!^S1_P @[Q%_UU@_D] 'N]%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>2?M%?\DYM?^PG%_Z+DKUNO)/VBO\ DG-K_P!A.+_T7)0!
MTGP?_P"24:!_UR?_ -&/7;UQ'P?_ .24:!_UR?\ ]&/7;T %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'S9\-?\ DXK6O^OB_P#_ $8:^DZ^
M;/AK_P G%:U_U\7_ /Z,-?2= !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI>MVEU=,I98D?YB!UQGK0!T-%%% !1110 4444 %%%% !1110 4444 %%%%
M!7DG[17_ "3FU_["<7_HN2O6Z\D_:*_Y)S:_]A.+_P!%R4 =)\'_ /DE&@?]
M<G_]&/7;UQ'P?_Y)1H'_ %R?_P!&/7;T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114<T\5M \\\J10QJ
M6>21@JJ!U))Z"@"2BN>T3QUX8\1ZC)8:1K%O=W4:EVCCW?=!P2"1@CD=*Z&@
M HHJ.:>*V@>>>5(H8U+/)(P55 ZDD]!0!)17/:)XZ\,>(]1DL-(UBWN[J-2[
M1Q[ON@X)!(P1R.E=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'S9\-?^3BM:_P"OB_\ _1AKZ3KY
ML^&O_)Q6M?\ 7Q?_ /HPU])T %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 45S6J?$#PGHNIC3=1UVT
M@O,@&+)8J?1L A3]<5TM !115/4M5T_1K-KO4[VWL[=>LD\@1<^F3W]J +E%
M<-_PN/P!YWE?\)'%NQG/D2[?SV8KKM-U33]8LUO--O;>\MFZ2P2!USZ9'?VH
M MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[-))!\ZR2MA51,?>(YY'][VKVSX;^')O"O@#2M*N0!=)&9)QZ.[%ROX9Q^%
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MX^_\DOG_ .ON'^9H C_9^_Y)D/\ K]E_]EKU.O+/V?O^29#_ *_9?_9:\_\
M$/C3Q1X'^-$D.HZU>S:0MX)3!)(3&;:0YP%Z?*"0/=: /I.BD5@RAE(*D9!'
M>O//C/XMN/"G@5VL+AH-0O9EMX)$.&0?>9A^ QG_ &A0!Z)17FWP2GUV_P#
M[:IKNHW-Z]Y<,UN;ARQ6-?EX)YY8-^E>;:Q\2]6\,_&O46OM3OYM&M)Y0;%)
M,HP\HA5"]!\VWGMUH ^DJ*^</+^+?Q1A?5[.Y?2]+;)MH4N6MD<>V/F?_>;C
M/3VS/#_Q&\9?#KQ>-(\67%W<V:R!+J&[<RNBG_EI&YR2 .0 <'Z\@ ^HJ*\
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M!V.17!:7X,^,'B&QBUQ=<OH#*/,A2?4I(W93R"%'"@^AQ0!Z/^T#_P DR/\
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MKSGCG/ ![_117RYHGQ>UGPYXNUZ?5;^]U*!4GCM;224F/S?-&W_=  ;IVXH
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MI7W3Z7,8<$\^6WS(?U8?\!KU2OF;]G/4C:^--2TUR56[L]P'J\;#'Z,U?3-
M!1110 4444 8_BS_ )$W7/\ L'S_ /HMJ\@_9H_Y!WB+_KK!_)Z]?\6?\B;K
MG_8/G_\ 1;5Y!^S1_P @[Q%_UU@_D] 'N]%%% !1110 4444 %%%% !1110
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MY.*UK_KXO_\ T8:^DZ^;/AK_ ,G%:U_U\7__ *,-?2= !1110 4444 %%%%
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M*** "BBB@ HHHH **** "BBB@#YP^'O_ "<GK_\ U]ZA_P"C&KZ/KYP^'O\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^;/ /_ "<MK/\
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M1>U/_KTE_P#0#7SY^S;_ ,C3K/\ UY+_ .AB@#V?XG?\DR\1?]>3UYA^S/\
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MY.='_887^0H ^H8XTBC6.-%1$ 5548  Z "OG/\ :3M(H]?T.[50)9;:2-F
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M.!)M.P_@V#^%8?[--XXN_$-B22C1PS =@06!_/(_*O7/^%<>"_\ H5]*_P#
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M@E(TGPDT7<<[3.H^GG/7H->>? [_ ))+I'^_/_Z.>O07=8HVD<A44%F)[ 4
M?*OP@_T;XWQ0+@J7NH^/0(Y_I7U97RK\#(VO_BV+L*2(X+B=O8'Y?YN*^JJ
M"BBB@ HHHH Q_%G_ ")NN?\ 8/G_ /1;5Y!^S1_R#O$7_76#^3UZ_P"+/^1-
MUS_L'S_^BVKR#]FC_D'>(O\ KK!_)Z /=Z*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#Y<_:*_Y*-:_]@R+_ -&25]-V'_(.MO\ KDG\A7S)^T5_
MR4:U_P"P9%_Z,DKZ;L/^0=;?]<D_D* +%>8ZK\"/">L:[?:M<W&J":\F>>2-
M)T"!V.21\F>I/?O7IU% 'C.J_LY>'9[5AI>J:A:7./E:8K*GX@!3^M>5^&]>
MUWX0_$"33;UW6VCG$=];[B8Y8SC]XH]=I# ]>Q[BOKJODSXVW,6J_%BZ@L0L
MLD:16S>6<[I,<CZ@D+^% 'UD"&4,I!!&01WI:@LX6M[&W@<Y:.-4)]2!BIZ
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SA\/?^3D]?\
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M^=:V\W)0GGS9,]6/4 ].IYQCW*@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /FSP#_ ,G+:S_U^ZA_
MZ&]%'@'_ ).6UG_K]U#_ -#>B@ ^ _\ R5O7O^O*X_\ 1\5?2=?-GP'_ .2M
MZ]_UY7'_ */BKZ3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \>_:%LM3U'PUI%II^GW=V/MC2R?9X6DVX0@9P#C[Q_6N_\  >FR:1X!
MT&QGB:*:*RB\V-QAD<J"P([$$FNBHH ^?-2T'6-6_:7BO7TJ]%A#=0R"X,#>
M4%CB4YW8QC<OKU-?0=%% 'D'Q8\,>-YO$MEXG\'7$VZWM!;R0V\VU^'9L[3P
MX.X#'/3I7&Q?%_XI:4/LM_X>2:91@M<Z;*CD^I"E1^0KZ1HH ^6K^U^*7Q;N
MK>&]T^>"P5@RB2$VULAZ;_FY8\G^\>>*]_\  ?@RS\"^&8M*MG\V4MYMQ.1@
MRR'J?8#  'H*Z:B@#AOB_;:O=_#;4H=%2XDN28]R6P)=H]XW  <GCKCMFN0_
M9[T[Q!I^G:TNK6U[;6;21?9H[I&3YL-O*ANWW,__ %J]HHH **** /*_C]I>
MH:MX"M(M.L;F\DCU*.1TMXC(RIY<HW$ 9QDC\ZT?@II][IGPSL[>_M)[6?SI
M7\J>,HV"QP<'GFO0Z* "OEO5/"OB'P%\8UU#1-%U"YLH[P7%N;:W=U>)_O1@
M@8X#,M?4E% %+68WFT/4(HD+R/;2*JJ,DDJ< 5X5^SYH.L:5XCUB;4=*OK.(
MVHC#W%N\8+;P<#<!S7T%10!Y?\=[C0$\ F#63*;J27=IZ0D!S, >>?X0&^;Z
M^N*\H\#?#GXCZGX>34M#UI]'LIB6BC>^F@,H_O!4!X/J<9Z].:Z;]I+3+YYM
M$U14=["-)('8#(C<D$9]-P_]!KK/!GQF\&S^'-/M;Z^&F7=O D+PS1-MRJ@9
M5@"-O'?!H XJY\(_&S0[5KJ#7[F^\L%C''J#3-CV60<_3FNL^#WQ6O?&%U/H
M>N)&=2AB,L5Q&NT2J" P9>@89!XX(SP,<Z?B'XX^#M(T^5["^.J7@!$<%NC
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MGID DC/X?A6Q\,/A)J[^(5\6^,@XN%E,\-M,VZ627.1))Z8/('7/7&.?>J*
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MN?\ 8/G_ /1;5Y!^S1_R#O$7_76#^3T >[T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5Y)^T5_P DYM?^PG%_Z+DKUNO)/VBO^2<VO_83B_\ 1<E '2?!
M_P#Y)1H'_7)__1CUV]<1\'_^24:!_P!<G_\ 1CUV] !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!\V?#7_DXK6O^OB__ /1AKZ3KYL^&O_)Q
M6M?]?%__ .C#7TG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?.'P]_Y.3U_P#Z^]0_]&-7T?7SA\/?^3D]?_Z^]0_]&-7T?0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ?-G@'_DY;6?^OW4/_0WHH\ _
M\G+:S_U^ZA_Z&]% !\!_^2MZ]_UY7'_H^*OI.OFSX#_\E;U[_KRN/_1\5?2=
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C^+/^1-US_L'S_P#H
MMJ\@_9H_Y!WB+_KK!_)Z]?\ %G_(FZY_V#Y__1;5Y!^S1_R#O$7_ %U@_D]
M'N]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %>2?M%?\DYM?\ L)Q?^BY*
M];KR3]HK_DG-K_V$XO\ T7)0!TGP?_Y)1H'_ %R?_P!&/7;UQ'P?_P"24:!_
MUR?_ -&/7;T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S9
M\-?^3BM:_P"OB_\ _1AKZ3KYL^&O_)Q6M?\ 7Q?_ /HPU])T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'SA\/?^3D]?_Z^]0_]&-7T?7SA
M\/?^3D]?_P"OO4/_ $8U?1] !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!\V> ?^3EM9_P"OW4/_ $-Z*/ /_)RVL_\ 7[J'_H;T4 <%X3\/
M>)M?\5W]CX<NG@U"*.225UN3"2@=01N'7YBO%=S_ ,*N^+O_ $&)_P#P;/\
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M *#$_P#X-G_QKZ7HH ^:/^%7?%W_ *#$_P#X-G_QH_X5=\7?^@Q/_P"#9_\
M&OI>B@#YH_X5=\7?^@Q/_P"#9_\ &C_A5WQ=_P"@Q/\ ^#9_\:^EZ* /FC_A
M5WQ=_P"@Q/\ ^#9_\:/^%7?%W_H,3_\ @V?_ !KZ7HH ^:/^%7?%W_H,3_\
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M\:/^%7?%W_H,3_\ @V?_ !KZ7HH ^:/^%7?%W_H,3_\ @V?_ !H_X5=\7?\
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M5WQ=_P"@Q/\ ^#9_\:^EZ* /FC_A5WQ=_P"@Q/\ ^#9_\:/^%7?%W_H,3_\
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M=\7?^@Q/_P"#9_\ &C_A5WQ=_P"@Q/\ ^#9_\:^EZ* /FC_A5WQ=_P"@Q/\
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M)_\ P;/_ (T?\*N^+O\ T&)__!L_^-?2]% 'S1_PJ[XN_P#08G_\&S_XT?\
M"KOB[_T&)_\ P;/_ (U]+T4 ?-'_  J[XN_]!B?_ ,&S_P"-'_"KOB[_ -!B
M?_P;/_C7TO10!\T?\*N^+O\ T&)__!L_^-'_  J[XN_]!B?_ ,&S_P"-?2]%
M 'S1_P *N^+O_08G_P#!L_\ C1_PJ[XN_P#08G_\&S_XU]+T4 ?-'_"KOB[_
M -!B?_P;/_C1_P *N^+O_08G_P#!L_\ C7TO10!\T?\ "KOB[_T&)_\ P;/_
M (T?\*N^+O\ T&)__!L_^-?2]% 'S1_PJ[XN_P#08G_\&S_XT?\ "KOB[_T&
M)_\ P;/_ (U]+T4 ?-'_  J[XN_]!B?_ ,&S_P"-'_"KOB[_ -!B?_P;/_C7
MTO10!\T?\*N^+O\ T&)__!L_^-'_  J[XN_]!B?_ ,&S_P"-?2]% 'S1_P *
MN^+O_08G_P#!L_\ C1_PJ[XN_P#08G_\&S_XU]+T4 ?-'_"KOB[_ -!B?_P;
M/_C1_P *N^+O_08G_P#!L_\ C7TO10!\T?\ "KOB[_T&)_\ P;/_ (T?\*N^
M+O\ T&)__!L_^-?2]% 'S1_PJ[XN_P#08G_\&S_XT?\ "KOB[_T&)_\ P;/_
M (U]+T4 ?-'_  J[XN_]!B?_ ,&S_P"-'_"KOB[_ -!B?_P;/_C7TO10!\T?
M\*N^+O\ T&)__!L_^-<UXX\%^._#VAQWGB;4)+BQ:X6-4:^:8>80Q!VD^@;F
MOKRO)/VBO^2<VO\ V$XO_1<E 'EOACP!\2-7\.65_HNIRQ:=,I,"+J+1@ ,0
M?E!XY!K6_P"%7?%W_H,3_P#@V?\ QKV#X/\ _)*- _ZY/_Z,>NWH ^:/^%7?
M%W_H,3_^#9_\:/\ A5WQ=_Z#$_\ X-G_ ,:^EZ* /FC_ (5=\7?^@Q/_ .#9
M_P#&C_A5WQ=_Z#$__@V?_&OI>B@#YH_X5=\7?^@Q/_X-G_QH_P"%7?%W_H,3
M_P#@V?\ QKZ7HH ^:/\ A5WQ=_Z#$_\ X-G_ ,:/^%7?%W_H,3_^#9_\:^EZ
M* /FC_A5WQ=_Z#$__@V?_&C_ (5=\7?^@Q/_ .#9_P#&OI>B@#YH_P"%7?%W
M_H,3_P#@V?\ QH_X5=\7?^@Q/_X-G_QKZ7HH ^:/^%7?%W_H,3_^#9_\:/\
MA5WQ=_Z#$_\ X-G_ ,:^EZ* /FC_ (5=\7?^@Q/_ .#9_P#&C_A5WQ=_Z#$_
M_@V?_&OI>B@#YH_X5=\7?^@Q/_X-G_QH_P"%7?%W_H,3_P#@V?\ QKZ7HH ^
M:/\ A5WQ=_Z#$_\ X-G_ ,:/^%7?%W_H,3_^#9_\:^EZ* /FC_A5WQ=_Z#$_
M_@V?_&C_ (5=\7?^@Q/_ .#9_P#&OI>B@#YH_P"%7?%W_H,3_P#@V?\ QH_X
M5=\7?^@Q/_X-G_QKZ7HH ^:/^%7?%W_H,3_^#9_\:/\ A5WQ=_Z#$_\ X-G_
M ,:^EZ* /FC_ (5=\7?^@Q/_ .#9_P#&C_A5WQ=_Z#$__@V?_&OI>B@#YH_X
M5=\7?^@Q/_X-G_QH_P"%7?%W_H,3_P#@V?\ QKZ7HH ^:/\ A5WQ=_Z#$_\
MX-G_ ,:/^%7?%W_H,3_^#9_\:^EZ* /FC_A5WQ=_Z#$__@V?_&C_ (5=\7?^
M@Q/_ .#9_P#&OI>B@#YH_P"%7?%W_H,3_P#@V?\ QH_X5=\7?^@Q/_X-G_QK
MZ7HH ^:/^%7?%W_H,3_^#9_\:/\ A5WQ=_Z#$_\ X-G_ ,:^EZ* /FC_ (5=
M\7?^@Q/_ .#9_P#&C_A5WQ=_Z#$__@V?_&OI>B@#YH_X5=\7?^@Q/_X-G_QH
M_P"%7?%W_H,3_P#@V?\ QKZ7HH ^:/\ A5WQ=_Z#$_\ X-G_ ,:/^%7?%W_H
M,3_^#9_\:^EZ* /FC_A5WQ=_Z#$__@V?_&C_ (5=\7?^@Q/_ .#9_P#&OI>B
M@#YH_P"%7?%W_H,3_P#@V?\ QH_X5=\7?^@Q/_X-G_QKZ7HH ^:/^%7?%W_H
M,3_^#9_\:/\ A5WQ=_Z#$_\ X-G_ ,:^EZ* /FC_ (5=\7?^@Q/_ .#9_P#&
MC_A5WQ=_Z#$__@V?_&OI>B@#YH_X5=\7?^@Q/_X-G_QH_P"%7?%W_H,3_P#@
MV?\ QKZ7HH ^:/\ A5WQ=_Z#$_\ X-G_ ,:/^%7?%W_H,3_^#9_\:^EZ* /F
MC_A5WQ=_Z#$__@V?_&C_ (5=\7?^@Q/_ .#9_P#&OI>B@#YH_P"%7?%W_H,3
M_P#@V?\ QH_X5=\7?^@Q/_X-G_QKZ7HH ^:/^%7?%W_H,3_^#9_\:/\ A5WQ
M=_Z#$_\ X-G_ ,:^EZ* /BS0?#OB?4O'%WH^EW3QZY$\RS2BY*$LI(?YQR<G
M\Z[S_A5WQ=_Z#$__ (-G_P :D^&O_)Q6M?\ 7Q?_ /HPU])T ?-'_"KOB[_T
M&)__  ;/_C1_PJ[XN_\ 08G_ /!L_P#C7TO10!\T?\*N^+O_ $&)_P#P;/\
MXT?\*N^+O_08G_\ !L_^-?2]% 'S1_PJ[XN_]!B?_P &S_XT?\*N^+O_ $&)
M_P#P;/\ XU]+T4 ?-'_"KOB[_P!!B?\ \&S_ .-'_"KOB[_T&)__  ;/_C7T
MO10!\T?\*N^+O_08G_\ !L_^-'_"KOB[_P!!B?\ \&S_ .-?2]% 'S1_PJ[X
MN_\ 08G_ /!L_P#C1_PJ[XN_]!B?_P &S_XU]+T4 ?-'_"KOB[_T&)__  ;/
M_C1_PJ[XN_\ 08G_ /!L_P#C7TO10!\T?\*N^+O_ $&)_P#P;/\ XT?\*N^+
MO_08G_\ !L_^-?2]% 'S1_PJ[XN_]!B?_P &S_XT?\*N^+O_ $&)_P#P;/\
MXU]+T4 ?-'_"KOB[_P!!B?\ \&S_ .-'_"KOB[_T&)__  ;/_C7TO10!\T?\
M*N^+O_08G_\ !L_^-'_"KOB[_P!!B?\ \&S_ .-?2]% 'S1_PJ[XN_\ 08G_
M /!L_P#C1_PJ[XN_]!B?_P &S_XU]+T4 ?-'_"KOB[_T&)__  ;/_C1_PJ[X
MN_\ 08G_ /!L_P#C7TO10!\T?\*N^+O_ $&)_P#P;/\ XT?\*N^+O_08G_\
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M[XN_]!B?_P &S_XT?\*N^+O_ $&)_P#P;/\ XU]+T4 ?-'_"KOB[_P!!B?\
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M_!L_^-?2]% 'S1_PJ[XN_P#08G_\&S_XT?\ "KOB[_T&)_\ P;/_ (U]+T4
M?-'_  J[XN_]!B?_ ,&S_P"-'_"KOB[_ -!B?_P;/_C7TO10!\T?\*N^+O\
MT&)__!L_^-'_  J[XN_]!B?_ ,&S_P"-?2]% 'S1_P *N^+O_08G_P#!L_\
MC1_PJ[XN_P#08G_\&S_XU]+T4 ?-'_"KOB[_ -!B?_P;/_C1_P *N^+O_08G
M_P#!L_\ C7TO10!\T?\ "KOB[_T&)_\ P;/_ (T?\*N^+O\ T&)__!L_^-?2
M]% 'S1_PJ[XN_P#08G_\&S_XT?\ "KOB[_T&)_\ P;/_ (U]+T4 ?-'_  J[
MXN_]!B?_ ,&S_P"-'_"KOB[_ -!B?_P;/_C7TO10!\T?\*N^+O\ T&)__!L_
M^-'_  J[XN_]!B?_ ,&S_P"-?2]% 'S1_P *N^+O_08G_P#!L_\ C1_PJ[XN
M_P#08G_\&S_XU]+T4 ?-'_"KOB[_ -!B?_P;/_C1_P *N^+O_08G_P#!L_\
MC7TO10!\T?\ "KOB[_T&)_\ P;/_ (T?\*N^+O\ T&)__!L_^-?2]% 'S1_P
MJ[XN_P#08G_\&S_XT?\ "KOB[_T&)_\ P;/_ (U]+T4 ?-'_  J[XN_]!B?_
M ,&S_P"-'_"KOB[_ -!B?_P;/_C7TO10!\T?\*N^+O\ T&)__!L_^-'_  J[
MXN_]!B?_ ,&S_P"-?2]% 'S1_P *N^+O_08G_P#!L_\ C1_PJ[XN_P#08G_\
M&S_XU]+T4 ?-'_"KOB[_ -!B?_P;/_C1_P *N^+O_08G_P#!L_\ C7TO10!\
MT?\ "KOB[_T&)_\ P;/_ (T?\*N^+O\ T&)__!L_^-?2]% 'S1_PJ[XN_P#0
M8G_\&S_XT?\ "KOB[_T&)_\ P;/_ (U]+T4 ?-'_  J[XN_]!B?_ ,&S_P"-
M'_"KOB[_ -!B?_P;/_C7TO10!\T?\*N^+O\ T&)__!L_^-'_  J[XN_]!B?_
M ,&S_P"-?2]% 'S1_P *N^+O_08G_P#!L_\ C1_PJ[XN_P#08G_\&S_XU]+T
M4 ?-'_"KOB[_ -!B?_P;/_C1_P *N^+O_08G_P#!L_\ C7TO10!\T?\ "KOB
M[_T&)_\ P;/_ (T?\*N^+O\ T&)__!L_^-?2]% 'S1_PJ[XN_P#08G_\&S_X
MT?\ "KOB[_T&)_\ P;/_ (U]+T4 ?-'_  J[XN_]!B?_ ,&S_P"-'_"KOB[_
M -!B?_P;/_C7TO10!\T?\*N^+O\ T&)__!L_^-'_  J[XN_]!B?_ ,&S_P"-
M?2]% 'S1_P *N^+O_08G_P#!L_\ C1_PJ[XN_P#08G_\&S_XU]+T4 ?-'_"K
MOB[_ -!B?_P;/_C1_P *N^+O_08G_P#!L_\ C7TO10!\T?\ "KOB[_T&)_\
MP;/_ (T?\*N^+O\ T&)__!L_^-?2]% 'RK\(K*^L_CDEK?2%[RVDNX[IB^[<
MZJZL<_Q?-WHK7\ _\G+:S_U^ZA_Z&]% !\!_^2MZ]_UY7'_H^*OI.OFSX#_\
ME;U[_KRN/_1\5?2= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C
M^+/^1-US_L'S_P#HMJ\@_9H_Y!WB+_KK!_)Z]?\ %G_(FZY_V#Y__1;5Y!^S
M1_R#O$7_ %U@_D] 'N]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>2?M%
M?\DYM?\ L)Q?^BY*];KR3]HK_DG-K_V$XO\ T7)0!TGP?_Y)1H'_ %R?_P!&
M/7;UQ'P?_P"24:!_UR?_ -&/7;T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'S9\-?^3BM:_P"OB_\ _1AKZ3KYL^&O_)Q6M?\ 7Q?_ /HP
MU])T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SA\/?^3D]
M?_Z^]0_]&-7T?7SA\/?^3D]?_P"OO4/_ $8U?1] !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!\V> ?^3EM9_P"OW4/_ $-Z*/ /_)RVL_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<?\ DH5__P!@J3_T;%7T_0 4444 %%%% !1110 4444 %%%% !1110 4444
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MY.*UK_KXO_\ T8:^DZ^;/AK_ ,G%:U_U\7__ *,-?2= !1110 4444 %%%%
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M ^[=0F>WTVZFC.'CA=U..A )%?*OA7XQ^)K'Q1:WFN:W=W6FJ6-Q!L4[QM.
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MP;9^(1 LVIWX9FGD4$Q*&*A4]!QDGJ<_2N*_:/T6SL]6T;5K>%(Y[U)8[AE
M&\ILVD^IPQ&?84 >P?#GQK'X[\)Q:H8UANXW,-U$O19  <CO@@@CZXYQ76UX
M+^S/.S6OB2W/W4>W<?5A(#_Z"*]ZH *X+XF_$RT^'^G1(D2W6K7()M[<GY5
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MXWT2_P!VU8;V(N?]@L WZ$U]PU\#2J;>Z=!P8W('X&OO:&0301RCHZAA^(H
M?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 8_BS_ )$W7/\ L'S_ /HMJ\@_9H_Y!WB+_KK!_)Z]?\6?\B;KG_8/G_\
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MW5F/N22?QH UZ**1W6-&=V"HHRS,< #U- 'G?QQOK>T^%.IQ3D;[IX885/\
M$_F*WZ!6/X5S7[-]A-#X6U>^=2(KF[5(R?XMB\G\VQ^%<5\0_$5Y\6O'MGX<
M\.*9K&VD,<+C[LC?QS-_L@#CV&>^*^B/#'A^U\+>&['1;/F*UC"ER,%VZLQ]
MR23^- &O1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?-GPU_Y.*UK_KXO_\ T8:^DZ^;/AK_ ,G%:U_U
M\7__ *,-?2= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV9O^9H_[=/\ VM7O]>#?LUV=S;Q^)9)[>6*.0VP1G0J&(\W(!/7&1^8KWF@
MKXI^)%G)8_$KQ'%(,,U_+*/H[%Q^C"OM:O&/C1\*[SQ+,OB+08A+J$<8CN;8
M<&91T9?]H#C'< 8Y&" =I\*-4@U7X9:')"X8P6XMI!W5H_E(/Y _0BJ_QBU:
M'2?AAJ_FR;9+I!:Q+W9G."/^^=Q_"OF'1_$WBSP#>3PZ?=7>ES/_ *V"6$8)
M'&2C@C/7G%+>ZGXO^(NIQ)<27VL7*<1QQQY"9ZX50%7W.!T]J +WPET^34?B
MCH,<:D^5<>>Q] @+?TQ^-?1_QF_Y)+KW^Y%_Z.2L?X/?"^7P5:S:IJX0ZQ=(
M$\M3N%O'G)7/0L2!G''  ]]SXOV\UU\*M=AMX9)92D9"1J6) E0G@>P)H ^=
M_@E_R5[0O^WC_P!$25]?U\D_!2PO%^+&C2FTG$<8G+N8SA08) "3VY('XU];
M4 %%%% 'P+/_ ,?$O^^?YU]Y6'_(.MO^N2?R%?$-]X;URVU"XAETB_61)&5A
M]G?@Y^E:RZW\154*NJ>*0H& !<7& /SH ^IO'GCG3? ^@S7EU-&UZR$6MKN^
M>5^W'90>I_K@5\<6EK>Z_K<5M"IGOKZ<*H_O.[=_Q-=#I_@'QQXINQ*FC:E,
M\IYN;M613[EWQG\Z]^^%_P '[?P4XU75)8[S6F4JI09CMP>NW/)8]VX]!WR
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML4<F.F]0<4Z.*.)-D:*B^BC IU% !1110 4444 %%%% !1110 4444 %%%%
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M2236E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &/XL_Y$W7/^P?/_ .BVKR#]FC_D'>(O^NL'\GKU_P 6?\B;KG_8
M/G_]%M7D'[-'_(.\1?\ 76#^3T >[T444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5Y)^T5_R3FU_P"PG%_Z+DKUNO)/VBO^2<VO_83B_P#1<E '2?!__DE&
M@?\ 7)__ $8]=O7$?!__ ))1H'_7)_\ T8]=O0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ?-GPU_Y.*UK_ *^+_P#]&&OI.OFSX:_\G%:U
M_P!?%_\ ^C#7TG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ,6*-9&D6-0[?>8#D_6G
MT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!\X?#W_DY/7_\ K[U#_P!&-7T?7SA\/?\ DY/7_P#K
M[U#_ -&-7T?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-
MG@'_ ).6UG_K]U#_ -#>BCP#_P G+:S_ -?NH?\ H;T4 'P'_P"2MZ]_UY7'
M_H^*OI.OFSX#_P#)6]>_Z\KC_P!'Q5])T %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% &/XL_Y$W7/^P?/_Z+:O(/V:/^0=XB_P"NL'\GKU_Q9_R)
MNN?]@^?_ -%M7D'[-'_(.\1?]=8/Y/0![O1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7DG[17_).;7_L)Q?\ HN2O6Z\D_:*_Y)S:_P#83B_]%R4 =)\'
M_P#DE&@?]<G_ /1CUV]<1\'_ /DE&@?]<G_]&/7;T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% 'S9\-?^3BM:_Z^+__ -&&OI.OFSX:_P#)
MQ6M?]?%__P"C#7TG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 ?.'P]_P"3D]?_ .OO4/\ T8U?1]?.'P]_Y.3U_P#Z^]0_]&-7T?0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-G@'_DY;6?^OW4/_0W
MHH\ _P#)RVL_]?NH?^AO10!F?!_Q%I'A_P")FLWVK7\-I:RVL\:2R'AF,T9
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MP-_T,UC_ -]'_"N(_P"&;O#G_09U7\X__B:/^&;O#G_09U7\X_\ XF@#M_\
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M)H_X9N\.?]!G5?SC_P#B: .W_P"%J>!O^AFL?^^C_A1_PM3P-_T,UC_WT?\
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M_A1_PM3P-_T,UC_WT?\ "N(_X9N\.?\ 09U7\X__ (FC_AF[PY_T&=5_./\
M^)H [?\ X6IX&_Z&:Q_[Z/\ A1_PM3P-_P!#-8_]]'_"N(_X9N\.?]!G5?SC
M_P#B:/\ AF[PY_T&=5_./_XF@#M_^%J>!O\ H9K'_OH_X4?\+4\#?]#-8_\
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MP-_T,UC_ -]'_"N(_P"&;O#G_09U7\X__B:/^&;O#G_09U7\X_\ XF@#M_\
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M)H_X9N\.?]!G5?SC_P#B: .W_P"%J>!O^AFL?^^C_A1_PM3P-_T,UC_WT?\
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MPY_T&=5_./\ ^)H_X9N\.?\ 09U7\X__ (F@#M_^%J>!O^AFL?\ OH_X4?\
M"U/ W_0S6/\ WT?\*XC_ (9N\.?]!G5?SC_^)H_X9N\.?]!G5?SC_P#B: .W
M_P"%J>!O^AFL?^^C_A1_PM3P-_T,UC_WT?\ "N(_X9N\.?\ 09U7\X__ (FC
M_AF[PY_T&=5_./\ ^)H [?\ X6IX&_Z&:Q_[Z/\ A1_PM3P-_P!#-8_]]'_"
MN(_X9N\.?]!G5?SC_P#B:/\ AF[PY_T&=5_./_XF@#M_^%J>!O\ H9K'_OH_
MX4?\+4\#?]#-8_\ ?1_PKB/^&;O#G_09U7\X_P#XFC_AF[PY_P!!G5?SC_\
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MX9N\.?\ 09U7\X__ (FC_AF[PY_T&=5_./\ ^)H [?\ X6IX&_Z&:Q_[Z/\
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MC_A:G@;_ *&:Q_[Z/^%<1_PS=X<_Z#.J_G'_ /$T?\,W>'/^@SJOYQ__ !-
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M?\,W>'/^@SJOYQ__ !-'_#-WAS_H,ZK^<?\ \30!V_\ PM3P-_T,UC_WT?\
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M1_PH_P"%J>!O^AFL?^^C_A7$?\,W>'/^@SJOYQ__ !-'_#-WAS_H,ZK^<?\
M\30!V_\ PM3P-_T,UC_WT?\ "C_A:G@;_H9K'_OH_P"%<1_PS=X<_P"@SJOY
MQ_\ Q-'_  S=X<_Z#.J_G'_\30!V_P#PM3P-_P!#-8_]]'_"C_A:G@;_ *&:
MQ_[Z/^%<1_PS=X<_Z#.J_G'_ /$T?\,W>'/^@SJOYQ__ !- ';_\+4\#?]#-
M8_\ ?1_PH_X6IX&_Z&:Q_P"^C_A7$?\ #-WAS_H,ZK^<?_Q-'_#-WAS_ *#.
MJ_G'_P#$T >?^ _$>CZ;\<-5UB\U"&'3I9KQDN'/RL&<E?S%>[_\+4\#?]#-
M8_\ ?1_PKYQ\)^ K#Q!\4K_PK<75S':6TMRBRQ[=Y$;$#.1CG'I7J_\ PS=X
M<_Z#.J_G'_\ $T =O_PM3P-_T,UC_P!]'_"C_A:G@;_H9K'_ +Z/^%<1_P ,
MW>'/^@SJOYQ__$T?\,W>'/\ H,ZK^<?_ ,30!V__  M3P-_T,UC_ -]'_"C_
M (6IX&_Z&:Q_[Z/^%<1_PS=X<_Z#.J_G'_\ $T?\,W>'/^@SJOYQ_P#Q- ';
M_P#"U/ W_0S6/_?1_P */^%J>!O^AFL?^^C_ (5Q'_#-WAS_ *#.J_G'_P#$
MT?\ #-WAS_H,ZK^<?_Q- ';_ /"U/ W_ $,UC_WT?\*/^%J>!O\ H9K'_OH_
MX5Q'_#-WAS_H,ZK^<?\ \31_PS=X<_Z#.J_G'_\ $T =O_PM3P-_T,UC_P!]
M'_"C_A:G@;_H9K'_ +Z/^%<1_P ,W>'/^@SJOYQ__$T?\,W>'/\ H,ZK^<?_
M ,30!V__  M3P-_T,UC_ -]'_"C_ (6IX&_Z&:Q_[Z/^%<1_PS=X<_Z#.J_G
M'_\ $T?\,W>'/^@SJOYQ_P#Q- ';_P#"U/ W_0S6/_?1_P */^%J>!O^AFL?
M^^C_ (5Q'_#-WAS_ *#.J_G'_P#$T?\ #-WAS_H,ZK^<?_Q- ';_ /"U/ W_
M $,UC_WT?\*/^%J>!O\ H9K'_OH_X5Q'_#-WAS_H,ZK^<?\ \31_PS=X<_Z#
M.J_G'_\ $T =O_PM3P-_T,UC_P!]'_"C_A:G@;_H9K'_ +Z/^%<1_P ,W>'/
M^@SJOYQ__$T?\,W>'/\ H,ZK^<?_ ,30!V__  M3P-_T,UC_ -]'_"C_ (6I
MX&_Z&:Q_[Z/^%<1_PS=X<_Z#.J_G'_\ $T?\,W>'/^@SJOYQ_P#Q- ';_P#"
MU/ W_0S6/_?1_P */^%J>!O^AFL?^^C_ (5Q'_#-WAS_ *#.J_G'_P#$T?\
M#-WAS_H,ZK^<?_Q- ';_ /"U/ W_ $,UC_WT?\*/^%J>!O\ H9K'_OH_X5Q'
M_#-WAS_H,ZK^<?\ \31_PS=X<_Z#.J_G'_\ $T =O_PM3P-_T,UC_P!]'_"C
M_A:G@;_H9K'_ +Z/^%<1_P ,W>'/^@SJOYQ__$T?\,W>'/\ H,ZK^<?_ ,30
M!V__  M3P-_T,UC_ -]'_"C_ (6IX&_Z&:Q_[Z/^%<1_PS=X<_Z#.J_G'_\
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M?\*/^%J>!O\ H9K'_OH_X5Q'_#-WAS_H,ZK^<?\ \31_PS=X<_Z#.J_G'_\
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MJ_G'_P#$T?\ #-WAS_H,ZK^<?_Q- ';_ /"U/ W_ $,UC_WT?\*/^%J>!O\
MH9K'_OH_X5Q'_#-WAS_H,ZK^<?\ \31_PS=X<_Z#.J_G'_\ $T =O_PM3P-_
MT,UC_P!]'_"C_A:G@;_H9K'_ +Z/^%<1_P ,W>'/^@SJOYQ__$T?\,W>'/\
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MU/ W_0S6/_?1_P */^%J>!O^AFL?^^C_ (5Q'_#-WAS_ *#.J_G'_P#$T?\
M#-WAS_H,ZK^<?_Q- ';_ /"U/ W_ $,UC_WT?\*/^%J>!O\ H9K'_OH_X5Q'
M_#-WAS_H,ZK^<?\ \31_PS=X<_Z#.J_G'_\ $T =O_PM3P-_T,UC_P!]'_"C
M_A:G@;_H9K'_ +Z/^%<1_P ,W>'/^@SJOYQ__$T?\,W>'/\ H,ZK^<?_ ,30
M!V__  M3P-_T,UC_ -]'_"C_ (6IX&_Z&:Q_[Z/^%<1_PS=X<_Z#.J_G'_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /FSX:_\G%:U_P!?%_\ ^C#7TG7S9\-?^3BM:_Z^+_\ ]&&OI.@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^</A[_R<GK_ /U]
MZA_Z,:OH^OG#X>_\G)Z__P!?>H?^C&KZ/H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /FSP#_R<MK/_ %^ZA_Z&]%'@'_DY;6?^OW4/_0WH
MH /@/_R5O7O^O*X_]'Q5])U\V? ?_DK>O?\ 7E<?^CXJ^DZ "BBB@ HHKRB^
M_:$\'65]-;+;:M<B)RGFPP1[&QW&YP<?A0!ZO17D _:-\'D_\@[7!_VPB_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C^+/\ D3=<_P"P?/\
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ME79+'GU7T]P2/>@#I:**\S\6_&_PSX6U.338X[C4KN([9?LVWRXV[J6)ZCT
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MJ6)ZCT ..AP: /2Z*X#P3\7O#GC6\^P0>=8Z@1E;>ZVCS?78P)!QZ<'VKOZ
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M .2MZ]_UY7'_ */BKZ3H **** "O@6?_ (^)?]\_SK[ZKX%G_P"/B7_?/\Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;.WNH23'*JG*G&,C)]#7 Q?M'^%FDQ)I6KHG]X)&?TWUWGA3X@>&_&:L-'U
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M$OW.7GL87?\ WM@S^N:W* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /FSP#_ ,G+:S_U^ZA_Z&]%'@'_ ).6UG_K]U#_ -#>B@ ^ _\
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MGQ(\%V,!EE\4:4R@9Q#<K*W_ 'RA)K%\&_%C3?''B^\T72[&=;:WM6N%NY6
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M*UK_ *^+_P#]&&OI.OFSX:_\G%:U_P!?%_\ ^C#7TG0 4444 %%%% !1110
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M[MXYU'H'4,/YU<K.\/Z<VD>&M*TQR"UG9Q6Y([E$"_TK1H ^</VE/^1AT/\
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MWN4*3RHUPZD8(WL67/OM*ULW7C;PQ9:R-'N=<LHM0+!/(:4!@QZ ]@>G!]:
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M_P!F^2(^"=4B!'FKJ)9N>=IC3'\FKF_V@_\ 2/''ARTMR!=F#C'4;I,+^H-
M'T37@W[2X7[%X<)^]YEQCZ8CS_2O>:^>/VEKU7U+P]8@_/%#-,PSV<H!_P"@
M&@#U;X4EF^%WAXOU^RX_#<<?I78USO@*R?3OA_H%K(,.EA#O'HQ4$C\S714
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MB<CW5\ 'Z$_6OJ>B@#Y*LO@1X]NI0DVG6UFI.-\]W&0/?Y"Q_2O;/A?\)X?
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M7_L)Q?\ HN2@#I/@_P#\DHT#_KD__HQZ[>N(^#__ "2C0/\ KD__ *,>NWH
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M4Y=TF/\ GE&02/Q8K^1KK?A3X3/A'P'9VLT92]N?]*N@1R'8#Y?^ J%'U!H
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M /7WJ'_HQJ^CZ^</A[_R<GK_ /U]ZA_Z,:OH^@ HHHH **** "BBB@ HHHH
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M V2-98GC<95U*D>QKYVU'X$>+/#^H/>^#]=#*/N8F:WG ],CY3]<CZ5]%T4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 52O='TS4F#7VG6ET1T,\"O
M_,5=HH S[30='L)?-L])L;:3^_#;(A_,"M"BB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#'\6?\B;KG_8/G_P#1;5Y!^S1_R#O$7_76#^3UZ_XL_P"1-US_ +!\
M_P#Z+:O(/V:/^0=XB_ZZP?R>@#W>BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "O)/VBO\ DG-K_P!A.+_T7)7K=>2?M%?\DYM?^PG%_P"BY* .D^#_ /R2
MC0/^N3_^C'KMZXCX/_\ )*- _P"N3_\ HQZ[>@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ I-B[]^T;\8W8YQZ4M% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 UD5]NY0VTY&1G!]:=110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-GPU_
MY.*UK_KXO_\ T8:^DZ^;/AK_ ,G%:U_U\7__ *,-?2= !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !3719%VNH8=<$9IU% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 $ C!&12*JHH5%"J!
M@ # %+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?.'P]_Y.3U_P#Z^]0_]&-7T?7SA\/?^3D]?_Z^]0_]&-7T?0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4CHKKM=0R^A&12T4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !U&#2*BHH5%
M"J.  , 4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!\V> ?\ DY;6?^OW4/\ T-Z*/ /_ "<MK/\ U^ZA_P"AO10 ? ?_ )*W
MKW_7E<?^CXJ^DZ^+_"<OC"+Q7?MX2%R=5,<@G\A%9O+WKNR&&,;MM=S]L^._
M]W5?^_$/^% 'TO17S1]L^._]W5?^_$/^%'VSX[_W=5_[\0_X4 ?2]%?-'VSX
M[_W=5_[\0_X4?;/CO_=U7_OQ#_A0!]+T5\T?;/CO_=U7_OQ#_A1]L^._]W5?
M^_$/^% 'TO17S1]L^._]W5?^_$/^%'VSX[_W=5_[\0_X4 ?2]%?-'VSX[_W=
M5_[\0_X4?;/CO_=U7_OQ#_A0!]+T5\T?;/CO_=U7_OQ#_A1]L^._]W5?^_$/
M^% 'TO17S1]L^._]W5?^_$/^%'VSX[_W=5_[\0_X4 ?2]%?-'VSX[_W=5_[\
M0_X4?;/CO_=U7_OQ#_A0!]+T5\T?;/CO_=U7_OQ#_A1]L^._]W5?^_$/^% '
MTO17S1]L^._]W5?^_$/^%'VSX[_W=5_[\0_X4 ?2]%?-'VSX[_W=5_[\0_X4
M?;/CO_=U7_OQ#_A0!]+T5\T?;/CO_=U7_OQ#_A1]L^._]W5?^_$/^% 'TO17
MS1]L^._]W5?^_$/^%'VSX[_W=5_[\0_X4 ?2]%?-'VSX[_W=5_[\0_X4?;/C
MO_=U7_OQ#_A0!]+T5\T?;/CO_=U7_OQ#_A1]L^._]W5?^_$/^% 'TO17S1]L
M^._]W5?^_$/^%'VSX[_W=5_[\0_X4 ?2]%?-'VSX[_W=5_[\0_X4?;/CO_=U
M7_OQ#_A0!]+T5\T?;/CO_=U7_OQ#_A1]L^._]W5?^_$/^% 'TO17S1]L^._]
MW5?^_$/^%'VSX[_W=5_[\0_X4 ?2]%?-'VSX[_W=5_[\0_X4?;/CO_=U7_OQ
M#_A0!]+T5\T?;/CO_=U7_OQ#_A1]L^._]W5?^_$/^% 'TO17S1]L^._]W5?^
M_$/^%'VSX[_W=5_[\0_X4 ?2]%?-'VSX[_W=5_[\0_X4?;/CO_=U7_OQ#_A0
M!]+T5\T?;/CO_=U7_OQ#_A1]L^._]W5?^_$/^% 'TO17S1]L^._]W5?^_$/^
M%'VSX[_W=5_[\0_X4 ?2]%?-'VSX[_W=5_[\0_X4?;/CO_=U7_OQ#_A0!]+T
M5\T?;/CO_=U7_OQ#_A1]L^._]W5?^_$/^% 'TO17S1]L^._]W5?^_$/^%'VS
MX[_W=5_[\0_X4 ?2]%?-'VSX[_W=5_[\0_X4?;/CO_=U7_OQ#_A0!]+T5\T?
M;/CO_=U7_OQ#_A1]L^._]W5?^_$/^% 'TO17S1]L^._]W5?^_$/^%'VSX[_W
M=5_[\0_X4 ?2]%?-'VSX[_W=5_[\0_X4?;/CO_=U7_OQ#_A0!]+T5\T?;/CO
M_=U7_OQ#_A1]L^._]W5?^_$/^% 'TO17S1]L^._]W5?^_$/^%'VSX[_W=5_[
M\0_X4 ?2]%?-'VSX[_W=5_[\0_X4?;/CO_=U7_OQ#_A0!]+T5\T?;/CO_=U7
M_OQ#_A1]L^._]W5?^_$/^% 'TO17S1]L^._]W5?^_$/^%'VSX[_W=5_[\0_X
M4 ?2]%?-'VSX[_W=5_[\0_X4?;/CO_=U7_OQ#_A0!]+T5\T?;/CO_=U7_OQ#
M_A1]L^._]W5?^_$/^% 'TO17S1]L^._]W5?^_$/^%'VSX[_W=5_[\0_X4 ?2
M]%?-'VSX[_W=5_[\0_X4?;/CO_=U7_OQ#_A0!]+T5\T?;/CO_=U7_OQ#_A1]
ML^._]W5?^_$/^% 'TO17S1]L^._]W5?^_$/^%'VSX[_W=5_[\0_X4 ?2]%?-
M'VSX[_W=5_[\0_X4?;/CO_=U7_OQ#_A0!]+T5\T?;/CO_=U7_OQ#_A1]L^._
M]W5?^_$/^% 'TO17S1]L^._]W5?^_$/^%'VSX[_W=5_[\0_X4 ?2]%?-'VSX
M[_W=5_[\0_X4?;/CO_=U7_OQ#_A0!]+T5\T?;/CO_=U7_OQ#_A1]L^._]W5?
M^_$/^% 'TO17S1]L^._]W5?^_$/^%'VSX[_W=5_[\0_X4 ?2]%?-'VSX[_W=
M5_[\0_X4?;/CO_=U7_OQ#_A0!]+T5\T?;/CO_=U7_OQ#_A1]L^._]W5?^_$/
M^% 'TO17S1]L^._]W5?^_$/^%'VSX[_W=5_[\0_X4 ?2]%?-'VSX[_W=5_[\
M0_X4?;/CO_=U7_OQ#_A0!]+T5\T?;/CO_=U7_OQ#_A1]L^._]W5?^_$/^% '
MTO17S1]L^._]W5?^_$/^%'VSX[_W=5_[\0_X4 ?2]%?-'VSX[_W=5_[\0_X4
M?;/CO_=U7_OQ#_A0!]+T5\T?;/CO_=U7_OQ#_A1]L^._]W5?^_$/^% 'TO17
MS1]L^._]W5?^_$/^%'VSX[_W=5_[\0_X4 ?2]%?-'VSX[_W=5_[\0_X4?;/C
MO_=U7_OQ#_A0!]+T5\T?;/CO_=U7_OQ#_A1]L^._]W5?^_$/^% 'TO17S1]L
M^._]W5?^_$/^%'VSX[_W=5_[\0_X4 ?2]%?-'VSX[_W=5_[\0_X4?;/CO_=U
M7_OQ#_A0!]+T5\T?;/CO_=U7_OQ#_A1]L^._]W5?^_$/^% 'TO17S1]L^._]
MW5?^_$/^%'VSX[_W=5_[\0_X4 >_^+/^1-US_L'S_P#HMJ\@_9H_Y!WB+_KK
M!_)ZY74KOXV-I=V+]=3^Q&%Q<;H(@/+VG=G Z8S7,^ I_'\4%]_PA0NS&63[
M3]GC1N<';G</K0!]CT5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]
M+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_
M[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5
M_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\
MT?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_
MX4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_
M$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/
MCO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;
M/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\
MA0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\
MW=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_
M '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]
M+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_
M[\0_X4?;/CO_ '=5_P"_$/\ A0!]+UY)^T5_R3FU_P"PG%_Z+DK@_MGQW_NZ
MK_WXA_PKFO'%Q\3)=#C7Q@M\--^T*4\^*-5\W#8Y49SC=0!]"_!__DE&@?\
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M_A0!]+T5\T?;/CO_ '=5_P"_$/\ A1]L^._]W5?^_$/^% 'TO17S1]L^._\
M=U7_ +\0_P"%'VSX[_W=5_[\0_X4 ?2]%?-'VSX[_P!W5?\ OQ#_ (4?;/CO
M_=U7_OQ#_A0!]+T5\T?;/CO_ '=5_P"_$/\ A1]L^._]W5?^_$/^% 'TO17S
M1]L^._\ =U7_ +\0_P"%'VSX[_W=5_[\0_X4 ?2]%?-'VSX[_P!W5?\ OQ#_
M (4?;/CO_=U7_OQ#_A0!]+T5\T?;/CO_ '=5_P"_$/\ A1]L^._]W5?^_$/^
M% 'TO17S1]L^._\ =U7_ +\0_P"%'VSX[_W=5_[\0_X4 ?2]%?-'VSX[_P!W
M5?\ OQ#_ (4?;/CO_=U7_OQ#_A0!]+T5\T?;/CO_ '=5_P"_$/\ A1]L^._]
MW5?^_$/^% 'TO17S1]L^._\ =U7_ +\0_P"%'VSX[_W=5_[\0_X4 ?2]%?-'
MVSX[_P!W5?\ OQ#_ (4?;/CO_=U7_OQ#_A0!]+T5\T?;/CO_ '=5_P"_$/\
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M/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\
MA0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\
MW=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_
M '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]
M+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_
M[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5
M_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\
MT?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_
MX4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_
M$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/
MCO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;
M/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\
MA0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\
MW=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_
M '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]
M+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_
M[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5
M_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\
MT?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_
MX4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_
M$/\ A0!]+T5\T?;/CO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!]+T5\T?;/
MCO\ W=5_[\0_X4?;/CO_ '=5_P"_$/\ A0!)X!_Y.6UG_K]U#_T-Z*R/A$VI
M-\<D;4M_V\R79O=X /F;7WYQP#O]** -?X#_ /)6]>_Z\KC_ -'Q5])U\V?
M?_DK>O?]>5Q_Z/BKZ3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/_Z,>NWKB/@__P DHT#_ *Y/_P"C'KMZ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#YL^&O_)Q6M?\ 7Q?_ /HPU])U\V?#7_DXK6O^OB__
M /1AKZ3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G#X>_
M\G)Z_P#]?>H?^C&KZ/KYP^'O_)R>O_\ 7WJ'_HQJ^CZ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#YL\ _\G+:S_P!?NH?^AO11X!_Y.6UG
M_K]U#_T-Z* #X#_\E;U[_KRN/_1\5?2=?-GP'_Y*WKW_ %Y7'_H^*OI.@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7DG[17_).;7_L)Q?^BY*];KR3]HK_ ))S
M:_\ 83B_]%R4 =)\'_\ DE&@?]<G_P#1CUV]<1\'_P#DE&@?]<G_ /1CUV]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFW[1 #E2#T=3Z'!XZC\B=SQGXNL/!7AR?5[_ "X4[(85.&FD/11Z="2>P!-
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MFK3KNBMMVT(O3>Y[#/0=3@].M>&S_&SXBZG<.]E>) JC<8K6Q1U4?\"5C^M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>L_C;J0M-1\/^-]):QNIK62-)UA>)E9D(421MSR<<C\N] &?^S;_ ,C3K/\
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M3V*L!Z%R=WX?A4OA_P"/.NZ9KRZ7XUTN.)/,"2R+"T,L&?XF0]0/0 ''KTH
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MG##(/*]_PKR_P%\/M6^)FJ7LGV\0PP%6N;R?,C%FS@ 9RQ.">2.G7I72^/\
MX*P>"?",NM+KDEY)%)&AC-L(P=QQG.XXH @_9ZG>+XD21JQ"RV$JL/7#(?Z5
MW7[25E<S>'-&O(PQM[>Y=)<#@%U&TG_ODC\:X']G[_DIH_Z\I?\ V6OJ#4],
MLM9TZ?3]1MH[FTG7;)%(,AA_CGD'L: /F#X+?$#1/!5]J$.M0M''>[ MZB;S
M%MSE6 YVG(/'<=/3Z*C_ .$4\<V<5T@TW6(87#HX"R&)AR/=3[<5X_XJ_9S8
M&2Y\+:D".HL[SK]%D'Z CZFO'=.U+7? OB9I;:26QU*SE,<L9/!(/*,.C*<4
M ?:6N_\ (O:G_P!>DO\ Z :^*?"?_(Y:'_V$(/\ T8M?8XU)==\ G4XDVK>Z
M89U3.=N^/./PSBOC/P[.EKXGTFXD8+'%>0NS,<  ."2: /NNODCXZ_\ )5]1
M_P"N4'_HM:^MZ^0_C;=07?Q5U1K>9)518HV*'(#+&H(^H/!H ]]^"7_)(="_
M[>/_ $?)7SG\6O\ DJ?B#_KX'_H"U]&?!+_DD.A?]O'_ */DKYS^+7_)4_$'
M_7P/_0%H ]2^#WPDTB\\/0^(O$-K'>R7@W6UNYS'''G&Y@.K'G@\ 8[]/7]&
M\(Z#X?LKNRTK38[6VO&+3QJS$.2-IZDX&.PXK)^%?_)+_#W_ %Z#^9K2\:>(
M?^$4\':GK802/:Q9C5NA=B%7/MN84 9&C^ ? _@>'[2EE9PMG_C[OW#,#[,_
M"_ABJ_B[Q-X UKPY?:;?:]HERLD#^6HNHW*M@[2N#PP.,5\SV<7B+XG^,X+2
M:]>ZU"[8XDN'PD2@%F./X5 !X ^@KU.3]F^.UTR:XN/$SO+%$TA6.S 7@9QD
MO^OZ4 >-^$YWMO&.B3Q,5>._@8$?]=%K[:U;_D#7W_7O)_Z":^(?#7_(TZ1_
MU^P_^ABOM[5O^0-??]>\G_H)H ^$[.V:]OK>U1@KS2+&I;H"3CG\Z^P_"WPL
M\+>&M&CLVTNTO[@J//N;N!9&D;OC<#M'L/U/-?(>CRI!KEA+*P2-+F-F8]
MP)-?=\<B2QK)&ZO&X#*RG(8'H0: /D;XR^#[/PAXV\O38_*L+V$7,40/$9)(
M91[9&1]<=J]<_9UU&2Z\!WEE(VX6=ZPC']U&56Q_WUN/XUPO[1M_#/XSTVRC
M8,]M99DQ_"68D#\@#^-=9^S9;.GAG6KHC]W)>+&I]2J G_T(4 >0_%K_ )*G
MX@_Z^!_Z M?3?PK_ .27^'O^O0?S-?,GQ:_Y*GX@_P"O@?\ H"U]-_"O_DE_
MA[_KT'\S0!\H>-M<E\1^--6U25RPFN6$?M&IVH/P4"OI/PAXO^'7A/PS9:39
M^(-.3RHU\YP2#+)@;F8XY)/]!VKY4O;>2TO[FVE!$D,K1L#U!!(-?05G^SKH
M=[907</B*]:*>-9$81(0589'\Z ."^-=SX7U+Q1;:IX;N[:<W,)^U_9^!Y@/
M#'CJ0?TKUG]GK47O/AW-:2.6-E>R1HI/W48*X_5FK)_X9KT?_H8+[_ORE>B>
M O =CX T>>PL[F:Y,\QFDEE !)P   .@P* .KHHHH ^!9_\ CXE_WS_.OO*P
M_P"0=;?]<D_D*^#9_P#CXE_WS_.OO*P_Y!UM_P!<D_D* +%?$/CI(X_B!XC2
M+[BZG<@#T_>-Q7V+XI\2V'A+P_=:OJ$JK'"IV)GYI7_A1?4G_$]!7Q+(]WK6
ML.X0S7E[<$[5'+R.W0?4F@#ZV^'^[_A2FF[^O]G2?E\V/TKY.T+_ )&'3/\
MK[B_]#%?9UCI(T+X?PZ4,9M--\EB.[+'@G\3DU\8Z%_R,.F?]?<7_H8H ^P/
MBA97.H?#/7[:T#&8VQ<*@R6"D,0/J 17RK\/_$=GX3\:Z?K-_:&ZMH"V]% +
M+E2-RYXR,Y_PZU]L5X_XR^ .C:W<2WV@W/\ 9-TY+-!LW0,?8#E/PR/04 =O
MI'BSPAX]LFM;2\LM021<R64ZC?COF-AD_7&*Z"PL+32["&QL;>.WM85VQQ1C
M"J/:OBOQ+X7UWP'KR6FHJ;>Z4"6">"0[6&>&1A@]1[$5]/?![Q==^,/ L=SJ
M#^9?6DS6LTG>3 !#'W(89]P: /E_QMKDOB/QIJVJ2N6$URPC]HU.U!^"@5])
M^$/%_P .O"?AFRTFS\0:<GE1KYS@D&63 W,QQR2?Z#M7RI>V\EI?W-M*")(9
M6C8'J""0:^@K/]G70[VR@NX?$5ZT4\:R(PB0@JPR/YT <%\:[GPOJ7BBVU3P
MW=VTYN83]K^S\#S >&/'4@_I7K/[/6HO>?#N:TD<L;*]DC12?NHP5Q^K-63_
M ,,UZ/\ ]#!??]^4KT3P%X#L? &CSV%G<S7)GF,TDLH ).   !T&!0!%/\-O
M![^([OQ)?:9#<7<YWR&Z;=$I  )V'Y>V><U:N/&'@FTMVM)M?T)(L;6@^U1$
M8]"H/3\*^6_B#X^U;QQX@N US*--68K:6:,0@4'"DCNQZY/KZ5Z%H_[-MU/9
M1S:OKZ6MPZ@M;P6_F;#Z%RPR1[#\: /*?'$6E0^-M770WA?3/M!:W,!RFTX.
M%]@21^%?6_PXG>X^&_AV21BS?8(ER?9<#^5?(?C#0%\+^+-1T5+@W"VD@02L
MNTMP#TR<=:^M_AC_ ,DR\._]>24 ?(6N6MQI/BB_MKV,M/;W;B19!]\ACU]C
M_6OJOPE\6/!_B:U@MH[R+3KHJ$^Q76(\<8VJ?NL.P Y]A2^._A-H'CF0WDN^
MQU3;M^UP '?C@;U_BP/H??%?._CSX5Z[X#1;JZ:&[TZ1]B74&>&[!E/*DX/J
M/>@#ZVTW1-+T=[EM-T^VLS<OYDWD1A [8QD@5\W_ +0VN2WWCBWT@.?L^G6R
MG9_TTD^8G_OG9^5=)^SYXUU"^N+OPO?W#SPPV_VBT:1LM& P5D!]/F! [8/X
M<'\=+>2'XL:G(X(6>*"1,]QY2KQ^*F@#M_@IK7@CPKX9>]U/5K*WUF[D;S/-
M^_'&#A5'' .-WOD>@IWQLU[P3XI\+1W.FZK97.L6LR^48OOM&>&4G'(YS^'U
MK$^'?P:TGQOX0@UF36KJ"=I)(Y8HT5@C*W'7_9VG\:ZK_AFO1_\ H8+[_ORE
M '*_LXZB\'C+4M.+D17-D9-N>"Z.N/T9J^F:\X\"?!_2_ NN2:M!J-U=SM"8
M5$JJJJ"02>.IX_G7H] !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% &/XL_Y$W7/^P?/_Z+:O(/V:/^0=XB_P"NL'\GKU_Q9_R)NN?]
M@^?_ -%M7D'[-'_(.\1?]=8/Y/0![O1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRTMR%5WN)=YVCL, "@#Q[]H_7)9=?TK0E<B"WM_M3KV+NQ49^@7_ ,>->U>
MO#-KX4\&Z=IUO$BR^2LEQ(JX,DI +,?7G@9[ "OG[]H6&2+XDQR,#MEL(F0^
MP9Q_,5]/6%S'>Z?;7414QSQ+(I4\$, 1C\Z *^M:%I?B+3GT_5[&*[M7Y*2#
MH?4$<@^XYIFKPQV_A>_@A0)%'92(BCHH"$ 5IUGZ[_R+VI_]>DO_ * : /E/
MX.^"[7QGXR\O4,-86,?VB:'_ )[<@*OTR>?88[U]=1QQPQ)%$BI&@"JBC 4#
MH .U?-W[-O\ R-.L_P#7DO\ Z&*^DZ /G3]I#79I-8TK0$<B"*'[7(HZ,[$J
MN?H%;_OJO3O!VK^!?"GA6PTFU\2Z"GE1 RM_:$.7D(RS$[N3G],#M7C/[1%N
M\7Q$MYF!V3:?&5/;AW!'^?6O1K/X!>"+RR@NHYM4*31K(I%RN"",C^#WH U?
MB)K?@KQ+X#U>P?Q%HD\PMWEME2_B+><@+)M^;.21CCJ"1WKB/V:]4E/]O:2S
M$PCRKF-?1CE6_/"?E74?\,]>"_\ GKJO_@0O_P 174^#/AQH'@62ZETA;EI;
MD*KO<2[SM'88 % '07VC:9J=Q:W%_86UU+:L6@::(.8R<9*YZ'@?E4]Q>VMH
M,W-S#"/620+_ #KQSXY?$G4/#KP>'-%E>VNKB$3SW2-AT0D@*I[$[22>H&/6
MLS0/V>CJ5C'?^*-;NQ>W"AWA@ +(3V9VSN/X?G0!7_:'NM$U.TT2]T^^LKJ[
MCDDA<V\RNVP@$9P>@(./J:]6^%L[7'PP\/._46BI^"DJ/T%>$_%SX7Z)X!TK
M3KK2KK4)GN9VC<74B,  N>-J+7N7PE_Y)9X?_P"O<_\ H;4 >)_&%;C0/C5;
M:Y>6S3V3/;7,*,/ED6/:&0?BIR/]KWKZ \->-/#_ (NM5FT?4H9G*[G@+;98
M_P#>0\CZ]/0FK'B/POH_BS338:S9)<PYRI.0T;>JL.0?\FO#/%OP#OM$CDU?
MPEJ<TWV<&46\IV3J!SE'7 )]L#ZDT ?1"QHKLZHH9_O$#D_6OG;]I#79I-8T
MK0$<B"*'[7(HZ,[$JN?H%;_OJNE^!OQ'U+Q/]JT'6IC<W=K#Y\-RWWWC!"D-
MZD$KSU.>:X+]HBW>+XB6\S [)M/C*GMP[@C_ #ZT >S>#M7\"^%/"MAI-KXE
MT%/*B!E;^T(<O(1EF)W<G/Z8':JGQ$UOP5XE\!ZO8/XBT2>86[RVRI?Q%O.0
M%DV_-G)(QQU!([UE6?P"\$7EE!=1S:H4FC612+E<$$9'\'O4W_#/7@O_ )ZZ
MK_X$+_\ $4 <O^S7JDI_M[268F$>5<QKZ,<JWYX3\JJ_M)ZM,VK:+HP<B&.!
MKID'\3,Q4$_0*V/J:];\&?#C0/ LEU+I"W+2W(57>XEWG:.PP *\._:,@=/'
M]C,22DFFH![$229'ZC\Z /=?AUX8MO"O@G3;&&)%GDA6:Z<#EY6 +$GOCH/8
M"JWQ,\'Z5XK\(WIOH0+FS@DFMKE1\\;*I.,]U..1_7!KI](NX[_1;&\A96BG
MMXY4*]"&4$8_.J_B8A?"FL$D "QF))_W#0!X!^S;_P C3K/_ %Y+_P"ABOI.
MOFS]FW_D:=9_Z\E_]#%?2= !1110 4444 %%%% !1110 4444 %%%% !1110
M!\V?#7_DXK6O^OB__P#1AKZ3KYL^&O\ R<5K7_7Q?_\ HPU])T %%%% !111
M0 4444 %%%% !1110 4444 %5[__ )!US_UR?^1JQ5>__P"0=<_]<G_D: /F
M3]G7_DHUU_V#)?\ T9'7U'7RY^SK_P E&NO^P9+_ .C(Z^HZ "ODNT!_X:-8
M08'_ !4<F?\ O\=W]:^I-<UBT\/Z)>:M?2!+:UB,CDGKCH![DX ]S7S+\&=/
MN/$_Q;_MF:/<ELTM[.W8.^0H^NYL_P# 30!ZI\?]<ETOX?K8P.5?4KE87(Z^
M6 6;\R%'T)K*^"5WX0\->"4NKS7='MM6OW9YUGO(DD10Q54()R!@;L?[5,_:
M3@=O#FB7 !\M+MT8^[)D?^@FLWX=?![PGXM\"Z=K-W+J NIPXF$4ZA0RNR]-
MIQP ?QH ]:N_&'@B_LYK2Z\2Z!+;S(8Y(VU"$AE(P0?FKP'X.74>B_&B73+2
MY$MG<&YM%D1PRRJF65@1P<[!@CU]Z]-_X9Z\%_\ /75?_ A?_B*U_#'P<\+>
M%-=@UBP%[)=P!O*,\P95+*5)P .Q/6@#$_:$UN73O D&G0.5;4KD)(1WC0;B
M/^^MGX9IWP"\,VNF^!4ULQ(U]J;N3(5^9(U8J$!],J6_$>E8O[2L+MHV@3@'
MRTN)48^[*I'_ *":[CX-74=U\*-#*%<QI)&P'8K(PY]^A_&@#MKFU@O;:2VN
MH8YX)5*R12*&5@>Q!ZU5T?1=.\/Z9'INE6J6MG&6*1*20"Q+'KSU)J_10!\?
MZGX?;Q3\<M2T03"$7>L3JTF,[5#L6(]\ X]Z^L=&T:P\/Z3;Z9IELEO:0+M1
M%_F3W)ZD]Z^:] _Y.=E_[#%W_*2OJ.@#RGX_ZY+I?P_6Q@<J^I7*PN1U\L L
MWYD*/H365\$KOPAX:\$I=7FNZ/;:M?NSSK/>1)(BABJH03D# W8_VJ9^TG [
M>'-$N #Y:7;HQ]V3(_\ 036;\.O@]X3\6^!=.UF[EU 74X<3"*=0H979>FTX
MX /XT >M7?C#P1?V<UI=>)= EMYD,<D;:A"0RD8(/S5X#\'+J/1?C1+IEI<B
M6SN#<VBR(X9953+*P(X.=@P1Z^]>F_\ #/7@O_GKJO\ X$+_ /$5K^&/@YX6
M\*:[!K%@+V2[@#>49Y@RJ64J3@ =B>M ':ZEIEAK%DUEJ5I#=VKD%H9D#*2#
MD9!]Q4F;6PMD7,-M @VJ.$50.P["N'^+OCFX\#^$UFL-O]I7DGDV[,,B/C+/
M@\' P /4BO*?!?PFU3XCZ>GB;Q-KUT(;EF\D9\R60 X)RQPHR" ,'IV&* /0
M?C1?>']7^&VI0+J>G37MNT<T$:W",X<. < '/W68?C6?^SA<O)X)U.V;E8M0
M++_P*-./T_6L#QU\$/#GA;P-J6M6E_JLMW:1JRK+)'L)+JIR @/?UK8_9M_Y
M%;6?^OU?_0!0!0_:4T^\DMM!U%$=[.%IHI"!\L;ML*Y^H4_]\UVOPQ^(?AS7
M?#.EZ9%=P6FI6UO';O92D(2RJ%RF?O XSQD^M=YJ&GV>JV,UC?VT5S:S+MDB
ME7<K#Z5XMXJ_9UL;@27/A?4'M)>JVET2\9]@_P!Y?QW4 >X&-#()"BEP" V.
M0#U&?P'Y5Y7\?]<ETOX?K8P.5?4KE87(Z^6 6;\R%'T)KB/A3X]\1:'XVC\%
M^(YIIH7E:V"W#[WMI1T ;NIQC&2.01[[_P"TG [>'-$N #Y:7;HQ]V3(_P#0
M30 _X)7?A#PUX)2ZO-=T>VU:_=GG6>\B21%#%50@G(&!NQ_M5Z+=^,/!%_9S
M6EUXET"6WF0QR1MJ$)#*1@@_-7DOPZ^#WA/Q;X%T[6;N74!=3AQ,(IU"AE=E
MZ;3C@ _C74_\,]>"_P#GKJO_ ($+_P#$4 >9?!RZCT7XT2Z9:7(EL[@W-HLB
M.&654RRL".#G8,$>OO7IO[06M2:;\/DL87*MJ-TL3X_YYJ"Y_4*/H36OX8^#
MGA;PIKL&L6 O9+N -Y1GF#*I92I. !V)ZURG[25NS>%M&N03MCO6C(]V0D?^
M@F@"[^S]X8M=/\%_V^T2->ZC(X64CYEB1MH4>GS*Q]^/2O3==T+3?$FD3:7J
MMJEQ:S#!5NJGLRGL1V(KD/@G=1W/PGT<(5+0F:)P/X2)6//X$'\:] H ^2O
M&FIHOQ]M=*CD:2.RU&YME=A@L$$B@G\J^M:^6/#)#?M,3$$$'6KT@CZRU]3T
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'SA\/?^3D]?_Z^]0_]&-7T
M?7SA\/?^3D]?_P"OO4/_ $8U?1] !1110 4444 %%%% !1110 4444 %%%%
M!1110 5\N?M%?\E&M?\ L&1?^C)*^HZ^7/VBO^2C6O\ V#(O_1DE 'TW8?\
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MV0<J?4$<@^X-7X98YX8YHF#QR*&5@<@@C(-/H QO%*+'X*UJ-%"HNG3A0.@
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MSWNJ(JZO?[?,0'/DQCHF?7)R<>P[5WFE^'M%T-2-*TFRLL]3;P*A/U('-:5
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M\/?]>@_F:W[O0-&OYS/>:387,Q&#)-;(['\2,U?CC2&-8XD5(T&%51@ >@%
M'S'\:OAM?Z3X@N_$FFVKS:5>.9IS&N3;R'[VX#^$GG/3G'IG&\(_&KQ/X2TR
M+3%6UO[*+B)+I6W1K_=5E(X^N:^M^HP:YZ[\">$KZ<S7/AO2I)3U<VJ9/UXY
MH ^?-3_:%\7WL)BLX-.L"1CS(HB[CZ;R1^E>\?#.\U?4/AYI-WKK3-J4JR-*
MTR;6(\QMA(P/X=OX5I:=X0\-Z1*)=.T'3;64'(DBMD5A_P "QFMJ@ HHHH ^
M![I&CO)T=2KK(P8'J#FNW3XT_$&.-8T\0810% ^QP< ?\ KZTET?2YY6EETV
MSDD8Y9W@4DGW.*9_86C_ /0*L?\ P'3_  H ^,KF\\5^/-2032:EK-UT1%5I
M-F?11PH_(5[C\)O@U-H%[%XA\2HGV^/FULP0PA/]]R."WH!P.O7I[1#!#;1"
M*")(HQT1%"@?@*DH IZM_P @:^_Z]Y/_ $$U\.Z#_P C#IG_ %]Q?^ABON[J
M,&LR/PYH<-RMS%HVG)<*VX2K:H&!]<XSF@#&^)L^K6OPZUB?0Y)X]1CC1XW@
M^^ )%WXQ_L[J\*T?]H;Q386JP:A:6.HE1@3.IC<_7:<'\A7U#6%J'@OPQJMP
M;B_\/Z9<3DY,LEJA8_4XR: /DSQCXQUKXE>(+>::T4RHGDVUI:1LQ SGCJ6)
M_P BOI/X0^#[GP;X'CM;]=E]=RFZGCSGRR0 %^H"C/N375Z7X=T71,G2M(L;
M(D8+6UND98>Y R:TJ /F'XU?#:_TGQ!=^)--M7FTJ\<S3F-<FWD/WMP'\)/.
M>G./3.-X1^-7B?PEID6F*MK?V47$272MNC7^ZK*1Q]<U];]1@USUWX$\)7TY
MFN?#>E22GJYM4R?KQS0!\^:G^T+XOO83%9P:=8$C'F11%W'TWDC]*]X^&=YJ
M^H?#S2;O76F;4I5D:5IDVL1YC;"1@?P[?PK2T[PAX;TB42Z=H.FVLH.1)%;(
MK#_@6,UM4 ?%'CCPIJ'@KQ7<V<\+QQ"4R6DR@[9(\Y4J?4< CL:[\_M&>(3H
MPMDTJR&H;-GVLEB,XQN\OIGOUQGMVKZ.O]-L-5MC;:C96UY 3DQ7$2R+GZ,"
M*R[#P3X6TN[6ZL?#VF6]PO*RQVR!E/L<<?A0!\;>([/6[?44NO$"3K?:A&+O
M-Q]]U9B Q'49VGCTQ7UW\,O^29>'?^O)/Y5O7VBZ5J<BR7^F6=VZC:K3P+(0
M/0$BKD44<,211(L<: *J*,!0.@ ["@#Y7TSXT>.?"E]<:?JI2_:*5EDBOD(D
M0YY 88/YY%9_COXOZSXZTF/2IK*UL[,2"1UBRS2,.F2>@YZ 5]3ZKX=T77 !
MJNDV5Z5&%-Q KE?H2,BJUAX,\+Z7.L]CX>TNWF4Y65+5 ZGV;&10!Y)^S_X&
MU'39[OQ-J=M+;":'[/:12J59U)#,^#R!\H ]>?:M;XX_#F\\3VEOKNC0&?4+
M.,QS0(/FFBSD;?4J2>.X/M@^PT4 ?%_@[X@^(OA_<SIIS1F*1OWUG=1DH6'&
M2 00P]B/?-=K=?M'>)Y82MOI>E0.1]\K(^/H-W^-?0FJ>%?#^MR>9JFBZ?>2
M?\])K=6;\R,U4MO /A"TF$L'AG24D'1OLB$CZ9'% '#?!#Q1XG\61Z[?^(+B
M6>#?"+5C$J(#\^\+@#./DS^%>MTB(L:*B*%51@*!@ 4M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &/XL_Y$W7/^P?/_ .BVKR#]
MFC_D'>(O^NL'\GKU_P 6?\B;KG_8/G_]%M7D'[-'_(.\1?\ 76#^3T >[T44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5Y)^T5_R3FU_P"PG%_Z+DKUNO)/
MVBO^2<VO_83B_P#1<E '2?!__DE&@?\ 7)__ $8]=O7$?!__ ))1H'_7)_\
MT8]=O0 4444 %%%% !1110 4444 %%%% !1110 5PGQE4M\)=>"@D[(CQ_UV
M2N[IKHDL;1R(KHPPRL,@CW% 'R5\-?BM_P *\TZ^M/[%_M#[5*LF[[5Y6W Q
MC&QLUV5U^TM=RQ;++PM#%.>%:6\,H_[Y"*?UKW7^PM'_ .@58_\ @.G^%2P:
M7I]K)YEO86L+_P!Z.%5/Y@4 ?,]IX2\??&#7HM2UP2V=@/E%Q-&8XXT[B*,\
MM]?S-?2/A_0;#PSH=KI&FQ>7:VZ;5SU8]V8]R3DFM*B@#S'XS_#ZX\9Z#!>:
M6@?5=/W%(^AFC.-R ^O (_$=Z\X\#_&VZ\&Z3'X=\1:1<SBR_=QNIV31K_<9
M6ZXZ#D<8%?2M9NI^'=$UK!U32+"](& US;I(1]"1D4 >3WW[2/A^. G3]$U.
M>7'"W!CB7/U#-_*NT^&7B[6/&F@7.J:MIB6"_:2ELJ(P#Q[5.<L?FY)&1@<>
MU;5CX-\,:;(LEEX>TN"5>DD=H@8?\"QFMR@#RCXX> +KQ7HEOJFE0F;4M.#9
MA49::(\D#U((R!WR>^*\[\!?'"Y\):1'H6N:9+=P6A\N&2-MDL2@G*,#UQT'
M3'2OINL?4_"?AW693-J>AZ==S'_EK-;(S_\ ?1&: /#==^.>O^*F71O!FCSV
MUQ<':)0?-G(_V0!A?KSCVZU[?<)=1>!I8[YMUXNFE9VSG,@B^8Y^N:NZ;HNE
M:-&8]+TRSLD;JMM L8/UV@5=(# @@$'@@T ?-O[-O_(TZS_UY+_Z&*^DZI66
MD:9ICN]AIUI:,XPY@@6,M]<#FKM 'F/QG^'UQXST&"\TM ^JZ?N*1]#-&<;D
M!]> 1^([UYQX'^-MUX-TF/P[XBTBYG%E^[C=3LFC7^XRMUQT'(XP*^E:S=3\
M.Z)K6#JFD6%Z0,!KFW20CZ$C(H \GOOVD?#\<!.GZ)J<\N.%N#'$N?J&;^5=
MI\,O%VL>-- N=4U;3$L%^TE+941@'CVJ<Y8_-R2,C X]JVK'P;X8TV19++P]
MI<$J])([1 P_X%C-;E 'SU^T/X2OWU2S\46D#2V@MQ;W)C!)B968AF] 0V,^
MWN*U]&_:-T7^QX1K&F:B-11 )/LRHT<C =02P(SUQCCU->VLH92K %2,$'O6
M"_@;PG)<BX;PSHYE'.XV4?7UZ=: /FSXC>)_$OQ TQ?$$^G-8^&[6<0VJM_'
M(V<G=CYSA3G' Z=>OO\ \)?^26>'_P#KW/\ Z&U=5<:?97EH+2ZL[>>V&,0R
MQ*R<=/E(QQ4L%O#:P)!;PQPPQC:D<:A54>@ Z4 >+:U\:M6\'>.]4TC7M$$V
MG),?LTD.8Y/*[,,\.,?3G/-1ZW^T=I!TJ5=$TF_-^Z%4:[")&A(Z_*S$X].,
M^M>S7^EZ?JL'D:C8VUY%_P \[B%9%_)@:SK/P7X7T^836?AW2H)0VX2)9QA@
M?8XR/PH \C_9^\$:CIT]WXGU&"2V2> VUK%(I5G4LK,^#V^4 >O-=5\9_A]<
M>,]!@O-+0/JNG[BD?0S1G&Y ?7@$?B.]>G44 ?-7@?XVW7@W28_#OB+2+F<6
M7[N-U.R:-?[C*W7'0<CC KJ[[]I'P_' 3I^B:G/+CA;@QQ+GZAF_E7K&I^'=
M$UK!U32+"](& US;I(1]"1D55L?!OAC39%DLO#VEP2KTDCM$##_@6,T 8OPR
M\7:QXTT"YU35M,2P7[24ME1& >/:ISEC\W)(R,#CVKGOCEX$N_%6@6VIZ7 T
MVH::6)A09:6)L;@!W((! ^O?%>KT4 ?,_P /?CBWA70X]#US3Y[N&URMO+"P
M#HO]QE.,X['/MVJYJ_C/Q3\:+L>'?#6G2:?HY8?:YW;.5ZYD8< >B#).._;W
M+4/"'AO5KG[3J&@:9=3DY,LUJC.?J2,FM*RL;/3;5;6QM(+6W3[L4$81!] .
M* /G3]FW_D:=9_Z\E_\ 0Q7TG5.STG3=.DDDL=/M+5Y/]8T$*H7^I YJY0 4
M444 %%%% !1110 4444 %%%% !1110 4444 ?-GPU_Y.*UK_ *^+_P#]&&OI
M.OFSX:_\G%:U_P!?%_\ ^C#7TG0 4444 %%%% !1110 4444 %%%% !1110
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M%%% !1110 4444 %%%% !1110!\V> ?^3EM9_P"OW4/_ $-Z*/ /_)RVL_\
M7[J'_H;T4 'P'_Y*WKW_ %Y7'_H^*OI.OFSX#_\ )6]>_P"O*X_]'Q5])T %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% &/XL_P"1-US_ +!\_P#Z
M+:O(/V:/^0=XB_ZZP?R>O7_%G_(FZY_V#Y__ $6U>0?LT?\ (.\1?]=8/Y/0
M![O1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7DG[17_).;7_L)Q?^BY*]
M;KR3]HK_ ))S:_\ 83B_]%R4 =)\'_\ DE&@?]<G_P#1CUV]<1\'_P#DE&@?
M]<G_ /1CUV] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\V
M?#7_ ).*UK_KXO\ _P!&&OI.OFSX:_\ )Q6M?]?%_P#^C#7TG0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8+'_ +\O0!]#_;[/_G[@_P"_@H^WV?\ S]P?]_!7SQ_PS7K'_0P6/_?EZ/\
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M8+'_ +\O0!]#_;[/_G[@_P"_@H^WV?\ S]P?]_!7SQ_PS7K'_0P6/_?EZ/\
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M (9KUC_H8+'_ +\O1_PS7K'_ $,%C_WY>@#Z'^WV?_/W!_W\%'V^S_Y^X/\
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M7K'_ $,%C_WY>@#Z'^WV?_/W!_W\%'V^S_Y^X/\ OX*^>/\ AFO6/^A@L?\
MOR]'_#->L?\ 0P6/_?EZ /H?[?9_\_<'_?P4?;[/_G[@_P"_@KYX_P"&:]8_
MZ&"Q_P"_+T?\,UZQ_P!#!8_]^7H ^A_M]G_S]P?]_!1]OL_^?N#_ +^"OGC_
M (9KUC_H8+'_ +\O1_PS7K'_ $,%C_WY>@#Z'^WV?_/W!_W\%'V^S_Y^X/\
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M7K'_ $,%C_WY>@#Z'^WV?_/W!_W\%'V^S_Y^X/\ OX*^>/\ AFO6/^A@L?\
MOR]'_#->L?\ 0P6/_?EZ /H?[?9_\_<'_?P4?;[/_G[@_P"_@KYX_P"&:]8_
MZ&"Q_P"_+T?\,UZQ_P!#!8_]^7H ^A_M]G_S]P?]_!1]OL_^?N#_ +^"OGC_
M (9KUC_H8+'_ +\O1_PS7K'_ $,%C_WY>@#Z'^WV?_/W!_W\%'V^S_Y^X/\
MOX*^>/\ AFO6/^A@L?\ OR]'_#->L?\ 0P6/_?EZ /H?[?9_\_<'_?P4?;[/
M_G[@_P"_@KYX_P"&:]8_Z&"Q_P"_+T?\,UZQ_P!#!8_]^7H ^A_M]G_S]P?]
M_!1]OL_^?N#_ +^"OGC_ (9KUC_H8+'_ +\O1_PS7K'_ $,%C_WY>@#Z'^WV
M?_/W!_W\%'V^S_Y^X/\ OX*^>/\ AFO6/^A@L?\ OR]'_#->L?\ 0P6/_?EZ
M /H?[?9_\_<'_?P4?;[/_G[@_P"_@KYX_P"&:]8_Z&"Q_P"_+T?\,UZQ_P!#
M!8_]^7H ^A_M]G_S]P?]_!1]OL_^?N#_ +^"OGC_ (9KUC_H8+'_ +\O1_PS
M7K'_ $,%C_WY>@#Z'^WV?_/W!_W\%'V^S_Y^X/\ OX*^>/\ AFO6/^A@L?\
MOR]'_#->L?\ 0P6/_?EZ /H?[?9_\_<'_?P4?;[/_G[@_P"_@KYX_P"&:]8_
MZ&"Q_P"_+T?\,UZQ_P!#!8_]^7H ^A_M]G_S]P?]_!1]OL_^?N#_ +^"OGC_
M (9KUC_H8+'_ +\O1_PS7K'_ $,%C_WY>@#Z'^WV?_/W!_W\%'V^S_Y^X/\
MOX*^>/\ AFO6/^A@L?\ OR]'_#->L?\ 0P6/_?EZ /H?[?9_\_<'_?P4?;[/
M_G[@_P"_@KYX_P"&:]8_Z&"Q_P"_+T?\,UZQ_P!#!8_]^7H @^'$T2?M#:S(
M\J+&;B^PQ8 'YSWKZ.^WV?\ S]P?]_!7QQX?\ W7B#QY=^%(KV&*>V>9#.ZD
MJWEL0>.O.*] _P"&:]8_Z&"Q_P"_+T ?0_V^S_Y^X/\ OX*/M]G_ ,_<'_?P
M5\\?\,UZQ_T,%C_WY>C_ (9KUC_H8+'_ +\O0!]#_;[/_G[@_P"_@H^WV?\
MS]P?]_!7SQ_PS7K'_0P6/_?EZ/\ AFO6/^A@L?\ OR] 'T/]OL_^?N#_ +^"
MC[?9_P#/W!_W\%?/'_#->L?]#!8_]^7H_P"&:]8_Z&"Q_P"_+T ?0_V^S_Y^
MX/\ OX*/M]G_ ,_<'_?P5\\?\,UZQ_T,%C_WY>C_ (9KUC_H8+'_ +\O0!]#
M_;[/_G[@_P"_@H^WV?\ S]P?]_!7SQ_PS7K'_0P6/_?EZ/\ AFO6/^A@L?\
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M5\\?\,UZQ_T,%C_WY>C_ (9KUC_H8+'_ +\O0!]#_;[/_G[@_P"_@H^WV?\
MS]P?]_!7SQ_PS7K'_0P6/_?EZ/\ AFO6/^A@L?\ OR] 'T/]OL_^?N#_ +^"
MC[?9_P#/W!_W\%?/'_#->L?]#!8_]^7H_P"&:]8_Z&"Q_P"_+T ?0_V^S_Y^
MX/\ OX*/M]G_ ,_<'_?P5\\?\,UZQ_T,%C_WY>C_ (9KUC_H8+'_ +\O0!]#
M_;[/_G[@_P"_@H^WV?\ S]P?]_!7SQ_PS7K'_0P6/_?EZ/\ AFO6/^A@L?\
MOR] 'T/]OL_^?N#_ +^"C[?9_P#/W!_W\%?/'_#->L?]#!8_]^7H_P"&:]8_
MZ&"Q_P"_+T ?0_V^S_Y^X/\ OX*/M]G_ ,_<'_?P5\\?\,UZQ_T,%C_WY>C_
M (9KUC_H8+'_ +\O0!]#_;[/_G[@_P"_@H^WV?\ S]P?]_!7SQ_PS7K'_0P6
M/_?EZ/\ AFO6/^A@L?\ OR] 'T/]OL_^?N#_ +^"C[?9_P#/W!_W\%?/'_#-
M>L?]#!8_]^7H_P"&:]8_Z&"Q_P"_+T ?0_V^S_Y^X/\ OX*/M]G_ ,_<'_?P
M5\\?\,UZQ_T,%C_WY>C_ (9KUC_H8+'_ +\O0!]#_;[/_G[@_P"_@H^WV?\
MS]P?]_!7SQ_PS7K'_0P6/_?EZ/\ AFO6/^A@L?\ OR] 'T/]OL_^?N#_ +^"
MC[?9_P#/W!_W\%?/'_#->L?]#!8_]^7H_P"&:]8_Z&"Q_P"_+T ?0_V^S_Y^
MX/\ OX*/M]G_ ,_<'_?P5\\?\,UZQ_T,%C_WY>C_ (9KUC_H8+'_ +\O0!]#
M_;[/_G[@_P"_@H^WV?\ S]P?]_!7SQ_PS7K'_0P6/_?EZ/\ AFO6/^A@L?\
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M5\\?\,UZQ_T,%C_WY>C_ (9KUC_H8+'_ +\O0!]#_;[/_G[@_P"_@H^WV?\
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MX*/M]G_S]P?]_!7SQ_PS7K'_ $,%C_WY>C_AFO6/^A@L?^_+T ?0_P!OL_\
MG[@_[^"C[?9_\_<'_?P5\\?\,UZQ_P!#!8_]^7H_X9KUC_H8+'_OR] 'T/\
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M^7H_X9KUC_H8+'_OR] 'T/\ ;[/_ )^X/^_@H^WV?_/W!_W\%?/'_#->L?\
M0P6/_?EZ/^&:]8_Z&"Q_[\O0!%\/V5OVE-896!5KW4""#U^9Z*ROA)I$FD_'
M0:9)*LCZ=)=P.ZC <HKH2/QYHH UO@/_ ,E;U[_KRN/_ $?%7TG7S9\!_P#D
MK>O?]>5Q_P"CXJ^DZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^</A[_ ,G)Z_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ^</A[_R<GK_ /U]ZA_Z,:OH^OG#X>_\G)Z_
M_P!?>H?^C&KZ/H **** "BBB@ HHHH **** "BBB@ HHHH **SM;U[2O#FGF
M_P!8OHK.UW!/,D/5CT  Y)X/ ]#7,_\ "X/ /_0QP?\ ?J3_ .)H [>BN:TG
MX@^$M<G6#3O$%C+,YPL32;'8^RM@FNEH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **X6'XN>$Y_%_\ PC27-P;T
MW'V82>2?*,N=NT-UZ\9QCWKNJ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#YL\ _P#)RVL_]?NH?^AO11X!_P"3EM9_Z_=0_P#0
MWHH /@/_ ,E;U[_KRN/_ $?%7TG7S9\!_P#DK>O?]>5Q_P"CXJ^DZ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\6?\B;KG_8/G_\ 1;5Y!^S1
M_P @[Q%_UU@_D]>O^+/^1-US_L'S_P#HMJ\@_9H_Y!WB+_KK!_)Z /=Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *\D_:*_Y)S:_]A.+_ -%R5ZW7DG[1
M7_).;7_L)Q?^BY* .D^#_P#R2C0/^N3_ /HQZ[>N(^#_ /R2C0/^N3_^C'KM
MZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YL^&O_)Q6M?]
M?%__ .C#7TG7S9\-?^3BM:_Z^+__ -&&OI.@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ^</A[_ ,G)Z_\ ]?>H?^C&KZ/KYP^'O_)R>O\
M_7WJ'_HQJ^CZ "BBB@ HHHH **** "BBB@ HHHH **** /&/VD?^1-TD?]1#
M_P!IO6%\-?@[X9\6>!+#6=1DU 74[2AQ#,JK\LC*, J>P%;O[2/_ ")ND_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,?Q9_P B;KG_ &#Y_P#T6U>0?LT?\@[Q%_UU@_D]>O\
MBS_D3=<_[!\__HMJ\@_9H_Y!WB+_ *ZP?R>@#W>BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "O)/VBO^2<VO\ V$XO_1<E>MUY)^T5_P DYM?^PG%_Z+DH
M Z3X/_\ )*- _P"N3_\ HQZ[>N(^#_\ R2C0/^N3_P#HQZ[>@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ^;/AK_P G%:U_U\7_ /Z,-?2=
M?-GPU_Y.*UK_ *^+_P#]&&OI.@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ^</A[_R<GK__ %]ZA_Z,:OH^OG#X>_\ )R>O_P#7WJ'_ *,:
MOH^@ HHHH **** "BBB@ HHHH **** "BBB@#QC]I'_D3=)_["'_ +3>O/\
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M+W7Q"MK)W(@M+- %'.&8EF./7&W\A7T#X'\/KX6\%Z5H^T"2" &;'>1OF?\
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M+S' WJ =WME2#Z9)]* .UHK&@\7>&KF[6T@\0Z3+<LVU88[V-G)] H;.:V:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR_$6O6?AC0+O6M0\PVMJH9Q$NYCD@  9')) ZUJ5PGQF_P"22Z]_N1?^CDH
MY/\ X:1\.?\ 0&U7\H__ (JK=A^T1X1N9A'=6NIV:D_ZQXE=1]=K$_D#7+?
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MEIEN;B_O+>T@'!DGE6-1^).* +-%9^G:]H^L%AIFK6%\5^\+:Y27'UVDUH4
M%%%8MQXO\,VEP;>Y\1:1#.#@QR7L:L#]"V: -JBH[>X@NX%GMIHYHGY62-@R
MGZ$5)0 454O]4T_2H?.U&^MK.+^_<3+&OYL15;3_ !+H.K3>3INMZ;>2_P!R
MVNXY&_)2: -2BBB@ HHHH **** /FSX:_P#)Q6M?]?%__P"C#7TG7S9\-?\
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MTB$2ZEJ%I91'H]S,L8/XL10!<HK-T[Q%HFKR&/3-9T^]<=5MKI)"/P4FM*@
MHJK'J=A->O917ML]W&,O LJEU^JYR*CU'6=*T=%?4]2L[)6^ZUS.L8/TW$4
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M\>?^267G_7Q#_P"ABO&_@%_R5"#_ *])OY"O9/CS_P DLO/^OB'_ -#%>-_
M+_DJ$'_7I-_(4 >R?'G_ ))9>?\ 7Q#_ .ABO&_@%_R5"#_KTF_D*]D^//\
MR2R\_P"OB'_T,5XW\ O^2H0?]>DW\A0!]7T444 >2?M%?\DYM?\ L)Q?^BY*
M\C^">NZ7X>\>27NKWL5G;&RDC$DIP-Q9<#]#7KG[17_).;7_ +"<7_HN2OG_
M ,$^#;SQSKS:38W,%O,L+3;Y\[< @8X!YYH ^E?$'QL\&Z1ILTUGJ2ZE=A3Y
M5O;JQW-VRQ& ,]><^QKY9T[3M0\3Z_%9V<+3WU[-PJCN3DD^@'))["MWQO\
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MN;^<#[1>.N"V/X5'\*^V3[D\5T^IZG9:-IL^H:C<QVUI NZ260\*/ZGV')H
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M!7S+\!M'U>#XBRWCZ;=6]H+259'DB94&2N%R1R<@<>Q]*^FJ "BBB@ HHHH
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M%@?.MT?Z1&@"O^SSXQO;Q[[PO>S/-'!#]IM6=LF-0P5D&>WS*0.W->O>,_\
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MB_\ Z$K_ ,<F_P *\]\7ZEXE\?>+;;5%\-W5M>>7'"D<,$C;F5B0>1[_ *4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.S1,&4Z= IQV*H 1^!!%9GQ+\ 0_$#P_':"X6VO;9S+;3,N0"1@JW?:>.G3
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MXSU[;&O!S.;B4#^ZH^ZH_'\#7N^A:'I_AO1K?2M+@$-I;KA5ZDGN2>Y)Y)H
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M!\X?#W_DY/7_ /K[U#_T8U?1]?.'P]_Y.3U__K[U#_T8U?1] !1110 4444
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M#^3T >[T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\X?#W_ ).3U_\
MZ^]0_P#1C5]'U\X?#W_DY/7_ /K[U#_T8U?1] !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'C'[2/_(FZ3_V$/_:;UTGP._Y)+I'^_/\
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M/\;H!\WX@@_4FNSH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^;/ /\ R<MK/_7[J'_H;T4> ?\ DY;6?^OW4/\ T-Z* #X#_P#)6]>_
MZ\KC_P!'Q5])U\V? ?\ Y*WKW_7E<?\ H^*OI.@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Q_%G_(FZY_V#Y__ $6U>0?LT?\ (.\1?]=8/Y/7
MK_BS_D3=<_[!\_\ Z+:O(/V:/^0=XB_ZZP?R>@#W>BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK\7:7XM\8PR:1(9K:RM_LYGQA9&W,25]1SC/?Z5]4Z3_ ,@:Q_Z]X_\ T$4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\D_:*_Y)S:_P#83B_]%R5Z
MW7DG[17_ "3FU_["<7_HN2@#I/@__P DHT#_ *Y/_P"C'KMZXCX/_P#)*- _
MZY/_ .C'KMZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YL
M^&O_ "<5K7_7Q?\ _HPU])U\V?#7_DXK6O\ KXO_ /T8:^DZ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#YP^'O_)R>O_\ 7WJ'_HQJ^CZ^
M</A[_P G)Z__ -?>H?\ HQJ^CZ "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** .4\?^!K3Q]H,>F75U):M%,)XIHU#%6 (P0>H()_2O,_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 8_BS_ )$W7/\ L'S_ /HMJ\@_9H_Y!WB+_KK!_)Z]?\6?\B;KG_8/
MG_\ 1;5Y!^S1_P @[Q%_UU@_D] 'N]%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>2?M%?\DYM?^PG%_Z+DKUNO)/VBO\ DG-K_P!A.+_T7)0!TGP?_P"2
M4:!_UR?_ -&/7;UQ'P?_ .24:!_UR?\ ]&/7;T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'S9\-?\ DXK6O^OB_P#_ $8:^DZ^;/AK_P G
M%:U_U\7_ /Z,-?2= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML?\ P N/_CE'_"\/B/\ ]"Q8_P#@!<?_ !ROH^B@#YP_X7A\1_\ H6+'_P
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M6+'_ , +C_XY1_PO#XC_ /0L6/\ X 7'_P <KZ/HH ^</^%X?$?_ *%BQ_\
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M_A>'Q'_Z%BQ_\ +C_P".4?\ "\/B/_T+%C_X 7'_ ,<KZ/HH ^</^%X?$?\
MZ%BQ_P# "X_^.4?\+P^(_P#T+%C_ . %Q_\ '*^CZ* /G#_A>'Q'_P"A8L?_
M   N/_CE'_"\/B/_ -"Q8_\ @!<?_'*^CZ* /G#_ (7A\1_^A8L?_ "X_P#C
ME'_"\/B/_P!"Q8_^ %Q_\<KZ/HH ^</^%X?$?_H6+'_P N/_ (Y1_P +P^(_
M_0L6/_@!<?\ QROH^B@#YP_X7A\1_P#H6+'_ , +C_XY1_PO#XC_ /0L6/\
MX 7'_P <KZ/HH ^</^%X?$?_ *%BQ_\  "X_^.4?\+P^(_\ T+%C_P" %Q_\
M<KZ/HH ^</\ A>'Q'_Z%BQ_\ +C_ ..4?\+P^(__ $+%C_X 7'_QROH^B@#Y
MP_X7A\1_^A8L?_ "X_\ CE'_  O#XC_]"Q8_^ %Q_P#'*^CZ* /G#_A>'Q'_
M .A8L?\ P N/_CE'_"\/B/\ ]"Q8_P#@!<?_ !ROH^B@#YP_X7A\1_\ H6+'
M_P  +C_XY1_PO#XC_P#0L6/_ ( 7'_QROH^B@#YP_P"%X?$?_H6+'_P N/\
MXY1_PO#XC_\ 0L6/_@!<?_'*^CZ* /G#_A>'Q'_Z%BQ_\ +C_P".4?\ "\/B
M/_T+%C_X 7'_ ,<KZ/HH ^</^%X?$?\ Z%BQ_P# "X_^.4?\+P^(_P#T+%C_
M . %Q_\ '*^CZ* /G#_A>'Q'_P"A8L?_   N/_CE'_"\/B/_ -"Q8_\ @!<?
M_'*^CZ* /G#_ (7A\1_^A8L?_ "X_P#CE'_"\/B/_P!"Q8_^ %Q_\<KZ/HH
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M6/\ X 7'_P <KZ/HH ^</^%X?$?_ *%BQ_\  "X_^.4?\+P^(_\ T+%C_P"
M%Q_\<KZ/HH ^</\ A>'Q'_Z%BQ_\ +C_ ..4?\+P^(__ $+%C_X 7'_QROH^
MB@#YP_X7A\1_^A8L?_ "X_\ CE'_  O#XC_]"Q8_^ %Q_P#'*^CZ* /F;4OC
M+\0M0TN[LKCPW9I#<0O%(RV-P"%92"02^,X-<SX"\:^*_ \%]'HNBQW2W3(T
MIN+65]I4'&-K#'4]:^OZ* /G#_A>'Q'_ .A8L?\ P N/_CE'_"\/B/\ ]"Q8
M_P#@!<?_ !ROH^B@#YP_X7A\1_\ H6+'_P  +C_XY1_PO#XC_P#0L6/_ ( 7
M'_QROH^B@#YP_P"%X?$?_H6+'_P N/\ XY1_PO#XC_\ 0L6/_@!<?_'*^CZ*
M /G#_A>'Q'_Z%BQ_\ +C_P".4?\ "\/B/_T+%C_X 7'_ ,<KZ/HH ^</^%X?
M$?\ Z%BQ_P# "X_^.4?\+P^(_P#T+%C_ . %Q_\ '*^CZ* /G#_A>'Q'_P"A
M8L?_   N/_CE'_"\/B/_ -"Q8_\ @!<?_'*^CZ* /G#_ (7A\1_^A8L?_ "X
M_P#CE'_"\/B/_P!"Q8_^ %Q_\<KZ/HH ^</^%X?$?_H6+'_P N/_ (Y1_P +
MP^(__0L6/_@!<?\ QROH^B@#YP_X7A\1_P#H6+'_ , +C_XY1_PO#XC_ /0L
M6/\ X 7'_P <KZ/HH ^</^%X?$?_ *%BQ_\  "X_^.4?\+P^(_\ T+%C_P"
M%Q_\<KZ/HH ^</\ A>'Q'_Z%BQ_\ +C_ ..4?\+P^(__ $+%C_X 7'_QROH^
MB@#YP_X7A\1_^A8L?_ "X_\ CE'_  O#XC_]"Q8_^ %Q_P#'*^CZ* /G#_A>
M'Q'_ .A8L?\ P N/_CE'_"\/B/\ ]"Q8_P#@!<?_ !ROH^B@#YP_X7A\1_\
MH6+'_P  +C_XY1_PO#XC_P#0L6/_ ( 7'_QROH^B@#YP_P"%X?$?_H6+'_P
MN/\ XY1_PO#XC_\ 0L6/_@!<?_'*^CZ* /G#_A>'Q'_Z%BQ_\ +C_P".4?\
M"\/B/_T+%C_X 7'_ ,<KZ/HH ^</^%X?$?\ Z%BQ_P# "X_^.4?\+P^(_P#T
M+%C_ . %Q_\ '*^CZ* /G#_A>'Q'_P"A8L?_   N/_CE'_"\/B/_ -"Q8_\
M@!<?_'*^CZ* /G#_ (7A\1_^A8L?_ "X_P#CE<UXX^(?C+QIH<>F:QH4%M;)
M<+,'@M)D8L P RS$8PQ[5]:44 ?+7ACXJ^.O#?ARRTC3O#UK-:6RE8Y);*=F
M8%B>2K@'DGM6M_PO#XC_ /0L6/\ X 7'_P <KZ/HH ^</^%X?$?_ *%BQ_\
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M_A>'Q'_Z%BQ_\ +C_P".4?\ "\/B/_T+%C_X 7'_ ,<KZ/HH ^</^%X?$?\
MZ%BQ_P# "X_^.4?\+P^(_P#T+%C_ . %Q_\ '*^CZ* /G#_A>'Q'_P"A8L?_
M   N/_CE'_"\/B/_ -"Q8_\ @!<?_'*^CZ* /G#_ (7A\1_^A8L?_ "X_P#C
ME'_"\/B/_P!"Q8_^ %Q_\<KZ/HH ^</^%X?$?_H6+'_P N/_ (Y1_P +P^(_
M_0L6/_@!<?\ QROH^B@#YP_X7A\1_P#H6+'_ , +C_XY1_PO#XC_ /0L6/\
MX 7'_P <KZ/HH ^</^%X?$?_ *%BQ_\  "X_^.4?\+P^(_\ T+%C_P" %Q_\
M<KZ/HH ^</\ A>'Q'_Z%BQ_\ +C_ ..4?\+P^(__ $+%C_X 7'_QROH^B@#Y
MP_X7A\1_^A8L?_ "X_\ CE'_  O#XC_]"Q8_^ %Q_P#'*^CZ* /G#_A>'Q'_
M .A8L?\ P N/_CE'_"\/B/\ ]"Q8_P#@!<?_ !ROH^B@#YP_X7A\1_\ H6+'
M_P  +C_XY1_PO#XC_P#0L6/_ ( 7'_QROH^B@#YP_P"%X?$?_H6+'_P N/\
MXY1_PO#XC_\ 0L6/_@!<?_'*^CZ* /G#_A>'Q'_Z%BQ_\ +C_P".4?\ "\/B
M/_T+%C_X 7'_ ,<KZ/HH ^</^%X?$?\ Z%BQ_P# "X_^.4?\+P^(_P#T+%C_
M . %Q_\ '*^CZ* /G#_A>'Q'_P"A8L?_   N/_CE'_"\/B/_ -"Q8_\ @!<?
M_'*^CZ* /G#_ (7A\1_^A8L?_ "X_P#CE'_"\/B/_P!"Q8_^ %Q_\<KZ/HH
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MBQ_\ +C_ ..4?\+P^(__ $+%C_X 7'_QROH^B@#YP_X7A\1_^A8L?_ "X_\
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M#XC_ /0L6/\ X 7'_P <KZ/HH ^</^%X?$?_ *%BQ_\  "X_^.4?\+P^(_\
MT+%C_P" %Q_\<KZ/HH ^-M$\4^)M&\>7OB>STA9-3N9)I)('MI#&ID8EL*"&
M&">.:[K_ (7A\1_^A8L?_ "X_P#CE?1]% 'SA_PO#XC_ /0L6/\ X 7'_P <
MH_X7A\1_^A8L?_ "X_\ CE?1]% 'SA_PO#XC_P#0L6/_ ( 7'_QRC_A>'Q'_
M .A8L?\ P N/_CE?1]% 'SA_PO#XC_\ 0L6/_@!<?_'*/^%X?$?_ *%BQ_\
M "X_^.5]'T4 ?.'_  O#XC_]"Q8_^ %Q_P#'*/\ A>'Q'_Z%BQ_\ +C_ ..5
M]'T4 ?.'_"\/B/\ ]"Q8_P#@!<?_ !RC_A>'Q'_Z%BQ_\ +C_P".5]'T4 ?.
M'_"\/B/_ -"Q8_\ @!<?_'*/^%X?$?\ Z%BQ_P# "X_^.5]'T4 ?.'_"\/B/
M_P!"Q8_^ %Q_\<H_X7A\1_\ H6+'_P  +C_XY7T?10!\X?\ "\/B/_T+%C_X
M 7'_ ,<H_P"%X?$?_H6+'_P N/\ XY7T?10!\X?\+P^(_P#T+%C_ . %Q_\
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M_P  +C_XY7T?10!\X?\ "\/B/_T+%C_X 7'_ ,<H_P"%X?$?_H6+'_P N/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img159889792_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img159889792_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1("DL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7@'MI'K'_"<Z#_S]/_WZ;_"C_A.=!_Y^G_[]-_A7D]%'U> >VD>L?\)SH/\
MS]/_ -^F_P */^$YT'_GZ?\ []-_A7D]%'U> >VD>L?\)SH/_/T__?IO\*/^
M$YT'_GZ?_OTW^%>3T4?5X![:1ZQ_PG.@_P#/T_\ WZ;_  H_X3G0?^?I_P#O
MTW^%>3T4?5X![:1ZQ_PG.@_\_3_]^F_PH_X3G0?^?I_^_3?X5Y/11]7@'MI'
MK'_"<Z#_ ,_3_P#?IO\ "C_A.=!_Y^G_ ._3?X5Y/11]7@'MI'K'_"<Z#_S]
M/_WZ;_"C_A.=!_Y^G_[]-_A7D]%'U> >VD>L?\)SH/\ S]/_ -^F_P */^$Y
MT'_GZ?\ []-_A7D]%'U> >VD>L?\)SH/_/T__?IO\*/^$YT'_GZ?_OTW^%>3
MT4?5X![:1ZQ_PG.@_P#/T_\ WZ;_  H_X3G0?^?I_P#OTW^%>3T4?5X![:1Z
MQ_PG.@_\_3_]^F_PH_X3G0?^?I_^_3?X5Y/11]7@'MI'K'_"<Z#_ ,_3_P#?
MIO\ "C_A.=!_Y^G_ ._3?X5Y/11]7@'MI'K'_"<Z#_S]/_WZ;_"C_A.=!_Y^
MG_[]-_A7D]%'U> >VD>MQ>--#FF2)+ER[L%4>4W4_A4WB#Q7I'AC[/\ VK.\
M7VC=Y>V-GSMQGH/]H5Y1IO\ R%+3_KLG_H0K3^.7_,!_[>/_ &G652E&,DD:
M1FVFSJ?^%K>$?^?^7_P'?_"C_A:WA'_G_E_\!W_PKYXHI>S0<[/H?_A:WA'_
M )_Y?_ =_P#"C_A:WA'_ )_Y?_ =_P#"OGBBCV:#G9]#_P#"UO"/_/\ R_\
M@._^%'_"UO"/_/\ R_\ @._^%?/%%'LT'.SZ'_X6MX1_Y_Y?_ =_\*/^%K>$
M?^?^7_P'?_"OGBBCV:#G9]#_ /"UO"/_ #_R_P#@._\ A1_PM;PC_P _\O\
MX#O_ (5\\44>S0<[/H?_ (6MX1_Y_P"7_P !W_PH_P"%K>$?^?\ E_\  =_\
M*^>**/9H.=GT/_PM;PC_ ,_\O_@._P#A1_PM;PC_ ,_\O_@._P#A7SQ11[-!
MSL^A_P#A:WA'_G_E_P# =_\ "C_A:WA'_G_E_P# =_\ "OGBBCV:#G9]#_\
M"UO"/_/_ "_^ [_X4?\ "UO"/_/_ "_^ [_X5\\44>S0<[/H?_A:WA'_ )_Y
M?_ =_P#"C_A:WA'_ )_Y?_ =_P#"OGBBCV:#G9]#_P#"UO"/_/\ R_\ @._^
M%'_"UO"/_/\ R_\ @._^%?/%%'LT'.SZ'_X6MX1_Y_Y?_ =_\*/^%K>$?^?^
M7_P'?_"OGBBCV:#G9]#_ /"UO"/_ #_R_P#@._\ A1_PM;PC_P _\O\ X#O_
M (5\\44>S0<[/H?_ (6MX1_Y_P"7_P !W_PH_P"%K>$?^?\ E_\  =_\*^>*
M*/9H.=GT/_PM;PC_ ,_\O_@._P#A1_PM;PC_ ,_\O_@._P#A7SQ11[-!SL^A
M_P#A:WA'_G_E_P# =_\ "C_A:WA'_G_E_P# =_\ "OGBBCV:#G9]#_\ "UO"
M/_/_ "_^ [_X4?\ "UO"/_/_ "_^ [_X5\\44>S0<[/H?_A:WA'_ )_Y?_ =
M_P#"C_A:WA'_ )_Y?_ =_P#"OGBBCV:#G9]#_P#"UO"/_/\ R_\ @._^%'_"
MUO"/_/\ R_\ @._^%?/%%'LT'.SZ'_X6MX1_Y_Y?_ =_\*/^%K>$?^?^7_P'
M?_"OGBBCV:#G9]#_ /"UO"/_ #_R_P#@._\ A1_PM;PC_P _\O\ X#O_ (5\
M\44>S0<[/H?_ (6MX1_Y_P"7_P !W_PH_P"%K>$?^?\ E_\  =_\*^>**/9H
M.=GT/_PM;PC_ ,_\O_@._P#A1_PM;PC_ ,_\O_@._P#A7SQ11[-!SL^A_P#A
M:WA'_G_E_P# =_\ "C_A:WA'_G_E_P# =_\ "OGBBCV:#G9]#_\ "UO"/_/_
M "_^ [_X4?\ "UO"/_/_ "_^ [_X5\\44>S0<[/H?_A:WA'_ )_Y?_ =_P#"
MC_A:WA'_ )_Y?_ =_P#"OGBBCV:#G9]#_P#"UO"/_/\ R_\ @._^%'_"UO"/
M_/\ R_\ @._^%?/%%'LT'.SZ'_X6MX1_Y_Y?_ =_\*/^%K>$?^?^7_P'?_"O
MGBBCV:#G9]#_ /"UO"/_ #_R_P#@._\ A1_PM;PC_P _\O\ X#O_ (5\\44>
MS0<[/H?_ (6MX1_Y_P"7_P !W_PH_P"%K>$?^?\ E_\  =_\*^>**/9H.=GT
M/_PM;PC_ ,_\O_@._P#A1_PM;PC_ ,_\O_@._P#A7SQ11[-!SL^A_P#A:WA'
M_G_E_P# =_\ "C_A:WA'_G_E_P# =_\ "OGBBCV:#G9]#_\ "UO"/_/_ "_^
M [_X4?\ "UO"/_/_ "_^ [_X5\\44>S0<[/H?_A:WA'_ )_Y?_ =_P#"C_A:
MWA'_ )_Y?_ =_P#"OGBBCV:#G9]#_P#"UO"/_/\ R_\ @._^%.3XJ>$I'5%O
MI2S$ ?Z._7\J^=JFM/\ C\@_ZZ+_ #H]F@YV?5&I:O9Z2L;7<A02$A<*3G'T
MK/\ ^$PT7_GX?_OTW^%9GC[_ %%C_O/_ "%</7@8O'U:-5PBE9'OX/+Z5:BI
MR;NSTO\ X3#1?^?A_P#OTW^%'_"8:+_S\/\ ]^F_PKS2BN?^U:_9?U\SI_LF
MAW?]?(]+_P"$PT7_ )^'_P"_3?X4?\)AHO\ S\/_ -^F_P *\THH_M6OV7]?
M,/[)H=W_ %\CTO\ X3#1?^?A_P#OTW^%'_"8:+_S\/\ ]^F_PKS2BC^U:_9?
MU\P_LFAW?]?(]+_X3#1?^?A_^_3?X4?\)AHO_/P__?IO\*\THH_M6OV7]?,/
M[)H=W_7R/2_^$PT7_GX?_OTW^%'_  F&B_\ /P__ 'Z;_"O-**/[5K]E_7S#
M^R:'=_U\CTO_ (3#1?\ GX?_ +]-_A1_PF&B_P#/P_\ WZ;_  KS2BC^U:_9
M?U\P_LFAW?\ 7R/2_P#A,-%_Y^'_ ._3?X4?\)AHO_/P_P#WZ;_"O-**/[5K
M]E_7S#^R:'=_U\CTO_A,-%_Y^'_[]-_A1_PF&B_\_#_]^F_PKS2BC^U:_9?U
M\P_LFAW?]?(]+_X3#1?^?A_^_3?X4?\ "8:+_P _#_\ ?IO\*\THH_M6OV7]
M?,/[)H=W_7R/2_\ A,-%_P"?A_\ OTW^%'_"8:+_ ,_#_P#?IO\ "O-**/[5
MK]E_7S#^R:'=_P!?(]+_ .$PT7_GX?\ []-_A1_PF&B_\_#_ /?IO\*\THH_
MM6OV7]?,/[)H=W_7R/2_^$PT7_GX?_OTW^%'_"8:+_S\/_WZ;_"O-**/[5K]
ME_7S#^R:'=_U\CTO_A,-%_Y^'_[]-_A1_P )AHO_ #\/_P!^F_PKS2BC^U:_
M9?U\P_LFAW?]?(]+_P"$PT7_ )^'_P"_3?X4?\)AHO\ S\/_ -^F_P *\THH
M_M6OV7]?,/[)H=W_ %\CTO\ X3#1?^?A_P#OTW^%'_"8:+_S\/\ ]^F_PKS2
MBC^U:_9?U\P_LFAW?]?(]+_X3#1?^?A_^_3?X4?\)AHO_/P__?IO\*\THH_M
M6OV7]?,/[)H=W_7R/2_^$PT7_GX?_OTW^%'_  F&B_\ /P__ 'Z;_"O-**/[
M5K]E_7S#^R:'=_U\CTO_ (3#1?\ GX?_ +]-_A1_PF&B_P#/P_\ WZ;_  KS
M2BC^U:_9?U\P_LFAW?\ 7R/2_P#A,-%_Y^'_ ._3?X4?\)AHO_/P_P#WZ;_"
MO-**/[5K]E_7S#^R:'=_U\CTO_A,-%_Y^'_[]-_A1_PF&B_\_#_]^F_PKS2B
MC^U:_9?U\P_LFAW?]?(]+_X3#1?^?A_^_3?X4?\ "8:+_P _#_\ ?IO\*\TH
MH_M6OV7]?,/[)H=W_7R/2_\ A,-%_P"?A_\ OTW^%'_"8:+_ ,_#_P#?IO\
M"O-**/[5K]E_7S#^R:'=_P!?(]+_ .$PT7_GX?\ []-_A1_PF&B_\_#_ /?I
MO\*\THH_M6OV7]?,/[)H=W_7R/2_^$PT7_GX?_OTW^%'_"8:+_S\/_WZ;_"O
M-**/[5K]E_7S#^R:'=_U\CTO_A,-%_Y^'_[]-_A1_P )AHO_ #\/_P!^F_PK
MS2BC^U:_9?U\P_LFAW?]?(]+_P"$PT7_ )^'_P"_3?X4?\)AHO\ S\/_ -^F
M_P *\THH_M6OV7]?,/[)H=W_ %\CTO\ X3#1?^?A_P#OTW^%'_"8:+_S\/\
M]^F_PKS2BC^U:_9?U\P_LFAW?]?(]+_X3#1?^?A_^_3?X4?\)AHO_/P__?IO
M\*\THH_M6OV7]?,/[)H=W_7R/2_^$PT7_GX?_OTW^%'_  F&B_\ /P__ 'Z;
M_"O-**/[5K]E_7S#^R:'=_U\CTO_ (3#1?\ GX?_ +]-_A1_PF&B_P#/P_\
MWZ;_  KS2BC^U:_9?U\P_LFAW?\ 7R/2_P#A,-%_Y^'_ ._3?X4?\)AHO_/P
M_P#WZ;_"O-**/[5K]E_7S#^R:'=_U\CTO_A,-%_Y^'_[]-_A1_PF&B_\_#_]
M^F_PKS2BC^U:_9?U\P_LFAW?]?(]+_X3#1?^?A_^_3?X4?\ "8:+_P _#_\
M?IO\*\THH_M6OV7]?,/[)H=W_7R/2_\ A,-%_P"?A_\ OTW^%'_"8:+_ ,_#
M_P#?IO\ "O-**/[5K]E_7S#^R:'=_P!?(]:TW6++5O-^QR,_E8W94C&<XZ_0
MU?KB_ '_ #$?^V?_ +-7:5[&%JRJT5.6[_S/%Q=&-&LZ<=E_D%%%%=!S!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 9'BC_ )%C4/\ KD?YUXW7LGBC_D6-0_ZY'^=>-UV8;X6<
M];<****Z#$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +6F_\A2T_
MZ[)_Z$*T_CE_S ?^WC_VG69IO_(4M/\ KLG_ *$*T_CE_P P'_MX_P#:=<];
MXT:T_A9Y#1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %36G_'Y!_UT7^=0U-:?\?D'_71?YT ?0OC[_46/^\_\A7#UW'C
M[_46/^\_\A7#U\?F/^\2^7Y'V&6_[M'Y_F%%%%<)WA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% ':^ /\ F(_]L_\ V:NTKB_
M'_,1_P"V?_LU=I7TV7_[M'Y_FSY;,O\ >I?+\D%%%%=IPA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME5Q15V>$SVT]LP6>"2)CR!(A4G\ZBKW_ .+NF"]\%-=*N9+*9)<XYVGY2/\
MQX'\*\ HC+F5PDK,EAMI[EBL$,DK 9(C4L?TI)H)K>3RYXGB?&=KJ5/Y&O<_
M@WIWV;PG/>LOSW=P2#CJBC:/UW5Q7QBU!;KQBEJF/]$ME1O]YLM_(K24KRL-
MQTN>>T4459(4444 %%%% !5G3K&74]2M;" J)KF58D+G !8X&?;FJU;7@_\
MY'31/^OZ'_T,4F".EUCX3:QH^D7.HR7MC+';1F1T0MDJ.N,K7 5]/^-?^1)U
MK_KSD_\ 0:^8*F$FUJ5))!1115DA115K3=.N=6U*WL+--]Q.X1%SCGU/L.M
M%95+,%4$D\ #O6G'X:UZ6/S(]$U)T_O+:N1^>*^@?#7A'1_!VF"0+";E$W7%
M[+@'IS@G[J^WYUF3_%OPK#<&)9KF90<>9' =OZX/Z5ESM[(OD[L\!F@FMI3%
M/%)%(.J2*5(_ U'7JGQ/\4Z!XC\/6!TRZ2>Y2YR08RKHFTYSD=,[?RKRNKB[
MHEJS"BBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %3
M6G_'Y!_UT7^=0U-:?\?D'_71?YT ?0OC[_46/^\_\A7#UW'C[_46/^\_\A7#
MU\?F/^\2^7Y'V&6_[M'Y_F%%%%<)WA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %21P2R@F.)W Z[5)Q4==[X$N0^G7-M_%'+O_  8?_6-=&&HJ
MM44&['/BJ[H4G42N<(Z-&Q5U*L.Q&#3:[+Q[;8EL[H#J&C8_3D?S-<;2Q%'V
M-1P[#PU;VU)5.Y)'!-*,QQ.X]54FF,K(Q5E*L.H(P:]:T:U^Q:-:08P5C!;_
M 'CR?U-<KX]M=L]I=@?>4QL?IR/YFNNME[I4?:7U[''0S%5:_LK::ZG'5)'!
M-*"8XG<#NJDU'7K&A6OV/0[.'&#Y89A[GD_SK#"87ZQ)J]K&^,Q?U:*=KMGE
M!!4D$$$=0:2K^M7(N]:O)U^ZTI"^X' _E5"N::2DTCJ@W**;"BBBI*"BBB@
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MJ?\ "J'PWN8EDOK5B!*X1U'<@9!_+(_.M%4E[+FZD."Y[&Y_PC/AG2X5-S%
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MJ6D$F3'+,B-@]BP!KT35_ ^GR:>RZ9:^5=;E"L96( R,YR3VS7 :-_R'-/\
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MN>M\:-:?PL\AHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH R/%'_(L:A_UR/\Z\;KV3Q1_R+&H?]<C_ #KQNNS#?"SGK;A111708A7L
M7A/_ )%>P_ZYG^9KQVO8/",B2>%['8P;:A!P>AR>*Y\3\*-:.YYQXL_Y&B__
M .N@_D*L^"&G7Q1;B'=M*L)0.FW!Z_CC\<5Z)=>&M'O+E[BXL4DED.68LW/Z
MTL4&BZ!&Q06MF#]YF8 G\3R:CVR<.5(KV;4KW&^)PA\,ZAYGW?)./KV_7%<9
MX!T>WO;F>]N8UD$!"QJPR-QYS^']:3Q?XLBU2'[!8;C;;@TDI&-^.@ ].],\
M":U;Z=>3VEU((X[C!61CA589X/US^E.,)1I,'*+FCJO$WBI= :*%+?SIY%W
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M^-V/^6N[;_Z!7&?&W4<RZ5IBMT5[AQ]?E7^35[!7SA\2M475?'-\\4@>&#;
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M(13WYZGIV]:\CJZ:LB9N["BBBM" HHHH **** "BBB@ HHHH **** "BBB@
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M0O'+N#&12<$8]"*XO0-7.CZDL[ M"XV2*/3U'N*]&8:=KU@5S'<P-SP>5/\
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M,]##9A1;C1A%HXNBBBO,/5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .U\ ?\Q'_MG_[-7:5Q?@#_ )B/_;/_ -FKM*^FR_\ W:/S_-GR
MV9?[U+Y?D@HHHKM.$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\??ZBQ_WG_D*X>OC\Q_WB7R_(^PRW_=H_/\ ,****X3O"BBB@ HHHH ****
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M0K3^.7_,!_[>/_:=<];XT:T_A9Y#1112&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %36G_'Y!_UT7^=0U-:?\?D'_71?YT ?
M0OC[_46/^\_\A7#UW'C[_46/^\_\A7#U\?F/^\2^7Y'V&6_[M'Y_F%%%%<)W
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ':^
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M0_Z&O0__  8P_P#Q5>8?\,UZ/_T,%]_WY2C_ (9KT?\ Z&"^_P"_*4 >G_\
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M=^$/^AKT/_P8P_\ Q5'_  G?A#_H:]#_ /!C#_\ %5YA_P ,UZ/_ -#!??\
M?E*/^&:]'_Z&"^_[\I0!Z?\ \)WX0_Z&O0__  8P_P#Q5'_"=^$/^AKT/_P8
MP_\ Q5>8?\,UZ/\ ]#!??]^4H_X9KT?_ *&"^_[\I0!Z?_PG?A#_ *&O0_\
MP8P__%4?\)WX0_Z&O0__  8P_P#Q5>8?\,UZ/_T,%]_WY2C_ (9KT?\ Z&"^
M_P"_*4 >G_\ "=^$/^AKT/\ \&,/_P 51_PG?A#_ *&O0_\ P8P__%5YA_PS
M7H__ $,%]_WY2C_AFO1_^A@OO^_*4 >G_P#"=^$/^AKT/_P8P_\ Q5'_  G?
MA#_H:]#_ /!C#_\ %5YA_P ,UZ/_ -#!??\ ?E*/^&:]'_Z&"^_[\I0!Z?\
M\)WX0_Z&O0__  8P_P#Q5'_"=^$/^AKT/_P8P_\ Q5>8?\,UZ/\ ]#!??]^4
MH_X9KT?_ *&"^_[\I0!Z?_PG?A#_ *&O0_\ P8P__%4?\)WX0_Z&O0__  8P
M_P#Q5>8?\,UZ/_T,%]_WY2C_ (9KT?\ Z&"^_P"_*4 >G_\ "=^$/^AKT/\
M\&,/_P 51_PG?A#_ *&O0_\ P8P__%5YA_PS7H__ $,%]_WY2C_AFO1_^A@O
MO^_*4 >G_P#"=^$/^AKT/_P8P_\ Q5'_  G?A#_H:]#_ /!C#_\ %5YA_P ,
MUZ/_ -#!??\ ?E*/^&:]'_Z&"^_[\I0!Z?\ \)WX0_Z&O0__  8P_P#Q5'_"
M=^$/^AKT/_P8P_\ Q5>8?\,UZ/\ ]#!??]^4H_X9KT?_ *&"^_[\I0!Z?_PG
M?A#_ *&O0_\ P8P__%4?\)WX0_Z&O0__  8P_P#Q5>8?\,UZ/_T,%]_WY2C_
M (9KT?\ Z&"^_P"_*4 >G_\ "=^$/^AKT/\ \&,/_P 51_PG?A#_ *&O0_\
MP8P__%5YA_PS7H__ $,%]_WY2C_AFO1_^A@OO^_*4 >G_P#"=^$/^AKT/_P8
MP_\ Q5'_  G?A#_H:]#_ /!C#_\ %5YA_P ,UZ/_ -#!??\ ?E*/^&:]'_Z&
M"^_[\I0!Z?\ \)WX0_Z&O0__  8P_P#Q5'_"=^$/^AKT/_P8P_\ Q5>8?\,U
MZ/\ ]#!??]^4H_X9KT?_ *&"^_[\I0!Z?_PG?A#_ *&O0_\ P8P__%4?\)WX
M0_Z&O0__  8P_P#Q5>8?\,UZ/_T,%]_WY2C_ (9KT?\ Z&"^_P"_*4 >G_\
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M=^$/^AKT/_P8P_\ Q5'_  G?A#_H:]#_ /!C#_\ %5YA_P ,UZ/_ -#!??\
M?E*/^&:]'_Z&"^_[\I0!Z?\ \)WX0_Z&O0__  8P_P#Q5'_"=^$/^AKT/_P8
MP_\ Q5>8?\,UZ/\ ]#!??]^4H_X9KT?_ *&"^_[\I0!Z?_PG?A#_ *&O0_\
MP8P__%4?\)WX0_Z&O0__  8P_P#Q5>8?\,UZ/_T,%]_WY2C_ (9KT?\ Z&"^
M_P"_*4 >G_\ "=^$/^AKT/\ \&,/_P 51_PG?A#_ *&O0_\ P8P__%5YA_PS
M7H__ $,%]_WY2C_AFO1_^A@OO^_*4 >G_P#"=^$/^AKT/_P8P_\ Q5'_  G?
MA#_H:]#_ /!C#_\ %5YA_P ,UZ/_ -#!??\ ?E*/^&:]'_Z&"^_[\I0!Z?\
M\)WX0_Z&O0__  8P_P#Q5'_"=^$/^AKT/_P8P_\ Q5>8?\,UZ/\ ]#!??]^4
MH_X9KT?_ *&"^_[\I0!Z?_PG?A#_ *&O0_\ P8P__%4?\)WX0_Z&O0__  8P
M_P#Q5>8?\,UZ/_T,%]_WY2C_ (9KT?\ Z&"^_P"_*4 >G_\ "=^$/^AKT/\
M\&,/_P 51_PG?A#_ *&O0_\ P8P__%5YA_PS7H__ $,%]_WY2C_AFO1_^A@O
MO^_*4 >G_P#"=^$/^AKT/_P8P_\ Q5'_  G?A#_H:]#_ /!C#_\ %5YA_P ,
MUZ/_ -#!??\ ?E*/^&:]'_Z&"^_[\I0!Z?\ \)WX0_Z&O0__  8P_P#Q5'_"
M=^$/^AKT/_P8P_\ Q5>8?\,UZ/\ ]#!??]^4H_X9KT?_ *&"^_[\I0!Z?_PG
M?A#_ *&O0_\ P8P__%4?\)WX0_Z&O0__  8P_P#Q5>8?\,UZ/_T,%]_WY2C_
M (9KT?\ Z&"^_P"_*4 >G_\ "=^$/^AKT/\ \&,/_P 51_PG?A#_ *&O0_\
MP8P__%5YA_PS7H__ $,%]_WY2C_AFO1_^A@OO^_*4 >G_P#"=^$/^AKT/_P8
MP_\ Q5'_  G?A#_H:]#_ /!C#_\ %5YA_P ,UZ/_ -#!??\ ?E*/^&:]'_Z&
M"^_[\I0!Z?\ \)WX0_Z&O0__  8P_P#Q5'_"=^$/^AKT/_P8P_\ Q5>8?\,U
MZ/\ ]#!??]^4H_X9KT?_ *&"^_[\I0!Z?_PG?A#_ *&O0_\ P8P__%4?\)WX
M0_Z&O0__  8P_P#Q5>8?\,UZ/_T,%]_WY2C_ (9KT?\ Z&"^_P"_*4 >G_\
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M=^$/^AKT/_P8P_\ Q5'_  G?A#_H:]#_ /!C#_\ %5YA_P ,UZ/_ -#!??\
M?E*/^&:]'_Z&"^_[\I0!Z?\ \)WX0_Z&O0__  8P_P#Q5'_"=^$/^AKT/_P8
MP_\ Q5>8?\,UZ/\ ]#!??]^4H_X9KT?_ *&"^_[\I0!Z?_PG?A#_ *&O0_\
MP8P__%4?\)WX0_Z&O0__  8P_P#Q5>8?\,UZ/_T,%]_WY2C_ (9KT?\ Z&"^
M_P"_*4 >G_\ "=^$/^AKT/\ \&,/_P 51_PG?A#_ *&O0_\ P8P__%5YA_PS
M7H__ $,%]_WY2C_AFO1_^A@OO^_*4 >G_P#"=^$/^AKT/_P8P_\ Q5'_  G?
MA#_H:]#_ /!C#_\ %5YA_P ,UZ/_ -#!??\ ?E*/^&:]'_Z&"^_[\I0!Z?\
M\)WX0_Z&O0__  8P_P#Q5'_"=^$/^AKT/_P8P_\ Q5>8?\,UZ/\ ]#!??]^4
MH_X9KT?_ *&"^_[\I0!Z?_PG?A#_ *&O0_\ P8P__%4?\)WX0_Z&O0__  8P
M_P#Q5>8?\,UZ/_T,%]_WY2C_ (9KT?\ Z&"^_P"_*4 >G_\ "=^$/^AKT/\
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M (9KT?\ Z&"^_P"_*4 >G_\ "=^$/^AKT/\ \&,/_P 51_PG?A#_ *&O0_\
MP8P__%5YA_PS7H__ $,%]_WY2C_AFO1_^A@OO^_*4 >G_P#"=^$/^AKT/_P8
MP_\ Q5'_  G?A#_H:]#_ /!C#_\ %5YA_P ,UZ/_ -#!??\ ?E*/^&:]'_Z&
M"^_[\I0!Z?\ \)WX0_Z&O0__  8P_P#Q5'_"=^$/^AKT/_P8P_\ Q5>8?\,U
MZ/\ ]#!??]^4H_X9KT?_ *&"^_[\I0!Z?_PG?A#_ *&O0_\ P8P__%4?\)WX
M0_Z&O0__  8P_P#Q5>8?\,UZ/_T,%]_WY2C_ (9KT?\ Z&"^_P"_*4 >G_\
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M=^$/^AKT/_P8P_\ Q5'_  G?A#_H:]#_ /!C#_\ %5YA_P ,UZ/_ -#!??\
M?E*/^&:]'_Z&"^_[\I0!Z?\ \)WX0_Z&O0__  8P_P#Q5'_"=^$/^AKT/_P8
MP_\ Q5>8?\,UZ/\ ]#!??]^4H_X9KT?_ *&"^_[\I0!Z?_PG?A#_ *&O0_\
MP8P__%4?\)WX0_Z&O0__  8P_P#Q5>8?\,UZ/_T,%]_WY2C_ (9KT?\ Z&"^
M_P"_*4 >G_\ "=^$/^AKT/\ \&,/_P 51_PG?A#_ *&O0_\ P8P__%5YA_PS
M7H__ $,%]_WY2C_AFO1_^A@OO^_*4 =WXC\:^%)_#M]%#XGT621HB%1+^(DG
MV :O*/[>T?\ Z"UA_P"!*?XUN?\ #->C_P#0P7W_ 'Y2C_AFO1_^A@OO^_*5
MK3JN"M8SG34G<P_[>T?_ *"UA_X$I_C1_;VC_P#06L/_  )3_&MS_AFO1_\
MH8+[_ORE'_#->C_]#!??]^4K3ZR^Q/L5W,/^WM'_ .@M8?\ @2G^-']O:/\
M]!:P_P# E/\ &MS_ (9KT?\ Z&"^_P"_*4?\,UZ/_P!#!??]^4H^LOL'L5W,
M/^WM'_Z"UA_X$I_C1_;VC_\ 06L/_ E/\:W/^&:]'_Z&"^_[\I1_PS7H_P#T
M,%]_WY2CZR^P>Q7<P_[>T?\ Z"UA_P"!*?XT?V]H_P#T%K#_ ,"4_P :W/\
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M[@_[^#_&O5?^&:]'_P"A@OO^_*4?\,UZ/_T,%]_WY2CVK#D/*OM]G_S]P?\
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M^X/^_@_QKU7_ (9KT?\ Z&"^_P"_*4?\,UZ/_P!#!??]^4H]JPY#RK[?9_\
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MW_?E*/:L.0\J^WV?_/W!_P!_!_C1]OL_^?N#_OX/\:]5_P"&:]'_ .A@OO\
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MJCFY6N>KA\RE0IJFHWL4O^$BT/\ Z#.G?^!2?XT?\)%H?_09T[_P*3_&KO\
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M3#^9A_;$_P"5%+_A(M#_ .@SIW_@4G^-'_"1:'_T&=._\"D_QJ[_ ,,UZ/\
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M *&"^_[\I1_9,/YF']L3_E12_P"$BT/_ *#.G?\ @4G^-'_"1:'_ -!G3O\
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M_P"$BT/_ *#.G?\ @4G^-'_"1:'_ -!G3O\ P*3_ !J[_P ,UZ/_ -#!??\
M?E*/^&:]'_Z&"^_[\I1_9,/YF']L3_E12_X2+0_^@SIW_@4G^-'_  D6A_\
M09T[_P "D_QJ[_PS7H__ $,%]_WY2C_AFO1_^A@OO^_*4?V3#^9A_;$_Y44O
M^$BT/_H,Z=_X%)_C1_PD6A_]!G3O_ I/\:N_\,UZ/_T,%]_WY2C_ (9KT?\
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MZ/\ ]#!??]^4H_X9KT?_ *&"^_[\I1_9,/YF']L3_E12_P"$BT/_ *#.G?\
M@4G^-'_"1:'_ -!G3O\ P*3_ !J[_P ,UZ/_ -#!??\ ?E*/^&:]'_Z&"^_[
M\I1_9,/YF']L3_E1V/PTU&QU#^U/L5[;W.SRM_DRJ^W._&<'CH?RKO58,H92
M"I&01T-?+7Q"\*7GP@_L[_A'O$NJ1_VIYOG^5*8<^5LVYV'G_6-UZ5])>&BY
M\*Z.99&DD-E#N=SDL=@R3[FO0H451IJFGL>;B*SK5'4:M<\ ^ __ "5O7O\
MKRN/_1\5?2=?-GP'_P"2MZ]_UY7'_H^*OI.MC$**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** / /VF?^97_P"WO_VC7M?AK_D5M(_Z\H?_ $ 5XI^TS_S*_P#V]_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!X!^TS_S*_P#V]_\ M&O:
M_#7_ "*VD?\ 7E#_ .@"O%/VF?\ F5_^WO\ ]HU[7X:_Y%;2/^O*'_T 4 >
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M_:->U^&O^16TC_KRA_\ 0!7BG[3/_,K_ /;W_P"T:]K\-?\ (K:1_P!>4/\
MZ * / /@/_R5O7O^O*X_]'Q5])U\V? ?_DK>O?\ 7E<?^CXJ^DZ "BBB@ K+
M\2_\BMJ__7E-_P"@&M2LOQ+_ ,BMJ_\ UY3?^@&@#XATG_D,V/\ U\1_^A"O
MO*O@W2?^0S8_]?$?_H0K[RH YCQ?X_\ #W@B!'UB[(GD&8K6%=\KCU [#W)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \ _:9_P"97_[>_P#VC7M?AK_D5M(_Z\H?_0!7BG[3/_,K_P#;
MW_[1KVOPU_R*VD?]>4/_ * * / /@/\ \E;U[_KRN/\ T?%7TG7R%\._'=CX
M(\=:IK-[:W,\-Q!+"J0;=P+2HP)R0,84UZM_PTCX<_Z VJ_E'_\ %4 >ST5X
MQ_PTCX<_Z VJ_E'_ /%4?\-(^'/^@-JOY1__ !5 'L]%>,?\-(^'/^@-JOY1
M_P#Q5'_#2/AS_H#:K^4?_P 50![/17C'_#2/AS_H#:K^4?\ \51_PTCX<_Z
MVJ_E'_\ %4 >ST5XQ_PTCX<_Z VJ_E'_ /%4?\-(^'/^@-JOY1__ !5 'L]%
M>,?\-(^'/^@-JOY1_P#Q5'_#2/AS_H#:K^4?_P 50![/17C'_#2/AS_H#:K^
M4?\ \51_PTCX<_Z VJ_E'_\ %4 >ST5XQ_PTCX<_Z VJ_E'_ /%4?\-(^'/^
M@-JOY1__ !5 'L]%>,?\-(^'/^@-JOY1_P#Q5'_#2/AS_H#:K^4?_P 50![/
M17C'_#2/AS_H#:K^4?\ \51_PTCX<_Z VJ_E'_\ %4 >ST5XQ_PTCX<_Z VJ
M_E'_ /%4?\-(^'/^@-JOY1__ !5 'L]%>,?\-(^'/^@-JOY1_P#Q5'_#2/AS
M_H#:K^4?_P 50![/17C'_#2/AS_H#:K^4?\ \51_PTCX<_Z VJ_E'_\ %4 >
MST5XQ_PTCX<_Z VJ_E'_ /%4?\-(^'/^@-JOY1__ !5 'L]%>,?\-(^'/^@-
MJOY1_P#Q5'_#2/AS_H#:K^4?_P 50![/17C'_#2/AS_H#:K^4?\ \51_PTCX
M<_Z VJ_E'_\ %4 >ST5XQ_PTCX<_Z VJ_E'_ /%4?\-(^'/^@-JOY1__ !5
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M2/AS_H#:K^4?_P 50![/17C'_#2/AS_H#:K^4?\ \51_PTCX<_Z VJ_E'_\
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M-(^'/^@-JOY1_P#Q5'_#2/AS_H#:K^4?_P 50![/17C'_#2/AS_H#:K^4?\
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M_P#Q5'_#2/AS_H#:K^4?_P 50![/17C'_#2/AS_H#:K^4?\ \51_PTCX<_Z
MVJ_E'_\ %4 >ST5XQ_PTCX<_Z VJ_E'_ /%4?\-(^'/^@-JOY1__ !5 'L]%
M>,?\-(^'/^@-JOY1_P#Q5'_#2/AS_H#:K^4?_P 50![/17C'_#2/AS_H#:K^
M4?\ \51_PTCX<_Z VJ_E'_\ %4 >ST5XQ_PTCX<_Z VJ_E'_ /%4?\-(^'/^
M@-JOY1__ !5 'L]%>,?\-(^'/^@-JOY1_P#Q5'_#2/AS_H#:K^4?_P 50![/
M17C'_#2/AS_H#:K^4?\ \51_PTCX<_Z VJ_E'_\ %4 >ST5XQ_PTCX<_Z VJ
M_E'_ /%4?\-(^'/^@-JOY1__ !5 'L]%>,?\-(^'/^@-JOY1_P#Q5'_#2/AS
M_H#:K^4?_P 50![/17C'_#2/AS_H#:K^4?\ \51_PTCX<_Z VJ_E'_\ %4 >
MST5XQ_PTCX<_Z VJ_E'_ /%4?\-(^'/^@-JOY1__ !5 'L]%>,?\-(^'/^@-
MJOY1_P#Q5'_#2/AS_H#:K^4?_P 50![/17C'_#2/AS_H#:K^4?\ \51_PTCX
M<_Z VJ_E'_\ %4 >ST5XQ_PTCX<_Z VJ_E'_ /%4?\-(^'/^@-JOY1__ !5
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M2/AS_H#:K^4?_P 50![/17C'_#2/AS_H#:K^4?\ \51_PTCX<_Z VJ_E'_\
M%4 >ST5XQ_PTCX<_Z VJ_E'_ /%4?\-(^'/^@-JOY1__ !5 'L]%>,?\-(^'
M/^@-JOY1_P#Q5'_#2/AS_H#:K^4?_P 50![/17BG_#26@^9@:'J6SUW1Y_+/
M]:D_X:1\.?\ 0&U7\H__ (J@#V>BO&/^&D?#G_0&U7\H_P#XJC_AI'PY_P!
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M1\.?] ;5?RC_ /BJ/^&D?#G_ $!M5_*/_P"*H ]GHKQC_AI'PY_T!M5_*/\
M^*H_X:1\.?\ 0&U7\H__ (J@#V>BO&/^&D?#G_0&U7\H_P#XJC_AI'PY_P!
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M1\.?] ;5?RC_ /BJ/^&D?#G_ $!M5_*/_P"*H ]GHKQC_AI'PY_T!M5_*/\
M^*H_X:1\.?\ 0&U7\H__ (J@#V>BO&/^&D?#G_0&U7\H_P#XJC_AI'PY_P!
M;5?RC_\ BJ /9Z*\8_X:1\.?] ;5?RC_ /BJ/^&D?#G_ $!M5_*/_P"*H ]G
MHKQ<_M(^','&C:KG_MG_ /%4V/\ :2T Y\S0]27TVM&?ZB@#VJBO&/\ AI'P
MY_T!M5_*/_XJC_AI'PY_T!M5_*/_ .*H ]GHKQC_ (:1\.?] ;5?RC_^*H_X
M:1\.?] ;5?RC_P#BJ /9Z*\8_P"&D?#G_0&U7\H__BJ/^&D?#G_0&U7\H_\
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M_P#BJ /9Z*\8_P"&D?#G_0&U7\H__BJ/^&D?#G_0&U7\H_\ XJ@#V>BO&/\
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M?] ;5?\ R'_\50![/17BB?M): 2?,T/4E]-K1G^HI_\ PTCX;_Z VJ_E'_\
M%4 >T45XO_PTCX;_ .@-JOY1_P#Q5'_#2/AO_H#:K^4?_P 50![117B__#2/
MAO\ Z VJ_E'_ /%4?\-(^&_^@-JOY1__ !5 'M%%>+_\-(^&_P#H#:K^4?\
M\51_PTCX;_Z VJ_E'_\ %4 >T45XO_PTCX;_ .@-JOY1_P#Q5'_#2/AO_H#:
MK^4?_P 50![117B__#2/AO\ Z VJ_E'_ /%4?\-(^&_^@-JOY1__ !5 'M%%
M>+_\-(^&_P#H#:K^4?\ \51_PTCX;_Z VJ_E'_\ %4 >T45XO_PTCX;_ .@-
MJOY1_P#Q5'_#2/AO_H#:K^4?_P 50![117B__#2/AO\ Z VJ_E'_ /%4?\-(
M^&_^@-JOY1__ !5 'M%%>+_\-(^&_P#H#:K^4?\ \51_PTCX;_Z VJ_E'_\
M%4 >T45XO_PTCX;_ .@-JOY1_P#Q5'_#2/AO_H#:K^4?_P 50![117B__#2/
MAO\ Z VJ_E'_ /%4?\-(^&_^@-JOY1__ !5 'M%%>+_\-(^&_P#H#:K^4?\
M\51_PTCX;_Z VJ_E'_\ %4 >T45XO_PTCX;_ .@-JOY1_P#Q5'_#2/AO_H#:
MK^4?_P 50![117B__#2/AO\ Z VJ_E'_ /%4?\-(^&_^@-JOY1__ !5 'M%%
M>+_\-(^&_P#H#:K^4?\ \51_PTCX;_Z VJ_E'_\ %4 >T45XO_PTCX;_ .@-
MJOY1_P#Q5'_#2/AO_H#:K^4?_P 50![117B__#2/AO\ Z VJ_E'_ /%4?\-(
M^&_^@-JOY1__ !5 'M%%>+_\-(^&_P#H#:K^4?\ \51_PTCX;_Z VJ_E'_\
M%4 >T45XO_PTCX;_ .@-JOY1_P#Q5'_#2/AO_H#:K^4?_P 50![117B__#2/
MAO\ Z VJ_E'_ /%4?\-(^&_^@-JOY1__ !5 'M%%>+_\-(^&_P#H#:K^4?\
M\51_PTCX;_Z VJ_E'_\ %4 >T45XO_PTCX;_ .@-JOY1_P#Q5'_#2/AO_H#:
MK^4?_P 50![117B__#2/AO\ Z VJ_E'_ /%4?\-(^&_^@-JOY1__ !5 'M%%
M>+_\-(^&_P#H#:K^4?\ \51_PTCX;_Z VJ_E'_\ %4 >T45XO_PTCX;_ .@-
MJOY1_P#Q5'_#2/AO_H#:K^4?_P 50![117B__#2/AO\ Z VJ_E'_ /%4?\-(
M^&_^@-JOY1__ !5 'M%%>+_\-(^&_P#H#:K^4?\ \51_PTCX;_Z VJ_E'_\
M%4 >T45XO_PTCX;_ .@-JOY1_P#Q5'_#2/AO_H#:K^4?_P 50![117B__#2/
MAO\ Z VJ_E'_ /%4?\-(^&_^@-JOY1__ !5 'M%%>+_\-(^&_P#H#:K^4?\
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M_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%%
M'+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0
MKZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?
M\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5
M_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%%
M'+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0
MKZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?
M\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5
M_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%%
M'+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0
MKZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?
M\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5
M_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%%
M'+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0
MKZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?
M\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5
M_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%%
M'+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0
MKZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?
M\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5
M_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%%
M'+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0
MKZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?
M\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5
M_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%%
M'+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0
MKZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?
M\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5
M_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%%
M'+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0
MKZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?
M\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5
M_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%%
M'+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0
MKZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?
M\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5
M_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%%
M'+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0
MKZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?
M\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5
M_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%%
M'+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0
MKZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?
M\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5
M_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%%
M'+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0
MKZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?
M\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5
M_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%%
M'+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0
MKZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?
M\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5
M_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (4?\*X\%_\ 0KZ5_P" R_X5U%%
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M_ 9?\*/^%<>"_P#H5]*_\!E_PKJ** .7_P"%<>"_^A7TK_P&7_"C_A7'@O\
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M!7_0KZ5_X#+_ (4?\*W\%?\ 0KZ5_P" R_X5U%% '+_\*W\%?]"OI7_@,O\
MA1_PK?P5_P!"OI7_ (#+_A7444 <O_PK?P5_T*^E?^ R_P"%'_"M_!7_ $*^
ME?\ @,O^%=110!R__"M_!7_0KZ5_X#+_ (4?\*W\%?\ 0KZ5_P" R_X5U%%
M'+_\*W\%?]"OI7_@,O\ A1_PK?P5_P!"OI7_ (#+_A7444 <O_PK?P5_T*^E
M?^ R_P"%'_"M_!7_ $*^E?\ @,O^%=110!R__"M_!7_0KZ5_X#+_ (4?\*W\
M%?\ 0KZ5_P" R_X5U%% '+_\*W\%?]"OI7_@,O\ A1_PK?P5_P!"OI7_ (#+
M_A7444 <O_PK?P5_T*^E?^ R_P"%'_"M_!7_ $*^E?\ @,O^%=110!R__"M_
M!7_0KZ5_X#+_ (4?\*W\%?\ 0KZ5_P" R_X5U%% '+_\*W\%?]"OI7_@,O\
MA1_PK?P5_P!"OI7_ (#+_A7444 <O_PK?P5_T*^E?^ R_P"%'_"M_!7_ $*^
ME?\ @,O^%=110!R__"M_!7_0KZ5_X#+_ (4?\*W\%?\ 0KZ5_P" R_X5U%%
M'+_\*W\%?]"OI7_@,O\ A1_PK?P5_P!"OI7_ (#+_A7444 <O_PK?P5_T*^E
M?^ R_P"%'_"M_!7_ $*^E?\ @,O^%=110!R__"M_!7_0KZ5_X#+_ (4?\*W\
M%?\ 0KZ5_P" R_X5U%% '+_\*W\%?]"OI7_@,O\ A1_PK?P5_P!"OI7_ (#+
M_A7444 <O_PK?P5_T*^E?^ R_P"%'_"M_!7_ $*^E?\ @,O^%=110!R__"M_
M!7_0KZ5_X#+_ (4?\*W\%?\ 0KZ5_P" R_X5U%% '+_\*W\%?]"OI7_@,O\
MA1_PK?P5_P!"OI7_ (#+_A7444 <O_PK?P5_T*^E?^ R_P"%'_"M_!7_ $*^
ME?\ @,O^%=110!R__"M_!7_0KZ5_X#+_ (4?\*W\%?\ 0KZ5_P" R_X5U%%
M'+_\*W\%?]"OI7_@,O\ A1_PK?P5_P!"OI7_ (#+_A7444 <O_PK?P5_T*^E
M?^ R_P"%'_"M_!7_ $*^E?\ @,O^%=110!R__"M_!7_0KZ5_X#+_ (4?\*W\
M%?\ 0KZ5_P" R_X5U%% '+_\*W\%?]"OI7_@,O\ A1_PK?P5_P!"OI7_ (#+
M_A7444 <O_PK?P5_T*^E?^ R_P"%'_"M_!7_ $*^E?\ @,O^%=110!R__"M_
M!7_0KZ5_X#+_ (4?\*W\%?\ 0KZ5_P" R_X5U%% '+_\*W\%?]"OI7_@,O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH R_$O_ "*VK_\ 7E-_Z :\4_9F_P"9H_[=/_:U>U^)?^16U?\
MZ\IO_0#7BG[,W_,T?]NG_M:@#W^BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ JO?_ /(.N?\ KD_\C5BJ]_\ \@ZY_P"N
M3_R- '@'[-'_ "$?$7_7*#^;U]#U\\?LT?\ (1\1?]<H/YO7T/0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUKR&W^//Q NHA+;^'M-FC)P'CLIV!_$25VG[1W_)/;#_ +"L?_HJ6M3X#?\
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M9!&\#IN ZX+  _2NOH *#P#@9]JQ_$GB?2/"6E?VEK5U]GMC((U(0L68YP
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M5"D  !6'/)[]J\Y7]H'QTZAET322I&01:3X(_P"_E7?VE?\ D,Z!_P!>\O\
MZ$M>U^!/^2>^&O\ L%6O_HI: /"5^/\ X[W#.A:61GH+2?\ ^.5]'6,\EUI]
MM<2Q&*26)7>,_P !(!(_"K%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 9?B7_D5M7_Z\IO\ T UXI^S-_P S1_VZ?^UJ]K\2_P#(K:O_ ->4
MW_H!KQ3]F;_F:/\ MT_]K4 >_P!%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(2%4LQ  &23
MVH Y3XB>-H/ GA>34F1)KN1A%:P,<>8Y]?8#)/Y=Z\H\(?'CQ)KOB_2])OM-
MTH6]Y<)"S0QR*Z[CC()<C]*R]6FG^-?Q?BT^V=_[ T\D;U/ A4C>X]W. /;;
MZ&L=;>*U_:-AM[>-8X8M:C2-%& JA@ ![ 4 ?5]<1\0OB9I7@"UC6>-KO4IU
M+06B';D=-S-_"N>.Y/IUQV]?)\T1^(GQ^>SOI6DM9-1DB '_ #PAW$*/3*I^
MI- '11?&'XG:RCWFD>&T>S4YW6^GRRK@>K9.?PQTK;\'_'][K5TTOQ;IT-B\
MDGEBZ@#(D3=,2(Q) SWSQZ5[?!!#:V\=O;Q)%#&H1(T4*J@=  .@KPG]HSPQ
M;+9:=XFMX52X\[[+<LHP9 5)0GZ;2,^X]!0![T"" 0<@]"**X7X/Z[+KWPST
MN:X??<6X:UD;UV'"Y]]NVNZH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO?_ /(.N?\ KD_\C5BJ
M]_\ \@ZY_P"N3_R- '@'[-'_ "$?$7_7*#^;U]#U\\?LT?\ (1\1?]<H/YO7
MT/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!A^+/%ND^#-%?5-6F*1@[8XT&7E?LJCN?T%>)
M3?'7QIX@O)(O"OAE&B7G:MO)=2X]3MP!^7XUC^,;BY^*?QLCT"">06%O.;2/
M'2-$YF<#ID[6Y[X45](Z+HFG>'M*ATS2[6.VM81A40=3W)/<GN3R: /!8_C3
M\0O#\L3^)O#&+5B 3-9RVSM_NL>,_A7T#>W+V^EW%U#$99(X6D2/NQ"D@?CT
MJPRJZE64,IZ@C(I: /FD_'_QWDXT+2@/0VD__P <I/\ A?\ X[_Z >E?^ D_
M_P <KZ7HH ^9)?VA_&L&/-TC1H\]-]M,,_\ D2O?O!FNS>)O!^F:S<0I#-=P
M[WC3.T')'&><<5\Z?$74+CXE?&"'0]/<M;PS"P@(Y P?WLGY[CGN%%?3^G6%
MOI>FVNGVB;+>UB6&)?15&!^@H LT444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X!^TS_P RO_V]
M_P#M&O:_#7_(K:1_UY0_^@"O%/VF?^97_P"WO_VC7M?AK_D5M(_Z\H?_ $ 4
M > ? ?\ Y*WKW_7E<?\ H^*OI.OFSX#_ /)6]>_Z\KC_ -'Q5])T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 <#\2_"7AJ]\/:SX@U+2
MHI]0M=.E,4S,P(*JQ3H0#R:\M^!?@30?%&DZO>:YIJ7@CG2*'>[+MPI+?=(Z
MY7\JN?$WXS17MAXA\(1:--%*)7M#<O.,?))@G;CN%/?O7-?#7XO6O@#PY/I;
MZ++>23737#2K<!!RJKC&T_W?UH UOCKX1\->$[#14T72XK.>ZEE+LKNQ94"\
M<D]V%>I> OASX9TO1= U==(B&KK9Q2O<%W)\QHQN."<=SVKY_P#B?\1D^(=[
MITT>GO91V<;KL>4/N+$$GH/05[U\,OB?:^.9KC3;?29K(6-NC!FE#AA]W' &
M#0!Z/7-_$'_DG/B3_L&7'_HLUTE<W\0?^2<^)/\ L&7'_HLT >.?LT?\A'Q%
M_P!<H/YO7T/7SQ^S1_R$?$7_ %R@_F]?0] '%_%7PYJ7BKP!>Z7I*K)>,\;I
M&SA?,VL"1D\?GZ5S'P.\"^(/!MOK,FNVZVK7;1"* 2I(?DWY8E20,[@.O:O6
MZ* "BBB@#R#]H[_DGMA_V%8__14M7O@5=6\7PNLTDN(D;[1-PS@'[YJC^T=_
MR3VP_P"PK'_Z*EKS3P-\%;CQMX8AUJ/7(K19)'3RFMRY&TXSG<* /<?'WQ+T
M7PAH=RR7UO/JKQLMM:Q.';?C@MC[JCKSC..*\@_9Y\-7-[XJN/$4B$6EC$T2
M.?XY7&,#UPN[/U'K75Z1^S=I%M<"35M<NKZ,'/E0PB 'V)RQ_+%>PZ7I5AHF
MG0Z?IMK%:VD(PD48P!_B?4GDT >4?'WQK<Z'HMKH&G3-%<:DK-/(APRPCC /
M^T<CZ CO1\-O@OH5KX>M=2\162W^HW<:RF*8GRX%/(4*."<8R3GT'OY[^T/)
M(_Q(A5\[4T^()]-SG^9-=8EM\?PBA+RW"8&W"V>,?]\T 7?BG\'M C\*7NM>
M'[(6-Y81F=XHV/ERQKRV0>A R1C'3'TT?@%XMN->\)W&DWCM)/I+(B2,<DPO
MG8/PVL/IBN=O-,^/5_97%G=7-O);W$;12H19C<K#!&0N>AK=^"GP\\0^"[K5
MKG6XXH%N4CCCB24.6())8D<#&<?B: *'[2G_ "+VA_\ 7V__ *!7>?"7_DEG
MA_\ Z]S_ .AM7!_M*?\ (O:'_P!?;_\ H%=Y\)?^26>'_P#KW/\ Z&U '@.N
MQM\,?CF+N(&.SCNUND"CK;R_?4?0%U_"OK!'61%=&#*PR&!R"*\-_:.\.^?I
M6F>(H4R]LYM9R/[C<J3[!@1_P.NV^$7B5==^&>GSSS#S;!3:7#,>GEC@D_[F
MTYH \O\ VBM=>]\0:5X;MB7%O'Y\B+SND<X4?4 ?^/U[AX,T!/"_@_2]&4 -
M;0 2D=Y#\SG\6)KYZ\#PM\1_CM-K,RE[2&X>_(;LB$")?S\O\ :^HJ /ESX1
M_P#)=9_]^[_]FKZ,\4:[%X9\+ZCK4R[EM(&D"$_>;HJ_BQ _&OG/X1_\EUG_
M -^[_P#9J]9^/$CI\*[U4SM>>%7Y[;P?Y@4 >/?#GP=<_%CQ=J&L>(;J>2TA
M827+@X,SMG;&#_"  >G0  8R"/:+WX(> KNQ:WCTA[5]N%GAN9-Z^_S,0?Q!
MK _9P2,>!-2<']X=28-]!''C^9KV*@#AOAGX"N? %AJ=A+J*WD$]UYL!"E2J
M[0.1T#<=O05W-%% !7RI\2/^3AY?^OVQ_P#1<-?5=?*GQ(_Y.'E_Z_;'_P!%
MPT =K^T=X:\ZPTWQ+"GSP-]DN"!_ V2A^@.X?\"%=_\ ";Q-_P )1\/-/N))
M-]W:K]DN,GG>@ !/N5VG\:W_ !7H47B;PKJ6C2XQ=P,BD_POU1OP8 _A7@'P
M"UZ70_&M]X9O<QB^4J$;^&>+/'ME=P^H% 'M/Q-\4?\ ")> ]1U&-]ETZ_9[
M7G!\U^ 1]!EO^ UYU^SGX8^SZ7J'B:=/WETWV6V)Z^6IRY'L6P/^ &L+X\ZY
M/X@\::9X0T[,K6Q4-&O\=Q+C:/P4K_WT:]\\.:)!X<\.:?H]MCR[2!8]P&-S
M?Q-]2<G\: /FCX;_ /)P\7_7[??^BYJ^JZ^5/AO_ ,G#Q?\ 7[??^BYJ^J7=
M8T9W8*B@EF8X 'J: /)?#WP \/6$KW.O75QK5R[%L.3%'SW(!W$^Y;\*V=;^
M"W@O5-+EM[;24L+DH1%<6[L"C=B03AAZYKCM>^.^HW^M-H_@71?M\FXJL\D;
M2&7'4K&N"![D].PIIU'X^W7[R+2[>%?[H^S+^COF@#GOV?M5O-+\=:AX?EDQ
M!<0N6B[":,CD?AN'OQZ5[5\3M6O-$^&^MW]@SI=)"%1T^\F]U0L/3 8G/M7@
M7P6-P?C*INQBYVW/G 8^_@[NG'7/2OI_5--M-8TNZTV^B$MK<QF*5#W4C]#[
MT > ? GP-X9\1Z1J.J:Q:QW]Y%<^2L$I)6--H(;;W))(YS]WZUZ3JOP8\&:C
M/!<6VGMIMQ#*L@>S;:&P<X*G*X^@!KRC5/A9X[^'>K2:KX/NY[NW'1[4CSMO
M7:\1X?\  $=\"M_P;^T!(U]'I?C&R6W<MY9O85*A&SC]XAZ>Y'3TH ]G\0WT
MVF>&M5O[=2T]M9S31J!G+*A(_45\X_!/PQHWC;Q%K-YXD!O[F%5E2&5S^]9V
M;?(V.N"!_P!]?2OIUUCN(&1PLD4BX(/(92/U%?.WB?X,>)O"VM-K?@6YEDB5
MB\<44NRXA!ZJ,\.O;KD],&@#TW6_@SX)UFU:--)2PFQ\L]D?+93]/NG\17;V
M-HEAI]M9QLS1V\2Q*6ZD* !G\J\ \-_'O6=(OQIGC;36?8VR2=(O*GC/J\?
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MKT?QX ?AYXER,_\ $JNO_135XY^S/_Q\>)?]RV_G)0!VGQ]_Y)?/_P!?</\
M,UY1\,?A[J/Q$M[9]8O)XO#6ELT<,:'!D=F+LJ>G)^9NO0#V]7^/O_)+Y_\
MK[A_F:C_ &?O^29#_K]E_P#9: */CGX(^&#X4O+C0+%K'4;2%IHRLSN)=H)*
ML&)ZC//'..U>-^!T\5^+8#X%TB]>+3+B7[3=9^[&@P&+'KMZ?+W.*^O=0 .F
MW0(R#"^0?H:^;/V</^1ZU/\ [!C?^C8Z /3[;X#^!XM&%E-9SSW)7#7IN'63
M=C[P .T?3&/7->.>#3>?#KXY1:,)B\;7HT^7G ECD(",1Z\HWU%?5]?+GC@
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MYMY4E@E4/'(ARK*1D$'N*\._:$\(:;'HEMXEM+:."]%R(+AHU"B56#'<V.K
M@<^A]A70_L_:G/?_  W:"=F865[);Q$G/R;5<#\"YH ]4HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** ,OQ+_ ,BMJ_\ UY3?^@&O%/V9O^9H_P"W
M3_VM7M?B7_D5M7_Z\IO_ $ UXI^S-_S-'_;I_P"UJ /?Z*** "BBB@ HHHH
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MBV-Q=:G<W<<*W%Q)RHPS-M48 'R]\GGK0!V/[.3EOA]?J0<+JDF#_P!LHO\
M/XUZ_7EWP!L'L_AC'.PP+R[FG7Z#$?\ [3KU&@ HHHH **** "BBB@ HHHH
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MAY=OQ8G\*W* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%G"Z*H VY5VX^C&OI**"&#/E1)'GKL4#-<!_PJFU;XH'QM)JLSR>;YHM3$,
MA-@^;/0=>E>AT 07=Y:V%NUQ>7,-O N TDSA%&>!DGBN.\=^)M!N/ 'B&&#6
M]-EEDTZ=41+N-F8E#@  \FM7QOX0MO''AQM'NKF6V0RI*)(@"05]C]37F?\
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MB:U.+6UO65HYI!A8I1P0Q[ C')Z$=J^A-0\6^'=*LS=WNMV$,(7<&,ZDL/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLS?\S1_VZ?\ M:@#W^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M% !1110 4444 %%%% !1110 4444 %5[_P#Y!US_ -<G_D:L57O_ /D'7/\
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M7'_H^*OI.OFSX#_\E;U[_KRN/_1\5?2= !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 >5?&WX?WGC#2+.^T>U$^
MJV3[/+#!3)$W49) X.#^)KL_ G]L+X)TJ+7K9K?4H81#,CL&)VG:&)!(R0 ?
MQKHJ* "BBB@ HHHH **** "BBB@ HHHH **** &NS+&S*A=@"0H.,GTYKPWX
M;?#[Q%-\2+[Q?XNT]K60,\T"/(K;I7)Z8)X52<9]1Z5[I10 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ?-FI_\ )U:?]?L'_HA:^DZ^;-3_ .3JT_Z_8/\ T0M?
M2= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9?B7_D5M7_
M .O*;_T UXI^S-_S-'_;I_[6KVOQ+_R*VK_]>4W_ * :\4_9F_YFC_MT_P#:
MU 'O]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YLU/_ ).K
M3_K]@_\ 1"U])U\V:G_R=6G_ %^P?^B%KZ3H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#+\2_\BMJ_P#UY3?^@&O%/V9O^9H_[=/_ &M7
MM?B7_D5M7_Z\IO\ T UXI^S-_P S1_VZ?^UJ /?Z*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J]__P @ZY_ZY/\ R-6*
MKW__ "#KG_KD_P#(T > ?LT?\A'Q%_UR@_F]?0]?/'[-'_(1\1?]<H/YO7T/
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPH_X6%\:?^A<OO\ P2R?X5]'T4 ?.'_"POC3_P!"Y??^"63_  H_X6%\:?\
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MPH_X6%\:?^A<OO\ P2R?X5]'T4 ?.'_"POC3_P!"Y??^"63_  H_X6%\:?\
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MPH_X6%\:?^A<OO\ P2R?X5]'T4 ?.'_"POC3_P!"Y??^"63_  H_X6%\:?\
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MPH_X6%\:?^A<OO\ P2R?X5]'T4 ?.'_"POC3_P!"Y??^"63_  H_X6%\:?\
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M\(AIL]YYWE?:O*LFN-F-^S.T?+G+?7'M7UEXE_Y%;5_^O*;_ - ->*?LS?\
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M&G_H7+[_ ,$LG^%?1]% 'SA_PL+XT_\ 0N7W_@ED_P */^%A?&G_ *%R^_\
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M_@ED_P */^%A?&G_ *%R^_\ !+)_A7T?10!\X?\ "POC3_T+E]_X)9/\*/\
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M&G_H7+[_ ,$LG^%?1]% 'SA_PL+XT_\ 0N7W_@ED_P */^%A?&G_ *%R^_\
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MN\)L[^#=#:08D.GVY88Q@^6N:\8_:9_YE?\ [>__ &C7M?AK_D5M(_Z\H?\
MT 4 > ? ?_DK>O?]>5Q_Z/BKZ3KYL^ __)6]>_Z\KC_T?%7TG0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'S9J?\ R=6G_7[!_P"B%KZ3KYLU/_DZM/\ K]@_]$+7TG0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &7XE_Y%;5_^O*;_P!
M->*?LS?\S1_VZ?\ M:O:_$O_ "*VK_\ 7E-_Z :\4_9F_P"9H_[=/_:U 'O]
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB@ HHHH ^;-3_P"3JT_Z_8/_ $0M?2=?-FI_\G5I_P!?L'_HA:^DZ "BBB@
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M)0![+1110 4444 %%%% !1110 4444 %%%% !1110 4444 9?B7_ )%;5_\
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M(/TK4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ JO?_\ (.N?^N3_ ,C5BJ]__P @ZY_ZY/\ R- '
M@'[-'_(1\1?]<H/YO7T/7SQ^S1_R$?$7_7*#^;U]#T %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%?.6M>)_B9\0_$6H:9X:BN;+3;6X> FV;R@-I(R\QQSQT!_ UEWOP?\
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MX5MO&GABYT2ZGD@28JRRQC)1E((.._3I6-\.?AK9_#R"_$%]+>SWK)YDCH$
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MMWN;60,I='0;L _[6-I^M<+^S;K4\^FZUHLLFZ*V>.X@4]M^X/\ AE5/U)H
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M?J!7U'KO_(O:G_UZ2_\ H!H \L\)?'>TU+2M8U#Q%;0:?%8^4(E@<N\[/O\
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M@3S&@+[U=,@%E/'0D9!'&1UKT*OE?0K:+PS^T?'96(\NWCU.2%$7HJ."-OT
M;'X5]44 ?+GPC_Y+K/\ []W_ .S5]1U\N?"/_DNL_P#OW?\ [-7U'0 4444
M?*G[/W_)31_UY2_^RU]5U\J?L_?\E-'_ %Y2_P#LM?5= ''?$KQ??^"/"ZZQ
M8Z='>XN$CE$CE1&K _-Q[X'XT?#7QROCWPRVI/;I;74,S0SPHVX*1@@C/.""
M/QS6WXGT.+Q)X8U+1IL!;N!HPQ_A;JK?@P!_"OGOX":U-H/CZ^\.7N8OMJ-&
M8V_AGBR<?EO'Y4 ?35>1:W\9+RU^)J>$M)TB"\3[5':M,TI!+L1NQ@<!<D?@
M:]-U[5H=!T"_U:X_U5G \Q&<;MHR!]2>/QKYX^ VCS>(/'^H>)KT&0V:M(7(
M^]/*3S^6\_B* /:_B-XNG\$>$I-9M[6.YD69(Q'(Q4?,>O%<:_QWTVS\"V&K
MWEHKZQ>B0IIT$G "NR;F8CY0=OH2>U7_ (^_\DOG_P"ON'^9KCO@)X TN^L'
M\5ZC&EU.D[0VL+KE(BN,N1W;GCTQGKT *#?M#^*+6Z1[SP[8I:OAD0K*CLOL
MQ)!^NVO5M.^+'AB\\$-XHGN3;01MY4MN_,JRXSY8'\1/4$<8Y.,'&QXXT"T\
M2^#M3TZZB5]T#O$Q7)CD"DJP]P?TR.]?+_PD\&6OC?QA]AU"5A8VL)NIHE)!
ME 95"Y'3)89/7&: .WU']H?Q!+,]SI'AVV33$;;ONEDD8_5E*JI]N?QKT+X:
M_%NQ\>.^GW-N+'5XU+^2&W)*HZE#ZCNI_7G'H%O86=K8+86]K#%9JGEB!$ 0
M+Z8Z8KY8>R3P9^T3;V>GYA@CU:%45>-L4VW*CVVR$?2@#ZOKR+PQ\;(]2\1Z
MW9:W;6NG:?IL$LWVD2DD[)50+C').[H.<UZ[7QUX8\*Q>,_BK-HT\[06[W4\
MDK(/F**Q) ]STSVH ]%U7]H/6+RZF7PMX<66VB_Y:W2/(Q'J50C;],FM/P7^
MT#;ZMJD6G>(["*P:9MB7<+GR@Q/ <-RH]\GWP.:]?TC1]/T+38M/TNTBM;6(
M86.,8_$^I]SR:\!_:(\)VFGWMAXCLH5B:]=H;L+P&D !5L>I ;/T% 'T97RW
M\:6"_&>!F("A+8DGMS7NWPOUB;7?AKH=]<.7G,!B=B<EC&Q3)]SMS^->!_'2
M!KKXMFW4@-+! @)Z GB@#T'Q9\?(+34WTSPGI@U69&*M<N28V(_N*O+CWR/;
M(YK%T+]HN^CU%+?Q-HL$<);;)+9AT:+W*,3GZ9']*]<\$>!=)\#:.EG81*]R
MRC[3=LO[R9N^3V'HO0?7)KS[]HCPY9W'A>V\0+$B7UK.L+2 <R1L#P?7! (]
M,GUH ]BM+N"_LX+RUE66WGC62*1>C*1D$?A4U>:_ F^EO/A=9I*Q;[-/+"I/
M]T-N'Y;L?A7I5 !7RI\2/^3AY?\ K]L?_1<-?5=?*GQ(_P"3AY?^OVQ_]%PT
M )X\TJ\^%?Q8AUC2T,=I)+]LM .%*D_O(OIR1C^ZPKZ>T75[37M%L]5L7WVU
MW$LJ$]0#V/N#P?<5R?Q8\&#QGX+GA@C#:E:9N+0]RP^\G_ AD?7'I7F_[//C
M(QS7/A"\<X?=<66X]"/OH/\ T+\&]: ,K]I'_D<M)_[!_P#[4>OH/PU_R*VD
M?]>4/_H KY\_:1_Y'+2?^P?_ .U'KZ#\-?\ (K:1_P!>4/\ Z * *'C+QMHW
M@?2A?:M,VZ0E8+>/!DF8=0H]!W)X'XBO&I/V@/%6J3/_ &!X5MVC7LR2W##Z
ME-O:N;\727'Q(^.1T?SF%LMY]ABYXCCC)\PCW.UV_$5]0:7I=CHNG0Z?IMK'
M;6L*[4CC& /\3ZD\F@#P_1?VBIXM0%KXGT$6Z9P\MJ6#1_6-^3^>?8U[G87]
MIJEA!?6,Z3VLZ!XI4.0RFO/OC1X,LO$/@F^U46Z#5-,A,\4XX8QK\SJ?4;=Q
M'H?J:Y;]G#7YKC2]6T&9RR6CI<6X/\(?(<#VR ?JQH ]BUW7-/\ #>C7&JZI
M<""T@7+,>23V '<D\ 5X1?\ [1&NWU^\/ASP[;F,9V"X5YI&4=R$(Q].<>II
M?VD==E;4-(\/HY$*1&\E4'[S$E%S] K?]]5ZI\,?!]IX1\&V44<"+?7,237D
MO5G<C.,^BYP!^/<T >>Z9\=;;7-,U31_$5@NEWLMK-'%*I/E,Y0X5@>4/IU'
MTK%_9K_Y&'7/^O1/_0Z]/^*?@#2?%GAJ\O9(D@U2S@>:&[5?F(4$[&]5./PZ
MCW\P_9K_ .1AUS_KT3_T.@#Z/) &2<"O&/%OQ^M+#4GTSPQIW]JW"ML-PS'R
MBWHBKR_UX]LUT7QN\03:!\-[H6TACGOY5LU=3@@,"6_-58?C7,_ 'P]I6G^%
MSXBN3;G4;R1UB>0C=%$IVX7/3)#9]>* ,5OCKXXTATFUWPA#%:L1C,$UN6'L
MSEA^E>O^"?'6D>.]):]TQG22(A;BVEQOA8],XZ@X.#WQZ@@:U_\ V1JEC-8W
MSVEQ:S*4DBD=2K"OFWX73R>$OCE/H4%P7LI9[BQ<DY\Q5W&-OKE5_,T ?45%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-FI_\G5I_U^P?
M^B%KZ3KYLU/_ ).K3_K]@_\ 1"U])T %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 FU=V[ W8QG'.*6BH+V\MM.LI[R\F2"V@0R2R.<!5 R2: /
MGS]I86_]K>'RH7[5Y$WF'OLW+M_7?^M>Q_#E)H_AOX<6<DO_ &?">>RE05'Y
M8KYZ=;WXV_%LLB21Z:I"EL?ZBU0]_P#:;)_%O05]4PPQV\$<$*!(HU"(B]%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^27S_P#7W#_,T 1_L_?\DR'_ %^R_P#LM>IUY9^S]_R3(?\ 7[+_ .RUZG0
M5\J?$C_DX>7_ *_;'_T7#7U77RI\2/\ DX>7_K]L?_1<- 'U77RW\6_#USX
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MBBB@ HHHH **** /FS4_^3JT_P"OV#_T0M?2=?-FI_\ )U:?]?L'_HA:^DZ
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M %Y3?^@&O%/V9O\ F:/^W3_VM0![_1110 4444 %%%% !1110 4444 %%%%
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M^!O"T7@WPA8Z*C*\D2EIY%'#R,<L?IG@>P%=%0 4444 %%%% !1110 4444
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M;2/^O*'_ - % '@'P'_Y*WKW_7E<?^CXJ^DZ^;/@/_R5O7O^O*X_]'Q5])T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 96N>&M%\2Q11
M:SIMO>I"Q:,2KG83UP:T8((K6WBMX(UBAB0)'&@P%4#  '8 5)10!C+X2\/I
MX@.O+I-J-5))^U;/GR1C/UQQFMFBB@#*U?PSH>OO$^KZ39WSQ B-KB$.5!Z@
M$UF?\*X\%_\ 0KZ5_P" R_X5U%% '+_\*X\%_P#0KZ5_X#+_ (5IZ1X9T/P^
M\KZ1I-G8M, )&MX@A8#H#CZUJT4 5=1TVRU>PFL-0M8KJTF&)(95W*W.>GU
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MK_WRI _2MS1?#6B>'8FCT?2[6R#?>,,8#-]6ZG\:U:* "BBB@ HHHH ****
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M.K3_ *_8/_1"U])U\V:G_P G5I_U^P?^B%KZ3H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#+\2_\ (K:O_P!>4W_H!KQ3]F;_ )FC_MT_
M]K5[7XE_Y%;5_P#KRF_] ->*?LS?\S1_VZ?^UJ /?Z*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J]_\ \@ZY_P"N3_R-
M6*KW_P#R#KG_ *Y/_(T > ?LT?\ (1\1?]<H/YO7T/7SQ^S1_P A'Q%_UR@_
MF]?0] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\
MV:G_ ,G5I_U^P?\ HA:^DZ^;-3_Y.K3_ *_8/_1"U])T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ,3@%@<9!)QG)Z\]:]K^"5G;VWPJTF6&%(Y+@RR3,HY=O,9<GUX4#\*WOB%
MEQ\.?$B2 $#3;A^1W5"P_4"@#$^$GCJ;QQX4::^*?VG9R>3<[!@/QE7QVR,_
MBIZ5W]?/W[,[MYGB9,_+BV./?][7T#0!\K^(7_X1;]I W(^5!JD,S$?W90I?
M]':OJBOE/XV_N/C%)+'R_EV[_B /\!7U90 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'S9J?\ R=6G_7[!_P"B%KZ3KYLU/_DZM/\ K]@_]$+7
MTG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &7XE_Y%;5_
M^O*;_P! ->*?LS?\S1_VZ?\ M:O:_$O_ "*VK_\ 7E-_Z :\4_9F_P"9H_[=
M/_:U 'O]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^;-3_Y.K3_K]@_]
M$+7TG7S9J?\ R=6G_7[!_P"B%KZ3H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#+\2_P#(K:O_ ->4W_H!KQ3]F;_F:/\ MT_]K5[7XE_Y
M%;5_^O*;_P! ->*?LS?\S1_VZ?\ M:@#W^BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ JO?\ _(.N?^N3_P C5BJ]_P#\
M@ZY_ZY/_ "- '@'[-'_(1\1?]<H/YO7T/7SQ^S1_R$?$7_7*#^;U]#T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 > ?M,_\RO\ ]O?_ +1KVOPU
M_P BMI'_ %Y0_P#H KQ3]IG_ )E?_M[_ /:->U^&O^16TC_KRA_] % '@'P'
M_P"2MZ]_UY7'_H^*OI.ODSX7^,](\(?$+5M6U9YEM9[>:%#''N.YI48<?137
MLG_"_? W_/Q??^ I_P : /3Z*\P_X7[X&_Y^+[_P%/\ C1_POWP-_P _%]_X
M"G_&@#T^BO,/^%^^!O\ GXOO_ 4_XT?\+]\#?\_%]_X"G_&@#T^BO,/^%^^!
MO^?B^_\  4_XT?\ "_? W_/Q??\ @*?\: /3Z*\P_P"%^^!O^?B^_P# 4_XT
M?\+]\#?\_%]_X"G_ !H ]/HKS#_A?O@;_GXOO_ 4_P"-'_"_? W_ #\7W_@*
M?\: /3Z*\P_X7[X&_P"?B^_\!3_C1_POWP-_S\7W_@*?\: /3Z*\P_X7[X&_
MY^+[_P !3_C1_P +]\#?\_%]_P" I_QH ]/HKS#_ (7[X&_Y^+[_ ,!3_C1_
MPOWP-_S\7W_@*?\ &@#T^BO,/^%^^!O^?B^_\!3_ (T?\+]\#?\ /Q??^ I_
MQH ]/HKS#_A?O@;_ )^+[_P%/^-'_"_? W_/Q??^ I_QH ]/HKS#_A?O@;_G
MXOO_  %/^-'_  OWP-_S\7W_ ("G_&@#T^BO,/\ A?O@;_GXOO\ P%/^-'_"
M_? W_/Q??^ I_P : /3Z*\P_X7[X&_Y^+[_P%/\ C1_POWP-_P _%]_X"G_&
M@#T^BO,/^%^^!O\ GXOO_ 4_XT?\+]\#?\_%]_X"G_&@#T^BO,/^%^^!O^?B
M^_\  4_XT?\ "_? W_/Q??\ @*?\: /3Z*\P_P"%^^!O^?B^_P# 4_XT?\+]
M\#?\_%]_X"G_ !H ]/HKS#_A?O@;_GXOO_ 4_P"-'_"_? W_ #\7W_@*?\:
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MBO,/^%^^!O\ GXOO_ 4_XT?\+]\#?\_%]_X"G_&@#T^BO,/^%^^!O^?B^_\
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M!O\ GXOO_ 4_XT?\+]\#?\_%]_X"G_&@#T^BO,/^%^^!O^?B^_\  4_XT?\
M"_? W_/Q??\ @*?\: /3Z*\P_P"%^^!O^?B^_P# 4_XT?\+]\#?\_%]_X"G_
M !H ]/HKS#_A?O@;_GXOO_ 4_P"-'_"_? W_ #\7W_@*?\: /3Z*\P_X7[X&
M_P"?B^_\!3_C1_POWP-_S\7W_@*?\: /3Z*\P_X7[X&_Y^+[_P !3_C1_P +
M]\#?\_%]_P" I_QH ]/HKS#_ (7[X&_Y^+[_ ,!3_C1_POWP-_S\7W_@*?\
M&@#T^BO,/^%^^!O^?B^_\!3_ (T?\+]\#?\ /Q??^ I_QH ]/HKS#_A?O@;_
M )^+[_P%/^-'_"_? W_/Q??^ I_QH ]/HKS#_A?O@;_GXOO_  %/^-'_  OW
MP-_S\7W_ ("G_&@#T^BO,/\ A?O@;_GXOO\ P%/^-'_"_? W_/Q??^ I_P :
M /3Z*\P_X7[X&_Y^+[_P%/\ C1_POWP-_P _%]_X"G_&@#T^BO,/^%^^!O\
MGXOO_ 4_XT?\+]\#?\_%]_X"G_&@#T^BO,/^%^^!O^?B^_\  4_XT?\ "_?
MW_/Q??\ @*?\: /3Z*\P_P"%^^!O^?B^_P# 4_XT?\+]\#?\_%]_X"G_ !H
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M[5B53\OU!KV7_A?O@;_GXOO_  %/^- 'I]%>8?\ "_? W_/Q??\ @*?\:/\
MA?O@;_GXOO\ P%/^- 'I]%>8?\+]\#?\_%]_X"G_ !H_X7[X&_Y^+[_P%/\
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MX&_Y^+[_ ,!3_C0!Z?17F'_"_? W_/Q??^ I_P :/^%^^!O^?B^_\!3_ (T
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M*\J(OG9YF<^GWA0!]3T5YA_POWP-_P _%]_X"G_&C_A?O@;_ )^+[_P%/^-
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M>8?\+]\#?\_%]_X"G_&C_A?O@;_GXOO_  %/^- 'I]%>8?\ "_? W_/Q??\
M@*?\:/\ A?O@;_GXOO\ P%/^- 'I]%>8?\+]\#?\_%]_X"G_ !H_X7[X&_Y^
M+[_P%/\ C0!Z?17F'_"_? W_ #\7W_@*?\:/^%^^!O\ GXOO_ 4_XT >GT5Y
MA_POWP-_S\7W_@*?\:/^%^^!O^?B^_\  4_XT >GT5YA_P +]\#?\_%]_P"
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M /3Z*\P_X7[X&_Y^+[_P%/\ C1_POWP-_P _%]_X"G_&@#T^BO,/^%^^!O\
MGXOO_ 4_XT?\+]\#?\_%]_X"G_&@#T^BO,/^%^^!O^?B^_\  4_XT?\ "_?
MW_/Q??\ @*?\: /3Z*\P_P"%^^!O^?B^_P# 4_XT?\+]\#?\_%]_X"G_ !H
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MXT?\+]\#?\_%]_X"G_&@#T^BO,/^%^^!O^?B^_\  4_XT?\ "_? W_/Q??\
M@*?\: /3Z*\P_P"%^^!O^?B^_P# 4_XT?\+]\#?\_%]_X"G_ !H ]/HKS#_A
M?O@;_GXOO_ 4_P"-'_"_? W_ #\7W_@*?\: /3Z*\P_X7[X&_P"?B^_\!3_C
M1_POWP-_S\7W_@*?\: /3Z*\P_X7[X&_Y^+[_P !3_C1_P +]\#?\_%]_P"
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M^%)?#S_H7O\ R=N/_CE=_10!P'_"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\
M)VX_^.5W]% ' ?\ "DOAY_T+W_D[<?\ QRC_ (4E\//^A>_\G;C_ ..5W]%
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M_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.5W]% ' ?\ "DOAY_T+W_D[<?\
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M'_QRC_A27P\_Z%[_ ,G;C_XY7?T4 <!_PI+X>?\ 0O?^3MQ_\<H_X4E\//\
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M\//^A>_\G;C_ ..5W]% ' ?\*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\
MCE=_10!P'_"DOAY_T+W_ ).W'_QRC_A27P\_Z%[_ ,G;C_XY7?T4 <!_PI+X
M>?\ 0O?^3MQ_\<H_X4E\//\ H7O_ "=N/_CE=_10!P'_  I+X>?]"]_Y.W'_
M ,<H_P"%)?#S_H7O_)VX_P#CE=_10!\HWWA'0X?V@%\,1V.-&-U%&;;S7^Z8
ME8C=NW=23UKV_P#X4E\//^A>_P#)VX_^.5Y7J?\ R=6G_7[!_P"B%KZ3H X#
M_A27P\_Z%[_R=N/_ (Y1_P *2^'G_0O?^3MQ_P#'*[^B@#@/^%)?#S_H7O\
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M^3MQ_P#'*[^B@#@/^%)?#S_H7O\ R=N/_CE'_"DOAY_T+W_D[<?_ !RN_HH
MX#_A27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'*[^B@#@/\ A27P\_Z%
M[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<KOZ* . _X4E\//^A>_\G;C_P".4?\
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M_D[<?_'*/^%)?#S_ *%[_P G;C_XY7?T4 <!_P *2^'G_0O?^3MQ_P#'*/\
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M^%)?#S_H7O\ R=N/_CE=_10!P'_"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\
M)VX_^.5W]% ' ?\ "DOAY_T+W_D[<?\ QRC_ (4E\//^A>_\G;C_ ..5W]%
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M_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.5W]% ' ?\ "DOAY_T+W_D[<?\
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M'_QRC_A27P\_Z%[_ ,G;C_XY7?T4 <!_PI+X>?\ 0O?^3MQ_\<H_X4E\//\
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M+1HT&%6Q@ 'H!&M>+?M,_P#,K_\ ;W_[1KVOPU_R*VD?]>4/_H H \ ^ _\
MR5O7O^O*X_\ 1\5?2=?-GP'_ .2MZ]_UY7'_ */BKZ3H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"0JEF(  R2>U-CFCF7=%(D
MB@XRK C- #Z*** "BBB@ HHHH **** "BBB@ HHHH ***CEGA@ ,LJ1YZ;V
MS0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\V:G_R=6G_7
M[!_Z(6OI.OFS4_\ DZM/^OV#_P!$+7TG0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% &7XE_P"16U?_ *\IO_0#7BG[,W_,T?\ ;I_[6KVO
MQ+_R*VK_ /7E-_Z :\4_9F_YFC_MT_\ :U 'O]%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !5>_\ ^0=<_P#7)_Y&K%5[
M_P#Y!US_ -<G_D: / /V:/\ D(^(O^N4'\WKZ'KYX_9H_P"0CXB_ZY0?S>OH
M>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?AF@#JZ*R/$'BG1/"UF+K6M1ALXVSL#G+/CKM49+?@*Y;3_C5X#U&[6V763
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MIJVI!;L@,;>%&D=0>YQT_&@#K:*S- \0:9XGTB+5-(N?M%I(2 ^TJ00<$$$
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MYX'_  %LCZ%:]CKY!^"^N-HGQ-TT%L0WV;.0>N_[O_CX6OKZ@ HHHH ****
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M.E=77RC\'I)]!^-$.F*Y97:XLY=O1@JL<_\ ?2 U]74 %%%% !1110 4444
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MS(NE%#E3D<A,T >A_L\^,+O4;.^\-7TSS?8D6>T9SDK'G:R9] 2N/J?:O/\
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M?^UJ /?Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVQ7U?HM__:NA:?J.W;]KMHY]H[;E#?UH O4444 %%%% !1110 4444 %%%%
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MW 9QZ#KZCK7S!([2R-(YRS$L3ZDU]#>%/V=8;2]CNO$^HQW:1G/V2U#!'/\
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MZ9'7&*\_^'?P4O/!GBR#7+O68+@0(ZK#%"1N+*5Y)/'7TH ]CKX%G_X^)?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU)H Z'PSH<'AKPUI^C6^#':0K&6_O-U9OQ8D_C6K110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5
M>_\ ^0=<_P#7)_Y&K%5[_P#Y!US_ -<G_D: / /V:/\ D(^(O^N4'\WKZ'KY
MX_9H_P"0CXB_ZY0?S>OH>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:^DZ^;-3_P"3JT_Z_8/_ $0M?2= !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 9?B7_ )%;5_\ KRF_] ->*?LS?\S1_P!NG_M:O:_$O_(K
M:O\ ]>4W_H!KQ3]F;_F:/^W3_P!K4 >_T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %5[_P#Y!US_ -<G_D:L57O_ /D'
M7/\ UR?^1H \ _9H_P"0CXB_ZY0?S>OH>OGC]FC_ )"/B+_KE!_-Z^AZ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P
M#]IG_F5_^WO_ -HU[7X:_P"16TC_ *\H?_0!7BG[3/\ S*__ &]_^T:]K\-?
M\BMI'_7E#_Z * / /@/_ ,E;U[_KRN/_ $?%7TG7S9\!_P#DK>O?]>5Q_P"C
MXJ^DZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JO?\ _(.N?^N3_P C5BJ]_P#\@ZY_ZY/_ "- '@'[-'_(
M1\1?]<H/YO7T/7SQ^S1_R$?$7_7*#^;U]#T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '@'[3/_ #*__;W_ .T:]K\-
M?\BMI'_7E#_Z *\4_:9_YE?_ +>__:->U^&O^16TC_KRA_\ 0!0!\C>#_&NI
M^#O%NH:MIMC#=7$\<D+Q2*Q"JTBL3\I!ZJ!^-=]_PT%XO_Z%NQ_[]3?_ !51
M_ ?_ )*WKW_7E<?^CXJ^DZ /G#_AH+Q?_P!"W8_]^IO_ (JC_AH+Q?\ ]"W8
M_P#?J;_XJOH^B@#YP_X:"\7_ /0MV/\ WZF_^*H_X:"\7_\ 0MV/_?J;_P"*
MKZ/HH ^</^&@O%__ $+=C_WZF_\ BJ/^&@O%_P#T+=C_ -^IO_BJ^CZ* /G#
M_AH+Q?\ ]"W8_P#?J;_XJC_AH+Q?_P!"W8_]^IO_ (JOH^B@#YP_X:"\7_\
M0MV/_?J;_P"*H_X:"\7_ /0MV/\ WZF_^*KZ/HH ^</^&@O%_P#T+=C_ -^I
MO_BJ/^&@O%__ $+=C_WZF_\ BJ^CZ* /G#_AH+Q?_P!"W8_]^IO_ (JC_AH+
MQ?\ ]"W8_P#?J;_XJOH^B@#YP_X:"\7_ /0MV/\ WZF_^*H_X:"\7_\ 0MV/
M_?J;_P"*KZ/HH ^</^&@O%__ $+=C_WZF_\ BJ/^&@O%_P#T+=C_ -^IO_BJ
M^CZ* /G#_AH+Q?\ ]"W8_P#?J;_XJC_AH+Q?_P!"W8_]^IO_ (JOH^B@#YP_
MX:"\7_\ 0MV/_?J;_P"*H_X:"\7_ /0MV/\ WZF_^*KZ/HH ^</^&@O%_P#T
M+=C_ -^IO_BJ/^&@O%__ $+=C_WZF_\ BJ^CZ* /G#_AH+Q?_P!"W8_]^IO_
M (JC_AH+Q?\ ]"W8_P#?J;_XJOH^B@#YP_X:"\7_ /0MV/\ WZF_^*H_X:"\
M7_\ 0MV/_?J;_P"*KZ/HH ^</^&@O%__ $+=C_WZF_\ BJ/^&@O%_P#T+=C_
M -^IO_BJ^CZ* /G#_AH+Q?\ ]"W8_P#?J;_XJC_AH+Q?_P!"W8_]^IO_ (JO
MH^B@#YP_X:"\7_\ 0MV/_?J;_P"*H_X:"\7_ /0MV/\ WZF_^*KZ/HH ^</^
M&@O%_P#T+=C_ -^IO_BJ/^&@O%__ $+=C_WZF_\ BJ^CZ* /G#_AH+Q?_P!"
MW8_]^IO_ (JC_AH+Q?\ ]"W8_P#?J;_XJOH^B@#YP_X:"\7_ /0MV/\ WZF_
M^*H_X:"\7_\ 0MV/_?J;_P"*KZ/HH ^</^&@O%__ $+=C_WZF_\ BJ/^&@O%
M_P#T+=C_ -^IO_BJ^CZ* /G#_AH+Q?\ ]"W8_P#?J;_XJC_AH+Q?_P!"W8_]
M^IO_ (JOH^B@#YP_X:"\7_\ 0MV/_?J;_P"*H_X:"\7_ /0MV/\ WZF_^*KZ
M/HH ^</^&@O%_P#T+=C_ -^IO_BJ/^&@O%__ $+=C_WZF_\ BJ^CZ* /G#_A
MH+Q?_P!"W8_]^IO_ (JC_AH+Q?\ ]"W8_P#?J;_XJOH^B@#YP_X:"\7_ /0M
MV/\ WZF_^*H_X:"\7_\ 0MV/_?J;_P"*KZ/HH ^</^&@O%__ $+=C_WZF_\
MBJ/^&@O%_P#T+=C_ -^IO_BJ^CZ* /G#_AH+Q?\ ]"W8_P#?J;_XJC_AH+Q?
M_P!"W8_]^IO_ (JOH^B@#YP_X:"\7_\ 0MV/_?J;_P"*H_X:"\7_ /0MV/\
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M/^&@O%__ $+=C_WZF_\ BJ^CZ* /G#_AH+Q?_P!"W8_]^IO_ (JC_AH+Q?\
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M_AH+Q?\ ]"W8_P#?J;_XJOH^B@#YP_X:"\7_ /0MV/\ WZF_^*H_X:"\7_\
M0MV/_?J;_P"*KZ/HH ^</^&@O%__ $+=C_WZF_\ BJ/^&@O%_P#T+=C_ -^I
MO_BJ^CZ* /G#_AH+Q?\ ]"W8_P#?J;_XJC_AH+Q?_P!"W8_]^IO_ (JOH^B@
M#YP_X:"\7_\ 0MV/_?J;_P"*H_X:"\7_ /0MV/\ WZF_^*KZ/HH ^</^&@O%
M_P#T+=C_ -^IO_BJ/^&@O%__ $+=C_WZF_\ BJ^CZ* /G#_AH+Q?_P!"W8_]
M^IO_ (JC_AH+Q?\ ]"W8_P#?J;_XJOH^B@#YP_X:"\7_ /0MV/\ WZF_^*H_
MX:"\7_\ 0MV/_?J;_P"*KZ/HH ^</^&@O%__ $+=C_WZF_\ BJ/^&@O%_P#T
M+=C_ -^IO_BJ^CZ* /G#_AH+Q?\ ]"W8_P#?J;_XJC_AH+Q?_P!"W8_]^IO_
M (JOH^B@#YP_X:"\7_\ 0MV/_?J;_P"*H_X:"\7_ /0MV/\ WZF_^*KZ/HH
M^</^&@O%_P#T+=C_ -^IO_BJ/^&@O%__ $+=C_WZF_\ BJ^CZ* /G#_AH+Q?
M_P!"W8_]^IO_ (JC_AH+Q?\ ]"W8_P#?J;_XJOH^B@#YP_X:"\7_ /0MV/\
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M_AH+Q?\ ]"W8_P#?J;_XJC_AH+Q?_P!"W8_]^IO_ (JOH^B@#YP_X:"\7_\
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M_P -!>+_ /H6['_OU-_\57T?10!\X?\ #07B_P#Z%NQ_[]3?_%4?\-!>+_\
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M\-!>+_\ H6['_OU-_P#%5]'T4 ?.'_#07B__ *%NQ_[]3?\ Q5'_  T%XO\
M^A;L?^_4W_Q5?1]% 'SA_P -!>+_ /H6['_OU-_\51_PT%XO_P"A;L?^_4W_
M ,57T?10!\X?\-!>+_\ H6['_OU-_P#%4?\ #07B_P#Z%NQ_[]3?_%5]'T4
M?.'_  T%XO\ ^A;L?^_4W_Q5'_#07B__ *%NQ_[]3?\ Q5?1]% 'SA_PT%XO
M_P"A;L?^_4W_ ,51_P -!>+_ /H6['_OU-_\57T?10!\X?\ #07B_P#Z%NQ_
M[]3?_%4?\-!>+_\ H6['_OU-_P#%5]'T4 ?.'_#07B__ *%NQ_[]3?\ Q5'_
M  T%XO\ ^A;L?^_4W_Q5?1]% 'SA_P -!>+_ /H6['_OU-_\51_PT%XO_P"A
M;L?^_4W_ ,57T?10!\X?\-!>+_\ H6['_OU-_P#%4?\ #07B_P#Z%NQ_[]3?
M_%5]'T4 ?.'_  T%XO\ ^A;L?^_4W_Q5'_#07B__ *%NQ_[]3?\ Q5?1]% '
MSA_PT%XO_P"A;L?^_4W_ ,51_P -!>+_ /H6['_OU-_\57T?10!\X?\ #07B
M_P#Z%NQ_[]3?_%4?\-!>+_\ H6['_OU-_P#%5]'T4 ?.'_#07B__ *%NQ_[]
M3?\ Q5,F^/WBZ:"2)O#MB%=2I(BEX!'^]7TE5>__ .0=<_\ 7)_Y&@#X]^'O
MCW5O L]_+I6G07C72HL@E5SM"DXQM(]37=_\-!>+_P#H6['_ +]3?_%58_9H
M_P"0CXB_ZY0?S>OH>@#YP_X:"\7_ /0MV/\ WZF_^*H_X:"\7_\ 0MV/_?J;
M_P"*KZ/HH ^</^&@O%__ $+=C_WZF_\ BJ/^&@O%_P#T+=C_ -^IO_BJ^CZ*
M /G#_AH+Q?\ ]"W8_P#?J;_XJC_AH+Q?_P!"W8_]^IO_ (JOH^B@#YP_X:"\
M7_\ 0MV/_?J;_P"*H_X:"\7_ /0MV/\ WZF_^*KZ/HH ^</^&@O%_P#T+=C_
M -^IO_BJ/^&@O%__ $+=C_WZF_\ BJ^CZ* /G#_AH+Q?_P!"W8_]^IO_ (JC
M_AH+Q?\ ]"W8_P#?J;_XJOH^B@#YP_X:"\7_ /0MV/\ WZF_^*H_X:"\7_\
M0MV/_?J;_P"*KZ/HH ^</^&@O%__ $+=C_WZF_\ BJ/^&@O%_P#T+=C_ -^I
MO_BJ^CZ* /G#_AH+Q?\ ]"W8_P#?J;_XJC_AH+Q?_P!"W8_]^IO_ (JOH^B@
M#YP_X:"\7_\ 0MV/_?J;_P"*H_X:"\7_ /0MV/\ WZF_^*KZ/HH ^</^&@O%
M_P#T+=C_ -^IO_BJ/^&@O%__ $+=C_WZF_\ BJ^CZ* /G#_AH+Q?_P!"W8_]
M^IO_ (JC_AH+Q?\ ]"W8_P#?J;_XJOH^B@#YP_X:"\7_ /0MV/\ WZF_^*H_
MX:"\7_\ 0MV/_?J;_P"*KZ/HH ^</^&@O%__ $+=C_WZF_\ BJ/^&@O%_P#T
M+=C_ -^IO_BJ^CZ* /G#_AH+Q?\ ]"W8_P#?J;_XJC_AH+Q?_P!"W8_]^IO_
M (JOH^B@#YP_X:"\7_\ 0MV/_?J;_P"*H_X:"\7_ /0MV/\ WZF_^*KZ/HH
M^</^&@O%_P#T+=C_ -^IO_BJ/^&@O%__ $+=C_WZF_\ BJ^CZ* /G#_AH+Q?
M_P!"W8_]^IO_ (JC_AH+Q?\ ]"W8_P#?J;_XJOH^B@#YP_X:"\7_ /0MV/\
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MV/\ WZF_^*KZ/HH ^</^&@O%_P#T+=C_ -^IO_BJ/^&@O%__ $+=C_WZF_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!\V:G_ ,G5I_U^P?\ HA:^DZ^;-3_Y.K3_ *_8/_1"U])T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E^)?^16U?_KR
MF_\ 0#7BG[,W_,T?]NG_ +6KVOQ+_P BMJ__ %Y3?^@&O%/V9O\ F:/^W3_V
MM0![_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 57O_\ D'7/_7)_Y&K%5[__ )!US_UR?^1H \ _9H_Y"/B+_KE!_-Z^
MAZ^>/V:/^0CXB_ZY0?S>OH>@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH \ _:9_YE?_ +>__:->U^&O^16TC_KRA_\
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MW:R9VRPN&4XX(R.]?+_[0/\ R4T_]>47_LU>N? +_DE\'_7W-_,4 >GT444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'S9J?\ R=6G_7[!_P"B%KZ3
MKYLU/_DZM/\ K]@_]$+7TG0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &7XE_Y%;5_^O*;_P! ->*?LS?\S1_VZ?\ M:O:_$O_ "*VK_\
M7E-_Z :\4_9F_P"9H_[=/_:U 'O]%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 54U/4[/1M+N=2OYA#:6T9DED(SA1[#DGV'
M6K=>(_M%^)VL]$L/#<#X:^;[1<8/_+-#\H/L6Y_X!0!ZCX6\8:+XRLIKS1+B
M2>&&3RG9X63#8!Q\P&>"*W:Y+X:>&E\*^ =,T\IMN'C%Q<G')E?DY^G"_P#
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M7_7*#^;U]#T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%Z=X1\46LFDQ>19W\)D\@?=C=3AMOH#D'';GMB@#ZMCD26-9(W5XW 964Y#
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M)). !7BGB3]HK2]/OI+70]*?4D0E3=23>4C$=U&TEA[G%=/\<-2N=-^%]_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YLU/_ ).K
M3_K]@_\ 1"U])U\V:G_R=6G_ %^P?^B%KZ3H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#+\2_\BMJ_P#UY3?^@&O%/V9O^9H_[=/_ &M7
MM?B7_D5M7_Z\IO\ T UXI^S-_P S1_VZ?^UJ /?Z*** "BBB@ HHHH ****
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M/B+_ *Y0?S>OH>OGC]FC_D(^(O\ KE!_-Z^AZ "BBB@ HHHH **** "BBB@
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MTKU?X$;O^%56.[IY\^WZ;S_7- '$?LSM&)/$R''FD6Q'^[^]S_,5=_:6,?\
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M_9Y3U)_V6/.?4D>F>)\$_$C7_ DL@TR6.6SE;=+:7 +1L>FX8(*G'<'TSG%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSM^V2X^GWLT/\;?!UKKFH:3J,UW8S65Q);O)+;ED=D8J2I3<<9'<"FZO\<_
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M(EB'T4 ?TH L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY<_BQ)K;HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^;-3
M_P"3JT_Z_8/_ $0M?2=?-FI_\G5I_P!?L'_HA:^DZ "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH R_$O_(K:O\ ]>4W_H!KQ3]F;_F:/^W3
M_P!K5[7XE_Y%;5_^O*;_ - ->*?LS?\ ,T?]NG_M:@#W^BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO?_\ (.N?^N3_
M ,C5BJ]__P @ZY_ZY/\ R- '@'[-'_(1\1?]<H/YO7T/7SQ^S1_R$?$7_7*#
M^;U]#T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3P-_T,UC_P!]'_"N0_X9Q\(?]!+7/^_\/_QJC_AG'PA_T$M<_P"_\/\ \:H
MZ_\ X6IX&_Z&:Q_[Z/\ A1_PM3P-_P!#-8_]]'_"N0_X9Q\(?]!+7/\ O_#_
M /&J/^&<?"'_ $$M<_[_ ,/_ ,:H Z__ (6IX&_Z&:Q_[Z/^%'_"U/ W_0S6
M/_?1_P *Y#_AG'PA_P!!+7/^_P##_P#&J/\ AG'PA_T$M<_[_P /_P :H Z_
M_A:G@;_H9K'_ +Z/^%'_  M3P-_T,UC_ -]'_"N0_P"&<?"'_02US_O_  __
M !JC_AG'PA_T$M<_[_P__&J .O\ ^%J>!O\ H9K'_OH_X4?\+4\#?]#-8_\
M?1_PKD/^&<?"'_02US_O_#_\:H_X9Q\(?]!+7/\ O_#_ /&J .O_ .%J>!O^
MAFL?^^C_ (4?\+4\#?\ 0S6/_?1_PKD/^&<?"'_02US_ +_P_P#QJC_AG'PA
M_P!!+7/^_P##_P#&J .O_P"%J>!O^AFL?^^C_A1_PM3P-_T,UC_WT?\ "N0_
MX9Q\(?\ 02US_O\ P_\ QJC_ (9Q\(?]!+7/^_\ #_\ &J .O_X6IX&_Z&:Q
M_P"^C_A1_P +4\#?]#-8_P#?1_PKD/\ AG'PA_T$M<_[_P /_P :H_X9Q\(?
M]!+7/^_\/_QJ@#K_ /A:G@;_ *&:Q_[Z/^%'_"U/ W_0S6/_ 'T?\*Y#_AG'
MPA_T$M<_[_P__&J/^&<?"'_02US_ +_P_P#QJ@#K_P#A:G@;_H9K'_OH_P"%
M'_"U/ W_ $,UC_WT?\*Y#_AG'PA_T$M<_P"_\/\ \:H_X9Q\(?\ 02US_O\
MP_\ QJ@#K_\ A:G@;_H9K'_OH_X4?\+4\#?]#-8_]]'_  KD/^&<?"'_ $$M
M<_[_ ,/_ ,:H_P"&<?"'_02US_O_  __ !J@#K_^%J>!O^AFL?\ OH_X4?\
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M!+7/^_\ #_\ &J .O_X6IX&_Z&:Q_P"^C_A1_P +4\#?]#-8_P#?1_PKD/\
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MT,UC_P!]'_"N0_X9Q\(?]!+7/^_\/_QJC_AG'PA_T$M<_P"_\/\ \:H Z_\
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M/ W_ $,UC_WT?\*Y#_AG'PA_T$M<_P"_\/\ \:H_X9Q\(?\ 02US_O\ P_\
MQJ@#K_\ A:G@;_H9K'_OH_X4?\+4\#?]#-8_]]'_  KD/^&<?"'_ $$M<_[_
M ,/_ ,:H_P"&<?"'_02US_O_  __ !J@#K_^%J>!O^AFL?\ OH_X4?\ "U/
MW_0S6/\ WT?\*Y#_ (9Q\(?]!+7/^_\ #_\ &J/^&<?"'_02US_O_#_\:H Z
M_P#X6IX&_P"AFL?^^C_A1_PM3P-_T,UC_P!]'_"N0_X9Q\(?]!+7/^_\/_QJ
MC_AG'PA_T$M<_P"_\/\ \:H Z_\ X6IX&_Z&:Q_[Z/\ A1_PM3P-_P!#-8_]
M]'_"N0_X9Q\(?]!+7/\ O_#_ /&J/^&<?"'_ $$M<_[_ ,/_ ,:H Z__ (6I
MX&_Z&:Q_[Z/^%'_"U/ W_0S6/_?1_P *Y#_AG'PA_P!!+7/^_P##_P#&J/\
MAG'PA_T$M<_[_P /_P :H Z__A:G@;_H9K'_ +Z/^%'_  M3P-_T,UC_ -]'
M_"N0_P"&<?"'_02US_O_  __ !JC_AG'PA_T$M<_[_P__&J .O\ ^%J>!O\
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M#K_^%J>!O^AFL?\ OH_X4?\ "U/ W_0S6/\ WT?\*Y#_ (9Q\(?]!+7/^_\
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M_P##_P#&J .O_P"%J>!O^AFL?^^C_A1_PM3P-_T,UC_WT?\ "N0_X9Q\(?\
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M_OH_X4?\+4\#?]#-8_\ ?1_PKD/^&<?"'_02US_O_#_\:H_X9Q\(?]!+7/\
MO_#_ /&J .O_ .%J>!O^AFL?^^C_ (4?\+4\#?\ 0S6/_?1_PKD/^&<?"'_0
M2US_ +_P_P#QJC_AG'PA_P!!+7/^_P##_P#&J .O_P"%J>!O^AFL?^^C_A1_
MPM3P-_T,UC_WT?\ "N0_X9Q\(?\ 02US_O\ P_\ QJC_ (9Q\(?]!+7/^_\
M#_\ &J .O_X6IX&_Z&:Q_P"^C_A1_P +4\#?]#-8_P#?1_PKD/\ AG'PA_T$
MM<_[_P /_P :H_X9Q\(?]!+7/^_\/_QJ@#K_ /A:G@;_ *&:Q_[Z/^%'_"U/
M W_0S6/_ 'T?\*Y#_AG'PA_T$M<_[_P__&J/^&<?"'_02US_ +_P_P#QJ@#K
M_P#A:G@;_H9K'_OH_P"%'_"U/ W_ $,UC_WT?\*Y#_AG'PA_T$M<_P"_\/\
M\:H_X9Q\(?\ 02US_O\ P_\ QJ@#K_\ A:G@;_H9K'_OH_X4?\+4\#?]#-8_
M]]'_  KD/^&<?"'_ $$M<_[_ ,/_ ,:H_P"&<?"'_02US_O_  __ !J@#S>_
M\1Z/+^T6FO)J$+:4+N)_M0/R;1"H)_,$5[O_ ,+4\#?]#-8_]]'_  KYTO/
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M_P +4\#?]#-8_P#?1_PH_P"%J>!O^AFL?^^C_A7(?\,X^$/^@EKG_?\ A_\
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M ,+4\#?]#-8_]]'_  H_X6IX&_Z&:Q_[Z/\ A7(?\,X^$/\ H):Y_P!_X?\
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M1Y?V5T7._P S.=RM_<'IWH ]_P#^%J>!O^AFL?\ OH_X4?\ "U/ W_0S6/\
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M-_T,UC_WT?\ "N0_X9Q\(?\ 02US_O\ P_\ QJC_ (9Q\(?]!+7/^_\ #_\
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MJ .O_P"%J>!O^AFL?^^C_A1_PM3P-_T,UC_WT?\ "N0_X9Q\(?\ 02US_O\
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MC_WT?\*Y#_AG'PA_T$M<_P"_\/\ \:H_X9Q\(?\ 02US_O\ P_\ QJ@#K_\
MA:G@;_H9K'_OH_X4?\+4\#?]#-8_]]'_  KD/^&<?"'_ $$M<_[_ ,/_ ,:H
M_P"&<?"'_02US_O_  __ !J@#K_^%J>!O^AFL?\ OH_X4?\ "U/ W_0S6/\
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M-_T,UC_WT?\ "N0_X9Q\(?\ 02US_O\ P_\ QJC_ (9Q\(?]!+7/^_\ #_\
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MJ .O_P"%J>!O^AFL?^^C_A1_PM3P-_T,UC_WT?\ "N0_X9Q\(?\ 02US_O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'S9J?_)U:?\ 7[!_Z(6OI.OFS4_^
M3JT_Z_8/_1"U])T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!E^)?^16U?_KRF_P#0#7BG[,W_ #-'_;I_[6KVOQ+_ ,BMJ_\ UY3?^@&O
M%/V9O^9H_P"W3_VM0![_ $444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %5[_\ Y!US_P!<G_D:L57O_P#D'7/_ %R?^1H
M\ _9H_Y"/B+_ *Y0?S>OH>OGC]FC_D(^(O\ KE!_-Z^AZ "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 > ?M,_\ ,K_]O?\ [1KVOPU_R*VD?]>4/_H KQ3]IG_F
M5_\ M[_]HU[7X:_Y%;2/^O*'_P! % '@'P'_ .2MZ]_UY7'_ */BKZ3KYL^
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MKW4++381-?7EO:Q$[0\\JHI/IDGK3;'5=.U0.=/O[6[$>-YMYEDVYZ9P3BO
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MPTUFT:6Z!63+VE[:L4^9<9'JK#(_.@#[+IDTT5O"\T\J11(,L[L%51ZDGI7
M?![QQ<>-?");4&#:E8R>1</C'F#&5? Z9&0?=3ZUXE\:_&M_K_C*\T=97CTS
M3)3 D"MP\B\,[#N<Y ] /<T ?1,OQ$\&0SB%_%&D[_:Z0@?4@X%;UG?6FHVR
MW-C=074#?=E@D#J?H1Q7S=HG[/.JZMH-IJ,NMVMM+<PK,L'DE]H89 +9'.#S
M@'\:[?X/_#WQ)X%\2:NNJB)K&:W41S03;HY'#?W3A@0,]1WH [3X@^$_#7BO
M2((O$EW]CB@DW17(G6(HQ'(!8$<XZ$=JSOAWX%\'>%I[RZ\-ZB=1N9$$<L[W
M4<S(F<[?D  !(!Z=JY/]I+_D5=&_Z_3_ .@&N;_9K_Y&'7/^O1/_ $.@#Z/J
MAJFN:3HD(EU74K2R0]#<3*F?ID\UR?Q6\>'P)X6\^U"-J=VYAM%89"G&6<CN
M%&/Q(KY@TC1_$OQ'\2M% TU_J$H+S3W$APB^K,>@YP!^ % 'UI!\1?!ES-Y4
M7B?2MY;: URJY/L2:Z2.1)HUDB=71AE64Y!'J#7R9XC^!_B[PYI$NIN+*]@A
M3?*MG(S.B]SAE&0/;-0_"OXC7W@[Q!;6EQ<N^B7,@CN(7;*Q9./,7T(SDXZC
M\, 'US++'#$\LKK'&@+,[' 4#J2>U4[+6]*U*5HK#4[*ZD4;BD%PKD#UP#6#
M\3?^29>(O^O)_P"5?(WAOQ/J/A2_GO\ 2G6.[DMW@64C)C#8RP]^.* /LS5_
M%OA[0)!%JVM6-G*1D1RS*'QZ[>M6=*U[2-=A:72=3M+Y$X8V\ROM^N#Q^-?*
M%O\ ";Q[KNF/KITV24S@S?Z1.!/,#SNPQR2??DUS'AWQ!JGA#Q!#J6GRR07,
M#XDC)(#J#\R./0XP1_44 ?<U%5=,OX=5TJSU&WSY%W D\>>NUE##]#5J@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?Q?\"+W1KC ,UU,8I#_RSD&TJWX'K[9% 'IW@3Q5#XR\(66L1E1*Z[+B,?\
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M\-_^3AXO^OV^_P#1<U 'U71110!R'BCP7X(U[58+WQ%9VCWP4)&TERT190>
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MK\-?\BMI'_7E#_Z *\4_:9_YE?\ [>__ &C7M?AK_D5M(_Z\H?\ T 4 > ?
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M0.A3RF//X@'Z@4 >H_M)?\BMHW_7ZW_H!KF_V:_^1AUS_KT3_P!#KI/VDO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#YLU/_ ).K3_K]@_\ 1"U])U\V:G_R=6G_ %^P?^B%KZ3H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#+\2_\BMJ_P#UY3?^@&O%/V9O
M^9H_[=/_ &M7M?B7_D5M7_Z\IO\ T UXI^S-_P S1_VZ?^UJ /?Z*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC0@?0%F/XU[37CG[.'_(BZG_ -A-O_14=>QT 0WEW#865Q>7+A(+>-I9&/\
M"JC)/Y"OF?X56DWCSXR7?B2]0F*VD>^8'D!R<1)^&<C_ '*]-^//B/\ L7X?
MO81/MN=5D%N .HC'S.?Y+_P*F_ 3PY_8W@ :C*FVYU64S$D<^6ORH/\ T)O^
M!4 >IUYI\>?^267G_7Q#_P"ABO2Z\T^//_)++S_KXA_]#% &7^SC_P D]O\
M_L*R?^BHJ]?KR#]G'_DGM_\ ]A63_P!%15Z_0!'/_P >\O\ N'^5?,G[./\
MR4*__P"P5)_Z-BKZ>=0Z,AZ,,'%?*GP0OHO#_P 539W[>5)<0RV/S' $FY2
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M '@'P'_Y*WKW_7E<?^CXJ^DZ^;/@/_R5O7O^O*X_]'Q5])T %%%% !7S)8?
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M7%K=17L[W#02OY<B,YW$#/RD9)YR*^AZ* /DV#X&_$&]D5+BRA@53M5Y[Q&
M'J-I8X_#M7M?PS^$UGX",M]<70OM6F3RS*$VI$O4J@//)ZD^G0<Y]'HH \X^
M,7@?5O''A^QMM(:W\^VN3*RS.4W*5(X.#STZUC_!KX;:]X(U'4[S63:JMS"L
M4:12[VR&R2>,8_&O7Z* ,KQ'X=T[Q5H=QI&J0F2VF'53AD8=&4]B/\\5\Z:[
M^SUXHL;I_P"R)[34K8GY"9!%(![AN/R-?4%% 'R59_ GQ[=2A)M-M[12<;Y[
MN,@>_P A8_I7M?PV^$6G^!G_ +1NYQ?:RR[?."X2$'J$'J>FX\X[#G/I5% &
M)XQT>X\0>#M6TFT>-;B[MGBC,A(4,1QDC/%>(> _@MXLT+QQIFJZA]ACM;.;
MS'*S[BP /0 ?SQ7T510 5\Y^./@IXLUOQMJFJ6'V&2UO+@RHS3[2H/8@C^6:
M^C** ,;PEI,^A>$=(TJY:-I[2UCAD:,DJ6"@'&>U;-%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?-FI_P#)U:?]?L'_ *(6OI.OFS4_^3JT_P"OV#_T0M?2= !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9?B7_D5M7_Z\IO_
M $ UXI^S-_S-'_;I_P"UJ]K\2_\ (K:O_P!>4W_H!KQ3]F;_ )FC_MT_]K4
M>_T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&F9'F?:+\S9'^ZI.X^Q('O5KQC\ KS&E6_A1;=HHH2MU-=2[7DD+9W'CIC@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ JO?\ _(.N?^N3_P C5BJ]_P#\@ZY_ZY/_ "- '@'[-'_(1\1?
M]<H/YO7T/7SQ^S1_R$?$7_7*#^;U]#T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4$ C!&1110!G2^']%FE$LND6$
MD@.0[6R$@_7%788(;:(1011Q1CHD:A0/P%244 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 > ?M,_\RO_ -O?_M&O:_#7_(K:1_UY0_\
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M\E'_  TIH_\ T+]]_P!_DKT__A!/"'_0J:'_ ."Z'_XFC_A!/"'_ $*FA_\
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M2FC_ /0OWW_?Y*]/_P"$$\(?]"IH?_@NA_\ B:/^$$\(?]"IH?\ X+H?_B:
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M"_??]_DKT_\ X03PA_T*FA_^"Z'_ .)H_P"$$\(?]"IH?_@NA_\ B: /,/\
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M[_O\E'_#2FC_ /0OWW_?Y*]/_P"$$\(?]"IH?_@NA_\ B:/^$$\(?]"IH?\
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M'_#2FC_]"_??]_DKT_\ X03PA_T*FA_^"Z'_ .)H_P"$$\(?]"IH?_@NA_\
MB: /,/\ AI31_P#H7[[_ +_)1_PTIH__ $+]]_W^2O3_ /A!/"'_ $*FA_\
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MA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)H \P_X:4T?_H7[[_O\E'_  TIH_\
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MH_\ T+]]_P!_DKT__A!/"'_0J:'_ ."Z'_XFC_A!/"'_ $*FA_\ @NA_^)H
M\P_X:4T?_H7[[_O\E'_#2FC_ /0OWW_?Y*]/_P"$$\(?]"IH?_@NA_\ B:/^
M$$\(?]"IH?\ X+H?_B: /,/^&E-'_P"A?OO^_P E'_#2FC_]"_??]_DKT_\
MX03PA_T*FA_^"Z'_ .)H_P"$$\(?]"IH?_@NA_\ B: /,/\ AI31_P#H7[[_
M +_)1_PTIH__ $+]]_W^2O3_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^
M"Z'_ .)H \P_X:4T?_H7[[_O\E'_  TIH_\ T+]]_P!_DKT__A!/"'_0J:'_
M ."Z'_XFC_A!/"'_ $*FA_\ @NA_^)H \P_X:4T?_H7[[_O\E'_#2FC_ /0O
MWW_?Y*]/_P"$$\(?]"IH?_@NA_\ B:/^$$\(?]"IH?\ X+H?_B: /,/^&E-'
M_P"A?OO^_P E'_#2FC_]"_??]_DKT_\ X03PA_T*FA_^"Z'_ .)H_P"$$\(?
M]"IH?_@NA_\ B: /,/\ AI31_P#H7[[_ +_)1_PTIH__ $+]]_W^2O3_ /A!
M/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)H \P_X:4T?_H7[[_O\E'_
M  TIH_\ T+]]_P!_DKT__A!/"'_0J:'_ ."Z'_XFC_A!/"'_ $*FA_\ @NA_
M^)H \P_X:4T?_H7[[_O\E'_#2FC_ /0OWW_?Y*]/_P"$$\(?]"IH?_@NA_\
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M\E'_  TIH_\ T+]]_P!_DKT__A!/"'_0J:'_ ."Z'_XFC_A!/"'_ $*FA_\
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M2FC_ /0OWW_?Y*]/_P"$$\(?]"IH?_@NA_\ B:/^$$\(?]"IH?\ X+H?_B:
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M_P"A4T/_ ,%T/_Q-'_"">$/^A4T/_P %T/\ \30!YA_PTIH__0OWW_?Y*/\
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M_P 30!YA_P -*:/_ -"_??\ ?Y*/^&E-'_Z%^^_[_)7I_P#P@GA#_H5-#_\
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MK81 J0AP0=O!KR']GG0M'UO_ (2/^U=*L;_R?LWE_:K=)=F?-SC<#C.!^0H
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M_#2FC_\ 0OWW_?Y*]/\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\
MXF@#S#_AI31_^A?OO^_R4?\ #2FC_P#0OWW_ '^2O3_^$$\(?]"IH?\ X+H?
M_B:/^$$\(?\ 0J:'_P""Z'_XF@#S#_AI31_^A?OO^_R4?\-*:/\ ]"_??]_D
MKT__ (03PA_T*FA_^"Z'_P")H_X03PA_T*FA_P#@NA_^)H \P_X:4T?_ *%^
M^_[_ "4?\-*:/_T+]]_W^2O3_P#A!/"'_0J:'_X+H?\ XFC_ (03PA_T*FA_
M^"Z'_P")H \P_P"&E-'_ .A?OO\ O\E'_#2FC_\ 0OWW_?Y*]/\ ^$$\(?\
M0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XF@#S#_AI31_^A?OO^_R4?\ #2FC
M_P#0OWW_ '^2O3_^$$\(?]"IH?\ X+H?_B:/^$$\(?\ 0J:'_P""Z'_XF@#S
M#_AI31_^A?OO^_R4?\-*:/\ ]"_??]_DKT__ (03PA_T*FA_^"Z'_P")H_X0
M3PA_T*FA_P#@NA_^)H \P_X:4T?_ *%^^_[_ "4?\-*:/_T+]]_W^2O3_P#A
M!/"'_0J:'_X+H?\ XFC_ (03PA_T*FA_^"Z'_P")H \P_P"&E-'_ .A?OO\
MO\E'_#2FC_\ 0OWW_?Y*]/\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+
MH?\ XF@#S#_AI31_^A?OO^_R4?\ #2FC_P#0OWW_ '^2O3_^$$\(?]"IH?\
MX+H?_B:/^$$\(?\ 0J:'_P""Z'_XF@#S#_AI31_^A?OO^_R4?\-*:/\ ]"_?
M?]_DKT__ (03PA_T*FA_^"Z'_P")H_X03PA_T*FA_P#@NA_^)H \P_X:4T?_
M *%^^_[_ "4?\-*:/_T+]]_W^2O3_P#A!/"'_0J:'_X+H?\ XFC_ (03PA_T
M*FA_^"Z'_P")H \P_P"&E-'_ .A?OO\ O\E'_#2FC_\ 0OWW_?Y*]/\ ^$$\
M(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XF@#S#_AI31_^A?OO^_R4?\
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MH?\ X+H?_B:/^$$\(?\ 0J:'_P""Z'_XF@#S#_AI31_^A?OO^_R4?\-*:/\
M]"_??]_DKT__ (03PA_T*FA_^"Z'_P")H_X03PA_T*FA_P#@NA_^)H \P_X:
M4T?_ *%^^_[_ "4?\-*:/_T+]]_W^2O3_P#A!/"'_0J:'_X+H?\ XFC_ (03
MPA_T*FA_^"Z'_P")H \P_P"&E-'_ .A?OO\ O\E'_#2FC_\ 0OWW_?Y*]/\
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M?_B:/^$$\(?]"IH?_@NA_P#B: /,/^&E-'_Z%^^_[_)1_P -*:/_ -"_??\
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M03PA_P!"IH?_ (+H?_B: /,/^&E-'_Z%^^_[_)1_PTIH_P#T+]]_W^2O3_\
MA!/"'_0J:'_X+H?_ (FC_A!/"'_0J:'_ ."Z'_XF@#S#_AI31_\ H7[[_O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/FS4_P#DZM/^OV#_ -$+7TG7S9J?_)U:?]?L'_HA:^DZ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>_\ VC7M?AK_ )%;2/\ KRA_] % '@'P'_Y*WKW_ %Y7'_H^*OI.OFSX#_\
M)6]>_P"O*X_]'Q5])T %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!\V:G_R=6G_ %^P?^B%KZ3K
MYLU/_DZM/^OV#_T0M?2= !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 9?B7_D5M7_Z\IO\ T UXI^S-_P S1_VZ?^UJ]K\2_P#(K:O_ ->4
MW_H!KQ3]F;_F:/\ MT_]K4 >_P!%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !5>__ .0=<_\ 7)_Y&K%5[_\ Y!US_P!<
MG_D: / /V:/^0CXB_P"N4'\WKZ'KYX_9H_Y"/B+_ *Y0?S>OH>@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***Y3XC>*[CP7X*N]9M((I[F-D2))<[
M,LP&6P0<8ST- '5T5\WV7QS^(NI0M-8>&K"ZB5MI>"PN'4' .,B3K@C\ZD@_
M:%\4:?=HNN^&[/RVYV1K+;N1ZC>6_E0!]&45S/@OQUHWCK2S=Z7*5ECP)[:7
M DA)Z9'<'L1P?KD5TU !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%?/7BWXG>.M,^+4VB6,NVT2[CBALOLJ-YR''.XKN
M^;.<@T ?0M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 > ?M,_\RO\ ]O?_ +1KVOPU_P BMI'_ %Y0_P#H KQ3]IG_
M )E?_M[_ /:->U^&O^16TC_KRA_] % '@'P'_P"2MZ]_UY7'_H^*OI.OFSX#
M_P#)6]>_Z\KC_P!'Q5])T %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!\V:G_R=6G_7[!_Z(6OI
M.OFS4_\ DZM/^OV#_P!$+7TG0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &7XE_P"16U?_ *\IO_0#7BG[,W_,T?\ ;I_[6KVOQ+_R*VK_
M /7E-_Z :\4_9F_YFC_MT_\ :U 'O]%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !5>_\ ^0=<_P#7)_Y&K%5[_P#Y!US_
M -<G_D: / /V:/\ D(^(O^N4'\WKZ'KYX_9H_P"0CXB_ZY0?S>OH>@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\T^//\ R2R\_P"OB'_T,5Z77FGQ
MY_Y)9>?]?$/_ *&* ,O]G'_DGM__ -A63_T5%7I?B#P]IGB?1Y],U6V6>WE4
MCD?,A[,I[$>M>5?L]:E86?@&_CNKVV@<ZI(P6655)'E1<X)]J[7QA\3_  YX
M3TJ:8ZC;7=\4/V>T@D#L[XXW;?NK[G\,GB@#P3X1W-SX:^,L6E"8F.26>QG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /FS4_\ DZM/^OV#_P!$+7TG7S9J?_)U:?\ 7[!_Z(6OI.@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,OQ+_R*VK_ /7E-_Z
M:\4_9F_YFC_MT_\ :U>U^)?^16U?_KRF_P#0#7BG[,W_ #-'_;I_[6H ]_HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***@O;VVT
MVQFO;R=(+:!"\LKG 51U)H GHK&\/^*]"\5132Z)J45XL! EV @H3G&00#S@
M_E6S0 4444 %%<_8>.?#.IZZ^B66L6\VI(S*8%SG*YW '&#C!Z'M704 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2<<9P.IKH)[#X]:=NF\Z^F5>\<\$N?\ @.23^51_LV_\C3K/_7DO_H8KZ3H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 > ?M,_\ ,K_]O?\
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MG\S6+XL^#GB+P;X>DUK4KO3)+='1&2WED9\L<#@H!^M:/[/W_)31_P!>4O\
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M^QM&-OLVY*(9.F,[_O;O]K.?>OE#Q5I8\*^-M0L+&Y8K976;>96^8#AD.1W
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S9J?\
MR=6G_7[!_P"B%KZ3KYLU/_DZM/\ K]@_]$+7TG0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &7XE_Y%;5_^O*;_P! ->*?LS?\S1_VZ?\
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M_J)0-R>X 8@?05]5UX99?LYB#5;6\N_%DERL,J.R?8=K.%.<;C(<?7!KW.@
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M_AG2\_Z'F?\ \ 3_ /'JZ+P!\%H_!'B<:W)KS7\BQ.B1BU\K!;@DG>V>,\4
M>JT444 %%%% !1110 4444 %%%% !5>__P"0=<_]<G_D:L57O_\ D'7/_7)_
MY&@#P#]FC_D(^(O^N4'\WKZ'KYX_9H_Y"/B+_KE!_-Z^AZ "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P#]IG_F5_\
MM[_]HU[7X:_Y%;2/^O*'_P! %>*?M,_\RO\ ]O?_ +1KVOPU_P BMI'_ %Y0
M_P#H H \ ^ __)6]>_Z\KC_T?%7TG7S9\!_^2MZ]_P!>5Q_Z/BKZ3H ****
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M5NK.4@M&S%>0<@Y!!!^AK&\/?#CPEX5U$ZAHND+;710IYIGDD(4]0-[''X4
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M7_)4_$'_ %\#_P! 6O??"7@OP_XP^$WAR'6].CN"EH!'*"5DCY/1ASCVZ>U
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M1IOP6\!Z;(L@T7[3(O0W4SR#\5SM/Y5W=O;PVMO';V\,<,,8VI'&H55'H .
M* )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS-YF?3/W/_'JZ_1_!/AS0=&N=(T[2H4T^Z8O/!(S2K(2 .=Y.> .*YJ;X'>
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M&M^@ K'\6?\ (G:Y_P!@^?\ ]%M6Q3719(VC=0R,"&4C((/:@#Y)^#_CC2?
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M#%;]IX#\+V&@7.AVNCP1:?=+MGC4MNE'^T^=Q^N: .'_ &=?^2<W7_83E_\
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M<+6T;1/'=,ZC!.0055N?P]*[GP9H$OA?P?IFBS3K/+:0['D7."223C/;G H
MW:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV9O^9H_[=/\ VM0![_1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?U/0YI"PL95E@![))G('L&4G_@5>E>/B@^'?B7?T_LNY_/RVQ^M>(_LV!O\
MA)-;(^[]C3/UW\?UH [KXT_$#7/ R:(NBFW4WIG,K2Q;S\GEX Y_VS^0KO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!E^)?\ D5M7_P"O*;_T UXI^S-_S-'_ &Z?^UJ]K\2_\BMJ_P#UY3?^
M@&O%/V9O^9H_[=/_ &M0![_1110 4444 %%%% !1110 4444 %%%% !1110
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MA+5;/Q3#XPT^!Y+9D3SI(T),$D?1F] 0%Y]1],@&YH?[.6DK91R:_JM]->L
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MFC!BXVG#$GUY[XH ZVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \ _:9_YE?_M[_P#:->U^&O\ D5M(_P"O*'_T 5XI^TS_
M ,RO_P!O?_M&O:_#7_(K:1_UY0_^@"@#P#X#_P#)6]>_Z\KC_P!'Q5])U\V?
M ?\ Y*WKW_7E<?\ H^*OI.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /FS4_^3JT_Z_8/_1"U
M])U\V:G_ ,G5I_U^P?\ HA:^DZ "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH R_$O\ R*VK_P#7E-_Z :\4_9F_YFC_ +=/_:U>U^)?^16U
M?_KRF_\ 0#7BG[,W_,T?]NG_ +6H ]_HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM/BMKDMS<PPQM9S@/(X4$^?'QDU]$_V[H_\ T%;'_P "$_QH T**S_[=T?\
MZ"MC_P"!"?XT?V[H_P#T%;'_ ,"$_P : -"BL_\ MW1_^@K8_P#@0G^-']NZ
M/_T%;'_P(3_&@#0HK/\ [=T?_H*V/_@0G^-']NZ/_P!!6Q_\"$_QH T**S_[
M=T?_ *"MC_X$)_C1_;NC_P#05L?_  (3_&@#0HK/_MW1_P#H*V/_ ($)_C1_
M;NC_ /05L?\ P(3_ !H T**S_P"W='_Z"MC_ .!"?XT?V[H__05L?_ A/\:
M-"BL_P#MW1_^@K8_^!"?XT?V[H__ $%;'_P(3_&@#0HK/_MW1_\ H*V/_@0G
M^-']NZ/_ -!6Q_\  A/\: -"BL_^W='_ .@K8_\ @0G^-']NZ/\ ]!6Q_P#
MA/\ &@#0HK/_ +=T?_H*V/\ X$)_C1_;NC_]!6Q_\"$_QH T**S_ .W='_Z"
MMC_X$)_C1_;NC_\ 05L?_ A/\: -"BL_^W='_P"@K8_^!"?XT?V[H_\ T%;'
M_P "$_QH T**S_[=T?\ Z"MC_P"!"?XT?V[H_P#T%;'_ ,"$_P : -"BL_\
MMW1_^@K8_P#@0G^-']NZ/_T%;'_P(3_&@#0HK/\ [=T?_H*V/_@0G^-']NZ/
M_P!!6Q_\"$_QH T**S_[=T?_ *"MC_X$)_C1_;NC_P#05L?_  (3_&@#0HK/
M_MW1_P#H*V/_ ($)_C1_;NC_ /05L?\ P(3_ !H T**S_P"W='_Z"MC_ .!"
M?XT?V[H__05L?_ A/\: -"BL_P#MW1_^@K8_^!"?XT?V[H__ $%;'_P(3_&@
M#0HK/_MW1_\ H*V/_@0G^-']NZ/_ -!6Q_\  A/\: -"BL_^W='_ .@K8_\
M@0G^-']NZ/\ ]!6Q_P# A/\ &@#0HK/_ +=T?_H*V/\ X$)_C1_;NC_]!6Q_
M\"$_QH T**S_ .W='_Z"MC_X$)_C1_;NC_\ 05L?_ A/\: -"BL_^W='_P"@
MK8_^!"?XT?V[H_\ T%;'_P "$_QH T**S_[=T?\ Z"MC_P"!"?XT?V[H_P#T
M%;'_ ,"$_P : -"BL_\ MW1_^@K8_P#@0G^-']NZ/_T%;'_P(3_&@#0HK/\
M[=T?_H*V/_@0G^-']NZ/_P!!6Q_\"$_QH T**S_[=T?_ *"MC_X$)_C1_;NC
M_P#05L?_  (3_&@#0HK/_MW1_P#H*V/_ ($)_C1_;NC_ /05L?\ P(3_ !H
MT**S_P"W='_Z"MC_ .!"?XT?V[H__05L?_ A/\: -"BL_P#MW1_^@K8_^!"?
MXT?V[H__ $%;'_P(3_&@#0HK/_MW1_\ H*V/_@0G^-']NZ/_ -!6Q_\  A/\
M: -"BL_^W='_ .@K8_\ @0G^-']NZ/\ ]!6Q_P# A/\ &@#0HK/_ +=T?_H*
MV/\ X$)_C1_;NC_]!6Q_\"$_QH T**S_ .W='_Z"MC_X$)_C1_;NC_\ 05L?
M_ A/\: -"BL_^W='_P"@K8_^!"?XT?V[H_\ T%;'_P "$_QH T**S_[=T?\
MZ"MC_P"!"?XT?V[H_P#T%;'_ ,"$_P : -"BL_\ MW1_^@K8_P#@0G^-']NZ
M/_T%;'_P(3_&@#0HK/\ [=T?_H*V/_@0G^-']NZ/_P!!6Q_\"$_QH T**S_[
M=T?_ *"MC_X$)_C1_;NC_P#05L?_  (3_&@#0HK/_MW1_P#H*V/_ ($)_C1_
M;NC_ /05L?\ P(3_ !H T**S_P"W='_Z"MC_ .!"?XT?V[H__05L?_ A/\:
M-"BL_P#MW1_^@K8_^!"?XT?V[H__ $%;'_P(3_&@#0HK/_MW1_\ H*V/_@0G
M^-']NZ/_ -!6Q_\  A/\: -"BL_^W='_ .@K8_\ @0G^-']NZ/\ ]!6Q_P#
MA/\ &@#0HK/_ +=T?_H*V/\ X$)_C1_;NC_]!6Q_\"$_QH T**S_ .W='_Z"
MMC_X$)_C1_;NC_\ 05L?_ A/\: -"BL_^W='_P"@K8_^!"?XT?V[H_\ T%;'
M_P "$_QH T**S_[=T?\ Z"MC_P"!"?XT?V[H_P#T%;'_ ,"$_P : -"BL_\
MMW1_^@K8_P#@0G^-']NZ/_T%;'_P(3_&@#0HK/\ [=T?_H*V/_@0G^-']NZ/
M_P!!6Q_\"$_QH T**S_[=T?_ *"MC_X$)_C1_;NC_P#05L?_  (3_&@#0HK/
M_MW1_P#H*V/_ ($)_C1_;NC_ /05L?\ P(3_ !H T**S_P"W='_Z"MC_ .!"
M?XT?V[H__05L?_ A/\: -"BL_P#MW1_^@K8_^!"?XT?V[H__ $%;'_P(3_&@
M#0HK/_MW1_\ H*V/_@0G^-']NZ/_ -!6Q_\  A/\: -"BL_^W='_ .@K8_\
M@0G^-']NZ/\ ]!6Q_P# A/\ &@#0HK/_ +=T?_H*V/\ X$)_C1_;NC_]!6Q_
M\"$_QH T**S_ .W='_Z"MC_X$)_C1_;NC_\ 05L?_ A/\: -"BL_^W='_P"@
MK8_^!"?XT?V[H_\ T%;'_P "$_QH T**S_[=T?\ Z"MC_P"!"?XT?V[H_P#T
M%;'_ ,"$_P : -"BL_\ MW1_^@K8_P#@0G^-']NZ/_T%;'_P(3_&@#0HK/\
M[=T?_H*V/_@0G^-']NZ/_P!!6Q_\"$_QH T**S_[=T?_ *"MC_X$)_C1_;NC
M_P#05L?_  (3_&@#0HK/_MW1_P#H*V/_ ($)_C1_;NC_ /05L?\ P(3_ !H
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M0!H45G_V[H__ $%;'_P(3_&C^W='_P"@K8_^!"?XT :%%9_]NZ/_ -!6Q_\
M A/\:/[=T?\ Z"MC_P"!"?XT :%%9_\ ;NC_ /05L?\ P(3_ !H_MW1_^@K8
M_P#@0G^- &A16?\ V[H__05L?_ A/\:/[=T?_H*V/_@0G^- &A16?_;NC_\
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MZ'HK/_MW1_\ H*V/_@0G^-']NZ/_ -!6Q_\  A/\: -"BL_^W='_ .@K8_\
M@0G^-']NZ/\ ]!6Q_P# A/\ &@#0HK/_ +=T?_H*V/\ X$)_C1_;NC_]!6Q_
M\"$_QH T**S_ .W='_Z"MC_X$)_C1_;NC_\ 05L?_ A/\: -"BL_^W='_P"@
MK8_^!"?XT?V[H_\ T%;'_P "$_QH T**S_[=T?\ Z"MC_P"!"?XT?V[H_P#T
M%;'_ ,"$_P : -"BL_\ MW1_^@K8_P#@0G^-']NZ/_T%;'_P(3_&@#0HK/\
M[=T?_H*V/_@0G^-']NZ/_P!!6Q_\"$_QH T**S_[=T?_ *"MC_X$)_C1_;NC
M_P#05L?_  (3_&@#0HK/_MW1_P#H*V/_ ($)_C1_;NC_ /05L?\ P(3_ !H
MT**S_P"W='_Z"MC_ .!"?XT?V[H__05L?_ A/\: -"BL_P#MW1_^@K8_^!"?
MXT?V[H__ $%;'_P(3_&@#0HK/_MW1_\ H*V/_@0G^-']NZ/_ -!6Q_\  A/\
M: -"BL_^W='_ .@K8_\ @0G^-']NZ/\ ]!6Q_P# A/\ &@#0HK/_ +=T?_H*
MV/\ X$)_C1_;NC_]!6Q_\"$_QH T**S_ .W='_Z"MC_X$)_C1_;NC_\ 05L?
M_ A/\: -"BL_^W='_P"@K8_^!"?XT?V[H_\ T%;'_P "$_QH T**S_[=T?\
MZ"MC_P"!"?XT?V[H_P#T%;'_ ,"$_P : -"BL_\ MW1_^@K8_P#@0G^-']NZ
M/_T%;'_P(3_&@#0HK/\ [=T?_H*V/_@0G^-']NZ/_P!!6Q_\"$_QH T**S_[
M=T?_ *"MC_X$)_C1_;NC_P#05L?_  (3_&@#0HK/_MW1_P#H*V/_ ($)_C1_
M;NC_ /05L?\ P(3_ !H T**S_P"W='_Z"MC_ .!"?XT?V[H__05L?_ A/\:
M-"BL_P#MW1_^@K8_^!"?XT?V[H__ $%;'_P(3_&@#0HK/_MW1_\ H*V/_@0G
M^-']NZ/_ -!6Q_\  A/\: -"BL_^W='_ .@K8_\ @0G^-']NZ/\ ]!6Q_P#
MA/\ &@#0HK/_ +=T?_H*V/\ X$)_C1_;NC_]!6Q_\"$_QH T**S_ .W='_Z"
MMC_X$)_C1_;NC_\ 05L?_ A/\: -"BL_^W='_P"@K8_^!"?XT?V[H_\ T%;'
M_P "$_QH T**S_[=T?\ Z"MC_P"!"?XT?V[H_P#T%;'_ ,"$_P : -"BL_\
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M_P#H*V/_ ($)_C0!H45G_P!NZ/\ ]!6Q_P# A/\ &C^W='_Z"MC_ .!"?XT
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MH_\ T%;'_P "$_QH_MW1_P#H*V/_ ($)_C0!H45G_P!NZ/\ ]!6Q_P# A/\
M&C^W='_Z"MC_ .!"?XT :%%9_P#;NC_]!6Q_\"$_QH_MW1_^@K8_^!"?XT :
M%%9_]NZ/_P!!6Q_\"$_QH_MW1_\ H*V/_@0G^- &A16?_;NC_P#05L?_  (3
M_&C^W='_ .@K8_\ @0G^- &A16?_ &[H_P#T%;'_ ,"$_P :/[=T?_H*V/\
MX$)_C0!H45G_ -NZ/_T%;'_P(3_&C^W='_Z"MC_X$)_C0!H45G_V[H__ $%;
M'_P(3_&C^W='_P"@K8_^!"?XT :%%9_]NZ/_ -!6Q_\  A/\:/[=T?\ Z"MC
M_P"!"?XT :%%9_\ ;NC_ /05L?\ P(3_ !H_MW1_^@K8_P#@0G^- &A16?\
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M !='_#-%Y_T,\'_@&?\ XNOH>B@#YX_X9HO/^AG@_P# ,_\ Q='_  S1>?\
M0SP?^ 9_^+KZ'HH ^>/^&:+S_H9X/_ ,_P#Q='_#-%Y_T,\'_@&?_BZ^AZ*
M/GC_ (9HO/\ H9X/_ ,__%T?\,T7G_0SP?\ @&?_ (NOH>B@#YX_X9HO/^AG
M@_\  ,__ !='_#-%Y_T,\'_@&?\ XNOH>B@#YX_X9HO/^AG@_P# ,_\ Q='_
M  S1>?\ 0SP?^ 9_^+KZ'HH ^>/^&:+S_H9X/_ ,_P#Q='_#-%Y_T,\'_@&?
M_BZ^AZ* /GC_ (9HO/\ H9X/_ ,__%T?\,T7G_0SP?\ @&?_ (NOH>B@#YX_
MX9HO/^AG@_\  ,__ !='_#-%Y_T,\'_@&?\ XNOH>B@#YX_X9HO/^AG@_P#
M,_\ Q='_  S1>?\ 0SP?^ 9_^+KZ'HH ^>/^&:+S_H9X/_ ,_P#Q='_#-%Y_
MT,\'_@&?_BZ^AZ* /GC_ (9HO/\ H9X/_ ,__%T?\,T7G_0SP?\ @&?_ (NO
MH>B@#YX_X9HO/^AG@_\  ,__ !='_#-%Y_T,\'_@&?\ XNOH>B@#YX_X9HO/
M^AG@_P# ,_\ Q='_  S1>?\ 0SP?^ 9_^+KZ'HH ^>/^&:+S_H9X/_ ,_P#Q
M='_#-%Y_T,\'_@&?_BZ^AZ* /GC_ (9HO/\ H9X/_ ,__%T?\,T7G_0SP?\
M@&?_ (NOH>B@#YX_X9HO/^AG@_\  ,__ !='_#-%Y_T,\'_@&?\ XNOH>B@#
MYX_X9HO/^AG@_P# ,_\ Q='_  S1>?\ 0SP?^ 9_^+KZ'HH ^>/^&:+S_H9X
M/_ ,_P#Q='_#-%Y_T,\'_@&?_BZ^AZ* /GC_ (9HO/\ H9X/_ ,__%T?\,T7
MG_0SP?\ @&?_ (NOH>B@#YX_X9HO/^AG@_\  ,__ !='_#-%Y_T,\'_@&?\
MXNOH>B@#YX_X9HO/^AG@_P# ,_\ Q='_  S1>?\ 0SP?^ 9_^+KZ'HH ^>/^
M&:+S_H9X/_ ,_P#Q='_#-%Y_T,\'_@&?_BZ^AZ* /GC_ (9HO/\ H9X/_ ,_
M_%T?\,T7G_0SP?\ @&?_ (NOH>B@#YX_X9HO/^AG@_\  ,__ !='_#-%Y_T,
M\'_@&?\ XNOH>B@#YX_X9HO/^AG@_P# ,_\ Q='_  S1>?\ 0SP?^ 9_^+KZ
M'HH ^>/^&:+S_H9X/_ ,_P#Q='_#-%Y_T,\'_@&?_BZ^AZ* /GC_ (9HO/\
MH9X/_ ,__%T?\,T7G_0SP?\ @&?_ (NOH>B@#YX_X9HO/^AG@_\  ,__ !='
M_#-%Y_T,\'_@&?\ XNOH>B@#YX_X9HO/^AG@_P# ,_\ Q='_  S1>?\ 0SP?
M^ 9_^+KZ'HH ^>/^&:+S_H9X/_ ,_P#Q='_#-%Y_T,\'_@&?_BZ^AZ* /GC_
M (9HO/\ H9X/_ ,__%T?\,T7G_0SP?\ @&?_ (NOH>B@#YX_X9HO/^AG@_\
M ,__ !='_#-%Y_T,\'_@&?\ XNOH>B@#YX_X9HO/^AG@_P# ,_\ Q='_  S1
M>?\ 0SP?^ 9_^+KZ'HH ^>/^&:+S_H9X/_ ,_P#Q='_#-%Y_T,\'_@&?_BZ^
MAZ* /GC_ (9HO/\ H9X/_ ,__%T?\,T7G_0SP?\ @&?_ (NOH>B@#YX_X9HO
M/^AG@_\  ,__ !='_#-%Y_T,\'_@&?\ XNOH>B@#YX_X9HO/^AG@_P# ,_\
MQ='_  S1>?\ 0SP?^ 9_^+KZ'HH ^>/^&:+S_H9X/_ ,_P#Q='_#-%Y_T,\'
M_@&?_BZ^AZ* /GC_ (9HO/\ H9X/_ ,__%T?\,T7G_0SP?\ @&?_ (NOH>B@
M#YX_X9HO/^AG@_\  ,__ !='_#-%Y_T,\'_@&?\ XNOH>B@#YX_X9HO/^AG@
M_P# ,_\ Q='_  S1>?\ 0SP?^ 9_^+KZ'HH ^>/^&:+S_H9X/_ ,_P#Q='_#
M-%Y_T,\'_@&?_BZ^AZ* /GC_ (9HO/\ H9X/_ ,__%T?\,T7G_0SP?\ @&?_
M (NOH>B@#YX_X9HO/^AG@_\  ,__ !='_#-%Y_T,\'_@&?\ XNOH>B@#YX_X
M9HO/^AG@_P# ,_\ Q='_  S1>?\ 0SP?^ 9_^+KZ'HH ^>/^&:+S_H9X/_ ,
M_P#Q='_#-%Y_T,\'_@&?_BZ^AZ* /GC_ (9HO/\ H9X/_ ,__%T?\,T7G_0S
MP?\ @&?_ (NOH>B@#YX_X9HO/^AG@_\  ,__ !='_#-%Y_T,\'_@&?\ XNOH
M>B@#YX_X9HO/^AG@_P# ,_\ Q='_  S1>?\ 0SP?^ 9_^+KZ'HH ^>/^&:+S
M_H9X/_ ,_P#Q='_#-%Y_T,\'_@&?_BZ^AZ* /GC_ (9HO/\ H9X/_ ,__%T?
M\,T7G_0SP?\ @&?_ (NOH>B@#YX_X9HO/^AG@_\  ,__ !='_#-%Y_T,\'_@
M&?\ XNOH>B@#YX_X9HO/^AG@_P# ,_\ Q='_  S1>?\ 0SP?^ 9_^+KZ'HH
M^>/^&:+S_H9X/_ ,_P#Q='_#-%Y_T,\'_@&?_BZ^AZ* /GC_ (9HO/\ H9X/
M_ ,__%T?\,T7G_0SP?\ @&?_ (NOH>B@#YX_X9HO/^AG@_\  ,__ !='_#-%
MY_T,\'_@&?\ XNOH>B@#YX_X9HO/^AG@_P# ,_\ Q='_  S1>?\ 0SP?^ 9_
M^+KZ'HH ^>/^&:+S_H9X/_ ,_P#Q='_#-%Y_T,\'_@&?_BZ^AZ* /GC_ (9H
MO/\ H9X/_ ,__%T?\,T7G_0SP?\ @&?_ (NOH>B@#YX_X9HO/^AG@_\  ,__
M !='_#-%Y_T,\'_@&?\ XNOH>B@#YX_X9HO/^AG@_P# ,_\ Q='_  S1>?\
M0SP?^ 9_^+KZ'HH ^>/^&:+S_H9X/_ ,_P#Q='_#-%Y_T,\'_@&?_BZ^AZ*
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M&?\ XNOH>B@#YX_X9HO/^AG@_P# ,_\ Q='_  S1>?\ 0SP?^ 9_^+KZ'HH
M^>/^&:+S_H9X/_ ,_P#Q='_#-%Y_T,\'_@&?_BZ^AZ* /GC_ (9HO/\ H9X/
M_ ,__%T?\,T7G_0SP?\ @&?_ (NOH>B@#YX_X9HO/^AG@_\  ,__ !='_#-%
MY_T,\'_@&?\ XNOH>B@#YX_X9HO/^AG@_P# ,_\ Q='_  S1>?\ 0SP?^ 9_
M^+KZ'HH ^>/^&:+S_H9X/_ ,_P#Q='_#-%Y_T,\'_@&?_BZ^AZ* /GC_ (9H
MO/\ H9X/_ ,__%T?\,T7G_0SP?\ @&?_ (NOH>B@#YX_X9HO/^AG@_\  ,__
M !='_#-%Y_T,\'_@&?\ XNOH>B@#YX_X9HO/^AG@_P# ,_\ Q='_  S1>?\
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M/^&:+S_H9X/_  #/_P 71_PS1>?]#/!_X!G_ .+KZ'HH ^>/^&:+S_H9X/\
MP#/_ ,71_P ,T7G_ $,\'_@&?_BZ^AZ* /GC_AFB\_Z&>#_P#/\ \71_PS1>
M?]#/!_X!G_XNOH>B@#YX_P"&:+S_ *&>#_P#/_Q='_#-%Y_T,\'_ (!G_P"+
MKZ'HH ^>/^&:+S_H9X/_  #/_P 71_PS1>?]#/!_X!G_ .+KZ'HH ^>/^&:+
MS_H9X/\ P#/_ ,71_P ,T7G_ $,\'_@&?_BZ^AZ* /GC_AFB\_Z&>#_P#/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>tcrt-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-11-14T01:22:04.2360+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/BalanceSheets" xlink:href="tcrt-20220930.xsd#BalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity" xlink:href="tcrt-20220930.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows" xlink:href="tcrt-20220930.xsd#StatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#DisclosureOrganizationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#DisclosureFinancingsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" xlink:href="tcrt-20220930.xsd#DisclosureDebtScheduleOfDebtDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityDetails" xlink:href="tcrt-20220930.xsd#DisclosureDebtScheduleOfDebtMaturityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityParentheticalDetails" xlink:href="tcrt-20220930.xsd#DisclosureDebtScheduleOfDebtMaturityParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtPrepaymentPremiumPercentageDetails" xlink:href="tcrt-20220930.xsd#DisclosureDebtScheduleOfDebtPrepaymentPremiumPercentageDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tcrt-20220930.xsd#DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsDetails" xlink:href="tcrt-20220930.xsd#DisclosureFairValueMeasurementsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="tcrt-20220930.xsd#DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:href="tcrt-20220930.xsd#DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:href="tcrt-20220930.xsd#DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#LeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails" xlink:href="tcrt-20220930.xsd#DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails" xlink:href="tcrt-20220930.xsd#DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails" xlink:href="tcrt-20220930.xsd#DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#DisclosureWarrantsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#DisclosureJointVentureAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/BalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WarrantsIssuedInTermLoan" xlink:label="tcrt_WarrantsIssuedInTermLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AccretionOfTermLoanFinalPayment" xlink:label="tcrt_AccretionOfTermLoanFinalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IssuanceCostsInAccountsPayableAndAccruedExpenses" xlink:label="tcrt_IssuanceCostsInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="tcrt_WarrantsIssuedInTermLoan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="tcrt_AccretionOfTermLoanFinalPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="tcrt_IncreaseDecreaseInLeaseLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="tcrt_IssuanceCostsInAccountsPayableAndAccruedExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tcrt_IncreaseDecreaseInRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnTerminationOfLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentTypeAxis" xlink:label="tcrt_PaymentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="tcrt_PaymentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_StockOfferedDuringPeriodShares" xlink:label="tcrt_StockOfferedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EquityDistributionAgreementMember" xlink:label="tcrt_EquityDistributionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SiliconValleyBankMember" xlink:label="tcrt_SiliconValleyBankMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermLoanMember" xlink:label="tcrt_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AtTheMarketOfferingMember" xlink:label="tcrt_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WarrantsMember" xlink:label="tcrt_WarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare" xlink:label="tcrt_IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcrt_StockOfferedDuringPeriodShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_EquityDistributionAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="tcrt_SiliconValleyBankMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_TermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_StockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcrt_AtTheMarketOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_WarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcrt_IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermLoanAgreementMember" xlink:label="tcrt_TermLoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_TermLoanAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_FullyDrawnAmount" xlink:label="tcrt_FullyDrawnAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermLoanMember" xlink:label="tcrt_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermATrancheMember" xlink:label="tcrt_TermATrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermBMilestoneMember" xlink:label="tcrt_TermBMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermBTrancheMember" xlink:label="tcrt_TermBTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EquityMilestoneMember" xlink:label="tcrt_EquityMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WarrantsExpirationDate" xlink:label="tcrt_WarrantsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ZeroMilestoneMember" xlink:label="tcrt_ZeroMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TenthScheduledPaymentMember" xlink:label="tcrt_TenthScheduledPaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EightScheduledPaymentMember" xlink:label="tcrt_EightScheduledPaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PercentageOfPrepaymentsPremium" xlink:label="tcrt_PercentageOfPrepaymentsPremium"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DebtInstrumentPrepaymentPremium" xlink:label="tcrt_DebtInstrumentPrepaymentPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AdditionalNumberOfWarrantsIssued" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_InterestExpenseAmortizedDate" xlink:label="tcrt_InterestExpenseAmortizedDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PercentageOfPrepaymentPremium" xlink:label="tcrt_PercentageOfPrepaymentPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_FullyDrawnAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_TermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="tcrt_TermATrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_TermBMilestoneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="tcrt_TermBTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_EquityMilestoneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_WarrantsExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_SecuredDebtMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_ZeroMilestoneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_TenthScheduledPaymentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_EightScheduledPaymentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfPrepaymentsPremium" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_DebtInstrumentPrepaymentPremium" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_AdditionalNumberOfWarrantsIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_InterestExpenseAmortizedDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfPrepaymentPremium" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_InitialBorrowingZeroMilestonesMember" xlink:label="tcrt_InitialBorrowingZeroMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EquityMilestoneMember" xlink:label="tcrt_EquityMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PrincipalPaymentBeginningDate" xlink:label="tcrt_PrincipalPaymentBeginningDate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EquityAndTermBMilestoneMember" xlink:label="tcrt_EquityAndTermBMilestoneMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_InitialBorrowingZeroMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_EquityMilestoneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PrincipalPaymentBeginningDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_EquityAndTermBMilestoneMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityParentheticalDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtPrepaymentPremiumPercentageDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_BeforeAugustSixTwoThousandTwentyTwoMember" xlink:label="tcrt_BeforeAugustSixTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DebtInstrumentPrincipalPaymentsPercentage" xlink:label="tcrt_DebtInstrumentPrincipalPaymentsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember" xlink:label="tcrt_AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember" xlink:label="tcrt_AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_BeforeAugustSixTwoThousandTwentyTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_DebtInstrumentPrincipalPaymentsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="us-gaap_FairValueInputsLevel12And3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel12And3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TwoThousandTwelveStockOptionPlanMember" xlink:label="tcrt_TwoThousandTwelveStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_InducementStockOptionsMember" xlink:label="tcrt_InducementStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandTwelveStockOptionPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tcrt_InducementStockOptionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_VinetiIncMember" xlink:label="tcrt_VinetiIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PocketExpenses" xlink:label="tcrt_PocketExpenses"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EdenBiocellMember" xlink:label="tcrt_EdenBiocellMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WatermillAndRobertWPostmaMember" xlink:label="tcrt_WatermillAndRobertWPostmaMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_RelatedPartyTransactionReimbursedAmount" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AdditionalLoansCommitted" xlink:label="tcrt_AdditionalLoansCommitted"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_VinetiIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_PocketExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_EdenBiocellMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_WatermillAndRobertWPostmaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_RelatedPartyTransactionReimbursedAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_AdditionalLoansCommitted" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MdAndersonAgreementAndWorldwideLicenseMember" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ClassOfWarrantOrRightDomainDomain" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DueDateAxis" xlink:label="tcrt_DueDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DueDateDomain" xlink:label="tcrt_DueDateDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DueDateDomain" xlink:label="tcrt_DueDateDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PostMarketingApprovalMember" xlink:label="tcrt_PostMarketingApprovalMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentTypeAxis" xlink:label="tcrt_PaymentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PerformanceBasedPaymentsMemberMember" xlink:label="tcrt_PerformanceBasedPaymentsMemberMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ClassOfWarrantOrRightAxisAxis" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ClassOfWarrantOrRightDomainDomain" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MilestonePaymentsMaximumAmount" xlink:label="tcrt_MilestonePaymentsMaximumAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TcellReceptorMember" xlink:label="tcrt_TcellReceptorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OneTimeBenchmarkPaymentsMember" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_QuarterlyPaymentsUnderContract" xlink:label="tcrt_QuarterlyPaymentsUnderContract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_CRADAAgreementMember" xlink:label="tcrt_CRADAAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_CARProductsMember" xlink:label="tcrt_CARProductsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PatentAndTechnologyLicenseAgreementMember" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LicenseAgreementCommencingDate" xlink:label="tcrt_LicenseAgreementCommencingDate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LicensedProductsMember" xlink:label="tcrt_LicensedProductsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AnnualLicenseFees" xlink:label="tcrt_AnnualLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LicenseAgreementWithPgenTherapeuticsMember" xlink:label="tcrt_LicenseAgreementWithPgenTherapeuticsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AggregateAmountPotentiallyReimburseableAmount" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MaximumAmountOfAdditionalMilestonesPayable" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MaximumAmountOfRoyaltyPayable" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MaximumRoyaltyAmount" xlink:label="tcrt_MaximumRoyaltyAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_QuarterlyExpenseIncurred" xlink:label="tcrt_QuarterlyExpenseIncurred"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ContributionPayableOnPerAnnumBasis" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MinimumRoyaltiesAmountPayable" xlink:label="tcrt_MinimumRoyaltiesAmountPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_RoyaltiesAmountPayableThereafter" xlink:label="tcrt_RoyaltiesAmountPayableThereafter"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ObligationsDueUnderContract" xlink:label="tcrt_ObligationsDueUnderContract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AggregateMinimumAnnualRoyaltiesPaid" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DescriptionOfFirstBenchmarkPayable" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PotentialBenchmarkPaymentsPayable" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AggregateBenchmarkPaymentsPayable" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AgreementTerminationNoticePeriod" xlink:label="tcrt_AgreementTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AggregatePotentialBenchmarkPayments" xlink:label="tcrt_AggregatePotentialBenchmarkPayments"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AccrualsPriorToFirstMarketingApproval" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms" xlink:label="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_InitialBenchmarkPaymentDue" xlink:label="tcrt_InitialBenchmarkPaymentDue"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LicenseExpense" xlink:label="tcrt_LicenseExpense"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentUnderLicenseAgreement" xlink:label="tcrt_PaymentUnderLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MilestonePayment" xlink:label="tcrt_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonAgreementAndWorldwideLicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_ClassOfWarrantOrRightDomainDomain" xlink:to="tcrt_MdAndersonWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_DueDateAxis" xlink:to="tcrt_DueDateDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_DueDateAxis" xlink:to="tcrt_DueDateDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_DueDateDomain" xlink:to="tcrt_PostMarketingApprovalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_PerformanceBasedPaymentsMemberMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_ClassOfWarrantOrRightAxisAxis" xlink:to="tcrt_ClassOfWarrantOrRightDomainDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_ClassOfWarrantOrRightAxisAxis" xlink:to="tcrt_ClassOfWarrantOrRightDomainDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_IntrexonCorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MilestonePaymentsMaximumAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_TcellReceptorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_OneTimeBenchmarkPaymentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_QuarterlyPaymentsUnderContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_CRADAAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_CARProductsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_PatentAndTechnologyLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseAgreementCommencingDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_LicensedProductsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AnnualLicenseFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_LicenseAgreementWithPgenTherapeuticsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateAmountPotentiallyReimburseableAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfAdditionalMilestonesPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfRoyaltyPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_DueDateAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_PaymentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumRoyaltyAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_ClassOfWarrantOrRightAxisAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_QuarterlyExpenseIncurred" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ContributionPayableOnPerAnnumBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MinimumRoyaltiesAmountPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_RoyaltiesAmountPayableThereafter" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ObligationsDueUnderContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateMinimumAnnualRoyaltiesPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_DescriptionOfFirstBenchmarkPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PotentialBenchmarkPaymentsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateBenchmarkPaymentsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AgreementTerminationNoticePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregatePotentialBenchmarkPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AccrualsPriorToFirstMarketingApproval" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_InitialBenchmarkPaymentDue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PaymentUnderLicenseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OtherIncomeExpenseMember" xlink:label="tcrt_OtherIncomeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MaMember" xlink:label="tcrt_MaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_HoustonTexasMember" xlink:label="tcrt_HoustonTexasMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment" xlink:label="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SubleaseTermCommencedEndDateAmendment" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OperatingLeasesExpirationMonthAndYear" xlink:label="tcrt_OperatingLeasesExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OperatingLeaseArea" xlink:label="tcrt_OperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_GainLossOnModificationOfLease" xlink:label="tcrt_GainLossOnModificationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" xlink:label="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AnnualBaseRent" xlink:label="tcrt_AnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LesseeOperatingLeaseMonthlyRentalPayment" xlink:label="tcrt_LesseeOperatingLeaseMonthlyRentalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SubleaseArea" xlink:label="tcrt_SubleaseArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseIncome" xlink:label="us-gaap_LeaseIncome"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="tcrt_OtherIncomeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="tcrt_MaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="tcrt_HoustonTexasMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_SubleaseTermCommencedEndDateAmendment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_OperatingLeasesExpirationMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_OperatingLeaseArea" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_GainLossOnModificationOfLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_AnnualBaseRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_LesseeOperatingLeaseMonthlyRentalPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_SubleaseArea" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseIncome" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_NonVestedStockMember" xlink:label="tcrt_NonVestedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OutsideTwoThousandTwelvePlanMember" xlink:label="tcrt_OutsideTwoThousandTwelvePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TwoThousandAndTwelveEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TwoThousandAndThreeEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndThreeEquityIncentivePlanMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_OutsideTwoThousandTwelvePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedRestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandAndThreeEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedRestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_NewWarrantsMember" xlink:label="tcrt_NewWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SecuritiesPurchaseAgreementMember" xlink:label="tcrt_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_BlackScholesModelMember" xlink:label="tcrt_BlackScholesModelMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_FairValueOfWarrants" xlink:label="tcrt_FairValueOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SvbWarrantsMember" xlink:label="tcrt_SvbWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PlacementAgentFeesAndOtherRelatedExpenses" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_NonOperatingIncomeExpenseInducementOfWarrants" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCallOrExerciseFeatures" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_NewWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_BlackScholesModelMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="tcrt_AgreementTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_MdAndersonWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_FairValueOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_SvbWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_PlacementAgentFeesAndOtherRelatedExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_NonOperatingIncomeExpenseInducementOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCallOrExerciseFeatures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Dividends" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EdenBioCellMember" xlink:label="tcrt_EdenBioCellMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ZiopharmMember" xlink:label="tcrt_ZiopharmMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ShareSubscriptionAgreementMember" xlink:label="tcrt_ShareSubscriptionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TriArmMember" xlink:label="tcrt_TriArmMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="tcrt_EdenBioCellMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="tcrt_ZiopharmMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="tcrt_ShareSubscriptionAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_TriArmMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>tcrt-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-11-14T01:22:04.0702+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://alaunos.com/20220930" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:tcrt="http://alaunos.com/20220930" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tcrt-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tcrt-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tcrt-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tcrt-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/BalanceSheets" id="BalanceSheets">
        <link:definition>100010 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2" id="DisclosureDebtScheduleOfDebtDetails2">
        <link:definition>100020 - Disclosure - Debt - Schedule of Debt (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2" id="DisclosureLeasesOperatingLeaseLiabilitiesDetails2">
        <link:definition>100030 - Disclosure - Leases - Operating Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>100040 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations" id="StatementsOfOperations">
        <link:definition>100050 - Statement - STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
        <link:definition>100060 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>100070 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureOrganization" id="DisclosureOrganization">
        <link:definition>100080 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/Financings" id="Financings">
        <link:definition>100090 - Disclosure - Financings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>100110 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>100120 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/NetLossPerShare" id="NetLossPerShare">
        <link:definition>100130 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>100140 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>100150 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/Leases" id="Leases">
        <link:definition>100160 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/StockBasedCompensation" id="StockBasedCompensation">
        <link:definition>100170 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/Warrants" id="Warrants">
        <link:definition>100180 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureRestructuring" id="DisclosureRestructuring">
        <link:definition>100190 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/JointVenture" id="JointVenture">
        <link:definition>100200 - Disclosure - Joint Venture</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>100210 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100220 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>100230 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>100240 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/NetLossPerShareTables" id="NetLossPerShareTables">
        <link:definition>100250 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/LeasesTables" id="LeasesTables">
        <link:definition>100260 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
        <link:definition>100270 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureRestructuringTables" id="DisclosureRestructuringTables">
        <link:definition>100280 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" id="DisclosureOrganizationAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Organization - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails" id="DisclosureFinancingsAdditionalInformationDetails">
        <link:definition>100300 - Disclosure - Financings - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" id="DisclosureDebtScheduleOfDebtDetails">
        <link:definition>100310 - Disclosure - Debt - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails" id="DisclosureDebtAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityDetails" id="DisclosureDebtScheduleOfDebtMaturityDetails">
        <link:definition>100330 - Disclosure - Debt - Schedule of Debt Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityParentheticalDetails" id="DisclosureDebtScheduleOfDebtMaturityParentheticalDetails">
        <link:definition>100340 - Disclosure - Debt - Schedule of Debt Maturity (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtPrepaymentPremiumPercentageDetails" id="DisclosureDebtScheduleOfDebtPrepaymentPremiumPercentageDetails">
        <link:definition>100350 - Disclosure - Debt - Schedule of Debt Prepayment Premium Percentage (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100360 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>100370 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails">
        <link:definition>100380 - Disclosure - Net Loss Per Share - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" id="DisclosureLeasesComponentsOfLeaseExpenseDetails">
        <link:definition>100410 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails" id="DisclosureLeasesOperatingLeaseLiabilitiesDetails">
        <link:definition>100420 - Disclosure - Leases - Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails" id="LeasesAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails" id="DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails">
        <link:definition>100440 - Disclosure - Stock-Based Compensation Expense Included in Statement of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" id="DisclosureStockbasedCompensationAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails" id="DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails">
        <link:definition>100460 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails" id="DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails">
        <link:definition>100470 - Disclosure - Stock-Based Compensation - Stock Option Activity Under Stock Option Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails" id="DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails">
        <link:definition>100480 - Disclosure - Stock-Based Compensation - Summary of Non-Vested Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" id="DisclosureWarrantsAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Warrants - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" id="DisclosureJointVentureAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Joint Venture - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_WarrantsDisclosureAbstract" name="WarrantsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AgreementTypeAxis" name="AgreementTypeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ClassOfWarrantOrRightAxisAxis" name="ClassOfWarrantOrRightAxisAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_DueDateAxis" name="DueDateAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PaymentTypeAxis" name="PaymentTypeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AccretionOfTermLoanFinalPayment" name="AccretionOfTermLoanFinalPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_AccrualsPriorToFirstMarketingApproval" name="AccrualsPriorToFirstMarketingApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_AdditionalLoansCommitted" name="AdditionalLoansCommitted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AdditionalNumberOfWarrantsIssued" name="AdditionalNumberOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_AggregateAmountPotentiallyReimburseableAmount" name="AggregateAmountPotentiallyReimburseableAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AggregateBenchmarkPaymentsPayable" name="AggregateBenchmarkPaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AggregateMinimumAnnualRoyaltiesPaid" name="AggregateMinimumAnnualRoyaltiesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AggregatePotentialBenchmarkPayments" name="AggregatePotentialBenchmarkPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AgreementTerminationNoticePeriod" name="AgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_AnnualBaseRent" name="AnnualBaseRent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_AnnualLicenseFees" name="AnnualLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_ContributionPayableOnPerAnnumBasis" name="ContributionPayableOnPerAnnumBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_DebtInstrumentPrepaymentPremium" name="DebtInstrumentPrepaymentPremium" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_DebtInstrumentPrincipalPaymentsPercentage" name="DebtInstrumentPrincipalPaymentsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_DescriptionOfFirstBenchmarkPayable" name="DescriptionOfFirstBenchmarkPayable" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" name="DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_FairValueOfWarrants" name="FairValueOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_FullyDrawnAmount" name="FullyDrawnAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_GainLossOnModificationOfLease" name="GainLossOnModificationOfLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_GainLossOnOperatingLeaseModification" name="GainLossOnOperatingLeaseModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_IncreaseDecreaseInLeaseLiabilities" name="IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_IncreaseDecreaseInRightOfUseAsset" name="IncreaseDecreaseInRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_InitialBenchmarkPaymentDue" name="InitialBenchmarkPaymentDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_InterestExpenseAmortizedDate" name="InterestExpenseAmortizedDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare" name="IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_IssuanceCostsInAccountsPayableAndAccruedExpenses" name="IssuanceCostsInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment" name="LesseeOperatingLeaseMonthlyAverageRentalPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_LesseeOperatingLeaseMonthlyRentalPayment" name="LesseeOperatingLeaseMonthlyRentalPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_LicenseAgreementCommencingDate" name="LicenseAgreementCommencingDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_LicenseExpense" name="LicenseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_MaximumAmountOfAdditionalMilestonesPayable" name="MaximumAmountOfAdditionalMilestonesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MaximumAmountOfRoyaltyPayable" name="MaximumAmountOfRoyaltyPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MaximumRoyaltyAmount" name="MaximumRoyaltyAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" name="MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MilestonePaymentsMaximumAmount" name="MilestonePaymentsMaximumAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MinimumRoyaltiesAmountPayable" name="MinimumRoyaltiesAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" name="MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_NonOperatingIncomeExpenseInducementOfWarrants" name="NonOperatingIncomeExpenseInducementOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_ObligationsDueUnderContract" name="ObligationsDueUnderContract" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_OperatingLeaseArea" name="OperatingLeaseArea" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_OperatingLeasesExpirationMonthAndYear" name="OperatingLeasesExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" name="OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms" name="PaymentForHistoricalCostsOfTheLicensedPrograms" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_PaymentUnderLicenseAgreement" name="PaymentUnderLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" name="PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" name="PercentageOfOriginalPrincipalDueAsAFinalPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PercentageOfPrepaymentPremium" name="PercentageOfPrepaymentPremium" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PercentageOfPrepaymentsPremium" name="PercentageOfPrepaymentsPremium" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" name="PercentageOfSubLicensingIncomePayableToRelatedParty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PlacementAgentFeesAndOtherRelatedExpenses" name="PlacementAgentFeesAndOtherRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_PocketExpenses" name="PocketExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_PotentialBenchmarkPaymentsPayable" name="PotentialBenchmarkPaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_PrincipalPaymentBeginningDate" name="PrincipalPaymentBeginningDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_QuarterlyExpenseIncurred" name="QuarterlyExpenseIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_QuarterlyPaymentsUnderContract" name="QuarterlyPaymentsUnderContract" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" name="RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_RelatedPartyTransactionReimbursedAmount" name="RelatedPartyTransactionReimbursedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_RoyaltiesAmountPayableThereafter" name="RoyaltiesAmountPayableThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_StockOfferedDuringPeriodShares" name="StockOfferedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_SubleaseArea" name="SubleaseArea" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_SubleaseTermCommencedEndDateAmendment" name="SubleaseTermCommencedEndDateAmendment" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_WarrantsExpirationDate" name="WarrantsExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_WarrantsIssuedInTermLoan" name="WarrantsIssuedInTermLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AgreementTypeDomain" name="AgreementTypeDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ClassOfWarrantOrRightDomainDomain" name="ClassOfWarrantOrRightDomainDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_DueDateDomain" name="DueDateDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PaymentTypeDomain" name="PaymentTypeDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember" name="AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember" name="AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_BeforeAugustSixTwoThousandTwentyTwoMember" name="BeforeAugustSixTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_BlackScholesModelMember" name="BlackScholesModelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CARProductsMember" name="CARProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" name="CollaborationAgreementWithSolasiaPharmaKkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CRADAAgreementMember" name="CRADAAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EdenBiocellMember" name="EdenBiocellMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EdenBioCellMember" name="EdenBioCellMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EightScheduledPaymentMember" name="EightScheduledPaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EquityAndTermBMilestoneMember" name="EquityAndTermBMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EquityDistributionAgreementMember" name="EquityDistributionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EquityMilestoneMember" name="EquityMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_HoustonTexasMember" name="HoustonTexasMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_InducementStockOptionsMember" name="InducementStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_InitialBorrowingZeroMilestonesMember" name="InitialBorrowingZeroMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_IntrexonCorporationMember" name="IntrexonCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_LicenseAgreementWithPgenTherapeuticsMember" name="LicenseAgreementWithPgenTherapeuticsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" name="LicenseAgreementWithTheNationalCancerInstituteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_LicensedProductsMember" name="LicensedProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MaMember" name="MaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MdAndersonAgreementAndWorldwideLicenseMember" name="MdAndersonAgreementAndWorldwideLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" name="MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MdAndersonWarrantMember" name="MdAndersonWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_NewWarrantsMember" name="NewWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_NonVestedRestrictedStockMember" name="NonVestedRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_NonVestedStockMember" name="NonVestedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_OneTimeBenchmarkPaymentsMember" name="OneTimeBenchmarkPaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_OtherIncomeExpenseMember" name="OtherIncomeExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_OutsideTwoThousandTwelvePlanMember" name="OutsideTwoThousandTwelvePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PatentAndTechnologyLicenseAgreementMember" name="PatentAndTechnologyLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PerformanceBasedPaymentsMemberMember" name="PerformanceBasedPaymentsMemberMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PostMarketingApprovalMember" name="PostMarketingApprovalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ShareSubscriptionAgreementMember" name="ShareSubscriptionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SiliconValleyBankLoanMember" name="SiliconValleyBankLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SiliconValleyBankMember" name="SiliconValleyBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SvbWarrantsMember" name="SvbWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TcellReceptorMember" name="TcellReceptorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TenthScheduledPaymentMember" name="TenthScheduledPaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TermATrancheMember" name="TermATrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TermBMilestoneMember" name="TermBMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TermBTrancheMember" name="TermBTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TermLoanAgreementMember" name="TermLoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" name="TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TriArmMember" name="TriArmMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TwoThousandAndThreeEquityIncentivePlanMember" name="TwoThousandAndThreeEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember" name="TwoThousandAndTwelveEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember" name="TwoThousandAndTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TwoThousandTwelveStockOptionPlanMember" name="TwoThousandTwelveStockOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_VinetiIncMember" name="VinetiIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_WarrantsMember" name="WarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_WatermillAndRobertWPostmaMember" name="WatermillAndRobertWPostmaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ZeroMilestoneMember" name="ZeroMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ZiopharmMember" name="ZiopharmMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" name="ZiopLicenseAgreementWithTheNationalCancerInstituteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_FinancingArrangementsDisclosureTextBlock" name="FinancingArrangementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock" name="StockOptionsAndRestrictedStockAwardsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_WarrantTextBlock" name="WarrantTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>tcrt-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-11-14T01:22:03.2635+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/CoverPage" xlink:href="tcrt-20220930.xsd#CoverPage" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/BalanceSheets" xlink:href="tcrt-20220930.xsd#BalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/BalanceSheetsParenthetical" xlink:href="tcrt-20220930.xsd#BalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations" xlink:href="tcrt-20220930.xsd#StatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity" xlink:href="tcrt-20220930.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows" xlink:href="tcrt-20220930.xsd#StatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureOrganization" xlink:href="tcrt-20220930.xsd#DisclosureOrganization" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/Financings" xlink:href="tcrt-20220930.xsd#Financings" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:href="tcrt-20220930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebt" xlink:href="tcrt-20220930.xsd#DisclosureDebt" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/FairValueMeasurements" xlink:href="tcrt-20220930.xsd#FairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/NetLossPerShare" xlink:href="tcrt-20220930.xsd#NetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/RelatedPartyTransactions" xlink:href="tcrt-20220930.xsd#RelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/CommitmentsAndContingencies" xlink:href="tcrt-20220930.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/Leases" xlink:href="tcrt-20220930.xsd#Leases" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/StockBasedCompensation" xlink:href="tcrt-20220930.xsd#StockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/Warrants" xlink:href="tcrt-20220930.xsd#Warrants" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureRestructuring" xlink:href="tcrt-20220930.xsd#DisclosureRestructuring" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/JointVenture" xlink:href="tcrt-20220930.xsd#JointVenture" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/SubsequentEvents" xlink:href="tcrt-20220930.xsd#SubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tcrt-20220930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtTables" xlink:href="tcrt-20220930.xsd#DisclosureDebtTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/FairValueMeasurementsTables" xlink:href="tcrt-20220930.xsd#FairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/NetLossPerShareTables" xlink:href="tcrt-20220930.xsd#NetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/LeasesTables" xlink:href="tcrt-20220930.xsd#LeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/StockBasedCompensationTables" xlink:href="tcrt-20220930.xsd#StockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureRestructuringTables" xlink:href="tcrt-20220930.xsd#DisclosureRestructuringTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#DisclosureOrganizationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#DisclosureFinancingsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" xlink:href="tcrt-20220930.xsd#DisclosureDebtScheduleOfDebtDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityDetails" xlink:href="tcrt-20220930.xsd#DisclosureDebtScheduleOfDebtMaturityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityParentheticalDetails" xlink:href="tcrt-20220930.xsd#DisclosureDebtScheduleOfDebtMaturityParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtPrepaymentPremiumPercentageDetails" xlink:href="tcrt-20220930.xsd#DisclosureDebtScheduleOfDebtPrepaymentPremiumPercentageDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tcrt-20220930.xsd#DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsDetails" xlink:href="tcrt-20220930.xsd#DisclosureFairValueMeasurementsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="tcrt-20220930.xsd#DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:href="tcrt-20220930.xsd#DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:href="tcrt-20220930.xsd#DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#LeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails" xlink:href="tcrt-20220930.xsd#DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails" xlink:href="tcrt-20220930.xsd#DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails" xlink:href="tcrt-20220930.xsd#DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails" xlink:href="tcrt-20220930.xsd#DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#DisclosureWarrantsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" xlink:href="tcrt-20220930.xsd#DisclosureJointVentureAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/BalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/BalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_GainLossOnOperatingLeaseModification" xlink:label="tcrt_GainLossOnOperatingLeaseModification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="tcrt_GainLossOnOperatingLeaseModification" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_12"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_13"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WarrantsIssuedInTermLoan" xlink:label="tcrt_WarrantsIssuedInTermLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AccretionOfTermLoanFinalPayment" xlink:label="tcrt_AccretionOfTermLoanFinalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IssuanceCostsInAccountsPayableAndAccruedExpenses" xlink:label="tcrt_IssuanceCostsInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="tcrt_WarrantsIssuedInTermLoan" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="tcrt_AccretionOfTermLoanFinalPayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="tcrt_IncreaseDecreaseInLeaseLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="tcrt_IssuanceCostsInAccountsPayableAndAccruedExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tcrt_IncreaseDecreaseInRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureOrganization" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/Financings" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_FinancingArrangementsDisclosureTextBlock" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="tcrt_FinancingArrangementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureDebt" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/FairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/NetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/RelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/Leases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/StockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_StockOptionsAndRestrictedStockAwardsTextBlock" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/Warrants" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WarrantsDisclosureAbstract" xlink:label="tcrt_WarrantsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WarrantTextBlock" xlink:label="tcrt_WarrantTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_WarrantsDisclosureAbstract" xlink:to="tcrt_WarrantTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureRestructuring" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/JointVenture" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/SubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/FairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/NetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/LeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/StockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureRestructuringTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentTypeAxis" xlink:label="tcrt_PaymentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="tcrt_PaymentTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_StockOfferedDuringPeriodShares" xlink:label="tcrt_StockOfferedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EquityDistributionAgreementMember" xlink:label="tcrt_EquityDistributionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SiliconValleyBankMember" xlink:label="tcrt_SiliconValleyBankMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankingAndThriftInterestAbstract" xlink:label="us-gaap_BankingAndThriftInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermLoanMember" xlink:label="tcrt_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AtTheMarketOfferingMember" xlink:label="tcrt_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WarrantsMember" xlink:label="tcrt_WarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare" xlink:label="tcrt_IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcrt_StockOfferedDuringPeriodShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_EquityDistributionAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="tcrt_SiliconValleyBankMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_StockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcrt_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_WarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcrt_IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_CreditFacilityAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VariableRateAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermLoanAgreementMember" xlink:label="tcrt_TermLoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_TermLoanAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_FullyDrawnAmount" xlink:label="tcrt_FullyDrawnAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermLoanMember" xlink:label="tcrt_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermATrancheMember" xlink:label="tcrt_TermATrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermBMilestoneMember" xlink:label="tcrt_TermBMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermBTrancheMember" xlink:label="tcrt_TermBTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EquityMilestoneMember" xlink:label="tcrt_EquityMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WarrantsExpirationDate" xlink:label="tcrt_WarrantsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ZeroMilestoneMember" xlink:label="tcrt_ZeroMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TenthScheduledPaymentMember" xlink:label="tcrt_TenthScheduledPaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EightScheduledPaymentMember" xlink:label="tcrt_EightScheduledPaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PercentageOfPrepaymentsPremium" xlink:label="tcrt_PercentageOfPrepaymentsPremium"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DebtInstrumentPrepaymentPremium" xlink:label="tcrt_DebtInstrumentPrepaymentPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AdditionalNumberOfWarrantsIssued" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_InterestExpenseAmortizedDate" xlink:label="tcrt_InterestExpenseAmortizedDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PercentageOfPrepaymentPremium" xlink:label="tcrt_PercentageOfPrepaymentPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_FullyDrawnAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="tcrt_TermATrancheMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_TermBMilestoneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="tcrt_TermBTrancheMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_EquityMilestoneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_WarrantsExpirationDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_SecuredDebtMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_ZeroMilestoneMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_TenthScheduledPaymentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_EightScheduledPaymentMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfPrepaymentsPremium" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_DebtInstrumentPrepaymentPremium" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_AdditionalNumberOfWarrantsIssued" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_InterestExpenseAmortizedDate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfPrepaymentPremium" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RestrictedCash" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_InitialBorrowingZeroMilestonesMember" xlink:label="tcrt_InitialBorrowingZeroMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EquityMilestoneMember" xlink:label="tcrt_EquityMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PrincipalPaymentBeginningDate" xlink:label="tcrt_PrincipalPaymentBeginningDate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EquityAndTermBMilestoneMember" xlink:label="tcrt_EquityAndTermBMilestoneMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_InitialBorrowingZeroMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_EquityMilestoneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PrincipalPaymentBeginningDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_EquityAndTermBMilestoneMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtPrepaymentPremiumPercentageDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_BeforeAugustSixTwoThousandTwentyTwoMember" xlink:label="tcrt_BeforeAugustSixTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DebtInstrumentPrincipalPaymentsPercentage" xlink:label="tcrt_DebtInstrumentPrincipalPaymentsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember" xlink:label="tcrt_AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember" xlink:label="tcrt_AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_BeforeAugustSixTwoThousandTwentyTwoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_DebtInstrumentPrincipalPaymentsPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="us-gaap_FairValueInputsLevel12And3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel12And3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TwoThousandTwelveStockOptionPlanMember" xlink:label="tcrt_TwoThousandTwelveStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_InducementStockOptionsMember" xlink:label="tcrt_InducementStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandTwelveStockOptionPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tcrt_InducementStockOptionsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_PlanNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_VinetiIncMember" xlink:label="tcrt_VinetiIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PocketExpenses" xlink:label="tcrt_PocketExpenses"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EdenBiocellMember" xlink:label="tcrt_EdenBiocellMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WatermillAndRobertWPostmaMember" xlink:label="tcrt_WatermillAndRobertWPostmaMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_RelatedPartyTransactionReimbursedAmount" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AdditionalLoansCommitted" xlink:label="tcrt_AdditionalLoansCommitted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_VinetiIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_PocketExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_EdenBiocellMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_WatermillAndRobertWPostmaMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_RelatedPartyTransactionReimbursedAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_AdditionalLoansCommitted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MdAndersonAgreementAndWorldwideLicenseMember" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ClassOfWarrantOrRightDomainDomain" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DueDateAxis" xlink:label="tcrt_DueDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DueDateDomain" xlink:label="tcrt_DueDateDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PostMarketingApprovalMember" xlink:label="tcrt_PostMarketingApprovalMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentTypeAxis" xlink:label="tcrt_PaymentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PerformanceBasedPaymentsMemberMember" xlink:label="tcrt_PerformanceBasedPaymentsMemberMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ClassOfWarrantOrRightAxisAxis" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MilestonePaymentsMaximumAmount" xlink:label="tcrt_MilestonePaymentsMaximumAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TcellReceptorMember" xlink:label="tcrt_TcellReceptorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OneTimeBenchmarkPaymentsMember" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_QuarterlyPaymentsUnderContract" xlink:label="tcrt_QuarterlyPaymentsUnderContract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_CRADAAgreementMember" xlink:label="tcrt_CRADAAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_CARProductsMember" xlink:label="tcrt_CARProductsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PatentAndTechnologyLicenseAgreementMember" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LicenseAgreementCommencingDate" xlink:label="tcrt_LicenseAgreementCommencingDate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LicensedProductsMember" xlink:label="tcrt_LicensedProductsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AnnualLicenseFees" xlink:label="tcrt_AnnualLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LicenseAgreementWithPgenTherapeuticsMember" xlink:label="tcrt_LicenseAgreementWithPgenTherapeuticsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AggregateAmountPotentiallyReimburseableAmount" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MaximumAmountOfAdditionalMilestonesPayable" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MaximumAmountOfRoyaltyPayable" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MaximumRoyaltyAmount" xlink:label="tcrt_MaximumRoyaltyAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_QuarterlyExpenseIncurred" xlink:label="tcrt_QuarterlyExpenseIncurred"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ContributionPayableOnPerAnnumBasis" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MinimumRoyaltiesAmountPayable" xlink:label="tcrt_MinimumRoyaltiesAmountPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_RoyaltiesAmountPayableThereafter" xlink:label="tcrt_RoyaltiesAmountPayableThereafter"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ObligationsDueUnderContract" xlink:label="tcrt_ObligationsDueUnderContract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AggregateMinimumAnnualRoyaltiesPaid" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DescriptionOfFirstBenchmarkPayable" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PotentialBenchmarkPaymentsPayable" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AggregateBenchmarkPaymentsPayable" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AgreementTerminationNoticePeriod" xlink:label="tcrt_AgreementTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AggregatePotentialBenchmarkPayments" xlink:label="tcrt_AggregatePotentialBenchmarkPayments"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AccrualsPriorToFirstMarketingApproval" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms" xlink:label="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_InitialBenchmarkPaymentDue" xlink:label="tcrt_InitialBenchmarkPaymentDue"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LicenseExpense" xlink:label="tcrt_LicenseExpense"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentUnderLicenseAgreement" xlink:label="tcrt_PaymentUnderLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MilestonePayment" xlink:label="tcrt_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonAgreementAndWorldwideLicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ClassOfWarrantOrRightDomainDomain" xlink:to="tcrt_MdAndersonWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_DueDateAxis" xlink:to="tcrt_DueDateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_DueDateDomain" xlink:to="tcrt_PostMarketingApprovalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_PerformanceBasedPaymentsMemberMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ClassOfWarrantOrRightAxisAxis" xlink:to="tcrt_ClassOfWarrantOrRightDomainDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_IntrexonCorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MilestonePaymentsMaximumAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_TcellReceptorMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_OneTimeBenchmarkPaymentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_QuarterlyPaymentsUnderContract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_CRADAAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_CARProductsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_PatentAndTechnologyLicenseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseAgreementCommencingDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_LicensedProductsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AnnualLicenseFees" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="dei_LegalEntityAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_LicenseAgreementWithPgenTherapeuticsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateAmountPotentiallyReimburseableAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfAdditionalMilestonesPayable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfRoyaltyPayable" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_DueDateAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_PaymentTypeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumRoyaltyAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_ClassOfWarrantOrRightAxisAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_QuarterlyExpenseIncurred" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureLineItems" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ContributionPayableOnPerAnnumBasis" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MinimumRoyaltiesAmountPayable" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_RoyaltiesAmountPayableThereafter" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ObligationsDueUnderContract" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateMinimumAnnualRoyaltiesPaid" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_DescriptionOfFirstBenchmarkPayable" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PotentialBenchmarkPaymentsPayable" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateBenchmarkPaymentsPayable" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AgreementTerminationNoticePeriod" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregatePotentialBenchmarkPayments" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AccrualsPriorToFirstMarketingApproval" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_InitialBenchmarkPaymentDue" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseExpense" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PaymentUnderLicenseAgreement" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MilestonePayment" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OtherIncomeExpenseMember" xlink:label="tcrt_OtherIncomeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MaMember" xlink:label="tcrt_MaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_HoustonTexasMember" xlink:label="tcrt_HoustonTexasMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment" xlink:label="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SubleaseTermCommencedEndDateAmendment" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OperatingLeasesExpirationMonthAndYear" xlink:label="tcrt_OperatingLeasesExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OperatingLeaseArea" xlink:label="tcrt_OperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_GainLossOnModificationOfLease" xlink:label="tcrt_GainLossOnModificationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" xlink:label="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AnnualBaseRent" xlink:label="tcrt_AnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LesseeOperatingLeaseMonthlyRentalPayment" xlink:label="tcrt_LesseeOperatingLeaseMonthlyRentalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SubleaseArea" xlink:label="tcrt_SubleaseArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseIncome" xlink:label="us-gaap_LeaseIncome"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="tcrt_OtherIncomeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="tcrt_MaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="tcrt_HoustonTexasMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDeposit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_SubleaseTermCommencedEndDateAmendment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_OperatingLeasesExpirationMonthAndYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_OperatingLeaseArea" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_GainLossOnModificationOfLease" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_AnnualBaseRent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_LesseeOperatingLeaseMonthlyRentalPayment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_SubleaseArea" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseIncome" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_NonVestedStockMember" xlink:label="tcrt_NonVestedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OutsideTwoThousandTwelvePlanMember" xlink:label="tcrt_OutsideTwoThousandTwelvePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TwoThousandAndTwelveEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TwoThousandAndThreeEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndThreeEquityIncentivePlanMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_OutsideTwoThousandTwelvePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedRestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandAndThreeEquityIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedRestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_NewWarrantsMember" xlink:label="tcrt_NewWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WarrantsDisclosureAbstract" xlink:label="tcrt_WarrantsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SecuritiesPurchaseAgreementMember" xlink:label="tcrt_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_BlackScholesModelMember" xlink:label="tcrt_BlackScholesModelMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_FairValueOfWarrants" xlink:label="tcrt_FairValueOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SvbWarrantsMember" xlink:label="tcrt_SvbWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PlacementAgentFeesAndOtherRelatedExpenses" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_NonOperatingIncomeExpenseInducementOfWarrants" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCallOrExerciseFeatures" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_NewWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_WarrantsDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_SecuritiesPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_BlackScholesModelMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="tcrt_AgreementTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_MdAndersonWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_FairValueOfWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_SvbWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_PlacementAgentFeesAndOtherRelatedExpenses" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_NonOperatingIncomeExpenseInducementOfWarrants" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCallOrExerciseFeatures" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Dividends" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EdenBioCellMember" xlink:label="tcrt_EdenBioCellMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ZiopharmMember" xlink:label="tcrt_ZiopharmMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ShareSubscriptionAgreementMember" xlink:label="tcrt_ShareSubscriptionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TriArmMember" xlink:label="tcrt_TriArmMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="tcrt_EdenBioCellMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="tcrt_ZiopharmMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="tcrt_ShareSubscriptionAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_TriArmMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>tcrt-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-11-14T01:22:06.6194+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AdditionalLoansCommitted" xlink:label="tcrt_AdditionalLoansCommitted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MilestonePayment" xlink:label="tcrt_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AnnualLicenseFees" xlink:label="tcrt_AnnualLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_FullyDrawnAmount" xlink:label="tcrt_FullyDrawnAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EquityAndTermBMilestoneMember" xlink:label="tcrt_EquityAndTermBMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AtTheMarketOfferingMember" xlink:label="tcrt_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LicensedProductsMember" xlink:label="tcrt_LicensedProductsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OtherIncomeExpenseMember" xlink:label="tcrt_OtherIncomeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MaximumAmountOfRoyaltyPayable" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SiliconValleyBankMember" xlink:label="tcrt_SiliconValleyBankMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TcellReceptorMember" xlink:label="tcrt_TcellReceptorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WatermillAndRobertWPostmaMember" xlink:label="tcrt_WatermillAndRobertWPostmaMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AggregateAmountPotentiallyReimburseableAmount" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankingAndThriftInterestAbstract" xlink:label="us-gaap_BankingAndThriftInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MaximumAmountOfAdditionalMilestonesPayable" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SubleaseArea" xlink:label="tcrt_SubleaseArea"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare" xlink:label="tcrt_IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PotentialBenchmarkPaymentsPayable" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="us-gaap_FairValueInputsLevel12And3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MaMember" xlink:label="tcrt_MaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AnnualBaseRent" xlink:label="tcrt_AnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DebtInstrumentPrincipalPaymentsPercentage" xlink:label="tcrt_DebtInstrumentPrincipalPaymentsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_GainLossOnModificationOfLease" xlink:label="tcrt_GainLossOnModificationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ContributionPayableOnPerAnnumBasis" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TenthScheduledPaymentMember" xlink:label="tcrt_TenthScheduledPaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_FinancingArrangementsDisclosureTextBlock" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermLoanAgreementMember" xlink:label="tcrt_TermLoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AccretionOfTermLoanFinalPayment" xlink:label="tcrt_AccretionOfTermLoanFinalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AccrualsPriorToFirstMarketingApproval" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PatentAndTechnologyLicenseAgreementMember" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EdenBiocellMember" xlink:label="tcrt_EdenBiocellMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DescriptionOfFirstBenchmarkPayable" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_InitialBorrowingZeroMilestonesMember" xlink:label="tcrt_InitialBorrowingZeroMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ShareSubscriptionAgreementMember" xlink:label="tcrt_ShareSubscriptionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_NonVestedStockMember" xlink:label="tcrt_NonVestedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentTypeAxis" xlink:label="tcrt_PaymentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermBTrancheMember" xlink:label="tcrt_TermBTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SecuritiesPurchaseAgreementMember" xlink:label="tcrt_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_StockOptionsAndRestrictedStockAwardsTextBlock" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SvbWarrantsMember" xlink:label="tcrt_SvbWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DueDateDomain" xlink:label="tcrt_DueDateDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EightScheduledPaymentMember" xlink:label="tcrt_EightScheduledPaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WarrantsMember" xlink:label="tcrt_WarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_InducementStockOptionsMember" xlink:label="tcrt_InducementStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MaximumRoyaltyAmount" xlink:label="tcrt_MaximumRoyaltyAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WarrantsIssuedInTermLoan" xlink:label="tcrt_WarrantsIssuedInTermLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MdAndersonAgreementAndWorldwideLicenseMember" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WarrantsDisclosureAbstract" xlink:label="tcrt_WarrantsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TriArmMember" xlink:label="tcrt_TriArmMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_NonOperatingIncomeExpenseInducementOfWarrants" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PercentageOfPrepaymentPremium" xlink:label="tcrt_PercentageOfPrepaymentPremium"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OneTimeBenchmarkPaymentsMember" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PocketExpenses" xlink:label="tcrt_PocketExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_BeforeAugustSixTwoThousandTwentyTwoMember" xlink:label="tcrt_BeforeAugustSixTwoThousandTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ObligationsDueUnderContract" xlink:label="tcrt_ObligationsDueUnderContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment" xlink:label="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MilestonePaymentsMaximumAmount" xlink:label="tcrt_MilestonePaymentsMaximumAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermBMilestoneMember" xlink:label="tcrt_TermBMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_StockOfferedDuringPeriodShares" xlink:label="tcrt_StockOfferedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ClassOfWarrantOrRightAxisAxis" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" xlink:label="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentUnderLicenseAgreement" xlink:label="tcrt_PaymentUnderLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AggregatePotentialBenchmarkPayments" xlink:label="tcrt_AggregatePotentialBenchmarkPayments"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_RelatedPartyTransactionReimbursedAmount" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_VinetiIncMember" xlink:label="tcrt_VinetiIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DebtInstrumentPrepaymentPremium" xlink:label="tcrt_DebtInstrumentPrepaymentPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TwoThousandAndThreeEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndThreeEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EquityDistributionAgreementMember" xlink:label="tcrt_EquityDistributionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_GainLossOnOperatingLeaseModification" xlink:label="tcrt_GainLossOnOperatingLeaseModification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MinimumRoyaltiesAmountPayable" xlink:label="tcrt_MinimumRoyaltiesAmountPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermATrancheMember" xlink:label="tcrt_TermATrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EdenBioCellMember" xlink:label="tcrt_EdenBioCellMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AggregateBenchmarkPaymentsPayable" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_FairValueOfWarrants" xlink:label="tcrt_FairValueOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AgreementTerminationNoticePeriod" xlink:label="tcrt_AgreementTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_QuarterlyPaymentsUnderContract" xlink:label="tcrt_QuarterlyPaymentsUnderContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ZiopharmMember" xlink:label="tcrt_ZiopharmMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_RoyaltiesAmountPayableThereafter" xlink:label="tcrt_RoyaltiesAmountPayableThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_EquityMilestoneMember" xlink:label="tcrt_EquityMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PercentageOfPrepaymentsPremium" xlink:label="tcrt_PercentageOfPrepaymentsPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_NewWarrantsMember" xlink:label="tcrt_NewWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ZeroMilestoneMember" xlink:label="tcrt_ZeroMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OutsideTwoThousandTwelvePlanMember" xlink:label="tcrt_OutsideTwoThousandTwelvePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TermLoanMember" xlink:label="tcrt_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PrincipalPaymentBeginningDate" xlink:label="tcrt_PrincipalPaymentBeginningDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TwoThousandAndTwelveEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IssuanceCostsInAccountsPayableAndAccruedExpenses" xlink:label="tcrt_IssuanceCostsInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember" xlink:label="tcrt_AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PerformanceBasedPaymentsMemberMember" xlink:label="tcrt_PerformanceBasedPaymentsMemberMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OperatingLeaseArea" xlink:label="tcrt_OperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LesseeOperatingLeaseMonthlyRentalPayment" xlink:label="tcrt_LesseeOperatingLeaseMonthlyRentalPayment"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LicenseAgreementWithPgenTherapeuticsMember" xlink:label="tcrt_LicenseAgreementWithPgenTherapeuticsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_TwoThousandTwelveStockOptionPlanMember" xlink:label="tcrt_TwoThousandTwelveStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_CARProductsMember" xlink:label="tcrt_CARProductsMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AggregateMinimumAnnualRoyaltiesPaid" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_OperatingLeasesExpirationMonthAndYear" xlink:label="tcrt_OperatingLeasesExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PostMarketingApprovalMember" xlink:label="tcrt_PostMarketingApprovalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember" xlink:label="tcrt_AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_InitialBenchmarkPaymentDue" xlink:label="tcrt_InitialBenchmarkPaymentDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_HoustonTexasMember" xlink:label="tcrt_HoustonTexasMember"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LicenseAgreementCommencingDate" xlink:label="tcrt_LicenseAgreementCommencingDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_AdditionalNumberOfWarrantsIssued" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCallOrExerciseFeatures" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_SubleaseTermCommencedEndDateAmendment" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_QuarterlyExpenseIncurred" xlink:label="tcrt_QuarterlyExpenseIncurred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_InterestExpenseAmortizedDate" xlink:label="tcrt_InterestExpenseAmortizedDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_DueDateAxis" xlink:label="tcrt_DueDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms" xlink:label="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseIncome" xlink:label="us-gaap_LeaseIncome"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WarrantsExpirationDate" xlink:label="tcrt_WarrantsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_BlackScholesModelMember" xlink:label="tcrt_BlackScholesModelMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_PlacementAgentFeesAndOtherRelatedExpenses" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_CRADAAgreementMember" xlink:label="tcrt_CRADAAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_WarrantTextBlock" xlink:label="tcrt_WarrantTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_ClassOfWarrantOrRightDomainDomain" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LicenseExpense" xlink:label="tcrt_LicenseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalLoansCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional loans committed.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalLoansCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Loans Committed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalLoansCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Loans Committed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss applicable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One time milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock in connection with at the market offering, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual License Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty equity incentive plan [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FullyDrawnAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fully drawn amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FullyDrawnAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fully Drawn Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FullyDrawnAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fully drawn amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Terms [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts included in accrued expenses and accounts payable related to property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityAndTermBMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity and Term B Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityAndTermBMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity and Term B Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Interest Rate During Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicensedProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">licensed products [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OtherIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Income Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OtherIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OtherIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other income expense member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of royalty payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount of Royalty Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum royalty amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Unvested Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Imputed interest and adjustments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Imputed interest and adjustments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Silicon valley bank.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Description Of option To terminate Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TcellReceptorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tcell receptor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TcellReceptorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">T-cell receptor</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Executive Officer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WatermillAndRobertWPostmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WatermillAndRobertWPostmaMember</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WatermillAndRobertWPostmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Watermill And Robert W Postma [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WatermillAndRobertWPostmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Watermill And Robert W Postma.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of sub licensing income, attributable to related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Sub licensing Income Payable to Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Portion of income payable to related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Amount Potentially Reimburseable Amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Amount Potentially Reimburseable Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reimbursement of historical costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Long-Term Debt and Capital Securities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance of Long-term Debt and Capital Securities, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BankingAndThriftInterestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Banking and Thrift, Interest [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of additional milestones payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount of Additional Milestones Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected additional milestones payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SubleaseArea</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease area.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance and sale of common stock in public offering price per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance And Sale of Common Stock In Public Offering Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance &amp; sale of common stock in public offering price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Potential Benchmark Payments Payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Benchmark Payments Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Potential Benchmark Payments Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel12And3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2, and Level 3 Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel12And3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MA [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Boston, MA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases, Operating [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual base rent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Base Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual Base Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Subsidiary or Equity Method Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DebtInstrumentPrincipalPaymentsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument principal payments percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DebtInstrumentPrincipalPaymentsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt instrument Principal Payments Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DebtInstrumentPrincipalPaymentsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument principal payments percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnModificationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (loss) on modification of lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnModificationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) On Modification Of Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnModificationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain (Loss) On Modification Of Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash proceeds from sale of equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contribution payable on per annum basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contribution Payable on Per Annum Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contribution payable on per annum basis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TenthScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenth Scheduled Payment Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TenthScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenth Scheduled Payment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TenthScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenth Scheduled Payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 (excluding the six months ended June 30, 2021)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Includes disclosures related to financing receivables and financing guarantees in which the company is the guarantor.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Arrangements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Number Of Shares Outstanding Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term Loan Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled restricted common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccretionOfTermLoanFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion of term loan final payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccretionOfTermLoanFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Of Term Loan Final Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccretionOfTermLoanFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of term loan final payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Debt [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Joint Venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments due prior to the first marketing approval</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accruals Prior to First Marketing Approval</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments due prior to the first marketing approval for TCR products.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent and technology license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent And Technology License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EdenBiocellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eden Biocell.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EdenBiocellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eden Biocell [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs and Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Previously Reported [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Previously Reported</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Description Of First Benchmark Payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of First Benchmark Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Description Of First Benchmark Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings per share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InitialBorrowingZeroMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial borrowing zero milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InitialBorrowingZeroMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Borrowing Zero Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InitialBorrowingZeroMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Borrowing Zero Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareSubscriptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Subscription Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareSubscriptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Subscription Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash related to the Company's debt agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Vested Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Vested Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of securities into which the class of warrant converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial borrowing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial term loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IntrexonCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intrexon Corporation/Precigen [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IntrexonCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intrexon Corporation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from collateral account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermBTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term B Tranche.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermBTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term B Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermBTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term B Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity interest in affilated entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument Redemption Period One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities Purchase Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-Based Compensation Expense on All Employee and Non-Employee Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Options and Restricted Stock Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options and Restricted Stock Awards [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additonal tranche facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum borrowing capacity under the credit facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Number Of Diluted Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SvbWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Svb Warrants [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SvbWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Svb Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SvbWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SVB Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation costs related to unvested restricted stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DueDateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due date [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EightScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eighth Scheduled Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EightScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eighth Scheduled Payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EightScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eighth Scheduled Payment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and Administrative [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefit and Share-Based Payment Arrangement, Noncash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee Benefit and Share-based Payment Arrangement, Noncash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of common stock (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Long-Term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InducementStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inducement Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InducementStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InducementStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement stock options member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumRoyaltyAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum royalty amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumRoyaltyAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Royalty Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumRoyaltyAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of royalty.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplementary disclosure of cash flow information:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction expenses from transactions with related party advisory fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party Advisory Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsIssuedInTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued in term loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsIssuedInTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants issued in term loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsIssuedInTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued in a term loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MD Anderson Agreement and Worldwide License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson Agreement and Worldwide License.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument Redemption Period Two Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Receivables, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Hierarchy [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TriArmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tri Arm</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TriArmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tri Arm [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TriArmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TriArm [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Operating Income Expense Inducement Of Warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Operating Income Expense Inducement Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash inducement warrant expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment premium percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of prepayment premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of prepayment premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Time Benchmark Payments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted stock awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PocketExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pocket expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PocketExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pocket Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PocketExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pocket expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Net, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Receivables, Net, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock $0.001 par value; 420,000,000 shares authorized, 216,182,042 shares issued and outstanding at September 30, 2022 and 350,000,000 shares authorized, 216,127,443 shares issued and outstanding at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BeforeAugustSixTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Before august six two thousand twenty two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BeforeAugustSixTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Before August Six Two Thousand Twenty Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BeforeAugustSixTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">On or before August 6, 2022 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Term (Years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Warrants or Options Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ObligationsDueUnderContract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Obligations due under contract.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ObligationsDueUnderContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Obligations Due Under Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ObligationsDueUnderContract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Obligations due under contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of commission on gross proceeds from sale of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Commission On Gross Proceeds From Sale Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales commission as a percentage of gross proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument description of variable rate basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of Lessee Operating Lease Monthly Average Rental Payment .</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Monthly Average Rental Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Monthly Rental Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentsMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments maximum amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentsMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments, Maximum Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentsMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone maximum payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life in years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secured Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Secured Debt [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions Expected volatility Rate Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermBMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term B Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermBMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term B Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease rental expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Leases, Rent Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOfferedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock during period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOfferedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock offered during period shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOfferedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Offered During Period Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOfferedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued during period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class Of Warrant Or Right Axis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Axis [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of financing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases future minimum monthly payment due through year four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Monthly Payment Due Through Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating Leases Future Minimum Monthly Payment Due Through Year 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Periodic Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, periodic payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Periodic Payment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Land Subject to Ground Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ZiopLicenseAgreementWithTheNationalCancerInstituteMember</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ziop License Agreement With The National Cancer Institute [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ziop License Agreement With The National Cancer Institute [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The University Of Texas M D Anderson Cancer Center And The Texas A And M University System</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The University Of Texas M D Anderson Cancer Center And The Texas A And M University System [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The University of Texas MD Anderson Cancer Center and The Texas A &amp; M University System</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment under license agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Under License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment under license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized discount on Term Loan Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Award [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Subscribed but Unissued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a public offering, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of stock consideration received on transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregatePotentialBenchmarkPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate potential benchmark payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregatePotentialBenchmarkPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate potential benchmark payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregatePotentialBenchmarkPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate potential benchmark payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson License and the Research and Development Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MD Anderson License and the Research and Development Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related Party Transaction Reimbursed Amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Reimbursed Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction, reimbursed amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_VinetiIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vineti Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_VinetiIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vineti Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DebtInstrumentPrepaymentPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DebtInstrumentPrepaymentPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DebtInstrumentPrepaymentPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument prepayment premium.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand And Three Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Three Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2003 Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity distribution agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Distribution Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Distribution Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnOperatingLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (loss) on operating lease modification.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnOperatingLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) On Operating Lease Modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnOperatingLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on lease modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnOperatingLeaseModification_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on lease modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumRoyaltiesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Minimum Royalties Amount Payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumRoyaltiesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Royalties Amount Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumRoyaltiesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum royalties amount payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermATrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term A Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermATrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term A Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermATrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term A Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EdenBioCellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eden Bio Cell [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EdenBioCellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eden Bio Cell</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability, non-current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected recognition period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Aggregate Benchmark Payments Payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Benchmark Payments Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate Benchmark Payments Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Activity under Stock Option Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement with solasia pharma K.K.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement With Solasia Pharma KK [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from long-term debt borrowing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance of Long-term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement termination notice period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Termination Notice Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Agreement termination, notice period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commitments and contingencies (Note 9)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Md Anderson Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MD Anderson Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">MD Anderson Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Restructuring Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument Redemption Period Three Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Fund Long-Term Loans to Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to Fund Long-term Loans to Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QuarterlyPaymentsUnderContract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Quarterly payments under contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QuarterlyPaymentsUnderContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Payments Under Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QuarterlyPaymentsUnderContract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Quarterly payments under contract.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, initial maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date Range, Start</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopharmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ziopharm [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopharmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ziopharm [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: current portion of long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Debt, Current Maturities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current portion of long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion of long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from private placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RoyaltiesAmountPayableThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties amount payable thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RoyaltiesAmountPayableThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Amount Payable thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RoyaltiesAmountPayableThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties amount payable thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income and Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Expiry date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Frequency of Payment and Payment Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of payment terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of prepayments premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Prepayments Premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of prepayments premium.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NewWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZeroMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Zero Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZeroMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Zero Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options available for future grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OutsideTwoThousandTwelvePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Outside two thousand twelve plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OutsideTwoThousandTwelvePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outside Two Thousand Twelve Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OutsideTwoThousandTwelvePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outside 2012 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Silicon Valley Bank loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Silicon Valley Bank Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Forecast[Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease, Cost, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease (increase) in the carrying amount of right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) during the period in the carrying value of right of use asset reported as assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PrincipalPaymentBeginningDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Principal payment beginning date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PrincipalPaymentBeginningDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Principal Payment Beginning Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PrincipalPaymentBeginningDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal payment beginning date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fees and Expenses, Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses, Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand And Twelve Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twelve Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2012 Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Vested Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Vested Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non Vested Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplementary disclosure of noncash investing and financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IssuanceCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance costs in accounts payable and accrued expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IssuanceCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance costs in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IssuanceCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">August seven two thousand twenty three to term loan maturity date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">August Seven Two Thousand Twenty Three To term Loan Maturity Date [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Between August 7, 2023 and Term Loan Maturity Date [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lender Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PerformanceBasedPaymentsMemberMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Payments Member [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease area.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LesseeOperatingLeaseMonthlyRentalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee Operating Lease Monthly Rental Payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LesseeOperatingLeaseMonthlyRentalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Monthly Rental Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementWithPgenTherapeuticsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement with PGEN therapeutics.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementWithPgenTherapeuticsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement With PGEN Therapeutics [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement with the National Cancer Institute [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandTwelveStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twelve Stock Option Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt remaining borrowing capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CARProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CAR Products [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate minimum annual royalties paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Minimum Annual Royalties Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate minimum annual royalties paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding options issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock option, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">par value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeasesExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases expiration month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeasesExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Expiration Month and Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeasesExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease expiration month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Debt Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issue costs paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings per share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PostMarketingApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post Marketing Approval [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Increase) decrease in:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">August seven two thousand twenty two to august six two thousand twenty three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">August Seven Two Thousand Twenty Two to August Six Two Thousand Twenty Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Between August 7, 2022 and August 6, 2023 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, face amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InitialBenchmarkPaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First benchmark payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InitialBenchmarkPaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Benchmark Payment Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InitialBenchmarkPaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The first benchmark payment due upon the initiation of the Company's first sponsored phase.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_HoustonTexasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Houston Texas [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_HoustonTexasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Houston Texas [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_HoustonTexasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Houston, TX</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementCommencingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement commencing date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementCommencingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Commencing Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementCommencingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement commencing date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional number of warrants issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Number Of Warrants Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional number warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant exercise per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Call or Exercise Features</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) during the period in the carrying value of lease liabilities reported as liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease term commenced end date amendment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Term Commenced End Date Amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sublease term amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QuarterlyExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quarterly expense incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QuarterlyExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Expense Incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QuarterlyExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Quarterly expense incurred.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum sales revenue on which benchmark payments payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Sales Revenue On Which Benchmark Payments Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum sales revenue on which benchmark payments payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InterestExpenseAmortizedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest expense amortized date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InterestExpenseAmortizedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense Amortized Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InterestExpenseAmortizedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense amortized date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants fully vested upon issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DueDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due date [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after year four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Termination of Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on lease modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of employee stock options (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted stock awards (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for historical costs of the licensed programs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for Historical Costs of the Licensed Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for historical costs of the licensed programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility, interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of employee stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease Income, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Black-Scholes Model [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Black Scholes Model [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Black-Scholes Model [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of original principal due as a final payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Original Principal Due as a Final Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of original principal due as a final payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relationship to Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Placement agent fees and other related expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Placement Agent Fees And Other Related Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Placement agent fees and other expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum Sales Revenue On Which Benchmark Payments Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Sales Revenue On Which Benchmark Payments Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CRADAAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CRADA Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CRADAAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CRADA Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure pertaining to the warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class Of Warrant Or Right.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Domain [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of expense related to License payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AdditionalLoansCommitted" xlink:to="tcrt_AdditionalLoansCommitted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MilestonePayment" xlink:to="tcrt_MilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AnnualLicenseFees" xlink:to="tcrt_AnnualLicenseFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_FullyDrawnAmount" xlink:to="tcrt_FullyDrawnAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EquityAndTermBMilestoneMember" xlink:to="tcrt_EquityAndTermBMilestoneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AtTheMarketOfferingMember" xlink:to="tcrt_AtTheMarketOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicensedProductsMember" xlink:to="tcrt_LicensedProductsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OtherIncomeExpenseMember" xlink:to="tcrt_OtherIncomeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumAmountOfRoyaltyPayable" xlink:to="tcrt_MaximumAmountOfRoyaltyPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SiliconValleyBankMember" xlink:to="tcrt_SiliconValleyBankMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" xlink:to="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TcellReceptorMember" xlink:to="tcrt_TcellReceptorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WatermillAndRobertWPostmaMember" xlink:to="tcrt_WatermillAndRobertWPostmaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" xlink:to="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AggregateAmountPotentiallyReimburseableAmount" xlink:to="tcrt_AggregateAmountPotentiallyReimburseableAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_BankingAndThriftInterestAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumAmountOfAdditionalMilestonesPayable" xlink:to="tcrt_MaximumAmountOfAdditionalMilestonesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SubleaseArea" xlink:to="tcrt_SubleaseArea_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare" xlink:to="tcrt_IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PotentialBenchmarkPaymentsPayable" xlink:to="tcrt_PotentialBenchmarkPaymentsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel12And3Member" xlink:to="us-gaap_FairValueInputsLevel12And3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaMember" xlink:to="tcrt_MaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AnnualBaseRent" xlink:to="tcrt_AnnualBaseRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DebtInstrumentPrincipalPaymentsPercentage" xlink:to="tcrt_DebtInstrumentPrincipalPaymentsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_GainLossOnModificationOfLease" xlink:to="tcrt_GainLossOnModificationOfLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ContributionPayableOnPerAnnumBasis" xlink:to="tcrt_ContributionPayableOnPerAnnumBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TenthScheduledPaymentMember" xlink:to="tcrt_TenthScheduledPaymentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_FinancingArrangementsDisclosureTextBlock" xlink:to="tcrt_FinancingArrangementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TermLoanAgreementMember" xlink:to="tcrt_TermLoanAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AccretionOfTermLoanFinalPayment" xlink:to="tcrt_AccretionOfTermLoanFinalPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AccrualsPriorToFirstMarketingApproval" xlink:to="tcrt_AccrualsPriorToFirstMarketingApproval_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PatentAndTechnologyLicenseAgreementMember" xlink:to="tcrt_PatentAndTechnologyLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EdenBiocellMember" xlink:to="tcrt_EdenBiocellMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DescriptionOfFirstBenchmarkPayable" xlink:to="tcrt_DescriptionOfFirstBenchmarkPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_InitialBorrowingZeroMilestonesMember" xlink:to="tcrt_InitialBorrowingZeroMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ShareSubscriptionAgreementMember" xlink:to="tcrt_ShareSubscriptionAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NonVestedStockMember" xlink:to="tcrt_NonVestedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_PaymentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IntrexonCorporationMember" xlink:to="tcrt_IntrexonCorporationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TermBTrancheMember" xlink:to="tcrt_TermBTrancheMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SecuritiesPurchaseAgreementMember" xlink:to="tcrt_SecuritiesPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock" xlink:to="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SvbWarrantsMember" xlink:to="tcrt_SvbWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DueDateDomain" xlink:to="tcrt_DueDateDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EightScheduledPaymentMember" xlink:to="tcrt_EightScheduledPaymentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WarrantsMember" xlink:to="tcrt_WarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_InducementStockOptionsMember" xlink:to="tcrt_InducementStockOptionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumRoyaltyAmount" xlink:to="tcrt_MaximumRoyaltyAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" xlink:to="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WarrantsIssuedInTermLoan" xlink:to="tcrt_WarrantsIssuedInTermLoan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonAgreementAndWorldwideLicenseMember" xlink:to="tcrt_MdAndersonAgreementAndWorldwideLicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WarrantsDisclosureAbstract" xlink:to="tcrt_WarrantsDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TriArmMember" xlink:to="tcrt_TriArmMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NonOperatingIncomeExpenseInducementOfWarrants" xlink:to="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfPrepaymentPremium" xlink:to="tcrt_PercentageOfPrepaymentPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OneTimeBenchmarkPaymentsMember" xlink:to="tcrt_OneTimeBenchmarkPaymentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PocketExpenses" xlink:to="tcrt_PocketExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_BeforeAugustSixTwoThousandTwentyTwoMember" xlink:to="tcrt_BeforeAugustSixTwoThousandTwentyTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ObligationsDueUnderContract" xlink:to="tcrt_ObligationsDueUnderContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:to="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment" xlink:to="tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MilestonePaymentsMaximumAmount" xlink:to="tcrt_MilestonePaymentsMaximumAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TermBMilestoneMember" xlink:to="tcrt_TermBMilestoneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_StockOfferedDuringPeriodShares" xlink:to="tcrt_StockOfferedDuringPeriodShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ClassOfWarrantOrRightAxisAxis" xlink:to="tcrt_ClassOfWarrantOrRightAxisAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour" xlink:to="tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandSubjectToGroundLeases" xlink:to="us-gaap_LandSubjectToGroundLeases_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" xlink:to="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" xlink:to="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PaymentUnderLicenseAgreement" xlink:to="tcrt_PaymentUnderLicenseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AggregatePotentialBenchmarkPayments" xlink:to="tcrt_AggregatePotentialBenchmarkPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" xlink:to="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_RelatedPartyTransactionReimbursedAmount" xlink:to="tcrt_RelatedPartyTransactionReimbursedAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_VinetiIncMember" xlink:to="tcrt_VinetiIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DebtInstrumentPrepaymentPremium" xlink:to="tcrt_DebtInstrumentPrepaymentPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TwoThousandAndThreeEquityIncentivePlanMember" xlink:to="tcrt_TwoThousandAndThreeEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EquityDistributionAgreementMember" xlink:to="tcrt_EquityDistributionAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_GainLossOnOperatingLeaseModification" xlink:to="tcrt_GainLossOnOperatingLeaseModification_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MinimumRoyaltiesAmountPayable" xlink:to="tcrt_MinimumRoyaltiesAmountPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TermATrancheMember" xlink:to="tcrt_TermATrancheMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EdenBioCellMember" xlink:to="tcrt_EdenBioCellMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AggregateBenchmarkPaymentsPayable" xlink:to="tcrt_AggregateBenchmarkPaymentsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_FairValueOfWarrants" xlink:to="tcrt_FairValueOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" xlink:to="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AgreementTerminationNoticePeriod" xlink:to="tcrt_AgreementTerminationNoticePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonWarrantMember" xlink:to="tcrt_MdAndersonWarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_QuarterlyPaymentsUnderContract" xlink:to="tcrt_QuarterlyPaymentsUnderContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ZiopharmMember" xlink:to="tcrt_ZiopharmMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_RoyaltiesAmountPayableThereafter" xlink:to="tcrt_RoyaltiesAmountPayableThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EquityMilestoneMember" xlink:to="tcrt_EquityMilestoneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfPrepaymentsPremium" xlink:to="tcrt_PercentageOfPrepaymentsPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NewWarrantsMember" xlink:to="tcrt_NewWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ZeroMilestoneMember" xlink:to="tcrt_ZeroMilestoneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OutsideTwoThousandTwelvePlanMember" xlink:to="tcrt_OutsideTwoThousandTwelvePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SiliconValleyBankLoanMember" xlink:to="tcrt_SiliconValleyBankLoanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TermLoanMember" xlink:to="tcrt_TermLoanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:to="tcrt_IncreaseDecreaseInRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PrincipalPaymentBeginningDate" xlink:to="tcrt_PrincipalPaymentBeginningDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember" xlink:to="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NonVestedRestrictedStockMember" xlink:to="tcrt_NonVestedRestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IssuanceCostsInAccountsPayableAndAccruedExpenses" xlink:to="tcrt_IssuanceCostsInAccountsPayableAndAccruedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember" xlink:to="tcrt_AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PerformanceBasedPaymentsMemberMember" xlink:to="tcrt_PerformanceBasedPaymentsMemberMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OperatingLeaseArea" xlink:to="tcrt_OperatingLeaseArea_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LesseeOperatingLeaseMonthlyRentalPayment" xlink:to="tcrt_LesseeOperatingLeaseMonthlyRentalPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicenseAgreementWithPgenTherapeuticsMember" xlink:to="tcrt_LicenseAgreementWithPgenTherapeuticsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" xlink:to="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TwoThousandTwelveStockOptionPlanMember" xlink:to="tcrt_TwoThousandTwelveStockOptionPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_AgreementTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CARProductsMember" xlink:to="tcrt_CARProductsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AggregateMinimumAnnualRoyaltiesPaid" xlink:to="tcrt_AggregateMinimumAnnualRoyaltiesPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OperatingLeasesExpirationMonthAndYear" xlink:to="tcrt_OperatingLeasesExpirationMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PostMarketingApprovalMember" xlink:to="tcrt_PostMarketingApprovalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember" xlink:to="tcrt_AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_InitialBenchmarkPaymentDue" xlink:to="tcrt_InitialBenchmarkPaymentDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_HoustonTexasMember" xlink:to="tcrt_HoustonTexasMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicenseAgreementCommencingDate" xlink:to="tcrt_LicenseAgreementCommencingDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AdditionalNumberOfWarrantsIssued" xlink:to="tcrt_AdditionalNumberOfWarrantsIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCallOrExerciseFeatures" xlink:to="us-gaap_CommonStockCallOrExerciseFeatures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:to="tcrt_IncreaseDecreaseInLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SubleaseTermCommencedEndDateAmendment" xlink:to="tcrt_SubleaseTermCommencedEndDateAmendment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_QuarterlyExpenseIncurred" xlink:to="tcrt_QuarterlyExpenseIncurred_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:to="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_InterestExpenseAmortizedDate" xlink:to="tcrt_InterestExpenseAmortizedDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DueDateAxis" xlink:to="tcrt_DueDateAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms" xlink:to="tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseIncome" xlink:to="us-gaap_LeaseIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WarrantsExpirationDate" xlink:to="tcrt_WarrantsExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_BlackScholesModelMember" xlink:to="tcrt_BlackScholesModelMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" xlink:to="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PlacementAgentFeesAndOtherRelatedExpenses" xlink:to="tcrt_PlacementAgentFeesAndOtherRelatedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:to="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CRADAAgreementMember" xlink:to="tcrt_CRADAAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WarrantTextBlock" xlink:to="tcrt_WarrantTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ClassOfWarrantOrRightDomainDomain" xlink:to="tcrt_ClassOfWarrantOrRightDomainDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicenseExpense" xlink:to="tcrt_LicenseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>tcrt-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-11-14T01:22:03.1911+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/BalanceSheets" xlink:href="tcrt-20220930.xsd#BalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2" xlink:href="tcrt-20220930.xsd#DisclosureDebtScheduleOfDebtDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2" xlink:href="tcrt-20220930.xsd#DisclosureLeasesOperatingLeaseLiabilitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations" xlink:href="tcrt-20220930.xsd#StatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows" xlink:href="tcrt-20220930.xsd#StatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:href="tcrt-20220930.xsd#DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/BalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="tcrt_GainLossOnOperatingLeaseModification" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_GainLossOnOperatingLeaseModification" xlink:label="tcrt_GainLossOnOperatingLeaseModification"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tcrt_IncreaseDecreaseInRightOfUseAsset" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tcrt_IncreaseDecreaseInLeaseLiabilities" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="12" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="tcrt-20220930.xsd#tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435935054784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Alaunos Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001107421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TCRT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,182,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-1475642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8030 El Rio Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">355-4099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435935165632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 37,807<span></span>
</td>
<td class="nump">$ 76,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">13,938<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">2,911<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">849<span></span>
</td>
<td class="nump">1,666<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">55,505<span></span>
</td>
<td class="nump">78,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,050<span></span>
</td>
<td class="nump">10,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">2,247<span></span>
</td>
<td class="nump">4,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">67,344<span></span>
</td>
<td class="nump">94,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,984<span></span>
</td>
<td class="nump">1,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">22,668<span></span>
</td>
<td class="nump">7,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,675<span></span>
</td>
<td class="nump">6,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Lease liability, current</a></td>
<td class="nump">542<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">32,869<span></span>
</td>
<td class="nump">16,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Lease liability, non-current</a></td>
<td class="nump">2,334<span></span>
</td>
<td class="nump">4,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">35,231<span></span>
</td>
<td class="nump">36,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock $0.001 par value; 420,000,000 shares authorized, 216,182,042 shares issued and outstanding at September 30, 2022 and 350,000,000 shares authorized, 216,127,443 shares issued and outstanding at December 31, 2021</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">903,365<span></span>
</td>
<td class="nump">900,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(871,468)<span></span>
</td>
<td class="num">(842,852)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">32,113<span></span>
</td>
<td class="nump">58,057<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 67,344<span></span>
</td>
<td class="nump">$ 94,865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435934964512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">420,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">216,182,042<span></span>
</td>
<td class="nump">216,127,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">216,182,042<span></span>
</td>
<td class="nump">216,127,443<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435934922848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 2,911<span></span>
</td>
<td class="nump">$ 398<span></span>
</td>
<td class="nump">$ 2,911<span></span>
</td>
<td class="nump">$ 398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,893<span></span>
</td>
<td class="nump">14,521<span></span>
</td>
<td class="nump">19,411<span></span>
</td>
<td class="nump">41,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,282<span></span>
</td>
<td class="nump">8,173<span></span>
</td>
<td class="nump">10,217<span></span>
</td>
<td class="nump">25,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_GainLossOnOperatingLeaseModification', window );">Gain on lease modification</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(133)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">11,175<span></span>
</td>
<td class="nump">22,694<span></span>
</td>
<td class="nump">29,495<span></span>
</td>
<td class="nump">66,896<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,264)<span></span>
</td>
<td class="num">(22,296)<span></span>
</td>
<td class="num">(26,584)<span></span>
</td>
<td class="num">(66,498)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="num">(841)<span></span>
</td>
<td class="num">(444)<span></span>
</td>
<td class="num">(2,266)<span></span>
</td>
<td class="num">(444)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(587)<span></span>
</td>
<td class="num">(437)<span></span>
</td>
<td class="num">(1,987)<span></span>
</td>
<td class="num">(459)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,851)<span></span>
</td>
<td class="num">$ (22,733)<span></span>
</td>
<td class="num">$ (28,571)<span></span>
</td>
<td class="num">$ (66,957)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, Basic</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, Diluted</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number Of Shares Outstanding Basic</a></td>
<td class="nump">215,098,995<span></span>
</td>
<td class="nump">214,542,465<span></span>
</td>
<td class="nump">215,015,377<span></span>
</td>
<td class="nump">214,310,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number Of Diluted Shares Outstanding</a></td>
<td class="nump">215,098,995<span></span>
</td>
<td class="nump">214,542,465<span></span>
</td>
<td class="nump">215,015,377<span></span>
</td>
<td class="nump">214,310,349<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_GainLossOnOperatingLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on operating lease modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_GainLossOnOperatingLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435930910912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 123,982<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">$ 887,868<span></span>
</td>
<td class="num">$ (764,101)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,591,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of employee stock options</a></td>
<td class="nump">1,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of employee stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,601,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancelled restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(410,435)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants</a></td>
<td class="nump">788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,957)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="nump">68,707<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">899,549<span></span>
</td>
<td class="num">(831,058)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,145,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">88,281<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">896,390<span></span>
</td>
<td class="num">(808,325)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,559,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancelled restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(288,344)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants</a></td>
<td class="nump">788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,733)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,733)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="nump">68,707<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">899,549<span></span>
</td>
<td class="num">(831,058)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,145,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">58,057<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">900,693<span></span>
</td>
<td class="num">(842,852)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,127,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of employee stock options</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of employee stock options (in shares)</a></td>
<td class="nump">26,250<span></span>
</td>
<td class="nump">26,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">$ (45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancelled restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(232,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,571)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,571)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="nump">32,113<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">903,365<span></span>
</td>
<td class="num">(871,468)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,182,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">40,180<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">902,536<span></span>
</td>
<td class="num">(862,572)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,174,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of employee stock options</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of employee stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,851)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="nump">$ 32,113<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">$ 903,365<span></span>
</td>
<td class="num">$ (871,468)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,182,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435934756608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,571)<span></span>
</td>
<td class="num">$ (66,957)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,065<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of financing costs</a></td>
<td class="nump">634<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash', window );">Stock-based compensation</a></td>
<td class="nump">2,651<span></span>
</td>
<td class="nump">9,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncreaseDecreaseInRightOfUseAsset', window );">Decrease (increase) in the carrying amount of right-of-use assets</a></td>
<td class="nump">2,306<span></span>
</td>
<td class="num">(529)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on lease modification</a></td>
<td class="num">(133)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(1,800)<span></span>
</td>
<td class="nump">3,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">7,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,525<span></span>
</td>
<td class="num">(3,169)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(2,371)<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(22,102)<span></span>
</td>
<td class="num">(46,342)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(2,964)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(2,964)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt borrowing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(45)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(2,083)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(2,107)<span></span>
</td>
<td class="nump">25,962<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(24,309)<span></span>
</td>
<td class="num">(23,344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">76,054<span></span>
</td>
<td class="nump">115,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">51,745<span></span>
</td>
<td class="nump">91,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,603<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts included in accrued expenses and accounts payable related to property and equipment</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of lease liabilities reported as liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_IncreaseDecreaseInRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of right of use asset reported as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_IncreaseDecreaseInRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435934616176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Organization</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alaunos Therapeutics, Inc., which is referred to herein as &#8220;Alaunos,&#8221; or the &#8220;Company,&#8221; is a clinical-stage oncology-focused cell therapy company developing adoptive TCR-T cell therapies, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. On January 25, 2022, the Company changed its corporate name from ZIOPHARM Oncology, Inc. to Alaunos Therapeutics, Inc. The Company is leveraging its proprietary, non-viral </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">gene transfer platform and its cancer hotspot mutation TCR library to design and manufacture autologous cell therapies that target neoantigens arising from shared tumor-specific mutations in key oncogenic genes, including </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS, TP53 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s operations to date have consisted primarily of conducting research and development and raising capital to fund those efforts. In May 2021, the Company announced that it will be winding down its existing Controlled IL-12 clinical program. The Company continues to seek a partner for this program.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company follows the guidance of Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements - Going Concern, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its financial statements are issued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has operated at a loss since its inception in 2003 and has no recurring revenue from operations.&#8239;The Company anticipates that losses will continue for the foreseeable future. As of September 30, 2022, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8239;million of cash and cash equivalents and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of restricted cash related to the Company's debt agreement (see Note 4). The Company&#8217;s accumulated deficit at September 30, 2022 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">871.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8239;million.&#8239;Given its current development plans and cash management efforts, the Company anticipates cash resources will be sufficient to fund operations into the second quarter of 2023.&#8239;The Company&#8217;s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in the Company&#8217;s focus and direction of its research and development programs, competitive and technical advances, patent developments, regulatory changes or other developments. If adequate additional funds are not available when required, management may need to curtail its development efforts and planned operations to conserve cash.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the current cash forecast, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements, which raises substantial doubt as to the Company's ability to continue as a going concern. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of September 30, 2022, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">216,182,042</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock outstanding and an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,545,557</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock reserved for issuance pursuant to outstanding stock options and warrants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures required by generally accepted accounting principles in the United States, or GAAP, have been condensed or omitted pursuant to such rules and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is management&#8217;s opinion that the accompanying unaudited interim financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair presentation of the financial position of the Company and its results of operations and cash flows for the periods presented. The unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2021, included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on March 30, 2022, or the Annual Report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results disclosed in the statements of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full fiscal year 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">statements </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140436102631264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_FinancingArrangementsDisclosureTextBlock', window );">Financings</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financings</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Loan and Security Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2021, the Company entered into a Loan and Security Agreement (the "Loan and Security Agreement") with Silicon Valley Bank and affiliates of Silicon Valley Bank (collectively, "SVB").  The Loan and Security Agreement provided for an initial term loan of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million funded at the closing (the "Term A Tranche"), with an additional tranche of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million available if certain funding and clinical milestones were met by August 31, 2022 (the "Term B Tranche").</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective December 28, 2021, the Company, entered into a First Amendment (the &#8220;Amendment&#8221;) to the Loan and Security Agreement (as so amended, the "Amended Loan and Security Agreement").</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Amended Loan and Security Agreement extended the interest-only period through August 31, 2022. The Amended Milestones (as defined below) were not met by the Company on or prior to August 31, 2022, and therefore, the interest-only period was not extended beyond August 31, 2022. The Amendment also eliminated the Term B Tranche, which remained unfunded, leaving only the Term A Tranche (the "SVB Facility"). Under the Amended Loan and Security Agreement, the SVB Facility will mature on August 1, 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Please refer to Note 4 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for further discussion of the Loan and Security Agreement and the Amended Loan and Security Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2022 Equity Distribution Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 12, 2022, the Company entered into an Equity Distribution Agreement (the "Equity Distribution Agreement") with Piper Sandler &amp; Co. ("Piper Sandler"), pursuant to which the Company can offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million through Piper Sandler as its sales agent in an "at the market offering." Piper Sandler will receive a commission of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the gross proceeds of any common stock sold under the Equity Distribution Agreement. During the three and nine months ended September 30, 2022, there have been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> sales of the Company's common stock under the Equity Distribution Agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_FinancingArrangementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Includes disclosures related to financing receivables and financing guarantees in which the company is the guarantor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_FinancingArrangementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435934582368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Significant Accounting Policies</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s significant accounting policies were identified in the Company&#8217;s Annual Report. There have been no material changes in those policies since the filing of its Annual Report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435936034016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying values of the Company's debt obligation were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.682%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.092%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.998000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loan and Security Agreement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,461</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,209</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized discount on Loan and Security Agreement</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">793</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,091</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,668</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,118</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of September 30, 2022, the SVB Facility was fully drawn in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The SVB Facility bears interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and (b) the current published U.S. prime rate, plus a margin of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of September 30, 2022, interest on the outstanding loans was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. The Amended Loan and Security Agreement provided for an interest-only period through August 31, 2022. On or prior to August 31, 2022, the Company had not (i) received at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net cash proceeds from the sale of the Company&#8217;s equity securities after the date of the Amended Loan and Security Agreement, on terms acceptable to SVB, nor (ii) achieved positive data in the first cohort of the Library TCR-T Trial endorsed by an independent safety monitoring committee as a safe dose to proceed (together, the &#8220;Amended Milestones&#8221;), and, therefore, the interest-only period was not extended beyond August 31, 2022. Commencing on September 1, 2022, aggregate outstanding borrowings are payable in twelve consecutive, equal monthly installments of principal plus accrued interest.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All outstanding obligations under the Amended Loan and Security Agreement are due and payable on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 1, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will also owe SVB </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the original principal amounts borrowed as a final payment (the "Final Payment"). The Company is </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">permitted </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to make up to two prepayments, subject to a prepayment premium of the amount being prepaid, ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, of the SVB Facility, each such prepayment to be at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million plus all accrued and unpaid interest on the portion being prepaid.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of not achieving the Amended Milestones on or prior to August 31, 2022, the Amended Loan and Security Agreement required the Company to cash collateralize half of the sum of the then-outstanding principal amount of the SVB Facility, plus an amount equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the original principal amount of the SVB Facility. As of September 30, 2022, the Company has collateralized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is classified as restricted cash on the balance sheet. So long as no event of default has occurred and subject to certain other terms related to the remaining outstanding balance under the SVB Facility being satisfied, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million will be released from the collateral account following the eighth scheduled payment of principal and interest, and a further $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million will be released following the tenth scheduled payment of principal and interest. The SVB Facility and related obligations under the Amended Loan and Security Agreement are secured by substantially all of the Company&#8217;s properties, rights and assets, except for its intellectual property (which is subject to a negative pledge under the Amended Loan and Security Agreement). In addition, the Amended Loan and Security Agreement contains customary representations, warranties, events of default and covenants.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with its entry into the Loan and Security Agreement, the Company issued to SVB warrants to purchase (i) up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">432,844</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock, in the aggregate, and (ii) up to an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">432,842</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, in the aggregate, in the event the Company achieved certain clinical milestones, in each case at an exercise price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with its entry into the Amendment, the Company amended and restated the warrants issued to SVB. As amended and restated, the warrants are for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">649,615</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock, in the aggregate, at an exercise price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.16</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or the SVB Warrants. The SVB Warrants expire on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 6, 2031</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance costs for the Loan and Security Agreement, including the Amended Loan and Security Agreement, were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and primarily related to the SVB Warrants, which will be amortized into interest expense over the period to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 1, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Interest expense was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the three months ended September 30, 2022 and was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the nine months ended September 30, 2022, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the three and nine months ended September 30, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of the Amended Loan and Security Agreement as of September 30, 2022 approximates its face value.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435934546128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></p><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></div><div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of September 30, 2022 and December 31, 2021 are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.66%;"/>
        <td style="width:0.992%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.277000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.992%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.288%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.113%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.058%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.113%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.504999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of<br/>September 30,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,807</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,807</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.388%;"/>
        <td style="width:0.965%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.965%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.274%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.076%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.905%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.076%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.353%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of<br/>December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,222</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,222</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been no changes to the valuation methods during the nine months ended September 30, 2022. We had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> financial assets or liabilities that were classified as Level 2 or Level 3 during the nine months ended September 30, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI https://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435933943552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">6.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, inducement stock options, unvested restricted stock and warrants, have not been included in the computation of diluted net loss per share for any of the periods presented as the result would be anti-dilutive. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such potentially dilutive shares of common stock consisted of the following as of September 30, 2022 and 2021, respectively:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.904%;"/>
        <td style="width:1.642%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.202%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.642%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.61%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,623,215</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,072,894</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inducement stock options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">940,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,510,655</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,922,342</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,705,571</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,485,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,386,620</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140436102560800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">7.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related Party Transactions</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration with Vineti Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 9, 2020, the Company entered into a master service agreement and statement of work with Vineti, Inc. ("Vineti"). Pursuant to the agreement, Vineti has been developing a software platform to coordinate and orchestrate the order, cell collection and manufacturing process for the Company&#8217;s T-cell therapy, or TCR-T, clinical programs. Heidi Hagen, who became a director of the Company in June 2019 and resigned November 2, 2021 and the Company's Interim Chief Executive Officer on February 25, 2021 and resigned on August 30, 2021, is a co-founder and former officer of Vineti. During the three and nine months ended September 30, 2022, the Company recorded </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expenses for Vineti, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of expenses for the three months ended September 30, 2021 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the nine months ended September 30, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">WaterMill Settlement Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 4, 2021, the Company entered into an agreement, or the Settlement Agreement, with WaterMill Asset Management Corp. and Robert W. Postma (collectively, the "WaterMill Parties"). Pursuant to the Settlement Agreement, the Company increased the size of its board of directors from eight to nine directors and appointed Mr. Postma to fill the newly created directorship.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with the Settlement Agreement, the Company agreed to reimburse the WaterMill Parties for up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of their reasonable out-of-pocket expenses out of a total of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in fees and expenses actually incurred by the WaterMill Parties in connection with (i) the WaterMill Parties' solicitation of written consents from the Company's stockholders to vote in favor of certain proposals, as set forth in the definitive consent statement filed by the WaterMill Parties on October 30, 2020, and (ii) the negotiation, execution, and effectuation of the Settlement Agreement. As of February 19, 2021, the Company has fully reimbursed the WaterMill Parties an aggregate amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Joint Venture with TriArm Therapeutics/Eden BioCell</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 18, 2018, the Company and TriArm Therapeutics, Ltd. (&#8220;TriArm&#8221;) launched Eden BioCell, Ltd. (&#8220;Eden BioCell&#8221;) as a joint venture to lead commercialization of the Company&#8217;s </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-generated CAR-T therapies in the People&#8217;s Republic of China (including Macau and Hong Kong), Taiwan and Korea. The Company licensed to Eden BioCell the rights in Greater China for its third-generation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-generated CAR-T therapies targeting the CD19 antigen. Eden BioCell is owned equally by the Company and TriArm and the parties share decision-making authority. TriArm has contributed $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to Eden BioCell and has committed up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to this joint venture. TriArm also manages all clinical development in the territory pursuant to a master services agreement between TriArm and Eden BioCell. James Huang was the founder and serves as managing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">partner </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of Panacea Venture, which is an investor in TriArm. Mr. Huang is the Chair of the Company's board of directors and has been a director since July 2020. He also serves as a member of Eden BioCell&#8217;s board of directors.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three and nine months ended September 30, 2022, Eden BioCell incurred a net loss and the Company continues to have no commitment to fund its operations. In September 2021, TriArm and Alaunos mutually agreed to dissolve the Eden BioCell joint venture. Refer to Note 12 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Joint Venture</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for further details.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435937187136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">9.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive License Agreement with PGEN Therapeutics</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 5, 2018, the Company entered into an exclusive license agreement, or License Agreement, with PGEN Therapeutics, or PGEN, a wholly owned subsidiary of Precigen Inc., or Precigen, which was formerly known as Intrexon Corporation. Pursuant to the terms of the License Agreement, the Company has exclusive, worldwide rights to research, develop and commercialize (i) TCR products designed for neoantigens for the treatment of cancer, (ii) products utilizing Precigen&#8217;s RheoSwitch&#174; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (iii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the Ares Trading Agreement. Under the License Agreement, the Company also has exclusive, worldwide rights for certain patents relating to the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The Company is required to use commercially reasonable efforts, as defined in the License Agreement, to develop and commercialize IL-12 products, CD19 products, BCMA products and TCR Products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In consideration of the licenses and other rights granted by PGEN, the Company will pay PGEN an annual license fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the Company has agreed to reimburse PGEN for certain historical costs of the licensed programs up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which was fully paid during the year ended December 31, 2019.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will make milestone payments totaling up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for each exclusively licensed program upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions. In addition, the Company will pay PGEN tiered royalties ranging from low-single digits to high-single digits on the net sales derived from the sale of any approved IL-12 products and CAR products. The Company will also pay PGEN royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of any approved TCR products, up to a maximum royalty amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate. The Company will also pay PGEN </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">twenty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> percent of any sublicensing income received by us relating to the licensed products. The Company is responsible for all development costs associated with each of the licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PGEN will pay the Company royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of PGEN&#8217;s CAR products, up to a maximum royalty amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the Company entered into an amendment to the License Agreement relating to the transfer of certain materials and PGEN&#8217;s obligations to provide transition assistance relating to the IL-12 products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement and 2015 Research and Development Agreement &#8212;The University of Texas MD Anderson Cancer Center</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 13, 2015</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company, together with Precigen, entered into the MD Anderson License with MD Anderson (which Precigen subsequently assigned to PGEN). Pursuant to the MD Anderson License, the Company, together with PGEN, holds an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs, arising from the laboratory of Laurence Cooper, M.D., Ph.D., who served as the Company&#8217;s Chief Executive Officer from May 2015 until February 2021 and was formerly a tenured professor of pediatrics at MD Anderson.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 17, 2015, the Company, Precigen and MD Anderson entered into the 2015 R&amp;D Agreement to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. The rights and obligations of Precigen under the 2015 R&amp;D Agreement were assigned to the Company pursuant to the Fourth Amendment to 2015 R&amp;D Agreement which was entered into on September 19, 2019 (the &#8220;Fourth Amendment&#8221;) with an effective date of October 5, 2018. The activities under the 2015 R&amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the 2015 R&amp;D Agreement for a period of three years and in an amount of no less than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and no greater than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per year. On November 14, 2017, the Company entered into an amendment to the 2015 R&amp;D Agreement, extending its term until April 15, 2021. In connection with the execution of the 2019 R&amp;D Agreement described below, on October 22, 2019, the Company amended the 2015 R&amp;D Agreement to extend the term of the 2015 R&amp;D Agreement until December 31, 2026 and to allow cash resources on hand at MD Anderson under the 2015 R&amp;D Agreement to be used for development costs under the 2019 R&amp;D Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson License, the Company, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if the Company and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if the Company and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by the Company and Precigen, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both the Company and Precigen and may be terminated by the mutual written agreement of the Company, PGEN, and MD Anderson.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2019 Research and Development Agreement&#8212;The University of Texas MD Anderson Cancer Center</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 22, 2019, the Company entered into the 2019 Research and Development Agreement, or the 2019 R&amp;D Agreement, with MD Anderson, pursuant to which the parties agreed to collaborate with respect to the TCR program. Under the 2019 R&amp;D Agreement, the parties will, among other things, collaborate on programs to expand the Company's TCR library and conduct clinical trials. The activities under the 2019 R&amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will own all inventions and intellectual property developed under the 2019 R&amp;D Agreement and the Company will retain all rights to intellectual property for oncology products manufactured using non-viral gene transfer technologies under the 2019 R&amp;D Agreement, including the Company's</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology. The Company has granted MD Anderson an exclusive license for such intellectual property outside the field of oncology and to develop and commercialize TCR products manufactured using viral gene transfer technologies limited to autologous products if used for cancer treatment or prevention, and a non-exclusive license for allogenic anti-tumor TCR products manufactured using viral-based technologies.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2019 R&amp;D Agreement, the Company agreed, beginning on January 1, 2021, to reimburse MD Anderson up to a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for development costs under the 2019 R&amp;D Agreement, after the funds from the 2015 R&amp;D Agreement are exhausted. In addition, the Company will pay MD Anderson royalties on net sales of its TCR products. The Company is required to make performance-based payments upon the successful completion of clinical and regulatory benchmarks relating to its TCR products. The aggregate potential benchmark payments are $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, of which only $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">will be due prior to the first marketing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the Company's TCR products. The royalty rates and benchmark payments owed to MD Anderson may be reduced upon the occurrence of certain events. The Company also agreed to sell its TCR products to MD Anderson at preferential prices and will sell the Company's TCR products in Texas exclusively to MD Anderson for a limited period of time following the first commercial sale of the Company's TCR products. For the three months ended September 30, 2022, the Company incurred clinical expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from MD Anderson related to this agreement compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the three months ended September 30, 2021. For the nine months ended September 30, 2022, the Company incurred clinical expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from MD Anderson related to this agreement compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the nine months ended September 30, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2019 R&amp;D Agreement will terminate on December 31, 2026 and either party may terminate the 2019 R&amp;D Agreement following written notice of a material breach. The 2019 R&amp;D Agreement also contains customary provisions related to indemnification obligations, confidentiality and other matters.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the execution of the 2019 R&amp;D Agreement, on October 22, 2019, the Company issued MD Anderson a warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,333,333</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock, which is referred to as the MD Anderson Warrant. Please refer to Note 11 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrants</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for further discussion of the MD Anderson Warrant. The MD Anderson Warrant has an initial exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and vests upon the occurrence of certain clinical milestones. As of September 30, 2022, the milestones have not been met.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with the NCI</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 28, 2019, the Company entered into a patent license agreement, or the Patent License, with the National Cancer Institute, or the NCI. Pursuant to the Patent License, the Company holds an exclusive, worldwide license to certain intellectual property to develop and commercialize patient-derived (autologous), peripheral blood T-cell therapy products engineered by transposon-mediated gene transfer to express TCRs reactive to mutated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neoantigens. In addition, pursuant to the Patent License, the Company holds an exclusive, worldwide license to certain intellectual property for manufacturing technologies to develop and commercialize autologous, peripheral blood T-cell therapy products engineered by non-viral gene transfer to express TCRs, as well as a non-exclusive, worldwide license to certain additional manufacturing technologies. On May 29, 2019, January 8, 2020, September 28, 2020, April 16, 2021, May 4, 2021, and August 13, 2021 the Company amended the Patent License to expand its TCR library to include additional TCRs reactive to mutated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">KRAS </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TP53 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neoantigens licensed from the NCI.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms of the Patent License require the Company to pay the NCI minimum annual royalties in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which amount will be reduced to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million once the aggregate minimum annual royalties paid by the Company equals $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is also required to make performance-based payments upon successful completion of clinical and regulatory benchmarks relating to the licensed products. Of such payments, the aggregate potential benchmark payments are $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, of which aggregate payments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million are due only after marketing approval in the United States or in Europe, Japan, Australia, China or India. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The first benchmark payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was due upon the initiation of the Company's first sponsored Phase 1 clinical trial of a licensed product or licensed process in the field of use licensed under the Patent License. The Company paid the first benchmark payment during the nine months ended September 30, 2022.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the Company is required to pay the NCI one-time benchmark payments following aggregate net sales of licensed products at certain aggregate net sales ranging from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion. The aggregate potential amount of these benchmark payments is $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company must also pay the NCI royalties on net sales of products covered by the Patent License at rates in the low to mid-single digits depending upon the technology included in a licensed product. To the extent the Company enters into a sublicensing agreement relating to a licensed product, the Company is required to pay the NCI a percentage of all consideration received from a sublicensee, which percentage will decrease based on the stage of development of the licensed product at the time of the sublicense.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Patent License will expire upon expiration of the last patent contained in the licensed patent rights, unless terminated earlier. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The NCI may terminate or modify the Patent License in the event of a material breach, including if the Company does not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company may terminate the Patent License, or any portion thereof, in the Company's sole discretion at any time upon </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#8217; written notice to the NCI. In addition, the NCI has the right to: (i) require the Company to sublicense the rights to the product candidates covered by the Patent License upon certain conditions, including if the Company is not reasonably satisfying required health and safety needs and (ii) terminate or modify the Patent License, including if the Company is not satisfying requirements for public use as specified by federal regulations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three months ended September 30, 2022, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in license payments to the NCI under this agreement, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the three months ended September 30, 2021.  For the nine months ended September 30, 2022,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in license payments to the NCI under this agreement, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the nine months ended September 30, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cooperative Research and Development Agreement (CRADA) with the NCI</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 9, 2017, the Company entered into a Cooperative Research and Development Agreement (the &#8220;CRADA&#8221;) with the NCI. The purpose of this collaboration was to advance a personalized TCR-T approach for the treatment of solid tumors. Using the Company's </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology, the NCI would analyze a patient&#8217;s own cancer cells, identify their unique neoantigens and TCRs reactive against those neoantigens and then use the Company's </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology to transpose one or more TCRs into T cells for re-infusion. Research conducted under the CRADA will be at the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI, in collaboration with the Company's researchers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is responsible for providing the NCI with the test materials necessary for them to conduct their studies, and eventually, clinical trials pursuant to the CRADA. Inventions, data and materials discovered or produced in connection with performance of the research plan under the CRADA will remain the sole property of the party who produced the discovery. The parties will jointly own all inventions jointly discovered under the research plan. The owner of any invention under the CRADA will make the decision to file a patent covering the invention, or in the case of a jointly owned invention, the Company will have the first opportunity to file a patent covering the invention. If the Company fails to provide timely notice of its decision to the NCI or decide not to file a patent covering the joint invention, the NCI has the right to make the filing. For any invention solely owned by the NCI or jointly made by the NCI and the Company for which a patent application was filed, the U.S. Public Health service grants the Company an exclusive option to elect an exclusive or non-exclusive commercialization license. For inventions owned solely by the NCI or jointly owned by the NCI and the Company, which are licensed according to the terms described above, the Company agreed to grant to the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world. The Company is also required to grant the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world for any of the Company's solely owned inventions. The agreement may be terminated by any of the parties upon 60 days prior written consent.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The NCI has a cleared Investigational New Drug Application, or IND, that would permit them to begin this trial. To the Company's knowledge, the trial has not yet enrolled due to matters internal to the NCI and unrelated to the Company's technology. The progress and timeline for this trial, including the timeline for dosing patients, are under control of the NCI.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2019, the Company extended the CRADA with the NCI until January 9, 2022, committing an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to this program. In March 2022, the Company entered into an amendment to the CRADA that is retroactive, effective January 9, 2022 to extend the term of the CRADA until January 9, 2023. In June 2022, the Company entered into the Fourth Amendment to the CRADA (the "CRADA Fourth Amendment") which, among other things, extended the term of the CRADA until January 9, 2025. In connection with the CRADA Fourth Amendment, the Company agreed to contribute $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per year, payable on a quarterly basis, beginning in the first quarter of 2023. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t record expenses under the CRADA for the three and nine months ended September 30, 2022, as compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the three months ended September 30, 2021 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the nine months ended September 30, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent and Technology License Agreement&#8212;The University of Texas MD Anderson Cancer Center and the Texas A&amp;M University System</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&amp;M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the agreement, the Company may be required to make additional payments to the Licensors upon achievement of certain milestones in varying amounts which, on a cumulative basis could total up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. In addition, the Licensors are entitled to receive royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. During the three and nine months ended September 30, 2022, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was expensed as a one-time milestone payment under the terms of the agreement, compared to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the three and nine months ended September 30, 2021. During the three and nine months ended September 30, 2022 and 2021, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t incur royalty expenses on sales under this agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreement with Solasia Pharma K.K.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia Pharma K. K. ("Solasia"), which was amended on July 31, 2014 to include an exclusive worldwide license and amended on October 14, 2021 to revise certain payment schedule details (as so amended, the "Solasia License and Collaboration Agreement"). Pursuant to the Solasia License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the license, the Company is eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenue generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company&#8217;s licensors, as defined in the Solasia License and Collaboration Agreement, will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Solasia License and Collaboration Agreement with the licensors, as described above.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, Solasia announced that darinaparsin had been approved from relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare in Japan. During the three and nine months ended September 30, 2022, the Company recorded $2.9 million of collaboration revenue under the Solasia License and Collaboration Agreement primarily related to Solasia's achievement of certain sales-based milestones in Japan. During the three and nine months ended September 30, 2021, the Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of collaboration revenue under the Solasia License and Collaboration Agreement. During the three and nine months ended September 30, 2022 and 2021, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t record royalty revenues on net sales of darinaparsin under this agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435937192736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Leases, Operating [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">8.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, the Company modified its real estate lease agreement executed on December 15, 2020 with MD Anderson for office space in Houston, which reduced the Company's leased space from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,111</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,228</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet. As a result, the associated lease liability and right-of-use asset were remeasured to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million based on revised lease payments. A gain of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded on the lease modification during the nine months ended September 30, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, the Company executed an agreement to sub-sublease </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,772</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of subleased office space in Boston. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the sub-sublease is from July 1, 2022 to June 30, 2025 and provides the sub-subtenant with an option to extend through to July 31, 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. For the three and nine months ended September 30, 2022, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand in lease income, which is classified within other income (expense), net in the statement of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435933943552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_StockOptionsAndRestrictedStockAwardsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">10.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-Based Compensation</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.367%;"/>
        <td style="width:3.316%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.553%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.665%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.641%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.665%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.665%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.338999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Three Months Ended September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Nine Months Ended September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">673</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,115</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">663</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,836</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,978</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,742</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">808</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,651</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,857</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company granted an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,275,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stock options during the three months ended September 30, 2022, with a weighted-average grant date fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.52</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, and granted an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,667,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stock options during the nine months ended September 30, 2022, with a weighted-average grant date fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.67</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The Company granted an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,755,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">stock options during the three months ended September 30, 2021, with a weighted-average grant date fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.08</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, and granted an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,150,438</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stock options during the nine months ended September 30, 2021, with a weighted-average grant date fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.91</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three and nine months ended September 30, 2022 and 2021, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.661%;"/>
        <td style="width:1.336%;"/>
        <td style="width:15.999%;"/>
        <td style="width:1.336%;"/>
        <td style="width:15.999%;"/>
        <td style="width:1.336%;"/>
        <td style="width:15.999%;"/>
        <td style="width:1.336%;"/>
        <td style="width:15.999%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Three Months Ended September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Nine Months Ended September 30,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.94</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.62</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.89</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.96</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.63</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.62</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected life in years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.23</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.27</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82.43</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85.89</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.84</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74.49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85.89</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74.80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.528%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:1.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.743198935713313%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock option activity under the Company&#8217;s stock option plans for the nine months ended September 30, 2022 is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.903%;"/>
        <td style="width:0.993%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.799%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.215%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.504%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.993%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.828999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.215%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.551%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted- Average Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted- Average Contractual Term (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,665,869</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,667,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.08</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,683,904</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.40</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, September 30, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,623,215</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.85</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.27</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,572</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable, September 30, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,211,631</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.69</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.01</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">510</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,410,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.85</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.53</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options available for future grant, September 30, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,245,494</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At September 30, 2022, total unrecognized compensation costs related to unvested stock options outstanding amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The cost is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.01</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the status of unvested restricted stock for the nine months ended September 30, 2022 is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.459%;"/>
        <td style="width:1.154%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.669%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.115%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,198,580</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.10</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">280,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.82</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">305,679</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.28</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,901</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested, September 30, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">940,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.41</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At September 30, 2022, total unrecognized compensation costs related to unvested restricted stock outstanding amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The cost is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.83</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_StockOptionsAndRestrictedStockAwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Options and Restricted Stock Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_StockOptionsAndRestrictedStockAwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435934546128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_WarrantsDisclosureAbstract', window );"><strong>Warrants Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_WarrantTextBlock', window );">Warrant</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">11.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Company&#8217;s November 2018 private placement that provided net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, the Company issued warrants to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,939,394</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, which became exercisable six months after the closing of the private placement (the "November 2018 Warrants"). The November 2018 Warrants had an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.01</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and have a five-year term. The fair value of the November 2018 Warrants was estimated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million using a Black-Scholes model with the following assumptions: expected volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, expected life of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 26, 2019 and September 12, 2019, the Company entered into agreements with existing investors whereby the investors exercised the November 2018 Warrants for an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,803,031</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.01</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. Proceeds from the warrant exercise after deducting placement agent fees and other related expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company issued participating investors new warrants to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,803,031</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of common stock (the "2019 Warrants") as consideration for the warrant holders to exercise their November 2018 Warrants. The 2019 Warrants will expire on the fifth anniversary of the initial exercise date and have an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The 2019 Warrants were valued using a Black-Scholes valuation model and resulted in a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million non-cash charge in the Company&#8217;s statement of operations in 2019.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 22, 2019, the Company entered into the 2019 R&amp;D Agreement with MD Anderson. In connection with the execution of the 2019 R&amp;D Agreement, the Company issued the MD Anderson Warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,333,333</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. The MD Anderson Warrant has an initial exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and grant date fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The MD Anderson Warrant expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2026 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and vests upon the occurrence of certain clinical milestones. The Company will recognize expense on the MD Anderson Warrant in the same manner as if the Company paid cash for services to be rendered. For the three and nine months ended September 30, 2022 and September 30, 2021, the Company did not recognize any expense related to the MD Anderson Warrant as the clinical milestones had not been achieved.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. Refer to Note 4 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In connection with the Loan and Security Agreement, the Company issued SVB warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">432,844</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of common stock with an exercise</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">price </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$2.22</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The warrants have a</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ten-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> life and were fully vested upon issuance. The fair value of the warrants was estimated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million using a Black-Scholes model with the following assumptions: expected volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.31</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, expected life of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends. On December 28, 2021, the Company entered into the Amendment, as described in Note 4 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in connection with which, the original warrants issued to SVB were amended and restated. As amended and restated, the SVB Warrants are for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">649,615</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, in the aggregate, at an exercise price per share of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$1.16</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The SVB Warrants expire on August 6, 2031 and were fully vested upon issuance. Using a Black-Scholes model with an expected volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, expected life of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends, the Company recorded a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million increase in the fair value of the SVB Warrants due to the modification of the SVB Warrants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed whether the SVB Warrants require accounting as derivatives. The Company determined that the SVB Warrants were (1) indexed to the Company&#8217;s own stock and (2) classified in stockholders&#8217; equity in accordance with FASB Accounting Standards Codification (&#8220;ASC&#8221;) Topic 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As such, the Company has concluded the SVB Warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#8217; equity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_WarrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to the warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_WarrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_WarrantsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_WarrantsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435937187136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Joint Venture<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Joint Venture</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">12.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Joint Venture</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 18, 2018, the Company entered into a Framework Agreement with TriArm whereby the parties agreed to launch Eden BioCell, to lead clinical development and commercialization of certain </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-generated CAR-T therapies as set forth in a separate license agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 3, 2019, Eden BioCell was incorporated in Hong Kong as a private company. Eden BioCell, the Company and TriArm entered into a Share Subscription Agreement on January 23, 2019, where the Company and TriArm agreed to contribute certain intellectual property, services and cash (only with respect to TriArm) to Eden BioCell to subscribe for a certain number of newly issued ordinary shares in the share capital of Eden BioCell.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The closing of the transaction occurred on July 5, 2019. The Framework Agreement and Share Subscription Agreements were each respectively amended to be effective as of this date. Upon consummation of the joint venture, Eden BioCell and the Company also entered into a license agreement, pursuant to which the Company licensed the rights to Eden BioCell for third generation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-generated CAR-T therapies targeting the CD19 antigen for the territory of China (including Macau and Hong Kong), Taiwan and Korea. TriArm and the Company each received a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% equity interest in the joint venture in exchange for their contributions to Eden BioCell.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that Eden BioCell was considered a variable interest entity, or VIE, and concluded that it is not the primary beneficiary of the VIE as it did not have the power to direct the activities of the VIE. As a result, the Company accounts for the equity interest in Eden BioCell under the equity method of accounting as it has the ability to exercise significant influence.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, Eden BioCell began treating patients in a clinical trial with the Company&#8217;s investigational CD19 RPM CAR-T cell therapy, under the IND cleared by the Taiwan FDA in December 2020. In the first half of 2021, two patients were treated in this trial. The lead investigator at National Taiwan University in Taipei, has reported no serious adverse safety events in either of these patients. Laboratory results continue to support, as previously published, that non-viral </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gene transfer is effective in genetically modifying autologous T-cells. Patients were infused two days after gene transfer, thus shortening the turnaround time and demonstrating an advantage over viral methods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on laboratory data from the first two patients generated between March and May 2021, the TriArm/Eden team concluded, in concert with the investigator and the Company, that further process development work is required.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2021, TriArm and the Company mutually agreed to dissolve the joint venture.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three and nine months ended September 30, 2022 and September 30, 2021, Eden BioCell incurred a net loss. The Company continues to have no commitment to fund its operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435934646640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">13.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent Events</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has evaluated subsequent events from the balance sheet date through the date on which these financial statements were issued. The Company did not have any material subsequent events that impacted its financial statements or disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435937271728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures required by generally accepted accounting principles in the United States, or GAAP, have been condensed or omitted pursuant to such rules and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is management&#8217;s opinion that the accompanying unaudited interim financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair presentation of the financial position of the Company and its results of operations and cash flows for the periods presented. The unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2021, included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on March 30, 2022, or the Annual Report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results disclosed in the statements of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full fiscal year 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">statements </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435937296032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying values of the Company's debt obligation were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.682%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.092%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.998000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loan and Security Agreement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,461</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,209</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized discount on Loan and Security Agreement</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">793</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,091</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,668</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,118</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435937289936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of September 30, 2022 and December 31, 2021 are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.66%;"/>
        <td style="width:0.992%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.277000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.992%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.288%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.113%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.058%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.113%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.504999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of<br/>September 30,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,807</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,807</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.388%;"/>
        <td style="width:0.965%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.965%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.274%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.076%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.905%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.076%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.353%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of<br/>December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,222</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,222</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435934633120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such potentially dilutive shares of common stock consisted of the following as of September 30, 2022 and 2021, respectively:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.904%;"/>
        <td style="width:1.642%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.202%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.642%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.61%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,623,215</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,072,894</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inducement stock options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">940,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,510,655</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,922,342</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,705,571</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,485,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,386,620</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435935132304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Stock-Based Compensation Expense on All Employee and Non-Employee Awards</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.367%;"/>
        <td style="width:3.316%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.553%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.665%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.641%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.665%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.789%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.665%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.338999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Three Months Ended September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Nine Months Ended September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">673</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,115</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">663</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,836</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,978</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,742</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">808</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,651</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,857</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three and nine months ended September 30, 2022 and 2021, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.661%;"/>
        <td style="width:1.336%;"/>
        <td style="width:15.999%;"/>
        <td style="width:1.336%;"/>
        <td style="width:15.999%;"/>
        <td style="width:1.336%;"/>
        <td style="width:15.999%;"/>
        <td style="width:1.336%;"/>
        <td style="width:15.999%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Three Months Ended September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Nine Months Ended September 30,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.94</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.62</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.89</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.96</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.63</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.62</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected life in years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.23</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.27</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.25</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82.43</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85.89</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.84</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74.49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85.89</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74.80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity under Stock Option Plan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock option activity under the Company&#8217;s stock option plans for the nine months ended September 30, 2022 is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.903%;"/>
        <td style="width:0.993%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.799%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.215%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.504%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.993%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.828999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.215%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.551%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted- Average Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted- Average Contractual Term (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,665,869</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,667,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.08</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,683,904</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.40</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, September 30, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,623,215</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.85</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.27</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,572</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable, September 30, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,211,631</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.69</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.01</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">510</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,410,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.85</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.53</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options available for future grant, September 30, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,245,494</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Summary of Unvested Restricted Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the status of unvested restricted stock for the nine months ended September 30, 2022 is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.459%;"/>
        <td style="width:1.154%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.669%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.115%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,198,580</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.10</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">280,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.82</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">305,679</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.28</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,901</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested, September 30, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">940,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.41</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At September 30, 2022, total unrecognized compensation costs related to unvested restricted stock outstanding amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The cost is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.83</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435934864752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 37,807<span></span>
</td>
<td class="nump">$ 76,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash related to the Company's debt agreement</a></td>
<td class="nump">13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 871,468<span></span>
</td>
<td class="nump">$ 842,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">420,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">216,182,042<span></span>
</td>
<td class="nump">216,127,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">216,182,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">33,545,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435936016800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financings - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 12, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-Based Payment Arrangement, Tranche One [Member] | Silicon Valley Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Initial term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-Based Payment Arrangement, Tranche Two [Member] | Silicon Valley Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Additonal tranche facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcrt_EquityDistributionAgreementMember', window );">Equity Distribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_StockOfferedDuringPeriodShares', window );">Sale of stock during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock', window );">Percentage Of Commission On Gross Proceeds From Sale Of Common Stock</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on gross proceeds from sale of common stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_StockOfferedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock offered during period shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_StockOfferedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tcrt_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tcrt_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcrt_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcrt_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435930887200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 22,668<span></span>
</td>
<td class="nump">$ 24,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of long-term debt</a></td>
<td class="num">(22,668)<span></span>
</td>
<td class="num">(7,868)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">23,461<span></span>
</td>
<td class="nump">25,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount on Term Loan Agreement</a></td>
<td class="num">$ (793)<span></span>
</td>
<td class="num">$ (1,091)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435932408528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Line of credit facility, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_InterestExpenseAmortizedDate', window );">Interest expense amortized date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash related to the Company's debt agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=tcrt_TermLoanMember', window );">Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment', window );">Percentage of original principal due as a final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Line of credit facility, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Cash proceeds from sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Warrants issued</a></td>
<td class="nump">649,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_WarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">Aug.  06,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms', window );">Description of payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company will also owe SVB 5.75% of the original principal amounts borrowed as a final payment (the "Final Payment"). The Company is permitted to make up to two prepayments, subject to a prepayment premium of the amount being prepaid, ranging from 1.00% to 2.00%, of the SVB Facility, each such prepayment to be at least $5.0 million plus all accrued and unpaid interest on the portion being prepaid.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt instrument description of variable rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The SVB Facility bears interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) 7.75% and (b) the current published U.S. prime rate, plus a margin of 4.5%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DebtInstrumentPrepaymentPremium', window );">Prepayment premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AdditionalNumberOfWarrantsIssued', window );">Additional number warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Debt instrument, initial maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member] | Debt Instrument Redemption Period One | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfPrepaymentsPremium', window );">Percentage of prepayments premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member] | Debt Instrument Redemption Period One | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfPrepaymentsPremium', window );">Percentage of prepayments premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member] | Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_FullyDrawnAmount', window );">Fully drawn amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash related to the Company's debt agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member] | Term Loan [Member] | Tenth Scheduled Payment Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from collateral account</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member] | Term Loan [Member] | Eighth Scheduled Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from collateral account</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member] | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Issuance costs</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AdditionalNumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AdditionalNumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DebtInstrumentPrepaymentPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DebtInstrumentPrepaymentPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_FullyDrawnAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fully drawn amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_FullyDrawnAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_InterestExpenseAmortizedDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense amortized date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_InterestExpenseAmortizedDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of original principal due as a final payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PercentageOfPrepaymentsPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of prepayments premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PercentageOfPrepaymentsPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_WarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Expiration Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_WarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reference rate used for variable rate of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeStart1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeStart1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of the required periodic payments of interest, principal, or both, and the amount, if set, or a description of a formula upon which payment is based.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=tcrt_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=tcrt_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=tcrt_TenthScheduledPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=tcrt_TenthScheduledPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=tcrt_EightScheduledPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=tcrt_EightScheduledPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435930877088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 36,807<span></span>
</td>
<td class="nump">$ 75,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 36,807<span></span>
</td>
<td class="nump">$ 75,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435934635344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member', window );">Fair Value, Inputs, Level 2, and Level 3 Member</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435934777008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">34,485,557<span></span>
</td>
<td class="nump">35,386,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">22,922,342<span></span>
</td>
<td class="nump">22,705,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">10,623,215<span></span>
</td>
<td class="nump">11,072,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tcrt_InducementStockOptionsMember', window );">Inducement Stock Options | Two Thousand Twelve Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">97,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">940,000<span></span>
</td>
<td class="nump">1,510,655<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tcrt_InducementStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tcrt_InducementStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tcrt_TwoThousandTwelveStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tcrt_TwoThousandTwelveStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435932273536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 19, 2021</div></th>
<th class="th"><div>Feb. 04, 2021</div></th>
<th class="th"><div>Dec. 18, 2018</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_VinetiIncMember', window );">Vineti Inc [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees', window );">Related Party Transaction Expenses From Transactions With Related Party Advisory Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_EdenBiocellMember', window );">Eden Biocell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Payments to Fund Long-term Loans to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AdditionalLoansCommitted', window );">Additional Loans Committed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_WatermillAndRobertWPostmaMember', window );">WatermillAndRobertWPostmaMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PocketExpenses', window );">Pocket expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Fees and Expenses, Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_RelatedPartyTransactionReimbursedAmount', window );">Related party transaction, reimbursed amount</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AdditionalLoansCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional loans committed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AdditionalLoansCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PocketExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pocket expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PocketExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction expenses from transactions with related party advisory fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_RelatedPartyTransactionReimbursedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction Reimbursed Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_RelatedPartyTransactionReimbursedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToFundLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_VinetiIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_VinetiIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_EdenBiocellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_EdenBiocellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_WatermillAndRobertWPostmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_WatermillAndRobertWPostmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435925644656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 28, 2019</div></th>
<th class="th"><div>Aug. 17, 2015</div></th>
<th class="th"><div>Jan. 13, 2015</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 22, 2019</div></th>
<th class="th"><div>Feb. 19, 2019</div></th>
<th class="th"><div>Oct. 05, 2018</div></th>
<th class="th"><div>Aug. 24, 2004</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,893,000<span></span>
</td>
<td class="nump">$ 14,521,000<span></span>
</td>
<td class="nump">$ 19,411,000<span></span>
</td>
<td class="nump">$ 41,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,911,000<span></span>
</td>
<td class="nump">398,000<span></span>
</td>
<td class="nump">2,911,000<span></span>
</td>
<td class="nump">398,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ClassOfWarrantOrRightAxisAxis=tcrt_MdAndersonWarrantMember', window );">MD Anderson Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonAgreementAndWorldwideLicenseMember', window );">MD Anderson Agreement and Worldwide License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_LicenseAgreementCommencingDate', window );">License agreement commencing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 13,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember', window );">MD Anderson License and the Research and Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregateAmountPotentiallyReimburseableAmount', window );">Reimbursement of historical costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_QuarterlyExpenseIncurred', window );">Quarterly expense incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregatePotentialBenchmarkPayments', window );">Aggregate potential benchmark payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AccrualsPriorToFirstMarketingApproval', window );">Payments due prior to the first marketing approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_CRADAAgreementMember', window );">CRADA Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_QuarterlyExpenseIncurred', window );">Quarterly expense incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ContributionPayableOnPerAnnumBasis', window );">Contribution payable on per annum basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ObligationsDueUnderContract', window );">Obligations due under contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tcrt_CARProductsMember', window );">CAR Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MaximumRoyaltyAmount', window );">Maximum Royalty Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember', window );">The University of Texas MD Anderson Cancer Center and The Texas A &amp; M University System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MilestonePaymentsMaximumAmount', window );">Milestone maximum payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PaymentUnderLicenseAgreement', window );">Payment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MilestonePayment', window );">One time milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember', window );">The University of Texas MD Anderson Cancer Center and The Texas A &amp; M University System | Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PaymentUnderLicenseAgreement', window );">Payment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember', window );">License Agreement with the National Cancer Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_LicenseExpense', window );">License Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember', window );">License Agreement with the National Cancer Institute [Member] | One Time Benchmark Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_InitialBenchmarkPaymentDue', window );">First benchmark payment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember', window );">Ziop License Agreement With The National Cancer Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MinimumRoyaltiesAmountPayable', window );">Minimum royalties amount payable</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_RoyaltiesAmountPayableThereafter', window );">Royalties amount payable thereafter</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregateMinimumAnnualRoyaltiesPaid', window );">Aggregate minimum annual royalties paid</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DescriptionOfFirstBenchmarkPayable', window );">Description Of First Benchmark Payable</a></td>
<td class="text">The first benchmark payment of $0.1 million was due upon the initiation of the Company's first sponsored Phase 1 clinical trial of a licensed product or licensed process in the field of use licensed under the Patent License. The Company paid the first benchmark payment during the nine months ended September 30, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones', window );">Description Of option To terminate Agreement</a></td>
<td class="text">The NCI may terminate or modify the Patent License in the event of a material breach, including if the Company does not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTerminationNoticePeriod', window );">Agreement termination, notice period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember', window );">Ziop License Agreement With The National Cancer Institute [Member] | Performance Based Payments Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregateBenchmarkPaymentsPayable', window );">Aggregate Benchmark Payments Payable</a></td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember', window );">Ziop License Agreement With The National Cancer Institute [Member] | One Time Benchmark Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PotentialBenchmarkPaymentsPayable', window );">Potential Benchmark Payments Payable</a></td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember', window );">Ziop License Agreement With The National Cancer Institute [Member] | Post Marketing Approval [Member] | Performance Based Payments Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregateBenchmarkPaymentsPayable', window );">Aggregate Benchmark Payments Payable</a></td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember', window );">Ziop License Agreement With The National Cancer Institute [Member] | licensed products [Member] | One Time Benchmark Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable', window );">Maximum Sales Revenue On Which Benchmark Payments Payable</a></td>
<td class="nump">1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable', window );">Minimum sales revenue on which benchmark payments payable</a></td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember', window );">Collaboration Agreement With Solasia Pharma KK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember', window );">Collaboration Agreement With Solasia Pharma KK [Member] | Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember', window );">Intrexon Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AnnualLicenseFees', window );">Annual License Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MaximumAmountOfAdditionalMilestonesPayable', window );">Expected additional milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms', window );">Payment for historical costs of the licensed programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember', window );">Intrexon Corporation | T-cell receptor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MaximumAmountOfRoyaltyPayable', window );">Maximum royalty amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty', window );">Portion of income payable to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | MD Anderson License and the Research and Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | MD Anderson License and the Research and Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AccrualsPriorToFirstMarketingApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments due prior to the first marketing approval for TCR products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AccrualsPriorToFirstMarketingApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AggregateAmountPotentiallyReimburseableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Amount Potentially Reimburseable Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AggregateAmountPotentiallyReimburseableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AggregateBenchmarkPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Aggregate Benchmark Payments Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AggregateBenchmarkPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AggregateMinimumAnnualRoyaltiesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate minimum annual royalties paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AggregateMinimumAnnualRoyaltiesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AggregatePotentialBenchmarkPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential benchmark payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AggregatePotentialBenchmarkPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AnnualLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual License Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AnnualLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ContributionPayableOnPerAnnumBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contribution payable on per annum basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ContributionPayableOnPerAnnumBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DescriptionOfFirstBenchmarkPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Description Of First Benchmark Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DescriptionOfFirstBenchmarkPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_InitialBenchmarkPaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The first benchmark payment due upon the initiation of the Company's first sponsored phase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_InitialBenchmarkPaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_LicenseAgreementCommencingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement commencing date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_LicenseAgreementCommencingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_LicenseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to License payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_LicenseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MaximumAmountOfAdditionalMilestonesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of additional milestones payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MaximumAmountOfAdditionalMilestonesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MaximumAmountOfRoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of royalty payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MaximumAmountOfRoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MaximumRoyaltyAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of royalty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MaximumRoyaltyAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Sales Revenue On Which Benchmark Payments Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MilestonePaymentsMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments maximum amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MilestonePaymentsMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MinimumRoyaltiesAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Minimum Royalties Amount Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MinimumRoyaltiesAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum sales revenue on which benchmark payments payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ObligationsDueUnderContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations due under contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ObligationsDueUnderContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for historical costs of the licensed programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PaymentUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment under license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PaymentUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of sub licensing income, attributable to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PotentialBenchmarkPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Potential Benchmark Payments Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PotentialBenchmarkPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_QuarterlyExpenseIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Quarterly expense incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_QuarterlyExpenseIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_RoyaltiesAmountPayableThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties amount payable thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_RoyaltiesAmountPayableThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ClassOfWarrantOrRightAxisAxis=tcrt_MdAndersonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ClassOfWarrantOrRightAxisAxis=tcrt_MdAndersonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonAgreementAndWorldwideLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonAgreementAndWorldwideLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_CRADAAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_CRADAAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tcrt_CARProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tcrt_CARProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PaymentTypeAxis=tcrt_OneTimeBenchmarkPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PaymentTypeAxis=tcrt_OneTimeBenchmarkPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PaymentTypeAxis=tcrt_PerformanceBasedPaymentsMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PaymentTypeAxis=tcrt_PerformanceBasedPaymentsMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DueDateAxis=tcrt_PostMarketingApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DueDateAxis=tcrt_PostMarketingApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tcrt_LicensedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tcrt_LicensedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tcrt_TcellReceptorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tcrt_TcellReceptorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435936127280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">$ 2,247<span></span>
</td>
<td class="nump">$ 2,247<span></span>
</td>
<td class="nump">$ 4,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_GainLossOnModificationOfLease', window );">Gain (Loss) On Modification Of Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SubleaseArea', window );">SubleaseArea | ft&#178;</a></td>
<td class="nump">4,772<span></span>
</td>
<td class="nump">4,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The term of the sub-sublease is from July 1, 2022 to June 30, 2025 and provides the sub-subtenant with an option to extend through to July 31, 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=tcrt_OtherIncomeExpenseMember', window );">Other Income Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseIncome', window );">Lease income</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=tcrt_HoustonTexasMember', window );">Houston, TX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_OperatingLeaseArea', window );">Operating Lease Area | ft&#178;</a></td>
<td class="nump">3,228<span></span>
</td>
<td class="nump">3,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported | Houston, TX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_OperatingLeaseArea', window );">Operating Lease Area | ft&#178;</a></td>
<td class="nump">18,111<span></span>
</td>
<td class="nump">18,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_GainLossOnModificationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on modification of lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_GainLossOnModificationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_OperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease area.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_OperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_SubleaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease area.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_SubleaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=tcrt_OtherIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=tcrt_OtherIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=tcrt_HoustonTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=tcrt_HoustonTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435931324960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense Included in Statement of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 808<span></span>
</td>
<td class="nump">$ 2,371<span></span>
</td>
<td class="nump">$ 2,651<span></span>
</td>
<td class="nump">$ 9,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">535<span></span>
</td>
<td class="nump">673<span></span>
</td>
<td class="nump">2,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 663<span></span>
</td>
<td class="nump">$ 1,836<span></span>
</td>
<td class="nump">$ 1,978<span></span>
</td>
<td class="nump">$ 7,742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435933075248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options, granted</a></td>
<td class="nump">1,275,000<span></span>
</td>
<td class="nump">2,755,000<span></span>
</td>
<td class="nump">4,667,500<span></span>
</td>
<td class="nump">7,150,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="nump">$ 1.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcrt_NonVestedStockMember', window );">Unvested Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs related to unvested restricted stock outstanding</a></td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcrt_NonVestedRestrictedStockMember', window );">Unvested Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs related to unvested restricted stock outstanding</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcrt_NonVestedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcrt_NonVestedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcrt_NonVestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcrt_NonVestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435936022928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">2.94%<span></span>
</td>
<td class="nump">0.89%<span></span>
</td>
<td class="nump">1.63%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">3.62%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">3.62%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">82.43%<span></span>
</td>
<td class="nump">72.53%<span></span>
</td>
<td class="nump">74.49%<span></span>
</td>
<td class="nump">72.53%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">85.89%<span></span>
</td>
<td class="nump">72.84%<span></span>
</td>
<td class="nump">85.89%<span></span>
</td>
<td class="nump">74.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">6 years 2 months 23 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435924018800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity Under Stock Option Plan (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,665,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">1,275,000<span></span>
</td>
<td class="nump">2,755,000<span></span>
</td>
<td class="nump">4,667,500<span></span>
</td>
<td class="nump">7,150,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,683,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance</a></td>
<td class="nump">10,623,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,623,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,665,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, at end of period</a></td>
<td class="nump">3,211,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,211,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,410,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grant</a></td>
<td class="nump">15,245,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,245,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance</a></td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, at end of period</a></td>
<td class="nump">$ 2.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, at end of period</a></td>
<td class="nump">$ 3,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, at end of period</a></td>
<td class="nump">$ 510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435936020832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Non-Vested Restricted Stock (Details) - Non Vested Restricted Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance | shares</a></td>
<td class="nump">1,198,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">280,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(305,679)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled | shares</a></td>
<td class="num">(232,901)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance | shares</a></td>
<td class="nump">940,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance | $ / shares</a></td>
<td class="nump">$ 2.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">0.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">2.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled | $ / shares</a></td>
<td class="nump">3.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance | $ / shares</a></td>
<td class="nump">$ 1.41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcrt_NonVestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcrt_NonVestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435928376528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
<th class="th"><div>Oct. 22, 2019</div></th>
<th class="th"><div>Sep. 12, 2019</div></th>
<th class="th"><div>Nov. 11, 2018</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Fair Value Assumptions Expected volatility Rate Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.89%<span></span>
</td>
<td class="nump">72.84%<span></span>
</td>
<td class="nump">85.89%<span></span>
</td>
<td class="nump">74.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Fair Value Assumptions Risk Free Interest Rate Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.62%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">3.62%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_MdAndersonWarrantMember', window );">MD Anderson Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities into which the class of warrant converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_FairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_SvbWarrantsMember', window );">SVB Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCallOrExerciseFeatures', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants fully vested upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_BlackScholesModelMember', window );">Black-Scholes Model [Member] | Silicon Valley Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair Value Assumptions Expected Term1</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCallOrExerciseFeatures', window );">Exercise price</a></td>
<td class="text">$1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="nump">649,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_BlackScholesModelMember', window );">Black-Scholes Model [Member] | SVB Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_FairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair Value Assumptions Expected Term1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities into which the class of warrant converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,803,031<span></span>
</td>
<td class="nump">18,939,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_FairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Fair Value Assumptions Expected volatility Rate Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Fair Value Assumptions Risk Free Interest Rate Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair Value Assumptions Expected Term1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PlacementAgentFeesAndOtherRelatedExpenses', window );">Placement agent fees and other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | New Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities into which the class of warrant converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,803,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_NonOperatingIncomeExpenseInducementOfWarrants', window );">Non-cash inducement warrant expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_NonOperatingIncomeExpenseInducementOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Operating Income Expense Inducement Of Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_NonOperatingIncomeExpenseInducementOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PlacementAgentFeesAndOtherRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Placement agent fees and other related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PlacementAgentFeesAndOtherRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCallOrExerciseFeatures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describe the call and/or exercise rights, prices and dates of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCallOrExerciseFeatures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_MdAndersonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcrt_MdAndersonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_SvbWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcrt_SvbWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_BlackScholesModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_BlackScholesModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcrt_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140435934956128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Joint Venture - Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Jul. 05, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=tcrt_ZiopharmMember', window );">Ziopharm [Member] | Eden Bio Cell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest in affilated entity</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=tcrt_ZiopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=tcrt_ZiopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=tcrt_EdenBioCellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=tcrt_EdenBioCellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>tcrt-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:tcrt="http://alaunos.com/20220930"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tcrt-20220930.xsd" xlink:type="simple"/>
    <context id="C_93030e80-98ca-4f83-b767-ef2910a9d17a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:NewWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-12</instant>
        </period>
    </context>
    <context id="C_a649b50f-8367-4a1c-9108-4b85ebc15317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_2bca986a-5228-45f5-a440-a7d273a6f156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="C_e4a8cbd7-35ae-461e-b1af-edf4446dbfd9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:WatermillAndRobertWPostmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-19</startDate>
            <endDate>2021-02-19</endDate>
        </period>
    </context>
    <context id="C_30990001-d5dc-4069-a5b6-498c28245fdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_afa5d5a2-bab5-4430-b57c-13817635e7f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7ec0e0fa-abc4-4590-ac2a-da156b639f99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_c96f4f1f-d9a3-4eec-bc21-3fbaa7eeea85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_5f43bb33-c6dd-42f3-b81e-2d16c0d279f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_2fba5838-cd3f-40d2-8f7f-5f1b833834f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_4466f87e-f227-46f8-9092-8a32178d41c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_808c9e76-ba2c-4353-bc47-63c7e812ba3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tcrt:OtherIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_3996230c-eb63-4bd8-8c4e-4eda38f443db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_5478d947-5881-4b9c-a88f-5e7d9771c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_82a2d9da-2739-4328-a38b-dd5018876817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_a553ea37-cf6b-45d6-ab63-a4294c165977">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_c3dfd279-a1be-4e60-9b23-62f589a95c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="C_7d15c91c-08c2-4355-817a-d947ee9b15f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_acc8d98b-3c82-4d2e-af71-6452e557354e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_9aba2ab5-4f85-4c2d-b196-c03836210ab0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_80a697e6-5126-46ff-850f-6f438cf69024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_eab945c1-a1b6-41ab-91d4-85e2fc2020c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:EdenBiocellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-18</startDate>
            <endDate>2018-12-18</endDate>
        </period>
    </context>
    <context id="C_3da54949-f086-4986-984c-e1d5c3f603ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_66586099-2ff8-40bd-a3af-a61d770bbd1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_f3be7956-1a1a-486d-a035-b032462f33aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_4d9975fc-c543-4fdc-bc21-cb9c1de3ac67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_17466d85-cda1-4e4a-b4fb-9d479415d434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_71ac7c9c-ed62-4708-9f1f-3794c7da2b64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_1a1e5081-81c7-406f-aac2-68d4a56e7396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:TcellReceptorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="C_0af67efe-5cc6-4bd3-95da-2269b35a5117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-11</startDate>
            <endDate>2018-11-11</endDate>
        </period>
    </context>
    <context id="C_fee32fa6-5000-4631-b097-9b1fea30a290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:CARProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="C_29c774b1-4d47-4209-8c47-fcd96e1f3895">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_e42a7258-b17a-4571-a2b7-a79071424b63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7b60904b-b0fd-4742-a7f1-5ed95c47a6af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_0aa8acc8-3dfc-4c50-ae31-5fef3f1e4dce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:NewWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-12</startDate>
            <endDate>2019-09-12</endDate>
        </period>
    </context>
    <context id="C_e5b94b60-824a-4f1d-94d2-dc6c1840957d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_e5a16ee8-f8ba-419a-ad14-c822ec3582a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_7c362f59-d6f4-4a7a-a1c8-b74ebbed16b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:ClassOfWarrantOrRightAxisAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-22</instant>
        </period>
    </context>
    <context id="C_d7ec9466-e3f0-4f95-aecc-fbe0889180ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_f915cb95-5e51-4689-a7fd-3b9969b8b324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_18e705d4-75c3-4f8b-9dd7-e32c9e97b572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_4ecb5cc8-f37c-4b95-98a1-b053f202010f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_db352027-c319-4fed-873e-eafcb7007f91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-28</instant>
        </period>
    </context>
    <context id="C_89811c97-bb62-4965-936e-16929f7b6833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-11</instant>
        </period>
    </context>
    <context id="C_84042aae-9850-43a9-a32f-e85af10ed288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_d4b5db92-6383-4c43-b62a-d3bc3bc3fc9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_b761c5a5-7e64-42b4-b347-bff79c80c526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tcrt:OtherIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_18443f2c-6ffb-47e1-8f0b-7587c06dbd8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2a8ceb76-7648-4132-8aa2-02c65b7eb518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_9a1f34d1-4746-4f1f-bc5a-c6ce280ea3a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_ba03628a-d489-4082-b85c-544300569f10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_f1c90eed-e7e4-4ee2-b023-7eca1c8b450c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-12</startDate>
            <endDate>2019-09-12</endDate>
        </period>
    </context>
    <context id="C_11eda09f-c5af-4a19-be29-445f8325d410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_26c0546e-3ae0-436e-bf65-3135619b6131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_d882f9ce-a213-4796-9543-c22ad26eb67a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-28</startDate>
            <endDate>2021-12-28</endDate>
        </period>
    </context>
    <context id="C_7a3c172f-d546-462c-a72b-21a8a3e086bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_429d7895-53ce-476f-b62a-71d570bab848">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f90f3da9-4b30-43f4-8f71-7dedd967f4ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_c5ce15ce-9e47-4fdd-9332-0e26a6a95756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_de243d37-ed59-4bdb-a446-2678a29190e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_72bda269-9480-4b72-b4ce-a8fa1e5d2d6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_84332a9b-1768-4928-b9c2-d0cfdbef460f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_8607731b-da93-4afa-873b-c41bd854fae0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_7384efec-4e47-4d02-8bce-8365f7e0295a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_2dfd9017-3654-4240-b560-4fa92df974b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_2de808d8-5984-43d6-9ce6-49b4e1114951">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-22</instant>
        </period>
    </context>
    <context id="C_9975e9e7-b6d2-44f8-8f9b-4428ca4a25ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_87c24bba-d603-4bbb-92e5-692a66baf6fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6a801914-4bd9-4d79-be9c-781ec8a7881d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_00a63ae4-63b6-4ac6-941f-4be4fd9e3e98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_11392846-50b9-4407-b98d-7bf6aba70e2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="C_eddf6b5e-242d-4045-be96-1b91012cb2f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-28</startDate>
            <endDate>2021-12-28</endDate>
        </period>
    </context>
    <context id="C_23567fca-d299-4618-8b07-c800715f57a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:AgreementTypeAxis">tcrt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-11</startDate>
            <endDate>2018-11-11</endDate>
        </period>
    </context>
    <context id="C_56ad9b91-5908-46ac-b885-5f4b458e6dd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0ecd0af9-f624-419c-bc04-78328b1a47e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_4cbcc52b-1414-4969-a546-6beaa8636012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_23eae7ee-dd71-428c-93da-1b90bf020452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:VinetiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_516cb031-f3e7-4387-8ebb-eb61b7eb9ea0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_dfc4b9a9-6363-4eb4-84cc-324cdd9e5c5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-19</instant>
        </period>
    </context>
    <context id="C_2619a848-009e-46c2-a1f5-04328671628d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-28</instant>
        </period>
    </context>
    <context id="C_79174d62-d06a-4299-a8be-9fb31ca9fadb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-12</instant>
        </period>
    </context>
    <context id="C_efc00410-6d5c-495a-a72b-6d6351214b08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0d490f67-76f7-406e-84c4-387e0d9d6db5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_243ddad6-e77f-4cec-bf28-7f9b590baafd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-28</startDate>
            <endDate>2019-05-28</endDate>
        </period>
    </context>
    <context id="C_f647c291-0b62-43fd-84a5-54f70a4da70b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_c328dc7e-2261-4512-872c-da4fb630f2c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_41ac8d4f-13d9-476b-a18c-5b3fef9ae897">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0a8415e0-ec1d-4ed0-a8c1-83dd21690b46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_1e4f7846-958f-4ab8-a4e6-79d28f2b664d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-22</startDate>
            <endDate>2019-10-22</endDate>
        </period>
    </context>
    <context id="C_9dc3ba53-2c20-4736-8bee-cb0366b44f23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tcrt:InducementStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_95ff3701-048e-464c-829f-6c697a0744f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tcrt:InducementStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_1e52479f-7e44-4216-b266-a0446569c844">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:WatermillAndRobertWPostmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-04</startDate>
            <endDate>2021-02-04</endDate>
        </period>
    </context>
    <context id="C_49c4b845-edf1-48ac-b363-86d2eb87b129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_e9a0185b-e5d0-4a1e-9377-e759cf76ceb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_a1c325e4-fe22-4b5f-8e61-12cd0023447b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_5278975e-6f79-4550-9b7e-1506a2f6d459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_464be36f-cadb-4d42-b6ec-60d3e858ae0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_c370e803-a7b8-487c-bccf-7d82d4dbd10d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_bd378eef-0abd-4f06-8c55-ed8f64bbee7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">tcrt:ZiopharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">tcrt:EdenBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-05</instant>
        </period>
    </context>
    <context id="C_e6c3e2ec-e88b-4a8e-a9a1-8a82c2d398ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2004-08-24</instant>
        </period>
    </context>
    <context id="C_dc8e2d26-10b6-486b-8a26-6ca99f89115b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_e81d9a09-eee0-481c-8976-f48c00938da7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_8d40e9e7-c9cf-4667-ba64-23d8853c4fdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_c14220fc-6b7b-43f8-af8e-400952313273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:DueDateAxis">tcrt:PostMarketingApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:PerformanceBasedPaymentsMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-28</instant>
        </period>
    </context>
    <context id="C_90eeab4e-d329-4773-9ae7-51f760c71986">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0ea0be7a-caae-4842-adc5-35fca4e7eea4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_5748e941-3c1c-4556-8329-7aeb6d259272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_ba7ea719-3efa-42ac-a0b2-dbaed33d86b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="C_baf45bdc-d90e-4313-afd6-a2ad17b87cdf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_2a85659d-9529-4877-90ee-9305d6b05bd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_c373b210-56f0-4a58-9d24-8f12d518d218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:VinetiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_89339f1e-48c2-46f1-afa9-1bd72a4dccef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:VinetiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_d56c397d-06d5-47bb-8033-e0542dd94f41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonAgreementAndWorldwideLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-13</startDate>
            <endDate>2015-01-13</endDate>
        </period>
    </context>
    <context id="C_1d421d03-41e0-4a9e-bb6e-dcc0101f73f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_35c36f71-52c6-4199-9a71-a3ae673b76aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_e1e34188-3704-4285-90a2-81f9b25a98ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_bf4cb307-d956-44e9-9223-82983a351431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_d9980554-eb5e-4c04-98a8-4a1d013e4bb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e0eb70e2-a850-4290-9f2b-2c099994757c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_28481c26-2de7-4e94-9943-6a2deb168a5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_ef34299f-cc59-4eaa-9859-4aff997142c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_05de267d-66f3-4500-b8af-4de14cc90182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7dcce1df-cf39-47fd-a123-bd1b19d85aed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_db440a89-812a-473c-bea3-ef4ccf784d27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_cf9a58e2-50b7-4e9f-b6e9-8386b05eaea6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_5eb44bc0-03fd-4514-a7c0-b540f7cb6ad2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_e3064554-7470-4ef4-931d-019f0af3c58c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_4f490ba4-b156-491d-bf6f-129ecf662eb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_c3c976de-0ee5-455d-bee2-a9edd8244900">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_9b2f5a35-750a-426b-8208-95bde28e9376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">tcrt:EightScheduledPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-28</startDate>
            <endDate>2021-12-28</endDate>
        </period>
    </context>
    <context id="C_d9252104-b0ce-41b0-bd34-3724646ef25e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_6e455d27-ae8e-4cd2-8656-5e6b3044aec4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2019-09-12</startDate>
            <endDate>2019-09-12</endDate>
        </period>
    </context>
    <context id="C_bcd49289-aef5-458e-9a35-82903fd7c003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_9b8825bb-408d-4786-bba0-1843af5bb11e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_399029cd-00f2-489c-89bd-afddf96d9013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_6c30b44b-f58e-4273-8a2f-4d08ae4922ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_d5737b6f-9713-4bf0-9447-bffb6837ae58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_d0485a7c-1400-45f5-9110-483d8d21ebfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_72dbe520-f3b4-4e1f-9462-73da4d9acb9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_682aeb79-9f3f-49f6-9a66-66cc8398ab88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_c4985865-020d-4fdb-bec6-b066804fcca8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:PerformanceBasedPaymentsMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-28</instant>
        </period>
    </context>
    <context id="C_5c32ad95-bd53-4f35-853e-22b717e70798">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_5287bb43-2308-4e1c-a17a-766d2905368b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:VinetiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_9c77e152-785d-4e6f-99b7-b0d56fb1dc63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">tcrt:TenthScheduledPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-28</startDate>
            <endDate>2021-12-28</endDate>
        </period>
    </context>
    <context id="C_2daa022b-a09a-4371-9536-aff338b7b832">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_ce1c210f-7d8b-4de3-bdac-77591a3466bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_e0570a01-faa7-4744-91fc-66333e256702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_36e64732-f6d5-4615-89f1-3872af4ff2ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-17</startDate>
            <endDate>2015-08-17</endDate>
        </period>
    </context>
    <context id="C_7dd83c2e-6421-445b-a010-82fe8ad08521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_ba706fc5-e9e4-4f6d-9180-2a783ebf0530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b6a2cd0a-f5d0-4a9f-af29-87bb8204f6f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_168c2abe-f9d8-4189-b7ee-13828dea54d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:EdenBiocellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-18</instant>
        </period>
    </context>
    <context id="C_0ed707b3-bea7-4926-b6bd-f4064815e868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_fcea062a-308f-4809-8835-154dace3f34b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_d7baac48-135d-4e1f-805c-4570972d3951">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-17</startDate>
            <endDate>2015-08-17</endDate>
        </period>
    </context>
    <context id="C_90c6bc67-1b17-4053-8728-b194d7b2b725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2022-11-09</instant>
        </period>
    </context>
    <context id="C_2cec0f62-e0a7-444b-9c62-04422644e817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-22</instant>
        </period>
    </context>
    <context id="C_b8f27772-b294-42ff-a235-56681aee8001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_a89460f1-fee5-4a24-9dc9-1ef04a688e53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_339531a2-8a7b-42ff-b485-df3b013ebeb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_51a11843-7d5f-4914-9b59-f8771ccffffc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_07609204-d289-4b94-b19f-777a70145f62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_1d8421da-db98-4345-93d7-f06de09f53d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_8d739f65-8890-4484-9fa8-db2c2788d308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-12</startDate>
            <endDate>2022-08-12</endDate>
        </period>
    </context>
    <context id="C_c4d2468d-d204-46a0-a52f-8c6f952adf7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-28</instant>
        </period>
    </context>
    <context id="C_4abb6de4-1411-454e-b48d-575b66944575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_5dd32c50-d442-41ca-9a9b-395b972f0c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_43bf232f-663e-498c-8a53-386a3a861e53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:LicensedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-28</startDate>
            <endDate>2019-05-28</endDate>
        </period>
    </context>
    <context id="C_5987d6f3-3485-4951-8af9-679dc649bb35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_6d7f681b-28a7-43ca-b90c-86f100ef11da">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_8bb8fe40-36d1-44f3-9dfe-c009108bcb68">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      id="F_541a6189-2782-4c24-a058-0c6f39bcf8ff"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      id="F_62f37d4f-d871-46f0-9b1f-f747f80e2282"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_9259c4f9-b69b-4b2f-a1b0-998dafd316f9">0001107421</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_414c6922-9484-41e3-94da-3c97f527a5d5">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_4429bf30-fa90-413c-864e-749d3ef038c6">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_471d5552-4ae9-4207-8302-37e192a6990f">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_bd171d35-9254-45e1-bed9-931174218030">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_8eca71a0-168d-4ba4-8adc-bd9a86097197">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_a01d15a2-304c-4ef6-b474-db5228d80811">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_06c62e7e-2e8d-45f7-8d15-8c95bb56dbcb">001-33038</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_51ed4df5-4bb9-4887-b398-ec6a13fb6f08">Alaunos Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_38c80208-8e2d-4cf8-ac5c-e1469367b6e1">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_9b6eaecb-abad-4601-a903-b9210367d4ee">84-1475642</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_0b67f143-0e1e-4826-bbe4-95070fd2c6d1">8030 El Rio Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_56494f64-71c0-419a-9eed-d34f44a4294f">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_f5804463-e19b-44a8-9f69-191a95b8003e">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_814343ab-9f6b-45b8-8923-d5e371cc5e78">77054</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_100b0d39-8883-4913-ba9b-7075aef022fa">346</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_ce165e6f-3b59-4673-a37c-b42aa07cd7f2">355-4099</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_06473b7a-acd3-4a83-ad69-fea7aea9dd36">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_b07e9cfe-8ace-4e78-af2d-37617187a3fa">TCRT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_02e74f8f-139a-482a-88ff-61cf00b49806">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_c036c237-945d-49d4-920d-559163a9eec7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_16eccd87-d2cd-4983-8238-ff3fb26dc9d5">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_7a8b07f3-7dc3-47fb-8556-d65b019cb51b">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_1f6fea9b-0444-4792-90c4-ba0522368bac">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_26b1fde3-4819-4702-8606-5f950eafe3d4">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_b83de4a8-0c56-4add-be25-2bbe66c0d360">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_90c6bc67-1b17-4053-8728-b194d7b2b725"
      decimals="INF"
      id="F_7668cf4d-a5be-402c-8268-7766b3b088e1"
      unitRef="U_shares">216182042</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_97df6927-ebd6-4a9f-a9df-7439bf6fb361"
      unitRef="U_USD">37807000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_d35b4e28-c39d-4431-b1ba-3d92ee7cd2be"
      unitRef="U_USD">76054000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_acd3db16-2978-456f-963b-ee83b280061e"
      unitRef="U_USD">13938000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_be2fa4f6-c75f-4765-8145-ea42d6db6605"
      unitRef="U_USD">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_bbeb6729-e290-47ba-935a-9c9545adb5f8"
      unitRef="U_USD">2911000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_dfbc6008-2c61-4358-a3f4-5835b7f4a2c4"
      unitRef="U_USD">1111000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_e1d12d08-94c1-412a-b057-c58269b11c3e"
      unitRef="U_USD">849000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_c59afb90-e9b7-4d08-bf55-49730566844d"
      unitRef="U_USD">1666000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_724837c8-48e2-4ce8-95e0-821e16fcfd68"
      unitRef="U_USD">55505000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_93918fc0-6eb7-4164-81cc-0bbc6de9c925"
      unitRef="U_USD">78831000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_2c059a35-d576-4943-9bbb-4ccc19745b7d"
      unitRef="U_USD">9050000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_0a7ae154-5da6-4397-88ed-f7a7f34b8452"
      unitRef="U_USD">10941000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_e5129ef6-89a2-46e9-891c-5820afac7005"
      unitRef="U_USD">2247000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_daaf7519-083b-4a60-8960-e2fc4e9f4342"
      unitRef="U_USD">4420000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_54bb4a87-89e2-46bf-a677-d36485c14d84"
      unitRef="U_USD">42000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_f51f3f78-bcbe-4992-905a-1331e5afa03c"
      unitRef="U_USD">42000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_1f7d853e-83be-4b9c-a574-cc5c74bb5b62"
      unitRef="U_USD">500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_f67a3214-3c58-40eb-afbd-96dac7cfb594"
      unitRef="U_USD">631000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_d59f003e-b032-472c-a0fd-1106fe71f0f3"
      unitRef="U_USD">67344000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_b2bbf632-090b-422a-bb6e-2f65ce729e2e"
      unitRef="U_USD">94865000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_ffefe0e0-7caf-4a2d-bb3e-3cd9201d1b12"
      unitRef="U_USD">1984000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_3dc238a8-6242-40bf-999b-0f0fe2e82eff"
      unitRef="U_USD">1368000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_c4334e6c-ab2d-44fe-8828-ca93be7f4079"
      unitRef="U_USD">22668000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_a025654d-9ce3-4af4-9c13-f9ed5cd6a94d"
      unitRef="U_USD">7868000</us-gaap:LongTermDebtCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_dc21524d-e485-4764-9e53-739f5122d934"
      unitRef="U_USD">7675000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_33ce52be-a203-4dac-b25b-f611590880b1"
      unitRef="U_USD">6076000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_82eb5a9a-d742-4bf8-9efc-cf6f69808142"
      unitRef="U_USD">542000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_f49573fe-2bdc-4476-8a69-fc58a8e707a3"
      unitRef="U_USD">729000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_3a802d7b-0d9d-497e-a972-9ef68f9f796f"
      unitRef="U_USD">32869000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_2f38b62d-6c04-4a4e-9d1c-2901f3da30d3"
      unitRef="U_USD">16041000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_72275e87-182e-4066-85b1-29721f908af7"
      unitRef="U_USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_b4dece6d-b4c5-4d14-b23c-d6a25fcb7d2a"
      unitRef="U_USD">16250000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_744f530b-9c9f-461d-a1df-292ab3dfd222"
      unitRef="U_USD">2334000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_d7da3a00-6a86-4fd2-8aef-f15dc2bcbd74"
      unitRef="U_USD">4518000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_f4f39d91-81ab-4783-9f34-4171aed983b0"
      unitRef="U_USD">28000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_d659bd1a-a121-4c94-b846-a6b99803114d"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_ed5f66c5-2dea-4f33-aa72-cd62b4f5ea03"
      unitRef="U_USD">35231000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_e0e0f1ff-cf8d-47ad-994c-cd469ec9289a"
      unitRef="U_USD">36809000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="3"
      id="F_49ffba22-bad0-4f90-9c32-8746346263c3"
      unitRef="U_USDollarShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="3"
      id="F_9169ab67-8942-451f-a9be-baf59935e413"
      unitRef="U_USDollarShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="INF"
      id="F_7f90bfc3-1a3a-4b2c-906f-c3a34f612f15"
      unitRef="U_shares">420000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="INF"
      id="F_ebfffcae-8dae-40df-b0f1-b1a48b2d0a94"
      unitRef="U_shares">216182042</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="INF"
      id="F_767abb74-696d-4112-bfc7-857e26fd6436"
      unitRef="U_shares">216182042</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="INF"
      id="F_570ed151-09b2-45e4-9e3d-a3d5b19f7c8b"
      unitRef="U_shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="INF"
      id="F_7983aaa2-fe12-4634-b89c-6147d53734ba"
      unitRef="U_shares">216127443</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="INF"
      id="F_0f23e264-cd70-4b5c-a09e-ccd91f997e8f"
      unitRef="U_shares">216127443</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_7ed00a0a-ded4-45c0-a549-5a664fe32432"
      unitRef="U_USD">216000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_be583140-ad70-4bd5-bd30-d1eb43453aa8"
      unitRef="U_USD">216000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_9479ba3c-c9e3-4a4c-81b3-2a1ffc5ff60e"
      unitRef="U_USD">903365000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_4e81bc8e-2559-4edb-a397-0206701dbbd3"
      unitRef="U_USD">900693000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_e95d8395-d4df-4c99-bc64-0cd2d91ee660"
      unitRef="U_USD">-871468000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_94f2071c-5942-4f34-8834-15aa0510a0b0"
      unitRef="U_USD">-842852000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_b1b91799-90dc-4fe3-8265-f5ac6b4603c5"
      unitRef="U_USD">32113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_69ac99ce-2539-47ba-bf72-ab1f84847a6f"
      unitRef="U_USD">58057000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_fbc50839-3f70-4016-88f9-49a3aa2dad08"
      unitRef="U_USD">67344000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_cd991104-a9f2-4961-9466-51d4270dce33"
      unitRef="U_USD">94865000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="-3"
      id="F_2f0c489c-502a-44f1-b4ce-55d7bdceb59a"
      unitRef="U_USD">2911000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="-3"
      id="F_5d4a493e-4c83-4b11-83b9-f69753ba6d7d"
      unitRef="U_USD">398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_a4f97d9f-ac46-4e85-922c-64f1b705692a"
      unitRef="U_USD">2911000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_b69fb25b-f38c-475f-8506-c5fd5d5a215c"
      unitRef="U_USD">398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="-3"
      id="F_25c9e908-bb9a-4f21-8b67-4fc43e648a61"
      unitRef="U_USD">7893000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="-3"
      id="F_c0d44ca7-a8e2-4eb6-b2a3-fa0a2166799f"
      unitRef="U_USD">14521000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_7f955f06-bfac-4479-a13f-4144ff6be45d"
      unitRef="U_USD">19411000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_716215a2-890d-4a0a-bced-6149b54a897b"
      unitRef="U_USD">41427000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="-3"
      id="F_5ce4997a-4269-45c1-85fc-262e27faca7b"
      unitRef="U_USD">3282000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="-3"
      id="F_ff9fde76-6c47-4ce1-bbc1-b6aca536150a"
      unitRef="U_USD">8173000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_b595b859-9c41-48d2-84fe-6bd719a35400"
      unitRef="U_USD">10217000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_9dd01eba-1586-49a1-a4a5-5bb2ccf3a7f9"
      unitRef="U_USD">25469000</us-gaap:GeneralAndAdministrativeExpense>
    <tcrt:GainLossOnOperatingLeaseModification
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="-3"
      id="F_172ad272-9ce0-45ad-963b-f951a4139565"
      unitRef="U_USD">0</tcrt:GainLossOnOperatingLeaseModification>
    <tcrt:GainLossOnOperatingLeaseModification
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="-3"
      id="F_08886c53-fa3c-49bc-b45f-ae0f6a2672cd"
      unitRef="U_USD">0</tcrt:GainLossOnOperatingLeaseModification>
    <tcrt:GainLossOnOperatingLeaseModification
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_a4b1792d-15a5-4aef-a449-df5f45b3e38d"
      unitRef="U_USD">133000</tcrt:GainLossOnOperatingLeaseModification>
    <tcrt:GainLossOnOperatingLeaseModification
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_6eeebfb0-842f-4964-9c4b-56f9bbf9abb0"
      unitRef="U_USD">0</tcrt:GainLossOnOperatingLeaseModification>
    <us-gaap:OperatingExpenses
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="-3"
      id="F_1b867378-9dd1-482e-a48c-38c00f9640ef"
      unitRef="U_USD">11175000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="-3"
      id="F_575f71d7-fd94-4508-90d8-587a016c26d7"
      unitRef="U_USD">22694000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_df3b2cea-1e63-4442-84d4-a95b22dd4d1e"
      unitRef="U_USD">29495000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_c7cb5cba-168d-4d45-a13e-3c99840bca5a"
      unitRef="U_USD">66896000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="-3"
      id="F_16031e3a-54be-42da-9786-0a84528b9f73"
      unitRef="U_USD">-8264000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="-3"
      id="F_a334fc99-1419-49e5-b57a-8bd49f12b221"
      unitRef="U_USD">-22296000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_e3e4ce54-b766-44c8-b779-5544cae72ec7"
      unitRef="U_USD">-26584000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_0ee86fff-9fd9-4d20-8b0b-3976eeb89e3f"
      unitRef="U_USD">-66498000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="-3"
      id="F_641e7d05-8cb6-42f5-a345-fae780cb18bf"
      unitRef="U_USD">841000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="-3"
      id="F_57953f83-6944-40b4-b3fa-175358fcd1c6"
      unitRef="U_USD">444000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_84d59aed-deeb-47e1-84be-02ebc72cb55e"
      unitRef="U_USD">2266000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_38a4f1db-d710-4139-905d-bcf57d1c3329"
      unitRef="U_USD">444000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="-3"
      id="F_546af589-fbff-4a54-830c-5eb6179fd17a"
      unitRef="U_USD">254000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="-3"
      id="F_1e239db7-ddb8-4b27-ad99-deda17705d19"
      unitRef="U_USD">7000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_b48ffb0f-56ce-408b-9612-de61c0f76666"
      unitRef="U_USD">279000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_c3e3909c-c9e7-4cba-ba25-743648ce0d4a"
      unitRef="U_USD">-15000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="-3"
      id="F_cd2f8df2-a888-4286-a235-ac15c64dd35b"
      unitRef="U_USD">-587000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="-3"
      id="F_ef8b6dc8-dcd1-491b-ac96-f89d64686bcd"
      unitRef="U_USD">-437000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_748ae110-1811-440b-bd5a-cca60a564bee"
      unitRef="U_USD">-1987000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_264d3dbd-31dd-4300-93a5-f72dfbd1f544"
      unitRef="U_USD">-459000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="-3"
      id="F_872feaaa-2fdf-47ec-9b1d-e3aa0137912e"
      unitRef="U_USD">-8851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="-3"
      id="F_aa66adad-25db-4564-9aaf-6d9466b9b951"
      unitRef="U_USD">-22733000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_af292e37-7ffa-459a-ba06-0058e658af44"
      unitRef="U_USD">-28571000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_100b27a5-45ba-4c84-86af-f1e5e4e038e5"
      unitRef="U_USD">-66957000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="2"
      id="F_601dae83-602c-4512-9ada-8b1f29868a20"
      unitRef="U_USDollarShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="2"
      id="F_002e8620-1823-4eb3-b960-5f7fcdae78a4"
      unitRef="U_USDollarShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="2"
      id="F_26c7eb5a-5090-44aa-8355-e4ecdeee6fe8"
      unitRef="U_USDollarShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="2"
      id="F_0c138377-8a23-4df5-afc6-4598a1ec26b7"
      unitRef="U_USDollarShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="2"
      id="F_4c353d5c-6267-45a6-9525-49991e5ccdcf"
      unitRef="U_USDollarShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="2"
      id="F_17037473-b4a5-4d22-81af-259eb648d18e"
      unitRef="U_USDollarShare">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="2"
      id="F_8f325bda-d220-4796-85a6-a3de2ae051c2"
      unitRef="U_USDollarShare">-0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="2"
      id="F_9e6bc9c1-0035-4885-b666-0a982f6e6c58"
      unitRef="U_USDollarShare">-0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="0"
      id="F_fdd544c6-f0b8-4573-8b5f-dc93666a72cb"
      unitRef="U_shares">215098995</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="0"
      id="F_8de78eb0-e256-40b4-9d3f-2abb1362d6e4"
      unitRef="U_shares">215098995</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="0"
      id="F_9ce3ca5f-cf9e-49da-8633-e5cab987fd38"
      unitRef="U_shares">214542465</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="0"
      id="F_d94e214c-fa93-4b71-ba1b-7530b1a989f1"
      unitRef="U_shares">214542465</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="0"
      id="F_30ecadcd-83e0-4d59-b7d8-4740762cfe82"
      unitRef="U_shares">215015377</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="0"
      id="F_0547b53a-c9e0-4443-aee6-5c875328c449"
      unitRef="U_shares">215015377</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="0"
      id="F_59f0e52a-305b-445a-a77d-8ce831dae04e"
      unitRef="U_shares">214310349</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="0"
      id="F_2fe1a0c8-b4d2-4032-805a-ab6137c50308"
      unitRef="U_shares">214310349</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_ef34299f-cc59-4eaa-9859-4aff997142c7"
      decimals="INF"
      id="F_ef13180e-9e19-419d-a577-ed39ad07ee55"
      unitRef="U_shares">216174542</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_ef34299f-cc59-4eaa-9859-4aff997142c7"
      decimals="-3"
      id="F_58637450-8ed7-4a19-9a73-c0d9c4af9b13"
      unitRef="U_USD">216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7b60904b-b0fd-4742-a7f1-5ed95c47a6af"
      decimals="-3"
      id="F_e5d83ea2-0e18-425a-96c8-35b410379c06"
      unitRef="U_USD">902536000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_baf45bdc-d90e-4313-afd6-a2ad17b87cdf"
      decimals="-3"
      id="F_669a5f41-88bb-4ac3-9d63-ae19676a3f65"
      unitRef="U_USD">-862572000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c96f4f1f-d9a3-4eec-bc21-3fbaa7eeea85"
      decimals="-3"
      id="F_bbddab63-fab8-4a4f-a695-5c19ce124e8c"
      unitRef="U_USD">40180000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_84042aae-9850-43a9-a32f-e85af10ed288"
      decimals="-3"
      id="F_639e5eea-00ef-4656-9a1a-3395d4e8db39"
      unitRef="U_USD">808000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="-3"
      id="F_ee99f9f8-1694-429c-9307-0006365cdea7"
      unitRef="U_USD">808000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_9b8825bb-408d-4786-bba0-1843af5bb11e"
      decimals="INF"
      id="F_eef1ce40-a777-485a-bbc6-0963c4dc9a6f"
      unitRef="U_shares">26250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_84042aae-9850-43a9-a32f-e85af10ed288"
      decimals="-3"
      id="F_75ac78c5-a8ca-48d0-9ca0-f2551415affa"
      unitRef="U_USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="-3"
      id="F_e4616741-3d81-463b-9659-e03123227898"
      unitRef="U_USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_9b8825bb-408d-4786-bba0-1843af5bb11e"
      decimals="INF"
      id="F_423567fa-08d3-4bee-99f3-33b5baa0afc8"
      unitRef="U_shares">18750</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_84332a9b-1768-4928-b9c2-d0cfdbef460f"
      decimals="-3"
      id="F_998d7299-5a9e-4328-bc5b-468726c405fe"
      unitRef="U_USD">45000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="-3"
      id="F_272052e2-01fe-4826-84ca-da60bc0fd5b2"
      unitRef="U_USD">45000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_84332a9b-1768-4928-b9c2-d0cfdbef460f"
      decimals="-3"
      id="F_77eff0f4-35ee-46b7-8264-37ffb8194b8f"
      unitRef="U_USD">-8851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="-3"
      id="F_a2b386ae-f713-4605-914c-9cbec2998921"
      unitRef="U_USD">-8851000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_72bda269-9480-4b72-b4ce-a8fa1e5d2d6a"
      decimals="INF"
      id="F_205e50ea-fdec-4add-b09a-60980ab627d9"
      unitRef="U_shares">216182042</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_72bda269-9480-4b72-b4ce-a8fa1e5d2d6a"
      decimals="-3"
      id="F_883a2d32-b9dd-496f-b709-fa9d2a3f5b0e"
      unitRef="U_USD">216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_28481c26-2de7-4e94-9943-6a2deb168a5e"
      decimals="-3"
      id="F_1bc1aa71-48e5-4d6d-90b9-66bc5ef3749c"
      unitRef="U_USD">903365000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5eb44bc0-03fd-4514-a7c0-b540f7cb6ad2"
      decimals="-3"
      id="F_a690394a-40e1-4dd8-880b-cf7b0d381d44"
      unitRef="U_USD">-871468000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_08f97fb1-c5d3-4661-94f5-abf61b576db9"
      unitRef="U_USD">32113000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_05de267d-66f3-4500-b8af-4de14cc90182"
      decimals="INF"
      id="F_92027dfc-1320-4a03-bf09-49b2a310a514"
      unitRef="U_shares">216127443</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_05de267d-66f3-4500-b8af-4de14cc90182"
      decimals="-3"
      id="F_a208da07-eeaa-482e-bcce-d71d0d47410d"
      unitRef="U_USD">216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e42a7258-b17a-4571-a2b7-a79071424b63"
      decimals="-3"
      id="F_3b7b6d27-357f-4810-8815-ebed9a02885e"
      unitRef="U_USD">900693000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4cbcc52b-1414-4969-a546-6beaa8636012"
      decimals="-3"
      id="F_12d5c7ff-0547-4e13-9f9c-73b3a85702db"
      unitRef="U_USD">-842852000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_bdfe9485-c690-43b6-9c97-43880b0abf72"
      unitRef="U_USD">58057000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_41ac8d4f-13d9-476b-a18c-5b3fef9ae897"
      decimals="-3"
      id="F_c48535c4-b04c-4eb3-9b11-ec971dc4c82c"
      unitRef="U_USD">2651000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_741b4f59-53d9-4f90-8d76-401b2b6b8677"
      unitRef="U_USD">2651000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_e1e34188-3704-4285-90a2-81f9b25a98ba"
      decimals="INF"
      id="F_b601c7d9-39c2-4f97-ba68-d5d72f50d304"
      unitRef="U_shares">280000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_e1e34188-3704-4285-90a2-81f9b25a98ba"
      decimals="INF"
      id="F_8858a49b-d47a-429c-b81f-e13a59efbbe0"
      unitRef="U_shares">-232901</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_e1e34188-3704-4285-90a2-81f9b25a98ba"
      decimals="INF"
      id="F_54ce7a58-fd5d-4fcc-b99e-95c5a6150f81"
      unitRef="U_shares">26250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_41ac8d4f-13d9-476b-a18c-5b3fef9ae897"
      decimals="-3"
      id="F_aefadc33-4ce5-4c7e-a94d-996dd8bb486a"
      unitRef="U_USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_2c2c1062-9b17-4400-adaf-9b4a1ff68367"
      unitRef="U_USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_e1e34188-3704-4285-90a2-81f9b25a98ba"
      decimals="INF"
      id="F_8f217acc-8bc1-4a95-a84c-26e6ddbe046c"
      unitRef="U_shares">18750</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_c370e803-a7b8-487c-bccf-7d82d4dbd10d"
      decimals="-3"
      id="F_61be8d68-7f28-4c5b-ab5f-3fc3da821281"
      unitRef="U_USD">45000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_6c4e881b-fc0d-463e-926f-4afc1670e2ce"
      unitRef="U_USD">45000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_c370e803-a7b8-487c-bccf-7d82d4dbd10d"
      decimals="-3"
      id="F_9cc13728-22ad-46de-8a14-609c416d5483"
      unitRef="U_USD">-28571000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_767839c3-5903-4bfe-aec7-5a64a85d9593"
      unitRef="U_USD">-28571000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_72bda269-9480-4b72-b4ce-a8fa1e5d2d6a"
      decimals="INF"
      id="F_86941a1d-1f22-4925-a958-d1c66bf5d2d2"
      unitRef="U_shares">216182042</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_72bda269-9480-4b72-b4ce-a8fa1e5d2d6a"
      decimals="-3"
      id="F_e22f66a7-9d52-4052-9589-5941c6b51cd9"
      unitRef="U_USD">216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_28481c26-2de7-4e94-9943-6a2deb168a5e"
      decimals="-3"
      id="F_7ef6bb5c-f011-451c-bd75-aad707ae2673"
      unitRef="U_USD">903365000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5eb44bc0-03fd-4514-a7c0-b540f7cb6ad2"
      decimals="-3"
      id="F_2d6b1f8e-0594-4887-8710-a5b673135d42"
      unitRef="U_USD">-871468000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_210fde09-7480-49be-8723-8ad1eebf22e2"
      unitRef="U_USD">32113000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_18e705d4-75c3-4f8b-9dd7-e32c9e97b572"
      decimals="INF"
      id="F_4deed38a-0b0a-4843-be37-be66cb278519"
      unitRef="U_shares">215559148</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_18e705d4-75c3-4f8b-9dd7-e32c9e97b572"
      decimals="-3"
      id="F_83f66155-1e6c-4638-8cd6-cad29565cfc7"
      unitRef="U_USD">216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4f490ba4-b156-491d-bf6f-129ecf662eb2"
      decimals="-3"
      id="F_748d986b-9dc0-44ea-88e5-daf862aa238b"
      unitRef="U_USD">896390000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a89460f1-fee5-4a24-9dc9-1ef04a688e53"
      decimals="-3"
      id="F_c11e9991-e2ec-4bb5-bf21-5d8be78c1084"
      unitRef="U_USD">-808325000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4ecb5cc8-f37c-4b95-98a1-b053f202010f"
      decimals="-3"
      id="F_890830c4-4bb6-45a0-96e9-2be724c92055"
      unitRef="U_USD">88281000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7a3c172f-d546-462c-a72b-21a8a3e086bd"
      decimals="-3"
      id="F_e7954524-5c64-451f-8423-ba86bd1c3936"
      unitRef="U_USD">2371000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="-3"
      id="F_3f5f3016-89fe-4ca0-929b-1e527413d4c2"
      unitRef="U_USD">2371000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_7dcce1df-cf39-47fd-a123-bd1b19d85aed"
      decimals="INF"
      id="F_1b897ccc-cc4f-4f46-9ac2-2b1f4b6aa7fe"
      unitRef="U_shares">875000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_7dcce1df-cf39-47fd-a123-bd1b19d85aed"
      decimals="INF"
      id="F_81413e12-e48e-4c06-b0b6-63c85d610069"
      unitRef="U_shares">-288344</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_7a3c172f-d546-462c-a72b-21a8a3e086bd"
      decimals="-3"
      id="F_7875702f-76b3-44a7-a469-1756ea5c8b60"
      unitRef="U_USD">788000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="-3"
      id="F_6f127040-58ef-41ea-8838-6c7cabaf60b4"
      unitRef="U_USD">788000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="C_5dd32c50-d442-41ca-9a9b-395b972f0c54"
      decimals="-3"
      id="F_03cc99e6-c258-45cd-beec-e617f89b81bf"
      unitRef="U_USD">-22733000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="-3"
      id="F_a9aed183-de34-45a5-bdc2-0101fc533adf"
      unitRef="U_USD">-22733000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_5987d6f3-3485-4951-8af9-679dc649bb35"
      decimals="INF"
      id="F_f7e8503e-c2f0-4cc0-a14e-f884146950f6"
      unitRef="U_shares">216145804</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_5987d6f3-3485-4951-8af9-679dc649bb35"
      decimals="-3"
      id="F_7ce9c0cf-87b7-4316-889f-d2a20190cb20"
      unitRef="U_USD">216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6c30b44b-f58e-4273-8a2f-4d08ae4922ef"
      decimals="-3"
      id="F_9826dcf4-989e-4284-a53c-97e627ac72c1"
      unitRef="U_USD">899549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0d490f67-76f7-406e-84c4-387e0d9d6db5"
      decimals="-3"
      id="F_3ac7142d-3cc2-43eb-92d9-2738b7fe5477"
      unitRef="U_USD">-831058000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e81d9a09-eee0-481c-8976-f48c00938da7"
      decimals="-3"
      id="F_11d219a8-2c9c-43f2-a85e-77b1628639e4"
      unitRef="U_USD">68707000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_80a697e6-5126-46ff-850f-6f438cf69024"
      decimals="INF"
      id="F_e05d8372-5652-43d4-9e00-f91465306ef1"
      unitRef="U_shares">214591906</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_80a697e6-5126-46ff-850f-6f438cf69024"
      decimals="-3"
      id="F_88c2628e-b6fe-4e95-bbed-0f93d8c3b1ff"
      unitRef="U_USD">215000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d9980554-eb5e-4c04-98a8-4a1d013e4bb7"
      decimals="-3"
      id="F_3e093bc0-dd8b-4d99-9cb3-a6b8a835f549"
      unitRef="U_USD">887868000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_429d7895-53ce-476f-b62a-71d570bab848"
      decimals="-3"
      id="F_8a97651d-1813-409d-a1c9-4b4de2c3d827"
      unitRef="U_USD">-764101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_afa5d5a2-bab5-4430-b57c-13817635e7f3"
      decimals="-3"
      id="F_c172936c-deda-4147-b90f-9fe1de55f49d"
      unitRef="U_USD">123982000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_9aba2ab5-4f85-4c2d-b196-c03836210ab0"
      decimals="-3"
      id="F_70ce1b24-4554-41af-8dff-aaee471c1e8a"
      unitRef="U_USD">9857000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_9759f197-2cf3-4fde-8e2a-5585e2ee9096"
      unitRef="U_USD">9857000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_682aeb79-9f3f-49f6-9a66-66cc8398ab88"
      decimals="INF"
      id="F_cf2676af-4104-42c6-a082-ebef18af3d91"
      unitRef="U_shares">363109</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_9aba2ab5-4f85-4c2d-b196-c03836210ab0"
      decimals="-3"
      id="F_1eb2fbe5-1ce9-418c-abf2-9184bf540721"
      unitRef="U_USD">1037000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_1a1c02ce-2cbc-4918-9115-7e05d66739cd"
      unitRef="U_USD">1037000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_682aeb79-9f3f-49f6-9a66-66cc8398ab88"
      decimals="INF"
      id="F_d7c3c765-8531-4c43-822d-e99f8e8d00cd"
      unitRef="U_shares">1601224</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_682aeb79-9f3f-49f6-9a66-66cc8398ab88"
      decimals="-3"
      id="F_eaab58c0-7bb8-4045-ad77-545dfc1c1a2e"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_9aba2ab5-4f85-4c2d-b196-c03836210ab0"
      decimals="-3"
      id="F_3dacd262-7a28-424e-a993-2dd885ebb23e"
      unitRef="U_USD">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_682aeb79-9f3f-49f6-9a66-66cc8398ab88"
      decimals="INF"
      id="F_4697c336-dbb4-466c-b3a6-4c03120a230e"
      unitRef="U_shares">-410435</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_9aba2ab5-4f85-4c2d-b196-c03836210ab0"
      decimals="-3"
      id="F_3b91b585-669d-410c-8814-698cee341b5d"
      unitRef="U_USD">788000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_7b46386b-dc80-494d-82db-3f0d17d4ae5b"
      unitRef="U_USD">788000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="C_d7ec9466-e3f0-4f95-aecc-fbe0889180ae"
      decimals="-3"
      id="F_02ff9cee-211a-48ad-aaf5-7c996b8fe179"
      unitRef="U_USD">-66957000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_44565491-e261-4394-8301-955e00101340"
      unitRef="U_USD">-66957000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_5987d6f3-3485-4951-8af9-679dc649bb35"
      decimals="INF"
      id="F_22c42067-9977-4601-bb55-078925f335fe"
      unitRef="U_shares">216145804</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_5987d6f3-3485-4951-8af9-679dc649bb35"
      decimals="-3"
      id="F_23119875-b08b-458e-9788-ee012a3a51c8"
      unitRef="U_USD">216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6c30b44b-f58e-4273-8a2f-4d08ae4922ef"
      decimals="-3"
      id="F_f276b37d-fa28-4145-bcd9-2aba64112106"
      unitRef="U_USD">899549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0d490f67-76f7-406e-84c4-387e0d9d6db5"
      decimals="-3"
      id="F_d822a07b-e456-4a49-a94d-333ce438cf77"
      unitRef="U_USD">-831058000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e81d9a09-eee0-481c-8976-f48c00938da7"
      decimals="-3"
      id="F_f2b29bc3-26cf-4a62-8689-e69da676d1a7"
      unitRef="U_USD">68707000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_79807d8a-5180-4626-b94b-2a9894f7c294"
      unitRef="U_USD">-28571000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_504c31bf-3329-4af7-929b-86b9be7cced7"
      unitRef="U_USD">-66957000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_08c223ab-6342-4a31-9390-54f421c99c1f"
      unitRef="U_USD">2065000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_0032066f-647d-4278-a6a5-0affeef91eb6"
      unitRef="U_USD">1892000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_29965212-16b7-48c4-bcf6-00baedaee445"
      unitRef="U_USD">634000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_e1ac340d-c936-4a3b-8a8c-83589c246b4b"
      unitRef="U_USD">148000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_14ecd888-e820-44a5-bb3d-947a8d8e89a2"
      unitRef="U_USD">2651000</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_87dc58a7-973e-4a14-832c-7a5b5ad27eb3"
      unitRef="U_USD">9857000</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <tcrt:IncreaseDecreaseInRightOfUseAsset
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_a5df1ab5-29d7-4e62-82ee-a240f688ef9b"
      unitRef="U_USD">-2306000</tcrt:IncreaseDecreaseInRightOfUseAsset>
    <tcrt:IncreaseDecreaseInRightOfUseAsset
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_b1b6e810-0cba-4e77-ae43-c7e41b23d5cb"
      unitRef="U_USD">529000</tcrt:IncreaseDecreaseInRightOfUseAsset>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_4a7f3925-6a1d-4a15-a52b-916274ff764e"
      unitRef="U_USD">133000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_3add78b6-08b7-4418-b650-d5815025adb4"
      unitRef="U_USD">0</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_582f1e28-2291-42fb-aecb-e25731c5461a"
      unitRef="U_USD">1800000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_deabc69b-f487-4db8-b568-907cc8aa5f9f"
      unitRef="U_USD">-3155000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_c93901ab-4139-4841-bcbe-73d408e84b02"
      unitRef="U_USD">-817000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_ba337cbb-79e7-403d-95ee-222ff31c2215"
      unitRef="U_USD">-7646000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_a4e6eecc-4b00-4325-b498-2a6f3bc21c96"
      unitRef="U_USD">-131000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_ea0fed07-354d-4647-804a-67b0a20d5b43"
      unitRef="U_USD">-508000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_fdbc961b-716d-490d-8dd5-1f2238425e37"
      unitRef="U_USD">616000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_0724f86a-c6df-4e99-b847-2ccbacc01714"
      unitRef="U_USD">503000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_80e6e1bd-3bbb-4d18-af44-18b049dc473b"
      unitRef="U_USD">1525000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_a137e622-7d15-4753-a776-043f6414a70b"
      unitRef="U_USD">-3169000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <tcrt:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_d635498e-863e-40b5-ad60-0314bd42a24d"
      unitRef="U_USD">-2371000</tcrt:IncreaseDecreaseInLeaseLiabilities>
    <tcrt:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_d1aa0997-325e-4a51-8dc0-18118bec6b98"
      unitRef="U_USD">604000</tcrt:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_08aae338-0461-44c8-8cbd-bb6c969a412d"
      unitRef="U_USD">28000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_5053c281-0e8e-4827-8393-a01930cc2c69"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_884d9cc2-aaa6-4395-bdca-b0e88c6c1506"
      unitRef="U_USD">-22102000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_7ae5421d-141a-481c-8c9c-b8b0d50ab41a"
      unitRef="U_USD">-46342000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_5c34c10e-b6fd-476a-9863-bb30a5c94556"
      unitRef="U_USD">100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_95f00470-3cdd-4db0-8953-b1697c4fa289"
      unitRef="U_USD">2964000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_a4706655-a6e5-4630-bf67-31725c8b1261"
      unitRef="U_USD">-100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_bb9b6dc9-8b5d-4961-8041-82de1296552f"
      unitRef="U_USD">-2964000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_f66483e0-2539-4ad1-bd82-1b00625fa3a8"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_f6dfb381-6c9a-4974-89b3-e77b53966160"
      unitRef="U_USD">25000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_5c923977-d192-44ec-806f-6c80808ed4ce"
      unitRef="U_USD">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_6c94694c-44f6-4331-8c8c-ce5c04d79a03"
      unitRef="U_USD">75000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_da35d6c7-5ae3-4368-a0d1-d5db9a08e4bf"
      unitRef="U_USD">21000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_335392df-075e-4d42-9531-90de09e323ba"
      unitRef="U_USD">1037000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_adb1f63c-fb01-4c76-a98a-e9c6c38792cb"
      unitRef="U_USD">45000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_900ca4d7-4748-4221-bae6-96d3aec0291f"
      unitRef="U_USD">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_a86d5ecf-1acd-4111-8e88-a7c6bbf3a947"
      unitRef="U_USD">2083000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_9d041207-3074-4f47-b977-96a5ade07e49"
      unitRef="U_USD">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_6b04c175-6159-4ca2-8d96-9d00e041460a"
      unitRef="U_USD">-2107000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_79bb2c8a-c9a0-42d2-a5b7-299b2a524acb"
      unitRef="U_USD">25962000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_4e148e53-acc2-46be-8cc0-8b9dc7bab5bb"
      unitRef="U_USD">-24309000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_66f45f94-fadc-491a-a153-4df9beef2980"
      unitRef="U_USD">-23344000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_efca6a10-1720-473d-aae1-cf523f91a7e6"
      unitRef="U_USD">76054000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_afa5d5a2-bab5-4430-b57c-13817635e7f3"
      decimals="-3"
      id="F_1526e1d8-bb58-47b0-877b-3c1f8c624ff1"
      unitRef="U_USD">115069000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_e01d6279-62a0-494a-8684-56e51c56eb4b"
      unitRef="U_USD">51745000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e81d9a09-eee0-481c-8976-f48c00938da7"
      decimals="-3"
      id="F_e5144cfc-b6e4-4b2f-b6f3-c4e6d52da3dc"
      unitRef="U_USD">91725000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_b99dffb6-1e3e-4a1f-8d9e-290a5ee84a76"
      unitRef="U_USD">1603000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_6dca8541-b38b-489b-89ec-65953287f634"
      unitRef="U_USD">136000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_75714469-62e0-41f2-9a07-d133a178cfb3"
      unitRef="U_USD">74000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_f19eddfc-9ed1-404b-b063-b93a8e3fda6e"
      unitRef="U_USD">348000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_35241444-fb80-4e04-acc7-598acb04ca6d">&lt;div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;1.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Overview&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Alaunos Therapeutics, Inc., which is referred to herein as &#x201c;Alaunos,&#x201d; or the &#x201c;Company,&#x201d; is a clinical-stage oncology-focused cell therapy company developing adoptive TCR-T cell therapies, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. On January 25, 2022, the Company changed its corporate name from ZIOPHARM Oncology, Inc. to Alaunos Therapeutics, Inc. The Company is leveraging its proprietary, non-viral &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;gene transfer platform and its cancer hotspot mutation TCR library to design and manufacture autologous cell therapies that target neoantigens arising from shared tumor-specific mutations in key oncogenic genes, including &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;KRAS, TP53 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;EGFR.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s operations to date have consisted primarily of conducting research and development and raising capital to fund those efforts. In May 2021, the Company announced that it will be winding down its existing Controlled IL-12 clinical program. The Company continues to seek a partner for this program.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company follows the guidance of Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements - Going Concern, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its financial statements are issued.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has operated at a loss since its inception in 2003 and has no recurring revenue from operations.&#x202f;The Company anticipates that losses will continue for the foreseeable future. As of September 30, 2022, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x202f;million of cash and cash equivalents and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of restricted cash related to the Company's debt agreement (see Note 4). The Company&#x2019;s accumulated deficit at September 30, 2022 was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;871.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x202f;million.&#x202f;Given its current development plans and cash management efforts, the Company anticipates cash resources will be sufficient to fund operations into the second quarter of 2023.&#x202f;The Company&#x2019;s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in the Company&#x2019;s focus and direction of its research and development programs, competitive and technical advances, patent developments, regulatory changes or other developments. If adequate additional funds are not available when required, management may need to curtail its development efforts and planned operations to conserve cash.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on the current cash forecast, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements, which raises substantial doubt as to the Company's ability to continue as a going concern. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of September 30, 2022, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;216,182,042&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock outstanding and an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,545,557&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock reserved for issuance pursuant to outstanding stock options and warrants.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures required by generally accepted accounting principles in the United States, or GAAP, have been condensed or omitted pursuant to such rules and regulations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;It is management&#x2019;s opinion that the accompanying unaudited interim financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair presentation of the financial position of the Company and its results of operations and cash flows for the periods presented. The unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2021, included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on March 30, 2022, or the Annual Report.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The results disclosed in the statements of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full fiscal year 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;statements &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-5"
      id="F_43acf8f9-2b29-464a-95d5-a3d0922961c0"
      unitRef="U_USD">37800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-5"
      id="F_15468392-b587-4740-a174-386cb6b9b112"
      unitRef="U_USD">13900000</us-gaap:RestrictedCash>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-5"
      id="F_eebb403c-89ce-40e1-b75f-7860815e381e"
      unitRef="U_USD">-871500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_72bda269-9480-4b72-b4ce-a8fa1e5d2d6a"
      decimals="0"
      id="F_e85d2dbb-f1ad-4ca7-81bb-e4eff183e555"
      unitRef="U_shares">216182042</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_72bda269-9480-4b72-b4ce-a8fa1e5d2d6a"
      decimals="0"
      id="F_c6c6f7fa-8bc6-48ba-a8ef-d26387531833"
      unitRef="U_shares">33545557</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_f44fbbdf-5a95-4876-b1fe-d2b80857a358">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures required by generally accepted accounting principles in the United States, or GAAP, have been condensed or omitted pursuant to such rules and regulations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;It is management&#x2019;s opinion that the accompanying unaudited interim financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair presentation of the financial position of the Company and its results of operations and cash flows for the periods presented. The unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2021, included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on March 30, 2022, or the Annual Report.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The results disclosed in the statements of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full fiscal year 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_f7e8308f-effb-45bc-8499-5a1071e316c1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;statements &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <tcrt:FinancingArrangementsDisclosureTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_11468af4-be45-4642-aa7e-3153df992d66">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;2.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financings&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2021 Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 6, 2021, the Company entered into a Loan and Security Agreement (the "Loan and Security Agreement") with Silicon Valley Bank and affiliates of Silicon Valley Bank (collectively, "SVB").  The Loan and Security Agreement provided for an initial term loan of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million funded at the closing (the "Term A Tranche"), with an additional tranche of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million available if certain funding and clinical milestones were met by August 31, 2022 (the "Term B Tranche").&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective December 28, 2021, the Company, entered into a First Amendment (the &#x201c;Amendment&#x201d;) to the Loan and Security Agreement (as so amended, the "Amended Loan and Security Agreement").&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Amended Loan and Security Agreement extended the interest-only period through August 31, 2022. The Amended Milestones (as defined below) were not met by the Company on or prior to August 31, 2022, and therefore, the interest-only period was not extended beyond August 31, 2022. The Amendment also eliminated the Term B Tranche, which remained unfunded, leaving only the Term A Tranche (the "SVB Facility"). Under the Amended Loan and Security Agreement, the SVB Facility will mature on August 1, 2023.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Please refer to Note 4 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for further discussion of the Loan and Security Agreement and the Amended Loan and Security Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2022 Equity Distribution Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 12, 2022, the Company entered into an Equity Distribution Agreement (the "Equity Distribution Agreement") with Piper Sandler &amp;amp; Co. ("Piper Sandler"), pursuant to which the Company can offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million through Piper Sandler as its sales agent in an "at the market offering." Piper Sandler will receive a commission of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the gross proceeds of any common stock sold under the Equity Distribution Agreement. During the three and nine months ended September 30, 2022, there have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; sales of the Company's common stock under the Equity Distribution Agreement.&lt;/span&gt;&lt;/p&gt;</tcrt:FinancingArrangementsDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_4466f87e-f227-46f8-9092-8a32178d41c0"
      decimals="-5"
      id="F_28036758-d1bd-4ac9-9528-60ae45bc417f"
      unitRef="U_USD">25000000.0</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_72dbe520-f3b4-4e1f-9462-73da4d9acb9e"
      decimals="-5"
      id="F_6a4b0616-ec80-4c24-aac2-10bcd61a3784"
      unitRef="U_USD">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_8d739f65-8890-4484-9fa8-db2c2788d308"
      decimals="-5"
      id="F_79face5d-dd15-4e61-8dc9-165f0c9ec7ac"
      unitRef="U_USD">50000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <tcrt:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock
      contextRef="C_8d739f65-8890-4484-9fa8-db2c2788d308"
      decimals="3"
      id="F_eea2f425-81cc-4190-83e1-6de0515f8218"
      unitRef="U_pure">0.030</tcrt:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_bcd49289-aef5-458e-9a35-82903fd7c003"
      decimals="INF"
      id="F_3c2d7822-db45-4b1f-8531-2015f07dd976"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <tcrt:StockOfferedDuringPeriodShares
      contextRef="C_90eeab4e-d329-4773-9ae7-51f760c71986"
      decimals="INF"
      id="F_f6cfe0c9-63d7-4169-bb82-68d5efd0cdbd"
      unitRef="U_shares">0</tcrt:StockOfferedDuringPeriodShares>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_c7f83ce8-6c2f-436e-8a80-e4da5cd51e0b">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;3.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s significant accounting policies were identified in the Company&#x2019;s Annual Report. There have been no material changes in those policies since the filing of its Annual Report.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_46670282-984e-4637-bd32-c1dc6f8e98b9">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;4.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying values of the Company's debt obligation were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.682%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.092%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.998000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unamortized discount on Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of September 30, 2022, the SVB Facility was fully drawn in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The SVB Facility bears interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and (b) the current published U.S. prime rate, plus a margin of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As of September 30, 2022, interest on the outstanding loans was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%. The Amended Loan and Security Agreement provided for an interest-only period through August 31, 2022. On or prior to August 31, 2022, the Company had not (i) received at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net cash proceeds from the sale of the Company&#x2019;s equity securities after the date of the Amended Loan and Security Agreement, on terms acceptable to SVB, nor (ii) achieved positive data in the first cohort of the Library TCR-T Trial endorsed by an independent safety monitoring committee as a safe dose to proceed (together, the &#x201c;Amended Milestones&#x201d;), and, therefore, the interest-only period was not extended beyond August 31, 2022. Commencing on September 1, 2022, aggregate outstanding borrowings are payable in twelve consecutive, equal monthly installments of principal plus accrued interest.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All outstanding obligations under the Amended Loan and Security Agreement are due and payable on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company will also owe SVB &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of the original principal amounts borrowed as a final payment (the "Final Payment"). The Company is &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;permitted &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;to make up to two prepayments, subject to a prepayment premium of the amount being prepaid, ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, of the SVB Facility, each such prepayment to be at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million plus all accrued and unpaid interest on the portion being prepaid.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As a result of not achieving the Amended Milestones on or prior to August 31, 2022, the Amended Loan and Security Agreement required the Company to cash collateralize half of the sum of the then-outstanding principal amount of the SVB Facility, plus an amount equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the original principal amount of the SVB Facility. As of September 30, 2022, the Company has collateralized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which is classified as restricted cash on the balance sheet. So long as no event of default has occurred and subject to certain other terms related to the remaining outstanding balance under the SVB Facility being satisfied, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million will be released from the collateral account following the eighth scheduled payment of principal and interest, and a further $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million will be released following the tenth scheduled payment of principal and interest. The SVB Facility and related obligations under the Amended Loan and Security Agreement are secured by substantially all of the Company&#x2019;s properties, rights and assets, except for its intellectual property (which is subject to a negative pledge under the Amended Loan and Security Agreement). In addition, the Amended Loan and Security Agreement contains customary representations, warranties, events of default and covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with its entry into the Loan and Security Agreement, the Company issued to SVB warrants to purchase (i) up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;432,844&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, in the aggregate, and (ii) up to an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;432,842&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, in the aggregate, in the event the Company achieved certain clinical milestones, in each case at an exercise price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.22&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with its entry into the Amendment, the Company amended and restated the warrants issued to SVB. As amended and restated, the warrants are for up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;649,615&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company's common stock, in the aggregate, at an exercise price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.16&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, or the SVB Warrants. The SVB Warrants expire on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 6, 2031&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The issuance costs for the Loan and Security Agreement, including the Amended Loan and Security Agreement, were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and primarily related to the SVB Warrants, which will be amortized into interest expense over the period to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Interest expense was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the three months ended September 30, 2022 and was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the nine months ended September 30, 2022, compared to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the three and nine months ended September 30, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of the Amended Loan and Security Agreement as of September 30, 2022 approximates its face value.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_f382e4c9-0139-4f45-a4f6-31125a5f6fd0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying values of the Company's debt obligation were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.682%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.092%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.998000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unamortized discount on Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_c5ce15ce-9e47-4fdd-9332-0e26a6a95756"
      decimals="-3"
      id="F_7b844576-247a-4f7d-afde-3ed59082516f"
      unitRef="U_USD">23461000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_56ad9b91-5908-46ac-b885-5f4b458e6dd0"
      decimals="-3"
      id="F_86c5b3e8-ac0a-4501-9d2d-f7e58e257d95"
      unitRef="U_USD">25209000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_c5ce15ce-9e47-4fdd-9332-0e26a6a95756"
      decimals="-3"
      id="F_6f5a1d2d-e6af-42b4-b791-96b02c105257"
      unitRef="U_USD">793000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_56ad9b91-5908-46ac-b885-5f4b458e6dd0"
      decimals="-3"
      id="F_abd28360-240e-4ea2-99ac-cf2b98dbac94"
      unitRef="U_USD">1091000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_aae27ef6-eaff-4760-811d-74a9774c1182"
      unitRef="U_USD">22668000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_8dc55dde-6945-4874-85a7-ad6b7e176fb2"
      unitRef="U_USD">24118000</us-gaap:DebtInstrumentCarryingAmount>
    <tcrt:FullyDrawnAmount
      contextRef="C_49c4b845-edf1-48ac-b363-86d2eb87b129"
      decimals="-5"
      id="F_6682325a-e523-4dd5-b2d7-3aeb7bf04a20"
      unitRef="U_USD">25000000.0</tcrt:FullyDrawnAmount>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="C_399029cd-00f2-489c-89bd-afddf96d9013"
      id="F_c814b7b9-424c-4398-9462-3c4cc8361d64">The SVB Facility bears interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) 7.75% and (b) the current published U.S. prime rate, plus a margin of 4.5%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_29c774b1-4d47-4209-8c47-fcd96e1f3895"
      decimals="4"
      id="F_25ac0de1-e0af-4243-98b3-8ad1a0e83317"
      unitRef="U_pure">0.0775</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="3"
      id="F_89198912-e623-4de2-81ab-91e26f57baa9"
      unitRef="U_pure">0.045</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="C_29c774b1-4d47-4209-8c47-fcd96e1f3895"
      decimals="4"
      id="F_d654d37f-f106-44d1-b8f6-ffe31fce61c4"
      unitRef="U_pure">0.1075</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_1d421d03-41e0-4a9e-bb6e-dcc0101f73f0"
      decimals="-5"
      id="F_eb080228-d0f7-471a-a145-e0027adff5d4"
      unitRef="U_USD">50000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="C_399029cd-00f2-489c-89bd-afddf96d9013"
      id="F_9dd20f19-44ec-4d13-a455-6f41cc99b2db">2023-08-01</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms
      contextRef="C_464be36f-cadb-4d42-b6ec-60d3e858ae0d"
      id="F_c658d6d2-d550-448e-91ce-3d7dbb22f4f8">The Company will also owe SVB 5.75% of the original principal amounts borrowed as a final payment (the "Final Payment"). The Company is permitted to make up to two prepayments, subject to a prepayment premium of the amount being prepaid, ranging from 1.00% to 2.00%, of the SVB Facility, each such prepayment to be at least $5.0 million plus all accrued and unpaid interest on the portion being prepaid.</us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms>
    <tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment
      contextRef="C_1d421d03-41e0-4a9e-bb6e-dcc0101f73f0"
      decimals="4"
      id="F_3e384f61-0a50-4031-94a6-26baa238d531"
      unitRef="U_pure">0.0575</tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment>
    <tcrt:PercentageOfPrepaymentsPremium
      contextRef="C_35c36f71-52c6-4199-9a71-a3ae673b76aa"
      decimals="4"
      id="F_c85d903c-db2e-44ff-8ca3-4f8f3c286817"
      unitRef="U_pure">0.0100</tcrt:PercentageOfPrepaymentsPremium>
    <tcrt:PercentageOfPrepaymentsPremium
      contextRef="C_a1c325e4-fe22-4b5f-8e61-12cd0023447b"
      decimals="4"
      id="F_ab00b8cf-4a12-456f-8252-0fa6db007d31"
      unitRef="U_pure">0.0200</tcrt:PercentageOfPrepaymentsPremium>
    <tcrt:DebtInstrumentPrepaymentPremium
      contextRef="C_464be36f-cadb-4d42-b6ec-60d3e858ae0d"
      decimals="-5"
      id="F_9800f153-8bae-4276-853f-9e027644af27"
      unitRef="U_USD">5000000.0</tcrt:DebtInstrumentPrepaymentPremium>
    <tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment
      contextRef="C_1d421d03-41e0-4a9e-bb6e-dcc0101f73f0"
      decimals="4"
      id="F_f6beac48-fa88-4b2d-8ba9-f0fad9e5869a"
      unitRef="U_pure">0.0575</tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment>
    <us-gaap:RestrictedCash
      contextRef="C_e0eb70e2-a850-4290-9f2b-2c099994757c"
      decimals="-5"
      id="F_e55386df-d65c-4bc2-bced-2c86d71e5c74"
      unitRef="U_USD">13900000</us-gaap:RestrictedCash>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_9b2f5a35-750a-426b-8208-95bde28e9376"
      decimals="-5"
      id="F_846b84ed-9506-4760-a31e-2bc553e42618"
      unitRef="U_USD">2500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_9c77e152-785d-4e6f-99b7-b0d56fb1dc63"
      decimals="-5"
      id="F_367e9cb4-eeb6-4532-a235-68015917d0d0"
      unitRef="U_USD">4000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_0ecd0af9-f624-419c-bc04-78328b1a47e8"
      decimals="INF"
      id="F_4d6d62e0-7abc-4b5a-b316-a1ba4e3b76ff"
      unitRef="U_shares">432844</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <tcrt:AdditionalNumberOfWarrantsIssued
      contextRef="C_0ecd0af9-f624-419c-bc04-78328b1a47e8"
      decimals="INF"
      id="F_665a5171-2d70-4b87-b06a-58477ee1bf97"
      unitRef="U_shares">432842</tcrt:AdditionalNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0ecd0af9-f624-419c-bc04-78328b1a47e8"
      decimals="2"
      id="F_ea2f1ba3-3c06-4fec-b16f-f55d97fa3121"
      unitRef="U_USDollarShare">2.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="C_eddf6b5e-242d-4045-be96-1b91012cb2f2"
      decimals="INF"
      id="F_4ee10e58-3f86-41e5-899f-5cae6f9c6f7f"
      unitRef="U_shares">649615</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c3dfd279-a1be-4e60-9b23-62f589a95c69"
      decimals="INF"
      id="F_52edac97-80ef-4313-a7a1-988ace427f59"
      unitRef="U_USDollarShare">1.16</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:WarrantsExpirationDate
      contextRef="C_eddf6b5e-242d-4045-be96-1b91012cb2f2"
      id="F_771aaf27-e16a-4c72-bdac-38f7975fe4a5">2031-08-06</tcrt:WarrantsExpirationDate>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="C_ba7ea719-3efa-42ac-a0b2-dbaed33d86b1"
      decimals="-5"
      id="F_3ff0655d-a618-4ded-b67a-5219c3e2a404"
      unitRef="U_USD">1200000</us-gaap:DeferredFinanceCostsNet>
    <tcrt:InterestExpenseAmortizedDate
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_17bd9ba1-ab6d-4b68-bc4b-57ef610e07a7">2023-08-01</tcrt:InterestExpenseAmortizedDate>
    <us-gaap:InterestExpenseDebt
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="-5"
      id="F_0d29451f-792b-4291-a42b-15b9ee4df3ea"
      unitRef="U_USD">800000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-5"
      id="F_a8bef313-ec41-4a00-8e47-975a4f86e6eb"
      unitRef="U_USD">2300000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="-5"
      id="F_0c4b0896-a88a-40ce-b8a7-81d45d0ab582"
      unitRef="U_USD">400000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-5"
      id="F_1313daf2-866f-4edb-95b2-b13844437498"
      unitRef="U_USD">400000</us-gaap:InterestExpenseDebt>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_644b72b2-b150-4f2d-adaa-e4399b7b859a">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;5.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&#x2014;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of September 30, 2022 and December 31, 2021 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.66%;"/&gt;
        &lt;td style="width:0.992%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.277000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.992%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.288%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.113%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.113%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.504999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.388%;"/&gt;
        &lt;td style="width:0.965%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.965%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.274%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.076%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.905%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.076%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.353%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There have been no changes to the valuation methods during the nine months ended September 30, 2022. We had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; financial assets or liabilities that were classified as Level 2 or Level 3 during the nine months ended September 30, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_7f3ca421-5c4b-44b8-a9a0-807fab42d953">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of September 30, 2022 and December 31, 2021 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.66%;"/&gt;
        &lt;td style="width:0.992%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.277000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.992%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.288%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.113%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.113%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.504999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.388%;"/&gt;
        &lt;td style="width:0.965%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.965%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.274%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.076%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.905%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.076%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.353%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e3064554-7470-4ef4-931d-019f0af3c58c"
      decimals="-3"
      id="F_551a17d7-4588-493c-9359-3cd2b390e35a"
      unitRef="U_USD">36807000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_2a8ceb76-7648-4132-8aa2-02c65b7eb518"
      decimals="-3"
      id="F_e15ddf23-0688-4adf-8fc2-fb1dcfaa7e0c"
      unitRef="U_USD">36807000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e0570a01-faa7-4744-91fc-66333e256702"
      decimals="-3"
      id="F_e301820b-59a1-4925-8a09-b39cb68ee077"
      unitRef="U_USD">75222000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_ba706fc5-e9e4-4f6d-9180-2a783ebf0530"
      decimals="-3"
      id="F_392119fa-3bf8-496b-bcf6-578e0c38859e"
      unitRef="U_USD">75222000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_00a63ae4-63b6-4ac6-941f-4be4fd9e3e98"
      decimals="-3"
      id="F_fb3d9694-43e1-46c0-8743-5c16c60f5303"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_04dad3dd-6544-4265-a027-765e7788ebae">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;6.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, inducement stock options, unvested restricted stock and warrants, have not been included in the computation of diluted net loss per share for any of the periods presented as the result would be anti-dilutive. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Such potentially dilutive shares of common stock consisted of the following as of September 30, 2022 and 2021, respectively:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.904%;"/&gt;
        &lt;td style="width:1.642%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.202%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.642%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.61%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,623,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,072,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inducement stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;940,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,510,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,922,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,705,571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,485,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,386,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_5c61c2ae-c1af-440b-bba1-a8c7d834ed99">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Such potentially dilutive shares of common stock consisted of the following as of September 30, 2022 and 2021, respectively:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.904%;"/&gt;
        &lt;td style="width:1.642%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.202%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.642%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.61%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,623,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,072,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inducement stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;940,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,510,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,922,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,705,571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,485,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,386,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5c32ad95-bd53-4f35-853e-22b717e70798"
      decimals="0"
      id="F_ed91dd71-07ed-43a4-a6ff-64b163e02aa1"
      unitRef="U_shares">10623215</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_82a2d9da-2739-4328-a38b-dd5018876817"
      decimals="0"
      id="F_851c7875-3601-4194-b468-bc408d9ad70a"
      unitRef="U_shares">11072894</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_95ff3701-048e-464c-829f-6c697a0744f3"
      decimals="0"
      id="F_25723390-feee-44e8-8de0-79e8919b9560"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9dc3ba53-2c20-4736-8bee-cb0366b44f23"
      decimals="0"
      id="F_e9b63b25-7293-460e-b9d3-0144ba2ef3ae"
      unitRef="U_shares">97500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cf9a58e2-50b7-4e9f-b6e9-8386b05eaea6"
      decimals="0"
      id="F_c1b4cd68-0a43-4fab-bffb-af361040ee39"
      unitRef="U_shares">940000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d5737b6f-9713-4bf0-9447-bffb6837ae58"
      decimals="0"
      id="F_771c1fbe-a3ca-4f20-91a6-863f59c32779"
      unitRef="U_shares">1510655</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b6a2cd0a-f5d0-4a9f-af29-87bb8204f6f6"
      decimals="0"
      id="F_5d387ed0-cd07-431a-807f-10e500e910f4"
      unitRef="U_shares">22922342</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f3be7956-1a1a-486d-a035-b032462f33aa"
      decimals="0"
      id="F_a42d2109-2765-485a-9ce3-e643465231f4"
      unitRef="U_shares">22705571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="0"
      id="F_a81240f8-a984-43c8-9f1b-ef2f2efe8c0f"
      unitRef="U_shares">34485557</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="0"
      id="F_ce3fddaa-f3cd-40cf-8120-e1f97dc4dea5"
      unitRef="U_shares">35386620</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_c47e7dfd-fc8a-4a89-876b-70fb20361d09">&lt;div style="text-indent:0.0%;display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;7.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Related Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaboration with Vineti Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 9, 2020, the Company entered into a master service agreement and statement of work with Vineti, Inc. ("Vineti"). Pursuant to the agreement, Vineti has been developing a software platform to coordinate and orchestrate the order, cell collection and manufacturing process for the Company&#x2019;s T-cell therapy, or TCR-T, clinical programs. Heidi Hagen, who became a director of the Company in June 2019 and resigned November 2, 2021 and the Company's Interim Chief Executive Officer on February 25, 2021 and resigned on August 30, 2021, is a co-founder and former officer of Vineti. During the three and nine months ended September 30, 2022, the Company recorded &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; expenses for Vineti, compared to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of expenses for the three months ended September 30, 2021 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the nine months ended September 30, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;WaterMill Settlement Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On February 4, 2021, the Company entered into an agreement, or the Settlement Agreement, with WaterMill Asset Management Corp. and Robert W. Postma (collectively, the "WaterMill Parties"). Pursuant to the Settlement Agreement, the Company increased the size of its board of directors from eight to nine directors and appointed Mr. Postma to fill the newly created directorship.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In accordance with the Settlement Agreement, the Company agreed to reimburse the WaterMill Parties for up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of their reasonable out-of-pocket expenses out of a total of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in fees and expenses actually incurred by the WaterMill Parties in connection with (i) the WaterMill Parties' solicitation of written consents from the Company's stockholders to vote in favor of certain proposals, as set forth in the definitive consent statement filed by the WaterMill Parties on October 30, 2020, and (ii) the negotiation, execution, and effectuation of the Settlement Agreement. As of February 19, 2021, the Company has fully reimbursed the WaterMill Parties an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Joint Venture with TriArm Therapeutics/Eden BioCell&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On December 18, 2018, the Company and TriArm Therapeutics, Ltd. (&#x201c;TriArm&#x201d;) launched Eden BioCell, Ltd. (&#x201c;Eden BioCell&#x201d;) as a joint venture to lead commercialization of the Company&#x2019;s &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-generated CAR-T therapies in the People&#x2019;s Republic of China (including Macau and Hong Kong), Taiwan and Korea. The Company licensed to Eden BioCell the rights in Greater China for its third-generation &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-generated CAR-T therapies targeting the CD19 antigen. Eden BioCell is owned equally by the Company and TriArm and the parties share decision-making authority. TriArm has contributed $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to Eden BioCell and has committed up to an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;to this joint venture. TriArm also manages all clinical development in the territory pursuant to a master services agreement between TriArm and Eden BioCell. James Huang was the founder and serves as managing&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;partner &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of Panacea Venture, which is an investor in TriArm. Mr. Huang is the Chair of the Company's board of directors and has been a director since July 2020. He also serves as a member of Eden BioCell&#x2019;s board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the three and nine months ended September 30, 2022, Eden BioCell incurred a net loss and the Company continues to have no commitment to fund its operations. In September 2021, TriArm and Alaunos mutually agreed to dissolve the Eden BioCell joint venture. Refer to Note 12 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Joint Venture&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, for further details.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees
      contextRef="C_23eae7ee-dd71-428c-93da-1b90bf020452"
      decimals="-6"
      id="F_97977de9-be28-4ddb-b330-7697d17a7440"
      unitRef="U_USD">0</tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees>
    <tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees
      contextRef="C_89339f1e-48c2-46f1-afa9-1bd72a4dccef"
      decimals="-6"
      id="F_02148956-a162-4b15-a733-652e404f7a01"
      unitRef="U_USD">0</tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees>
    <tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees
      contextRef="C_5287bb43-2308-4e1c-a17a-766d2905368b"
      decimals="-5"
      id="F_866b4e7f-20d9-4bd1-9769-ae4db91c528c"
      unitRef="U_USD">100000</tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees>
    <tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees
      contextRef="C_c373b210-56f0-4a58-9d24-8f12d518d218"
      decimals="-5"
      id="F_45edc4e8-26d7-45de-a904-bfdd3fd8dfa4"
      unitRef="U_USD">400000</tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees>
    <tcrt:PocketExpenses
      contextRef="C_1e52479f-7e44-4216-b266-a0446569c844"
      decimals="-5"
      id="F_f5c23bc4-5680-4af4-8e53-e75da5c3b54a"
      unitRef="U_USD">400000</tcrt:PocketExpenses>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_1e52479f-7e44-4216-b266-a0446569c844"
      decimals="-5"
      id="F_f620b3d0-031f-486d-9a7d-e097047b64a7"
      unitRef="U_USD">700000</us-gaap:CostsAndExpensesRelatedParty>
    <tcrt:RelatedPartyTransactionReimbursedAmount
      contextRef="C_e4a8cbd7-35ae-461e-b1af-edf4446dbfd9"
      decimals="-5"
      id="F_10a9649a-fc6b-4e96-8d45-1e33a8759c5f"
      unitRef="U_USD">400000</tcrt:RelatedPartyTransactionReimbursedAmount>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="C_eab945c1-a1b6-41ab-91d4-85e2fc2020c5"
      decimals="-5"
      id="F_22c6c99d-0cb2-4a28-8439-542c878e4c16"
      unitRef="U_USD">10000000.0</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <tcrt:AdditionalLoansCommitted
      contextRef="C_168c2abe-f9d8-4189-b7ee-13828dea54d1"
      decimals="-5"
      id="F_e008a291-4658-4661-b3dd-7ceba339b7cc"
      unitRef="U_USD">25000000.0</tcrt:AdditionalLoansCommitted>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_d218845c-6d2f-4db2-aebf-e59ffc865dcd">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;8.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In April 2022, the Company modified its real estate lease agreement executed on December 15, 2020 with MD Anderson for office space in Houston, which reduced the Company's leased space from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,111&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,228&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet. As a result, the associated lease liability and right-of-use asset were remeasured to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million based on revised lease payments. A gain of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was recorded on the lease modification during the nine months ended September 30, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2022, the Company executed an agreement to sub-sublease &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,772&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet of subleased office space in Boston. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The term of the sub-sublease is from July 1, 2022 to June 30, 2025 and provides the sub-subtenant with an option to extend through to July 31, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. For the three and nine months ended September 30, 2022, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand in lease income, which is classified within other income (expense), net in the statement of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <tcrt:OperatingLeaseArea
      contextRef="C_5478d947-5881-4b9c-a88f-5e7d9771c267"
      decimals="INF"
      id="F_f552206d-aab1-4765-95c2-ec21c0083758"
      unitRef="U_sqft">18111</tcrt:OperatingLeaseArea>
    <tcrt:OperatingLeaseArea
      contextRef="C_1d8421da-db98-4345-93d7-f06de09f53d0"
      decimals="INF"
      id="F_cd8ca9ee-7316-456e-b733-14ed95071300"
      unitRef="U_sqft">3228</tcrt:OperatingLeaseArea>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_1d8421da-db98-4345-93d7-f06de09f53d0"
      decimals="-5"
      id="F_740c9266-cd4c-465d-bed3-3df3426b9027"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <tcrt:GainLossOnModificationOfLease
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-5"
      id="F_e6660854-d450-4844-8f66-533b3e9ceb12"
      unitRef="U_USD">100000</tcrt:GainLossOnModificationOfLease>
    <tcrt:SubleaseArea
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="0"
      id="F_ed8cab77-346e-4f0e-87cd-f03b68e6e9f1"
      unitRef="U_sqft">4772</tcrt:SubleaseArea>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_a1c3a241-5a9e-4936-97e1-3f90ac04a33d">The term of the sub-sublease is from July 1, 2022 to June 30, 2025 and provides the sub-subtenant with an option to extend through to July 31, 2026</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LeaseIncome
      contextRef="C_b761c5a5-7e64-42b4-b347-bff79c80c526"
      decimals="-3"
      id="F_408a27ab-2b23-4d68-a504-5dfb646a0aea"
      unitRef="U_USD">44000</us-gaap:LeaseIncome>
    <us-gaap:LeaseIncome
      contextRef="C_808c9e76-ba2c-4353-bc47-63c7e812ba3d"
      decimals="-3"
      id="F_5d9d61c4-63f7-4428-b69f-04972473203e"
      unitRef="U_USD">44000</us-gaap:LeaseIncome>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_7d4809ad-f7b1-4fd5-abb2-72dc00f760a7">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;9.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Exclusive License Agreement with PGEN Therapeutics&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On October 5, 2018, the Company entered into an exclusive license agreement, or License Agreement, with PGEN Therapeutics, or PGEN, a wholly owned subsidiary of Precigen Inc., or Precigen, which was formerly known as Intrexon Corporation. Pursuant to the terms of the License Agreement, the Company has exclusive, worldwide rights to research, develop and commercialize (i) TCR products designed for neoantigens for the treatment of cancer, (ii) products utilizing Precigen&#x2019;s RheoSwitch&#xae; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (iii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the Ares Trading Agreement. Under the License Agreement, the Company also has exclusive, worldwide rights for certain patents relating to the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The Company is required to use commercially reasonable efforts, as defined in the License Agreement, to develop and commercialize IL-12 products, CD19 products, BCMA products and TCR Products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In consideration of the licenses and other rights granted by PGEN, the Company will pay PGEN an annual license fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and the Company has agreed to reimburse PGEN for certain historical costs of the licensed programs up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which was fully paid during the year ended December 31, 2019.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company will make milestone payments totaling up to an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for each exclusively licensed program upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions. In addition, the Company will pay PGEN tiered royalties ranging from low-single digits to high-single digits on the net sales derived from the sale of any approved IL-12 products and CAR products. The Company will also pay PGEN royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of any approved TCR products, up to a maximum royalty amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the aggregate. The Company will also pay PGEN &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;twenty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; percent of any sublicensing income received by us relating to the licensed products. The Company is responsible for all development costs associated with each of the licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;PGEN will pay the Company royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of PGEN&#x2019;s CAR products, up to a maximum royalty amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.63%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2020, the Company entered into an amendment to the License Agreement relating to the transfer of certain materials and PGEN&#x2019;s obligations to provide transition assistance relating to the IL-12 products.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;License Agreement and 2015 Research and Development Agreement &#x2014;The University of Texas MD Anderson Cancer Center&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 13, 2015&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company, together with Precigen, entered into the MD Anderson License with MD Anderson (which Precigen subsequently assigned to PGEN). Pursuant to the MD Anderson License, the Company, together with PGEN, holds an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs, arising from the laboratory of Laurence Cooper, M.D., Ph.D., who served as the Company&#x2019;s Chief Executive Officer from May 2015 until February 2021 and was formerly a tenured professor of pediatrics at MD Anderson.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 17, 2015, the Company, Precigen and MD Anderson entered into the 2015 R&amp;amp;D Agreement to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. The rights and obligations of Precigen under the 2015 R&amp;amp;D Agreement were assigned to the Company pursuant to the Fourth Amendment to 2015 R&amp;amp;D Agreement which was entered into on September 19, 2019 (the &#x201c;Fourth Amendment&#x201d;) with an effective date of October 5, 2018. The activities under the 2015 R&amp;amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the 2015 R&amp;amp;D Agreement for a period of three years and in an amount of no less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and no greater than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million per year. On November 14, 2017, the Company entered into an amendment to the 2015 R&amp;amp;D Agreement, extending its term until April 15, 2021. In connection with the execution of the 2019 R&amp;amp;D Agreement described below, on October 22, 2019, the Company amended the 2015 R&amp;amp;D Agreement to extend the term of the 2015 R&amp;amp;D Agreement until December 31, 2026 and to allow cash resources on hand at MD Anderson under the 2015 R&amp;amp;D Agreement to be used for development costs under the 2019 R&amp;amp;D Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson License, the Company, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if the Company and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if the Company and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by the Company and Precigen, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both the Company and Precigen and may be terminated by the mutual written agreement of the Company, PGEN, and MD Anderson.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2019 Research and Development Agreement&#x2014;The University of Texas MD Anderson Cancer Center&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On October 22, 2019, the Company entered into the 2019 Research and Development Agreement, or the 2019 R&amp;amp;D Agreement, with MD Anderson, pursuant to which the parties agreed to collaborate with respect to the TCR program. Under the 2019 R&amp;amp;D Agreement, the parties will, among other things, collaborate on programs to expand the Company's TCR library and conduct clinical trials. The activities under the 2019 R&amp;amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company will own all inventions and intellectual property developed under the 2019 R&amp;amp;D Agreement and the Company will retain all rights to intellectual property for oncology products manufactured using non-viral gene transfer technologies under the 2019 R&amp;amp;D Agreement, including the Company's&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Sleeping Beauty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; technology. The Company has granted MD Anderson an exclusive license for such intellectual property outside the field of oncology and to develop and commercialize TCR products manufactured using viral gene transfer technologies limited to autologous products if used for cancer treatment or prevention, and a non-exclusive license for allogenic anti-tumor TCR products manufactured using viral-based technologies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the 2019 R&amp;amp;D Agreement, the Company agreed, beginning on January 1, 2021, to reimburse MD Anderson up to a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for development costs under the 2019 R&amp;amp;D Agreement, after the funds from the 2015 R&amp;amp;D Agreement are exhausted. In addition, the Company will pay MD Anderson royalties on net sales of its TCR products. The Company is required to make performance-based payments upon the successful completion of clinical and regulatory benchmarks relating to its TCR products. The aggregate potential benchmark payments are $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, of which only $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;will be due prior to the first marketing&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;approval &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of the Company's TCR products. The royalty rates and benchmark payments owed to MD Anderson may be reduced upon the occurrence of certain events. The Company also agreed to sell its TCR products to MD Anderson at preferential prices and will sell the Company's TCR products in Texas exclusively to MD Anderson for a limited period of time following the first commercial sale of the Company's TCR products. For the three months ended September 30, 2022, the Company incurred clinical expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million from MD Anderson related to this agreement compared to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the three months ended September 30, 2021. For the nine months ended September 30, 2022, the Company incurred clinical expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million from MD Anderson related to this agreement compared to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the nine months ended September 30, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2019 R&amp;amp;D Agreement will terminate on December 31, 2026 and either party may terminate the 2019 R&amp;amp;D Agreement following written notice of a material breach. The 2019 R&amp;amp;D Agreement also contains customary provisions related to indemnification obligations, confidentiality and other matters.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the execution of the 2019 R&amp;amp;D Agreement, on October 22, 2019, the Company issued MD Anderson a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,333,333&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company's common stock, which is referred to as the MD Anderson Warrant. Please refer to Note 11 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, for further discussion of the MD Anderson Warrant. The MD Anderson Warrant has an initial exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, expires on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and vests upon the occurrence of certain clinical milestones. As of September 30, 2022, the milestones have not been met.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;License Agreement with the NCI&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On May 28, 2019, the Company entered into a patent license agreement, or the Patent License, with the National Cancer Institute, or the NCI. Pursuant to the Patent License, the Company holds an exclusive, worldwide license to certain intellectual property to develop and commercialize patient-derived (autologous), peripheral blood T-cell therapy products engineered by transposon-mediated gene transfer to express TCRs reactive to mutated &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;KRAS, TP53&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;EGFR &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;neoantigens. In addition, pursuant to the Patent License, the Company holds an exclusive, worldwide license to certain intellectual property for manufacturing technologies to develop and commercialize autologous, peripheral blood T-cell therapy products engineered by non-viral gene transfer to express TCRs, as well as a non-exclusive, worldwide license to certain additional manufacturing technologies. On May 29, 2019, January 8, 2020, September 28, 2020, April 16, 2021, May 4, 2021, and August 13, 2021 the Company amended the Patent License to expand its TCR library to include additional TCRs reactive to mutated &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;KRAS &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;TP53 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;neoantigens licensed from the NCI.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The terms of the Patent License require the Company to pay the NCI minimum annual royalties in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which amount will be reduced to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million once the aggregate minimum annual royalties paid by the Company equals $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is also required to make performance-based payments upon successful completion of clinical and regulatory benchmarks relating to the licensed products. Of such payments, the aggregate potential benchmark payments are $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, of which aggregate payments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million are due only after marketing approval in the United States or in Europe, Japan, Australia, China or India. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The first benchmark payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was due upon the initiation of the Company's first sponsored Phase 1 clinical trial of a licensed product or licensed process in the field of use licensed under the Patent License. The Company paid the first benchmark payment during the nine months ended September 30, 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addition, the Company is required to pay the NCI one-time benchmark payments following aggregate net sales of licensed products at certain aggregate net sales ranging from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion. The aggregate potential amount of these benchmark payments is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company must also pay the NCI royalties on net sales of products covered by the Patent License at rates in the low to mid-single digits depending upon the technology included in a licensed product. To the extent the Company enters into a sublicensing agreement relating to a licensed product, the Company is required to pay the NCI a percentage of all consideration received from a sublicensee, which percentage will decrease based on the stage of development of the licensed product at the time of the sublicense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Patent License will expire upon expiration of the last patent contained in the licensed patent rights, unless terminated earlier. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The NCI may terminate or modify the Patent License in the event of a material breach, including if the Company does not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company may terminate the Patent License, or any portion thereof, in the Company's sole discretion at any time upon &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; days&#x2019; written notice to the NCI. In addition, the NCI has the right to: (i) require the Company to sublicense the rights to the product candidates covered by the Patent License upon certain conditions, including if the Company is not reasonably satisfying required health and safety needs and (ii) terminate or modify the Patent License, including if the Company is not satisfying requirements for public use as specified by federal regulations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the three months ended September 30, 2022, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in license payments to the NCI under this agreement, compared to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for the three months ended September 30, 2021.  For the nine months ended September 30, 2022,&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in license payments to the NCI under this agreement, compared to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the nine months ended September 30, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cooperative Research and Development Agreement (CRADA) with the NCI&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 9, 2017, the Company entered into a Cooperative Research and Development Agreement (the &#x201c;CRADA&#x201d;) with the NCI. The purpose of this collaboration was to advance a personalized TCR-T approach for the treatment of solid tumors. Using the Company's &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; technology, the NCI would analyze a patient&#x2019;s own cancer cells, identify their unique neoantigens and TCRs reactive against those neoantigens and then use the Company's &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; technology to transpose one or more TCRs into T cells for re-infusion. Research conducted under the CRADA will be at the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI, in collaboration with the Company's researchers.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is responsible for providing the NCI with the test materials necessary for them to conduct their studies, and eventually, clinical trials pursuant to the CRADA. Inventions, data and materials discovered or produced in connection with performance of the research plan under the CRADA will remain the sole property of the party who produced the discovery. The parties will jointly own all inventions jointly discovered under the research plan. The owner of any invention under the CRADA will make the decision to file a patent covering the invention, or in the case of a jointly owned invention, the Company will have the first opportunity to file a patent covering the invention. If the Company fails to provide timely notice of its decision to the NCI or decide not to file a patent covering the joint invention, the NCI has the right to make the filing. For any invention solely owned by the NCI or jointly made by the NCI and the Company for which a patent application was filed, the U.S. Public Health service grants the Company an exclusive option to elect an exclusive or non-exclusive commercialization license. For inventions owned solely by the NCI or jointly owned by the NCI and the Company, which are licensed according to the terms described above, the Company agreed to grant to the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world. The Company is also required to grant the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world for any of the Company's solely owned inventions. The agreement may be terminated by any of the parties upon 60 days prior written consent.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The NCI has a cleared Investigational New Drug Application, or IND, that would permit them to begin this trial. To the Company's knowledge, the trial has not yet enrolled due to matters internal to the NCI and unrelated to the Company's technology. The progress and timeline for this trial, including the timeline for dosing patients, are under control of the NCI.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2019, the Company extended the CRADA with the NCI until January 9, 2022, committing an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to this program. In March 2022, the Company entered into an amendment to the CRADA that is retroactive, effective January 9, 2022 to extend the term of the CRADA until January 9, 2023. In June 2022, the Company entered into the Fourth Amendment to the CRADA (the "CRADA Fourth Amendment") which, among other things, extended the term of the CRADA until January 9, 2025. In connection with the CRADA Fourth Amendment, the Company agreed to contribute $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million per year, payable on a quarterly basis, beginning in the first quarter of 2023. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t record expenses under the CRADA for the three and nine months ended September 30, 2022, as compared to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for the three months ended September 30, 2021 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the nine months ended September 30, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Patent and Technology License Agreement&#x2014;The University of Texas MD Anderson Cancer Center and the Texas A&amp;amp;M University System&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&amp;amp;M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the terms of the agreement, the Company may be required to make additional payments to the Licensors upon achievement of certain milestones in varying amounts which, on a cumulative basis could total up to an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. In addition, the Licensors are entitled to receive royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. During the three and nine months ended September 30, 2022, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was expensed as a one-time milestone payment under the terms of the agreement, compared to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the three and nine months ended September 30, 2021. During the three and nine months ended September 30, 2022 and 2021, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t incur royalty expenses on sales under this agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaboration Agreement with Solasia Pharma K.K.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia Pharma K. K. ("Solasia"), which was amended on July 31, 2014 to include an exclusive worldwide license and amended on October 14, 2021 to revise certain payment schedule details (as so amended, the "Solasia License and Collaboration Agreement"). Pursuant to the Solasia License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As consideration for the license, the Company is eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenue generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company&#x2019;s licensors, as defined in the Solasia License and Collaboration Agreement, will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Solasia License and Collaboration Agreement with the licensors, as described above.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2022, Solasia announced that darinaparsin had been approved from relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare in Japan. During the three and nine months ended September 30, 2022, the Company recorded $2.9 million of collaboration revenue under the Solasia License and Collaboration Agreement primarily related to Solasia's achievement of certain sales-based milestones in Japan. During the three and nine months ended September 30, 2021, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of collaboration revenue under the Solasia License and Collaboration Agreement. During the three and nine months ended September 30, 2022 and 2021, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t record royalty revenues on net sales of darinaparsin under this agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <tcrt:AnnualLicenseFees
      contextRef="C_2bca986a-5228-45f5-a440-a7d273a6f156"
      decimals="-5"
      id="F_db8e3685-57dc-4eb1-93a4-b3b6b0d7260a"
      unitRef="U_USD">100000</tcrt:AnnualLicenseFees>
    <tcrt:PaymentForHistoricalCostsOfTheLicensedPrograms
      contextRef="C_30990001-d5dc-4069-a5b6-498c28245fdb"
      decimals="-5"
      id="F_fb4dfb10-bca1-4163-bad4-1c1edf205d2e"
      unitRef="U_USD">1000000.0</tcrt:PaymentForHistoricalCostsOfTheLicensedPrograms>
    <tcrt:MaximumAmountOfAdditionalMilestonesPayable
      contextRef="C_2bca986a-5228-45f5-a440-a7d273a6f156"
      decimals="-5"
      id="F_8ecd849b-bd6c-451a-b218-8efc70ea989e"
      unitRef="U_USD">52500000</tcrt:MaximumAmountOfAdditionalMilestonesPayable>
    <tcrt:MaximumAmountOfRoyaltyPayable
      contextRef="C_1a1e5081-81c7-406f-aac2-68d4a56e7396"
      decimals="-5"
      id="F_88ff903a-f585-470f-bfa8-907925676e05"
      unitRef="U_USD">100000000.0</tcrt:MaximumAmountOfRoyaltyPayable>
    <tcrt:PercentageOfSubLicensingIncomePayableToRelatedParty
      contextRef="C_1a1e5081-81c7-406f-aac2-68d4a56e7396"
      decimals="2"
      id="F_9362cea4-258e-4b3a-8c60-79f4b9f93b40"
      unitRef="U_pure">0.20</tcrt:PercentageOfSubLicensingIncomePayableToRelatedParty>
    <tcrt:MaximumRoyaltyAmount
      contextRef="C_fee32fa6-5000-4631-b097-9b1fea30a290"
      decimals="-5"
      id="F_6562155d-537a-4b10-8752-c10922ddf755"
      unitRef="U_USD">100000000.0</tcrt:MaximumRoyaltyAmount>
    <tcrt:LicenseAgreementCommencingDate
      contextRef="C_d56c397d-06d5-47bb-8033-e0542dd94f41"
      id="F_bc60de9a-4587-4872-9891-fd2e53c7e61a">2015-01-13</tcrt:LicenseAgreementCommencingDate>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d7baac48-135d-4e1f-805c-4570972d3951"
      decimals="-5"
      id="F_9c4a9389-7811-42ef-8811-a4c5be10ae2c"
      unitRef="U_USD">15000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_36e64732-f6d5-4615-89f1-3872af4ff2ea"
      decimals="-5"
      id="F_dc742c35-5a77-4ee9-9d59-844fb369e106"
      unitRef="U_USD">20000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <tcrt:AggregateAmountPotentiallyReimburseableAmount
      contextRef="C_2cec0f62-e0a7-444b-9c62-04422644e817"
      decimals="-5"
      id="F_69ef0c35-0827-408e-89cc-7a17a28dd2e4"
      unitRef="U_USD">20000000.0</tcrt:AggregateAmountPotentiallyReimburseableAmount>
    <tcrt:AggregatePotentialBenchmarkPayments
      contextRef="C_2cec0f62-e0a7-444b-9c62-04422644e817"
      decimals="-5"
      id="F_6f200c14-7dde-45d3-b2d8-99647ee6e984"
      unitRef="U_USD">36500000</tcrt:AggregatePotentialBenchmarkPayments>
    <tcrt:AccrualsPriorToFirstMarketingApproval
      contextRef="C_2cec0f62-e0a7-444b-9c62-04422644e817"
      decimals="-5"
      id="F_9da9e07e-ad09-43d0-979c-98b49bf4ac6e"
      unitRef="U_USD">3000000.0</tcrt:AccrualsPriorToFirstMarketingApproval>
    <tcrt:QuarterlyExpenseIncurred
      contextRef="C_66586099-2ff8-40bd-a3af-a61d770bbd1b"
      decimals="-5"
      id="F_a16b89bd-8f3f-4155-b385-0cf440bf57e3"
      unitRef="U_USD">300000</tcrt:QuarterlyExpenseIncurred>
    <tcrt:QuarterlyExpenseIncurred
      contextRef="C_9975e9e7-b6d2-44f8-8f9b-4428ca4a25ee"
      decimals="-6"
      id="F_f12bd33e-0e34-429c-ac7c-ab5d3670ee6d"
      unitRef="U_USD">0</tcrt:QuarterlyExpenseIncurred>
    <tcrt:QuarterlyExpenseIncurred
      contextRef="C_3da54949-f086-4986-984c-e1d5c3f603ff"
      decimals="-5"
      id="F_80927a17-415a-46b1-9571-0b00472f3d22"
      unitRef="U_USD">700000</tcrt:QuarterlyExpenseIncurred>
    <tcrt:QuarterlyExpenseIncurred
      contextRef="C_2fba5838-cd3f-40d2-8f7f-5f1b833834f5"
      decimals="-6"
      id="F_fba0c194-ad56-4a84-a629-03620f4da7dd"
      unitRef="U_USD">0</tcrt:QuarterlyExpenseIncurred>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_7c362f59-d6f4-4a7a-a1c8-b74ebbed16b4"
      decimals="INF"
      id="F_76121070-0385-488f-9f4e-3bbaf07ab676"
      unitRef="U_shares">3333333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_7c362f59-d6f4-4a7a-a1c8-b74ebbed16b4"
      decimals="INF"
      id="F_14a18581-ec65-4c6c-9069-816da1137f9f"
      unitRef="U_USDollarShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_7c362f59-d6f4-4a7a-a1c8-b74ebbed16b4"
      id="F_3eac6cd2-b125-435e-b937-77c93b1e0448">2026-12-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <tcrt:MinimumRoyaltiesAmountPayable
      contextRef="C_2619a848-009e-46c2-a1f5-04328671628d"
      decimals="-5"
      id="F_77098cef-e0d6-43b7-b207-d47d54856ae0"
      unitRef="U_USD">300000</tcrt:MinimumRoyaltiesAmountPayable>
    <tcrt:RoyaltiesAmountPayableThereafter
      contextRef="C_2619a848-009e-46c2-a1f5-04328671628d"
      decimals="-5"
      id="F_3c57210e-9304-4b09-a83a-3bfb09c66885"
      unitRef="U_USD">100000</tcrt:RoyaltiesAmountPayableThereafter>
    <tcrt:AggregateMinimumAnnualRoyaltiesPaid
      contextRef="C_2619a848-009e-46c2-a1f5-04328671628d"
      decimals="-5"
      id="F_6ca84d7f-12f3-4073-841a-f0354033c81d"
      unitRef="U_USD">1500000</tcrt:AggregateMinimumAnnualRoyaltiesPaid>
    <tcrt:AggregateBenchmarkPaymentsPayable
      contextRef="C_c4985865-020d-4fdb-bec6-b066804fcca8"
      decimals="-5"
      id="F_86434bb6-a7c6-4b13-94b5-479c1d38124e"
      unitRef="U_USD">4300000</tcrt:AggregateBenchmarkPaymentsPayable>
    <tcrt:AggregateBenchmarkPaymentsPayable
      contextRef="C_c14220fc-6b7b-43f8-af8e-400952313273"
      decimals="-5"
      id="F_b6a8dfd4-bf56-47ba-b15f-9e0eec5e803a"
      unitRef="U_USD">3000000.0</tcrt:AggregateBenchmarkPaymentsPayable>
    <tcrt:DescriptionOfFirstBenchmarkPayable
      contextRef="C_243ddad6-e77f-4cec-bf28-7f9b590baafd"
      id="F_513e25a6-7938-4780-875d-9a13116aa4de">The first benchmark payment of $0.1 million was due upon the initiation of the Company's first sponsored Phase 1 clinical trial of a licensed product or licensed process in the field of use licensed under the Patent License. The Company paid the first benchmark payment during the nine months ended September 30, 2022.</tcrt:DescriptionOfFirstBenchmarkPayable>
    <tcrt:InitialBenchmarkPaymentDue
      contextRef="C_c4d2468d-d204-46a0-a52f-8c6f952adf7a"
      decimals="-5"
      id="F_40dc79f8-9fd1-4ff8-9441-fb89e53d904e"
      unitRef="U_USD">100000</tcrt:InitialBenchmarkPaymentDue>
    <tcrt:MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable
      contextRef="C_43bf232f-663e-498c-8a53-386a3a861e53"
      decimals="-5"
      id="F_ff7d0003-0dfc-46d8-b5c5-202158d79e8c"
      unitRef="U_USD">250000000.0</tcrt:MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable>
    <tcrt:MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable
      contextRef="C_43bf232f-663e-498c-8a53-386a3a861e53"
      decimals="-8"
      id="F_8c5897fc-996a-4c1a-8061-c8441cde1655"
      unitRef="U_USD">1000000000.0</tcrt:MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable>
    <tcrt:PotentialBenchmarkPaymentsPayable
      contextRef="C_db352027-c319-4fed-873e-eafcb7007f91"
      decimals="-5"
      id="F_6553bcd0-b78d-4cea-8903-ad75037ea723"
      unitRef="U_USD">12000000.0</tcrt:PotentialBenchmarkPaymentsPayable>
    <tcrt:DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones
      contextRef="C_243ddad6-e77f-4cec-bf28-7f9b590baafd"
      id="F_87c515fd-7c41-4832-a9ea-fa5703ce02bf">The NCI may terminate or modify the Patent License in the event of a material breach, including if the Company does not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event.</tcrt:DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones>
    <tcrt:AgreementTerminationNoticePeriod
      contextRef="C_243ddad6-e77f-4cec-bf28-7f9b590baafd"
      id="F_f2c69e5d-75f8-4f94-a01c-a8f6dc7d1ccf">P60D</tcrt:AgreementTerminationNoticePeriod>
    <tcrt:LicenseExpense
      contextRef="C_f90f3da9-4b30-43f4-8f71-7dedd967f4ce"
      decimals="-5"
      id="F_79f36641-5fb6-48fa-b537-dcc8a3695476"
      unitRef="U_USD">100000</tcrt:LicenseExpense>
    <tcrt:LicenseExpense
      contextRef="C_c3c976de-0ee5-455d-bee2-a9edd8244900"
      decimals="-5"
      id="F_f75f11df-138e-49ec-9f04-7978cc401260"
      unitRef="U_USD">300000</tcrt:LicenseExpense>
    <tcrt:LicenseExpense
      contextRef="C_0ed707b3-bea7-4926-b6bd-f4064815e868"
      decimals="-5"
      id="F_365e0291-a6c4-42c0-97b2-d817b6fc9a73"
      unitRef="U_USD">500000</tcrt:LicenseExpense>
    <tcrt:LicenseExpense
      contextRef="C_a553ea37-cf6b-45d6-ab63-a4294c165977"
      decimals="-5"
      id="F_8f60fe3c-8123-4185-8452-810716e07a86"
      unitRef="U_USD">600000</tcrt:LicenseExpense>
    <tcrt:ObligationsDueUnderContract
      contextRef="C_dfc4b9a9-6363-4eb4-84cc-324cdd9e5c5a"
      decimals="-5"
      id="F_ee83fe60-202f-408e-8b25-fc186612a731"
      unitRef="U_USD">5000000.0</tcrt:ObligationsDueUnderContract>
    <tcrt:ContributionPayableOnPerAnnumBasis
      contextRef="C_e5a16ee8-f8ba-419a-ad14-c822ec3582a9"
      decimals="-5"
      id="F_37e50be6-8062-4a74-b157-489407a73aed"
      unitRef="U_USD">1000000.0</tcrt:ContributionPayableOnPerAnnumBasis>
    <tcrt:QuarterlyExpenseIncurred
      contextRef="C_efc00410-6d5c-495a-a72b-6d6351214b08"
      decimals="INF"
      id="F_d4d02c65-ac0c-4b9c-898c-3b821c123d28"
      unitRef="U_USD">0</tcrt:QuarterlyExpenseIncurred>
    <tcrt:QuarterlyExpenseIncurred
      contextRef="C_11eda09f-c5af-4a19-be29-445f8325d410"
      decimals="INF"
      id="F_15edb454-1965-4d50-96ca-ddb7e404bd16"
      unitRef="U_USD">0</tcrt:QuarterlyExpenseIncurred>
    <tcrt:QuarterlyExpenseIncurred
      contextRef="C_db440a89-812a-473c-bea3-ef4ccf784d27"
      decimals="-6"
      id="F_17543f92-4df0-4958-9ba2-b2d8fb6291a8"
      unitRef="U_USD">0</tcrt:QuarterlyExpenseIncurred>
    <tcrt:QuarterlyExpenseIncurred
      contextRef="C_2daa022b-a09a-4371-9536-aff338b7b832"
      decimals="-5"
      id="F_491de165-9081-413c-930c-01cf7a3c1b42"
      unitRef="U_USD">1300000</tcrt:QuarterlyExpenseIncurred>
    <tcrt:MilestonePaymentsMaximumAmount
      contextRef="C_e6c3e2ec-e88b-4a8e-a9a1-8a82c2d398ef"
      decimals="-5"
      id="F_13de0d8c-b20a-4f88-af08-e6ae512c2a5a"
      unitRef="U_USD">4500000</tcrt:MilestonePaymentsMaximumAmount>
    <tcrt:MilestonePayment
      contextRef="C_8d40e9e7-c9cf-4667-ba64-23d8853c4fdb"
      decimals="-5"
      id="F_18de2c69-ef24-4128-9db5-0c0ff4089297"
      unitRef="U_USD">2500000</tcrt:MilestonePayment>
    <tcrt:MilestonePayment
      contextRef="C_0a8415e0-ec1d-4ed0-a8c1-83dd21690b46"
      decimals="-5"
      id="F_dee5f538-9927-48f6-825d-68d03c2e4a39"
      unitRef="U_USD">2500000</tcrt:MilestonePayment>
    <tcrt:PaymentUnderLicenseAgreement
      contextRef="C_6a801914-4bd9-4d79-be9c-781ec8a7881d"
      decimals="-5"
      id="F_2ea13ed6-b94d-4bf9-9c4d-dbb595b42525"
      unitRef="U_USD">100000</tcrt:PaymentUnderLicenseAgreement>
    <tcrt:PaymentUnderLicenseAgreement
      contextRef="C_7d15c91c-08c2-4355-817a-d947ee9b15f8"
      decimals="-5"
      id="F_48c9e808-a340-495b-be1a-8908c410bd17"
      unitRef="U_USD">100000</tcrt:PaymentUnderLicenseAgreement>
    <tcrt:PaymentUnderLicenseAgreement
      contextRef="C_d9252104-b0ce-41b0-bd34-3724646ef25e"
      decimals="-6"
      id="F_5bde8d2f-6b6b-49ac-862c-ca5c23402723"
      unitRef="U_USD">0</tcrt:PaymentUnderLicenseAgreement>
    <tcrt:PaymentUnderLicenseAgreement
      contextRef="C_2dfd9017-3654-4240-b560-4fa92df974b8"
      decimals="-6"
      id="F_25cd61f9-5538-40c0-a52e-ecfdbb786770"
      unitRef="U_USD">0</tcrt:PaymentUnderLicenseAgreement>
    <tcrt:PaymentUnderLicenseAgreement
      contextRef="C_7384efec-4e47-4d02-8bce-8365f7e0295a"
      decimals="-6"
      id="F_221d4ff7-4dbf-4d81-9b51-3ddf6a349236"
      unitRef="U_USD">0</tcrt:PaymentUnderLicenseAgreement>
    <tcrt:PaymentUnderLicenseAgreement
      contextRef="C_4d9975fc-c543-4fdc-bc21-cb9c1de3ac67"
      decimals="-6"
      id="F_c2fa0858-1b82-45ae-ac6a-e8b7235e1ff0"
      unitRef="U_USD">0</tcrt:PaymentUnderLicenseAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e9a0185b-e5d0-4a1e-9377-e759cf76ceb3"
      decimals="-5"
      id="F_f4572780-244a-4f58-b1f6-61b0e252bb9d"
      unitRef="U_USD">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_71ac7c9c-ed62-4708-9f1f-3794c7da2b64"
      decimals="-5"
      id="F_80dd405d-ccbf-4b81-8f70-2e5c6bb6f899"
      unitRef="U_USD">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_bf4cb307-d956-44e9-9223-82983a351431"
      decimals="-6"
      id="F_3edc1962-9f34-488a-980f-a0464064be33"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0ea0be7a-caae-4842-adc5-35fca4e7eea4"
      decimals="-6"
      id="F_9b8cf53f-9560-4ef6-9154-d745d9100a93"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7ec0e0fa-abc4-4590-ac2a-da156b639f99"
      decimals="-6"
      id="F_08386ddc-7276-44d7-a4fe-d33126d3e90e"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ce1c210f-7d8b-4de3-bdac-77591a3466bd"
      decimals="-6"
      id="F_7796408f-d01d-4119-ac17-7f8430b077da"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <tcrt:StockOptionsAndRestrictedStockAwardsTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_2a162be2-ea9d-4f74-95e6-1a27720e05a5">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;10.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.367%;"/&gt;
        &lt;td style="width:3.316%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.553%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.665%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.641%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.665%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.665%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.338999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company granted an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,275,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; stock options during the three months ended September 30, 2022, with a weighted-average grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.52&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, and granted an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,667,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; stock options during the nine months ended September 30, 2022, with a weighted-average grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.67&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. The Company granted an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,755,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;stock options during the three months ended September 30, 2021, with a weighted-average grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.08&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, and granted an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,150,438&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; stock options during the nine months ended September 30, 2021, with a weighted-average grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.91&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the three and nine months ended September 30, 2022 and 2021, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:30.661%;"/&gt;
        &lt;td style="width:1.336%;"/&gt;
        &lt;td style="width:15.999%;"/&gt;
        &lt;td style="width:1.336%;"/&gt;
        &lt;td style="width:15.999%;"/&gt;
        &lt;td style="width:1.336%;"/&gt;
        &lt;td style="width:15.999%;"/&gt;
        &lt;td style="width:1.336%;"/&gt;
        &lt;td style="width:15.999%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.94&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.62&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.89&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.96&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.63&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.62&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected life in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.23&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.00&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82.43&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85.89&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.53&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.84&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74.49&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85.89&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.53&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74.80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.528%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:1.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.743198935713313%;"&gt;2.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock option activity under the Company&#x2019;s stock option plans for the nine months ended September 30, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.903%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.799%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.215%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.504%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.828999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.215%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.551%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;(in thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted- Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted- Average Contractual Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,665,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,667,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,683,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, September 30, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,623,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.27&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable, September 30, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,211,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.01&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,410,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.53&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options available for future grant, September 30, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,245,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At September 30, 2022, total unrecognized compensation costs related to unvested stock options outstanding amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The cost is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.01&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A summary of the status of unvested restricted stock for the nine months ended September 30, 2022 is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.459%;"/&gt;
        &lt;td style="width:1.154%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.669%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.115%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,198,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;280,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;305,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested, September 30, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;940,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At September 30, 2022, total unrecognized compensation costs related to unvested restricted stock outstanding amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The cost is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.83&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</tcrt:StockOptionsAndRestrictedStockAwardsTextBlock>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_e65d3119-73f2-4de1-b4bc-b2cf512de8fe">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.367%;"/&gt;
        &lt;td style="width:3.316%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.553%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.665%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.641%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.665%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.789%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.665%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.338999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="C_b8f27772-b294-42ff-a235-56681aee8001"
      decimals="-3"
      id="F_d24de701-b315-43e8-9b5e-c91694195219"
      unitRef="U_USD">145000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_26c0546e-3ae0-436e-bf65-3135619b6131"
      decimals="-3"
      id="F_03d9a475-706b-4d8f-82aa-9d91945532a4"
      unitRef="U_USD">535000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_2a85659d-9529-4877-90ee-9305d6b05bd2"
      decimals="-3"
      id="F_9a67126d-8fe6-4555-9189-83e863294aa9"
      unitRef="U_USD">673000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_3996230c-eb63-4bd8-8c4e-4eda38f443db"
      decimals="-3"
      id="F_f9b61b5b-5958-4061-b945-c70151814367"
      unitRef="U_USD">2115000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_e5b94b60-824a-4f1d-94d2-dc6c1840957d"
      decimals="-3"
      id="F_278da34f-4aef-47f7-badf-82026555d821"
      unitRef="U_USD">663000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_d0485a7c-1400-45f5-9110-483d8d21ebfb"
      decimals="-3"
      id="F_ef7e5e8b-9ef5-4e55-a8b6-9c8faf268250"
      unitRef="U_USD">1836000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_d4b5db92-6383-4c43-b62a-d3bc3bc3fc9f"
      decimals="-3"
      id="F_19d6dee1-af93-4894-90df-f90d796a6271"
      unitRef="U_USD">1978000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_8607731b-da93-4afa-873b-c41bd854fae0"
      decimals="-3"
      id="F_d4ec8cde-21a7-43b2-806f-1a9945b81c59"
      unitRef="U_USD">7742000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="-3"
      id="F_b050ce03-f836-4f31-8c50-684e6d76a2f2"
      unitRef="U_USD">808000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="-3"
      id="F_4f4820b2-b9a2-42b2-aeda-60bc5b47c12c"
      unitRef="U_USD">2371000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="-3"
      id="F_c551c1dc-c534-4634-af48-e33c8f625b58"
      unitRef="U_USD">2651000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="-3"
      id="F_f43a2e95-2a3e-4ef1-83c8-ffd3ac2b0d74"
      unitRef="U_USD">9857000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="INF"
      id="F_ef6596c3-f460-4a0f-865b-193c115c378e"
      unitRef="U_shares">1275000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="2"
      id="F_15d1bc8a-8209-4c31-ba35-01aa1efde061"
      unitRef="U_USDollarShare">1.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="INF"
      id="F_129f95f4-9f04-4614-ace7-ebcf40a300e4"
      unitRef="U_shares">4667500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="2"
      id="F_ae3017d9-564a-4262-a9bf-658687827600"
      unitRef="U_USDollarShare">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="INF"
      id="F_5879f203-0b6c-42b5-adb7-9e3b45e44a14"
      unitRef="U_shares">2755000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="2"
      id="F_081e83e2-3cb1-4244-84f6-b8c9ebede9cb"
      unitRef="U_USDollarShare">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="INF"
      id="F_874c064b-bbbd-4c64-aa62-7c55cdd0879c"
      unitRef="U_shares">7150438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="2"
      id="F_11dacdbf-bf15-43fe-bb44-edec89fe8d4d"
      unitRef="U_USDollarShare">1.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_a294ebf0-b3e8-4ffe-97d0-fd9fd4517136">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the three and nine months ended September 30, 2022 and 2021, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:30.661%;"/&gt;
        &lt;td style="width:1.336%;"/&gt;
        &lt;td style="width:15.999%;"/&gt;
        &lt;td style="width:1.336%;"/&gt;
        &lt;td style="width:15.999%;"/&gt;
        &lt;td style="width:1.336%;"/&gt;
        &lt;td style="width:15.999%;"/&gt;
        &lt;td style="width:1.336%;"/&gt;
        &lt;td style="width:15.999%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.94&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.62&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.89&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.96&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.63&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.62&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected life in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.23&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.00&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82.43&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85.89&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.53&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.84&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74.49&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85.89&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.53&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74.80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="4"
      id="F_b25347c6-a809-4957-b411-217cda196358"
      unitRef="U_pure">0.0294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="4"
      id="F_3b3e355f-e910-4c49-9682-51ab6d20d20d"
      unitRef="U_pure">0.0362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="4"
      id="F_365fda4d-b0c9-4664-80a1-636ec2835f06"
      unitRef="U_pure">0.0089</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="4"
      id="F_a1d2a678-24c4-4532-90ca-fe6f55a4f0f9"
      unitRef="U_pure">0.0096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="4"
      id="F_7767e33b-c9d7-4fb5-9947-7c077d2804f3"
      unitRef="U_pure">0.0163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="4"
      id="F_b4724a64-10f4-418e-b4e5-62f736ed38a7"
      unitRef="U_pure">0.0362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="4"
      id="F_766d97c0-3888-4652-ab3a-604cdaeeb7bd"
      unitRef="U_pure">0.0050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="4"
      id="F_35f8b731-c2cd-46fd-b110-55642a9b385d"
      unitRef="U_pure">0.0115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_c328dc7e-2261-4512-872c-da4fb630f2c8"
      id="F_abe0c6da-1820-4963-aeb3-b21c8bae2430">P6Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5f43bb33-c6dd-42f3-b81e-2d16c0d279f7"
      id="F_954d6bc6-5551-4738-815a-81fd088dd657">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_fcea062a-308f-4809-8835-154dace3f34b"
      id="F_7be184cd-eabd-4650-8225-313d31f01502">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ba03628a-d489-4082-b85c-544300569f10"
      id="F_2bebfcd8-0302-4b48-b315-07f94f34531e">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_18443f2c-6ffb-47e1-8f0b-7587c06dbd8e"
      id="F_5de20be7-ee71-4fb4-8399-ec35624dda83">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_07609204-d289-4b94-b19f-777a70145f62"
      id="F_7ee3bab0-318c-4128-8c09-b5a8fbbc8aac">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5278975e-6f79-4550-9b7e-1506a2f6d459"
      id="F_19fb3e39-a5dc-436b-95e2-2ce9778021c1">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_dc8e2d26-10b6-486b-8a26-6ca99f89115b"
      id="F_5fe80b44-0300-46df-ad04-f53cfd187a71">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="4"
      id="F_d86c1b9e-84b5-46ae-a820-87035b36eb1b"
      unitRef="U_pure">0.8243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="4"
      id="F_3f225883-8431-4bf9-af09-f5b6d5957014"
      unitRef="U_pure">0.8589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="4"
      id="F_f978dda6-fdc7-4b45-b0d7-cc90b85c93f1"
      unitRef="U_pure">0.7253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="4"
      id="F_9570dbc3-15eb-408d-8414-9062e55673f5"
      unitRef="U_pure">0.7284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="4"
      id="F_69b34ed6-4fa3-48a9-8737-93c8e925f36f"
      unitRef="U_pure">0.7449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="4"
      id="F_f27277bc-6808-46cd-89de-ea08b4b605dc"
      unitRef="U_pure">0.8589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="4"
      id="F_89a1fcba-6da0-47d2-a02a-be66e26e5d29"
      unitRef="U_pure">0.7253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="4"
      id="F_deddf4a3-6a63-4641-9add-725017c0b9e0"
      unitRef="U_pure">0.7480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_5748e941-3c1c-4556-8329-7aeb6d259272"
      decimals="2"
      id="F_2560bcb9-5dcb-4b5d-8cd5-dd2d9fc454a3"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_7dd83c2e-6421-445b-a010-82fe8ad08521"
      decimals="2"
      id="F_44e504ff-b5a6-4c2a-82a9-b29f01509fa1"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="2"
      id="F_aa6eeee9-4ba4-46a2-98b2-9ba0a546477e"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_339531a2-8a7b-42ff-b485-df3b013ebeb1"
      decimals="2"
      id="F_7d81d177-0089-457e-99da-d67017eb036c"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_e21738cb-85ec-4437-ac68-7c9164337520">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock option activity under the Company&#x2019;s stock option plans for the nine months ended September 30, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.903%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.799%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.215%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.504%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.828999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.215%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.551%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;(in thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted- Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted- Average Contractual Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,665,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,667,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,683,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, September 30, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,623,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.27&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable, September 30, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,211,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.01&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,410,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.53&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options available for future grant, September 30, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,245,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="0"
      id="F_ef66c0d3-4230-4a2c-9248-d0f4229c5f37"
      unitRef="U_shares">10665869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="2"
      id="F_553e6a5b-6bdc-409b-8c4b-8c1ad2c87429"
      unitRef="U_USDollarShare">2.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="0"
      id="F_7264033e-e238-484a-be32-993d5698b43f"
      unitRef="U_shares">4667500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="2"
      id="F_f6af5ff9-8b5d-4abf-aa6e-6adb9961f97c"
      unitRef="U_USDollarShare">1.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="0"
      id="F_1bd5157f-18be-4c0b-91df-b8d5834d979e"
      unitRef="U_shares">26250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="2"
      id="F_79aed0c5-9421-4737-8d5f-c432d180ac4a"
      unitRef="U_USDollarShare">0.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="0"
      id="F_7ae6dd64-5de8-440a-98d2-60e78d61df4d"
      unitRef="U_shares">4683904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      decimals="2"
      id="F_ccf7dc6f-fab0-45e4-9a0d-5996ab81a6fe"
      unitRef="U_USDollarShare">3.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="0"
      id="F_8cf0a894-244c-4d2b-ad1b-acb5e60bfaee"
      unitRef="U_shares">10623215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="2"
      id="F_a12a1727-e08a-4d7a-8194-b9db343b56fe"
      unitRef="U_USDollarShare">1.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_3f9c00db-2380-43b7-8393-a144ab1eefbb">P8Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_92455ec2-73a1-494d-a849-9e10c183cf73"
      unitRef="U_USD">3572000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="0"
      id="F_0dde0b43-7914-4e4d-ac68-1af033ad877d"
      unitRef="U_shares">3211631</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="2"
      id="F_4d56e70a-5bb1-4b06-8692-f30f98bef1e5"
      unitRef="U_USDollarShare">2.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_25b4afe2-b8a3-4455-9276-6ad85069f814">P7Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="-3"
      id="F_93d008e8-7127-473a-ab95-b94d621e3c5e"
      unitRef="U_USD">510000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="0"
      id="F_0ed8dbc7-564e-4619-8d77-5297b62b3a6b"
      unitRef="U_shares">4410312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="2"
      id="F_4980b213-015e-41ec-9d91-ed05d26698a6"
      unitRef="U_USDollarShare">3.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_f915cb95-5e51-4689-a7fd-3b9969b8b324"
      id="F_adf42ec7-58c0-4d9f-a17f-693dde340498">P7Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_277ad1c2-e2ec-409f-b9ec-704d1983abe1"
      decimals="-3"
      id="F_3c94b6a0-9db3-484f-8eb6-357447bd591b"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_acc8d98b-3c82-4d2e-af71-6452e557354e"
      decimals="0"
      id="F_3f516dbd-f486-4cc1-83fe-0efbdf107820"
      unitRef="U_shares">15245494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_f647c291-0b62-43fd-84a5-54f70a4da70b"
      decimals="-5"
      id="F_5a8463e6-9762-4801-a3ba-a474ef7eedd5"
      unitRef="U_USD">7100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_de243d37-ed59-4bdb-a446-2678a29190e9"
      id="F_4b9d3b43-3a3d-4b99-9f12-5484bd3f2d75">P2Y3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_3a8a09a3-c235-4e23-8e06-f8f09356b7e7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A summary of the status of unvested restricted stock for the nine months ended September 30, 2022 is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.459%;"/&gt;
        &lt;td style="width:1.154%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.669%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.115%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,198,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;280,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;305,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested, September 30, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;940,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At September 30, 2022, total unrecognized compensation costs related to unvested restricted stock outstanding amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The cost is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.83&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_87c24bba-d603-4bbb-92e5-692a66baf6fa"
      decimals="INF"
      id="F_8bb85fa2-bce5-4042-8543-f1dc428197bd"
      unitRef="U_shares">1198580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_87c24bba-d603-4bbb-92e5-692a66baf6fa"
      decimals="2"
      id="F_81bdcbcb-7cc8-4f19-9133-3a1e5e829eb3"
      unitRef="U_USDollarShare">2.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_51a11843-7d5f-4914-9b59-f8771ccffffc"
      decimals="INF"
      id="F_8dc808c9-8de2-4d57-b987-8a82e3963341"
      unitRef="U_shares">280000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_51a11843-7d5f-4914-9b59-f8771ccffffc"
      decimals="2"
      id="F_f1c13d6d-771a-4f3d-a9cd-c5d69808a1f1"
      unitRef="U_USDollarShare">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_51a11843-7d5f-4914-9b59-f8771ccffffc"
      decimals="INF"
      id="F_45154115-dd79-418f-a229-4272306b2847"
      unitRef="U_shares">305679</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_51a11843-7d5f-4914-9b59-f8771ccffffc"
      decimals="2"
      id="F_26631d21-f6c8-48a2-8084-d069031cafd7"
      unitRef="U_USDollarShare">2.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_51a11843-7d5f-4914-9b59-f8771ccffffc"
      decimals="INF"
      id="F_acf8e23e-9772-4d58-91e3-b186ca3051cd"
      unitRef="U_shares">232901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_51a11843-7d5f-4914-9b59-f8771ccffffc"
      decimals="2"
      id="F_902d8824-0ff8-43b2-8386-79ccde0111cd"
      unitRef="U_USDollarShare">3.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_516cb031-f3e7-4387-8ebb-eb61b7eb9ea0"
      decimals="INF"
      id="F_c666ab8a-d3a8-45eb-b8b8-c205b517fa96"
      unitRef="U_shares">940000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_516cb031-f3e7-4387-8ebb-eb61b7eb9ea0"
      decimals="2"
      id="F_51ed11d6-f913-4862-a270-6a7e53f8aa8d"
      unitRef="U_USDollarShare">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_516cb031-f3e7-4387-8ebb-eb61b7eb9ea0"
      decimals="-5"
      id="F_32a89054-7256-428c-950a-582bf2376107"
      unitRef="U_USD">1200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_51a11843-7d5f-4914-9b59-f8771ccffffc"
      id="F_1a1bb154-2d9f-4e1f-b303-cbc0a832359b">P1Y9M29D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <tcrt:WarrantTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_2e6d97ab-dd44-48dc-aa03-22307c85acca">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;11.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the Company&#x2019;s November 2018 private placement that provided net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, the Company issued warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,939,394&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, which became exercisable six months after the closing of the private placement (the "November 2018 Warrants"). The November 2018 Warrants had an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.01&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and have a five-year term. The fair value of the November 2018 Warrants was estimated at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million using a Black-Scholes model with the following assumptions: expected volatility of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, risk free interest rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, expected life of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; dividends.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 26, 2019 and September 12, 2019, the Company entered into agreements with existing investors whereby the investors exercised the November 2018 Warrants for an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,803,031&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.01&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. Proceeds from the warrant exercise after deducting placement agent fees and other related expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company issued participating investors new warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,803,031&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional shares of common stock (the "2019 Warrants") as consideration for the warrant holders to exercise their November 2018 Warrants. The 2019 Warrants will expire on the fifth anniversary of the initial exercise date and have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The 2019 Warrants were valued using a Black-Scholes valuation model and resulted in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million non-cash charge in the Company&#x2019;s statement of operations in 2019.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On October 22, 2019, the Company entered into the 2019 R&amp;amp;D Agreement with MD Anderson. In connection with the execution of the 2019 R&amp;amp;D Agreement, the Company issued the MD Anderson Warrant to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,333,333&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock. The MD Anderson Warrant has an initial exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The MD Anderson Warrant expires on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2026 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and vests upon the occurrence of certain clinical milestones. The Company will recognize expense on the MD Anderson Warrant in the same manner as if the Company paid cash for services to be rendered. For the three and nine months ended September 30, 2022 and September 30, 2021, the Company did not recognize any expense related to the MD Anderson Warrant as the clinical milestones had not been achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. Refer to Note 4 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In connection with the Loan and Security Agreement, the Company issued SVB warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;432,844&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of common stock with an exercise&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;price &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$2.22&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. The warrants have a&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ten-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; life and were fully vested upon issuance. The fair value of the warrants was estimated at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million using a Black-Scholes model with the following assumptions: expected volatility of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, risk free interest rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.31&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, expected life of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten years &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; dividends. On December 28, 2021, the Company entered into the Amendment, as described in Note 4 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in connection with which, the original warrants issued to SVB were amended and restated. As amended and restated, the SVB Warrants are for up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;649,615&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, in the aggregate, at an exercise price per share of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$1.16&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The SVB Warrants expire on August 6, 2031 and were fully vested upon issuance. Using a Black-Scholes model with an expected volatility of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, risk free interest rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.49&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, expected life of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; dividends, the Company recorded a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million increase in the fair value of the SVB Warrants due to the modification of the SVB Warrants.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assessed whether the SVB Warrants require accounting as derivatives. The Company determined that the SVB Warrants were (1) indexed to the Company&#x2019;s own stock and (2) classified in stockholders&#x2019; equity in accordance with FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 815, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As such, the Company has concluded the SVB Warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#x2019; equity.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</tcrt:WarrantTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_23567fca-d299-4618-8b07-c800715f57a9"
      decimals="-5"
      id="F_64224953-b318-40fe-a6dd-8b499c586b8a"
      unitRef="U_USD">47100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_89811c97-bb62-4965-936e-16929f7b6833"
      decimals="0"
      id="F_33cc90d5-d850-48b9-9756-62368b3fa452"
      unitRef="U_shares">18939394</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_89811c97-bb62-4965-936e-16929f7b6833"
      decimals="2"
      id="F_a0b5e686-af0b-464c-b65f-2e7baf7389b4"
      unitRef="U_USDollarShare">3.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:FairValueOfWarrants
      contextRef="C_0af67efe-5cc6-4bd3-95da-2269b35a5117"
      decimals="-5"
      id="F_bcafc571-c668-46ee-8a6f-7f90517cfb78"
      unitRef="U_USD">18400000</tcrt:FairValueOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0af67efe-5cc6-4bd3-95da-2269b35a5117"
      decimals="2"
      id="F_4e78e08c-0a28-4d9d-b1b0-6d73f0691085"
      unitRef="U_pure">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0af67efe-5cc6-4bd3-95da-2269b35a5117"
      decimals="4"
      id="F_f2592c32-dd5d-403d-88bd-b58e0fe30327"
      unitRef="U_pure">0.0299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0af67efe-5cc6-4bd3-95da-2269b35a5117"
      id="F_de317674-1db9-4a53-820c-85cbb9269459">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:Dividends
      contextRef="C_0af67efe-5cc6-4bd3-95da-2269b35a5117"
      decimals="-3"
      id="F_70586038-c5ee-4223-89c3-1ce1a2fff08b"
      unitRef="U_USD">0</us-gaap:Dividends>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_79174d62-d06a-4299-a8be-9fb31ca9fadb"
      decimals="0"
      id="F_80f9d57b-cf73-48c6-be2b-913a1a5f68aa"
      unitRef="U_shares">17803031</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_79174d62-d06a-4299-a8be-9fb31ca9fadb"
      decimals="2"
      id="F_de256e7b-d437-4cfa-9610-0bde5c3a072e"
      unitRef="U_USDollarShare">3.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:PlacementAgentFeesAndOtherRelatedExpenses
      contextRef="C_f1c90eed-e7e4-4ee2-b023-7eca1c8b450c"
      decimals="-5"
      id="F_6ddb3763-bb15-4205-89cf-93edb397ac7b"
      unitRef="U_USD">1100000</tcrt:PlacementAgentFeesAndOtherRelatedExpenses>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_6e455d27-ae8e-4cd2-8656-5e6b3044aec4"
      decimals="-5"
      id="F_29654b7a-9525-4cbe-a5aa-2d857d7e5033"
      unitRef="U_USD">52500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_93030e80-98ca-4f83-b767-ef2910a9d17a"
      decimals="0"
      id="F_5b97d79d-10e0-4005-b53e-c12d835bbc69"
      unitRef="U_shares">17803031</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_93030e80-98ca-4f83-b767-ef2910a9d17a"
      decimals="2"
      id="F_b6677198-65cf-44f1-84fb-0c5e75a503b8"
      unitRef="U_USDollarShare">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:NonOperatingIncomeExpenseInducementOfWarrants
      contextRef="C_0aa8acc8-3dfc-4c50-ae31-5fef3f1e4dce"
      decimals="-5"
      id="F_9d4c445f-f11c-4102-83f5-3bcb41285be6"
      unitRef="U_USD">60800000</tcrt:NonOperatingIncomeExpenseInducementOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_2de808d8-5984-43d6-9ce6-49b4e1114951"
      decimals="INF"
      id="F_53d8bc80-c787-428b-abb6-1e57d5255a4b"
      unitRef="U_shares">3333333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2de808d8-5984-43d6-9ce6-49b4e1114951"
      decimals="3"
      id="F_fbedb509-2330-496a-b7d8-990fd30e3eb9"
      unitRef="U_USDollarShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:FairValueOfWarrants
      contextRef="C_1e4f7846-958f-4ab8-a4e6-79d28f2b664d"
      decimals="-5"
      id="F_339881bf-8874-4cd3-99ee-235aa8033b41"
      unitRef="U_USD">14500000</tcrt:FairValueOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_2de808d8-5984-43d6-9ce6-49b4e1114951"
      id="F_88e80d37-79bd-40a5-9dfb-bf6e2f543e20">2026-12-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="C_9a1f34d1-4746-4f1f-bc5a-c6ce280ea3a7"
      decimals="0"
      id="F_76d78735-454e-4ef2-933d-a584397d7977"
      unitRef="U_shares">432844</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:CommonStockCallOrExerciseFeatures
      contextRef="C_4abb6de4-1411-454e-b48d-575b66944575"
      id="F_fd2a54ef-6509-4c2a-9e1f-d487fa4c6aa5">$2.22</us-gaap:CommonStockCallOrExerciseFeatures>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_9a1f34d1-4746-4f1f-bc5a-c6ce280ea3a7"
      id="F_c701b5e0-3232-4a3c-90e2-30413774e8b5">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <tcrt:FairValueOfWarrants
      contextRef="C_17466d85-cda1-4e4a-b4fb-9d479415d434"
      decimals="-5"
      id="F_52c42325-1006-40be-ac33-9e0527845a29"
      unitRef="U_USD">800000</tcrt:FairValueOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_17466d85-cda1-4e4a-b4fb-9d479415d434"
      decimals="2"
      id="F_804d3ebf-d5b9-468f-b48e-ecbf034fd8c7"
      unitRef="U_pure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_17466d85-cda1-4e4a-b4fb-9d479415d434"
      decimals="4"
      id="F_2a1ab74c-0b4a-4b97-af53-c0f54a5c0dd4"
      unitRef="U_pure">0.0131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_17466d85-cda1-4e4a-b4fb-9d479415d434"
      id="F_4c8d7347-ff59-4dd2-8f52-baee5a119d1b">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:Dividends
      contextRef="C_17466d85-cda1-4e4a-b4fb-9d479415d434"
      decimals="-3"
      id="F_2bda0c60-1cb6-46a6-912d-ee31e06fda3c"
      unitRef="U_USD">0</us-gaap:Dividends>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_11392846-50b9-4407-b98d-7bf6aba70e2a"
      decimals="0"
      id="F_1c3fd316-4924-4e3d-b0ca-e83180c8034c"
      unitRef="U_shares">649615</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:CommonStockCallOrExerciseFeatures
      contextRef="C_d882f9ce-a213-4796-9543-c22ad26eb67a"
      id="F_f20f2f3f-4949-4ea1-bbf4-2d59a9cfd209">$1.16</us-gaap:CommonStockCallOrExerciseFeatures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_d882f9ce-a213-4796-9543-c22ad26eb67a"
      decimals="2"
      id="F_37764230-5aa6-443b-951b-dc1798e5605b"
      unitRef="U_pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_d882f9ce-a213-4796-9543-c22ad26eb67a"
      decimals="4"
      id="F_fcad4f7b-1068-41cf-b48d-ace53ef7b487"
      unitRef="U_pure">0.0149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_d882f9ce-a213-4796-9543-c22ad26eb67a"
      id="F_0bb384aa-14df-4d7e-a8ae-4ac21707efba">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:Dividends
      contextRef="C_d882f9ce-a213-4796-9543-c22ad26eb67a"
      decimals="-3"
      id="F_a3568b1b-efc5-4e46-8041-7ab2d92f5ed8"
      unitRef="U_USD">0</us-gaap:Dividends>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_d882f9ce-a213-4796-9543-c22ad26eb67a"
      decimals="-5"
      id="F_daba5fbe-ca7d-46eb-b4d0-73e8dfbe0081"
      unitRef="U_USD">200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_c0532276-1cc3-4f3a-a771-b733ccc97d40">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;12.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Joint Venture&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On December 18, 2018, the Company entered into a Framework Agreement with TriArm whereby the parties agreed to launch Eden BioCell, to lead clinical development and commercialization of certain &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-generated CAR-T therapies as set forth in a separate license agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 3, 2019, Eden BioCell was incorporated in Hong Kong as a private company. Eden BioCell, the Company and TriArm entered into a Share Subscription Agreement on January 23, 2019, where the Company and TriArm agreed to contribute certain intellectual property, services and cash (only with respect to TriArm) to Eden BioCell to subscribe for a certain number of newly issued ordinary shares in the share capital of Eden BioCell.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The closing of the transaction occurred on July 5, 2019. The Framework Agreement and Share Subscription Agreements were each respectively amended to be effective as of this date. Upon consummation of the joint venture, Eden BioCell and the Company also entered into a license agreement, pursuant to which the Company licensed the rights to Eden BioCell for third generation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Sleeping Beauty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-generated CAR-T therapies targeting the CD19 antigen for the territory of China (including Macau and Hong Kong), Taiwan and Korea. TriArm and the Company each received a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% equity interest in the joint venture in exchange for their contributions to Eden BioCell.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined that Eden BioCell was considered a variable interest entity, or VIE, and concluded that it is not the primary beneficiary of the VIE as it did not have the power to direct the activities of the VIE. As a result, the Company accounts for the equity interest in Eden BioCell under the equity method of accounting as it has the ability to exercise significant influence.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In March 2021, Eden BioCell began treating patients in a clinical trial with the Company&#x2019;s investigational CD19 RPM CAR-T cell therapy, under the IND cleared by the Taiwan FDA in December 2020. In the first half of 2021, two patients were treated in this trial. The lead investigator at National Taiwan University in Taipei, has reported no serious adverse safety events in either of these patients. Laboratory results continue to support, as previously published, that non-viral &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; gene transfer is effective in genetically modifying autologous T-cells. Patients were infused two days after gene transfer, thus shortening the turnaround time and demonstrating an advantage over viral methods.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on laboratory data from the first two patients generated between March and May 2021, the TriArm/Eden team concluded, in concert with the investigator and the Company, that further process development work is required.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2021, TriArm and the Company mutually agreed to dissolve the joint venture.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the three and nine months ended September 30, 2022 and September 30, 2021, Eden BioCell incurred a net loss. The Company continues to have no commitment to fund its operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_bd378eef-0abd-4f06-8c55-ed8f64bbee7f"
      decimals="2"
      id="F_39ea0984-f770-4c39-b7b9-94941ad26be9"
      unitRef="U_pure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_a649b50f-8367-4a1c-9108-4b85ebc15317"
      id="F_b0476faf-6f69-4792-bd65-a4512d46c5fa">&lt;div style="text-indent:0.0%;display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;13.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subsequent Events&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has evaluated subsequent events from the balance sheet date through the date on which these financial statements were issued. The Company did not have any material subsequent events that impacted its financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>57
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M6FB<6L=@/2A+ITZ;1QZ.P_X&P&&F:VD(6ZCC%AH'UX?3<](&DK7LVB8HQ,$
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MG;W8W_WN7Q0OZ^O3-5>*Y_7CCA(MVACHW[=<0Z)Y,3>R[0W\XE]02P,$%
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MB+>@U;XW OZSO#1;!O5T"H)(J[/L(0:[YE*-=8]!-JXE(]@;C>9\(\@ -&0
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MNMNH\DWS\N;'O*KR5?-QR>,%+^H&XO>[/*^^;=3O@Q[>,+[Z'U!+ P04
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MS8]]3%K[2HM8Z T[$-8TZKMYM+T"7T)K(<EQ$VI;IH-X<$V0V$V0WX[9V]H
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M-V-[LR?LS9/$UB9HLQ0WMM")5E[\>[[PP:$<_G,HX&COY+ ]HL@;7\E$70S
M :_<2@TN?_IA\O+X[3/>GG3>GCQG_4^3\>SJP[Y-1J)O57Q>X3J195[(VE@O
M[G/E9*7JH!,_%!]-,AJ*=:Z37&A/K%/.J50$*_"<TJ"1%S_]<#:='K]M+ SY
MZ^2ML$Z$7+5WKVU92;/I[L*:% E\UHDLCGP XX4U*%^[W!QE%J6.;1*PDXS
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MU],$;%R.XXLW=5A(5\;3>AM^EO3_!%H6H.^%H=YO7]A!_Q_*[']02P,$%
M  @ Z#MN53W-,EAF @  R@4  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6REE-]OVC 0Q_^5DROU:2(AT)91B 3=INVA$BK[\3#MP227Q*IC9_;1M/]]
M;0=2I@&:M!=B._?]W/=B[F:M-H^V0B1XKJ6R<U81-=,HLEF%-;<#W:!R;PIM
M:DYN:\K(-@9Y'D2UC)(XOHYJ+A1+9^%L9=*9WI(4"E<&[+:NN7E9HM3MG W9
M_N!!E!7Y@RB=-;S$-=*W9F7<+NHIN:A16:$5&"SF;#&<+L<^/@1\%]C:@S7X
M2C9:/_K-EWS.8F\()6;D"=P]GO .I?0@9^/WCLGZE%YXN-[3/X7:72T;;O%.
MRQ\BIVK.)@QR+/A6TH-N/^.NGBO/R[2TX1?:+G8\8I!M+>EZ)W8.:J&Z)W_>
M?8<#P20^(4AV@B3X[A(%EQ\X\71F= O&1SN:7X12@]J9$\I?RIJ,>RN<CM)U
M=QF@"UB+4HE"9%P1++),;Q4)5<)*2Y$)M+.(7#ZOBK(=>]FQDQ/L]W"O%546
M/JH<\S_UD?/9FTWV9I?)6> :FP&,XG>0Q$ERAC?JBQ\%WN@$[TB5\'.QL63<
MG^77L8([WO@XSS?0U#8\PSES'6+1/"%++R^&U_'M&;?CWNWX'/T_K^HL^[CS
MT0#^/2=\K1#N=-UP]7)Y,4F&-[<6[(&&OVF:O:9%@R!R=,>%P!R$ CJ"62BU
MY1(>L-&&!CZ3DU7\"6&#J$!IUQ&$1KB8K.*J=.1 TA;?<EFA,@SX0DCOPM4D
MZ"_XL8N*#OJK1E.&*6(AU-.U6G_:#ZI%UY]OX=V4N^>F%,J"Q,))X\'-%0/3
M38YN0[H)W;K1Y'H_+"LW;-'X />^T)KV&Y^@']_I*U!+ P04    " #H.VY5
MY9@5,XX(  !K%@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6RE6&MO
MVSH2_9Y?0?AV[TT U0_9>;5)@*3=8@O<8HLFO??#8C_0$FUS2XFZ)%7'^^OW
MS%"2Y3S<% NTL1Z<X<R9F3-#7:RM^^972@5Q7YC27PY6(51O1B.?K50A_=!6
MJL2;A76%#+AURY&OG)(Y"Q5FE([')Z-"ZG)P=<'//KNK"UL'HTOUV0E?%X5T
MFQME[/IR,!FT#[[HY2K0@]'51267ZE:%K]5GA[M1IR77A2J]MJ5P:G$YN)Z\
MN9G1>E[PAU9KW[L6Y,G<VF]T\S&_'(S)(&54%DB#Q,]W]4X90XI@QE^-SD&W
M)0GVKUOM']AW^#*77KVSYD^=A]7EX&P@<K60M0E?[/H?JO'GF/1EUGC^*]9Q
M;7HZ$%GM@RT:85A0Z#+^ROL&AY[ V?@9@;012-GNN!%;^5X&>77A[%HX6@UM
M=,&NLC2,TR4%Y38XO-60"U?OU3Q<C (TT?TH:Z1NHE3ZC-2Y^&3+L/+B[V6N
M\EWY$2SHS$A;,V[2O0IO5344TW$BTG&:[M$W[=R:LK[I'K?$>^TS8WWME/C7
M]=P'AQ3X]U/.1EVSIW516;SQE<S4Y0!Y[Y7[K@97O_XR.1F_W6/IK+-TMD_[
MLP'8+S4;"G;Q;J5$)IW;Z'(IODM3*R_L0@0\?F>+2I:;WSR2%"OMW.BEY$I8
M*R BO5A8@YKT;PZ ?E#%7#D.P7N5-3>3Y.#PE= E]-G:RS+W1QP@^C,Y^-U*
M5%69BUN5U4Z'C;A>.J50L4&\$NDTF9U,Z.(X2<?G!U]+65@7]']5+G($QM98
M!F/V:3D4I^=3<83?23(^GXBC@SL;I(D.07.:G)R<T<4LF4S.Q#7[ONL,F9LP
M'K=_W(@/,M.&]EB3^[4Q&Y$[N2ZCCP"EB&8MV.[A&!5G#" ;,M [&N9*.@^Y
M #!]$!+_Q,)8((Q(.!F4J&""+,NZ(#?!AS[ 37J+5:5/1"4W<FZ4**B4S"8A
M'60$W(>X(RL.Y9$X'9X>B[\Q1(?S(UX!H!SA4]4(*FH_%U^'MT-1.= E[PWE
MIO:P"$2[A&]0-1N2EN$>D#I?; 3CD<F,VF3,]D1$KA$F$,#>(%;.?M>T"!T$
M:[IM7ML2\ ,D;7/LYVR]7(GK>@G.H\QCHX;BGS#>D6?X&^S#]TD_T\5*YJ*T
M2!M]A'Z1*=!]3J :)3WER_%X&U&*>(F>ETF_(A,SI7*DA+,%J_02@=DMI%]_
M.4LGIV^]4'_5Y*&/KFI4G%Q0O&AM3H%OY%X 3L)8*U= 1Y8A)IP0\!.IEL 7
M!U_@C,Q66I$SE?6:NACM(]ND76@']S*[0GFU>_^NYPX]5MR]^_+Z3MPYC:J!
M-=9Y:)EO8AQR59&%B)&7"P6[D(DZ6$<!SVQ1Z! 4$X7D!2*WGHUKX!*'P2X5
M=G,Q# 10.G[;NOU)&T39ELKSB\G;HX10X+7HO-:I*/9D/E"F42C5?8C:YFIC
M >&C_$!PL%]&)@/*;5IW"2*7 'O)8>GE\]PZ\#2NX!S(L"U%0G2M# #.;$D!
M)K 3BCCP:^H4BZ#&&(H?UQ*2$P946!&++LM<#8M;OU!RQNQLOJ5B+VIXYUZ:
M+FQK7BM^W=H,MQM4HL]3$6NSK8HU$EY(XZVPZ\AAQY%1FE1!O$$19'WG1Z1!
MWZ!$140YL(BKY"9R,\D./O"SS_'9X&AW9^TIG)Q&.>5-(;\I45=T&=:41JI1
M!C+T]?P_&-3HG>R]H<M"$X4N^@0]5X0C+]/(*"?+)3W@\IT,QV-X!T4I7R6M
M;)^^$5,4%7;-5OW=(#17.Y318XP870*SB3!%H2[)A$?<65&KP_6.H4R^$M3D
M,3*2593AL;9I53\)ML7#S>-'#/B2W''$6XXBT0L1%#(#8HPTU'2D08,&D9I%
MBYK?@H__Y>M^(C_,F*>1CKB5[9I83-CXA6GXE-)];6RW(_A=UW+$=#(=GK=!
M3<1ZI9$#2-7,2._U0L=TIV ZG5'F,D!-7.?2R#(#*C1P#\6M16<$$,Q6 A0=
MS6U.!;R]S;A;QVSI97FF7)#4FHD.FQ[@%%G*M4*;(?6Q@AFC3UV-"5OF>#"7
MT"(/>O'D2T*3#%I_F\3,!G/232E.7;EM>5N<*,$9^3@@MKG)!QS4#,Z%>6U4
MWE'!#@>2FVTU,.$3<]2.O7R%*62\QY2=[4#\/[?;$T,:O6Y!_?]8E[M][)T(
M(@4CH*>B&Q A/#,HH$^"_VA" $41>#[BX;TBRE/WU/%Y+-(ACI*&#JLU%P&+
M;L1AEY\[#%E22Z-!H (T2_5S#H&F/^)=GNO )?!2'- 3*65]<RZE^0+$1D<B
M/&=@44XXC! VY#/7@^\7!"G.+!YCB6<KH+-L#NAKC7@3$I!RU&:;,M@[/X6=
M?N/K6#V4!(TEGB>6VF4H1L6C8>Q LVF:G,UFJ&2$]^&AJ0LAC4$P#>YFWY+N
ME-".%#&_>42+2N465@0Q;I'VMOB1NN9)))*^:]T$V-)&AA.ASF@JZ3H%BW-;
MR\A5.I'@_EZY3.,6-9/%,PF;TYQQACC,O30.G"*/49=-YL1:0V6$IL=T =B)
M2VR"3\@DNT)D(Y5&!/9D=IZ<3(Z?CM9O+XC3"\"8#"<G(J%FVY+JGXTQ6V9I
MGT!5I5U_^#JA_C.=-,,7N<PLG5D?/#ORPU0&IYDZ?S@)[!6))_D*;'&O"S@*
M/B(_THYC>5#$L5 Z;38/^TO?H;81MJ2\/:QS_+OY!GXK3,8"11Q=:@]P]O$4
M^O&A$$WUK\1X>-;9UP*#\Y]J3L*4=^3XX][.WD0=Z7#Z2 <ZY0]5))0IE701
M!+)E]HPMM-<+-$YBO!=2N_C]Y2=.?S0V/#G$]$/JN107$KG$^H=/?7,:]3X
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MBHGCQ2@25K?PI@[?'9;&>U.%RP)L398WX'EN8$Z[X /Z#U&G_P=02P,$%
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MVOMX^V+DW-Z!;Z7!&[4=S@3'_8($\/M$2M._D('5GR)G_P)02P,$%     @
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M240&7LER _L4U&XS;%\].QF[U39?R;E(H_V]!.?E<#Z>#,>3\"0XD9(?0D3
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MO 'O"^=B_\ &AO\@G/\?4$L#!!0    ( .@[;E5]W<U5;0(  )H%   9
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M)UI?P/G2&-IM_ '#.,Z> 5!+ P04    " #H.VY5URAHY!4%  "*#   &0
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MY1I)BL(4T.]7G*OG&U-!?5X__A=02P,$%     @ Z#MN59.LR7L# P  I D
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M"Z8>^.H;K/UT-%_,F31/LBIC.Z%%XH54/%N#44&6YN6;OJW780/@M@\ O#7
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MC(M/V?8GWOQ!<\4+LCBO_B7;YMKIB 1E7F1)$RSO((G2^G_VO7D0>P'6XD"
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M/\]1R-7(Z3I/#V[X(C'V@1L.<[; *9K;?*)HYM8L,4\QTUQFH' ^<LZZI^/
MQI<!=QQ7NC$&JV0FY;V=7,8CQ[,)H<#(6 9&MR6.40A+1&D\5)Q.O:0%-L=/
M[!]+[:1EQC2.I?C&8Y.,G!,'8IRS0I@;N?J$E9Z!Y8NDT.455E6LYT!4:"/3
M"DP9I#Q;W]ECY4,#T.V_ / K@/]60*\"]$JAZ\Q*61?,L'"HY J4C28V.RB]
M*=&DAF>VBE.CZ"TGG D_,J[@CHD"X1J9+A12B8R&0SC3&FG LABN.)MQP0U'
M_105 S/0 %-%;C JE.+9 LZ9YAKV+] P+O0!D?V.[&RLTVF@#N%V>@'[>P>P
M!SR#KXDL-*VNAZXAH39=-ZI$G:]%^2^(FF)^!#VO [[G^RWP\7;X!48$[Y;P
M[B;<)7MKC_W:8[_DZ[WJ<>=55S=\M%&?9:;^,/;[%2T EP93_:/-G'4V_?9L
M[+9PJG,6X<BA[UZC6J(3OG_7#;P/;5;MB&S#N%YM7&\;>SAF.@%\*/B2"=LM
M;6+7#$')8+>L9=@+3KSCH;MLJG@>=3SP;6\L6]+KU^GUMZ;WI9"&2C91/*(2
M4LN>E7L27#-U;XM,>RQ<QI0XCYBH*N\VJ[Y_A4L4T#UH$[9U[;^MXH[(-FP:
MU#8-_JOV'^S2N!V1;1@7U,8%_]S^P9O:_WE46_N[C6/$'N'4QPN>:1 X)YQW
M=$QFJ/6QN)X8F9<GRTP:.J?*84)_$JAL +V?2_I JHD]K.I_D_ 74$L#!!0
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M>*'2A,%"(%ED&15_7T/*=U/'<_87[I/U1ID+[FR2TS4L07W*%T*?N35*G&3
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M260.;8>T\NS$>O&Z]H365'Z8';W@=31#KY-H7VA-TPZSJ-<YN7V79@C/*WV
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MJ!926J.4#.KH]$ ]<>[Y&2;Q0WR2Z7V2+LHMQ*]1=I!*$-N-E($G]1Z>FE)
M-1W5#%0S4<U"-1O5'%1S4<U#-1_5 E0+*:U9J>ID]J![=N!I@$[2BVHZJAFH
M9J*:A6HVJCFHYJ*:AVH^J@6H%E):LY1H=2E1![?K>Y MSZ,J;B)4;&-"\M;4
MD[K_DRL'FKI&-1/5+%2S4<U!-1?5/%3S42U M9#2FI6C3ET/U/,#(\.EGWT:
M7KUO)Y_=H'%N5#-0S40U"]5L5'-0S44U#]5\5 M0+:2T9HVJX]R#_OD#)3**
M.D8U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 LIK5E*ZI#WX)6I@9/R1GMY(_W$
M@5)+REMK6QAWK-Z!DTL'FO-&-1/5+%2S4<U!-1?5/%3S42U M9#2FJ6CSGD/
MU#EOYL92DN4B**J.S,M8S.UJE2;?BC;<O2=T\F-4TU'-0#43U2Q4LU'-0347
MU3Q4\U$M0+60TIK%K,Z=#\Z?_'B 3GZ,:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ
M!:@64EJSE-3QZ8$ZW_S3]YY>FK'W:$2%IGY1S4 U$]4L5+-1S4$U%]4\5/-1
M+4"UD-*:E:-._0[4\5QD1/7\&;,,N3&%3M.,:CJJ&:AFHIJ%:C:J.:CFHIJ'
M:CZJ!:@64EJC@ WKK/'P_&F:AV@8&-5T5#-0S40U"]5L5'-0S44U#]5\5 M0
M+:2T9BFIP\!#]33-0?1],W?(EV@N,_&Y? 9R+8OS%_'[+)[,3AQ:57T=STG4
M,KI2[]?)%07-!*.:B6H6JMFHYJ":BVH>JOFH%J!:2&G-BJ+5%46="=Y-@IAM
M*DI:591RNH]-13F:)"-3S8XX/ X*:X,7"@H:%48U ]5,5+-0S48U!]5<5/-0
MS4>U -5"2FL6E#HJ/%1'A<?)?![=)>EV8J!GUVN^)/,HBZ-R.J!T$0G/4UY?
M4?=T\J (#?ZBFH%J)JI9J&:CFH-J+JIYJ.:C6H!J(:4U*TX=_!WVS[^^0L83
MQZBFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&E-4M)'?P=JH._S9.7:C346D_(
MS.(8U714,U#-1#5K>)RW[K<MYXOVZKRQ5Q?MU4,U']4"5 LIK5D#Z@3O4)W@
M_<D!C/@AMG/#/ZG'-&CR%M5T5#-0S40U"]5L5'-0S44U#]5\5 M0+:2T9A&J
MD[?#\Y.W0S1YBVHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%E):LY34R=NA.GG[
M]C$-F1H<HYJ.:@:JF95V>-?KV5# >GT3^_5-G-<W<=%WYJ&:CVH!JH64UCQ&
MZXSK4)UQ=99Y*K\7A^<X25?5H=IZB**)4U334<U -1/5+%2S4<U!-1?5/%3S
M42U M9#2&N5D5"=.1^<G3D=HXA35=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"VD
MM&8IJ1.G(W7B]':[2MWN^1M3RO9J@LY BVHZJAFH9J*:A6HVJCFHYJ*:AVH^
MJ@6CEU+:S9%?2/7:K!-:72?4.5+C^TI.\N*<(YI.X^J!O(/EA!2A435\<NE
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MU483%&W>-IWT0C 2JB'/C]^-X *G$4E7333F'KAN]0CLN <'3JN;E])SCL7
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ME&]&8L<9795&:3(BEN6-4AIG@]FTO';+9]-\+Y,X8[<<B7V:4OX\9TG^>#W
M@Y<+G^/-5A871K/ICF[8'9-?=[=<G8UJE%6<LDS$>88X6U\/;O!51.S"H&SQ
M+6:/XN@8%4.YS_,?Q<G'U?7 *GK$$K:4!015?P]LP9*D0%+]^*\"'=2<A>'Q
M\0MZ5 Y>#>:>"K;(D^_Q2FZO!_X K=B:[A/Y.7_\BU4#<@N\99Z(\A<]5FVM
M 5KNA<S3RECU((VSPS]]JAQQ9*!PN@U(94#:!LXK!G9E8+<,R&L&3F7@7,K@
M5@9NF^&U,7B5@5?Z_N"LTM,!E70VY?DCXD5KA58<E'*5ULK!<5;,K#O)U=U8
MV<G9G<R7/S[,E38KM,A3-6$%+27_@,I;Z)]=>7I3S(!8/J.OV8IQ_=YM0C/T
M-F"2QHEXIRR_W@7H[9MWZ T:(;&EG D49\HREN*]NJB.OVSSO:#92DQ'4HVB
MZ,MH6?5X?N@Q>:7'-OJ49W(K4*AZLNJP#\SVDW/VD=D>$P/ 2+F_UH"\:# G
M1L0[MALBVWJ/B$5(1X<6EYOC+G_\&GOX:^R1V3Q@2V6.N\PU7]KU?+9+//L5
MO+_WZ;V:G_D:W943KVM^'1"<;H0BE%^)'5VRZX&*U8+Q!S:8_?X;]JP_NK2!
M! L@P4)(L @(3-/4J35U3.BS.=O$619G&S2G*M0L69>H1HB^HD*"!0<PMP0K
M7O0/,VQYGNM[D^GHX5@P2-8("$P3S*T%<XV"_<EI)CMCZ]P]=089NY9EZ;Y8
MG+93S4[;!:?M',\K %N^/6TWQJ[EV+[>+C(.["?=YM5N\XQN"Y\87\:BVW%&
MT[[S&Q(L\$Y<^X%XQ&TK ,D9 8%I,HUKF<9&F19%"$J2;IF,IGUE@@0+QJ<R
M.9YO3RRG)10D:P0$I@GEUT+YYN<I6YUY:?A=H9G8!+NM<&0DZJO$I:PA)&O4
MR:J_AC0O3VHO3XQ>/B0! K%#]*+W"7N/J$0L6Q7+L!WC<=[YJ$Q..J1<@#T;
MMWQOI._K^PM)0TC2Z)34<;!E8]+M>6PUR9MUD>_I@TJ]"L^C=<[1>B_WG*%-
M\1;NS*^LTZG@$L=U)JU0L##3]_7]Q;PA*&\$A::+=)1A8V-*\KVL;JC\^N:!
M<;IAZ.4]CVYYW!V7*D2@UP@H6@"*%H*B15!HNM*D49K\>J)BQNBM+21:4*'Y
MQ\ONH3]N/YV0G!$4FJY94R_ QM35E*N8+7LK!5HIJ-"P?1Q,AY;?E@JT" "%
MIDO5E &PN0Y@S(_,MKW% JT 5&B:6-;P1"O0_!\*3=>JJ0!@<PG F"29;7MK
M!8D65&B:5O;P9($"R1E!H>E:-64'?*;N<#9/J@!\+=CX[23)3--;"*\KPK5)
M0U#2J&.@V@M0]W!3,<#FDL%/YT@5KMZ?=N%P86;O[?A+.$-0SJB#TS[66O=[
M4P# ?K^E]R+/)*=+N:<)^L)XBM[^RR@7[SI]#YE^+T#1 E"T$!0M@D+3-6_*
M$?A,/6(OA:1E2+OP&8/,]1>@:,&9L?KHN9B^R$;IX9/D&*WH<]='KQ"T7Q$4
MFOZ]M*E[D,OJ'KWCJ1FWK]:@:,&9,8]KK5^3&+0[T87=\5ZF'K8Z.J;KVY1,
MB+ED<K/9<+:ADJ&/*E['F8B7Z!M-]IV+$P):+ %%"T#10E"T" I-U[@IEA!S
ML:1WG*[PO.,U@CLFK;60F;6W?I=PAJ"<$12:KDM3$"'F@LC/QU;[Q%<N;G_7
M-9/WEN<"RA"4,NJ@M%K+U-'1=JR4\4VY<4Z@9;[/Y&$G2WVUWIQW4VY):UV?
MXZL%[K@>X*OPL/6N@3_L!/Q$^4:%2Y2PM:*RAF.56?+#YKK#B<QWY6:P^US*
M/"T/MXRN&"\:J/OK/)<O)P5!O<5Q]C]02P,$%     @ Z#MN5?+LO@TO P
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M:P]5!O.B,2DFDFU,,S!G4K469KA6S1QP;:#>+QF3AXDFJ-K#^ ]02P,$%
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #H.VY5RS;D=^4#  !#&P  #P
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M?U;O2-=548R@;*ZFFN?[;T#[[U?O?P)02P,$%     @ Z#MN52E=B*"3 0
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M!7&-@F,[37^4Y-+VVN;0%W!A"2B +=M)D[>O(3]2JQ0U2J7.!0N\.S-XI>\
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MT9]U_TGFGU!+ 0(4 Q0    ( .@[;E4'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ Z#MN5>VNJOKN
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ Z#MN59E<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #H.VY5)BJL,[\%  "S'@
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ Z#MN56AZA&^>!0  C1<  !@              ("! @X  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( .@[;E6E&3)7CP(
M "0'   8              " @=83  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " #H.VY5I=03/T(%  "2%P  &               @(&;
M%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ Z#MN56E4
M9-+E!P  ;3P  !@              ("!$QP  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( .@[;E6XF.3CUP8   4>   8
M  " @2XD  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #H
M.VY523&8IJ<*   +&@  &               @($[*P  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ Z#MN53W6]OX5!0  K0P  !@
M         ("!&#8  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( .@[;E4]S3)89@(  ,H%   8              " @6,[  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #H.VY5Y9@5,XX(  !K%@
M&0              @('_/0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( .@[;E5()E?_BP0  + +   9              " @<1&  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ Z#MN5081(+UH
M P  J <  !D              ("!ADL  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " #H.VY5^QRLYZ '  "4$@  &0
M@($E3P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( .@[
M;E5Z@\L8!AL  /=>   9              " @?Q6  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ Z#MN5:0U\2Z[ P  +0@  !D
M         ("!.7(  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " #H.VY5B&.+ZS4&   @$0  &0              @($K=@  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( .@[;E5//O'JN <  "P5
M   9              " @9=\  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ Z#MN54YAEH\1!P  31   !D              ("!AH0
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #H.VY5?=W-
M56T"  ":!0  &0              @('.BP  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( .@[;E77*&CD%04  (H,   9
M  " @7*.  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
MZ#MN51L(ASVD @  D04  !D              ("!OI,  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " #H.VY5[!S;D]$"  #7!@  &0
M            @(&9E@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( .@[;E5U]GB0X0(  !D&   9              " @:&9  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ Z#MN58ZC[&(C!@
MK \  !D              ("!N9P  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " #H.VY5VLXKHB #  #)"0  &0              @($3
MHP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( .@[;E6?
M.'KB3P0  +L7   9              " @6JF  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ Z#MN59.LR7L# P  I D  !D
M     ("!\*H  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .@[;E51U!CHX00  *TC   9              "
M@4C"  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ Z#MN
M54LP/4[@%@  7V4! !D              ("!8,<  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " #H.VY56-$$A <$  #Z$   &0
M        @(%WW@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( .@[;E6;M-/[F0,  +X0   9              " @;7B  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ Z#MN567[ [Y%!   [!4
M !D              ("!A>8  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " #H.VY5MT&YF\<#  !M$   &0              @($!ZP
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( .@[;E7.Y,)'
MZP4  .XH   9              " @?_N  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ Z#MN5?+LO@TO P  *@H  !D
M ("!(?4  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #H
M.VY5W4I.>84+   8BP  &0              @(&'^   >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( .@[;E63U;0*/@(  /($   9
M          " @4,$ 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#
M%     @ Z#MN5843:<!' P  RA0   T              ( !N 8! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " #H.VY5EXJ[',     3 @  "P
M    @ $J"@$ 7W)E;',O+G)E;'-02P$"% ,4    " #H.VY5RS;D=^4#  !#
M&P  #P              @ $3"P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ Z#MN52E=B*"3 0  XA@  !H              ( !)0\! 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ Z#MN58B,J3>E 0  +QD
M !,              ( !\! ! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ #$ ,0!.#0  QA(!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>170</ContextCount>
  <ElementCount>247</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>58</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100040 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureOrganization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Financings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/Financings</Role>
      <ShortName>Financings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/NetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Joint Venture</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/JointVenture</Role>
      <ShortName>Joint Venture</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://alaunos.com/20220930/taxonomy/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20220930/taxonomy/role/DisclosureDebt</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20220930/taxonomy/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20220930/taxonomy/role/NetLossPerShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20220930/taxonomy/role/StockBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Organization - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails</Role>
      <ShortName>Organization - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Financings - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails</Role>
      <ShortName>Financings - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Debt - Schedule of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails</Role>
      <ShortName>Debt - Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://alaunos.com/20220930/taxonomy/role/FairValueMeasurementsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Net Loss Per Share - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Stock-Based Compensation Expense Included in Statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails</Role>
      <ShortName>Stock-Based Compensation Expense Included in Statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails</Role>
      <ShortName>Stock-Based Compensation - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Stock-Based Compensation - Stock Option Activity Under Stock Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity Under Stock Option Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Stock-Based Compensation - Summary of Non-Vested Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Non-Vested Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Warrants - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails</Role>
      <ShortName>Warrants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="tcrt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Joint Venture - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails</Role>
      <ShortName>Joint Venture - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="tcrt-20220930.htm">tcrt-20220930.htm</File>
    <File>tcrt-20220930.xsd</File>
    <File>tcrt-20220930_cal.xml</File>
    <File>tcrt-20220930_def.xml</File>
    <File>tcrt-20220930_lab.xml</File>
    <File>tcrt-20220930_pre.xml</File>
    <File>tcrt-ex31_1.htm</File>
    <File>tcrt-ex32_1.htm</File>
    <File>tcrt-ex3_1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img159889792_0.jpg</File>
    <File>img159889792_1.jpg</File>
    <File>img159889792_2.jpg</File>
    <File>img159889792_3.jpg</File>
    <File>img159889792_4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="441">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>62
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tcrt-20220930.htm": {
   "axisCustom": 4,
   "axisStandard": 24,
   "contextCount": 170,
   "dts": {
    "calculationLink": {
     "local": [
      "tcrt-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tcrt-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "tcrt-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tcrt-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tcrt-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tcrt-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 510,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 6
   },
   "keyCustom": 53,
   "keyStandard": 194,
   "memberCustom": 36,
   "memberStandard": 20,
   "nsprefix": "tcrt",
   "nsuri": "http://alaunos.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Cover Page",
     "role": "http://alaunos.com/20220930/taxonomy/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Debt",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Fair Value Measurements",
     "role": "http://alaunos.com/20220930/taxonomy/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Net Loss per Share",
     "role": "http://alaunos.com/20220930/taxonomy/role/NetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Related Party Transactions",
     "role": "http://alaunos.com/20220930/taxonomy/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Commitments and Contingencies",
     "role": "http://alaunos.com/20220930/taxonomy/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Leases",
     "role": "http://alaunos.com/20220930/taxonomy/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Stock-Based Compensation",
     "role": "http://alaunos.com/20220930/taxonomy/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcrt:WarrantTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Warrants",
     "role": "http://alaunos.com/20220930/taxonomy/role/Warrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcrt:WarrantTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Joint Venture",
     "role": "http://alaunos.com/20220930/taxonomy/role/JointVenture",
     "shortName": "Joint Venture",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Subsequent Events",
     "role": "http://alaunos.com/20220930/taxonomy/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_acc8d98b-3c82-4d2e-af71-6452e557354e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - BALANCE SHEETS",
     "role": "http://alaunos.com/20220930/taxonomy/role/BalanceSheets",
     "shortName": "BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_acc8d98b-3c82-4d2e-af71-6452e557354e",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://alaunos.com/20220930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Debt (Tables)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://alaunos.com/20220930/taxonomy/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://alaunos.com/20220930/taxonomy/role/NetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://alaunos.com/20220930/taxonomy/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_acc8d98b-3c82-4d2e-af71-6452e557354e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Organization - Additional Information (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
     "shortName": "Organization - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_72bda269-9480-4b72-b4ce-a8fa1e5d2d6a",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "tcrt:FinancingArrangementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_4466f87e-f227-46f8-9092-8a32178d41c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Financings - Additional Information (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
     "shortName": "Financings - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "tcrt:FinancingArrangementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_4466f87e-f227-46f8-9092-8a32178d41c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_acc8d98b-3c82-4d2e-af71-6452e557354e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Debt - Schedule of Debt (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
     "shortName": "Debt - Schedule of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_acc8d98b-3c82-4d2e-af71-6452e557354e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:DebtInstrumentDescriptionOfVariableRateBasis",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Debt - Additional Information (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
     "shortName": "Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:DebtInstrumentDescriptionOfVariableRateBasis",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_e3064554-7470-4ef4-931d-019f0af3c58c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_e3064554-7470-4ef4-931d-019f0af3c58c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_acc8d98b-3c82-4d2e-af71-6452e557354e",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - BALANCE SHEETS (Parenthetical)",
     "role": "http://alaunos.com/20220930/taxonomy/role/BalanceSheetsParenthetical",
     "shortName": "BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_acc8d98b-3c82-4d2e-af71-6452e557354e",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_00a63ae4-63b6-4ac6-941f-4be4fd9e3e98",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_00a63ae4-63b6-4ac6-941f-4be4fd9e3e98",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Net Loss Per Share - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_23eae7ee-dd71-428c-93da-1b90bf020452",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_23eae7ee-dd71-428c-93da-1b90bf020452",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "tcrt:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_5748e941-3c1c-4556-8329-7aeb6d259272",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_7c362f59-d6f4-4a7a-a1c8-b74ebbed16b4",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_acc8d98b-3c82-4d2e-af71-6452e557354e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": "-5",
      "lang": null,
      "name": "tcrt:GainLossOnModificationOfLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_5748e941-3c1c-4556-8329-7aeb6d259272",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Stock-Based Compensation Expense Included in Statement of Operations (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails",
     "shortName": "Stock-Based Compensation Expense Included in Statement of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_5748e941-3c1c-4556-8329-7aeb6d259272",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_5748e941-3c1c-4556-8329-7aeb6d259272",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_5748e941-3c1c-4556-8329-7aeb6d259272",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_5748e941-3c1c-4556-8329-7aeb6d259272",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
     "shortName": "Stock-Based Compensation - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_5748e941-3c1c-4556-8329-7aeb6d259272",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_277ad1c2-e2ec-409f-b9ec-704d1983abe1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Stock-Based Compensation - Stock Option Activity Under Stock Option Plan (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity Under Stock Option Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_87c24bba-d603-4bbb-92e5-692a66baf6fa",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Stock-Based Compensation - Summary of Non-Vested Restricted Stock (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails",
     "shortName": "Stock-Based Compensation - Summary of Non-Vested Restricted Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_87c24bba-d603-4bbb-92e5-692a66baf6fa",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_5748e941-3c1c-4556-8329-7aeb6d259272",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - STATEMENTS OF OPERATIONS",
     "role": "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations",
     "shortName": "STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_5748e941-3c1c-4556-8329-7aeb6d259272",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_5748e941-3c1c-4556-8329-7aeb6d259272",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Warrants - Additional Information (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
     "shortName": "Warrants - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "tcrt:WarrantTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_6e455d27-ae8e-4cd2-8656-5e6b3044aec4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_bd378eef-0abd-4f06-8c55-ed8f64bbee7f",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Joint Venture - Additional Information (Details)",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
     "shortName": "Joint Venture - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_bd378eef-0abd-4f06-8c55-ed8f64bbee7f",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_afa5d5a2-bab5-4430-b57c-13817635e7f3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity",
     "shortName": "STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_afa5d5a2-bab5-4430-b57c-13817635e7f3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - STATEMENTS OF CASH FLOWS",
     "role": "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Organization",
     "role": "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcrt:FinancingArrangementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Financings",
     "role": "http://alaunos.com/20220930/taxonomy/role/Financings",
     "shortName": "Financings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcrt:FinancingArrangementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://alaunos.com/20220930/taxonomy/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcrt-20220930.htm",
      "contextRef": "C_a649b50f-8367-4a1c-9108-4b85ebc15317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 58,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r78",
      "r194",
      "r198",
      "r203",
      "r336",
      "r337",
      "r338",
      "r339",
      "r419",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r78",
      "r194",
      "r198",
      "r203",
      "r336",
      "r337",
      "r338",
      "r339",
      "r419",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r209",
      "r246",
      "r278",
      "r280",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r456",
      "r499",
      "r502",
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r209",
      "r246",
      "r278",
      "r280",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r456",
      "r499",
      "r502",
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r141",
      "r190",
      "r191",
      "r261",
      "r262",
      "r458",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r141",
      "r190",
      "r191",
      "r261",
      "r262",
      "r458",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r175",
      "r189",
      "r190",
      "r191",
      "r192",
      "r209",
      "r246",
      "r264",
      "r278",
      "r280",
      "r313",
      "r314",
      "r315",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r456",
      "r499",
      "r502",
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r175",
      "r189",
      "r190",
      "r191",
      "r192",
      "r209",
      "r246",
      "r264",
      "r278",
      "r280",
      "r313",
      "r314",
      "r315",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r456",
      "r499",
      "r502",
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r3",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r87",
      "r88",
      "r89",
      "r90",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r112",
      "r161",
      "r162",
      "r331",
      "r347",
      "r351",
      "r352",
      "r353",
      "r391",
      "r408",
      "r409",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r3",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r87",
      "r88",
      "r89",
      "r90",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r112",
      "r161",
      "r162",
      "r331",
      "r347",
      "r351",
      "r352",
      "r353",
      "r391",
      "r408",
      "r409",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r91",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]",
        "verboseLabel": "Forecast[Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r3",
      "r80",
      "r82",
      "r83",
      "r84",
      "r87",
      "r88",
      "r89",
      "r90",
      "r92",
      "r93",
      "r95",
      "r96",
      "r112",
      "r161",
      "r162",
      "r331",
      "r347",
      "r351",
      "r352",
      "r353",
      "r391",
      "r408",
      "r409",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r91",
      "r97",
      "r188",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r142",
      "r143",
      "r261",
      "r263",
      "r501",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r142",
      "r143",
      "r261",
      "r263",
      "r501",
      "r516",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r91",
      "r97",
      "r188",
      "r279",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r145",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_AccretionOfTermLoanFinalPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of term loan final payment.",
        "label": "Accretion Of Term Loan Final Payment",
        "terseLabel": "Accretion of term loan final payment"
       }
      }
     },
     "localname": "AccretionOfTermLoanFinalPayment",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AccrualsPriorToFirstMarketingApproval": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments due prior to the first marketing approval for TCR products.",
        "label": "Accruals Prior to First Marketing Approval",
        "terseLabel": "Payments due prior to the first marketing approval"
       }
      }
     },
     "localname": "AccrualsPriorToFirstMarketingApproval",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AdditionalLoansCommitted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional loans committed.",
        "label": "Additional Loans Committed",
        "terseLabel": "Additional Loans Committed"
       }
      }
     },
     "localname": "AdditionalLoansCommitted",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AdditionalNumberOfWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional number of warrants issued.",
        "label": "Additional Number Of Warrants Issued",
        "terseLabel": "Additional number warrants issued"
       }
      }
     },
     "localname": "AdditionalNumberOfWarrantsIssued",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcrt_AggregateAmountPotentiallyReimburseableAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Amount Potentially Reimburseable Amount.",
        "label": "Aggregate Amount Potentially Reimburseable Amount",
        "verboseLabel": "Reimbursement of historical costs"
       }
      }
     },
     "localname": "AggregateAmountPotentiallyReimburseableAmount",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AggregateBenchmarkPaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Aggregate Benchmark Payments Payable.",
        "label": "Aggregate Benchmark Payments Payable",
        "verboseLabel": "Aggregate Benchmark Payments Payable"
       }
      }
     },
     "localname": "AggregateBenchmarkPaymentsPayable",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AggregateMinimumAnnualRoyaltiesPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate minimum annual royalties paid.",
        "label": "Aggregate Minimum Annual Royalties Paid",
        "terseLabel": "Aggregate minimum annual royalties paid"
       }
      }
     },
     "localname": "AggregateMinimumAnnualRoyaltiesPaid",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AggregatePotentialBenchmarkPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate potential benchmark payments.",
        "label": "Aggregate potential benchmark payments",
        "terseLabel": "Aggregate potential benchmark payments"
       }
      }
     },
     "localname": "AggregatePotentialBenchmarkPayments",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AgreementTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination notice period.",
        "label": "Agreement Termination Notice Period",
        "verboseLabel": "Agreement termination, notice period"
       }
      }
     },
     "localname": "AgreementTerminationNoticePeriod",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tcrt_AgreementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement Type [Axis]"
       }
      }
     },
     "localname": "AgreementTypeAxis",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_AgreementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement Type [Domain]"
       }
      }
     },
     "localname": "AgreementTypeDomain",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_AnnualBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual base rent.",
        "label": "Annual Base Rent",
        "terseLabel": "Annual Base Rent"
       }
      }
     },
     "localname": "AnnualBaseRent",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_AnnualLicenseFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual License Fees",
        "label": "Annual License Fees"
       }
      }
     },
     "localname": "AnnualLicenseFees",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market Offering [Member]",
        "terseLabel": "Market Offering [Member]"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August seven two thousand twenty three to term loan maturity date.",
        "label": "August Seven Two Thousand Twenty Three To term Loan Maturity Date [Member]",
        "terseLabel": "Between August 7, 2023 and Term Loan Maturity Date [Member]"
       }
      }
     },
     "localname": "AugustSevenTwoThousandTwentyThreeToTermLoanMaturityDateMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtPrepaymentPremiumPercentageDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August seven two thousand twenty two to august six two thousand twenty three.",
        "label": "August Seven Two Thousand Twenty Two to August Six Two Thousand Twenty Three [Member]",
        "terseLabel": "Between August 7, 2022 and August 6, 2023 [Member]"
       }
      }
     },
     "localname": "AugustSevenTwoThousandTwentyTwoToAugustSixTwoThousandTwentyThreeMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtPrepaymentPremiumPercentageDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_BeforeAugustSixTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Before august six two thousand twenty two.",
        "label": "Before August Six Two Thousand Twenty Two [Member]",
        "terseLabel": "On or before August 6, 2022 [Member]"
       }
      }
     },
     "localname": "BeforeAugustSixTwoThousandTwentyTwoMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtPrepaymentPremiumPercentageDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_BlackScholesModelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Black-Scholes Model [Member].",
        "label": "Black Scholes Model [Member]",
        "terseLabel": "Black-Scholes Model [Member]"
       }
      }
     },
     "localname": "BlackScholesModelMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_CARProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAR Products [Member]"
       }
      }
     },
     "localname": "CARProductsMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_CRADAAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CRADA Agreement",
        "label": "CRADA Agreement [Member]"
       }
      }
     },
     "localname": "CRADAAgreementMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_ClassOfWarrantOrRightAxisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Axis.",
        "label": "Class Of Warrant Or Right Axis [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxisAxis",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_ClassOfWarrantOrRightDomainDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right.",
        "label": "Class Of Warrant Or Right Domain [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomainDomain",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_CollaborationAgreementWithSolasiaPharmaKkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement with solasia pharma K.K.",
        "label": "Collaboration Agreement With Solasia Pharma KK [Member]"
       }
      }
     },
     "localname": "CollaborationAgreementWithSolasiaPharmaKkMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_CommitmentsAndContingenciesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies Disclosure [Line Items]",
        "label": "Commitments and Contingencies Disclosure [Line Items]",
        "verboseLabel": "Accrued Payments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_CommitmentsAndContingenciesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies Disclosure [Table]",
        "label": "Commitments and Contingencies Disclosure [Table]",
        "terseLabel": "Commitments and Contingencies Disclosure [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_ContributionPayableOnPerAnnumBasis": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contribution payable on per annum basis.",
        "label": "Contribution Payable on Per Annum Basis",
        "terseLabel": "Contribution payable on per annum basis"
       }
      }
     },
     "localname": "ContributionPayableOnPerAnnumBasis",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_DebtInstrumentPrepaymentPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment premium.",
        "label": "Debt Instrument Prepayment Premium",
        "terseLabel": "Prepayment premium"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremium",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_DebtInstrumentPrincipalPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument principal payments percentage.",
        "label": "Debt instrument Principal Payments Percentage",
        "terseLabel": "Debt instrument principal payments percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrincipalPaymentsPercentage",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtPrepaymentPremiumPercentageDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_DescriptionOfFirstBenchmarkPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Description Of First Benchmark Payable.",
        "label": "Description Of First Benchmark Payable",
        "verboseLabel": "Description Of First Benchmark Payable"
       }
      }
     },
     "localname": "DescriptionOfFirstBenchmarkPayable",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones.",
        "label": "Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones",
        "verboseLabel": "Description Of option To terminate Agreement"
       }
      }
     },
     "localname": "DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_DueDateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due date [Axis]"
       }
      }
     },
     "localname": "DueDateAxis",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_DueDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due date [Domain]"
       }
      }
     },
     "localname": "DueDateDomain",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_EdenBioCellMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eden Bio Cell",
        "label": "Eden Bio Cell [Member]"
       }
      }
     },
     "localname": "EdenBioCellMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_EdenBiocellMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eden Biocell.",
        "label": "Eden Biocell [Member]"
       }
      }
     },
     "localname": "EdenBiocellMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_EightScheduledPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eighth Scheduled Payment.",
        "label": "Eighth Scheduled Payment [Member]",
        "terseLabel": "Eighth Scheduled Payment"
       }
      }
     },
     "localname": "EightScheduledPaymentMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_EquityAndTermBMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity and Term B Milestone [Member]",
        "label": "Equity and Term B Milestone [Member]"
       }
      }
     },
     "localname": "EquityAndTermBMilestoneMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_EquityDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity distribution agreement.",
        "label": "Equity Distribution Agreement [Member]",
        "terseLabel": "Equity Distribution Agreement"
       }
      }
     },
     "localname": "EquityDistributionAgreementMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_EquityMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity milestone.",
        "label": "Equity Milestone [Member]"
       }
      }
     },
     "localname": "EquityMilestoneMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_FairValueOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value of Warrants",
        "label": "Fair Value of Warrants",
        "terseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "FairValueOfWarrants",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_FinancingArrangementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Includes disclosures related to financing receivables and financing guarantees in which the company is the guarantor.",
        "label": "Financing Arrangements Disclosure [Text Block]",
        "terseLabel": "Financings"
       }
      }
     },
     "localname": "FinancingArrangementsDisclosureTextBlock",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/Financings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tcrt_FullyDrawnAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fully drawn amount.",
        "label": "Fully Drawn Amount",
        "terseLabel": "Fully drawn amount"
       }
      }
     },
     "localname": "FullyDrawnAmount",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_GainLossOnModificationOfLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on modification of lease.",
        "label": "Gain (Loss) On Modification Of Lease",
        "terseLabel": "Gain (Loss) On Modification Of Lease"
       }
      }
     },
     "localname": "GainLossOnModificationOfLease",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_GainLossOnOperatingLeaseModification": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on operating lease modification.",
        "label": "Gain (Loss) On Operating Lease Modification",
        "negatedLabel": "Gain on lease modification",
        "terseLabel": "Gain on lease modification"
       }
      }
     },
     "localname": "GainLossOnOperatingLeaseModification",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_HoustonTexasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Houston Texas [Member]",
        "label": "Houston Texas [Member]",
        "verboseLabel": "Houston, TX"
       }
      }
     },
     "localname": "HoustonTexasMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of lease liabilities reported as liabilities.",
        "label": "Increase Decrease In Lease Liabilities",
        "verboseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_IncreaseDecreaseInRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of right of use asset reported as assets.",
        "label": "Increase Decrease In Right Of Use Asset",
        "negatedLabel": "Decrease (increase) in the carrying amount of right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInRightOfUseAsset",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_InducementStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement stock options member.",
        "label": "Inducement Stock Options [Member]",
        "terseLabel": "Inducement Stock Options"
       }
      }
     },
     "localname": "InducementStockOptionsMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_InitialBenchmarkPaymentDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The first benchmark payment due upon the initiation of the Company's first sponsored phase.",
        "label": "Initial Benchmark Payment Due",
        "terseLabel": "First benchmark payment"
       }
      }
     },
     "localname": "InitialBenchmarkPaymentDue",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_InitialBorrowingZeroMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial borrowing zero milestones.",
        "label": "Initial Borrowing Zero Milestones [Member]",
        "terseLabel": "Initial Borrowing Zero Milestones [Member]"
       }
      }
     },
     "localname": "InitialBorrowingZeroMilestonesMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_InterestExpenseAmortizedDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense amortized date.",
        "label": "Interest Expense Amortized Date",
        "terseLabel": "Interest expense amortized date"
       }
      }
     },
     "localname": "InterestExpenseAmortizedDate",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "tcrt_IntrexonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrexon Corporation/Precigen [Member]",
        "verboseLabel": "Intrexon Corporation"
       }
      }
     },
     "localname": "IntrexonCorporationMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance and sale of common stock in public offering price per share.",
        "label": "Issuance And Sale of Common Stock In Public Offering Price Per Share",
        "terseLabel": "Issuance &amp; sale of common stock in public offering price per share"
       }
      }
     },
     "localname": "IssuanceAndSaleOfCommonStockInPublicOfferingPricePerShare",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "tcrt_IssuanceCostsInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance costs in accounts payable and accrued expenses.",
        "label": "Issuance costs in accounts payable and accrued expenses",
        "terseLabel": "Issuance costs in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IssuanceCostsInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year four.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_LesseeOperatingLeaseMonthlyAverageRentalPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Lessee Operating Lease Monthly Average Rental Payment .",
        "label": "Lessee Operating Lease Monthly Average Rental Payment",
        "terseLabel": "Operating Lease Monthly Rental Payment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyAverageRentalPayment",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_LesseeOperatingLeaseMonthlyRentalPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Monthly Rental Payment.",
        "label": "Lessee Operating Lease Monthly Rental Payment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyRentalPayment",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_LicenseAgreementCommencingDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement commencing date.",
        "label": "License Agreement Commencing Date",
        "terseLabel": "License agreement commencing date"
       }
      }
     },
     "localname": "LicenseAgreementCommencingDate",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "tcrt_LicenseAgreementWithPgenTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement with PGEN therapeutics.",
        "label": "License Agreement With PGEN Therapeutics [Member]"
       }
      }
     },
     "localname": "LicenseAgreementWithPgenTherapeuticsMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_LicenseAgreementWithTheNationalCancerInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement with the National Cancer Institute [Member]"
       }
      }
     },
     "localname": "LicenseAgreementWithTheNationalCancerInstituteMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_LicenseExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to License payments.",
        "label": "License Expense"
       }
      }
     },
     "localname": "LicenseExpense",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_LicensedProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "licensed products [Member]"
       }
      }
     },
     "localname": "LicensedProductsMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_MaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MA",
        "label": "MA [Member]",
        "verboseLabel": "Boston, MA"
       }
      }
     },
     "localname": "MaMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_MaximumAmountOfAdditionalMilestonesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of additional milestones payable.",
        "label": "Maximum Amount of Additional Milestones Payable",
        "verboseLabel": "Expected additional milestones payable"
       }
      }
     },
     "localname": "MaximumAmountOfAdditionalMilestonesPayable",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MaximumAmountOfRoyaltyPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of royalty payable.",
        "label": "Maximum Amount of Royalty Payable",
        "verboseLabel": "Maximum royalty amount"
       }
      }
     },
     "localname": "MaximumAmountOfRoyaltyPayable",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MaximumRoyaltyAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of royalty.",
        "label": "Maximum Royalty Amount",
        "terseLabel": "Maximum royalty amount"
       }
      }
     },
     "localname": "MaximumRoyaltyAmount",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Sales Revenue On Which Benchmark Payments Payable",
        "label": "Maximum Sales Revenue On Which Benchmark Payments Payable"
       }
      }
     },
     "localname": "MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MdAndersonAgreementAndWorldwideLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MD Anderson Agreement and Worldwide License.",
        "label": "MD Anderson Agreement and Worldwide License [Member]"
       }
      }
     },
     "localname": "MdAndersonAgreementAndWorldwideLicenseMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MD Anderson License and the Research and Development Agreement.",
        "label": "MD Anderson License and the Research and Development Agreement [Member]"
       }
      }
     },
     "localname": "MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_MdAndersonWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Md Anderson Warrant [Member]",
        "terseLabel": "MD Anderson Warrant [Member]",
        "verboseLabel": "MD Anderson Warrant [Member]"
       }
      }
     },
     "localname": "MdAndersonWarrantMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone Payment",
        "terseLabel": "One time milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MilestonePaymentsMaximumAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments maximum amount.",
        "label": "Milestone Payments, Maximum Amount",
        "terseLabel": "Milestone maximum payment"
       }
      }
     },
     "localname": "MilestonePaymentsMaximumAmount",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MinimumRoyaltiesAmountPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Minimum Royalties Amount Payable.",
        "label": "Minimum Royalties Amount Payable",
        "verboseLabel": "Minimum royalties amount payable"
       }
      }
     },
     "localname": "MinimumRoyaltiesAmountPayable",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum sales revenue on which benchmark payments payable.",
        "label": "Minimum Sales Revenue On Which Benchmark Payments Payable",
        "terseLabel": "Minimum sales revenue on which benchmark payments payable"
       }
      }
     },
     "localname": "MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_NewWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Warrants [Member]"
       }
      }
     },
     "localname": "NewWarrantsMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_NonOperatingIncomeExpenseInducementOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Operating Income Expense Inducement Of Warrants.",
        "label": "Non Operating Income Expense Inducement Of Warrants",
        "terseLabel": "Non-cash inducement warrant expense"
       }
      }
     },
     "localname": "NonOperatingIncomeExpenseInducementOfWarrants",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_NonVestedRestrictedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Vested Restricted Stock",
        "label": "Non Vested Restricted Stock [Member]",
        "terseLabel": "Unvested Restricted Common Stock",
        "verboseLabel": "Non Vested Restricted Stock [Member]"
       }
      }
     },
     "localname": "NonVestedRestrictedStockMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_NonVestedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Vested Stock [Member]",
        "label": "Non Vested Stock [Member]",
        "terseLabel": "Unvested Stock"
       }
      }
     },
     "localname": "NonVestedStockMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_ObligationsDueUnderContract": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations due under contract.",
        "label": "Obligations Due Under Contract",
        "verboseLabel": "Obligations due under contract"
       }
      }
     },
     "localname": "ObligationsDueUnderContract",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_OneTimeBenchmarkPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Time Benchmark Payments [Member]"
       }
      }
     },
     "localname": "OneTimeBenchmarkPaymentsMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_OperatingLeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease area.",
        "label": "Operating Lease Area"
       }
      }
     },
     "localname": "OperatingLeaseArea",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "tcrt_OperatingLeasesExpirationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases expiration month and year.",
        "label": "Operating Leases Expiration Month and Year",
        "verboseLabel": "Operating lease expiration month and year"
       }
      }
     },
     "localname": "OperatingLeasesExpirationMonthAndYear",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "tcrt_OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases future minimum monthly payment due through year four.",
        "label": "Operating Leases Future Minimum Monthly Payment Due Through Year Four",
        "verboseLabel": "Operating Leases Future Minimum Monthly Payment Due Through Year 2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumMonthlyPaymentDueThroughYearFour",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_OtherIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other income expense member.",
        "label": "Other Income Expense [Member]",
        "terseLabel": "Other Income Expense [Member]"
       }
      }
     },
     "localname": "OtherIncomeExpenseMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_OutsideTwoThousandTwelvePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outside two thousand twelve plan [Member]",
        "label": "Outside Two Thousand Twelve Plan [Member]",
        "terseLabel": "Outside 2012 Plan"
       }
      }
     },
     "localname": "OutsideTwoThousandTwelvePlanMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_PatentAndTechnologyLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent and technology license agreement.",
        "label": "Patent And Technology License Agreement [Member]"
       }
      }
     },
     "localname": "PatentAndTechnologyLicenseAgreementMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_PaymentForHistoricalCostsOfTheLicensedPrograms": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for historical costs of the licensed programs.",
        "label": "Payment for Historical Costs of the Licensed Programs",
        "terseLabel": "Payment for historical costs of the licensed programs"
       }
      }
     },
     "localname": "PaymentForHistoricalCostsOfTheLicensedPrograms",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_PaymentTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Type [Axis]"
       }
      }
     },
     "localname": "PaymentTypeAxis",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_PaymentTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Type [Domain]"
       }
      }
     },
     "localname": "PaymentTypeDomain",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_PaymentUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment under license agreement.",
        "label": "Payment Under License Agreement",
        "terseLabel": "Payment under license agreement"
       }
      }
     },
     "localname": "PaymentUnderLicenseAgreement",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission on gross proceeds from sale of common stock",
        "label": "Percentage Of Commission On Gross Proceeds From Sale Of Common Stock",
        "terseLabel": "Sales commission as a percentage of gross proceeds"
       }
      }
     },
     "localname": "PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of original principal due as a final payment.",
        "label": "Percentage of Original Principal Due as a Final Payment",
        "terseLabel": "Percentage of original principal due as a final payment"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalDueAsAFinalPayment",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_PercentageOfPrepaymentPremium": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of prepayment premium",
        "label": "Percentage of prepayment premium",
        "terseLabel": "Prepayment premium percentage"
       }
      }
     },
     "localname": "PercentageOfPrepaymentPremium",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "tcrt_PercentageOfPrepaymentsPremium": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of prepayments premium.",
        "label": "Percentage Of Prepayments Premium",
        "terseLabel": "Percentage of prepayments premium"
       }
      }
     },
     "localname": "PercentageOfPrepaymentsPremium",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sub licensing income, attributable to related party.",
        "label": "Percentage of Sub licensing Income Payable to Related Party",
        "verboseLabel": "Portion of income payable to related party"
       }
      }
     },
     "localname": "PercentageOfSubLicensingIncomePayableToRelatedParty",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcrt_PerformanceBasedPaymentsMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Based Payments Member [Member]"
       }
      }
     },
     "localname": "PerformanceBasedPaymentsMemberMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_PlacementAgentFeesAndOtherRelatedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement agent fees and other related expenses.",
        "label": "Placement Agent Fees And Other Related Expenses",
        "verboseLabel": "Placement agent fees and other expenses"
       }
      }
     },
     "localname": "PlacementAgentFeesAndOtherRelatedExpenses",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_PocketExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pocket expenses.",
        "label": "Pocket Expenses",
        "terseLabel": "Pocket expenses"
       }
      }
     },
     "localname": "PocketExpenses",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_PostMarketingApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post Marketing Approval [Member]"
       }
      }
     },
     "localname": "PostMarketingApprovalMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_PotentialBenchmarkPaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Potential Benchmark Payments Payable.",
        "label": "Potential Benchmark Payments Payable",
        "verboseLabel": "Potential Benchmark Payments Payable"
       }
      }
     },
     "localname": "PotentialBenchmarkPaymentsPayable",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_PrincipalPaymentBeginningDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal payment beginning date.",
        "label": "Principal Payment Beginning Date",
        "terseLabel": "Principal payment beginning date"
       }
      }
     },
     "localname": "PrincipalPaymentBeginningDate",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "tcrt_QuarterlyExpenseIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quarterly expense incurred.",
        "label": "Quarterly Expense Incurred",
        "terseLabel": "Quarterly expense incurred"
       }
      }
     },
     "localname": "QuarterlyExpenseIncurred",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_QuarterlyPaymentsUnderContract": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quarterly payments under contract.",
        "label": "Quarterly Payments Under Contract",
        "verboseLabel": "Quarterly payments under contract"
       }
      }
     },
     "localname": "QuarterlyPaymentsUnderContract",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction expenses from transactions with related party advisory fees.",
        "label": "Related Party Transaction Expenses From Transactions With Related Party Advisory Fees"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_RelatedPartyTransactionReimbursedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction Reimbursed Amount.",
        "label": "Related Party Transaction Reimbursed Amount",
        "terseLabel": "Related party transaction, reimbursed amount"
       }
      }
     },
     "localname": "RelatedPartyTransactionReimbursedAmount",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_RoyaltiesAmountPayableThereafter": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties amount payable thereafter.",
        "label": "Royalties Amount Payable thereafter",
        "terseLabel": "Royalties amount payable thereafter"
       }
      }
     },
     "localname": "RoyaltiesAmountPayableThereafter",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement.",
        "label": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tcrt_ShareSubscriptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Subscription Agreement",
        "label": "Share Subscription Agreement [Member]"
       }
      }
     },
     "localname": "ShareSubscriptionAgreementMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_SiliconValleyBankLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Valley Bank loan.",
        "label": "Silicon Valley Bank Loan [Member]",
        "terseLabel": "Silicon Valley Bank Loan [Member]"
       }
      }
     },
     "localname": "SiliconValleyBankLoanMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityParentheticalDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_SiliconValleyBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon valley bank.",
        "label": "Silicon Valley Bank [Member]"
       }
      }
     },
     "localname": "SiliconValleyBankMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_StockOfferedDuringPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock offered during period shares.",
        "label": "Stock Offered During Period Shares",
        "terseLabel": "Sale of stock during period",
        "verboseLabel": "Stock issued during period"
       }
      }
     },
     "localname": "StockOfferedDuringPeriodShares",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcrt_StockOptionsAndRestrictedStockAwardsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options and Restricted Stock Awards",
        "label": "Stock Options and Restricted Stock Awards [Text Block]",
        "verboseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockAwardsTextBlock",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tcrt_SubleaseArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease area.",
        "label": "Sublease Area",
        "terseLabel": "SubleaseArea"
       }
      }
     },
     "localname": "SubleaseArea",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "tcrt_SubleaseTermCommencedEndDateAmendment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease term commenced end date amendment.",
        "label": "Sublease Term Commenced End Date Amendment",
        "verboseLabel": "Sublease term amendment"
       }
      }
     },
     "localname": "SubleaseTermCommencedEndDateAmendment",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "tcrt_SvbWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Svb Warrants [Member].",
        "label": "Svb Warrants [Member]",
        "terseLabel": "SVB Warrants [Member]"
       }
      }
     },
     "localname": "SvbWarrantsMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TcellReceptorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tcell receptor [Member]",
        "verboseLabel": "T-cell receptor"
       }
      }
     },
     "localname": "TcellReceptorMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TenthScheduledPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenth Scheduled Payment.",
        "label": "Tenth Scheduled Payment [Member]",
        "terseLabel": "Tenth Scheduled Payment Member"
       }
      }
     },
     "localname": "TenthScheduledPaymentMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TermATrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term A Tranche [Member]",
        "label": "Term A Tranche [Member]",
        "terseLabel": "Term A Tranche [Member]"
       }
      }
     },
     "localname": "TermATrancheMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TermBMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term B Milestone [Member]",
        "label": "Term B Milestone [Member]"
       }
      }
     },
     "localname": "TermBMilestoneMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TermBTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term B Tranche.",
        "label": "Term B Tranche [Member]",
        "terseLabel": "Term B Tranche [Member]"
       }
      }
     },
     "localname": "TermBTrancheMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TermLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Agreement [Member]",
        "label": "Term Loan Agreement [Member]"
       }
      }
     },
     "localname": "TermLoanAgreementMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan member",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The University Of Texas M D Anderson Cancer Center And The Texas A And M University System",
        "label": "The University Of Texas M D Anderson Cancer Center And The Texas A And M University System [Member]",
        "terseLabel": "The University of Texas MD Anderson Cancer Center and The Texas A &amp; M University System"
       }
      }
     },
     "localname": "TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TriArmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tri Arm",
        "label": "Tri Arm [Member]",
        "terseLabel": "TriArm [Member]"
       }
      }
     },
     "localname": "TriArmMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TwoThousandAndThreeEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Three Equity Incentive Plan",
        "label": "Two Thousand And Three Equity Incentive Plan [Member]",
        "terseLabel": "2003 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndThreeEquityIncentivePlanMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TwoThousandAndTwelveEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Twelve Equity Incentive Plan",
        "label": "Two Thousand And Twelve Equity Incentive Plan [Member]",
        "terseLabel": "2012 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwelveEquityIncentivePlanMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TwoThousandAndTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty equity incentive plan [Member].",
        "label": "Two Thousand And Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyEquityIncentivePlanMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_TwoThousandTwelveStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twelve Stock Option Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwelveStockOptionPlanMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_VinetiIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vineti Inc.",
        "label": "Vineti Inc [Member]"
       }
      }
     },
     "localname": "VinetiIncMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_WarrantTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to the warrant.",
        "label": "Warrant [Text Block]",
        "verboseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantTextBlock",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tcrt_WarrantsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsDisclosureAbstract",
     "nsuri": "http://alaunos.com/20220930",
     "xbrltype": "stringItemType"
    },
    "tcrt_WarrantsExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiration Date",
        "label": "Warrants Expiration Date",
        "terseLabel": "Warrants expiration date"
       }
      }
     },
     "localname": "WarrantsExpirationDate",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "tcrt_WarrantsIssuedInTermLoan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued in term loan.",
        "label": "Warrants issued in term loan",
        "terseLabel": "Warrants issued in a term loan"
       }
      }
     },
     "localname": "WarrantsIssuedInTermLoan",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcrt_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants member.",
        "label": "Warrants [Member]",
        "terseLabel": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_WatermillAndRobertWPostmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Watermill And Robert W Postma.",
        "label": "Watermill And Robert W Postma [Member]",
        "terseLabel": "WatermillAndRobertWPostmaMember"
       }
      }
     },
     "localname": "WatermillAndRobertWPostmaMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_ZeroMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero Milestone [Member]",
        "label": "Zero Milestone [Member]"
       }
      }
     },
     "localname": "ZeroMilestoneMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZiopLicenseAgreementWithTheNationalCancerInstituteMember",
        "label": "Ziop License Agreement With The National Cancer Institute [Member]",
        "terseLabel": "Ziop License Agreement With The National Cancer Institute [Member]"
       }
      }
     },
     "localname": "ZiopLicenseAgreementWithTheNationalCancerInstituteMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcrt_ZiopharmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ziopharm [Member]",
        "label": "Ziopharm [Member]"
       }
      }
     },
     "localname": "ZiopharmMember",
     "nsuri": "http://alaunos.com/20220930",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25",
      "r422"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued Liabilities, Current, Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r320",
      "r321",
      "r322",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r83",
      "r84",
      "r85",
      "r86",
      "r97",
      "r147",
      "r148",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r320",
      "r321",
      "r322",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r380",
      "r381",
      "r388",
      "r389",
      "r390",
      "r391",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r459",
      "r460",
      "r461",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r282",
      "r323",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r205",
      "r251",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r46",
      "r65",
      "r229",
      "r385"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r12",
      "r77",
      "r130",
      "r133",
      "r139",
      "r155",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r336",
      "r338",
      "r364",
      "r420",
      "r422",
      "r475",
      "r489"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS:"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r24",
      "r77",
      "r155",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r336",
      "r338",
      "r364",
      "r420",
      "r422"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankingAndThriftInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Banking and Thrift, Interest [Abstract]"
       }
      }
     },
     "localname": "BankingAndThriftInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r6",
      "r79",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization",
        "verboseLabel": "Business"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r69",
      "r70",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Amounts included in accrued expenses and accounts payable related to property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r10",
      "r67"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "verboseLabel": "Cash balance"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r61",
      "r67",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r61",
      "r373"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplementary disclosure of noncash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r75",
      "r77",
      "r101",
      "r102",
      "r103",
      "r106",
      "r108",
      "r116",
      "r117",
      "r118",
      "r155",
      "r194",
      "r198",
      "r199",
      "r200",
      "r203",
      "r204",
      "r244",
      "r245",
      "r248",
      "r249",
      "r251",
      "r364",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r259",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Warrant exercise per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of Warrants",
        "verboseLabel": "Number of securities into which the class of warrant converted"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r479",
      "r495"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r193",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCallOrExerciseFeatures": {
     "auth_ref": [
      "r18",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describe the call and/or exercise rights, prices and dates of common stock.",
        "label": "Common Stock, Call or Exercise Features",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "CommonStockCallOrExerciseFeatures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Shares Subscribed but Unissued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockSharesSubscribedButUnissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r422"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock $0.001 par value; 420,000,000 shares authorized, 216,182,042 shares issued and outstanding at September 30, 2022 and 350,000,000 shares authorized, 216,127,443 shares issued and outstanding at December 31, 2021",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.",
        "label": "Costs and Expenses, Related Party",
        "terseLabel": "Fees and Expenses, Related Party"
       }
      }
     },
     "localname": "CostsAndExpensesRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": {
     "auth_ref": [
      "r69",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r74",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r223",
      "r230",
      "r231",
      "r233",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r76",
      "r78",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r236",
      "r237",
      "r238",
      "r239",
      "r386",
      "r476",
      "r477",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityParentheticalDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Line of credit facility, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r15",
      "r234",
      "r477",
      "r488"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Total debt",
        "totalLabel": "Total debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of reference rate used for variable rate of debt instrument.",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Debt instrument description of variable rate basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r206",
      "r236",
      "r237",
      "r384",
      "r386",
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityParentheticalDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtPrepaymentPremiumPercentageDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r31",
      "r209",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt Instrument, maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentMaturityDateRangeStart1": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date Range, Start",
        "terseLabel": "Debt instrument, initial maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDateRangeStart1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r32",
      "r76",
      "r78",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r236",
      "r237",
      "r238",
      "r239",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityParentheticalDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r32",
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Debt instrument, periodic payment",
        "totalLabel": "Debt Instrument, Periodic Payment, Total"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtPrepaymentPremiumPercentageDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtPrepaymentPremiumPercentageDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument Redemption Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "Debt Instrument Redemption Period Three Member"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Debt Instrument Redemption Period Two Member"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r32",
      "r76",
      "r78",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r232",
      "r236",
      "r237",
      "r238",
      "r239",
      "r252",
      "r255",
      "r256",
      "r257",
      "r383",
      "r384",
      "r386",
      "r387",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityParentheticalDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtPrepaymentPremiumPercentageDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r219",
      "r383",
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Unamortized discount on Term Loan Agreement",
        "totalLabel": "Debt Instrument, Unamortized Discount, Total"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r219",
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Issuance costs",
        "totalLabel": "Debt Issuance Costs, Net, Total"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits Assets, Noncurrent",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r65",
      "r172"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r285",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "verboseLabel": "Stock-Based Compensation Expense on All Employee and Non-Employee Awards"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r258",
      "r484"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "terseLabel": "Dividends",
        "totalLabel": "Dividends, Total"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r44",
      "r87",
      "r88",
      "r90",
      "r91",
      "r92",
      "r98",
      "r101",
      "r106",
      "r107",
      "r108",
      "r112",
      "r113",
      "r352",
      "r353",
      "r481",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings per share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r44",
      "r87",
      "r88",
      "r90",
      "r91",
      "r92",
      "r101",
      "r106",
      "r107",
      "r108",
      "r112",
      "r113",
      "r352",
      "r353",
      "r481",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings per share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.",
        "label": "Employee Benefit and Share-Based Payment Arrangement, Noncash",
        "totalLabel": "Employee Benefit and Share-based Payment Arrangement, Noncash, Total",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs related to unvested restricted stock outstanding"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Common Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r39",
      "r40",
      "r41",
      "r80",
      "r81",
      "r82",
      "r84",
      "r93",
      "r96",
      "r115",
      "r160",
      "r251",
      "r258",
      "r320",
      "r321",
      "r322",
      "r330",
      "r331",
      "r351",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r409",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows",
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Equity interest in affilated entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "verboseLabel": "Joint Venture"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/JointVenture"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r355",
      "r356",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r221",
      "r236",
      "r237",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r277",
      "r356",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel12And3Member": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3).",
        "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2, and Level 3 Member"
       }
      }
     },
     "localname": "FairValueInputsLevel12And3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r221",
      "r265",
      "r266",
      "r271",
      "r277",
      "r356",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r221",
      "r236",
      "r237",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r277",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r360",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Lease liability, current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, non-current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r232",
      "r250",
      "r342",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r392"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "negatedLabel": "Gain on lease modification"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense",
        "verboseLabel": "General and Administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r174",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails",
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails",
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "(Increase) decrease in:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Liabilities [Abstract]",
        "terseLabel": "Increase (decrease) in:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Receivables",
        "totalLabel": "Increase (Decrease) in Receivables, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r42",
      "r129",
      "r382",
      "r385",
      "r482"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest Expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r50",
      "r227",
      "r235",
      "r238",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense",
        "totalLabel": "Interest Expense, Debt, Total"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r60",
      "r62",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Operating lease rental expenses",
        "totalLabel": "Operating Leases, Rent Expense, Total"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r399",
      "r401"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Lease, Cost, Total",
        "verboseLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseIncome": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor.",
        "label": "Lease Income",
        "terseLabel": "Lease income",
        "totalLabel": "Lease Income, Total"
       }
      }
     },
     "localname": "LeaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesOperatingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Operating [Abstract]"
       }
      }
     },
     "localname": "LeasesOperatingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (excluding the six months ended June 30, 2021)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest and adjustments",
        "terseLabel": "Less: Imputed interest and adjustments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lease term, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r77",
      "r134",
      "r155",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r337",
      "r338",
      "r339",
      "r364",
      "r420",
      "r421"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r77",
      "r155",
      "r364",
      "r422",
      "r478",
      "r492"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r30",
      "r77",
      "r155",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r337",
      "r338",
      "r339",
      "r364",
      "r420",
      "r421",
      "r422"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r26",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Initial borrowing",
        "verboseLabel": "Initial term loan"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the frequency of the required periodic payments of interest, principal, or both, and the amount, if set, or a description of a formula upon which payment is based.",
        "label": "Line of Credit Facility, Frequency of Payment and Payment Terms",
        "terseLabel": "Description of payment terms"
       }
      }
     },
     "localname": "LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate during the reporting period.",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r26",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Additonal tranche facility",
        "verboseLabel": "Maximum borrowing capacity under the credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Debt remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtMaturityParentheticalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedLabel": "Less: current portion of long-term debt",
        "terseLabel": "Less: current portion of long-term debt",
        "totalLabel": "Long-term Debt, Current Maturities, Total",
        "verboseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r61",
      "r63",
      "r66"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r37",
      "r38",
      "r41",
      "r43",
      "r66",
      "r77",
      "r83",
      "r87",
      "r88",
      "r90",
      "r91",
      "r95",
      "r96",
      "r104",
      "r130",
      "r132",
      "r135",
      "r138",
      "r140",
      "r155",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r353",
      "r364",
      "r480",
      "r496"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows",
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity",
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r87",
      "r88",
      "r90",
      "r91",
      "r98",
      "r99",
      "r105",
      "r108",
      "r130",
      "r132",
      "r135",
      "r138",
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss applicable to common stockholders",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net",
        "totalLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r130",
      "r132",
      "r135",
      "r138",
      "r140"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r396",
      "r401"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease obligation",
        "totalLabel": "Operating Lease, Liability, Total",
        "verboseLabel": "Present value of lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails",
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r393"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r398",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r397",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock",
        "terseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Debt issuance costs",
        "terseLabel": "Debt issue costs paid"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": {
     "auth_ref": [
      "r52",
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.",
        "label": "Payments to Fund Long-Term Loans to Related Parties",
        "terseLabel": "Payments to Fund Long-term Loans to Related Parties"
       }
      }
     },
     "localname": "PaymentsToFundLongtermLoansToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate [Member]"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from collateral account"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from long-term debt borrowing",
        "totalLabel": "Proceeds from Issuance of Long-term Debt, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with security instrument that either represents a creditor or an ownership relationship with the holder of the investment security with a maturity of beyond one year or normal operating cycle, if longer. Includes proceeds from (a) debt, (b) capital lease obligations, (c) mandatory redeemable capital securities, and (d) any combination of (a), (b), or (c).",
        "label": "Proceeds from Issuance of Long-Term Debt and Capital Securities, Net",
        "terseLabel": "Gross proceeds from debt",
        "totalLabel": "Proceeds from Issuance of Long-term Debt and Capital Securities, Net, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "verboseLabel": "Proceeds from private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Cash proceeds from sale of equity",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r54",
      "r319"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r173",
      "r422",
      "r483",
      "r494"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property, Plant and Equipment, Net, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r422",
      "r493",
      "r515"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Receivables",
        "totalLabel": "Receivables, Net, Current, Total"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r272",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r272",
      "r412",
      "r416",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r410",
      "r411",
      "r413",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of long-term debt",
        "totalLabel": "Repayments of Long-Term Debt, Total"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r325",
      "r457",
      "r530"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r10",
      "r72",
      "r474",
      "r490"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash related to the Company's debt agreement",
        "totalLabel": "Restricted Cash, Total",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r10",
      "r72"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock",
        "verboseLabel": "Unvested Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r176",
      "r177",
      "r179",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRestructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r258",
      "r422",
      "r491",
      "r509",
      "r514"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r80",
      "r81",
      "r82",
      "r84",
      "r93",
      "r96",
      "r160",
      "r320",
      "r321",
      "r322",
      "r330",
      "r331",
      "r351",
      "r505",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r127",
      "r128",
      "r131",
      "r136",
      "r137",
      "r141",
      "r142",
      "r144",
      "r260",
      "r261",
      "r458"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty [Member]"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Issuance of common stock in connection with a public offering, net",
        "verboseLabel": "Sale of stock consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "verboseLabel": "Summary of Unvested Restricted Stock"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r180",
      "r181",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Costs"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r281",
      "r283",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r289",
      "r305",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock Option Activity under Stock Option Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r75",
      "r116",
      "r117",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.",
        "label": "Schedule of Subsidiary or Equity Method Investee [Table]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r11"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Cancelled",
        "terseLabel": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Fair Value Assumptions Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, Maximum",
        "verboseLabel": "Fair Value Assumptions Expected volatility Rate Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, Maximum",
        "verboseLabel": "Fair Value Assumptions Risk Free Interest Rate Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Options available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable, at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted",
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total",
        "verboseLabel": "Stock options, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted-average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Outstanding options issued",
        "verboseLabel": "Stock option, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfNonvestedRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised",
        "verboseLabel": "Exercise price of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "par value per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life in years",
        "verboseLabel": "Fair Value Assumptions Expected Term1"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r73",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r75",
      "r77",
      "r101",
      "r102",
      "r103",
      "r106",
      "r108",
      "r116",
      "r117",
      "r118",
      "r155",
      "r194",
      "r198",
      "r199",
      "r200",
      "r203",
      "r204",
      "r244",
      "r245",
      "r248",
      "r249",
      "r251",
      "r364",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r36",
      "r39",
      "r40",
      "r41",
      "r80",
      "r81",
      "r82",
      "r84",
      "r93",
      "r96",
      "r115",
      "r160",
      "r251",
      "r258",
      "r320",
      "r321",
      "r322",
      "r330",
      "r331",
      "r351",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r409",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows",
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows",
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r115",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows",
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r251",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r17",
      "r18",
      "r251",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "terseLabel": "Cancelled restricted common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r251",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "verboseLabel": "Restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r251",
      "r258",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "terseLabel": "Exercise of employee stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails",
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r251",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Aggregate offering price",
        "verboseLabel": "Issuance of common stock in connection with at the market offering, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r17",
      "r18",
      "r251",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "negatedLabel": "Restricted stock awards",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r251",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of employee stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r17",
      "r18",
      "r251",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of common stock (in Shares)",
        "terseLabel": "Repurchase of common stock (in Shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r17",
      "r18",
      "r251",
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r21",
      "r22",
      "r77",
      "r146",
      "r155",
      "r364",
      "r422"
     ],
     "calculation": {
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r423",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary or Equity Method Investee [Line Items]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r232",
      "r250",
      "r342",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r83",
      "r84",
      "r85",
      "r86",
      "r97",
      "r147",
      "r148",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r320",
      "r321",
      "r322",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r380",
      "r381",
      "r388",
      "r389",
      "r390",
      "r391",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r459",
      "r460",
      "r461",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Warrant Expiry date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants fully vested upon issuance"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r100",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted Average Number Of Diluted Shares Outstanding",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r98",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted Average Number Of Shares Outstanding Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alaunos.com/20220930/taxonomy/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "https://asc.fasb.org/topic&trid=2155941"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r531": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r532": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r533": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r534": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r535": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r536": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r537": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r538": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r539": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r540": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r541": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r542": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r543": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0000950170-22-024695-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-024695-xbrl.zip
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MS2%T27#8=^GY\&H@3%==BL3S$_N\XM0__:)9U\FFW3EA.P#E!0O=FOH:4,F
MM)G<9:I@J29&W3"-=X()DGA6M4_1B@D\GW36\I^ 1J;@GC%0Z)^KWXB;JTRC
ML]$;!O/<VFI7L-P8>"XMG5(/8TA*4!AOCX NEVZFGB'/NRH':3&:>- K>\?J
MQ],[$>$71 J][.@3Q@_$0X&YSK$G83>$L_Q."Q!'SEGP,II,FJCF9"6%?7>.
M'?XL;%'YP5S(:J@GO.)NXEB:U>;H4D:_GE.9,<Q9^QB-YMZWQ.ORF>DET\1G
M%2IF(=1]]%,VS%CC9<<G7K\170'T6[%3&/@Z_11":(IQYJL>;D4?#"N6=C5
MI:D_,TKO=A[>'@QE%N\!2)$:N3O(;D#[-FHA#IA_,]86OM] O;$M]<<-4*(,
M@AG16XW=^#65G!V >K!NM15K?=6"\C#^I-OGZ*J]2A@XB99/24B]QHKKR0!C
M+DD_U2;BU0VFEW,$CLH_R#?ZY-F#JNRU,RXN.X"6=4=IN>HHSY-4DK^U\=8_
MS^G[QXUA?(AZG.CYK2/?^W2U@,]/T)MLSHY#QVGY'^3W61J1=@"^WCH8(]#J
MV5W[T>U3E^X/RASXJ4U_*O#]?;?+=96DD^=ZQ>H!CQ*GQ'J#G!Z&1$$!L4]
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M3:4,2P5X>H6'$#"!#65(V.'JP.EOD0?!O 4YD/A,V&/[PP:8^RCPD)]EDY3
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M7-Y'.X7J6<.]GVVD)7OR 9@FOPV;U%[RBZGNZ/%(UZHGUH:F7W6XPY/>PY#
M][W[$C9F#+\8<[EC;^@G?4H_&GOGX[J(3SM+O/R&CAGF6,C 2G*?X3:]$_-
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MTZTO(FOB7A0/&^!84/[@,W>A5J,Q*OF"SZKKAQ%HFV$+2FSJA23RGNF7'^+
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M^ ^07H6RD9H'/,L3<O>*?U#8>8Q$G'!%B+T/84>FI,$MJ2CAC36;#P\8H4P
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M0/Y_6YSV/[N2=J\XCIPH_ /&N$<AT C-,1(&/&GE+6("N*J/7=E2M[J]>/N
M @0;_RGW$7$"M.JCK3(,(5314P&QUM&:S.<FIB3E6P#J*WR:=K__>LWY3NV\
M^+I]Y#OKFX=[^#85R.>[? "F6N6YRX9VPGZ7G^&J_%*-PU# D&HX4NL ?&Q%
M7\;S0:$<#O&'M_58P:%$Z66%SQ)T"Z8[A);CR'(K/KL5N=G$&@??_=D9.=7=
M;'))NXC.CE 58!ZCIJ7.BT-X9<[=W+2_;HNZUR$[>KN0<>W7C:JL;(FD%S?C
M+J4.,8;M)NMT=A;+.2P>4B"R53<;86P0JD(M=I]DH:VNUPM 2J)'(1LFJ%Y
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M-^H>+?@?P->>^>X?D'$[)OZ+\<V!=X?::0"\^TX1(P%D@/[]F6I)/N,^.LK
M+,:"E8Z@N<;Z".UUK^$L(B&E[CCF>9RFA5&@X@$E_5$3;'7!=UD?7+Z)X_=D
MEF5T-5C(M\GJ;9R&[\0%FOF.ETY?S.+K-TKA.&L=N3=G_AY]ZORR,U_=6-P%
M87=H495C=834Z"4/]URIT?&SGEC(/ JD907:GGW$(8S5X,:)KFBR*8' $JD
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M_'QTC;AHR"AXG_OPQ3_ <$SE(L2)Y6 @Z.CR]1?PF+ZLZ,];SD,%A-2H:#:
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MYQ(M;J_+7BWRQ;MDH(Q(X'QP-@[&5)G50BC'REPO[9AK=I_\,+>B7/LY \)
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M)55>A@83_?J"2F^Z68"97L+[!8%%DGE=.8!GVT3"GAW)%H4+P/9>0"0X>MQ
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M=7II+^R15.GUC+QW)6WVNF+9*:=>DW'4!7[^E0':]B0&<BR2QBO\+,N(:GU
M98;S +Y/P68___:+^)Y9Z;&##^*_UB]][L1%J@#_ +06 P.G&;/O!F-FJT!8
MQ2$[C6])O;2W2?#YV&9,PS!C%CX^-^3L7YF/A]+A+NM6WV_-&8A:0%JN_:SK
M)ADL1,>UTG9H^_92L;O9)DTAMT\TAXB$GM2]2ZGG<SM&EPT"0ZY>^7';R+&(
MS;[1!SQ:N.#U_%B:*BJR;>.^H%7;KQX2(%3G>D<Z[&UZQF_;2I:T[J;'G](@
MLRJ@U;Q_P+DE])4"!%>L<./WN(L^]HSG!SD#S5T\YML2R+.BZV7__=;V2Q!/
MF\P3D'J! J_)BL!\7F<(VY7R>%/"&.H-YK^=/VF5^CW?X7C34] Q_(7&<K7\
MTIYAA\9QXT4$%HB5C2SS?1VD-+MNT0<L2C.WG/GV8);W9?,M:==EL\WZ!%?9
M)]LKMF1?3SGT[.=RR7J'HD\,/.U!& JGDSDAROGJ?95$B.GB5&Y3STW9)M8?
M%^7(QS7P"7?M@ ?()>/CRJ;:"2?C;C<N0_@F3O@^^7RB)WMYGY]UW 0A9;KC
M;<N0>L];@LBS-=+'>VSY;@L-@-GY,*FC>S56TI:&8L;R&R13N6*H?:I_<&,?
MJ!_8\6'XCAK\_+7Y@V/U$E$O=R[M"F^F> YCH<DHT2:S1>3H W##B$A)1&OE
MWC)OD4:EX&A!<Q5_\G:-X M9P9FV^DVY2KDQIRY&6AF&W!1_I:;WNF[V$EL(
MYM>'S_?]F2"I!)F7 \'$9;R,W/44X+@]U#H;??\RH@RQ%U&>QQ<S%^X1SZ1"
MXQ^M>]\]JKB,A]<-L7*^6=H";=@]G^1+8-P4<7JA7SK#HRB$8WZ6I:%O$?.M
MDP1\X+V'AH(0*UC?N_<DZA+('QZ7Y;_JP&U/Y_3=S1])CQEE)@3)A;+:TIY\
M6LZR#-K+4]["-E<=.4PI_IZ2^ =PJ1BR]^#K%&FFPO6@^JP%P01ZU&2*!>1=
M-Z3!O<V>6WK?P^UKLN+D]ZO[;@M-3L!DWA8Z9;YSY1O5LG6R7T"_'YE$SK7_
M[O8LY.</[%H"V(V5E\A"8;K9,GC=>5M$QRC;Y470)R3U#/LK#'<^I_55SQM&
M@6SDJP!HZ<G#MK8C>"_+NYI6CD)WH^VT9SA/V'Q7\!X]_ P.H9T:$UFY^OK1
MY\WG@IRAQL]C7 R:G0/\1OS(FJ-?M=D:%DY$-E^[M:9HJM]!K_ MC46J#2R^
MK\BJ8:.U [$<WN6^TU6NGLG3 _"_B#_?<ET<]G3T-=HWEK\X;M=?H66-KSU#
MSNR[/J._>; SS#_AK'%>),PU:9?"Z7%%BK^V&<A0TJFHN^(GPO,E!5+.,5ZM
M'];T0U8^[:TY+[3V@[2X3Y\0@-U#@43,F@K..+VOBC:8L;/]0+#L?Q5!DM8(
M%RGP*7]@TOBU2EVA4OO6_02^>5:+ ZDR"M1VL^0A(:9EPW(/,C0L6_)Z?##X
M^(?91^YPW1!]K]BT"P]8WL/O6$[CE4.,V T@I=67&OW98?DB3J1H3$ A7"F^
M=?IQL;8.X0X,Z'X"U=T]I"RES_9I1$T\5E($$%&I/FA&C\ #%2#!]E4+DI@;
M,O-YUE'K:5G"^2K\"Y;A"5LC"0_IPY+OPT;73C<R33.:[ES(ZL=L%"I9J/@5
MAK\MG$OS6/18[GC.ZEWAF^4;5>],#[[KM=XP%X?>T?]VMX$Y*.W\W7N*[R$,
M> QO<X;B0?5EI,5+5/P4;6*V3H_'@ 5=+K^BNL_*E1Z,X^;2Z1HV]+<<83*8
M"1_R_<_YX>..#Z#%0TO'I*!W;J&X<S)C?MSW%P/J4)VWG%(P$G49W>B3;\T5
MA0INAHRV/P/M%B//HE>VV@'D%[W;YXS.:[QI22WN+)^V21F)(ON0WUZ;AU1D
MCGZXUU?$Y='YQ% TG,(&2=IG7QD=JW\!522Q*&8)& 5_5'G\;JD,%*ZPH$V5
MA!.6\U639DZDH5B,"NA(/J9T-X)WU]SI5)MAFO%?8#65LDL7'PX4ICJ-"87^
MW]$50>8#$QNX.%7>@U[&W901(8X+:#&\9M!50&"1^=CAMHK:;!=$:W(B@_D[
M_:B4HSBC)^G3*(@6]V1[THI[],Y"]04#=<X0#@4Z@B>8B *MJBF5B2AB_3[,
M)%C@E 1BU<\9%1F)7O@6<S)=87S#N'\9SRN?1OG+YW5) 1AD?7PR&BLMII]F
M^LK;;8T6)6ZITEH<4EHQCQ<YEWR>J"?\G%QF$):_4N*GGY9_].X UI=)LKSE
M5RU1TP5?40&N*"2G4KR>-#.&U>CNG.T63'/2_W"I1_'S';9O-*<XAI^W^$CZ
M51N4Q>M%R??BH[9O-? WWY*1X'Z;Q,:#E\C[<4;C3MWX@H,H(0"$7JY[]ZZ?
MA@V>F3#'Z7I/AI<")@EW@0,,A?'SA,^[[774&7R<5>BH\!.J+)&BN!H4H?+,
M+)R'X5"X#\\ (#(,*47!WMC[0AR2(,;\E1984=3KM&\*I\M -OGNH>XG%:R@
M^ ==Z&+,7][,R:39S"ONF/[AL-\6#(O2"'_&E> -HR_I I!\PA'L63C/,^==
MOJ@)4Y(+WX-"K:*$GZ-,3+,K(7^&ODU1N:\2[FK?<UIU'_W$W5:QLOQ.Y?CV
M1_WSUW)7Q/&89]P6K/\UKQI:FQ.G'9DO5QE$'U96E>A^ULLT>@EC"V=$[)2J
M@,ZMK=-6^K8M9ZOT;V0VVEY.*O'5>>3]?D&^S]PIR/AQ5K/4L_Y> &O+W6'*
M6>.G>Q+V@LZI4AD@R7(;<=!5S#U3?R^@XWN0\0()"+ZFDFA-[ DK-Q3IG<@D
M^9O:P#!VPDFICT(5_O+BV&"<<Z[,6J[U5.3GM-;0C9D) W"63A?FM 8SJHL9
M(<4'%-!S1V:'LI@@O^),)>E9'=EO#:ZK&%!'X$D%)OU]YTNM')"I&LC9U[5M
M"G_<L89%"U7D]MZM_20PK.[../^D]#_^JUEW7'- L01"$&P!+GJ@4MZMU"]L
MO KQB[,ILZ<-?3HG5"LFM7Q 8;S>MJF9[_;_,/7685%^4=?P/0PP=*,,K2 -
MT@P]J+3"T(W (-V=.H (CD.'-$-WMX+2)=W2G8)TB?KZ>Y[WO;[OW_//?9]S
MG;W76M<^>VV;VL84:Z[[K$W#T=/%PU!M&@S9&_HR&4O^>;W1X=X5G0,X84@3
M:$3SN1<MSC"#2ER\,+ED\3WH%FYVPJ+>KH7*1LP0#QWCD>P+0)&7[^T-USBJ
M*$'OE0Z)23,GN$A'WZ7(_[*7H/V'%%&T&*$@GTJ?IB><)&O\QXSXY_V_@"!^
M/OI$O%K#<-6VX85/[4N<25.A5VM*XR%&]@S/*E&VBR=P^C"74]6./F/'YW%/
MOCZL^PL0BJER"-6L,A:1:(KQ'#5GJL<DDN6BF N-"@2*0<0#3'B&)I*,2N%S
ME ,]1H;3%'?A'^GN[(]4O6"P7N ?SIF5C]7<Y,,N=ATD&HC[M,E?&G\2IMZF
M&_6$@R%39V$'<#H=8QE;AG>+Y[3\;6_YP"W?J#%D20'>1!%T[.><#7J4/XDS
M>)D_:SH 1OS\C8?:@K#1@%!UV'M<YCPB'BV'<J/I&%G94JVB!Z9"+JD;"6G
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ME%CRF?0KDW_'^@.V"[_*HW.)D,M*Q)&B\A,E\?[C!?ANDOR:(&LF(I5F$0?
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M^^T32HI"LP%XI5E09XTMWRO/CR@6FVCQ2V<J>=+A^ZO%3RX7)?F0CDR1D^D
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MC-.YZ>MDI9"+8B+(( 8$)[!F?=B/K6I@@.UPSA<(A>!O]HJ$2D]%\-/U+?4
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MMEJV:E%86,/*-HF=Y502\M/C#MI,+KVZF+P'[>+HC^A'I$UL[]S F8LJ??M
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MV]_W_@? "GQW.(47L5N""=8:"[&C):)UT6$\B<VT/'6R?P'FN\&!4I4+0S@
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M,QCR( GW'5^+:1J:ANJC(5&EDZ0#[,BEK,%"WZJ44!.L7+JX(<Q589K<,P<
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MQK:?E8M5I 0F&[-O<,K7T!BLW43K#/0IB_ (>9<B+YW,-R(\3,@-B3H#RKV
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M2F@P)@Y-<_-QZ%A2*"6@GFOB!&$7ZDXVX)4!RO!\:Y&)??'4&+W('(#R?-,
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M+<]X-I=P,=OQ%[ 8\1!R6W^1:.?7_JM-S76_,7PP.<2[#TLDE)7?XA^.MX@
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MKIJ]87G?B?P4L89B%23-11]KL*#][(E5'2H>D9V"!\6=S9L(T@<%M43BLN(
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M% 3^G.1/<@3TN(H^G.XO5*#[Y%(W-KPM?F40XV2U3R-(1B@L>IOL>#EI /G
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MIVU-[)G)'> VE?5.]MX&Q4MRO3]TG![9#!.ZU6NRCXSQHCSTF%) !R'@\;]
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MSQ90MSR+?4IX=Q*YE4Y'^7MI/H+"[ F1T DY$[]>[YP!E,+&_^HFX!"^/=F
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M9ISVWBVK(^<7)T9ME#33.>CG,DWU;_G*OP!_@N1-B,2X6FBO%K#B$&L<K/
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MAD ?.4(.<F7Z_4$B22)Y65'[;W^"]=JF"RS$HN%4T.04#MM8O3Z:+[;L<(A
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M 4VO/N581'[$*%=ZSJ.HM:H^$5=S+Z!+!+5M0&UZ@R:T6\]P[OOD45@3H20
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M2^+7N[3EU=#(;8]E*FK<0S*=Y8UZOO ZZ5,B]&D:?CIST-J(.16^+[EZ5U3
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MK-'@G$DL.A8FG^Q6!TK<"A $:R#_&'^?MZQ@%P/Y(7[BRUM9=O"KMF0A6]4
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MHX,(S0[:#(9QRX-LPET%.K?1IG(H!CS4V3,^(%D.8,TX;!^+'631#5-,H=P
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MTR/%;T>5GX55EM;0X I),=_KGE@*@62DF:0=EM^4+"%F(N++[QT2IB;\MBN
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M55+D^ETJ)<\/YH\"<0D8B88=3Z6(2B^HZ\G)3!]W<VC$_/G*]3 J.O:& GC
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M .&"XC;CYR(^I*D3L%_9,9S7@_=Q?&#A7>)9$UZ6)%FH;:L)ZV5!-CU[ 31
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MV^8N0<]VP.U-7!M6@(X2[OQ,(5FL^9LLB$L%Y]1?0%[:PK!U:3I^ZA+6ZGG
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M<5#]6Z^RDO_]AK*[S7<]!W#'H2ZS$_W2-ZFEEG>T>F['.]M'$DG3Z5&K$G(
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MN=D#(RYR;O-D&T&^23UH9L>>,A*I'5VB8&HCW$S?/4L!T-!VN!ZC<LKHMT9
M%N^Y;U\03L84+@7=\%6&Q!D7F\CXA1** ?%,_6#X/?^3N-*(14MNK,R,G3E3
M_*J?:K'@Z!#[@040-M3VPM,3TB%,TQ;'H;ZGW_ZE_!ZQG&+%R?)J=%*FG%P9
M>/0]VS).UYX_3:T-97J9H&]^8E7GV^B+*Q6GSA?HPEXWAP%9JDQF@FFB*X6G
M1Y_XNP<$%(1Y-H&Z_7[ABC1-)_\)B!C(<7P"K?(7"'N1O433$/,=_ODO0*P#
M4WHL<+"8>BH9!J L 1E:@1F!MO?/!>R)YBQK9:,%GO#%K<2CV638#1.X9LC6
M&YN>W)\WPP_66JRTY7K"?,EEDC4(XI>(KDBJ94ZTE+;Z=>LKX976';,1);7/
MHR?I4PU/26CS1;ED'8T?QWM'Y*_XKJ"99)E065S9N04'@II*WXHGN=U820[2
M;,A:QHGT[=BGCXS0U6/*C)5IAES8?S*/G)$E+=LA6F\T>V#F![!XQ,S4%$E:
MLK-W22D:6Y#TG%TF\.#60\EN? >GT$R;GUY?:X2O94+? R/KR19*_5(4>3]E
MC<O6):[\/V45Y*W^4SS78/^=/]P? K(Q+3#<N\Z<K]>#K5/SEI"1I><<3P0T
M-_N\-B=D!B@BW<+ VR:FTI=9<+9L.'#CS=OZY5T+U#MYB^=]NJ^1,TJ1.6=Z
MQ?EHYN:BW[E+TU+($@(';D?[S,.'\V*Y7 FSQ=H5+0;/!9*ZN _.Q@"'SW%.
MLCXJVDAU!#1]QZ0V)4X)D;1$DUBA$*0"^P]%.J' #T[!,,=+E5.QQYR7/&#H
M6CWB ]FGJ#Y44^?RV;%Q.ZX </R-;W4>U7N/A9E"T#Z@S9;D))]*U>(E0OX#
M;U?(=MBE[MK<\O$3<QCBL^I?@+TXTOR)0(0E[ \][F,7Y+/47^ 3/XKE4_?>
M\_H+4\,.:=,T[8J^0,1Y3=R;#VV;XY$/9^3IXSR?,;F]H"Y*IQ@[<!\XRC:X
MSO><!*I>_1J8BI2&'S=$? H)_%ERX&S8J,Q6+&?/X;]!Q^V;-82'=DO+F-Y?
M%",5:16@>[$_)NEQ&XW\+O8C2X!1_B&X!,V;G)^C-AWU37;F2'G\)Q>.F+\/
M/$JBF%;(4THR\H).J5GK' _K8^:@&-IJ-&IR_FTI<;T>P%G59/)E:1WT/?!A
MSXC;_=GG]^B>MAVBF._T/Z"FD)B:T/4PSK"!</!>!.7Y7G[+8GI1),BE@MI)
M:MFQ;N[?G]H-$Z%65',\_#-90W37U7]3Q7&XBV% @1'X.G.M=)5A<GR39"NQ
M\\$/:V:BU.[UMM?AUZ_2CJ$3/[TLKBA<IOW:28\7,4D69TZT]+T;9<H9H%O@
M'H>6Y0N%)$WFE$I[2Y_CX/7-"E79GR?\69P;\48$</$STTWIU!LJ,/KAJZ<T
M.X;FJDZ^3S<J?-Y3AE0/G6G/:H:6:F]UA4C]83R- IB,XU65_*U5HZ_U'R0<
M:G<,4[AQ=!L.P4';8?=T[EE#O3[1.>A^2@%CR4#?9FM8-*8L W!]T6Q3Y3)W
M_/H ]0EPJ^!:H>[C2IFC;-+97\5%FGZ[0H:.#D]_1^Z^N8M5Y\9MIJ7[83;0
MD!KMT+1,C:EO)N'U<<QB8E]NZ:BM*,>J/,572OP%G*VR;,<.IVJ9YK@ (1(6
ME*?]Q_)5[O/<^FY3\>BIG%9UL=%X!@ZC\/RC\D_O,U'?%7CK+)S&FYFU3'W8
ML8!"L?YK&\7?+9TNAQ,:.UBRM&6K_W!.+[+&OW,]FK,LT=18!\W8O_XMOU3F
ME+UZE6I&50W^';%.UO'Q:^;'UIQ[[V#SUP+A)OG&A=<ESVWZGB.+KGR@F:\W
M(-*">KG\00?657))QM8: 8XD*-[HI'$!17^QV-J\V[!-Z_\#3D"QOYFLY8*D
M]E8UAF>(CN[_ "$9&0X92/K3:U+>V>1-OG;EZ\I4TNE0.N4<J<?> X/X5S5,
M!):P=SNI9K!Z5%8Q@2#D$@CN*OVNIM&Z^>/,4'KW_P#KU7N+*:VY=<J?XEY%
M5ZY8RJ49=F=TH4<3#6S1TT,T4D>8Y/E8\!>2*D! S&221WQS7,12O"X>-BK#
MTK9L[Z.8$,P27J >=Q^M>E0Q<:GNRT9XF*R^='WH:Q_(OAD'1V)/'2G8"G"L
M,G\:9N&\X(#?=Y'%-*[6RS#GCBNP\X1A@G]X<*V.!0JYR %/J6.*>T>U6^8<
M'/ SS2!5+A]A/JQH B<L01L ([@\4Y3D*2BIWX-2'[ORC<,^N*-C$C:JC/KS
MB@ 7:!E7(4YXQWI2,*I*XP.I[TQ=J@CWZ^]-E)57'.<8R30!6FE<REE9@.F,
M4T2&1MIY4?@34$[$..I;&.#3MI\E0H.\?>- #BQ9&)P #D#/.*1I$:3.0O P
M31L;!]^,;<TV0$Q'Y1D<<B@!3N$@8LIP/PI/,&[( 7ZFF#>3\PV_+CIFG8#.
MPVG( Y(H GC=1&-K$9/3M3P^ ,.,^@JNLFQF5@..>G%2L0DF%(SD<[?6@"=5
MVKP>O\ZD4$ 1L<*!P/\ Z])QNR6X'H.II2IVD.-HR,'- #MS$85L8XP:<Z#;
MM."V<[LTS83D*P8KR.U(SA2=IQZ9&: 'ER. 2#QSBE.T'/?.<^IIH(^\'X [
MCO3@/D&2 0,@8H 7+*V?EZ< FFEFV[N-YX^@H91A5QNR,DYZ4,C84;1@_P"U
M0 'E.N,\^]&0I!;#9X//3TI<Y0-C /*@]<4A(*;RX^;@<>E  0-R[B/KGI3E
M8'+8(?L".!3 R AF89QTQUH63Y=C?)MZY[T #X/(/[P<\\9JG<Y4$ 9R<\5<
M+*_((; ^7C'ZU2NY&!&W"Y[9S0!3E8N1C/N>E-)8L3@8^M'&=I5A[YI,8/W<
M^O- #C('Y(P!QQVI4;;(I )[!J8 W+*<8/(/.:M0HO) )![4 6(G"C>Q9AW&
M*P=9\41:=:SQ;4P1DIG.:V[B\BAA8-B/([\XKR'Q:^Z5FDF"HS=NXH Q=7DM
M]4=[J ;6!YC]*P"&S\IP1ZC&*FFF6.Y(B+>7CKZU"Z!CO7<!USG- %JV26Z$
MBJ$6X5=P8M][VQ5/:V&#$;L_A2H<C<"RM_>!I=J@EN6'UH 9O);C' [\5-&L
M]]<):VD6Z65@J@>M-_UHV?+CU YJ:SOY-*U".XM1F2,Y4^] '4W?A*Z\#+!?
MZHZ>;(F8T5LD$CTKF)0VH3M.2SNWS-GBK_B+7=0\4M'>74V6B&WR_2LJVN&M
M;A9$))]QQ0 BJ8Y2G(SV(IEV6.QN-L8 S5F8?O2S/D-SD"J\H)4@$'CO0!]'
M>%+]M3\$:;=%A\RD'\#BK4@=X7V%<CM7-?#"[$OP]AASAX'QT]2:ZF+'FMRK
M9ZC&* ((HES\Q]\=J62+8#A01U'-6XE'(WI_=QBAT1N#][IP.* ,B0!6#')!
M.<"F=(SS\V>GM5N5&#.I("CY1QUJMB0N1@#W- #D=L!"2JYQ@#-,<8^3YD(Z
MG%'S#[Q'U%/<+N)WYXR0: (B R@D;CG&[.,4A7Y5)R23VIQ89Y!QCM2-RI*M
MC'- &AID8NH+VSP09H'5<]S@U\U:K8OI]]=V;@![>4H?PKZ0TJ?RM1C.\MR!
MTQ7C?Q1TK^S/'-\"WRW8,R\=,F@"3X/ON\>:8A/*M+C_ +\O7U+7RC\(21\2
M]*!(P1-_Z)>OJZ@#QKP9;F/QAXLOPF2M]<*#_P!M6K2:1Y969C]X]*3PQ#Y-
MSXJFR1NU&X_]&&G$'/!^8T  !Z4X!L<9('7-(.<9/-&"RDX/% #CDE?FZ]:D
MMU9IEP.F<YJ +M')YJU;%PK2-@8!&: +T!W2N[MNV_*,5+M52 #[U%:1X@&9
M.7YZ5(1TY)_"@!EV1]F=>,$'I6ZTB6_A>+^$F(8K"O<BW+_PY K2UC"Z-8KG
M@@#Z\4 9WBVX2#X5:D['#2VC*#[U\WV<C&UC67GZ=J]T^+=R=.^&,,8./-D$
M7Y@UX?!$9$C$?=>: )[^&>-80&/E$ @U)>:PLIB M0&5=I<#K6CJ%Q:77AJ*
MVC<"[@;)/J*R4,4<09P68CIB@"I(^]LX/L:ZSP]>RMY?F.HV\#WKF&19"#G"
M>@%6+"7[+/N7) - 'NNE3+)#'EAD<5K;B1D"N(\/ZN!912OR[CY0:[&"X\U%
M)3J.U %@"10,O@^@H9'&#V/8TW8!R <^M*./F);GMB@ ),8)P&_I0'=CGD,.
MGI00,'@\]J Q8!0-N* %+EQSG<.U)OX(P,CUJO/>VUN6#R&1_P"ZM9LFJR<^
M3&L8/<\FL*F)IPT;.NC@JU75+3S-H99@21P.*3SU0D%E4CCDUS;W,\GWY7/M
MGBHJY99@ND3NCE#^U+\#I5E@Y+2Q[NV&%.4H[#;*&;W-<Q14_P!H/^4MY1'I
M/\#J?+S_ *R3';B@($)R-_'!KFEGE3&V1ACWJU'JMP@VMM<>XP:UCCX/XE8Y
MZF555\+3_ V\,H#-M '2C+.,^:,^@JE!J4+C:&\IC_?Z?G5MO[Q<$8Z@=:ZX
M5(S5XNYY]2E.F[35AX6,<NO6E(09<,./3M3/,#DKN(Q[=:9M0 G)V]QZU9F.
M)RN2^[GBI#Y>=Z9W'J!3=RG&T?(.@/%(/D)4A03W!S0!(&&<*N*7S5.U5BR?
M[U1D.V!D;??BI$)("D%1["@!J!Y ?,B P<8I6@89".>>N>U2M^Y4L22O7BF;
M@7W$G#CIB@"'9)OV$J3C&32LBIMR-S_[-2G8-_!R!WIFY3\PCX^M  6 4[5!
M&:CE9@V\*,=.:,1DG"D'ZU#/,1\ID 7OB@"K=*)"%;/X4X[XX409'K]*B8>?
M(&!)(Z&I5L9Y(C*THZXY/- $0<$D'"D\#WJ208B'EY5L]#WIDEC(C*"2P)SF
MH%5B2/0'@F@!_F*71< MGH:=,=I?9\LF.W2E%NQV@*JD=3FGF-HV?YOQQ0 Q
M6?RSNR2?XJ!+A@K\BE,K A2!M)IZ1^<I,1&_MF@"2.9?F4*1Q5E/+8D[L?WL
MUFH7-P$9#N'#'TJP&#?.O)//- %I-C%V)(7HN:4*!M63YAV-(H:49R PZ TY
M"0=C'!]: $^7(QD,:>=F_ P2/2ALHNT<GN1VIN_Y]K*=N.3B@!50-(5R-E)D
ML6)C !Z>U. C*8@<C Y&*0,6/EH" .230!"Z($.PC=W-0;=H W@KUP:L_)&&
M'<]Q4)13UX84 564HOSJ"Q["HV8XW!?N]C4\@0$DL=P''%0R$@YWC!_2@"(8
MD)ZC/.!00!G<>.P-*P5B I&<=<]:3(Z Y&/RH 57VCY7W CG/:A-^ $E!S2A
M<<E@P]J:4W-A%X^M #M@!))+-ZCM2H%1B)0#GH:C4,!\H*K_ !>]6H\2J=\8
MX^Z<T #/A!@;5'4UFZCJ]KY(AF7<O0DU/=7*;65T/ X]#7%ZW=IL*C(]J ,'
MQ)$L=R3&5:-N5QTKELJ\A5R%;L!70M>P?V7/#<QEGS^[;TKGPL$O ;#^IH C
M$;JV[<#@]:>,2 LV2!08&C4*#N!/)S3H^$<L,#M0!8TO4[C2;\75JYC<#Y67
MJ*==:MJ.JS-<ZA=&=@<YD.:JH2W QTJ4[!;-N4;O8T :<$>G74<<MRYC^8#B
MH=;"0R80JR*ORGU%9LJQR6@5<A@:FD*RZ>8RWSH.IH ]M^&[^;X!MV*KE7[?
M2M>9F(RN,[AQ6%\+BC^!E4O]V3G\JW+@*PVH?XQS0!=0D1CAAZTX$A0"P&!T
M--WD(,$'&!UIQ3=*"3D8H 5L'@,#5:[W+$H'&>]6ECB,G09QZUGWB[@PW' Z
M8YH KA2(&8ODYQQ3"N['S8IT6?+VJ<J#DY%1LK*R\B@!NXALC(Q0?F^=LD=>
M:5B>R8]\T%,K@-PHH 3<R@Y)YZ 4T[N...](05P6SF@ID$*>O>@"/Q%;OJ?@
M2]MPB$HN02.17SM<HR,JMRRY%?3EDOFV5W:YW!HSD8KYMUZW-KJLT.>0Y_G0
M!G8[@9]17<?"!2/BEHIQQF;'_?EZXGE0#C#?SKMOA"2WQ3T4DGK-Q_VQ>@#Z
MMKY=^+ +?%?6!GC]QQ_VPCKZBKYA^*2!_BUJ_P#VP_\ 1,= '3> [?RM),GJ
M371G[QQ69X5B$'AZ/GJ36CD>M "\K2]1[T<$<THQV- " U9M%#/GTJLQ '6M
M"S3Y<^M %H =SB@\]#2X^;%+C% '1:&@2Q9^^35FR)83.>YJOI+8TMC[FG&;
M[-I=Q,.JJ30!\[>-9M_B>[]F(_6N?((3.>*T-?G^T:U=2G^)R:@M?*DMWC;[
MV.* *Z2=,=J[/PW?JH"MG.:X?[A(Q6OI-TT,@&>] 'L]C/YD2FKN:Y;0[\O$
MF6S73QG<@;- #@W&.U*.>W2FO(D:EBP '4FLJZU%Y<K%E%]>YK&M7A27O'3A
M\+4KNT=NY>GOXK<D???^Z.WXUESWDTY.6PO]T=*KTH!)P 23V%>55Q-2IILC
MWL/@:5'7=]V)15V+396P9/D7\S6A#8P18P@8^K<TZ>#J3U>A-;,:-/1.[\C%
M2&27[B,WT%6$TVX?JJK]36T/3I0<>M=D<!!?$[GGSS:H_@21EC27/651]!FG
M#21WG/\ WS_]>M'%+TYK58.CV.=YCB7]K\$9ITCL)N?=?_KU&VER@X#H?KQ6
MMG(H'3-)X.B^@UF.(7VOP1AO87*=8R?]TYJNRLIPP(/H1729!&<4UT61<,JL
M/0C-8SP$?LLZ:>;37QQ^XYRE!*D%201W%:TNF1/S&=A].HK/GLYK?EERO]X=
M*XZF&J4]6CTJ.-HUM$]>S)[?4Y(^)1O7U[UIQ7$<X!C8'^E<]3HY'B<.C%6'
M<5I1QDX:2U1AB,NIU-8:/\#IAFD''.>*S[741)\DF%?L>QJZ6XS7JTZD:BO%
MGA5:,Z4N6:'GTI&QWI!QU%)R_&*LR ]>*4 9IR1D\GI2$@\ 4 *,BD8@\YQ3
M2>.M-WJ <T /9@%&:H7$BGY1FEFGW<+5"[O(K9"\K@<4 60,+@4PLIX+ 5PV
MH^,W1V2!L5C?\)7>&3+.<4 >H,#GCFG!">@KF?#.MR:B^QVS79*H4=.10!'Y
M9V\BF$?-S5Y>@J.2($Y% %;;@<=*5".*.0V#3-PW@4 6 XJ4=<]JJY!/'6I0
MY51WH G&=U/Y-1H?ES3P>>:  Y[&I,Y'OBHSCJ#Q0K>] #Q\O%.4YIO49HYH
M 7(!ZTA(!S3'DP*KR3X''6@">28+WYJC).=_!J-Y&8^M0DXR2* 'M+SP:;YI
MSS32.>.*3G!S0!*)0#@YJ&YE C;8>?2HWDVKD52N+M0,_P 5 &7J99U); Q7
M&:I=*6*+VK?UN\;& W!KD9R'<^M %5D9CFHV&#@T]Y'4X[5&<N0* ) <ISVH
M2%Y3\BDFG&-HHAD=:GM;_P"R.&"YQ0 S^R+UN1"V/<4/9RVJAI1CVK?;Q?(T
M.Q8T7WQ6)?74UXP9FR* *C.6/7BD'7@TY57&#3O+7J.: $!Y]:O:9A=0A8G'
MS"J3$#M4MJW^D1X/\0H ]XB8&UC('512PMB7'K532Y3+80CJ=HJ\86C8.1@4
M 6"!2J01CM1D;1QUI-H["@!V.XJM<QADSUJS[4C)N4CUH S83M?!Z&HY5VN3
MVJ1U"2E>X-%PNU0?6@"N,YP10>.G6CK1UX)H 0DTTX/4T[IWII]J )8U+12)
MV(KP_683%K%PN,?.?YU[C;DEB/:O&_%<037I@#@[C_.@#EY  Y!ZT4^XC E-
M% 'T;J.W_A;\).,_V.O)_P"NLE,FVBYD.X'YC2:G(J_&2V0J23HZ_P#HV2EF
M3_29E*Y^8_SH 3HI"LH.>@I5!/WN:3:P&0 "*<ISRQZT - P#@<DT^ 9F5<@
M\Y(J,; Y[J*GM$+7& .G- %V)EEO7+-VP!4^&,2D#&#5>URLLQP ">]6QN$0
M XH #G'/)[8K0\-Y2.[G<?+G(_"L\?,F#DE?:M700D>@&7NV[.: %L;I+N*^
M5%;:0S9/TKY6C83ZM>R7#'_6L,=NIKZCT5E:TOB!S\W;VKY7MF7[9?ES_P M
MWX_X$: +%TB;MV_C'"K2V5C/?WEM;1CYYI B_B:L:?:R33%I$\N$?Q-WIVHW
M<D5Q'-;D1^6PVD=: 'ZWX>O-!UMM+N8"TNW=N0<8JG':074:P*RI<[MO-31:
MQ?7-W+/,YDD(QN?T_&J\V!.DV<!6#,10 MZ1I\PME8&1!\Q%6;2RDNXRR(!(
MBY.1R:@OKM&NO-B3>74<FHX)KE7WJ7#MP !UH ETVRFU*_%K"A,A)&#T'N?:
MO5='TF'2+%;>/YG/,DF.6/\ A5#PMH9TJR,UP,WD_,G'W!V7_&M^O(Q>(]H^
M6.R/HL!@_91YY?$_P"L2_P!;19&AMW'R\,_]!67XI\1>2!:6S':3B613U_V1
M_6L"*\3>TH/RGG;WK7"X7[<_N.?'8]W=*D_5G4QZB0X)8GZUH0ZJ4/( 7M7'
M+J".P\K(W<$&E%_)#,!U7'->D>*=PFNK$VYW^@%;<.II-$)Y6\M /XN]><"]
M%O$TKL,GH.N*S;C7)RG$C,A/ Z4 >E76MVL.XF;?GIM-58_$ULL@\Z)@/7CB
MO.X=7D#'(!7U)J*;4'>%RS9!- ';ZOKJO?91F:# *G/%44UL,[;''-<DMXUQ
M9F/=AEY&344=VJKMF0ESR,'I0!V?]OB(E7(9NU1)K693U+$<"N.DOG\SY<8[
MGTIXOER/+<[^QQ0!V":TXE"A\<Y/-:A\1@8_>8X'4]:\X6\FD_Y:!/?O3YM0
M#)LC8@CJQ[T >HV_B;+?>P%Y&>]:J:I:7\8^T.%8CY6':O%_[18!&=FP/3O5
MU-<8]-P Z<TI14E9E0G*#YHNS/59$V'A@R]F'0TRN&MO&$T*K$_)/KTKJM,U
M>UU2-C"X\Q/OIW'_ -:O(Q.%=/WH['T."QRK>Y/27YG0Z9?&.58I6^0\ GM7
M0>3M=02=K=ZXVKJ>)FT:U,MPAEA3@GJ5'^%;83$_\NY_(YLPP6]6FO5?J=8I
M$7R"/.?XZH74VQM@4D'J:YYOB=H>U=TOS;>0!5"Y^(>D$,T<I&<?+CK7I'BG
M5!HTC);)*GBE$[&(@*2.H]Z\_N/B=I<+%H86=B._2L:Z^)6IW9*65LJ(>DA/
M I2DHJ[9I2HU*TU"FFV^B/2[Z]AM8O.O;A($QT<UY_XB^)\4?FVNC1"1B-OF
M+7&W<M_J4C/?WLD@8YV+P*A6QMU& GXYKDECJ2VU/?H\*YA45Y)1]7_E<H3R
M37UUYMZTLDKC))/0TN3#$FTX8'H:O-90LH'S#'H:AET]2FX$LX'RYJH8VC+2
M]C/$<-9A17-R\R\G?\-&,NE\NYM_EYF .Y>U0WV(+B"1"6\L\D]!6OI\EO9V
M<5W?*3+&Y"1D=>*QKHQ7JO+M*.^2%S75N>"TXNSW/I#1)_/\.:;.ZDYA4 ]C
MQ52/7);:>>2XMI(H4.-[]*SOAIJ27O@F*-R6:!]A]L5VTR6T]G)$R*X\LE@1
MC/% C!B\4:#=1[A?0N3P1GH:O69MKR1I;&Z61<?,JGI7S5JU[+9:[?K;?)&)
MV 7=GO7I_P '[PZI/<IEEE5?F!8\T >CRQI*'C?Y9$YW'TJ*!G%NY1A(5; Q
MV%32%5E()(W?*01Z55C,EO<D1G",>A% %DJ?+4LV">E-D;<X7>!CJ>U.W<L?
MO<U!=1"2([ =S<YSTH :TC@N6!7'1AWJ:.Y5PI$@+XZ55D+&$(!D@54#%E.T
M;3C- &VI#9;S!GTIDDZIEQ@;3SGO65&)QU8^XJ7[.S+@-N'\0STH F>\3!D8
M,I]CUJ W>Z(M$?E'4"HVM?+"E&/'8BHS"=^=N">H!H //DD)R1L/8]:B.[!3
M[N#GFG. H SMQ^M'SL3R IZT *,NN0WT]:8=ZL,@\=2:=GY,*,#UIJDX"N?I
M[T ('&[@,/Y4\\D_-P:"Y92. .@%- W?*_!'3F@ SVY('<T@8Q'@\'GBEVD?
M-R!WH#!2<YXY'% %V&)G(9"K(1G%*VU58"3RSW4U664J!+$VW'!%,OKZ.2/+
M<.!U'>@#)U63Y&82 <]N]<7XBD;")',<8SUXK4U&<23$N2D>>F:X[5+IWD8P
M2!E7I0!D74K%_P!YD'/![&HXS(KEHY"A].QJ]YUM>P!+@;)5Z,*K264D2%XW
M$D0].M $L+2WEO);L &!R">]0-B%_)!5F./F7M5W0")=3$0Y)7H>]4;HI#?3
M$Q[6#D=<]Z &2++')\XS[BE255^1EZ]C1,<L)=V58=/2MGPYH5]XLG-M:(HD
MBY+-@<4 8LI#2#"Y4#I4\T'GJOEM\H'W:GUS3I]+U9[20JVQL':<U4>5DN 4
M!"L* (KN&6WC D8$##"OJ#1[I];\ V5PI#?*H)/HO%?,%RRR6[Y<F1>2#7TM
M\++B.]^'UG%@* &4\^] &Y:?/H,Z@8'.,5D6^]4V;?EP<9K:DM3IVC7>YCC)
M(^E8T6YK9,GIWH EQM7J.G2F(R[2Q0Y;O0QRA&>1WIRG:BAOF XS0!3OAF+H
M<#N:S@5+C).<UIW1WV3K@9#'GVK+4@_> ]J !CM8[:7J-KM[C'6AQC^'KWS3
M=RC'!SVH 1@@(Z^^:Y+XT+C1-*<%=N!@=ZZYAE0=V#GTKD?C1G^PM*&1T'%
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MO'VCZMXA.DHX60\1R]F/I73WUNUL2 PWY]>M &5(Q1CD,NXY))ZBES'O^8E
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M_HF.OIJOF_XB1,_Q;U=ATS!_Z)CH [#1D$>AP*.XJSFHK#Y=)@!':I1@<XH
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M,B@3.V<FF!0/F)_"HY)L?*!@4 .D<] U0,26YII;J:* $8\TG;.:49%&3WH
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MGE35;:"I89<#J10 OS$\D8QC(%+AB5*G..N:%VKSG 8?Q49'E[RK'G *GB@
M!5I%&#C=R>E79U\NU1& #-U8>E4U#N4V['(/0BK]R%DO$C!*,5Y]* +2?ZM"
M,8 QNHYP0@[XR>]*J%5/F(0%& PZ4FU@"-^?=* 'Z6Q76P2,$(<'KVIP<R:[
M:-M7!ER3CDFH+ J-=C"MD^6_\JT],A3[<\CQG<B;PQ]: /G[XHS*WQ-U-0C9
M3 )#=?E%<F\F5 RY/3'-;OC>^&I>.]6NU P9!\P[8&*RX+^.- /*5I,G#$4
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M@0#\_;BI)9/+0GOVJI.JLMN_()4EO?FJP>&53WY;'9Q%G<L&EAZ#]][OLO\
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M<,.PH 8A'&% P>A%21V_GSD-+LC')IRI(6!5"P/H*FO?*@B2U6,K*PW,<>M
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M[D!<T .+QC@88FI/#S+%JM[;,.9\,/H!41 6=22,$<XIT4QM+N*Z4#CY#^-
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M*%,8A'/X"OG#S&9XD9!N9P,U])7(\O2[/' \E1C_ ("* 'V!46_)P2<U;/+
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M0 [6)C!/;VCGY?+W8[9JJ  @*$X/IS3KJ=KNY:1BO/"@\\>E1G(4*#T[#M0
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MA/P\-6N?.D4E%; KV[1]#@M[:,;/E4<"O6P_\*/H? 9S;^T*UOYF8$.G7$F
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M96"'<".]36]N)<EY54'U/2K,=FUS92SX50@^;UJI!9R7$;3*?+B7C)[T 73
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M64CEP?*(YS0IMV@)CDS)NXR,8J"]NF;@DD X(]: $#+)-@OG)X ZU8/E6\S
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MH2.E0S*D>Y=S$G[I'2@#U_X/VK6_A^_O\'?-*H1O:NXN-F43?NE=CD5D^";
MZ5X'TRWFB82L"[<>]:<9=KXS(J,%/<T 7E*,H!C!P,X'6E4/G<%!4TK 'Y,$
M'&!Z4UOECVL!D>E "$$[BB@'.<>U+,RE51H\-D?Y%/6/E60GGKN_I4$K>=.B
M#A@"2: *-\I2XRS$#. >^*K@X8X+..W/-6+QAYF3NX'.1Q4"(JC(9!_= /-
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M0W2?\]%+ =CR"/SKCJ^?DFG9GZKDKC+"\T>K_P B.7I].E)QY1=C@]/EYI9
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M4DC)(X!)ZCK534GCFVB G+X4K[FGK&SD)&!GO6OX2\/OJOB^U@P'BC.^0>E
M'L'@_3(M#\)VMNH'F2('?CG-=%9ZB++2YR2/,'W1[U0NRBG ^0 87%4[6%G?
MYWR"<F@"Q9Q/#&9#_K)6+L3[\U:$F6^;T]*:&!;OM%.!)/RC)QC!H "$X'K[
MTQP<[5)"^F*4@%2S_*1V%*@8$-NZCOWH @NU/V09&#VID^Q;1 PP<=12WDC2
MR)&.F>33[M3':'(!XZT 8S9;A3WZXITD?[Q03DXP#Z4+@?,0PS30SGG(.>E
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MCD8*>!ZT -B'S$=32')DZ8J\;0VD!F!#AN..U42QSD]: )9;>2V8%A@$9JQ
M;:5&:3Y6 XJG+,[[0QS3XG5<J1G/2@!975F^7H*:)&P"2>.E.FA,* G'/05+
M9VSR_-U4=: &,9)%W-S[U7QDG)J::3YRJ?=I(HO-DQ0!'\RC*M3HF'FKY@^7
M/-*R^6Y'I3< C=0!I7=S&L:+;H%&.<516XGA8E'9<]<&FLX.*?)$QA5E&10
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M&[O+1X5AAR IQNKT_0+P7^A6D^[<2FUCZE>#_*O+;2*/S762 QKT4-SS7=>
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MI(Y- %E+5FLM[L$!.<-WJLP9D,>?W=:?B0QF^MT0_N1$<;>F:SU2/ P3GWH
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MEPPR,#/6@!J'<K@*&SP35>UXE:+<1AL$8J5$"@Y)7))RO%0HN+MB,\C(SWH
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MB&:$^I&./Y?K6%71Z-JNF:386<=S\]WYNU67^$-Q57Q'IAT_46=%Q!-\RXZ
M]Q7C8ZGRU.9=3[_A/&*5*6'D]5M_7];&*PR.#BHI8TX(.<8R<XJ:FE0$8  Y
MYJ\%B5#]W/8?$N2U,0_K6'5Y):KJ_-$3PO'(-I!(YR#30)-A.XA\Y# YJ5%V
M0[VR WKWJ>6#%C:);X::5N1Z<UZQ\ TT[,MR:HUYI<4+J#=1?Q>HJC-<(\0:
M:,+@\$GO3KBUGM)"LP$;X!XJE]G:XFW2Y\I>B'N?6LZM6--7DSLP. KXVHJ=
M&-^[Z+U9/&YE9I2,!N@]JDHK5\/Z-+K>J);HC&)?GF8?PH.OY]/QKPIRE6J7
MZL_5,/1HY9@U%OW8+5_BW\_^ >F_#6Q2VTJV<G$D[F1O;/3] /SKTXJN<GKC
M&:X&S86DL(@ 53@*H' KO4;S$5A@J17O4X<D5%=#\FQ>(>)KSK2^TVP!PO I
MR@#D=SFD/+ 9X'6C;P%!XJSG!L'&?6L'Q8%?2+F,KRT38/X5ND; .<Y/>N7\
M1W1GBN8<@*(7Y'TH ^7TA^SW%QDAQN(^E!5R0F\;3S2BW<7TVR3DRGBG2!5=
M@WRD'G% "PVBSSM&D@4@9W,<"FJ#;N<A2,\'-* #D(.#TJ,HS@\$ =C0!U>@
MZJ+1596.<XQ7J>BZ[#=*D9<EL=:\'@F>(C(^0=A7::%JFY45&VN#P!0![!M\
MPML(7 R">]0. 2R.H//45FZ9JBSHL<W! Y]ZU3\WR)M"GID<T 5]JQDXY/H:
M8(P3T^N#TJ1L8 ?C'?UIC;3T)3^M !Y>  W!'\50SS*(PI&X?WJD\_"X(R.F
M3Z5D7]XBJRHX [F@"CJ5XV2!+PO\)Z5R%YJ%O)<@/(<$_,!1K.H;6)67(SBN
M4N91YBG=SUS0!JZM?QO/^Y^90!UXQ6/)+N_>9W"B0,S;NN1T'>FB<11E3%SZ
M4 .!$GS+@NO45;L;:2_?RH!R3\V>@JB$)"N 5!_B'%6EOWMX#%:'#L/F<4 6
M]2T^ZLE$+1J81_$&K.($?.TL1VQUIPN;QX1'/*[J?4TW$S$JF3WSZ4 7S+]I
MTT0PH W\2]ZSFCDB4J04;TQ3][P,&#[9CZ4Q[B2Y.V4EG_O"@"X-"UJ32_M\
M-FTD ^7<N2:73_#'B#5Y4BBL_*R<;I/E'ZUH:7XJU>QA_LZ*<"VZX-17GBO7
M?,Q%>;0#P%R,T 2^(?#%WHTT%OE)&506VMD9JNEC%:VK&:4"X8< <XJ":\O+
MEUGENW,AZ@M49<W)+D_,!ACZT .!BAC8ALMC[U>C?"+3C'9W^IR L7.U#^->
M7S6LK!8HLEW.!^->^^%]-_L7PE9VS+B1EWMCU(H DOY&>41D[>>#5R"(1QKS
MD8[U2N-KSJW+8]?6KZ@A5#'J/RH >H5>I^@I^ [X7@^HIAY[ CH*7&X,(\AC
M0 K;E3#$'^M"X8')*[1W%&"7YY Z5'=3".$Y'- $*,TMX1N!4=A1?;!;X4-G
M/2DTX)M:0@@GG-,O0_F@DC;V% %$Y #8Y]*C;!VAB?? I[ L^&. *;G>O!P.
MQ- #?EC),;'/I1O<*00 /K2\*O!&>](1QEL?4T /U29;;P-J4[C *$ GBO"]
M1O+=="CAB;DDYQS7K_Q&N!:?#LPY_P!>V*\)NW$44-NJC"CDD=: *@R,;>*[
MCX1+CXI:*<Y.9O\ T2]<2$>0_+@#O7:_"(;?BIHJYSS-S_VQ>@#ZMKYB^+1
M^)>LDC_GA_Z)CKZ=KY@^+QS\2=8'_7'_ -$I0!T/P[G\_2#&3T)XKJBH#$5Y
MS\.+T1S& GJ:]'GXE.* &'TQ1DYQ0#3MO&<T  !)J]:G.:H"KMJV6P* %N8?
MXA5/.UN.M:Y3<OS#-9<T920YQ[4 'F%JW]"MQ/%(2,D5S@R>*ZCPE(OFS1GJ
M10!G^+M"2^T626) 60<BO,_!MILNKV<]5 C'XG)_D*]W*J+J2W;!61>]>8KI
M/]CWM] 1C=.7'T(&*Y<9*U)G=ET>;$+R):X?7;ZW/B&3S4#B(+&,_3)_4FNX
MKRG4'-QJES)UW2L<_C7)@(WFV>CFT[4XQ[LO:M)9O&&@B521VK%Y/.*MRLCQ
MJO<57.=]>J> 203RQY\MBN?2HVS(Y[L>M:6G6(FDVLRA3ZUT)TC2M,M#)+.K
M2,.@H XDQ,"13UA.PL> *L7;)YI,7(J&)BP,9[T 6-.MK:=RL[X]*AGMUBE8
M(V5!XI/*"MM_BJ26+R(P<Y)H ?#<%XS Q)':JDB$.5 .:?#\L@<BM07MK'B1
M8\N/44 8Q1@1E2,>M2P1%I1BIIKLW$VYD&TGL*LW"VB6X:)COH J3?-+ASTK
M>TJXTZULI/.&793BN:Y)W9I2<F@">589'8Q?+STJ-<1R AJC *ON/2E8AF^6
M@ D;>Y/K2+TQWH*XP*=Y;  T +Y:L1EL5?-K,+ 21<KW-9NPELULZ-?) K6T
MQRC]/:@#,LW*W&X]5IMS,]S/EF)YJQ=VOD7CJOW6.5(JI\T4N3S0!H#3=Q1V
M8!,54N)0LNQ!\BG%(TCS9)<C':H<8Z]:F45)6>QI1K3HU%4INS6QZ!X/N1-H
M[1YSY4A ]@>?YYKH:X[P2&BDNHST=5;'T/\ ]>NQKPZ]-4YN*/JZ6*>+C[:2
MLWOZGE^IVX@U.YA(X61@/IGC]*J[1Z5L^*4":],>F]5;],?TK'K-3J1T3:/L
M:5'"8BG&I4A&3LKW28458L[*YU"<0VL1ED/85V>C_#V1F$NJS!5'_+&(\GZM
MV_#\ZJ%"K5>B(Q&:8'!0M*:5NBW^Y'+Z-H5[K=P8[9,1K_K)6^Z@_P ?:O3=
M/TZ+3K-+6W&$3OW8]R?>K4446GVRVEG"L4*]%45+%&Y(.,BO7P^&5%7ZGY]G
M.=U,QERI6@ME^K_K0N:7*UM,&'7-=K#)YL2OZBN0CVI%\T9S]*LVNL/;$(5)
M3WKI/#.IHK*CUZU?A@RU*^LVJKD,3^% %YF"J6/05Q7B:\\^.50<J!TJWJ&M
MM<;DBR%/%8-\-UE,3UVT >(:F0VHRX&/F-55(#>]6=3.-3D _O&HEVYW$=*
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MFC,H4[ <$T#*!I2=J'Y2<4 6+/5;FVF2> LKH<D+WKU2_P!?,WA>TNYRVR9
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MQU?_ -I^,K^;<S*KE 1Z USJ[R<+SFI))C=74DW.^5BQ_&I"?(3$9!<\'(H
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M68\QEQU!; KG[^1Y(PJGYS\H4#CFOHCPMX,TO1OA\4^6-[NV$D\C<=1G'YT
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MRZ\BYV26Z[&(Q(OO7O \%Z+HW@-K>X0 11;Y),\Y]:^>V95EE:!B1O./<9H
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M?9Y2P,9 /%=MI&JQ7\1CXRO>O%X]4 LTMI 5*G@UUWA">9M8CC\U4C(R^XT
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M_+DCD]Z # '+-7<?"&0?\+1T50.\W_HEZX8=>.:[GX0_\E2T7@?>F_\ 1+T
M?5E?+_Q>RWQ+U=1_TQ_]$I7U!7S%\61_Q<W63_UQ_P#1,= '/>%;PV.J1\]3
M7M.0\,<H/WE!KP6WDV2+(.JFO:_#MT+[08),_.$H O#/4]*7@T=1\U P>W%
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M!L:WX1N=/TA+J9N0@/2N$+%G/>O1_'GC0:A9)96Q785 8BO/+11YP9A\N>:
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M>N* ,"1O)4*OWCUJ \\FII567YP>34&,"@!S-\@ Z4Z+;U/Y4Q1G--VX.<T
M32,&& ,"A4PN6I\$T>0KCBG72J#\AX[4 7M LC>ZDBCH#S7L-M&(K=(P. *X
M3X=:2]U=.ZJ2>*]:DTD6]N20=P'6@#G)FYQ5FS8;,53?/F-GUI879&R.* -3
MH.14%Q/M3:O7O44MT2N!59F).3S0 9[CK6E:KLBSC&:HV\>^0#!QWK3  7%
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M*V<#GWI(&62 ,@\S;G\* +23EOE95(V@Y]356[T6RO 3Y0CF;D2+U%$$J2,
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M201C8,XK/LVWW"/U/('UJ:]6VO(8KRT;!5MDB#UJ6PL4R@DD;!8$#WH ^?\
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M?:W<4\*G8&R,$U]'6=C'JOANXTZ[BW(RE64GO7SA?:1/H>M7.GR@Y1SY?TH
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M:R_AWKI\1>#A;2-FYLAMYZD ?_7K5."<?Q#K0 #).%P,]Z?&2'!/.#3-OS
M'&>N:4MAL;L"@#<23S$5F& 1BL^^7:Y:-<IW J6PF;:T;\D'(JV2CH590HH
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MN<FIXB=@"YWHV00: -;Q-K=SK^NK*7(6 *B 'H!Q5:_FBN9@&E+3!<50 ?\
M>XXW$<TGE.?F52Q!P6 H "K.-O2ESM!7H1TS38GWRL5SN'44V4N9,[<X'6@
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M $9 N;_=&,F@#N/A, ?BUI#+]W]]P>O^HDKZEKY<^%"K_P +6T1U!Y$_.?\
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M9X.<T 451G4.[%1GH:E\AG^Z!CVZT/M8 *I"]1FK%C));WD;LF_K\M %2?\
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MU6XQCC\JI(0&R:<PWT 3-?3L.6J(W,AI%PH(Q3>IH D\S(^8TJE:AQBE_BH
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MD)@49=J *J0^9E\851S[U$8Q*^!C\:EEN05$<7W!P<"H0=@SR3VQ0 ]U66-
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MT/J6K6VFQ<K'^\D^IZ?I_.NCDD6*-G;HHR<5+X=\/3K'-J=Q 3),=Q)'2N7
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MB'A?&/0T 7-4TB"SE)AE#I62P /M4SRLPP[DX]35=L$T (0.QII&#3NHZ4'
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MH" D !SSQB@"56#ADE/S@9!JLY\UNY)J^ABF#"/:)5&,'N*J;6 ;(XST'04
M0NK*2=VT]<@U.L^\!9OF!_2F% 1E<8QC\:5YE:)8Q%M9/UH 0HJOE7R.F<5H
M^&_#]UXHUB*QC5A &S*X' %9]C:7>K7\=E90O+-*VW:!S7T=X>T&#P]I$5G#
M#&L^T&60#EC0!/:V5MI.FQ65FGEQ0J%('&X]S56>=Y&*X0 'H5[U-<W'FL41
MLA>X]:IL7)4-@CU/<4 2814QD*_7I2(Y4[E^="<@'^$TS< P!! P<#UI!L"Y
M!(.,<T .:0/R5 SVQ4MM \H!7"IG[Q&:;''*\H55#9Z_2M<!(HO+";2!T'?Z
M4 -5#&%C:$-A<[EXS2]2I^Z1_"><4*-G(F !//M]:)&*0Y=U<<X9: *E](X?
M&\$=V48JG*P+#YL@]B*>6:1C(&PS#^+H:B# _P 0=@#E10 C+M[[0.M&'9=R
M,"0<\T@4'^$KGUIK1LS-@88<_+UH 7<3D'G/;TJIXSU== \#7& 5FO 84QUR
M16K8QK<2JIP7[XZUY5\4]=_M#7S8PN3!8C;MSU:@#SQU>>01YR<Y)J9V-LI@
M7J>N>:0#[.GF,0)&Z9[56).68MG)Y(H [CX/KCXJ:-U'^OX_[825]55\J_!X
M?\73T7&<#S_I_J)*^JJ /C?QH /'GB$MG_D)W/\ Z-:L5G#+C)&*V_&I8^//
M$('3^T[G_P!&M6'MW'@'/O0!:M&W1-"YRK=/K7MOPKUG^TM!FT6Y8-<6V3&/
M;H*\+C#!\8KH?!^NRZ+XAANE<J58*_/WA0![?,KI,PE)#@\4#<>^!6GJ(BO+
M6+4(/GBE (Q68'C"D[B* %!(/0'/?%2Q,K)M90,]ZC&=H((-"G;R.>] $L#^
M6_RYR#ZUKQ3;QA7!DQR*R,B922,%:;%<%/G1@6'9J -.57CE#,N0><K3CAF$
MD?4=J2WN$E (4JYZ@U9& N5*DGJ* *LL*7"$L/F';-9<T0!?0*"_B,X(9&!R
M":V'A!?S,[''2DD6.XC*2<,.I- &,6ROS$%QT*C%:%E-N $G#CI5.6TDMI,@
M!HVZ,.HI$D=7X!8J<\4 9GC/P8OB.,7M@1'?PC)"C&^N:\'ZBQ6?2;D%+BV)
M(5NNW//Z_P Z]-M+J.7#!FCE'8USOB3PE]KO8]=TA5CU&$YD3H)5[C\16->E
M[2#B=.%K^QJJ?3J-KA?&.ER0W*W4*$I,W4#[K?\ U^OYUV\4@EB5P"N>JL,$
M'N#3;B!;F!XFXW#@^A]:\BA5=&I=_,^AQ5!8BE9>J/-HM,'D>?-(B-CD&MV*
MVL?#.B+JRR"6>8_(#VKEM1T^ZCOY;>[)#HW4=&'8CVJ_<7"7%M#I\A5HT4%6
MST->XFFKH^6DG%V96U&Y?6-0&H#&YA\]:O@:;3+3Q.MQJ2D1H"03TS6"R"V0
MH!T/44H(,BMN ]Z8C?\ B!?6VI^)FN;4*;8J I Q7.(@9LDGD=35LK'<PD,,
M/'RI'>H(?WTK0X!;MZT 3W<\9MX0S[B!@FG:7HFH:S?1VUM"_EDC,N<@"BU\
M/7^J2K#]G=(@>6(KL9=?B\%Z4MEI66N2,/G]: -W6]1TOX>Z%:P1,)+PXW;#
MU^M9?B;1X/&WAR+7])8>="N9$[G_ #BO/-1EDU/4&NYURTO)![5O^!O$TGA+
M6UM+E2]A=':P/0$\4 8^G71-M<V[)M?&,-ZU6ME:4,LGRX].*[+Q_P"$9M-U
M,:S8(6L;H;CL'"YKE4$4,>X$2;AT]* ([8)]H5$4M@]34KK)->O\X&!TZ5$D
MX#;D0H1Z=:CE;,FYGSG^]0 \M&4,;J2X/7/2HMN]\*<H..>U68OL\$18H&=_
MXAVJ*UM[F[O([: J))&PI-#=AI-NR.K\&Z8%GFOW!.T>5'G]3_+]:[&J]C:+
M8V45NASL7!;U/<T7UW'8V,UU(?DB0L??T%>%6FZM1M'U6&I*A147TW.)\;:@
MSWPMHVR(UVA5/)8\G^E=GX"T!=$T-KRZ&RYN,')Y(':N3^'GA^3Q?XJDO;E"
M]M"_F.S#@MUQ7MOB'3XK;3UG@0*L6%*CN*]JE#D@H]CYFO5]K4<^YEV95I"-
M^.RD]ZW],#)*5$;#=]YL\&N7B8;%?!W$Y7'I7:VT86&,J67Y>A%69%DHK]\X
M]Z:5_AR?SJ"TMYHIYFD8%6^[BIVC;!(P3VS0 @YVJ_#>]1'S1*RF/*=5-1M)
M';N3-.I/4*352X\0Q1OMC7=QR3TH O,DKLC! !W%(D+M,595"=3Q61;Z]=-*
M6DB0Q?[.<BM2/5894&"%8] _% %L)C[K8'I3PN#P>_>H8DW?,2#].E3Y)![&
M@"&X+)$SH 2!7(ZA%(]PSNIR>1751K,D++,V_P!#5.ZMOW;2,5"JI/S4 <G+
M#;WEI+93H6$Z["#ZU\_:G8RZ3K%SI\J[#&Q /J*^EM,TO^U8GN#(8U#'8R]2
M:\H^+_AZ>RN8]5\L,?NR..AH \\>0C8HRP'O4JD21G*[7!_ U# _FJ/, 5?4
M]ZDDO #Y2@$#A<4 306T\DBJJ@9/7-+<F. >6C#?GYB*1'D3+;@DA' S59=J
M[MQZ]<>M #&C+.0K'>1Q7IOPEU6#1IKA-1*B20?(/6O.1.!&%5!O[9[4^TO;
MBUODGR3CUH TO&E^U[XBN6*"-=_!7TK$$OE+M5I'![9XJUJ_ES7GVD2./, R
MO;-1P1S;&:.,NJCDD=* "*X8*4=?E(X]J8Y2/!5OFS2'+#*$DY[U'+$B28+8
M;UH L1Q7-[/M@@:5CV6FO)+%*;66$K(.N5K4\%^(V\->)()EMUN%8[6!Y_*M
M[XAZS:77B*/[-8BW=DRYQ@DYH XY8FF3'(<=LUK6/A35-3TJ6\MX@5CZU32W
MCNY-T=R4<CHW%=MX.O[_ $?0[_3]T-RLP.U0Q)% ')6&D6ZP/'?72AAT ]:K
M2:#<,Y*3)Y0Z<U4U+3KZRN&-Q;M$&)(XI@(:$*\K9(Z"@"T=#N0P "'/3YA3
M)-+U"VE_>Q!%'O56.5[?]X)7^7IFK;:A=7<#++<GV)/:@"!I$\QEP0>E1+&
MQ.,8I54\8)([M4MK:W6I7RV%E&999#@8'3WH CMH;K4;A;*TA,L\APH':O;?
M!?@NV\)V@N;A1-JDH^;/.RK/A'P;9^%; 2R@2ZC(/F;NM;=S=):C+;MS=#0
MYF#R![@_NP<LA/6J6IZE+J<PC \FW3A(Q4$DGF=26#<Y--"\9(RQZ8H <"(S
MM89XH)9N.V.M(I5QM/&#WIQ4DA01B@!(]I!"YW>E:5M;+$JNRG<:6V@4(6QE
M^V*L;F+CY3QZT !W ;3SGTHP&.U,Y[@]J4%RQ. ,=JA:=;>)G8G<Q^[0 7DJ
M1P^6&^8UER/MPJ#IUS3F8O(TNVH=V"S%^30 ,<'Y1^-(Q(+<]>]()2A.7R#Q
MS0K\$+&<8H 5$DNI$B52>< US_Q3UQ=(TF#1X) )"N9@O\JZ^UE73-+N-2N7
M411*=H/K7SMXKUF77-:FN9'+EV) ]!Z4 8F_=(SG'-!8^I(]J%PC#*YJRH$:
MF1UY/0&@"..(D;GSL'/)I7E:3]W#'M'TZTG[RXE1#]TGH.U:$TD5@HCW9;VH
M RV@>, E3GO7<?!X?\74T4XZ^?\ ^B)*Y>*\AN&\MTZ\9KK?A/"L'Q=T=%((
M_?X_[\24 ?4U?*_Q@_Y*GK/K^X_]$1U]45\K_& X^*>L\?\ /#_T1'0!Q&>*
MG@?(*'O5?KR>E*KE7# =* +*L87Z<5>B8@"1.,53\P3KT 85+ =ORLU 'K_@
M_6%OM.2W?[Z#')K<="A.17D.A:JVFWRE#\I/->OQR"\M$F0YR : &<\4[FDP
M<=** )  5X-/AE>(GTJ$$@U(3QF@#1BG65<$8-*8JS5E:-LBK\%RL@PQP: '
M,GRG(XZ5D31F*4KV[?2MXG(Z<54N[831D@8=>1[URXNC[2%UNCOP&)]C4M+9
MF15RWGVCGD=Q5.E5MI]J\_#5_92UV9Z^-POMX:?$MC5DBBNX2C@%2.]>?^(_
M"<EM))<VQ#1]<"NVCE,8&TY4U:(2XA*L 588(KV4[ZH^:::=F>(,K#Y2,&@(
M".:[[Q!X11D:>U)#==N*XB:W>WD,<H((IB%@BC$;$'!%084Y..:E##&T5"W7
M@4 .BF,4@9!@TZZO)KLJ)6) J,C(]Z15+<$&@"(]>.E3>0\J[H^15^PT5[M_
MF;:GK5J\:VL(O*MB';H2: ,ZUMA V^0\U/<:O.T;0H<)C'6JC--+G@8J)E*'
MYA0!$F4;S >0<YKL-(GCURP:TF($B\ FN/(X/I5_3YS8HT\9(;- $NI:6VF7
M3)*V5ZC%4))0YPJX K3NM674PJW"C=TR*IO:('PCY/I0!7W\8 I@&2!FIWMF
MC0LU0;<C.: )&9-FT+R.]36FG37"LZE0 .]0F%A%YF>#6SX:TR?4)RS.RVD9
M^<CC<?[HJ9S4(\TBZ=.522A'=FKX4T7RR=0N%!;D0@_JW]*ZRD50BA5 "@8
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M )Y9+6T9I+F02RY^5%.:HOKET3O3"#/^K'I5!8U91-R6SDGO4[)&4(5"7/\
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M_P"B(Z^J:^6/B^ ?BEK/K^X_]$1T <+GU-310%AD\4^&!<;FYI\DJKP.OI0
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M1EY!Q4]D6C#.HYJ)LR2%FZDT -"C/H:0G!P>?>AN#@=:T+'1+S4<&*,[?4T
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M) ]32,'5V!8#!Q2G?A2N"M $L+AE92?DQP:C>/:Y8$\T@ W_ # A1V%2";#
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M<\4WE\JKLQJ5MD4>6;YCVH C*H@(9\M[=J:9$P><DTJF/LK9ZFF[Q@?N^<T
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M?U\P?%I$'Q0U=FX)\G_T2E?3]>"?%*RTV]\8WB2%4N,1[F[G]VN/TH \EEE
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M&()9!Y4"*O<XKM+31;&T12($+ <L10!Y-HGPR^T2*TZ-ZY;I7HNF^#],TV%
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MQD'A"?58Q-J*"UD)!RI!8CZ=!75:;I%EI46RVBPV,-(W+-]35ZE52QPH))[
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MBO967Z\TH(7D;U/L:"Y8']YGV;K0 9'8C@8^[4T(WJT1 ;/(-0EF*G &/44
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M<9QTJO#$SRJJQX(Z>]/\3>)K3P5H):4AK^=3Y<2]CTS0!S?Q/\6#2[)=!L)
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M'ED' 9N ?QKH[:_FU32UN+0;)@>58=_2KOV=;F%1>01NP'(/(S0!Q]C:NO\
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M]STH T8[.&W_ 'DS D=STJE>ZVB9BMP2?[W:LJXO;B]R)&PO]T=*@)5$Y(H
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MK-]XDUNXO[MB7<_*">%6DU[7=0\2ZJUY>R%Y,_=SPH]JS))/*W1IU/\ %F@
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M(="J06L+H,6X"YBC)A)N;<H 1HQ,3'IIZ,H%8L4# 9A///MMK;UAE2=<=(E
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M!WZ^QKE;T2W<B@R31JM6)CU2ZA<%:V+EK :AF'.4J-5QUHKRN@MHY8Q4OJ4
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M8(DZ26AP"1OCZV:KO&9CVWFOA@^8?EN? '\7,XNRZW:3$Z8G8,>SBD*<4XN
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M(;UO.</=?FP=8NE(:=MSR:[V[A=^F"SGJJ62L(RAO \%/.>%?]2\)NNJ1,+
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MJ@-R7$[6BKTF=^JMYP$$;T:,C"Y1==R?!K*?[:+Z"HN/$@X&,Y;)Q/]-O*D
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M<I?G+EW]P\+"%\N7 MYU#0AG&#1H<P4;:]7J8;Z:H&Z4M'R+'T&4I4U["0I
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MFP@T#/I7>B1Z!W#;U1RIKZOT_#D!-U'G'_6< *'GJ2AA6HG $N8\4P\ ,:'
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ML?F)BCUT)FN8W*;XO5QJ\#K2:>N#DT3@MZ8VMEWE<X[.[S8@ ?Y$(,R4((L
MM^^H4B=KJ(6W\/VF@)K%RK+Y_O8%#<U>[@J(_9.@(3783"7LW9]7T$,B<.EH
M:;]),[9=Z^J^ '8_TX#]I2\(U)?R4Q^^</+W%HS_:D<I08*1_<-@Z(87-IGP
M&OESSZK* \7?2\4G,($; PFH6;P(^X$#VW#CKDJP-..\P1X&X!2M?DU1@7 >
M"@[9\X>Q*D@ ^_Y5_Y_7X;'SF89ZPC/D;Y>XBU,$7>(/>]"_[+FD1.H<_T@F
M0;9O&FQ4R,4/I1LI-5M+J5U]:73D%4-@%7)?>*1!JWE:1B\F]&T$=VXL)>R
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M8=(VT[<Q.70*]KU?9RR>F78RE*,67O?J^06Y7QVU%,>_N5C RDT[VT@$AHD
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M7J<2YLQU?--@N$E@#9TY5C?K'E8GN;^/GU_4Y;S.5/-!-C$[S=*(O>Z<"0'
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MO.V"(FI/&LO5H:8XYVS5&/!_!#>:M%*L[#-Z9"Z?C,_R=R7V:NT1."X8-9+
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M+K^0AAAR/Z/;+SP&4;":THD7T,>5?>1EW[70_MML8[*-@K?L@TSTO#G5GR&
M ?%)"/[/@Z=*B,[Y%"MBM,7JRN.4L+,J)G7/+$U4]WTK7Y;P6\['F(LYSAKV
MBM<<9H$\BSP,K7Q?P[=]\UOQ$WFPQ!Y?$[2G-R5@D<1>[$#O+&)NOB-?"K2P
M&_$=ORM )[F3^ :]D-7TI:MC04T(J.?K/QL9JGU$$!XH'C;,)_L=TCN7P.N
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MN.5K,^.,K,BO0X8%4"!+\1#,I0 K)Y+6\.:LEDFS S16)4OSNX6*SKF4* V
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MNP3VJV^=NF"/0PPD)_:7F6@A-5QS#QX'JLMT.#*W?3&/&0<AAFQ)="$>W"E
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MAS^9Y.1&D%?\,TC:/>P0 F]*& WI:"AIF7<4# $WN3?X#WI.LMOW"AIT&&H
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M$('YX>QLRNKQ'$@#"O8$8T3->FAZ177*3^!4(Q'F6"H0\3(,7Y[[+-9("41
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MGV@'CMMZ&YM+Y3)G7AD4<:S5I2[U7*/%GD7A"1-W1&%<P$JS!*.Y3O,F<DS
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M%S857,V5%UJX9@GL,":XHZKZ[^,!<7@WWF8;+4X! WPC9+Y7!_$%@_NI.F,
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M__\J"GHZ\WD<B/CQZPU8__C-%<'_=>^I:;@T)VU 7('=H)\ ,+>7'JET-\!
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MRB;$3/JNQYIBQ1[/HV#J+4,'N$-W247UHGL''L?=[XK(A/3\">R"6\B'$H(
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MGY\KLJI3ZA<O*-9Q4L8"\0\*:H,NNYF7*L8?%<,T0V:K7W,M%/6L5JSJ8'N
MG^1^Q\DGL#H=_'%3L&L)8@@VC'1*TTGO01., 2I^?CV,V)!%;$YR/WTSY>-U
M$7@4UT+Z^@*CVJ@G^D$'5%L8M3W#-XFAM/_YU1CKWH4\7U6&5KVF?/6[V6M;
M2NCA@V%ZU"S_XS[H+ G"<%S!X HZT4Q6>Q*!M5T0MZR?MJF/@G 8OL@%S%IF
M,YS3U>+?\GSD3[_:QY6^*YM?LB.DJ;LI(L_P5M]&,&T5>8AX+!2FJX9C*XK
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M1H2HN[7H.DP_?986V!E*H^2Z)R8F=COU(:N^D=8T7T;5H:ZVS  VOQ0<MPH
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M.9YM>&Z$F[>(N&Q@U)#]5/&5^3X*24+:KK?BVWS#JVD9/"IY2Q^Z*"C$PMY
M48%=3#@;PL&6.CN+I3+I)?K%+-S8=U4S&[YQ"I%@HUOE6E_;@PJ]@*>E%K:
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MZLP^C]M*M9N;FTK2;/X/T\HB+[+"J_Y)LSW6WT"IA?67K"Y]X^@/XPZ08)3
M&YN7OZ @ G/DCY+E+$':-+_H,/S\H0'=%#]$T =JR:8K'; 1,W#_UND[D6S8
ML%SPR,2LOCQ6INEOYU9M0="@&&3S D8F->&'O8M(%+]W:\@F]06.EPM357Q_
M&#N7P?;AZI$9P!J5'_;S5>FJ^"T+,?;"Q9M PTT!Y1Y5MX4IGP1DD-7^<Q<,
MNMN0>6:\5WR!.XM)0D0"YECX#\VI&D:L(>1P0"IFN=!X:I2M0DH'TR>IYC*]
MR"QC^$Y__J-J#CG0@;F7JN\9-+8)D(.<^&14FV):"G?FM5V6#^F9] W)5$W?
M3_\K++,'O^"G*K]G,6=_D)DE?8<G[KURRXI0HNNKX^5^^OH3I-9/:>@C(I<.
MFAF5$YW\N OGB7I2E'Y9&%\S0\/U39NFYE>3&8HU(B.-ZLRI^D6*ZF@_&BXM
MNW/:XN7Q_%'(WIB$;E3X.,;*=I<!<JBX7,]7KU-SQGG.T343-=$^?,;"Q)\V
M*/*=B50*B^3MXT07\\<C):VP69QIYGKA0M>'^*W!:,C6WS>51Q_2-J9<N07S
M*7%]#/#'D=&),A_AC*$.3'7<!-W[%PB/P!6R?&7"Y @*/TNF-]U$=<&(P['X
MK=V19V5Z_\JO:Z[_[[82HH+/E"'47*@(L6]_L*3XOODWJPQ8JL1,,?OEON\K
M(O%X9'%IWH1(7Q&JC&1:E_FW$Z=)-CJFA%9-<X$+ ID3-JK0-5NJ#^D;LL_=
M]8+#^\SARFJ[X:Y5;45> CY3@"\C;ZXTJSR96 X;H]Q)[IZZ.F_7JKW(LS^;
MG[/*V*<W.LYT2F,[R,!1"^3 Y<CKJ=F BJL#*C";-,2Z&>4O4!K] EU$E%\=
MR%..-\(!9U8F%.-C?N:[\98ASNS+W"FOA6WFL'"L1#6\AGL;UW8=SH 63IHB
M0ZCL%%Y<T":M]=&48YCL&#A:\% X&>$DT@+K7>=67US=GEMM*3@X0Y9BK@8V
M'$>];CI?[4[9+6@]</NP._P',(EP?(@HM^3;/=9M.^/-UK"_JP33>-\Q[_.;
MN2O5JH*A=PXFRJ?#!K\7T++,8"8Q*,C*\?EX:6 %5+7'SD:F97<2CB$$4<].
MU"FM.=Z&TRZ4!N'9&7CBG 55MR>T+0B^G=A;SC=US)Z)Z<V@8.\B33^&,5"L
MQ+<T?6.K(7HI'RJ8$&:$Z2.@Z.N'4N9I@?.H;<A^)B&_\49@M!_"2# [C]*X
M.VU4)- 9[2SIE57/3!E)F3=R 0?!$#^,:17HGXN7/_NP7X66HY9")#A*#5_U
MT#!(3 &\]I.\*H]NTD.]\^(W%2BQ3 )HP;1XI6']<UP3.Z???(!*7XW-8\FB
M?OA 9[]LG+]PL-:MI<RR7^QFIV2'2)#F'+1+CWV1?8+?$0H:4V9 #7HDT1V;
MTUK'G7%V1]43KZHGW4O7F.M=8!>Y7KJ>)R;_Y,G[O,SO-6TZSN_9K8.##)Z?
M&30*U6SMR6/))Q3&0G?_FHC"71U"U ^K-J%'I][KJW.. MCP)Y2J>#]:2KT\
M^]_B-)4G_=%)#*7UUAN9G04E$NH'6W?\U/9V>UGAC9FH(WJZKHS3 T!E;B1[
M]4]4RE6&YZZX;ZH4>]$#C2.=-3ZFBL^*R<1)_I52KFB,0R!=4UE0--0I*SB6
MEY2.?7FK(O;YV?5_0&O(['"UD'P;$6#[@5A[4NZVG-+Z,\W;7U5F7W^V$T;%
M4(@?:_5_C2,8'4-B5TC@XZBY"=+%7%>4JD]KT<(1[U+'H,#!YEC"GAY)G9Q_
MH@&9Z%YC%9A)T%B<@KQA*805+JW<Q\>WG?[*JS;2-";@MW&K^]7$*T?/@\0T
MF,CN%UQ!D97T>/'[FJT 1^M/Y=_R_9'X@<9D7)H[7-(^1C=EIOXAV'O1+Q"'
MA3I^T6LGB.U.#Q?F1EE_'1P)>CM)'<):Y9Z 7*VO/T<#KP_O<_>1S^=2.HZW
M/_\1) SU5U-A=ZY8G,5F2A1^)]T3^?I/5F<96?6;0];/LM3Y$;&']%_^3I@0
M'MHPSX+WXQP3Q%]GT];J9(E+2!\-Z\1R2;MN"'))#+N &H?'[]BV:YO;<Y@Z
MJVP3\7RUE+B3=U41E0\]WS%^U'_-HQ:O9)/MMAEA7NPW-:#T0&BFOF%OXP*+
M#?&T*V1@[5%\"_*1;BM%I<1QBISE+FJ*IC);93>P+I[R3G3[>9(1[L(%?>DD
MQ:OK)O(+%26G+PO:$A%O3;I.-Q9GL1)*V)Z5WKL;K0Q&WV/.%7WHL1\/3P%)
MS+AU,=8$O7(]V&C2B> "A_(3KYHV% 2\".\^@8J]O;ZSM&MKLR 6PS_\ENNZ
MQ^?';1/A$H;[F'*A@QW?]5IZSO*3IQYRQ\@Q<[&Q-G54'9L:<VF&'1J6?4A@
MBNH<)0=!2#DN*U+<.":\-Q<5<X1T HZ-^/1,33(U^P*0V.K"4%9!&F:?W)-N
MB0H7]6]T;U\]MWLPQ7$K;!U]"SC)4U.HU";O\Z3\4Q)6-M6B!2G:S^WE\RP'
M]2:_R%-[6ES? GQGNB'E1ER-<$E:P->=2E"8TD[>L$;::\XP-07Z?MI-TI-P
M^TO6? 9'C_7 ?P )E(!!VNO5,U43N*KM/%PJUTF*E&8?79SW*\]W=6.]AVI8
MX'O@61MJ=F_6&$>(MQZ?"[P.)\"EW0V0(]TH;'W^"4T7&W,:=Z*-.*FSVZ!]
MW&Y]>4[WT2%+CWX6LQDJV*UUAQ>5KMD;/#/E-J PPAY8QW.<Q!SLXVFYN$D?
MOKIO^(7H*#>@,(=O:K)_)^#' %S"I+S=BB ^4!P5Q,ATKE1_:?J#LGA)H?@3
MCEOZ0"'#.;JA!OK531.QMH&XW2!R5VAM6GOE0XU@F9:N!*=<S"2),.#(7=I&
M34UP8^L^<G2SRI*Y/55GZ_J0NIJ.BI!:*:2Y(/3U<O&BNFNVPMO[0F+R??U;
MNE8*]-7T[#]8F:D[V1!WO1Q:_*2&1\1<7HI R2<KROF"(NE8X<^N[(9WLT5P
M;2P*<Z#?PZN(^]98<^T8O4P;L0 3[Z:7#-J<B09<.1U1^^)C.WHJZ@)]]XK*
M66(^W6]P*Q# +3_B@Z?G^?CPMNCPP=N.W\;P*KN//36[M?':X*.AB*\0R(5<
M"GGR-8B[KU_:E>&-MIH19'4,G73<!?*#D=;$>41%Z0EC;/JSU=%['< P,AFP
M5>EUP.SK;."J!O<[UE-H6#>C6.,?HN#\."T?J_OSP+ZU.YD?:/GH!9]K*&@U
MQ">$5SWI\<+0OCM-=%3RY1RK0W=4<V$F_3,33R]-P)\R][$Z)EQQI,XTPO'@
M/20.MSY<.+5-L _]2<2:;.-H+B,-1A^()'ZGNYC%969Z0! UNX*X^V+M:?8-
M&7L VD=X]>R&3>FNB^_;] YW'KOL7[6U^_U+:,-O$K:%WYLU'YIOJ-)Z NG+
MA=^K5TG2<^>:%Z[;<O&\3E]^^V2  $8Z"JATWTM53?%^"+RR2!KR%K0,+*OX
MKO=I@F( BS&Z\K6-R^5&ZX!E\K\]EN&3<H.P?4J!5MPIZG=]ZEKX.M:9E/K@
M5&>VC2K=>I?'L2UW8G"C:;1GTOU42RT5!1"YAS TY!PT\]?)48Q71YZ?2/?7
MO J!&HWA962**+V":'"!V?>@H(4[WW$V\O5TFU+WC@A%6^OMO(>5(MM16;Y0
MXH*=L+9SNDUSK0=$>J-QKF+OTO:VSUN='32<(Y[;B[IXO,BLR]/^5N=T'L=V
MOEID02&;X(KQ6NF*77$UB^$?/U_EJIJTTU]H9;FR\K2V.R%]>MJK^JZK6')T
M>P-FREU 'X2[X?;1//7SCZ8A5/&."[DOY3%X,K-4M$Y6+:ZK>UV5\9.]-0%6
M\U3>V*IG[\U"$EX!*J"**>_*BX_YZ8MSOF\9&8A5_X$G0=QQ<GE6H!) /("D
M&YX/I<U@[8)7<#)P@7)2#6QV]#[2*.&.]*B^P2'.9FQI2"JQ]T<2"+UXQ\1M
M[$._['3%^DUKX<B(KQ1R&,2,0&B^$[01A!$E(4:QMWV6B]C5Z)O]-+8-3H==
MI:HX"UXVW;]7 [)H\%4SK;B?/Q[X<6/60_3+MY2'YX4M96(<G4:?ZGI3_:D&
M#OCJUM&RPJX;FXNOH"X:/JF%-RO!A6<:[7&>T+[L80(^7P)\4#?QO\.".QC]
M@#O3HS%;947MH]XF*D&-72K 3'TEH F\+,[P8O,NS^]\: V4I#+8G Q<"GEV
MN0K/#YW%I+QLH4H5OU>QM5:\4WHX,2,G^<+I&;['[E@4Z(TC\O,+4</D9^T,
M;7Q@"@BU;)W L*!/1>ETI]8[VSWN(A%^Q ?Z'?FSF$ET@DS".N VT>N^/A2D
M>LPW04NB-&;23G@1_Y4^&AQ-!#QO<O@N1W*Y_ +2)N>1:B8FILV:$2@N#4EL
MJE7!E16$@C:"PV17C=;^__$B__?18^D5":&+T==S_C^X2P7J?^6,BV[Z_P.N
MG\(8@XD%<]L9@5&1?T"O"V !JOFY>N)5K GMK*5A3FS,.E@>&#P$5MY9)S-N
M6TQL3T)7^'9=9?UWX5+;]X-;$K\J<:=>[#P59@JUB\D%]+0$W%A)S.;B-U7R
M\A U+ZK;*.%L&JE*TWZ(PD6E34%T0UU:XR@K7*BMZ:>/&I@IPUC>LQRO9(^F
MRGBP^;XX^@)&?VRN3GL?2V\ :V[#J[^YSBYMN<P'EMZ)Q1\092>PPB766"$O
M%CG:O:[-*S^.6>Q^,MM6N4(3ZF#:B]=0KNC!'GTAS_1&\(75F5V&<=%PD?AB
MB@&/3-A,J+LK'N<,P>%Z4Z0'NF'=S=,#-NT"I V[-'=J&OH[["-^U 68$WRL
M$<-<VCC!V/Y!=(O2!+R])C55/E'0YW8&E&[U#5$G8^F[N_I$Q\,Q'G[K02/+
M\[,N^9_Y:/KZQ<"(J(\4$-BX(A"%ZJY-./?%>E[#C;7 +1+WI!6O+IO<#Q6X
M3;ZT_?O$OL!7V$+?=6&$8SZ^Q_C;2IQ"$T$5'),1A"20$6Q>V%W 3$0*4NS-
MLVNS44@?;_QE<=EV?+L* T)7XJ8(S"?'(UQ /]^VTZ!S6L H@7;F^0_#7""U
M*S4Y<:2O, Q'2@<TOOPUWJ2^E,CAQ3F1JXLPYB)5*^!U]]MSF4MXNWOQ]8NS
M1P]U,[;;*6\,."AUI(SE,-=B?W\V6&88_I2<T44*7ZL$ 60MR+IJ^$^%H=^D
MEI@?/GSLEE1J#:O95["XLOI58=9B9H&KS*((J/7X:04./%W/EM,B,8N^M*7H
M^L<I^2LB>K$?<W>]7N6:THD4UUB$I+5IAPZ%.TN[ /;3*J57N%(&\)K*_B--
M?YWN "0.WP;7,+:;PV(903N80E4W85I8]6!<ZV6^#E;K(E,(.WZ#%-I5]4A7
MZ,6-ON:O,QA90C\-GXHMR"\WH=E_BBOP7_2UI<:J.R>^?&SZQCG@YX)3?@[I
MFG_]02MWR[^_&F0ZM>M(YAO3$Q-#-H.H8^/'JE&&O8Y(/!"=GX:'80U[LJ+W
MX9&A W5*U#$,OT< ,K#6_/SGDHW;P%:+:\P\_(EIEP"XQ^NULQ0E5G*H02BA
MD/7V<VPE]X\7O$UKZ]3*1(DZ."!FR60W0OI%5#NC)B&.+>S)"4T%]R&@FZB_
MZ"F!Q*-E;HJ?$0'15)5Z]AFPD\+P8K23MXI2%=RFO;$5-1GZVB6UW8#@!2>>
M%#PFM9IGW:F"A/\"*C^F3"AVJ@R0S).,YV/"@$N<^JD,]F@-" 57&4V5:@[
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M8#S-+P3=E(,.FFQ6V?<HV*.R,93)@3_?LKD/%\BY)^A)4?(%;U@+&/&SCJ8
MS;R8YVCOX!/-C#,P1!G*<]45Q" LKU;6:&*C Q9%&EL=EA'"%"PNL51LC6 [
M-R>ZJE3@3G* AE8(HQVG3GH16[('0B!)=V*N9\XG@YUK)]P4NN)41/#XDOFJ
M/-H*6RT51A\&&7'O^?(NRNKK3D<W9\7=<[HQC=<N@DXZ)@[YQG$_&J=<0V_]
MHN/$^ZMJE_?-A5HF6?^>ALZ"(F<MW-OG!V24<A 1PBII/R42/66NV16M0\MG
M(0Z)0?]^[/77MP$;(PP_PB>]B7UB](X+F3H^I:CB7?'E%6LMI9TS]SL/@E/-
M+H[%6,<\UL:4J#%OD82=]J0;)R8;:"818Q6XAE"^4^VG39Y,7E.24%IN P<,
M-)S?Y+7]<,+5QI=L+=",6DW#>JD?;ZJX0V2<IC)Q7D#0"QX>WA :$=$&=M%Y
M G*; =E=).'J(NXH\Y)[M % +'=B+#KZG1+*7Z2V>/XWR5&FBNJV=7U](UDU
M,@/T_0M.RZM/1Z^J1T755.4*.QH4$&B#C)0UB5J"UT^#M>;7)7D8U#  \(&T
MIOO+<XO*K.4=<6D4X&IA=O0[EMURH'Y:Q@-DHA<N=1X[&;0FBCX\,QK@HD\V
M67@GND.H? RCN/Z*>1>DYGV;I4"Z>64>1%O^H;R2;-.\KT>BK_[U4$/UZP%I
MKOEVNL1]SV-KL> 8_17G+G=/+5>IOJ_^^3HX=8^:=R6W+O\!S=<$<6/LZLP2
MA-)57W$":OY8:RTNGUI^P^V_/K92+KD3MEA&)YJOJ5TT'8R(4US+QH8+OOK&
M3T+],LH'\A[Z:PJP[O#?) <7QJZD/YKGNM"PXOQRQN[A.%4BXY:/.[/X-?2>
MI,!^\*7+TX@!AA$&;R[P$!\]U]<_IY!!H2P0.;IJ_45"FSUO*;JNBOW4L!^)
M@^V (_5T/E4A^YF%4VG 5DM3?_D](H9.8!'$2R4V)\#-);&S[U36+?H#.2HV
MOJ6VB*OV'-1_K 'Y:+E_^D\&8P!O1%!@Q03%.#,_'48(#?G%^U9E#@'D(87=
M+_TT5_*?X\Q]2'S>KMF0&%FU#RZYA)#TYG3Y*1HK >HY1_91:U*R9$$8A9*I
MKSBXS,0W^LG05;(;C6Z6Y1=_XH^?7^&[ACK^K/V<.3X<^Q]  ?BF647W@>=K
MU275W?+>T#2XQRC<^3D[*:)0S6.KZ1;\B/^ ;XSMFNM^2M_- 3[ 6VAZ3B4P
M8GKW\PQ1N.C2HSE3 >8[0LMWR:U3%L-I'+H")*$GX4P7HK\&1+<U&NFRE;=H
MAK$ \]?1+WYO/_NROLO\'\ HSE1G_F%'IJ4)^KX2%L@M#EZXJ!$K8JSHL-UW
M'9:1[;'H^0] \9-]U2 CR&$QMA&\01);_1X_5EAD;\F@#-B+TD*,F.8[$4@D
MOMID:0@_-X[V%(D0%)'V8O'QX;0<Z"HN<0WU3%WS>$MN7\X%/GA_I]!:9<9"
M4=J5[W=)NRA+))+G,K2@UA0S9D0M<O3Y/V H0EBARS%:?&L%CLTS_2A_0:>_
M7,;QS&5O6!R)]69P_5D&70 WF=*U$<HHW70!^O;ET3DC"4Z=[X*FR#=^]MCV
MY2SJ;M3&H_K"-ESD1IO&[<-_0)<KQE /]J:1XN3[YPML:2HSV(6WPN.Q+0[V
M/0J#+OB#XD@,\:4-XM*+Y1AJ0AB;2P6/ +V?IN"7<BY0Z?L,FU25_X!@^XHR
MR12?I);OF5KH2!\8R>5'3-%Y8N[ZC;QR+J&09-#>?%%C_&$A%P;EG@LG],N0
MD'CQ+ :VMVLMDS@. A WDL#\;9=W]3M-&DN*GT8Z@GN55XC*%8G9GA0^<.EM
MG#FEZ5?]5:-0MXCT-S&D<WJNL]%%)Z_3XKT9X*&FEN;7M5S 22B8)KE;WX+A
MDF%^,^)6F:";$#C\8A:#2IEM7P)Y^O!EX(5^:O^T!/DR2S8II]4BD#TVK4Q!
MGSA"D#H36E"LLOKD3YAAB"B%U%4N<,L4F]5L;O6&C.MEC_NF5]W\[F9-X@4J
M!&?0I._\,0CD*[_SAV>UKEQUQU@^$TFL^4W XIO2)N-->Z7@WP&^U(*27/6'
MIWSC]B6%$=5MG=SM;8C9\(T/%76 W4L9RZ&G([J63HFX\\6C;&<!_]/@2QC3
ME\"71BW4Z;,GS3M7@2P)63'9<S88C0Q?@EI;SG>Q_X"?K9-P3 WR-,6 0HZX
M,G.;'MCK(XL2M125ID:),Q2@M'> XS):43$IEA9\HJ9E[?NW)?;^76NO=1E@
MWI;R83^\X^-F?.<'%_KK2L^,-$-MM]:R]?3@ZBU5)($>]F4?2H[%(O\BRCSH
MA=^P;XRLV<@7UG6Y'I6M$36@KFJRID1-[GNW\4Q0FLAPA>C?XIFKAN)6<_]T
MQ1!A>(VU[+$6<15G2DFT'PHP9BD)?.9;GJO-$)C<;3@1MJ\>F*R =7%D<.#'
MSPY(5V)HU([+>.2&/F8#:"2\NIEQ\3K@:U>^#M9[:$N8(")T<HPIJX+CXW@G
MIG_93!IJH:@.T/B@IWS92 WM=3NQ(W>FT%Q#>TY%75=4]OT(1N+9M(8<;/\'
M0(P&K,PV3+/M@,Z=?".+#Z!B_!Q,8A_#X:W^3RX@QE<<]IRZA7[Z+8T6RKW"
MK4VCY)\B\@=,_B%'U0G=93ZA#F9EY0CZ82"&ITDPEN"42V58+,T78L@UB"-Q
M@@ "NB\WE%1\K?("ZMR:4?MEFY4D-HO#S[LI_D"X;7)A4JW[LY@^T!(>'\DN
M)OW<=DQ")70@ON32A"4[[)U/L,]/(MX5[VFT^#!Y*#Z P(HZ@,S3V\?HS+@5
M]UZ,N*F2,RHID;CI\Y /1CK!65)>EO)4VDDKRH2U9TV:<TX\^0G!'CXS"UP=
MKW&(^9]!?$^FWPLBC!((+RL8JAFX6_-RZHUXWA+*!YX5M;DI%8T.E"M]6W\G
ML.S*LJET'OI/-^N(IHO=O7?IUE*<4VC+.SIS/:"?NM\L);O)9IK[.=4.GV/.
M6 _ N:-9TOT<#M?K:E,E,<8Q"BLH)!8]]A+)<MB6W'AJ-MQ71]*Z5(Z'N<!V
MDGQ<J\TH_C.5Z_I(%U.+W_@6GV!5= QKA]"5-,5U>N?DS5FPA:".(*+.3X#T
M!,QNF!E]M!#*.5'HI[,%"9$]86P!'?4*);5JQRTO\/,Q976'X5\$2%6>$H4Y
MQQ8]!/5], MAR:%.D8&O)&YO2&?^3-' _]3TUQ_(UA;V\U%Y4*&3=B6/468^
M(0=.2LI]W9X/Z3TB\Y]^+B#TM5!K^C]$G>57U._W]=]#=SETP] A()T#TMW=
MW2VM#E(RP,#0# A#EX!T*\W02"HEC8@@C1A\?G[7NM>Z_X'KP5G[[//:#\YU
M5!/>( !L<9"+7DN6Q1*Z)4'L4A)/X+B7F2NTA'3=2D73&6X;O2IP/CY 7#Z
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M$;Q8/+$TPN0SQ=>$+*"$_84WC8'*U3AF3,_0Q&N!3CU:FIL(_HIY@VB9G .
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MQ/Q)@,G_@*A*+>HE;IF;\HDLDIJIKFLPP)CBD?5\@&N\6OM#S*L?N@E[6?O
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MXNL)E&7]7"7X@:P/KC?W^PH1<F+W?+BR0^4HFBG$ZCWA0MX0 \.Z9DE_/K[
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M&(CAP9/B5VR/>BE%C[PCJNOF ?:H>3T\Q_90@$VD9 >3FV>F;@?-$W@N[VK
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M>@9L3X83I .LK7PAB6R*%_]8_G7L*UYL#XU6@U;6]G<"/W3D5P(?YV&E'C5
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MT$3+JZZ7PRTJY;=$;3@Q&J>#&^XFGG>B H$+J6+6[R0CR,AK:%%+&B[?<0<
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MX.WNZ#ES:1:VJ^:K--?:3U2@T[O;CKTIQU/;1,&F?PRA_*I>7;!Z_E$[6UW
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MTKFP(?,5#P3J1+JTS+X_QK8ND).H?\UA2Q*!]6XXL-YX]MM7^-T:6XJL'AJ
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MYNW[IQ02[R@D\>M &E/J :-;<< <9JG+%$!O##)Z\U')Y<;[CAO6FL\,G"D
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M[P9JH8D<AU7:?6@">>,%Q&I!]ZGECMK:V50NZ1AR0:K(NT9#@T"193@IR.]
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M\-+?Z?(D<BYW*.3P* .!D!53NYSUJ-BI(VJ>E-B>:1O*="QZ5.T7E=6VGTH
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M-Q_UR;^51:4RMIL)7IS_ #-2WO\ QX7'_7)OY&@#D,G'-* ,=*:#ZBG<XXH
MB=#G.:<5RHIQ7*]:0#IS0 D$GDR$5-.RLM5900=PH$@9.: ('QGBL[5;);ZU
M9<9;%:K*#T%1G &,4 >+ZQ8M9WCHPQS6>J]<]*] \8:7O8S(G;TKA,;25(H
M8JC' J9%&.>E- I7&%X- %R);5$W,1FK*:E# AV=:Q&)(QFD/ XH MW=^UR>
MIQ51E&W-.C4%L'O4SQA%H KY^3%,[T_K[4;.* $6,'IUJ54>,9Q3$!W@ 5=?
M_5@=Z *WF'-*6R*0QMUP:4+ZUE5K0I*\COR_+:^/J>SHKU?1#!N85-N8KM)S
M245Y-7&5)Z+1'Z%@.&\'A4G-<\N[V^2V_,**3<,XSS4AB<+NVG%90P]6>J1V
MXC-L!A?=J5$K=%K^"N,HIBN2<8Q4H"_WJU^HUNQP?ZT9=>W,_N8VBF&0 ^M*
MKJW2LYX:K#>)V4,\R_$.T*JOYZ?G8<OR.&7@BO0?#'BJP%B;&^8Q2'A6;[I_
M'M^->?455+%5*?6Z,\=D."QBNX\LNZT_X#.BU>6&+49BGW2>*RS()'W 9%4_
M,;&"20.F:GM945B'KUJ&(A66FY^?9ID^(RZ7OZQ>S6W_  &0W+ N O:H)6)4
M>E6;O8TF4(JL8I"?NG%;GDD2_,:#UXJW!:,Q)Q1]D*OEJ *NTGI2_=&.]6V*
M*,* 34'EY.3Q0!&I8L !DFN[\)>'I)IDN)$X'-8?AS26O]07*G:.<XKUW2[0
M6Z)'&O/3B@#2TFR*7 ;' %:TTP&5HMH#!%N;@FD95=Z (DY-2K&>F*M+:@ID
M<&C;MXQ0!#Y/RU"T!W<]*N$X6H7;<* (@J]!UH*$#I3@03P*=GCF@"!3MX]:
M-Q!XJ1+:1FS@@4YH=C=: *^IPF>UW#J!7 ZUIANX'0KDUZ,N&1E)KF[Z+$[C
M'>@#PK4[![&Z*.N,U5"[AQ7HGC#1?.03QID@<X%><MOB<J0010 C1.#FD#$'
M!JQ')OX-#6I)+#I0! <=JG24K%M%0E"AYIV>,4 *S;T]ZK@$R #N:L(R@$&F
MH0+A#[T ;D/AN\>Q^U%/W>.M8<J^7*5/:O4HKM&\);%QN"BO*[IBUR_UH ?&
M59\'I1,B ?+UID(VMS2RG#<4 1H-S >]6[@X557TJ!2 =V:5W+G- #&YI&SC
M%201^9)@GBI[J.-/ND$T 4<$=ZD8[E%,SGM3=W&* '&E,I8!:;VI5QF@!RH1
MU/%#JIH9^<=JDC 9: (#@'BF%3FIVC(;I1@ T 0C=3@"3S3G^]Q2AJ '12M&
MI [T\?O,@]345()"KB@ >(HWS=*"0HZ59D3S(PWI54@]* $+YX%;'AW2WO[Y
M<+D"LF*%IIE103FO4?">E?9+<2LN"1Z4 ;UC:K9VP0=<5:C3)R:9R35B-<4
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M8((P3ZDTZ*!!.RER<#- "O(!%Y40_&C=]GMUW#+&D529"<?+3E@,LA).0O-
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MQQ2^-]#M/#VJ+:Q3#)ST%=C\%[Z.TT:1)<(1DYKS;QW=W&H>-;ILET60[<T
M9YE!?8J9'K3U53N)48%,BCEC3YDP329*[@QQZT (9"[X#87TJ9X$2(.&P33(
M8XW<8/&>:O7MU:A5BBPQ6@!D5^8;8Q*N2?XJJ;V8LT@W_6HV?<X4+@GH!4DT
M<D2CS!MH B+%AA!BI BE<,V#47G1QC<34RLCINZT .MX(WG5&(P3]ZK]U%9V
M40"[9&-9J,,GG![4/'(/]8<YZ4 .-TS\+!QZU&ZCD]#2,Q5@.F*<NUR2QP*
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M56@@ <=:  #%2@C;BH%)[TX9S[4 2#*=#2-ZGDTT')IV0>: +NE6L=S<!7.
M:U->T:WM80T1!..U8$=P\3YC.#[58EU&XG3;(Y/UH H!2!S001S4^X=Q5V%+
M9U :@#-5=YQ5ZWB6$Y?I6C#86Q.Y:BN;%V8]EH H7<D;-\N*J$59ELS&QS4!
M^]B@",@DT\8'6GRQE ".]1A"PH '(SQ30PSTJ4*HX--(7M0!()24*@57(8MB
MGEO2MOP]H[:E=@.ORB@#6\&Z)Y\IFE7@=,UZ2(5BC5$  'I5/3].CT^W"1KC
MCFKJ[CUH 4  @8J4# IH7FE([9H 3 !S3F(%*$4#KFDD4 4 -WYX IZ@XIRQ
MJ$S3T *T '!%-"^].P!36/&10 X@ "DVCTH )4&E(H FO1G49CU'FM_.B;Y@
M HP#3[SS%OYB@!_>-U^M1S"X8*S!1]* )--N7L[P1M]US@5U4D:S1E3T-<7.
M&PCMP5.1BNGTF\2XM57)+J.: *+79TR[$;$F-SCGM3=:TN*_MOM5L )5&1CO
M5C6K".> N20P'&*AT6X:*)8)R-O1: /,M?TN+4K:573$\8P>.]>3W]J]G=&,
MK@ U]*>)M!>1#=6:#(&6'K7B_B_29%1IRF''+ "@#F1;+<0[>G%0;888V3/(
MXHBOT\DH<AAQ4(BCRS.6PW- %C27^S7@NE8X4T[4YFNKD3%R<>]0;X5C,<)/
M/7-,$9*G)-  9I"0J\U$8PC9).34@;8V!2F2+U.: (0TB]"=M2!F*Y"X_"D^
MT1CENU2->O*NPQ@)ZXH 0L6B]ZOV5CYUDT^.G>LQLA>.E;MI?FUT%HD"EBW>
M@#$0Q33LLA.15N&!6?U5>M,T\Q+>;;H ;S@8]ZTY(8H)Y4AY0,<'UKEQ=9TZ
M>F[/>X=RY8W%^^KQCJ_/LOZ[#:9+*L2;F/'\Z>3@9/2J6V:YD+!?D_AS7F8:
MA[:6NR/N,[S99=0O'6<ME^OR()+B25CN.U.RBB*\D0%1ROO1)"1(!(,<]JOQ
M:?#<IB+=N%>W"$8*T4?E^(Q%7$5'4K2NWW*L$274N.F:[/PW816$Q? )Q7(+
M9W%O*V%QBMW1]29&$<Q()XJC$]%AOTFE\GA<\<5>N]+MA9F5R68#-<S:Z?</
M(D\)R">YKJ3+/'IS*Z@MMH \O\32 J0B9^HKC"<RKO)4 \D5VWB"<LS!T QZ
M"N1<K*Q7'!]J 3L:#7-GY4?ERL6QAMPI]9(C57"*/SJ_ Y'[ML<=*\S&85)>
MTA\S[GAW/JDYK"8EWO\ "^OH_P!/N+<,SP/N0XXP?>JU[;"[@>>VXD7[P]ZE
MJ+SOLURA/$<G#?6HP%9J7LWLSHXKRZ,Z*Q<%[T='YK_@,RE654(D&#4A5L #
MO73:U8V$]E"]BY,I7+ ^M<L4GC?:RG(KUC\^'*C@_=&*:2PE'%!>1&&>E/9E
M8[CQQ0!7OBQ5=CD$\8!KVOX.>%DLK0:O< B3H,UY?X.\+3>(]80,#Y*MS7TO
M%#;Z5I45C",,% X% %V FXF,R,<#C%<]JL6-84.<9QP*V-+WIF(G"L<YS6/K
MB,-;3RR",#J: .FME"A(ATV@U,^5.,#%5+64O.G3[@Z5+,Y,P0T +(/+&X<D
MTU(1M,LW&.::TS2W_P!FP-H&:R/$FIS1[+6TQY@/S9]* )+W79-[1VJ@KC&3
M6/++<2 &60C)Z TT$D!&&/4BK"0PDX+$_6@"ND<7S9D;(%.M[IH',B.^%YQ4
M[10IR2:;')%D@+QWR* -G3=<BOCLD&UO<5<>V=6+H<CM7)W,J)@P_*R],<5U
M.C7?VJP4,<R <T *LLJY#J*M6T@?/&,5$WE!SN)W"ELY1)+(%' H I7UR%:3
M@96N;LW>37HI"O!:KVJ7Z)=SH>H/:L^RU%HKQ'D0! >#B@#L+IC"/.XXY&:X
M?XG>'_[=\-->( 9HTR *V]3U-;HQ@,0N.U26L\,]F]K*2488YH ^48DDCE>W
MD)!4X-7(;9-X&XUT'Q"\-OH^LM<P*PA=BQ-8"7:I"K#EL4 2,D2-@'-6]%T@
MSW9N9B!"OJ:S$>::7(49/2IXY;I(WC=]JD_PF@!=:OUN-1$:DB)/EPM5SN<@
M!<+CK0N8I@$4.3SSS4M[,^]%*!21V% #8E</N8\>E-W.[$ 8%1HRCYG9JFA@
MNYXVE@0&,=S0!%)$JG[Y)JPL:$ YQ5-;:X<DK@G/.35DHT46#]Z@!EU(8_E7
MFF6DI3)89-.B07-Y%"Q^^X7\Z]/N_A7%;:!]O5R9 N[&[CI0!YD6FD?>R_*:
M=(J !@QIIO)@S0;%VJ<9Q3X(FG<#M0 WYB,)R/>EB8 $KRU6);-HF/(QCUJ(
M,8$(4 G% $+"67[W%36X"9# D57#22 E^/I6J66'2XW(!R.M &?*R%_EX%.2
MQMI5:1Y67OQ4 >.8EAG%.\@RKA6.![T 7-'UJ31-2C:%V>+=SFNJ\4Q7&O6,
M-[:L<@;F -<8MJ4P6 P*OV7B:YL+A(< P9P<^E &7&CJS"Y)!7UJSB'RR0Q)
M-=!J>@MK=FVH6@' R0.*Y17,;F&08,?!H G66-1@=:2654 !0\]\5%Y>Z0,O
MW<\UT^K2Z9-IMM% /WWE@-QWH YQ0SC:.%-+);*@#+(Q([4Z2"2-5QC&.U,
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M9R#C&.U-GBB<$AB''7% #6$D;;A)[8ICB0MQSZTL4\;QE6/(XS0L@B;))(-
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MT4D >N*^?+JTETJ^EM;I2K*<<T .5%'!DXI_7@'=21B,@,3\OK4F5'* 8]:
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M(U#I(QID(^O\S4U]_P @^Y_ZY-_(T <9T/%*"W/)I@/-/R<]* !6R#FEZC-
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M;XE)/R3KQ82QKG0Y+%K6%MZS/3X@3?GFTV;;")9-$AQX,!^,?"'VDM3B51+
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MBR4?4))2]6%<'2@7 3FIDIGC*$9+'E3%+W=,04W9+/.# "ZX#:W-<\BS:NT
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M1K1@Y=/L_UJ '8]G2=#/@P8X8L_1&\_5<6D+S;[?R. _92;"<90+J;+P%=:
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ML*E^+;'YO!&K"YYD=&S3O^*Z11%=5:YO\/8L=$KTI0DP6,D-U1@1)U+9A4G
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M:Q>Z_P NS+-%16[O.Y& ![U*2 V,C->35PU2EJU\S]#P.=8+'+EC*S?1Z/\
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MM5-[N21@JJ5]Z "&ST^RDRJJKTZ;450XC7?]*HS6SO,,Y8FKJ6(6, -AC0!
M;J:=@NTA3VJ^L2K&/ER:=%;JBC(R:FH :B*HX&,TRXN$MXRS'I3;JZCM8B[L
M![5Q^K:NUV&"-MQP!ZT +J^M"[E\I(R!TS4%K:A$WL.M1Z=I[2@RROSVS5Z2
M"52$4DT (@CBY*Y-)YR^9O,9H>)T X)-+M=B-RD"@!S S'+KA?>D-PB+M'(%
M(UTOW2W IBSK+/MAM#(,=10!*+@,-S+Q4,MS&PQ_%V%68["YNY I@:%?>MBV
MT&WB8/( ["@##MM%NKZ0-(Q2/N#W%=%'';Z7&D-M%DDX(':B\O1 &AA7+XP
M.U)I5O,L/F7)+2'UH @\0NRV2[3C<<&L&V@8J &PHYQ6EK4IDNS"S84<@550
M)''@.,T =?6)XA/%NOJ&'\JVZQ=?"$VV]]I^; ]>E %3PY<.LDL#YQG"U<U^
MU$EL)@P1U( :L6QD:/4U;.%!Y'K763PI=VVQAD-S0!EQ7DUIY8E?S(RHYK1D
MM[;48!YBAEIEM9*D/ERC?@\9JS'$(V^7A?[M &-/H44;!H5P!VK+9;FUD<-
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MVPGDR;"-QWR* /GT2 J 9!FIH6<MB)3FO<G\*:*QP;")6^E1'P;IO9%B]P*
M/%@LV_YD(-7+>VO/-$WD,!].M>SQ>$K"%0?(28?WB*M1:39HP MD8?W<=* /
M&_['U#4F<QV[OGL!6K8?#76+Q/WA:!#W9:]>A@@@)$5HD1'IWJR;B4)MZY[4
M >=:;\*;:U</>WD;CN*["PT'1=,3-K:AF ^\*T) G67@_P!WUH4JRY"B/_9%
M "F960838:C\J-F&YP2>U.88&YQ@4YE+;3Y0 [-0 U8XUX6 R#U':G\GD#:.
MF*$5UR0Y3V'>@,&^8M^%  (\'[V#1\SN %)(ZFE$B*N6.[/?TJK<3LV$A<\]
M6':@"QY@3*^6?<4PR"0\?+CM31"Z1#S9"&/0^M.1?F_>#:/[WK0 ]5@P7E(.
M>@IX,:A#'R3U%!"!%1XQ@'AO6D5R'.V( ]J )4(+G*[1Z&F^8^24<$9QBD>2
M9V ,.T]N>M/W''EO"(CUW"@!5C*+D*2QZTTIN)^0H:0I*WSB0@=*54=03*YP
M.]  8\!59^#VII2#[Q/E,.A)ZU7FF5027SGH:MVND7%\R27 ,<8'!]10!$ T
M\GE1CSA_>7M6K9Z,8QYD[90?P^E/EO;#2T"0*AD'&*S+C4IKVX8)(8\#.P4
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M$!))))R3U-%%%:D!1110 59L[^YL)-\$A'JIY!^HJM10U<#NM,U:#4H\#"3
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M"S=ZG<ZE*1@A :2*SW$%ADBG.XDPD" >I%78OW:!>IQS0 \NT40"KBH/MK1
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MCM[+[X!9!JLFHKC*X'GASY'E%P>)IQ+XG-V!/IMY>IR?WM$14?"R1[J3E;>
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M"63@!@[_DQ\TT6(:)&20L6T)YHO!I4;)G!ELV/KI]&44W&5RE6K!>!M[D%+
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M BR@*[N",UP^X50EX%^Y":]K$]>;<[9DKK23"!%B_86LX$8\ '_#KW(E7?(
M;/YO.),=Q*WRP2'FK@9>+O_\?,<,E^(W_3#?!<BRPM^=W\!]R0VOD\6<P(](
M:CV*@K>WPP8QCU8XP'V+U%'[">[X?[.'5S+[8/@E_VX]";\E9(6J>OBF]Q&$
M1!09))6QZ_VN5SSPE'94DR I6ODD>*/D>E4)'RO<A]C'G/_?42'#*?Q?E)C_
M'R(&]QP\8-5@Z%_/V61A9_Z?IX/_\^_?[]*/ "*64&J#:5YV:9H2/_Z7*(RZ
M24[S_>:X,]&83:-S=W&6*I'L9K7V:] -:%-?W<M"R<;=LSS'9C!PU3;8P!+\
M*5-R_U#/U>$T86!5K,-[O,7+MFR;.SO;$$6+!)">03HIM9K3QR=LC)RLL:FN
M1WZ"<EJ[HHK[Q#?SJ$Q8CDJ/3(ZDJJ*7J<6K=?Y&E_Z^(&'ZTO'1E[&VD-/S
M!R!V_HZ5=L&7<"Q ^>6OXY+GYO5:BW5"AFO4D=J;=PRM9W\>@#C(S>37<B,#
M8Y.2VB%2_Q\D^W3IF2:_*G>5M3CT&?=MHC_#GB[?N#T /:WW=HO)N_WC<[M6
M7M -Q^%:U]33N5VF*0>0S%MB_S[3F6?FGMUB;$+M;'I$I-[<_(Z:.U'X)_[?
M2$2=%M-A5)-?I>2PG[L*OR+I;T(AJI2C?2&\C/W+?&P@K*1,]@87_*WXF:]8
MRWY[JAP#M@2).O?=]S_-;([.%"R7:B\CDAOH#PX<DN+@W1[Z><'=62;L!K0B
M<T=WD7DZ]A>W]FJR5BIW=%/_&X..8O0A_TB*J!0.8SC8Q&SA8&/ZF\>JHF";
M%OJTQTWT)U1132Z(RN_.TN#D)'.!\]\[_4155+T11Y6[ZL>1VHL/)?,E=:"_
M")B%0QN\\JP"CK^_>4*XLE), X?JO[VU!PD1XD7%;%!%_YO%PYO#N[9]\:AB
M-86/:<CV7QJF+E%6N\+UX^^F4_\VA4,V W[,8X<!.OJD!QFVC[G=AORJW<K"
M5KF2*FG=K!F^/VM=D1?EM@#_*?VG(=J3\%P4%;$2EOM[2"8<\?";,L+56CN/
M$"'I/OCO\!^!1:%.4!S^=S]D[8O1>9E*T;6E7,L%[GCQQ&I5%(SJ%";'8?H&
M>"_!^OS_(HQ'^BC?PU(Y'(37%CFWB..WI_]1&?R.[P/'8;XJ_SCP_^"\?]F&
M4DAR^N]HM?_,^N>DTO]_PR#P^*1?P^/[7UH5.19TV%]B95Y^+'YM\28Y H@R
M0Y_%7OXJ-&JA7L*#(PP_&H(W)Y*\S,4T$G.47Q?&00[37\"#%_VE$<Q(4'_)
M5?)2N^N9OGZ' OS.$J^UZ874[NR(LS$Y/0JEVH-?$<SYU-D1S,#_AR^D47%*
MD["JQA_FI](PNQCS]GN)NUVF5=1TQYKW+5KWBWUND'ECO.V8J0H^'+7J "NL
MYDQVRLK@13R3XSNVB9I!3DK(:QNMQ&1$67I*)/.0,S$PV<;G@QUW#ZOCRQ4G
M:)2:N@IR[7@S 8V<ZKZE4]:$YY@IT<);D:XX_9>-5EDKM(;7&@2_+N<"6MC"
MLO-=-+3-(].-1G<NC0E&/,-A2^]7YOUJFG/,;S;+C:^ZA$_U1YN?YZ?96T5E
MT+ROC3KIS @T'Q+>9&Q.C>B?,9$3R5&QGR5^7FXUX9S?5$_=S^;DX$'5,>/Q
M_4S-8,^"4,T 1CABH#])V!.V%QL[5BLH_NGJ 6!]?%XUF8Z7C-_O?<'M)<H@
MX56]X?3?%\,J(YBGF4^7HQ0ZGWECNE/=AY\9@PVMC\MECJU^\$4]5>&H75 4
MK0_:WX$@W+/U%&-BU&X,VC4Q$!*J27F0_.]A:_^O7WH5$YS5\TD98U;14D)K
MWVZB[^UJ"/E=Q"*@ZL)Y'V+\HC[8XIZC17Y<1SOJ*:-;G?YTZ!&'^JF@;T3.
M%?25KZ=34#&6D&J6^@3W[>5F_E'=W2??9_?^"G=YY7Q7X_!^)ZK@/@3^55K.
MV$/](M[8VF/Y8/6N5=NGOTF$V(L=6L3$&!_!EK7YOV<R_'_R.@@DV-G-OQH3
MI'>0"B"7W&\Z?+[#?36-HRXI6CN-/XR5F,R$&RU<C!1KR^]I5F#E%]/-053>
M+(1:\)2 X7VF.-I=E3_2]9/6TK=: 6+?[)(#N8_2O7$CCA=?OVGX=%L:*?P
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M9!E5V/):=3_Z2)HM,_QHV/?Z)_!78_K@/)2KTF"SKT=_X@M'&<^*O7>,=*_
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MS5"&)_44Y:)>Z,*72#F>W;+:JUPM@=XGU=Y ^<%DJ,TA>J'4,[0AK,=_U.,
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M*/\M UA30?@LXT&D;,\O^H[P0VB(OV#-0= @<D'&B3.G[]D]X+YTP>)B+$^
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M%6/,O)=ZFASWA\;KQ34PL9UUH:_IK[6DCQ!$XY9= \&?@F(LN]^RCY;=N6L
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M]Z<^-\8TX K846OY8MVMY>#>X_XX!,Y,%/8$X::3F\M@&U4Z_!P&M':IB(6
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M7- =G0[*9]0W'/S%-X)&=4ZV5@T'_>4-+G,6M9> SNE\_Y)>AI/YKT\PYMC
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M@N.LGE/LV.=8Z>9+KQ;C+XVVNAK(9?=-"SS(58Y_X5)4+HB3KW5^ T7/:3G
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M]%/R&CBT\03MCG7[&UX#B?8EU\ T\R5#RN0$/=KP2K6V[!IX$73H#H/T2_/
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M[Q/C\N&'UG<#T7,<_OT[E*N.8F?&]VR6R29L!OXJ<*]"HY=T'HU-,!RO</-
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M%E54Q?C:>V9G7BTPR3B/J@& $9[M5401/I\ME9"CS+?-Q0>TFDJHP&TP//C
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MJ2F/+$@FQOIDXCA"5;&J9[*5&9$,S(^6NFB"Y&#U?FG1RB:DGJU"0+ED13E
MY'L\6)50Q3"K-1!5@H64CSR^P(D"?63VQ'@ @1X.$!ML]]=BO&)MO&Y?%+K
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M9@R*+EBA*Y%:"3&HH?'P-;#5NRKK-4Z/DE@L0QMH0Z&JF1>+&D-.-.Z\WX]
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MB/:IWVUA6+1O\+9Z(_G(1+ETWZ=%[.+'SZ[)T9Q$*3')8['#?>C(@B>61)\
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MYK=U;.(%R_,AI!0(+K8K>]X112C\Y!23)]24F7J:#%PP05A?<$+WXT9!0B(
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M?T"AJ%GZ^^I*P")IT)Y0P#O;%AK?6- :]'J:Y@(I U!#R3(LTK\Y,M;)X<Y
M=2YJZO>*,N[:)IN9X>?%K(AS?0G#<ARQ_CPD2E;V =GU,QH3W(+-M1FXT*Q'
MY^!2X0512]TH/<FLXCQU7_\KD&=1U\:)>*,DAP2K!8=L\U<: &>)B1]);@+H
MB__QR_PHN$Y<TBZK+6X.%%QP<EJC[^1"S@G]E#OZ&4JZ^1 0,*U?A^M@AJT"
M8O98/<ZK:Z6K(N\D*5D0R4M'XY/\)MY5!0[2E-RVEX'"%%%1G/=:&!IU]9?/
MU9"%!6(]_#SCZ5Z)*?MD& 3JO%!!/?CF9'FM -!8^11G*Z6@T8%)8G=3^C;#
M(G(#//GFW  ZE4<VJ4'EIEGL[YK>?P6C'^:M))5JU>NI[CH>/V3=(,N-MY"5
MMJ8+[NGFO%>@%@>!G>U)5/S5B(B$MUJ(MK[C.^MSA"+-'#_Y&OW'*@L[?I"S
M"UNV WK>>OFV[@#EF)FI;Q3=YG2_R>;.C5:,$EX(^D*T;,>"&>I901W<V1OA
M?H%:^D\(55#YE^E+8Q&YZ)%:N,*W/WGE;^<2F9H.+6FQZ,O%*,0--8K;Q8@W
M7:&Z$8&R05QYZAEL+(FG^!U2XN#UX)!(3YUG .=!#'/7KV)L=C!EIIG^Z98B
M.'U6TRJ9-FZ(OHSN7#\!>' ,\RW[=N@BO5 8^D71*41#Q%')43!"I^%,DN3I
M11++0Z2RT=J7K9]8^S]T9_,_#YX:AC,?"#XZHFYM'B=])KHFKLN[OH9)E)9H
ML8YH?7;O5XM*4+AD91M]!C9<ET,FJ5SNGR1ZJ@P##:>LNIJ^M4?<@:O0#G#V
MM4[AGWXP6M:<'%'"K[,L2V5W?AI(NN:FP#X$\4XWK1INZ,3Z5MT%C%ARW\,$
M;BZ.<222JZ*5SH+#RX^(H&GBYL] ACMEXJT [XW.ZKN<=RK#>\V:^<;&!1.Y
M7B>HA^)4-H[EEHQ-^VXXHWF);C?S*$$*PY3O:E 4NI%=9?TZ8\5)>CT9VB>E
M>M_JU._%/^T_X1_-[!O/NI49:$V>NPE90G8+JY.W/35WHY3\<DGS[7:DM).C
MT),7(=;^:/]VW(*0 U[?Z%'!56IK"4:1*S,.2RAJ1^KU1ZB-,QY)Y"4E0!"(
M_E+U&4@QC_FX[:_S@*I<T+EZ76!F(EIW=:(,466/Y.@'WA,XK^0G^K=BQ)"Z
M_@ N].L.<)W/&_(J]1O=,)G-MJ' =&L*O_:BWXG6TJ] F"VDG*.7#;'GLS.5
MO0]"/V#"C2:*#<>S-UMQH4_T;\9 4:ON/M)Y7];YFG2K$O!K3)PQ^X@01S77
MH_OU9FGNF'8-5<IJ(><_U\D&9,ZU/D7C==*\X,[>7#9Q"'!%R=M_ZE#SPME8
M0WUE?B>+SZG=U#/$X$SF7]2I*__UILA14<"HUK?U;WM>;;@JS898'28,29^"
M*C\2+- 6.W =2(_6I2;/DOT,.]962W4#D7'G-)O [J:E(HP(@^F/U!FGJ;/0
MZ(IX7G:9<4. 3.E7JZTD9<Y9ICL:Q$L%BDDC-=G0-$%[ 4M2&/H&>G:42-#^
M'MJ?[L%VI1WB8:KB0EWH@$(FEZ@:\J>&W:?%+[$-PKKT(1OE$> ZV3@/XWI=
M]MK(0Q6?M]QI>VYC@)_Q*!MA*3-MM+IZW\'DCI#SU>K:33!YEKTVZ.*%8!63
MLK@3IYP^:H ;B*A>"/.M])AEF#_9GA=NQTH&P"E8Y:+*:H.JVI[+%BSK&&NC
M(]8$P]:PQ4F.;Q+5MB3UQNZ4-L S$&*GSB8K9SX>X*Y70U8DP59+'5,8D/F
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M?3G(^ WP5RJRKQH'BD\:SJE2W5;*77\D'8RTCN*,XM@UF"1MNJO+^ Z,_JT
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M$0E>%"5(/<4GAP<DLE'A%08QUB$_'8MABG>HV\H?/432L]8]8.@5U;5185G
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M"6^J[E&82?FW5W@1@OLF.MXF/>.V.NKW!2)R=AOMQ-Y6ST4HADE/1U4N]P"
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M1SH=956Q6H?Q]@E%>1V,EBAJ.YW-4V[<\D;5DLJ6,_H1R6B&S]H3 \SS<P#
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MT6/Q=/Y6P8G8-M6N$7O!-V]4\1Q!JTZO,TF-TNXAV^^5YAX38M^__JSZS,O
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M\TR=!%J)9P_4;'2\5(WQ<7&T-[K6[4OU\QDFP2'%J2]>9-UJ%RE2.GJ*@]A
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MG;;>!4G!O5\S.J4TQIKH7X<X93>2+T4_DV>A*&1!>[GPMJ(6C0@AXZ=U&L%
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M(/N6>K@[B\$IOE$TDZX)WL<#G.-Q,P3V-KA>+GQDV?X>>#D-*(R1#5)_V'/
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MP?HSM,E)_/3)Y51:AZVSBS,>C]S==H+1I^)<RI\55U]_H.2R@K2BM8#3.[=
M@ L /$"YW$5?^;%S1@W &L1:$YTJ26*1D#][EVF: =3CN<#G)-[;#;K1;[2@
MUIZK >CUYCT0ZD&B*>(/^75JVNZ%7>J=,703)],A]G@DW<1]YSP0;9+/DBX3
MT:AS8;^4VLS^;?CL,X<%=7B(/?1Z=?$N:6A$B[H]>X[97/\#5[QQ8UKVG5)
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MU)'T/+=T@LLDU,6&NG)X@<>H13DNH8'S?TZZUS=\ "SL."I*NL\<* T:1F/
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M1F:.&W+940R(3SP4> 9I22$<:DM_,+.K :?Z"!CY^O$=420I'$QU":;@:J?
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MJ5AB0!TGU4Z)<$ J=EI!S<;*)7D7<IP8*__EA6?1.QB/H-0H'S=SR!@#O(<
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M;<35K_6;.+OD[8D)6\N?O^(J::TSH#">B.@3^C KPEFDRW0<OT''>0"[8#]
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M:G*3HHDB)3;NB&C)4Y> )T!6 EYW\([/T]_:8EA]YXA[!Z@01"ZV/670^_X
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M6X:JY\S0T6;'LRM]<SOL99>4JYPYG=9:\N -Q=X;UF2O0I.E)XXV/M@HY!#
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MY#3BL*OUL;?.P9XL;WP<)YWBE(>*@Q++]X'=>4'?4]Q,2L/?V\O6]3;XD5
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MHX65QDF^::)@V?KM(]2N!_!(J"+SLU/NDO'L0F^=MWXNQ@Y^ !/( 2G8(7]
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MS78DLZ$Y1V^<%Y6Y@3M^,R&7$&T3;D/H^7M+'%>WQ=;0L-7R&*N"KNKV]6
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M_A]U8,I(OO'<7$0&+\F-CLA%@)94/:+F]>"3']34[A7T,^Y4493[N1XLHI2
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MR?4J'GNSA5!>?FR@E(\.>I:_=BC2IUJ(Q.OO+Z"9W[EK?O.MKI_;$4C[)AJ
M=?>E_R?O+V >EDC+*T4E \A"S.P013Y!TJ9RZCI/7C Q3*G6H?J$D'AO%%Y1
M[7=F8$]QH0N5PG;U1S7TS ]A%EQ<SY!XKGWU):[9\HH62 :==U_)9SXB37Z6
MJ&9FQSD-3QOZ<!ZR+#N:*K4\#0F5PM$)@7EPO"H:)F0?;XP_RYVP_>S\+K)Y
MZ<($YU9RXGQN@B),B>4P]!D%]L[/Y+NP#V7NYR?3;@M/8_D.\/A"6>*='=KH
M&M$[J/N%:#*]SYW$;&KFNK?K)XJO<U;WA$Q#W1=Y%>ANA(,D]$_;!% '40B2
MEY/;@>WM8$R-*TJ"FYF#]IXW#Y9,J: ]_;5QC3^=$1O)U*4!@[O]),]A"AS[
M4[L8207@^%>V6(>/38Y*F"+([\EHJ8\Q=4!&!6+]V-O<O=KON?YD3IKM6<4Q
MB%U>5G;RIPMIO[##-AXJV1VZ.*.OX/XQ/J=N;%+H9QKUV$A R64Y:ZL#?(?6
MOF'H4+)1\7!O/0%V$4J\#VD\Z1/C%I*(*/L85,)V)E3\VNWQT9XO?PEJF4(^
MKEML0:Q?E9&^*?#RFP3YCKN]_DX/<2R.!E]="YXV?^>KPS=Y7A-<>)R^L[+N
M$66LD)>JJ8C#O+<%JD;S6V8\V'6U\]YDY'D)<RNBS// -'F"]PI*.T$J64Q9
MSDCN_M^OS)++L)DVFJY9W/O/*:*P3P-"FU5Q1WW%)KJ)_Z@(8;6I"O?MHE!-
MR\83%#]J*(_#3'S2Y97"$W.K*6.FW61CQ76C;L8P"4J\B,&$JJ YX,L8RRB[
M*?\E+L$=(>(R6E$WN^'D1 BR8<R@::1PX3[*"XK^)Q0"@*&"[D,3Q(M\S#-,
M37H3,_UN;16'OT[(TV2Y0LJXX57N>DYU0^3VN@L3B-5XBT'W(-@TP]DX(M_K
MM5*DUU:6]DY"?L65;S?QC65UZQ#Y2VZ% P,=DBH#N7Z'*9#QJF0E'.VQ47>;
M ;'VND?X+$21Y;I<2+KC9CJD*3[@: 2PVJ.FJ,M\(!U(4R[C>N&3U!?KNJFX
MF>\\XE&YS%I@LW:C+1'N=F_J%;?<R5!KE!I&9GD>>M>S1^RJ=M,=DF0C7NY;
M*Q79R_R>(1J=180HQERZ!<--9RCUB-B2VC/6#0G]]5OU#<RZAJ17IISXM#.0
ME(@O.5@"K+W1SL8"4V^U)Z[M.W_#&,YCXQKGDOU'@ZQYB=08,(Q,>N+X"*'!
M_'^'BBG.BT$'GA 1!/_CL$UE&/X"^R.)[Y0ZTQ\PSG(KCX[M4UU\4)]\CJBC
MW,4<J/83<80JRFYY"A@S\TOE.9G0^FH>J#H4MLUII;L1)S,79)?I,5,4EKOV
M+-SZV#'B/1#L!9R%I\>;9MFQA-2\BME=<'D_H0Q//KLJM*;,_VZ:>K-%]>B:
M'<,B&W0S/(C_@Z,Q;?C< LL[H@7KIH/OC!;_2)V ,_*>8\];Q.5OX&/^"Y#2
M7_Q/=[R:_W+'@XM.R+S6ZNC5286#T8>U1N; 8K8"&C7YUFBD&8-3YI"<]6=I
M-)!L'K]27,L2>]<61-;X!)7L _BB4_?3!;A8T'<)RW?42>^S3;SO+-A5UGQG
MDNIZ=#Q@#"_(%,_+C1]\J++])B<KB(*+6FU\>/OE@__/4KA]HVL&]K'M#PZ4
M\>\^!PL_V.%Q#.TER)7LK"*6PYZALBUYYE4$O5G9.1+[O"C?*U9W//P'QD=1
M9HE@#XV[:]& I!09QG?:EK(J[,<>8H_Z48=%V.AME?5-_<?TI(,WYS1Y#HM^
MQA,9;W*_SL8+_.1AWCBG:_5!["0_BMQU[^;LD3LPO.B]JEB?G!'9NNEIO]62
M$NAMPQ4,G;B3VE/7?+.KM<&K^5,QWI&GQ]N_O]#8[Y5+8]4$1/6R($4"";Z>
MY2OTDSUF1Y9^L"<N?!,ZST_S8S_Y)RPQNS:&/-$C(NJX;J>U7?)DF&&"-V%@
M0KZ?]8N+ZL:+;,32UC_R$WE:[$Z8O$"BFA?OOUYTQD5'[Y1P12\3Y)*-2>A:
M]^4GGT[7W2]#&B:;LNS3@*\>N_F+TXB1B&! OT,?%'@Y^$MC68@;RN79]ZZS
MN $\AS>(775B/FPD((+M#E@L7 4,+26,T_^4,;@;J>D3_Y)ZH]7,!$Z9]F-^
MQZ-D"]']!=PG+84I[9>A[0^GN\KBTXOJ(*=9#KA7;I[JT5.$KXVAV2SDDK\5
MV;#S)6\S?E4\OVI->*A ^E1-1@YVC"=OH9GY/DP1.!>&"1<^20588B)[.7QM
M)Z#R'>6$)L=YNWJ$(^Y]UFB7O8XTW9:Y2[J+BM(C)UO*?H.B)X8O)H:VEF,4
M^/)0N"_M5373]"Q>7U<-EJ;]MWUDRV-TW2 QYMF+LHOE=ML4ZO3B3"+@(DU.
MR,K,?X0SP2?M?Z,?8H;)DV_O">J4\#.!%P(  U;]VDMN)X\UG0E@4P?N]8Q$
M5K[CFC(P0Z?I:PK:=I\0IC.4F#')-&33 <$-&SH?[BRRG5 B$\%\,6N"&K%G
M*\OZPM_S6<1'YP/=I\/V:$!8S>!! KH8($VZ_Q(PW!QOF/K]?K? :(?.6-_P
M_V(C<N)_-IB!?@$IX5>_@$#L<Q^ 9><]0ZK+[>S8].FQ D-D$@K^3+$%<'H6
M/U0C#Q(L&758QX#2%1?*N#QWA1*S99I.E^5J7!KJ?.KP&R:=NX2^4;S>+/(X
M)=JP&?%]\_;<<MK-:\Y)#9T7% L3K1>^& @;9EFOT7U#+LI#G+?N78=^;_0A
M9JSBKI_LJE4C_J,#2Z$1.R-)ZK;U)OL8TF'B%7]G* WUE54?>4K((;^TWS[W
M?,+\*.82=5];0??=TTE1.=LGU:G>R-?R-&&JA8=B_1#4'=_1[0K-["%;+MC:
M@<OPC$?)D7OD7@51H4MYE%;@!5T3;-U<Q^C]<DB_YL?#-O5S"+=N3A9_C.Z$
MM -VXX!$B-=AR+&&1I4Z7M']]G G!DR+X#T?FM,13Q^3'E4\6U_-%?\$J5L2
M*:L[L<LW^J=6H25X875*%,^+5U9R&[* H]Y]GD\IE':^72/4$H#SC;;&[=.C
M4RXZV!EU)/-: ,PHLVVK;.&POBGTU3Y%Z)V6F&*9MK KCUSH1S%O]6Z9HYSN
MJGJ][WDTR]ZR$C*0"JLU$YRY2J_:5*,P[XAW9V8R;EK&&VK5-?>6EA<[,$WX
MH>V?Q_:UDE-,*Z<>5S _B6%:CY)[Q$R[6\R)N:Y:KJI^%;M>@A/2"BN@Z;8+
M:=<(O)DE*_73;V_\[*.<K5]Q>YZR\Z;#C:9,DW/::NQ+/G\(7VG%KD_;P<_\
M=+M9@0:"3NQS;PKPU_.+"OYC_%YWT,$9J8N/?['EQE[)G422=_W'8A/;FNO9
M2U=#A;F!GHU=D0#(RY8BTQPJJZ*MV<][JHH^'#UIAR?;=UN'#CL)-AE;F8L,
M4[SJ1HO4YO9[7;^30/(O5K\'G. VP-,$]ZRBWD35J9LI$G&FB^1XA@ \W4I'
MPP(H6VK&5V2 ]P/T7XW;URNP\QI)2)CR8NW4,!A#UFCJY"XBWY/SBXGMYP9W
MS! T\HC(8YKWNJDZXU:'#  >$&/4L47#,D4 +TA/E".W;][ ^4.93O-1:*;@
M$T)S:E0F54_Z476-5D^;FYW]T$;1GX).$GSX2L>9S$WCI(X:<XIAXER=Z* .
MGW*VF+7*)$>*SGD7%G%,\S9K/NUNNE%%G@BTRS7PCFZ@@/:,-RHXX,0+TNNE
MTWN_^YLG&4ZKQ:Q#:34MLR0&_&'<%6"A$3Z _)VZ'4FT[LA[6N XX<FG<9+@
M 4S)-)\MC6V^/J^=WID;O+0?Z:R2&[R@C56R\]5:D - L5A505S63@BKAC5G
MO$OPL&+&M^U!HK/VF#^%B$6/5[<AUIC,*:PPVW2RX6)#_2C.Z59!5O-0P3SP
M=J]S6DK8+Z#.DOOP<1NT7$=R2D/E$_[3)0=<G_Q(7TN?8!C3T]_5>N9'5T-R
M!^EXJK;HQ3L#2L6WY)?VF@NZ<^\MN"K/1KR_Y!7;)+2(] CN<D$I5?#ST.7W
M]6<;+ESEZDF??S#4UJC?@.+^.ZQ'&=NC'EOR1*<&;%7]D0KI*\?UB+KTJ3F/
M9 =<P(<FE!>G)R_P&6E'^8H(W<7:TZ'@A?JS5;S>O+F\%D&K5X-E_)-FB,](
MP0[1,<Q0+X1RVKO.%EIR)>N+#CS!@GW^.X\6)\FADBQ;1F^T5U! [=XGMW3$
MTQ>:1VAQ(8L)MFU5])E-?*:J!U%JF W6?EYOE <Z?[":W  EYU+/15HE\AO*
M2N5^ 920 +C@=RJX>$=_P_L_KC]XEHN<+EY\BU?GX$B<^O$?HS^3&\,0/'#2
M>"A>4Y.)$ 1_I4P"H[H3]>8]?"F_.J!/ (/515C#_FGRI%ZH\7POX&LJ1%98
M@!!)M0CIL#25Q$AXRCA.TZ0&HWMPDI;#&@45*P3'3+-2J+0G+.U8"\F*]6J4
MIZ",0GK[0RP_5<;UNEO]V#3ER?"XQ&A=[%KAJ#TFHM8X:)@RIVFK?_HN%F6B
M?ELRT/LJ@X;7XS;V8\=&DM:@1.0IEZC]T3%?BK^< A;D>%L^]H% >TU V'D%
M37-=UM"V$JS0F"Q'T,(Y"-=?0D]X-;3VPT.9&K4Z'2?.ZHJA_3/'KQ.9..9!
M6UF%NJW-?"9B8C1K?NLR/NP51REJ@?-G)87E9@>4!>8_><;NDOI7KF"&DW-E
M,TD>J7M==,._ '\\"?VS5_H9=\1>TYS3-K?JW(5YELR]N@_EU*PUK4P+\U+/
M (N9?#1U_?H LEF..;;Z=U[7=_0$6G^.D2!37]NQSM.3M=NS5KZ(K]%P_0(>
M]^_K*=8)^KU8R"(O4PUE78/E'OTN:^<?'AXD, 6,6K_90OF%T/^,GV['$]N?
M/G,,2\.(T9:R<]@Q]AO^D(XY[X,_U%QJ:JI#9>BI:'VV:VEDVYX@M(I[Q:-T
M-/4*&?NEA1[7E?;Z4_"/G*\WLS+RGW__P! U;@5!0"?K*@?E7Q;Z0YGHR73'
MVA?O:/$/*Q(%,XTYY$EYRUD9!7*XN&YR&B@)(IL5\MI31X9E'O 6](/_Z!GU
M^?H*_;'X1Q1L5?RXJ^?]"5*UA?2N8*7&L:*\CJ6AN2US)_.+WM+F+^ \K$ZG
M0CN4G+?.IZ:C=\/*:-Z&9M\I&\&2B_IKIU(E"V(5B^XPF)^% JW&]1AF_2W?
MV*-^*'E@Q^G4Z^;(2,]/[C&?2>S.(+ZRX^]Y#8S$\3B%RF=EQF@GUFGZ'^\X
M4S&!X^J.\@N<'@H2;)3O[;*UTC^0)?YV^ MPFU518>:H1:.P%B(")9&$U.[*
M#856USEB7G>D&R'=.\N+A73[VSK "Q\H(^FVK,%#$M45M08?69X/\73K9%O?
MM J,91/W-.[Z3N\/"U:86F^JN7#BYSGKAX3,AAT2G_"O/LIRAE(=0+[,>=5/
M[-(-8(LX'QBAR2>P;YIV+\"I9""XO5/: _HZV)A%2,P1YNX' SO8.0QIUR:H
M_FBSF7,R-K:EYL?,RC[X/1\B/2[X9\DM$<E)B1_MSBK27R<5O-]R33930&+\
M*X;G992%5=X3(I#MGI*.Y@E!8N#IZ^+Q?\1A?QL0MEI96/@&E1Z\L*3HR#CN
M)J:$W%NF@1/;>0(N)M M3IVB&;,R0[0+F!N7D 2S?:L]RI.TI"K1Z::F#):N
MB@)P\B2?4N$Z-.*\)8A' ,=LBB-TF2>Y#U6>U</"![!]W$OTKU]/;ZMWA8IJ
M47AXK"OT HJBC9U6HI,;WA:FF$L':GU-K_&045-5)0+/H=2)P%=M%>A7C:[G
MLN!GXF>#G?(!&@DVQ\G6*8)$H/FK4XECCO^/*DJB80TXG_5:PC_#^05,JO[>
MOV9=6\1" %KT4),\.2:RCC7-W@9:X*5BCF,;8+:G'<UK;':NG];;NF^<@7 [
M"?@ZYEZL;WAE%95EC?8M\B3.9S;#ZX?"(Z;6:/%7W?XLDY^^3'*'D&U7^ZGG
M*+I]5>MSVN_L!;QP(6);+?K+"H0X$,&_LW_+8U5]:?.OW$!JJ1R,B*^?1J&!
M-K65B4![%P&L=<UQ2O3H5GLL+PWFMM097D;I1):6IR[TF-6:SEB%@]K"J<]
M\_LDD\G#0O=%9K&*%&N6>1'S@V4/#EP//(Q5[COJ=R/1LNA<TKLR/]4.K=3,
MV"/'GU9[@>4W0#^9P!@(_+^9WUD@V[*I=<Z[4&46JC27B)/0!1=;[-+7M_$A
MDI'[O"&1Z?,FV*WW9.%$\WJP8\3Y1BLJA9_8N2\W+C+^2J=HKJ_>Q\Y6=H+(
MPG<,5&C$RG7B58QCWMIP39.AX>CJAHUWKGW?>.[@:4PB"*82(Z\;ZB"B'4F?
MM(3^TL!34P=WIKR3_V&)VCUUE7AB,Z$2XDMCTR?-6B1QWKF@C,G;@8O$ 7W
MH2Y;'\:O$E720DFI$P+3][PP^E8YP F)$>OUW<H(3[#G!F<%M>Z@DA'?9#85
M3N*# Z%DS6(74;RFI/@B^\:>QV@6OG)<-"F\/Y@<X'88?3".W@BFB4$G.?HR
MP/OG?\V$^2L!H/Y)A2_H"56  (.,[PV,2:M\E\UH29C+WD&I"]:B^<68%["P
M;WM"1WQ7 EW868/!$ZW>CW^(M?J90[[>8;LRIAFLP(5%BF86YK=<X<BTXP,=
M=7L-K33C%[Z?]+^UNI;F\J^:1?\"O'X&EI//\,6(^Z0!?E%:FJB0S<T86XKW
M4#?)P:*D(QT$X'4M*0;+/Z(XG+$B_0V"//[83S6U.JS-*J_9YQBDXK6__@^U
MR1@+26_3+^"MV2E5@.I/7)AMM:B:@)?'+F%LTW]:4A7.K3T3C:G%:X&B$ON*
M77*V"R\;XS9-R0&&&#HLNI+!A^Y=&<Z]>F"V* ORJ.AJTS,DWFG'I9DRTT(5
MH_RH4!&?KV;0C8#6V@DL<8Q/8-)=<(P3BP?H:R,^G!$9B+^YQ( S1A(N -V/
M4R GCKW?<<5C48L1":(RSU;COYL8/$?K0>* C&V.([N.;;/(LX[5WF^0;8RI
M80Y.:622"S!W!.'[V/]?]ZO_B(^(C.!@A?]^@DI9+ZMO>X$O0?>]5J@D?9F.
M1BCF1+._ADFP^M&M]@AYZ?@:FMAO"/\__]@J<ZS&]B!:GK:.G];@)7%T+T66
MO!2-YF!:@MK*0Y9=2[5B@!2M*19DK82\<J%P-VH)W?N:.4W"Z@S%E@<S3&DH
M#KU7+/+T* &9=G_5,IT6W55\B,&$UMF<:4FV:^M=D4S+DP6C4[HX340G'6&;
MVG\,%D3BAG]?>W=5=5XTH;MZ6"FAN.6B!$IKLSUX$"2LAE%V\<&Q$#JN2FHJ
MR_/56 'EB*YJ3C^"8]$G-'!@W$L9)#-0>'B0L#>][AS7301:]^&[O; =&]#%
MV$@;/@XIBGV1L"4A_-VA58R2/ )AN?@NWK"BIW!2^>ASL?"F&5P4S?7]4M9V
M3M[KI9Z;B7_O]NA_%D8%@;62GA(+>:I)]YEAB9,'^A<73$2$37#!LPJS"3NZ
M";M[!/5X/%!R7-H8]_MS8BS3;.Z%M8X/9!@2\'D<(1MQQ (4JQGD\RU3FU,O
M10S722J1N"1M]@9JOD6Z<:H0)FUNO]1%+;8<7>0#FI62AQ& >"U(F 7-M9?6
MX;[YX%E!_D&!=UX,:6+RZVTXF_5>L':5X/6G<9J[MRQ3^\-G2;^ B.D/SCOY
M$M\_&G^$HGN1)4OAH:WI?-(9_4X?FU('"%G$6<H/%%<W1CQ 'RRQ-?E.G?2H
MEP*#5947I#^CE4DC:,Q2?>5:G.[["_AVLDI/>6JH5W]BL+E&+L]>,''.=&AJ
MAB=K#5ZXU3!SL)="BKK(%]URMO >-(WRO1YRGW8CW:(1>$\ED_>Q88@#_'OE
M#8GS7#&*I+^>?GQO /0:[9.3J5:XF(S_)(J*7TQ#NKG!?=!Z@";)SPBES/15
MOW3L%+Y3,0/G^C-#1,NLE$SAGAOM=%6)K2)@]/P;: PK_=8VDRA-U3E_IK>)
M3_FYUN*3GY-%WR:Y:+X4NV<C'BF9VK?]AJSYM/\$K:#I/B9T'$9?:+J9TOR(
MV,$L>_*O.X.2]98G4WS[!J]W#_2T=DWN\Q:>2Y @W9;,*9+AXI%' 4')R5P6
M00@D"+'_5%Q3@JFC>+?J:SW4;>.\M-O7U<D#[^T8ND$1A2N\M&>*N ]*#L[L
MS[<][V,+]^A7#*)<4MX!1QVG 09B,Z$*6,-NG<4G>RE83-K,A*+'VNSB.M@%
M0IMIGYN]=L2AZBTM:AB=4ZC(X7@&P\KMNL=9(ONN1)_QCF-80I-YX'"_8I^9
MI)#.F O.:DJ\*5 D*A-TAH7WT:HIN(%^(F=,G%;A07@%)Y'/[,?57N*"@EI6
M< (/XLB$V(;[:\HAP#**!A?K&NTE]K0FY53SW_MV4U;K1 8.!6> 301L%LZ/
MWMMK/^=T-DHN*%S^NJ"RE=A2?<8+FO$*1O'R:Q_2J9'ZI%W/]AL+MAPK[VI?
MTT4=@?95COFKW%GMVX:2Q5BB&*H8SGF!Q/^ZJBZ3&DW5$LUQB (9P,9XOZ%A
M_/Y6X@%U:$TDUYY"[K]O>LA8!U\R9# E?/>%9<\D^(XX5F4L^0*J1)AX44%R
MI;$>C*)R_:GG'A[4<=;K+Q%0M;OPL*&FQT!N"!T0.(CV+CH X&$0JQX!V5&9
MM%=SVCHA[\L9$Q2$Q$8L_>1GC&>8SLXD]E-X0=LDY/&P(OX8O4'&_.B&S:HU
M3>(+TP%C20UY^@C#G3) Z#57D6FK%83.4'9\,XH\O[HV_JVQK.W7(-ZZ>X4C
M@&]6D.318:J<:K7,'\?OL=)5_#<#=7GF=W[K?RQO;-0P(<?H>J$9@.#/[3?'
M"QN)=/D$G][X'+2ZTZI6/B9;WG[SK:Y+6;@SKN@=E%".TS!4)'VAR.@+2L;=
MI+DC+92B:CLC2,SVRB)QC5V2:A<\><M7S%Z4QP#_.5X[8]SV0&]%3MSK]8%N
M /94P'"Q?WB&['S'97E+3_V=9=K@STDHR4.#O1N-Y]UN+]EG("=6/1]P5ZY4
M>V-='_IZY<;5M7SL)#V\7U$L*D1+G&7B-YOAYW=TEA83B/&1FL=ACG[_%["'
MQ.<[ZN_E(\BK"(=4<Z(OP3)^X[Z<Z]BA-N8O-[/J]0:1(N$[(<VB=O=_HZ/9
MSW9YND5[S"N9Q:M?>:X7_)?J3ZCS^3LDU,?N^+IUT,E@N/@:^.^_4!\HZZ#\
M>62\9E*.K73JN_:(QXP+/&A:WDS&3C3#3")]&!I)B%,J:=2*-ZYWSLJ?O6+N
MSQM5(0NE?F.[4N SWK?#BE M(F*U#F-&M$LBMG10.B&*0>Z8&KOVFQN_ *K<
M-Q'&Q%H,)BT?#LM:W_^4D:LJN:TXY+L9P=\Q\1%>8($W735DR\6CYWWKGRHN
MO//^R9(Q%<"V5[-EQUIVH'EFQ2A+,Q"0Y-REE2+U;)O4ZV?)#77'"8/\*'TQ
M752R.1S=^>9[3QFAHG;,C.K!@_@.>=4!_):SVQICL6*O8.V9=.'HV\F8CUA=
M^-DQF%MZ=;.J0'*-I^C-?&E68E*;2IC)<7X-ZM&@L_.6 77RT6W1U:5C7],:
MEB"5=9Y&7>!9^6X?ES9"M.F+AM^$I_E6J+PN%E$1/1^505N;0%2IVC,PI99B
M]E\FN%L<0VXT;(VYZBFXBSVM5AK3+C_ /]'P5$WC8[]% )=4'$K$;UM "2QJ
M<<(3DW)?F-"P1&<8GLC'!WS'G3HO M"2X;1IQ-87'WLU:KD764J71S%J]RB2
M-6.?N$()(O,,7=/LMUKUH].[YAZ'/BNM*O5M;WL1)(TP;8D8 ;P=(]Q^C.(/
M;YM>2]_F:I([QI9_&Y.E3+JLT#C&BZ>NRE<B!$QL%E3-C?'="^HSG>D4A5[*
M #XQZ:C]EEH=UQ"Q@5(.\JL@D\?A&0!)G?9XJV1!;WZDMYG(,=S94*>'XER9
M6S8B1E41.+'7/OC.]RS?@R%9S#:)Y=%GA3V;_XW$YV]NV/.*NB3HR7DR![#L
M<81DH9,'9.(>3)ERD6F)R7@U='W'&$6I/M+_+,OV,8Z'7TRHHBR7RV;FJ;66
MIC$Z(,^>?=I#>SO-$U>HL(ONZL,P86S,^TUPL S75S/RQ>1R[I>=>QPS<-%N
M/?=TG0_!T3VO"S\2#P9.3;T=='::$,=0X%VGOA"!]P(/8S]L[X@G\7!+Y^FT
M"7S;:^Q.>_5"<#F!"?3#\[D35F'#@5J!4 FWV4-^ <RJP@4"YK !,B3>?C_E
M \)?@-$?1^QK5E7;_5L?E0-!G^OV'VPN3T*[,/4!)UK/_!I+Q&7Q&I??YM1G
M3H&86I!:S[V1EC+7\@/[8F)*G%G=PCQ/ 0W#NQKSML^1O8"[./DK?W=R)Q?8
MN,,9B\$P#9U\YT8YRT KIMNK6;J0&)?I0RDD$C\M@-Z/OREH6RE=MX8\R NR
M\;)G;&B\\7'B6K")]XJ>E*_#\8O 8!P7ELU?0"0UOCC5[&8:UX^BB%<'4&K7
MO]*9R3(542L/80#(^[O_8L88BV<7,6JG)SD^/DZ_LJ3MZI5IBO!J1G=J.!U<
M_-U14M!;O?HC(HXM_9NVN>AD6B>?R3,FF4]IC=]'7ALW-K:_ENCB@CXJ#=6B
M\*)+Y*[J%)TD\FM_MIU*%R=NC3:E3$_\<I6IT&C9!'LJ6PJG74!*U2@L0PWL
MHH"[DJWV9,D;HQ1.R4555-5C&=V,GP=H-T1U.U%EK-'HC\]\RYGAU3/O,*_=
MV-<D?PH@%B=1)P?U.T)(?*K*JJ#IG89$?"[2&%C\\7GVI]1U.> <LIO%4/E#
M(%RW7"[54]LQBM<Z-L183=RLZ?=E'N@F4%!---.AWG[_=S!/#4/E]P(N5;)A
M58\@PYM<A1C_D\*:0_9[:WA9BDG[C[TR6G'RG_DX^D?L\'J/[.U780XJ_BPQ
M1^UA*X=>AQ9 #[[BF4[;#V96@B@<,[@PRPO;YE+MJE/R^ R='".C^2L-:3-*
MS,6.IVW>^;'./U-L9S.\WSH;WE64K^PO!$F?/(*?C0!V99LW;6<--0E2 L,?
M%-O?ZD9\5YOOJ+\8RO7(C3]9E %DT&J6')S[;2=.[MP7F"-2AMU)466UR_SG
MO"!V_BP8\HB6YBC.T'2'>.3#CZ^P=-"1$OEA*V%>65UK2O1=M63#T1=K<%GI
M&PC_*N[RATN),[XR1/^QBL0Z1<NHZKL_A^# J6%L*VA$=* \AYZH(\ ,7<#&
MXG($4*%ZOK9!%%.EY#!'B7C+KF.SKV+83Z8/9&N%B5QKQ!MGKK/9\QG@IH)0
M71MBL)$GX?%90GE'=W5/P]SC#!UB3%+(4'"QZB+;BV'//,..[L=CB)I[);S/
MZ.*D<(Z5F#Z_$"L$;TB$DX-MR+\%@ICZQ81U:$R>^RF.;[2T?*"UJ,"$K.EX
MC,!$9)=CB4#_3S /H9,V>H F6+C[KV^"2^GP,'$\=H^24:#H++=M2UG+CZNV
M=38<@&?.:R" FY>@+7U9B>:@JN_GHA@XC;WV Q(N'3XZ9/[O7ULLCYU"[W-(
M%\"H<47E&G:T.TJ;  ;F(SF?3 LZMMR,,8P@^8I3PE-LA%EO,'G04E:=-\:=
MKC.4(+LRWN0>HK$!AQ)@)A#4XP>]]$;T"W82@7+0%Y&#D!+*P*F'/K,BE'VR
MZI,8]0<6ANC]O* 0U")&,GI3I+B9>P7&56RQJF<>KPL>T>S$Y2YUGZEL@)0)
MW]6D,JS008V?OP[P.B"ZUAA*BOL%8/5R_Z_MM/\SRGX!N-:/8"30S?N)MWUP
M80YT:_GZ,,U$ EI!+;']?!.A+789%=:[X7L>XQ^2,)@7R@>N>P&-!)D0<><@
MF*I\H.)U06-I972A84@?!):'()+7(HG"!I) F"P#1:BX]0C**0:[%VBV7E0>
M)T)(L%4J]T@P5&>U08AZ:FW/13 WBA^E>8;$I6(+VB>FQV3TZK\399G<'ZJ=
MKRG711/Z(?UGY)86$NV3W_M,$P]NEEWAZRLR2OM7L3Z 4WSJ22.$N5K45_&.
M+NHVG=1\)?T1]V.R >3]K;#'U<O"6@H=?8*,Y3416-A"W[7*'TM31/0"/G+=
M%01LRP47AH&:'9Q88K!:SO!#<&R+,<B\Z%-DB<&*Y-!W]/[""B0;^Z.[OF>S
M5U,"$W#6.#+Y;S)^Z\=AG?N6O W.&:'7$;W^1 RZ?60ED5>9.;TE7HH'*3_-
MRB61^#'AG=D%+8%EY<:,>[B2?YV98B*C?:D.);&:7!!Y)5SY;*5(*]";LY9_
M_N>\4/'9_S2J'/L%H(F*$TC4SD.?.$^THO6!G7UQH%:N(!/C6_Y)B1I1,5)*
M]@5@MTZI;HF.UIXRK<M>RF[%# >T\,'7*6#ZL>7 )EAS,YB3]?C$=0).P;?8
MM/S,O*D1\N9;V9/B0:(0Z XDJ]\GS,ZO((]Y57$B@=3;E@<!5(EVA#Q7S##G
MTY0V,\;;OCN7\72:/#!K[%=4=PYWT1!I1((.S1_44%[R&I3T\PS2C)Q,P6PO
MV>J9!CH&^<SN):\0.PE1ND(ITAX,,#*^?NJTIDW20_70L//)4-1#,>:1D.F!
M9AT)CX:Z@4^K'^6%*=4PO\1_3>CW_<2IA+TL<"H'ID@=AC<",\MUM?S-P:6I
M]!A5Y\J*R]_%APJ%OD.I=5##@6)CS.D8JI"1F57$D^628=+= D3/7U=!)!8!
MC^YC).1ZITEKV;WR4;OG]O>@^2K'QE)3/4%5T=+'L2L6'$NPI^3J=#^0H@SP
M6>TTP<EDD4NXT)SG;03'3$][I7Q..  QT))V?#?B2\KUT(Y?[ 'DIYAZM;-Z
M.=@54K(OD/=Y6?BJJ]GG**Y'O,-B'#^MHH(*P;E@8#;G*EU#F5Z>"9,;-W)4
M\;@O:>)K:D8-98(UJ"5O078,70OV1M@T_8O(=$K3HZH7")_G< >:3$"&DH7"
M3CW#L^A)R((H<:]*=??#!2&'<TAWF&,R7*R[>\,Q]*SNK#;\S490+4P$^@N(
M=U4:-?E/P#:.Q!/HM\"8K.:YJZ&Y.G#*)6D4=6)I/MY$A*G@KG[^(Z;V4RS6
M&Q5"XNS42-BPYM!3HO*UK>> 7(!YK4F3H1B\+_VYX6%",=$/-701D8]6Q5(>
MH(7HY JCD.P9WMIW5Y06.M&L*G26 >>+7N"7B:WUKDVT^'&$4"J53/,+ENRF
M@XGWJ&@JOC8\F *&)%F9?V2+A]!Y'BTG[6\H?LP1*2K"'EGX&?M N1^MJ?D&
M<T/V;9!.EN!5_RMC,,-K 69)(F#H+VQV1!MU3_[_,@\H=/S^WUWI\P6*#,\&
M_J<$#KQN=)I]4PDY_P5T19-:WT&D'\3RX)H\N[+M_J%D5-\PJHWQ:6'<?F91
MKBX"2F&.!N<85XA306<#B-ZNO<QBIM-+@U-MXP2J+><,A&AJY+W [4"]OY?^
M1< 52K1"]IS)O&-?A7C]O:4*<%Y&AY"CYQUIM5_L!<0"++9;A_N%&91\&*0?
M4Q1=5BAK+0C/D$3:)]N3S3'JR?]NE#CJC[9_ACX1=364ZX&YA_;V>5/J5.SF
MC-2E.R_6J>!Z?>\ARTD>VGCD8+JIAIDX_K]7$@,:.=%Y2>JR>C% _JSWT6+G
MK/!=FSU71'2K"PMAS/T1P!]\E-)5T)U%)AL/^,(9+C>UVQ$.^F;)XU8>3K""
MAA#3AA@&4DTUH#2EDL>VC)Y11VP731E31=@_F32J@6_ :U9=:3C>@N*G^F#Y
ML&$;>4 \+\*ITZENTT7$4-$R36J;:S,-2'W&<E+4\5TE"@EVXL.;O<<\(,_'
MH%YI>G]-#1PU5(-;$*MH;H2,B[*8E/\%*/U()5(BCQ\Z$-J'/A!2Z##%<W[!
M]:**?:'2'(.3*";39HX+B:/B7PBN.?YF9U:=)/N<!/-X\0[2]URJQ IQ'BW;
MQ_9\=2C.BA)Q\E-E_.S'94@*MHK.5RC1YTAJR?."[T-F21]E8YWWT]ZDA P@
ML67-HL!'=0S'>5M-!/%I[CUHZ_P;:15VN-D0\S,D#DR#/;*B4TB"R3GM\J?X
MFI&N%*?0$G(V>)]YLKL)0]>S0O'*N31RA,% \3I9G-.?"5R:KAZ*)>U"26CH
MV#.*V8MJQV_I ;TG<8D_,&*L*J (WH[I2L]>S0TL,[P=[L,%_)0+=97S5P9A
MPA W05I$B?'Y<4.'L09_DPW-O;LCT$HK:1 >OCZ@^.^T DU\P=V6D,$?U580
ME7S?HMS QU:,O+MB3&CD?_NJ\]6WPC;LIW$!?B!C)7(R!DTP0X;.A E6K3EN
M(K;.X>WO9F9_G  =@?/F?JE[S6DYN8SY8%E+@6XV$,-<UY ,ZMC[G06X-;)7
M@ZBR?NS&43Y_I ))S$89<T=5E^8?=L^%8 MP@X@2=(^GY:0]T=X)3LMD4V)B
MMD:3LBM+DHJ:Q&UJ>&'%9TOA25G5]\SJFO/^4UX0N)>Z0]6'/E62N4B4&EU^
M9FOJH5>A51BZ"C<ZX"K.VW"R'7/J "4ME]*;GM0<C\Y>H[2G:U/5FNPK*O V
MGD8M?(KTS=L[Q/[ E($ CAT??GUITQQ9\NQ^?[#N^=Z*4(U2&Z]\U;8F%;2"
MF39(\@"*];>(0<<MW;)E"ADRQUR#DV";Q"Q"CZ$1)$P.W&2;A.FC[P23;$=)
M)'W@-"]GV69[.<]Z+A+IM>@BNR5Y7J9UW!Y.//PM6#U5,LI^N8\%38%<CVQI
M*_7WRK?_K[9 Q-Q<4#!_IL38X,WK\.?X K-$H*0_WZH:?=N "_>/YD8 36*[
M:6Q9+RL:(2I_U_Z6+&BG\^=YQ?7D;I[8UCY4<.7N)4]^+8AJ@W7=L/JP!0UR
M@YTV3I"X;,)?<!D['ZLG@].BR]*VUPTYAG -3WHJ,JSX^#:++,U<H&9,8'J]
M]GAS VM5P!41)EG_IO:Z&B<MCS0!M=DX./C=B#T=)R*&"6SNS)),2E0E2^.J
MP:C-7'+P4HJ,8*T*B9&J=;S_\F%X1]9424@'E>V7#_DCQ2NE\@6O \RA6'D&
MP\4FN4P%K[WY]K3-6'1B!KF:S%GEQ@)_VD9YW+P)LWL1HF[((;@'H^_6?[<7
M\*SI?:-)327X[EXM:'Z&(U)B4Z^E_P?-#?G,M-5^\BILO)R62A=\_?!-'N!M
M\T3666&[$/A@G'A-FI/X:D P7S$5VH$-Q/5]$:!%Y3#-=Q+)L;SM%/750%0]
M#D3!6;BMX,Z(G")]LAR<=B_/DDN&" Q,X]JWP628[Z 4J_BW*B,"%T:+&85=
M%N<5<DW^R8?+3BP[D3E\(3L+9;E,:YL/8;.BCU$P?Q.EF!5OR<:^&<PB))Y2
MSW?*2U;%[=;(OBP:G*#M90Q?5%MD/_]+W54R>I.ERA'GTUS/^@I"P*55#?-M
M?)!<WA/K?6&_>O*WA;M:GI0T^E_^K[T+F/%O'F#1AH]R__'Z8*A*S;,0TT0E
M"%@O"6<03(2Y'.HU9]4""W^3SFQ?DT-O[EB<;^T1-T_7,Q.^SLY<+#GH'\>B
MVU0/%K(-AJ=.6?"SS/H)N%VLT ;>X$Z!#F,O\<18(J:20B8?<;TS*J8:+SJ'
MI!39K'@ME;R#4J9+*Z[[W$P%H3W?>:=SU\FKHONQHX3X8K/^@M)'#9TW0H#I
MJT:Y^O&45E$9"?.>L$80)JG6=2':QRA*/GPRED3]-K[Z*0J?R>R0>IPB.CAS
M3V2<0F=9B>X5;E:2'JNGH'UC&0,T,A *.<?4_<;(L+'%MRX\A264&E.J[!,6
M7?>TH5[7S(_'O8+CX0A+I8,UN*=ND:1R^DGTCXP9>Y^G,;79M )H]-O@P7[;
MT^;_P9DPPV!Z#ML$S_-2+PIA.4?Y=58YJPP-ZHYJ_CQ0,I)FHY4L9V<"_0+C
M8=0JL9>&UE&3+M*DKG(MA RR8574K_@7=UHD3@9>+4@LLV3%2,Z19L4UT+@%
M:0/+M?F*-U8=GRQ>%[CV"\ /)^!X&G[]UN)U"^=[NZK^&3B$?K/*+BUT3[9#
MALKFM"&!)TNLB!65<*C.**YFC7:7;K,ITP1?6IH^CXY@R&(68"T6P\Q[/OF0
M$XL,^<#\:8Y;";9\^/$[S74R]= 2J'.?,L!J&Q5PB*N\S6">E!]*4/&ED;%B
M=\%ZFB/(-)&RH0ZPNS*0/3TD5'N'3K0E^4W&$X);5NN1_!7'%J)ICDB#8U]_
M^[S'T\!W]L0+&*3P,-^' LUZ.O=,;Z8*R71$JIFK(LSO49Z^E$U_]WU-[=Y<
M%.Z N,,YT="[QR\YI[[(!23R$$NUVE\B<0;M(PT&BETZG(U&N_')>:MQR2_%
M'0*TGU:6\]/I^&P(?=?[Y-X75BQ5^+RU;^V##W#S_ :#R1(7WHJJ_&ZI5,9O
M3=;H3@\1"/63(XFHC9M[\-@D%7OGW"I=N86IFTD9\+O<^ UM!_-M$PPYN)HV
M(#VS8^(L]<':#?%&4 9*G>!5_;J\J7A.6@Q:JS9 ^W]/E%99VEZFV*#Y;_."
MVM9^LAW6R5M]*\?@,C&^\IGK7;]"?<%CZ6A]FEN6U%M]</B TK,BFW=).9_Y
M8S\1*+@HL&5(!KUFL'3@;8GK9LV!I$%:5CI;*1OWHV_*K[P/]QNLOF/M,:')
M5,7KRW$T8:UI&.9"935LQ&PWB:MI\1MKS$5LHX=;#+UCR4B1]Z610MI129AH
M9?*1S+E<Y7@NRKIO^RF?OX3OU"F0*W/RK&OY<T%Q$<]H,5_MD/(15<=67],&
MG'HH/QJE0ZMZ;)=E*T1@K^? ,#A*88VVW,+6Q:H>'9.3 'N)%;FH8-?M3%=)
MWRS _0HJ>3#3P&HR>";JCL3GFNE)UB_]9+9&B6H<3%4J 5?B7)87]*=%#1?'
MQ6]:G)4S+[]..+>,6__=X;P]?MC7Y,23!6-NYB#6RR79UF*X#FU:^*<,YE^+
MP,%>0-7J]]5_A@9.%JPHO2/P\OQ!V+7'T!G_Y=ML\!6F=$_^H<4.O37=IZ!Q
M]PC:6L3]C=]7?8F'J@.4]ESZU7(EIF&:95$2"I^=6XZTG!Z%&6%1'?M#>"J6
M7W(0,P]PS>(YOC_MSL%()ZVV:2ZF[ JZ6N70F,B)F;^S8?"K<;'559?C2,!4
M!-RX>DA;G)05JC:[^B?R(LS7F]_-:10X<E X\4 )'LAJ)*LI2W(]H\ML#]$C
MA$2UU*-SBS1F=BZV$($.R;%&P]RZHUY/</P$M$/4QBD\ @LX24?^J#JI_J@Z
MVVD"6Y2?*!%LF],<D6_<+KG6_F0IOPJD[W&;P58,N'0&%RR52V9:LE1&4>?#
M[WL,*": >!E?Q2<U415+/$G0"'ZWD&=WFQLC TBQRMI5DH(S-$HK5E4_Q5B?
MM'A)*,:%X3#0/_BJY_FER_ED71GP58DOZBS68SVJEY,Z+SG?#"":C4DJ[">*
MC;1:VT'R[1TOR3CCOW\0]I+[/B^HVT]Z,N&N3YJ6F.Z3PS%-F%4#:P<XN -R
MYHAPZ'PMYV<5 QOF6^01EA\\5<.,?*@9YX-0G)RV8VQXG]'WW*KL]3^AMYGV
MGIVPX\E)3<#I_UFR%<AN"^ )(^R)0!^+;4T6:*R>0+GZ:]>T_?_V,R!\I;BN
M3O%,0N8(X+LXT>[)DE<616C4-_7.\XIRMA3[6MAN=BO-ND/,F"W_>((G\ZGQ
M58YMX%<HQA@%;QUN3SX##H;-\5 U$QT<DN+4^54.!*>RF7KK-X\$HJ+(H]DF
M!)9RTI+_++^TGB!.'BA>L7ZML4>*$]PB4;"$4-&\#\-5<7^[2^='-Q$(=0HK
M4(U!39@D5<IXYS?9\%VD2*10\!!_@;4>?TIQMBD;NM/@M?,2+"9^I5S3SZH[
ME)4-%V5+S(&(27;FEOADL&'D.45Q2F4QY_V_-3/_-%Y*X;P;HH]6XOK&A-:7
M;L[XT9?ROOAQ1>&G1]:J>7H6A?=U@HUYUC_@I_-01A6,F.'3Y_G3KPT8LS%S
M#@<B@*]%Y</D/%4=8(;)DI1CU8C'DP<CM3+&>A@3H-_HD@WU@> 78&-,RH9U
M\BYTU%77-MBV-KB,GT\F*<\%TU7%.WKF'NPD5A'(O"=Y2JU0P/K9)% 90=#R
MN*I7%:V4(0%,""6HQ,WBML6*:T9Q>NUKE/\"../:;%\Q,!<X Y=(;'6#VBK*
M'4_;?3\!Y+"H*E]74!1GW9=.UYW/50;]K5F"%<J3MVTB+T(8[7.C3J'X;:T&
M!HM:'MCE-!7UJ\>E$B1?ASW-&C@+K32F?#2-A;4=OYV4:L;^<=XO;!4JRZVB
MH.@;-54&7.@/U\[S7FQ QKR"NT?LGS4UD(6?]MON0#H"5'F!J]7@K#K]4]Q@
M;6).$Z%KY4>R[_OU@?QXUN1O7 LE5R]_UL82T9',)=2OSM1"[GGW2RU4\J7K
MQ,@TJB8E;A) :20M7P?3!I'J4#SS%;-HWL2=*[PEVZ P&+YOST[).H06E54W
M;IOFE($5YSH#)S2:1,W48B'=\<CP,#^Q;*R2>)E==M\D!J&X"[\ISLZG6;QO
M(*CL-&9)N$I:BW0DM-;@EA:?"F;N4,/L3]0JD^VS%[Y0LDDL^4B/4?SOF2O]
M=^XP$)#ERW<,_DZ=A:.DB+994]GG@UE>%66M) 618F(&KY>B=&+]1([:Y[:B
M%]AZCR3I/H741YC728,!-H#AZ'K9FTC.KH@,T,#MP*\EKZ$@-DP#[!0U32<S
MN]AUCU4*'8@%7HC\D?J$O'')]XM)LNU;J_7;H2HNN\O)F?MX:J3DHVW4$%6+
M6B0 U%?@(O<ME^2+PC'+3.>]WJFDO<!">V?@/$*))'(7.N,%/974.GPB$Q6\
MBJB:*5(E?Y_DOXO6VWZ3=*.MW9XC5V1P!!\0F1F*+@;RD/B,QP+!^E14F[JA
M!P5\I]I5K]B2;N.;"8)-7(QE()_QP6N'5+A> K&M.%PBN;H.+550:DP997>'
MBP9\PB#LM-!_GU87GH#KKN&\,_K^5I2((]'(A)U^C^@2B7GU0 9#PUOT#=.N
MLF>U77Q[DK"(8"F]+JW:0P\(JT>7[. :-O!([(. [0[?<#!;W_(2]D+[%'T0
MOXRI?+DF<6OSTPI>4%Y>?V,4]MZ!CED48G32;J,A1+>"KSBJHD,?>+?EFG7.
M75SLJ@:O[.L7$BK1%C:Z*.KAHFI;@+/DOC1\0?_VT6=?'?]71-14XSB3\.KX
MT3(!Y0DV43$+!_9P;E!&VF;=B$U=9#68 #L+'9#T+#;<:WAAX6*&"8<ACQ31
M9_)_ 17_*4U,NL=(@MB]Q5&8V1F]_=%P][86M NA_!+?-?*XRPD?Y?Q26S7"
M@G.7A/M9Y\NW;U9A4,H"Q%E299PA-+<TC.U %]L3?K]"*F1M]BR0L+DFA*)J
MWY#QH^.3S.&N 2AFC(C:/6-]4/R(W.G:INEK^!9)C VE2+ZO&II\X)%M:0F#
M<L< GZ5SE%O!0+%9AQ O**1H/J7A%-BNYAU1L:<^MPH98/:&3#5Q]ZCWL41-
ME2VPI*!78B'Q595M\1_9A+![U!# 8:&?0I6%UY TCT7)<[+WV*P8.U:?\8V9
M5*]*EW8+GB'Q!'J%17W*4RU#7)TRHCPK6).?AFK'2(9J!+$L/:GG8K+<\F=Y
M>VP2BIVS1[R9<3* #CB=J4EB8OS[C0R+E,P$>UV;(@N+_.<$KETQ%E$79^.=
M(Y(N;O$"]BIWPJ>)$IZ-3O-(?*VC]NZ?3U\<;;75+.(+]CVHVL/:UV3WHWKR
MJ?S#ZZC42RO//!\^(A"D]343A#0!^OWEN S EZ.S!RKL+87^7$B+?Z_Y2)X4
MB4%*3X\N0[<H'<8,UW:_#&<M[>?.H7DQS=1J9$5OF@3>AU)LWQ_5*F"US0&<
MM<K<60PJ18N28I%\CF4 45B<C342ST3W:'^/HRV"P2W_J_C#^OHGAX3>8M'N
MFH&!#. !)+[X<7\@FSLN\>9"[X^) FR6+2ISY12%J?S:]XK-E*:S*_<L3&>_
MT%"VDH[M6>G61;36&TT\%,2 BXK_/:[E_4M5#DHF2 2 W@4:F82*BCLP$BY+
M*^)I4I^MXER]-I(UX===DBV8:),=5GHH3:!6_+NNL6DS94M3FIIB5ZJ;) B>
M%_A'JSE\U]J)*R? 4 :>7WSG7<)!EK%X?29 E^FS%5$;)#7C7$GR)J7D.2<"
M@IU,4JUX8^UB+Y55]-Y[$W42\CM9@\8ZJ@HH)T^&+^6(X-X*M77HL2",;V/W
M!N[,B[F3S3LZ*F2/+N+2_ L3R^<M:#A+W^!8 _AUAA\Q*_D:BO9G;MPL'C\2
M/M*D3@25Z^)8!*;IK]/-?N>HBY0>(.#]&G_0J.,)1?>R_'Z8;WT<A.N;Z=T>
M*2JN+KY\'YW4C0@TX&U[;%')IB9#D&#4U"O8U_50ZW?S)TC6NM+("Y2WJ$PJ
M-\DY8;C4\52^"*6(^"X-M[N7!N3J:3R(\;<M+TY0LM6,FLD8I,B.[RR>[.O#
M(,. ,WG)]1%Z.>K$D"G=SPSZD.>+5[<%(]=K"9(Q;Z!KI5&OUD(SC]Y(^]I*
MC_(-KO_R6@2?,@WPWRPEV_#;U,%%M6$>$)?Y8F!)#D"^WLPD[?2<0F6=,W0H
M:X)&[+G]RCJ1^+3TO_/DZZTJTC_&W!F3J\%46(?KKYV2"19BX]G4_IU4M;][
M]<$JC#Q[^)[T 9F&H7]2R:IQ-XQF-:DKMN]3RY7]6N]17P3^AV GN:=$(/W^
M3D+]>4S_3PX\9^61T*8$#.*7CS?:W+AQQRO/(8$B_7FQM8,9P7-J&#^0;LQ+
MP7H2<Y77!PQ>17;N7AP?64DY9DH[29=;E>*_0DEU/$[G55NI[_=:W4M81PS(
MB>U7M-49%-:_"][7+'/;M8_Y:J%],X;)32R;,BCS1/-4GR*7M?[XV6695=.D
M62)RCJP%D3 SLR"$$\G=0N,#V.>G1E+OJ"<PLT0S8A%=-PIN8L^2/3@Y53.$
M3D25F*8!G6'*-0@72;*S(IF1* &E!^(\O8:A0RPVY H,VN9S,T;+;SU)&#5"
ML+GO(_',>^^(&QN;% Z(Y*NIETLR/EV]*5JT^>ZF^4H6A>YS&/?)C+N)G23?
M=@5Y]#-I/7'=T!Z)'R=J9+T"C3N/6D.@]E=%/=<;7R5UL>]N#F)"UIM#2A:,
M6AVX1HE VO_CV RM!S0UH1%?+^@H!27&R_P_E+U56%QMMR6Z"H?@H0CN%MP=
M4K@%=RO<@[N%PB6X!P@4P3VX$]PMN+L$UZ"1DV_W/D^?T]V[]_]?K+OUK)OU
MSC''&/.=<WK4/D;0-B]4X$KTG!C+9NPXV&H->;\C!G9:GQ]W6]J3Y1-I7B8B
M_VN"NRH.5<GAI,CZ;3\.GXG"C/5\M6AI"V)9C<QLP_>&=LMF(G;4\4!;1'?Y
M*(G]S[!\5^C'[7;]&DLYF5\S+LJ^Z0G@R;+2HLZ6<Q#?Z4*=U+8R&NMYL9%E
M[#3R1)!)TS3K&Y\_0"=+..)"AX-Z5[965_*=I!)71=9YE4!4(^?>#IT@(I^&
M9PS!X,4HC%I?M/%Q+N>N@E3T>[ 6L]A1$G,7T37S=@HS0BF@ANR8@+\M-Z'V
MZ-:17^@:TW83GD#OKAV6ZSNXW@",>!E1TDNL"&<E4450E>%."L\9\LN[N#"?
MA:!/XEI%PW'LIELN?V?_ :"U0=\1:N;%F'D($RR(C].ORGX2:(\"-?XV6+_J
M);A#*KF@^C4/3LH,WQ.[)0_WB&ODYCVM9ME/9U1;^2]5B[E^\TGUWT67V]'(
M<YYVA(@Q(4X4X#-?OT]C=2,,X"K2ZPMI[4$%$_5SGXD^3R//'K#ZJZZ?:-4@
MC+XR?0PWC/%,?'1RS4U-($1'+*D"S-9ZH0-]+G)O=39A/ZW <=]F:XJHT7I3
M]'_KK_4\4J1-VO./.'JQBV]/H<#$!(8(49Z6UE<X+0=]:@2CAW4C+"8\#%Y%
MI?\>J"Q,)1PBYHNKT,]V2#SFQ@+<_1;RR.[< C[6<'7 >EQ&&F XQ#56T5)C
M=6;7>0;;HJ[%])5'=+3,0SD8P*XM(B-"#*AG C".5&S+.Q_TK5)R?F&LV)X#
M.E."/P2_*Y1N@9SD=?CKNI><&!COP5E+T<\@%&:!Q5,6U/JZB MEBV4^8V^;
MLI6Y5]OJ_74S\$+DB@#Z_YB$^E_E8SCFM_\_XOA1]IF@K#^$^+);?'"C[A:/
M:&'1,_ O_:Q-5P\*-C'_R7<Y_I[\<EP>%S45E9'B,^Q5'P5>('%XG\4$+7@9
M<\NFB@UIRW(:%/L##@AK2E5XF-K- >H25)@I,1$.+6R[W K,Y?$EO" ^<'*
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M&@1GF*<;CJ.M3RA_GS^:-*?+Y^VAU()T:1_TPIYKW:X,W<5*?5C,/K<"=?G
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M":'1#P+0F0']!U7[F%4)HB-CT2;7JA1JX%.G?5=2<3;OV(\!N[9(R9)\ M"
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MZL8BDIM/!:%9%K*OW*3?06L-J4^Y&$9WW\N$AF$T(PH90'F7\N50OMW0:%+
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M\R,/B8)A;=%Q\W.]WJ&!;.R9*"OJL3\_H0F2@B[>8?UL[5._??<6G(7\0-,
M[K4/QJE=H%_6SOT%6L0!5FW+FK.Q#NI@!DXB5JA_X2.!$N=\$74IM#?*@,[/
M_ ?J_F<@C3AXA2G^UV+P_S5'R(L)S2_L.9/+FL\ 2(#1S^JRG(C3BD,%^&.+
MD@>>,7@4.C/>-+&D^.\PJZ'\X%_'1'&YTE/:CWV3#)H(!WPN70?8P_^S9EPU
MTW5;6_G\].8,;>+C=(<+73]<)?62.?SIE:T$3>6Y\X^(?35W1K?^\M #PZK)
MLL\OI?0*4 2.(#2!J[]#D1*T4MYE-1Z+[Y\^BER2E5_?]!@8)QW6L9W3<(>1
ME8H>V:C-,!'U4-)S=Z!DY_FH+U^,9&*9NB&A;-];=?4;YFIC/OC0S,S8WO/.
MK=M!\#"W#+RN=:Z+4>A#19',,9\. MG_^]8V7L*S!A$;QQ",?;1Q<;!ZEVG=
M<VQ)Z=Y:TL]9,QNW.N*ZPN<'KW)AK*_G->Y7>IQ#F_F&,A!ILZJ&EJC$*+=E
M7I?F4/ )1>555?&>=VM=KK[Z\C?QOHPUQ2-U"+5$V+K.1/[[<^=(L1"3BIR#
M.H/AUT>Y:!NI)Z:2H@@CFE0/F3/JWLC"/OX/!E1KZ6)JF!/\NI)K*V!]A\K8
M9+JO!)H"]72!'<G9]O^X#N/K?#X<N2OK=V'"7GI+L&?M&<L[-^)_.D U33PG
MQ>YL2=EJB[J-W8):[OO;%;VD3@+49C?Q)MZ-&5&1$_SKR-N9-;M,F/] ;\6O
MNY'Z#$)5$<+/6H-KQ^"C&,WM4(L ,-"9N.?&2(%6MMCM,CO+\+P4/*]BO^MZ
MJ[SYXZP]!HMQ$A/ULMMB]H7.:&X6_VVH8(#NNM6T7"*6]8=9C#/5;>I"*8$@
MT<I!UY#X,FW_:&D^=,:X:9"Q128C<)$U?20G#SL&IT90:7^>%J0;EA3G.7Z3
M OX#.8)09&&<&?BXJ#]P;D;V)X<<F105[YTY(*.]K=OK^+(-3NT<+1..;9_,
MW/']9KN4C><[E=C3[A*VE"B L=:)M_2@4+#GR8?J,Y6\@B5&+J7N@FV45K;[
M$>=5*RJ2Y09\FRY-*1[;7PJ7"(*O*[9/+%7OO%\'^PC+'IA8;9B&J*\,<HE)
M3'0"0PRT+0X:0RK-54T/4M9HNLH%/FGK2RV-"0W,)Q3 7;K)K=NZ)*$T9\_2
ME[]PB5]QJ0.I5OM8]["')*4R=L/:=^E!1H7/@-^[/2.;+T&$NVT,L#>51'.D
MPDP\2*B$\L]6[YY@U$_*]*1.+ H!W:OAU.QATX]$ZYROI4WVDF4)5=.@POML
M'57-)G63\;>@0C@KR0D#82$"X_]F%F7Y-#A;QFX^>ER2@JC!?OB4ZHW/@*8-
M>W"[LLN>)$& 7-$@REXUVM,U"VH2D!5:P\%O^%>A<\&P^B^ZOVI$$)XRSLGO
MJ,UK<Y/DW%M!^7$+W@$J^_]=#$3R,X"K-?%#>M2[K+#)YC+1KI=PY;HYKT)J
M]M;?,XXS>.\FWD[K<A;R--!1 (.-G8\)1>QJN)[8;5(&Q1/MD7ZA@0>XVJUO
M^@%Z&!"Q+</UDE_2H+^M]452]-",TI''X!N2)']8+[[8.;F[BBU*=U++KY=>
M.Y-?J9)K7G/8$0X*/_36\G^7YB@^E,0!QB>UR^@XWRX[A]8B&GP-OWX_D$]D
M27!6A[++LJJ_VHH)M$41X*4Z)!-X.03=/$$O'O\>3"2KY(^S)R:YIE0FE>80
M-<\RL"]G .SPMZ*JSSC'IWU>;V7O6GX!&UP9;@7EC<K5.O;RCZ LOO+9$.IP
M,5@7D]E08&ZV==2[4^J]^H=#E=-BTA;YTEO=T@T;]M<5XL@KI4R#':X=LUT^
M?5ZC(6%>!5:T&P$\6>6%^C12D%G;6"KI<0]D@,?T>ZB]WG3YCH7VC3+''/F\
MB!I:EGH\^A_K3(;0KZ@<]LS$R?T<=LC=S33S'L#?)!3K]/@KX?]OU^!XL<C;
M1ZCGR?WU_W?"PGFIP(+L_UT-G]?(6O.6J9F0%MVJ4N-!X8+G&8B;)885_EF!
M RF+F._EMTL-4^?.;;Q8HZD@PLLB6CR]R]8:SBPH"MR#@[V9=O[O,GF5T3((
M<OB3I4F(\Z6:P5H&7)."-O_BQZ1GH/.*0?VY%8,OV79E@,P:#\G?XC_4O[O9
M4Z$*#G1)PC%6OF@4QP&2ZU$%ZB[^+*,2%]X( KR%SRE;^GI^4TH$W\@KM*<]
M#:EU4%[(4D<2L(\]2J\^M(KP<!;:^6Z&0,CB!GJ%'*^*FV*(E)T-2PJ+U!E1
MA[Z1JS84$8,Q\7(PH,)1IVLYYJ/L$B?*,O12"7(",T/YQ56? ,$\Z\7^ FXQ
MGS%R!-X1[]%:IG>=YG)3318K_1(YU57YZZ."Z&B(_'4175/67,>;JD4U3/MN
MWA!8RESZ%X! QMS0/IH^;'OU7J<G<ZH?B@KU'T?7O^S@9F5#R?73Q2Y_E$RI
M'C'#F!A"->ERPIS71-O4#D/P+_Y8_8>Y:<>.!34)N565?0':?O=*6K<NG/=@
MA\#VBPS=[P?!V )?)'F5'.P841,0:ICP"8-Z$PHDQ\7.GP\-SX ETG]!E78E
M?':_ 8'U_W?6HRBGMB'56PXO3EQ;H2R3N</D-7+#CH-_8$M[__TZE)M-SZF@
MP:FR^YQ6QFBV^M9T]<UVC@4ULHC/0)',^J7)S]82I=/@B!8!E!:O=Q/RA:@*
M-595RU QAK65CJ$R=_F*6D]6LXWC2\?9-A^/SOFWH9=3=M;%A89>.[WVN">O
MYA8DDS^6T/6=7@N,#%D5']R\ETLS?2M&T D5X3342SI7=[)=89'D*0M\B:DG
MJ,@;N%_W96WWD&%)<'33^\A@UCOM/@!#(5=O1LX#0OHH56:X*V*4[I&%"1#D
MSD;LO[JA>?W;8>YI/^/M9$V+[CKMT9%E>_7+^IC'EC/]U8^\47_NU="CS'%?
MKL$4F%C>;[FIL;"3XVUJ4Z8R'N'?CF/,Q C"PR_?S;L?-WG=N;73Y&:UZ];/
M]SIZ[DZN!VXSTE@60%4]C/JZQ@B"+79+?%WY?+U^1(NKBX0_%9Q>%HE)E5!&
M&TR2/*1(\M!V![=KRXJ-=CKW.Y=5B"^;UW%242_\"#X%1\N )Y,4^WN:PTG5
M/TC];PC$ *Y3RY750<MKF%62I;OW!$Z7P6?.H? 2?[F\SE[XTM:(5U!:?YEN
MMLP37_BXG J/X%5C>;#,C*%JPY^==^>T7X,][Y'IL0$"M+  \3=-9L9R#PLV
M8V=^@5@;Y^(E:6Y;UE7><@D.6;Q.UC=LAD-C*$5EDZBAA +H^=\X/$",EJEB
MH>SOUSFKTEZLY_[\)5:\T*96@"Q3JNY?2AVKM?D536_65ROM9&GZ9/A"G 6E
M]O0B#&#7[%CF;#Z]7!=^,RR\2:*A4,#AAD)%T3U=\X-N,9)6$;BW4)HIJQ7%
M<OZ8JG(URJ<+*]H'5:3SXP==R*;(<C'.%\0YS%S21DTHU8E&@R1RQS'M/N5@
M,_'*]2JK-]0TUR>088\XSNTCO1-+Y$2(Y3[,+!.*_>NLO^!;%A@'U*+:OQ*6
MF,<H&B[-X?[_Q4YK%*.1H9*"1@^R,"=J=V.\WPTBG@$W2#G-,[#Z-A*_.3!!
M_LU1LDFC#!"P4A2 ,ATM:6Y)>T*Q=?*$=YO4GK ?&W\\.TL:#FXJE%2'T%($
M=];.@D1_"-%,$T:*-)*?QV^96I*]9L#@?RQFJJP1'L;.S@,"X@F[[G+4KZ,6
M)#IK.!^)MF(G9(.)3&7W*9P:A%\.W.E*>E/75C]VZ,Y#Q<IGNT)YTJ)0Q(OE
MIH8YSP%,O\-/PN:]]'3)>T:/R;RAY#P04H,.=9#V 1*N:3N/:9"D=/'Z/.6P
MST^M0RO--7 7I=HWD7MA.8^71S/#N=@[O2A[:1!$[:8%MW,>1R2$^H^CU<^W
MUU"#'-U@'6G[_CLKK^G\=.6LUOJ^NB1&T^27+]ZZ,T*!CJ_7_W!#@($>(D>G
M72%\"@Y9,(Q%U);^]PP0&LV@U?B6?W;+7+Q$X,X39$T-[3C1OOT VTNB;ZXG
ML$M+J(W]A8A/$A;(*UA0*C;.J[%7<,[U0F 8Z ]XBTCA$!^U"U7(C3^RNICC
M*+N#,MP#V:X3<PSM7H8LZ;K'I#'D>;0QGDDK-2WWC&+J:"*A_%?/ (FT@_WU
M==]-']1?-\OH;K:B38%L9[G FK@7M6)TR4/99<G\O:4:NG>L#C&W"AM05(.&
MZ>TWX4G/ZZ=M3ON5MRP,0MSE1&Y4'51S_A\DZH^6]<+-?Y7"/Y%+V'>]A*V
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M<<S&:*(F(<E8D1:-(>V9,DM@X#7YL4-A_9GQJAKU".!'#>Z;NRV-&&YT.S)
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M_O&5Q<4G!$;B]JCQGV,!8;624%_^',#,@O_ED'D4 H/;F=M6/5240C/"D:<
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M&Q-0Y;?+VF9^\T M6TMP>*9?4=Q!#71UU'J!_%1Q*MWA8#R7<0RX]>)!K]6
M.G%Y[J!Z+H1^FW)X&D6@Y7-O_=BL@V:*(H %>W:Q^M.]*!K:9XJ1PPNQ_E?0
M#WICUM'FK8.M2H7H9_<=A6\@GQZK=A37VA\_^_R3!:O)M7LHA /X-]!F"QU'
M,\P9X7>L+9M- ^F_[C3"#Q"L",T]^2)'H1MO8D,4S%^\4U!J_ ;C@!(?[J/%
M8#7Q'7NE!>3ZVS=/<<"GQ>\\;RYF0V42W^E;B3MZ/1Q<'"P__?8^8MKK#/KN
M")QD<352&LR'4#D=]&1;*&"^WG*OYMQ2;_+T.7=>LHXZ^8\WS?3!Q91G+](%
M:8$M3@?_I$<#]+DG>;9F[,1<C'"M%CP:_9&7.[0A"IXPQ82YKOFW[^^-@K?6
M6EG-#Z9R=C@XN@M8$)E.H1SWWS"O1&CS?V&[CF$E^%12/GSWD['(0.2Z7O*"
M-9FN1E9W!4=V+>WJ*QZQD\CHP_QK]QX0YA,#1U?0"EDQ=#L7*S-U?#6*JVC"
M%TB7](1X.NN*B4##8G=9N!Y?.$HA-:-Z1=;:>3H8\E%!6OD  7H:+=G5I?"5
M5\.B\IXUNW/H63]1>="B$),R:JCEP9JXRY9;.9KQQ,[.<U.^N]7-Q_9AL! K
MP3!K$0F4<N;>PK1).2.J8=GAM0C#PAU''K]AQ]=Z+K.\;YRDYIZ^4]5.OEVE
M0S7?3Y3>[6Y).O>):$F%X\CR6?1*XA70T?(D(HC=*7&(8;7"XK.G2\//< FF
M\WZB[$W0P])*NWN1 $%.$9$V\F/,S4H:H>HBJQ6Z_..N*'$FT&W7*Z[8W='W
MCSF*$(YF'_.YM(H-4Q[3][8CBX+9^2$OR)JJA7KD'V:\COIP080RM31X]"Z]
MS%4A.<Z)U"NRF-U,;2EM:A9*'AMQ^!<3!CG 4*?%XKI +Y2MT]_TYY>(.I-P
MMMT@CGNZQ>*C.6O'SNI1]YY7,^'3+Y'\^^JK&$G"=W:V;>[J 3R!AY;L@EM7
MW4J?FO?LL02 )8=^5+()GD)C.<-X<U(JGK"UOIQ&BM D<2-Y_.+&%"R[T2^S
MJDA+96VYHM2[DS(2/$[('WYDWT^R?^5JUZ"K89ER]484Q*,]60MT)[\8?/\S
MG6Q5+KW;T'$XK%[DNJQ(7>F!O,I$W/TXOG!TAU<L8^O6DXM<(M?]IJW>,KBI
MG$9(V-716D@@_5AV@OT7URRG?U 0 XF*QZOT2K+<>78M!P7:C63BA%X:[S"0
MI/H1XZKH!Q$Q%\9E"T7??99%4/JY%GEF?FR_3S6LSGUBKI%O5.D6*G^QT7B+
ME6#3FK@"!UPQ+<#+_0M]F%*MT0)](GH4HXAPC64C-D1K,H7T+NHG2SS&YQ&)
MU\ 8=F(L6LO\\<2/ZR(&1XA4M/V\XI*8@7SZ,;3$-7F_Y<=,H_6Y&/74V=@]
M82*RQ ;&[[#U=KR,>D7$8K@HX.SG<00RMFZQ?>UXL:I-1\$[4YVHU56X\34.
MV(XUGYN?/L8!SJT9<(5BV'$7\*-5R4 \^%5Q+EO3VQIW:W\[[1PBK6E)6 E>
MJ9GDL^\=V*RJ/#O:AYZS 4LRXI7+P+.L@I?:5O.04EC ZW@"E?;&"1QPSF;A
MP3>=<D/#1P"#%X,E*22"+4R6L:_AA1QMA@>5>N5C\("'5.#)U<UC&+8K!OV,
M\ (F=PB;^&LEL(3.J;Q19'N4[^06.QIO@["^.Y6D+DB[#EO0-<S*;\>XXX!C
ME9:]A7WB32;#?UFSP1-F-:?Z@8+/P^X&5&V0W=%"+=S%]PG)Z,X-^PKAR]7%
M#>$;0I8EV;'GPH]Q %S]37#7^\=60KU<(J!K!>O[Z^I1VKJIJP(:)%R:%2<0
M:[;W/RB2;/6V$2BW.;T24X8/\F[2I;;@G")!- LA*>K+?#@.,,8!6VL$,0>+
MQ S<"O70WG#%A*UTE$F)4+9:Y]'Y4_P$)9:6#\K)VYSH>/S4'((>JQ3IJUW1
M1Y1]LV;YT7="X9GN@7L7+_2@H,?X,E:2V@":JFK1S<7'#8R)!5P$29VM:E/C
M1-(K+*Q?(M6RWXHQ]7+I%0G3:OKW3<:#DB3Q5Y"'WBB0B>"@,,%^_.64"UUF
M.(#"VH;\5?9T\-96G;,A$_%0!77X2.33;Q:N),K*^]BX.4PLE_"M2]!].A;L
M#.R<']@J%)1\[9*2\=YD>#2B^OUA+)1_?@EES*3OK&, W9S" :6%A'L\@2DP
M"R[&QF@<,/&*2(])8FT#1JLDLB%N3^:BM,.XO\E9.=2)O\N\A0%.31%+S0[P
M8?>ON-\HW,0LG YYH!I7T[".'[#TM;;P;2<";#7L6)4(?8\\LC>G]>P4BK]?
MR[X\;>THFO9Y\R"D>"!+=)M1Y[SK<J]CM"\.D,<!F-AG@M=5;1P?PL\6?NWA
MTL$BAL_YW>CMW"4!'YGQ[>_\D>JD[R,J=K=)8)MPO&ND&BX$$GS>P@%38&S7
M>[Z0J2F,2K3CXPC8!Q!$J"R?>661 0=H':;.J^K7YAABQW_Y#^KM&_HD-?G\
M]6]W&2<<DMEU*B4#-_<L_^#$;55)2.IVV#)/N)US 0>\PR> (5J(A N3#3]W
M_BV^<:6-DKJEQ^O!Q>R'QA\L!FLH42[!T.5[CS>78<<J)1[")*+8P>_0]0#\
M[D3H8_8O6\<0Z/9Y&T(RIKF^OUSVDH%^SVN;)[MU"Y,9N8Y?HMIOFB!Y+%00
M<;6N?[=1X,G2>R&%3, ^Z>Z[3672'3]P2D'-*)*6<I0).J<*S8)F&HWI>%&\
M9O\6#(&)]:,QE>JRYT4Y 2A,7^4!UB@CJI:P2&>OQU?LVDS'(V-J$4D!3Q@(
MRM:'9-_0F<W@BE"[*<IXWH[8I\PLW'PS3*>M!G*6>(T&8]R6AQ\X7I]229)_
M[*U(.+5B+#VA25MS._[X'/Y$%0=(AJ+GML$R(TB2_&6)=RGO9%I6&5'J0QNP
MV'=34YGE><V7*55>*^AY6A K7*L;+(O2CW-ZQM0VC'6D[^S:RN<I"/&BQ0$1
M(CB@*$RG$ >@/W# -O-ACW4K/AEB$DWO' CV?4R<LAW]RAM&NH74T?=,=])W
MZOFXX6F_*T^N\T-)_OLE[<$IJWQS2?21XFE"KKK#!V[ST12G"'!W\KI6?:#V
M9RRWW"Q-%1^1Q=U5S#RTT+5QTN/]Y5G23+>&XFR8A5G4A&N#^B=XLM66@>\0
MXV!UYAX)%9%2'^8K/J3Y$=-+&;.:NGQZ=4.3G$\$D0G;X*:%H=?#?/CMXC$K
MTDCZ[7"X%[KYMXAZ*$J(DH2\DC:C2WI\6+2)O<F, U+>]V%L?N6%V+R!+38)
M7WMT?E7.Q7OO[_FX*;_WLQ^MO;Q']NQ[;B@.&"+%=B4D <:;>:O8F=^JVG*4
M:;@HG-"!+Y.L_2G?J9^3];SG/$$.R=\P)*=P\9UEBR(.Z/A5+VPW%!Z4*4?X
M*5'3GZOKS5Y^.($=_-L0G\N#]W@?QV-%?H-I7Q&S<81W1$ Y]PQ[Z^>/7)3C
M,QZ\22NZ^$S)E'#SC(>>"PE# \C3+/D'A'' VW9L'QZLR&;6R3R%T0^EOMT7
MAD.=*"<0+2?X*]_U2-8O_94Y)WOT6U6T341C6W.81,!6S[(<P3<I,.HY%\2^
M9%=LE+#%T4#1XWQ_!7F!8&@K&9,H3M2,6O3L*=@]?M*(7^!:?USJZ;K?JD%J
M'CS*(&,=41LZAA#?&^23>I#+B@,JK;%=A6 @G'A#5"&G\K>[Z"Q$/^;9K=$$
MTZPF3)?MS21^)HHIS=V2M^B'+A!YIDID<>$ O5]E [SG$WU2_A"NP/A;'P)I
MRTHUCD@ 65?"!UT)RIW%FF3 ML./MW_EVYV]Y^&53?]28(@N1M#3DWZ>C36,
MO,I,H>[\U+MND'A#@&N=Z)?K081\+1O&C=M_BSQD]9GH@7/6R\"!MZJG]?DU
M(&"RS3\;[W-\K%WVP-3\@7\K\?BF/LP^^$8E=TII3<LE63%\5OC]$>_Z ?J)
M9HQW[G8?1F 5[_&<@@::SS3HX5'NN:-M.";IO0#[_5X!@2M1CRY,/M;!=R_.
ME_SF(J%0E_'76C9KDQ\>48^I"STBC1S" : "V;X+,_H]*SH6?GVI%;]U*.\$
MQT#6SAYA2/\<!!#:+(I>\.V +?, . "AC^U-BU]0*;FK.G9\CL'7]M(4$F$S
M]L&7G0^L,!;W3O3"QY]&^MC.UFH*$W??>8;DZMP]YL1.*+(T?4N_L2@TIPW&
M3HB WCA^SKWJ$$]XIGJUR(I#-W0P^HAWTW?^E7(L\B;X&$\;IAX@]AA=5EL_
M0H]^_<5*T#YG'=M!>#Y\62*(SLB0^A"![Z5^UV*;D0^@O\UG,VVX'#AFC69Z
MAH\]YZ]KT,?;<UU0-A,>/G'?MR&YY!Z 9D6N7 ;=(6!H:/EU@<(]H4_['A)<
MZ\>_;8F7(6-(_+QS'&PH&;^,]G\^?H(P@%Y\G(S*Y4H^L\7SGIA(]*473)6!
M(2;8+XWGQH [,^7/ACO(,,SV0;NA+7-Y'D/^SPJ:^D[*$$QU/@[H5SO' 1?!
M:(O4U\LC4]R.4285BGHLOQLRQ4Z/X( UB"<.\";%\F +SD.F.-K_O6F>FB>D
M[VI!$^(NR<<K"!P@JKV+O@)#II_;J^.+1^$)EA"*&C@RF18JV7(WIER$324T
M8BY9-^[=Q0'?X=L]^EB?RCG431RP)#F2;'/<7;P=HQZ$ ZS,<< A90,.:,+C
MDQ9:R0L[(YZ#S8OA@#"PFF?+7_OZ:U__U?NR&*ICX#D!T50F+)K=CYSH=*4O
MYGO#GYPI+L-!O!U+'"S?3K.T.62[""[UW=>6H *MKD!_>*EVC68'+G.CHA7?
MV ?-P!CAZYJ.$Y=,,^P[9U^RI@6G*<CM/0E@R$JHB1GPM;?A_A"N*&"X.88L
M@-]$36)X'Q0ZC&F\\3NF>7+9A-%WV. Z#N HG[F7Z1]^^^X'G^NLH.!&C/G>
MV<^,6.EG4K/640\8A]',BR9C2A86Y:*.-V_LAQ+I?6JOI#D+7A8T2Y/,,,]G
MKB&LK+XT(BG^^N3]\;*7PQSARP&7O D)+K::IT-FT!_$&]B[34S]K^/#!N2?
M"7\@0R,5YO.-2ZG:Y'=35U04Q1T^^CE#23AEIF<UHEONQ$I6\?VZR19UR7DS
M8I>\&=%S/*O>C8)EBJNZ<*=L,[FU47:Y'*]L]$E5)(RNF-+U$;]4HF2B9*D<
MK#O_QP".,;%6YT^OQ8I3&4ZQ(F[]'@&PWP>K,5]X^=QX_+@+THJOK?\8N-^%
M/E]X83O^W_\TX8+S@ I=^+NT.H7?(>KWD#PKW0%-. F5!".AOX/4[Q"YT5?E
M_M>^_A_?%^_;]C;^MK"N[N/U;&"Y7=!OI+X:VA7@'V]SW'',#^'O4]7>9!?>
M8/JF6W%%2/WG&YAJFP'Z.=+=14%<HN+5V-B+C$M?GQO2O!%88IQB>EL=55M<
M.J"SN8:(ST+"@TQB.LZ.,Z@//E0[@"/NJ,#V8E%PK/\-_.T2,.%],#;!_6S@
MB)UR?PS-[(4GBZF^>'G3U G]#D?)H/%B6^PRWA?>4; P4&?(E[.XX%,++'DC
M&=X]S7DX8-XH>4GRG]<9M?PU[Z]Y_\WFU;4OR>=8'D(8>.DN;Q@R+M6DK)]^
MA?JIHP3RS-TROQ=-^J>[.A4SB1(>E'E+LP^Q3!8W\/[0;DWPH#E5&G(!;6U!
MCQ5EN,H*GNS2)1F+4ZBMB(I3#KHP?AMT0;1R329VFU#M6AD1I!&<B!X)$2VZ
MMMW?NJ9<B%*>1U1.(P(=J4LMKKT=($6718 ;#Y6@MPY74U&I2ZD9DPT!60HA
MI_$G^Q+330&5I60H[SY;W:V**&TSL.'@BR?;],]9G_JHW;E\H=W#S?D(P3GL
M=7U.MU-H DD[/=,A&Y<T7G1\8M .CGV38+4UDA4;N4RAEE6_@)%M<?,N&4[9
M7]X()5$3[YM5GO9JJ"JH&>_ TP\#9QQPA5?,>(FS. XSL\4.$K!2K )W/$);
MS%FL@"^]-$ V!&_8R$V;H;BF,!;37LPZ,YHHVN.-WA5WLS27P"@:XD>7F@3A
MA8:*[M^_NC%8_E5Y_IKWU[S_W3Q;0=W%%XZVB(T/N1T]4Y&GMWSU*O=.VBNU
M9F/=+7)8H\Z^37>5X( ^(P)4?7.[T,&V,JM=?BS5CRVX5%IZDE%%99PK"3D/
M1_OX]81]2^VVLZ)4I]T;PZ-?3<C:;UDVG3!&6423!?D1(FH%]C2(/U:<.LCF
M;I:I!\&L-GZO=QS_C=;8P<Q:3A4DSR]G'Z1/F2+(L3._IUF_7UFV@$[%^"J?
M#FS_.Q\+GK3!OL(VYZ+7CB<AK8V_&YJJ^4>-Q@=CA1D,8QW<+2D7]7\_-/./
M'.T+- ;ZU1S&+U01C.3\_=#./PI#>7 7>)P7F@B:$G>)__V0\S\RPVS2GZ1;
MM,F]<,NT.MG?#]7^3H\.!>P''-]06)6L&-!C_J>QWSL+[TFQOQSY?Y\CG9))
M$=;6;QLM\FN#OK%=(N_Z<=G9+=E\,)R?]VU*W KUES07-_G\*"=F5)C;F\'M
M@N'YOKMO3Z[A@#'&?<23HKY%P0^;MR--_"IG3HMQ /$2I*==-J%V7V@Z*\&?
M7-@M@58XS+5P]IJ[RKQ!Y]WS'"$%E'K^NI9\XD*W>/"]G,&2?-F[+5*K[Z%-
MZC%K-3V] 5X<A7M-8242,PR>T+.CC(2CG>K%1&[9[%8+9ZIX<LSP:<#FKM9K
M"Z4,A$7GQQ7J=Q+WU.IS,V'*U<AV=+ S;!??<E.#]_F/^NAA'=G.V$/8&36"
M,?L3C,8-]ND9U7GI$2Q*  RL#<S.=>;(IZ97W)'(,*(2P@$7SB+7=5F"!75X
MGJF-3E(FK,?;SGJI,)2&9T_6K2J,EC.P/BJI=5'MU92XPC)&%%SH["QTU#T]
MW37X S6]/8P,_OAFA%\P9B1S)$&U.]%#O;Q@%Q1X"+^.&BD/&2FN\^'+MI$1
M--I^\^P[B6U[HWDFDDH6WEDYPJ@C1=<93;![G?SJF0&\U4U-X;W#.H?C@FMY
MW6=5ILHWK0:DP\G?*AL8]3+<C,LCK&=E.3]*GK.1'C'N%\4^4_DFH^HE29!)
M3!/#&#!4<[Z+ EGJJK_GE*L,].I5Z+2GT7&'?X0QGHY!M)+H(MH6Y9YY?[<B
M@SV&;^HY7K4;"3D0^F',JTS*U_#C. %"]%U9P7KA\Z?"E2@:LHB L*[(.(*<
ML[&/_X2KXV+JCH%XB+JP.E&< J7<<&C4:/N_@VG>@%]YM_E7(O]5$?]RY/\G
M1P9(([WRLW4AW?;LT\].ESYU&[G?ZA\K;.'6$:4?^)(1S" O0!:IZ^+Q$I)M
M.;!J:$/Y*,S>/%GQ,+19I?0FL"&]+JOSO=&9*=Y_BB]<D-XMZK&Z5EXVR# I
MC$5-)PL'3!5>:*[QQ6*)A>=,< #4!C;7K"-.V7XTX23@E0Y:M3X^AYZ>__,X
MA:>3;L 1]8D K'("3]NFP2=[BG^?N,B:OEFR!5:$VU>>>R:C,<TX '8);%V*
M Y*KH+OS1?>"A6LYFO]:_=]Z-;] OJL.DS.9 *AK/F$AST*SIW#8GG3^W=*P
M<U9QT5F:WB5M"7.7HFGLXC*IQC@V_6R,5Q?SL\XM[@O2YTJD,Z,;*&7L$I,U
M11A=KKJR#ZFA7ML#7=#+D4^UJ:;)IE/.#HW5^$QIW_%L3#Y8LX[;WD;7,M(*
MV.CV/H%;\8^Q6R\*=%NXS$O-LX64D6=#>S-QP(>L<ZRK-@Z88\?R<H=^KAH*
M%O'@])*^;V&GH*39^"UW@Y:W]S-Y]V.)KIY*5NE5)&C$'DO^>??TIS4.\*A$
MC<ABS%<5O5]_NJ>J-A-#2#\?OCI;:#^GI,_YO&J84P7@Y #H 68H/N'#3M!8
M'=C<*+[J%(KK1CX5T"?M89K4<#5RI7.E2PSB[=YXJDZNI_/BH&L@2/M*KQ1]
MT@AO>+5]]I0KF>0U#NEN'X6#@E.CQR_WOUY(#*%WZ,P)M;S?9;5F;.7R9KHS
M1W#9HYB3:!J)+M4P,)I7MT_7P/@JJ-H&Z:_"#-=1BHJ3=R\YZ<2M7-&X^C:<
MV_7"1V*3J2T<L+I#>HZ"Q(QP-$S F(+M?'_JI^0Y+G53#R=('2WXR#^HS)W"
M-/1AO>9Q0*,/_.\Q5B<35Q@S'D?DM%?_K\;!NO$&9Z'NB8U_OPSKOX' ED(1
M7T=(_UK^U_+_Q?)E>\E'/Y08X:H&9D>MFKJ=)G8E$JW7T2W%E%-CJL2S(Z[I
MT61B$[Q%H7LRK&GUI9W_]K+3/]".D@DZP-\JNDBGG95Q@.<MC$5G_D #_4S
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MM0K*P6G!D(Q62/H>CS%:U:K)L]4)>M()'JWNVO&BU[Q=7=? Z"=*GFQG!XM
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M&8QV*RSOAO;+*NWWCWHLRF.K-@C(PM%&&',YL:6W"5^?'CO%.S.-GWKUJU*
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MI0NZ=V^R^3)\G)X[Z \GZE>[/G9+Y\EZA@ETFS:\:F.)F9TQ=4+V$O4FNZ1
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MXTXG#B@9P2N*S1HC+4*GZ!DQ:YZ'4Q]^W'+2B! 5<EO:.U,E#8)N.LR=&.&
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MOOZZ4[2CO7%^@OQHY&E,A+*/V"BP)IJ*<:42L5?@2?40YKR$ 5[73VG4S],
M65D1/'N_L39OY4'Q9JL,OA<M7^?EWI"?0'G[=ZXF'=13G"1\%#&LU##BLEH
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M18Y!>PO"%>%?;@U_"Q1<@SD^(2LZ2YZ?WR?64N3Z,E_%F0SC"?K5IS].\6_
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MZ265W^RS+EJ%P-5_$*''Y!2R2X,"&D)^>UGCD!)BX)D ?8[^>V0W!($".E&
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MHG3GNP]/?8[(%IUZ0BU33/"-A:B"VA9287G:M%/=1_?R-J.?I^S"/+>.3.]
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M8(40RU@))2FK!)C9Y% ]=79FGI-L\OGP/&HR> 6F:9N[@V=JFCKS, YL\ 6
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MG)WC5KN*IL2:^$7CL5^/A1$*>?ZHBJX'7R]& ;1K@^M1I8]+CCM9 B6MNF-
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M,/N^>IV9[U2L_V1RZB#QRYHZ=#>URO$B\0$**)R?#KR ;K$LZZW%NU%TH_U
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M?B%QH017<A!)D@( U&'/D$<GQ/QUX/[7LL!+@68J=N_#E!-]:43]CDU^@Q8
M:LW(#2.$ 06XGX<F<?1M&-5'[YW1%*  GU]"]T^@"Q&._(83LJR7 V7V'_W(
MW3VO@'"?R"/(8P46S :NBY0%[',G#&<4XN-\ Y.!@^"P3\FI+^,;&6 6\E\#
M;*XD&"C3BM.JXTUS_SD"&$7DQ!N%%*.#^TLKHVJR?HWD;[(S-\ZXE!\M5W[
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M^Z>#*?^)$K+_0O(IJ;(P-?M-(XE4\#'^Y>;<K=&MEKF"SK]=O.F2F[NCC=,
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M[P!@IO-8 6?T))I]T4JZ&UN\Y3D$AYUKK,A\J!9\X9S6-@?)NZ%2*5@*\ZO
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M'>_X)?T^INA-T4:A7ATX6W\^QQR84Q@?@MYV- P)V<J3_W(S2.E'AVC:C"2
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M%=Y*6.5@R%=OBP(DOB,G]'K )L1#$-#<80<E]R2OA+[J<"EKO(#UZQG!S/@
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M:\W-!N6]G_F_LG\<LQ;W>-N&= Q8D?3UTWQ$@$Q7R1YW4-H_5B515%89<\%
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MX!OYML(_OCOG&#0<.F,X %V!0,GA#AO@7YED[3%A"E#X&2F.AN%MB:&5\Z3
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MC\8[ZB XBR+14T-Q-E'#*+#,(XXNXJ=<%$R)J;Y!UH*M%^XK[8OKU03$[^[
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MUD:L*M5$[T[K7M:JZ4LM&)R+[G+PDO6GZ:!2E6@Q!-&"B@$G@5:K TXN/&Y
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MS66'(#P8>3<K58^<#V&9WTO((D-S^!M2RUE"FJ*!0_HZ=;(4-*%X8>C]=L9
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MY.0MH&PAO0U0$"SOJ.GR;!])W2^L'ID__G0ZZOFK4AOO0"R?V0GV2,ZC&>Z
M>:3LZY2AIT4*Z52/@PP<." & S,>PA6<86CK6=JJ5]-\0VR%"D]$%U^W!&NZ
MEBTF9-L5_4%T,W LU;$B<7RD.J1*(#+28*CYL<0'LHA*)(GF]$ _09$NSI#&
MI2G9I3:;[(5E/&.[27.;K58Q8O(_&,$V"9=$GV'/(C/-+XUPS1ZT7WS[>1CR
M8CL6?!_F6\,-9W!4%7NN<*WH><3LG9LQK1W.BZ<\A#/^]J=R5!_OUGQ,U9D<
M;V,I+7F;$M&-S @,/[BP-?D&?,E5?G8=KB9@/_1R:2\]8FOVZ?3'&NGOVJ!Y
MDG@1TO<$JX__;I31DT<IS,CZ80AGXKCT2PJCI"L"[UH%!0:JU3HF;@ ,E*V,
M2X1#2VD6MQ)K"KPV1B58+[<4M,PF<Q)[']!%_Q^I/8%OY9WFK1.4R-W#X96*
M\>SB7N#@7B1G?$P>Z60K92\G9Z+=E4QB+Q%_0(L]QU@%[3M-<AVK3;]Y4;/Q
MU?DQUN</WD-\&<F* =L!#?#/4Y$#&SJ;2[2*6#5(6;6/TGB0$LD*_^")H%T5
M9R3Y9R0*XYLL+TI;?+N;0YK8[,E<J%>&YT"8\P4@S'^Q2(G1T:#).3"23B;?
MRL&.+LID=GQ?HOY*J)<0(V=2XBE_#J%4_U%0O),JNX%J-VL@Y6/2S^$]RJ??
M:XA]<EQM9&(9,,SKXPMPJ4P;J)1EVJP@/7\Z\%+;LB[)GU^^?G](]/=LN?]L
MS:1_I^D,I:,(&YQO?>$=E]4M\MJ^0E.@F;[SXA3%L;4N%]Z#Q[M<&DJ]6:.;
MCZI+"TOU"I2N2'=_48*; >72+R>191B"12<8,K2YDK8[]-9D]W/.G'Z[AU#-
M0NU._KV)K9$*A=.>",A'QN.T4^-_%F/\U66O=(9R?_0 U6?>8R7=HM+*S4O/
MFJ$3=5?A#!H*> _4U8MG="\WOGMK%Z0ZU"[7\?8S0<SQX J<0)RN2(.,K 4,
M=%O/L?E-D?5S$Z?5[O>S@[/MU4O5]TMZOX\J42#E!%CS!8WT5\Y-]9P>^--C
MX"<R7_)/M%UQT E6[D'A":[??ZZ V[9Q/0P=BS$:VGT^YZ0A0% [ZO08?IUO
M#/.X%W)%*4W'[!#D=R8RR-S0,(RRW,2/G39VBM1Q/Y<!;3H-IUU-&*76NS30
M$J\_PK"YY^-7L_9.$"3&3CCA+C3A%C6MF$(C*,#3> Z?XGB&+'U)0A,9[\'>
ME(3-@LW*HZURZ(VQ[7IW4"R2**SW9RWN +Y9-U-K?I;7NE7)SMY=YQA#5G47
M&Q+.823RHAH/ Z,[N'WBKT*'L7U-3C8WGO);M-C4[2:2MLZT>F-D9S5YX[AE
MJA3,"5F#W/4D,V2_%EZQ&3XH6XYU,P<_/(ZKNF%A1H7=5JDJX_1Y)]Q4OJL&
MS**N5SM_9,UOI U[0L7+^"08P)@0SDWZ0TD3IDNR#5Q28(I[&C<?D-\9N\ES
MBY2(V#CM2J##3OLARW3"6S84S(.W6G5M83WT4UQMU5*S@KL@")5+A5Z<52"C
M7-%Z[IG8OH<R6^N3!W45W!]6N]<ZP1(ONU^=.0:A1]M874 3WN_+$:>6IPVS
M7MIH[L#2MDZ+,ZI1MF(44=*;WA@BI\SE]LNZF:T,SU4B=+\1"&ZVP.D6L,2N
M4D.B=F=SF0K>T;Z(9@YK9/KF.UG/*#ARV /*^$W6 UIDRC(][W?:PTZS?O]X
MH+@5<Q<M,+U)B[Y%8JQ2-<A<'O;D8G95?H:^-J&/)%QK%0?\016&1%*R%ECA
M=RW+H%=I: ?5\C(7DV]!YK896M(,<5F)KX*'%XH@!.@CE8&-6Z+<&=_E;9B]
MNPHCI2+55 FOBLG-75KV7M?+G852F-9<1HZ/8Y.LZ< W7M^.I/_B^C)#9$NV
MQ\:\#F[L1K>PV8(0S@L\#NL8"?V\7HT\=82DP5(0[$1F?VG,6D*,ZK;KGYDC
M._V&])R&ZN<0=_,W:#C25Q%)56B=(9VNH]?-*D-!?D7<3X[MBXV[2C<C.F=1
M(UK!C0KK^"$K=*QMJ3'_@AS?#!3 :.2N3EP=S-ZUT-LX9%^G[+6\=HNRU#,T
M/LZ$<&(IRXK2,:R[08^^:BBWX%GI@PS2 J'IQVZ*H%(MI.[U_9FHYK& S$ZH
M!K:]GP5^\\,71^9']</\1K%3<XN(M&5QL'POC!/=T#CCVYAV-6R_";&M>?^(
MI:RT)K1'@/4&B5<JH=B=3=W:!@4E/^'@]%1';Q44H1[:W>3SK3#=CT2,G\^,
MC7@;0*7$27\HF>C]4#)9QR.!"YL0<CS4OXG$+P N"<<DF=X_OSTG*C:;0+,:
MS]#G2CWE(L0<.31)K>%-X*,9NR'*O(U(%Q.K@\1_JM%$G0U P>J422Q7M6O#
MSN@O*)$<=64H/5P9+VR]$GAL/H(EQTB$M\8S?LQ5N_RXP)JQJ_[-2]F.*?NN
M<RP#8"U@$C61XI",OJP]<--HRS)[G7$F'%A_\?*E8PYH2BF0;Y-RS#QA+-I[
M@M[8N^.F?XH#J'N<\.A3/N26(WR&(LIY+_5LQB0R\)P4O5W%J&B>Q^T;D[''
MYET0!A-WH2&6 27O8EHN*A;PJ+TNC</E2BM$LKLMP1X)Y6(MT0Z,?@FU8M B
M'*YW_@'<2+ULV]_ ?CM^I .UKO=&_(QK.2H!J_"P]BBRMJLF.3<2(O"M9)*&
MW*&K[5.I?:L.J0GABC/GHJD=#GB;0)5C'-XH^9!%,LB?):N%<:+SRL'':DFD
MR-&V0S2BJ?N-\'C%BO.;@?ROV\PZBI9<BX1II^/)'LS^$)T?+&[$2*/-C5&D
M1)>LX7SOAZ0QY2SB4[YC[R1:]V6$<GP;L%=*4$H^+_@JE=4YRTK7V*[1,/!@
MB<]A.+O<(8Z^&CV\C%=W@F1FFN<K]%G$YXF JE.R9L .]WG'Y_WU6-JBWIMS
M89H6C>Y;#RSMG]^4;RW/)?I9T&9/R:?BS40Z<O%>=4U9V,R*YEW6 H;"BTV&
M\<><+;\)1='80@]WX,>D'F*;C; M3E/P#W4=#T[5 @P^3V<N"<4!>O@E=.E4
M5>$,R-^=&8;N6VVH(>F?]Z>W"VQW8C#@+B=\Q8)).VN]^LYI79RI6]IUG;NA
M-B"LQ?(S2M_IT \'%!M/[H L>P_Z7(71<3,6U"V]Z$<MESMYY 5&%'0P??5W
M!&$)Z/>QI/(KYWX4$E*CT.@<K6VJUFZ$T?-==LN *21K*;'S<UYEGZP0H>"6
MV+98+-4"#F7\#SP?S2"::@7T\J*W)MKRCT1?CA]'0\CNT?NLP1VQ=ION@*]V
M*1(21>8W^GPPE$;Q^<O-_3%+S<OAI5;.P#+G-P@$/T.X$[ UT]CGU9"JQME-
M3!@>1:]N@!=,3D%'CK#R[_ 0:@2^I[4KO-7]MZ^W<<!%='\S$PC=RRH<7.S"
M_Z[4Z]'IL,NT)>\6"9Q=$]^)#7E PC^%:O+XJ%X(?2?KO-T=B.4J0Z9ZZF;=
MHB.1W#,J];HG: AV^N!.2(L/I,J@3RIZ%LC[;O8XH&X]P[PBJ'-U0N>N=HSO
M376^ T>V>$V!93V++%>%P:J[J%P5\W5%K 5=GY-$OCQ/H.@G2LD=,/^$BUTB
MV>>TW%C1V@ XA;Z;7M?\3C57@4620F2)+-/P0<+QPJR86*$H%$7? B.MTN,-
MH=+1_3Z2Y7DKJ?(5YZ>$ U/ZV#!@#GCI7N5!EI:6"PQBG&:5WHX.MH1/G8[N
MON\QH] S\4@@^>ZNN L'9J+&.^S_8>^]HYKLNKSA( H*2.\M* @H37HG("("
M8@ 5I 8%!(R(@$A+"$5Z!P'I($B1$I7>>U.*=*03D%X2:@@A?/&9^;[W+N\\
M,^O^GF=FWGG](VME95W7OJZ<L\\^OUW._HWD83/0R'OEM</2.M6/X@D&A[I.
MCN)<#WR5..'4"D3E?V,$FD,RJBT +WR'ZF5&Y!I<"9:!53/.)^ZN;FB\@ "5
MU I7V)EC^&/RI\;K*D4_2]$S"I]!7V D62\SZO-'(<+QMK;OL=#F%W?'8K[?
M$-LG(^VQ/P-8=IIG>>7]/&>O$U;LU0IDKN-ZC-O#;>YA-';O'.#"8]]PEQ0/
M>Y_U_$8^3-P4[Y\"8B$H(&X/U&-(3G0-0CYC42UPT/UQZ3!IJC[_,^XXQ\['
MU"2;79UF%T\!H1D[.GAUHL8''84"=ON_%Q)4)X@&%*9Q"L@L]TJ#A:"/461Y
M\[K,IX#;WX39UTV&MWAI97KG 6=?9&_+@+GJ709KS'6:06P1A5#)M;'!NRP]
M4'=I_MU[#6>N4F)% ' 1#7?;YJC0B?3J0D2+)(J-,/!BI=?>N96Z_9:VC +Z
M CF27![I\K,94B(V NZ:"U,:$Q/.BYU9$GH\\)6M]6K7(CM@31"9B)?&1+55
MS###N0=*RAWI+2P^^ADWOVEGTP ($OBG:TDSUUP&B]94SF-[#VZ-VHX@%].,
M>F303W67\F#G[E6B[ZD"=08LV-!6J(J\DJ=$"XL-1)29*4B:F'UL_:0?&Q%9
M=^8G>1]T:@7PKHX2)=:A:P*'XR7GHN\4"D0?Z@LD\7VV/?>8,YPT)I7>RZJ@
M'Q((8=E^=/R,<"5!T4_VO/7(^UURV,7,_)\%41-"2PXTJ(QP A ;;3<CR<+R
MJJOYB4ZJ5%<>=A"\ #10Z]0?;7A37AUX,,A1:&_XD%\C5IYQ48*X:H;USI89
MQ< >89&@UQ1VGFS@37NKW2MI/H^>!^62W^A$*I-;Q9@Q)\[UAW-?^A1F9NZ,
M(Q7<O:2U?Y7WU;VN2YH4-%GM $_0)BG18^PBXI(-R+&TUF]:-"YXBV,Z0W/0
M[9U^>"M[@8/7DIU2;O0 SOS^BY&LG.C6H4:3 [ /9$=GCKCJJQO?9M* WU4C
MN+$37YO2.>!W?RBM3M?50E^,2U035%T%\!KNZ8G ]HS0K'U!:;<AJ8['M$7]
M#I2>K\]3RK&NN?1[5P%P!J%'B0_]4<B6..8\E?(KA(PZ(=D);A0 K+HVQ]2?
MWSE:/];D?;T"TQE0O.].JW&57RA8UO9+M"O;7O-9+SI5+A&B;\.M>ZR*]5GU
M/ANF$WJC]&G<:QY.X%65)R>O:#K*5<ZO\&I@[:V$^+_ODT&KJ>4O58%;+>]A
MQ]YX?\/YS[H?M-X)$SDPE>9 K.:$:YV<,1HTL8FUGWB0%FYYML+WDIXRDRKA
M#<G3T-W9"(6&['<PQ>1=G;KDP>5-<<$$YHDFAJY>#\,XC&D'>V/@2R2EN]-S
M1YB&6-)!X7=5-T M$X6I;T"'<16P&  7TX!5HX T,%.T:]98R7[]C=O1@<FW
MI<D3ORY'K(%YT9=K=&4/ F)!I#$>=J*PN\C%CBQQQFQ.[?'5E?NN<ATD<Z2S
M*\@44;P )KN-.<^T:MCQ4DS0VP0HS-*5ZQ:O 1/X4_-^,=C_%, D'8*_D<Z
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M\(DSGXWZ#_9G).ULM#,5 >NC1V/L\U8/W:PV(X0S; -R)E_SV (6MH&CM:<
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M67>&^3:RV;[!/83DDCC_6>26ZE=9HO=JVS#J+6A/1SE]X[@]X071B3)V/KS
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M\_3#M$YQE7]]>A ^>C6WJ\5]Y8MO-S_Q&@7R7^^ E]Q.;Y1G*WPP,HAKGZ&
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MJ-K+16N$99_N8_?2D@#[V5$M0W\MO=%']C5B\/M8S-$^]+/\3LS+T6U3@NA
M5FVX5JZ)R9O8F['OV*/!Y2Q+J,J$W-Z.C%"KP*G[AC*U]%W!@7%\G:Y#LM $
MP.CX'6K1C@34Z!V7FANC?62J\<6^DJ(GAQENA0Z?H"8,8#R.I,8F)]!S]P5J
M$@47I%LX!@H>*T[ZZYE;^3VNGXZ$G+'&=2:=W'CWP8%5)6RD[P0N_:9M>?^Y
MG86E,A40+39_-BD(;C]34$7[H\Y732XG?$;3Y2XEO7',_DV,,PF@H?TTO;WI
M2P("- E"2SYG[G1"Z-WN*_?MCZM_/;"*-FDV/BRF+%US\2WV@T4A&)##9FU%
M5Q2P)YMR?/J'?@AL98*S")>Q;6W*=,,+PR]2[#N&.A]/7^O8*SR7"H;3+"#L
M!O3:>BA!NO<D$)O#E>1NJJ>$MZ1Z-3M AA=P6=*=QQ.N$RA7FLF ;;&GW#[&
M1CC-UGA\VZ>D9,>WO2LLM36&*O2K!#DE"6J(H2!5!PFPI3: .Q=VWN;8F;OK
M/7>C?QN9I6A@<QCSLBI%$/,BB56R-7NX\BEH&QGQ,.,!UJ]F\0;&VR*7XLHS
M&OF]<T'#Q@,HBJH,)@?<:GU(DX^7FU,OS413BX+,F:,]^B#\\Y@G9,]-VTQZ
M5-C8@-\D):RCDQZ<5.NT]#/Y,-B/TO/L@/QU[\]MYR+>J[(L0IB)#$_J-2K<
M2NRD#2WL9>BM[3(-^Y_J\;-P)ZP&RM.#;Z5;WL"7SCO3C8NF.135U;QD,7'*
MNB_M0]GF0C4DR_N&8A."S6P\0P*4]Z?QS(C6!A38$W$;VQQQ*CY7[7%EJ,)U
M\<?:<OSQPW$./[P4?7&2G:5[0F;K-V=D/C\>RMPB 9+L(-XZ6621HJ2CE^VL
M+B]&7]CY47F(0F!O[4$ \#2=$-0+P._,P0XXW1"'QV37^+K4WFCP'QS?Y)UB
M0=;'E,UB.-&D C#KRM<4KK3%/7.Q-V-RSZ-']A+#8UB#\]$7$MRJH^Z;/ QD
MMN($FH8?8I(\:V:,0^#J_#6F7KX7=K>T:_2_2GJ_[=?#4[,XS]]+*GOB=RKF
MB,(I?6-T3R'$S/!&,&7M@<K"S,=4\$WLD5X4E.&:9^^;_3GCF!\=/SZ^8_N6
M2HG@3@9^P(UF2S5;> 52;C;&^@TYW=-:#(YFYS4*6(%FL>PFM?'X+;5/@Z^E
MW=[=__[QVG,YB%=LN)/RDAWT#DS,S)Y7')\UQR%V;WR.N.).:9:G&ZL!HA+Q
M+P+6E&1/8$;3&;!KRDS8O(SW:D<=)9Y>XE$;VC;.':\RS]3WX(1/K;:.-]67
M+29^M@(\/I\U?>/&?HT"FQ%J:^;,]%.RCJ;<0FTA_9.LU+XU7&S.]^(.A.5)
MLEG9D(,;OP-QV;(RIJ %6057*!*MFBV5O'L]UL.!&_WM8Z#F4C* 18P;$Z_+
M@XY]_JC?+>+DUXO8$G/(V-W+.#QI[3?(ZG%G)9GNPX0N_V..N_7GS_'T=&IZ
M3QRGEHHZ-LJ4-.YMM7]\(-JZ?%>:+=6V%'@QS8U8B%LA 9LM9&<DKE%LQIB0
MX*M K-/[XY%=T_R\4>,^C,;-<YUL-F74W#MSHT\4:'_:0S+@.1YYHIB?VCAH
MMQNTB7N(OV83?RWA\UP%8FS\'XRCKW&KY$_.V&&K&D[?Z50KH1\'(@UR/R/=
M,L&U5<X'5# $IC'CD!H9^D+L@/U%_^$165E>9]GG+8@\U%VYD&@3\ FPBJ_$
MM!_2)Q1D,-F7T](BKS[HI/$2B0WEF&>FV.>!>^%2B#='FX@$V.%%H37Y [9Y
MT0QO/R$'0UKM+\^NJ;-KN+1]5GWMLZT"427\<N1@X7%T"X%&A:"FZX@&F!SX
MI9IDS*Q[\)EV0_4KK>TYX7<CN]I=?,.02L<YI:).P@0%?M:MS[%-G]QO"#/'
M\DI&OVLA%% BUWK)NT7SN!ZQ_F2_VTKKD9>5+-DZ^ *K%DQ_1;LVZ<WQ%M3+
MM/5Z[U2/FLE$@8^<I,6(BJW^RL)1_/7U)@,VVN:"5'67FO%&I[,T5:X*S4V'
M).LXP,[N"*FD)#@E>H$<8PE+T,!Y'++R[ZYW]#<]$X'\E;,R#/*O9#$ ^]Y_
MC;[6#5\\ ^-:13")2OD*W?3IT1J%?*RS&],8.1%8YL6USWTV*!DQ@;"#;)"7
MH9\P"6AM#B7_2A$?*]/.@:J SBHPTGFA+*>YA8[) EA!'Z4AZ'>_$V1J\549
M])J4XMAF?&@O3RVLPG9QB8NXX;NROW[9T54>;YT5>)]%=^!QF-:) Y,^Y= M
MI '>D?DU01J[\ZSS:_W8):.0T_.#_O+)^?_QWM,6C[[?B-U_6<5CK/=1IL9]
MF5/VZNTY$_J@5. YWCATDN"(Z^TM&5V?%53['/DRPGZ+@GTWDZ[_SX=FNSAT
M@%L&(Y[6+.7NAX%+M8EF-C67E2I3U!+O];,O+;"L3]/[7<)G=*1?DK=!S@Y7
M5&]QZBE=B)5^K2'9<&[I&L7JM7_%-YN4C"PZX@!%G-Z3@XDYC_;B:8Z5XAG4
MJ<WT*=LMFV3>&MWO=TE O_CD_A+>>P_!B]SM09P>_[:,,Z\TKF#?2/[.D?+0
M?$UV&8PPM\QSZ%!DFH,P>3(Z1$1)MF+[W:Z..XFNY7FH$U?6'P)*>'+T%(JW
MQ4[U?S+5@%D==GR.J3*G^$0"'D''((4+>U0-R%3HK"=<DZP6'Y,]0T 4BO_A
M1@+.-%_"MW587.&TJ<EL<;1[Z*6X[)@;6<C>J5/.+M<!>!^<OUO! '#P[R'3
MF@7@-YMPZ47-M%BG@_5%Q"7[K-47WT?T"-L\_7Z(4*0MCJPJS6NP4:71,2P]
MZC[BT3]+O[ZK/MG7%NV_O]LI;]-XIT7Y/$XFX%)M[9"B&-W^G3-Y<QN?;5_
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MI:/ZMT8KKCT=[%*Y<?&VRRDP@7;<7VDQ'/G(^6)>FJ.C\*8KOSB_\[50D?,
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M=VUTXX,>T[H5')YS=BC5. Y.C>O++9Q<L>#$;#J).F==LN-=4=MZR%/VLD8
M= +L3I:!T]^NY?Y1M=L 9( M"8AYA9B&]C4?_H</_LJO(!71KUP?<;]V2'YY
M1_Y4SWOY0,U,J@/,*\^>5N.ITSCA<:75XGH*_COGSMT,S0;??NG#X+#N #X
MF2$P_$2U9A/\=MG]5=A9Q8;+AG?+JW2,8^E57;ZT4ZTW@@NN4:RA3L#-/.9B
M3K#O4G.:]<K#*BK+QNR9@&*FU4#-YDE,3L65RS8/BTYI"P T.-A8?:L=7+($
M5A_+TC&(YO59L] B <TXO'$:W R?Y#M7ZKYT\T.=YX["?3IM;L< ET\S#98%
M73,O.L%W5"":>O.;ITW['J6TC]_LDA7:JY0]G,&9L7(FA!0Z[T4I[XUO\*9;
M-Q9?(#Z,A4G;0RK0854\O H]I1I]G7-WZ1,_"DF*>H/X-C+R'$)K&G$"K22
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MM<3DS)T;J*'N3_75<72'3H:HT6;>C\F.5.WWMO4HMG>.JCR":P^RX0G0L [
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MDD_?)BIL)IZ3*J;+.()@2K8]^7/@0SSDD!*#J5?.SW?@O,MV> NG9RD*+[S
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M8Q;#3ZL:7&XY0JP?*__DH?@9Z7>.=U_]V7X&HR*;)44BC-G^5J8MPV1)*0F
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MS$Z:O764^XF4O^!FJ?4U:Q"=GU9'>@UCO:EEA?,-I6GZ 3NJ#@)M5J4E?B0
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MD;U >P(KZTKSFBF&1%8780Q$NDG\RM##KRER@L_%?Y@,KW_24,(OT(U_A6-
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MZ"PI7;+\2U_H7Z<O]+_4'DOIB1@8]+F*\#.*E$4J]3)2I?;KGAW6@\S.A/I
M<#V_1HIB]M,%2RYPZC!/%3G%^'N-/?LOCG@@)$Z!N+#1QK7Y4^ 44&?_VR$.
MTM_E92I$CI'B)S%<XO^ZX?+?UO08K'"/6MVG)9$76L:0$S?DWQ^'2X=W)DZ)
M)9\"%Y8NY5?\Z[1/_A=:WL'!UY4:UYZ3;B;_"=XD%8H[3\ZF*/I7IU(@-/H1
MKA)3AAH3;][G%5[M8YX*B#[?K/B.;.R_+A'JBUSX59YZ=$+B.5*?H_Y8P@N
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M05=-WKT_^? "Z#LWVX(CA:@,AEO1\!2X).\SYN,X8G9G)_6*W=7QW2Z3F4+
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M.[0T!A\AVRA_WAW<>9C4:Z0_>&?TVE.AS.B?WHJPWGHY(MMOE;]T_V,B(0N
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M'[6ENI[+E:#]D0QQ,-9EV/:ME=2] Q9B$!_Y.CB,64\VN%7!9Z)?Y,,DR\6
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MC(>U?3X#7EZ/WXA\#<OW,<!K4GN\)GUVA)>[1GHA?SSZSM6Y?RF<]NDSX#8
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M%ZIL!&OK&)TP&U4I)E"WE1,?6VK_^L6_MRJ3PJPJ\+S?78%!:: 4R*307A@
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M% X@Y?XB$D/J3]%5G__'V?O/0:-V"*&" YEC6]!E%EO:IUZ E Y?(Y%R<^J
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MX5 9KFX\>Z@N<*5863 S*\*F#46_T7(#PSB_R?IZ8\U< _RQ[ZM'U',G8-<
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M] SN;KNJC[?)ORY\Y4-I66G&__$":-$H.@#T=,WGIGXJVS35AT[1.UFG*D=
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M("EBG7V?ER1%ETQM7#HV?)!$J20!^51BA;VZ?+L>'/]B,;3R=<]5E2\]=1=
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M-O3%/F-D>[EQ?*LDKS?&;D2ZK:WM.:W?M(T=+/]7AXW=E0<P4JKE: K2 C9
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M#_D78GN"0-E<$:?YB_.1T,6[&//DLNM?S=*[7(I^/&KB\N4!+5N*>ATOT5X
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M_[8RF2G3IE:;%PS4=/<V2UGLY.2DY5$F)_XSQ)PPA3G\QPUK7?#:<6S'-:4
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M199J"5'\()U?A7W$FX5--Z4T#+XMKD,&VBB*QC+O:UM-OH0XBJNEC/KEUD8
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M;%FT%*AB#?*A77+#I[HO/AGJ/I!_X3?R@/Q2=M]R2&-?1T1C17$Y+[(IQ:8
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M5E,3MZ]?]U3S1Z6<IPD>SZ<D9&H8KP+H,F](0]^HB@T1/TU^K&W4&V4WREA
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M3ATNF&FUP+6>'Z-&F0*'-VYUOOS[XOH_ZYQV9P(2GV2 &%H%'YR%+5W;+WI
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MYHI],HYKC=N$U(8R0SCWNZ; ^'A]$C!1^5L#XT$O>?4E3,'.@^LFK@_WUZK
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M#,7HT%FL;//-!E[JVGY^N[(8\9$UMX5.+PJP<AP)\!Z"0B7PKECNFG/8:E3
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M['UG5)/;NNY'D2@@$:6WJ*"@B"A5:0$+1:2)]"8" B*]2$\ *5(%!!24($5
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MMS>1/W^P]1]=2NA/;=8TY%]BV2%/RY]5HM$$P7\5L8(4.2JR#34:J5MNQY
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M?&5(P#NRGN9W@.+GGFYI@BA( *TJ>OZ0;FI/VID$('\4L3V'W20&KQ/>EI,
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M ,8/6TCN(P,09XKA-=,[4H9U:2>0FK?)P+*V62GN@*3M2P;V#D [T@MDH&R
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M.D6Z,<T4)Q^)MH$JEZ0FL/[C>A@VX0YN&.Y@P]?ZF*%J0_^R^<QKIGI'5+[
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M)DQHZX8_>30LS#A25ZO*Z1_"O3?_<V6@IG\CJP?-^YLSV#)  !Y$"?N=S,@
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M&H,/Q('N84^]+YN\4HW\R.SP*BKH J\VN"5+&78-W4,XZ(!PVR4S=1>JP*G
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MKCU\Y&6+$J8OY7S@\H9) RSO@.2%SJ.FKGP;(0E(G:^4^7#%FM-P0C(^X(H
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MXTG\J_0KK!(*B2^5FU=%YQ!<>+T'6-GPI:\IEEJCMX4_H?0DE(A%H/QYE=
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M?; \SZ=[F/JKOM0#I+)WJ@;?\T.KVF8QN&8KR;>^#[;1::VG.K-P)\S#MV,
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MD.WJXDO5X$M(N%]_#N.,@#"M7=<9+0UP<><]O1_H9;ZOZD2M"NPHC-U3 9S
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M=KL:5B+F)63E?"%T!@/%C !N!."748GY9<0?A/QZ^Y_C.6;@F(%C!HX9(&F
M^6BA]/I#W&3/H3D3>D2R/H>S++[) %QA AB*N0+:%@B*J''LGS@=[=Y_-TA6
MGZGH^ZKT+F39Q!1VJ.1YNT6EH39"9S3R]>[FS8!/$>2Y\1*']>\-4GW &.=,
MK#)^ C]251_R0TDM:== Y2L!D+@R58!K6OWNKT@ CO7<L;8_9N&8A6,6CEDX
M9N&8A?_'6+CNA59K8K@_Q>,9WUJBV@AT),1\?#;SNXFEQ]3_ XE@L;=*=.-\
M6LQ[J1=MS@T=$P00]:28M!NHD=W*@Z\?*>+[.7@D+O(Z4Y3$]!J4_^[?;B!
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M@AP Z2#@SY:8F?3O@>#_%K8GU+D#AK,WEQN]+/\R\<1#XPR3A&HHTQ?G1(H
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MQOE[<&QZS_DKYE8Z1J3R$H"7=HBO'R4=RY>0?EV4)T\N=_+Y,CMCA:I@[PB
M#?T3>[MV.;.@IRZ\QA0B; 2 <3.N#+J1TK WD7XR:=<5M3R.E8?.G4A@,--<
M:%8G *]MO\7D,4!FF09\O(@6NR'QAQE1%JP\KH&>M/F"\6AY[AY#26.D7.0
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MVW]@RLC_J(>\=3ZDT9'%&//ZNQ?[[4-) \USKVX[Z5Y2H+.6A7U:22>MZN?
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M:B\7)B]=+"0Q8,]+G)5>;T!@7^-04^F6="NG+0,-F5-P3]AY! 7=T962PDO
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M!?F=\_M.WU&YB YS%PPH_\[X9)^1#<J1F>B)Y\7,/8NQ^*WS9NH(*?J'SGO
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M3!F9K>YQMV$IG+[].'U!?T1@C\NDULPD 3KWMA=_M3K!^PKVNBJ%P,^5-Y?
ME3DQT/K7LT$0<3Y^6.K+;_HG@S9+S.<GCLQJ7@R?4 >B>]-5N,^(INUYS0N2
M"?%T3P&T2>"Z6B@[^>SL[=X^2:L$S=QY%=!FR'9F^)WPC&@%+M^"G#10!>#)
MDP;O;LN&3\R:G-U$U.4'5F*ABWQJ6,0;]!D_1H7[L>W=^S?9(K\U0BG?U84
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M_4'DA%->6_%A*809VQ.%W5=5TL*Z-.*/:9^PE8VKV!N;6GO_="E9'+=%;F3
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M !$   !T8W)T+3(P,C(P.3,P+FAT;>R]>W?;.)(W_/]^"K[9G7VZSVLXQ)6
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M_^FO_N+K>#X'G8OS A3<@]B>86:% O"@F&2(80]LSYR&-5)%X*30W/'EF2Z
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M0%]'OCXOK;\.A@ZK"SV:7O0%OZ+?_S[L1TQWTH*K)2EY68U&VLSE8_^D]NV
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M":#J0FPKK9#Q! 2.\2 IX8X-3\PV?O-O3<A0V)PSX1'5/D9)X"\3! ?H1;G
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M1P=Q4LA8%X9$*!1BG.=(F<(CS'.A21".\<'9JK7%*]?CK8!_8CP5 5GM3#S
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MZ110R@01 %TI;X,0Q)M-EZ1UN'*X/Z?!4JL*X3S*O><Q.1$HY&/817GG)&%
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MP-8&^,]@"_!O*Q-Z5XUC_J5WWT)CB[P0N2(Y0RX6>C&C8F&^"@@,C2YRS#C
MBJ$1[QL[4AP[&9M?:^2,DHA1QI&BKD A%\[G*G#J!A=@;@_*71B(/_OJI-:3
MT]+JT9*<_:6:-=-JW-6GKM(J]-B]0KJ"JB XDE+E@+0EZ+J@)9"&6%)(Z6@^
MV(C2X$HBY<-*6F\.?5PBL2-,2 ?J+O9Y%CI'FI. I!5!<:)=* :[A_ID$<%[
M9_2%).+W8W\, W_V8WMZINO?KR<1K\S)ZBU]F&EC0*TRA!FXYXPS'V&?0[S@
M1@C%&/PQ5 9Y.=)-\S[,=US>UX>Q)<5RRM^YF5];]8GRZSER@#M'B>4Y<HP1
MQ+#52&EE$"!YHPH2<LL'=RCCX+RI 02.&36!4-#*0E /#H6TX(1QBJ@4FFHI
M\("]XF%5>]R=;+=L-=Q\R'W<M!EVX6;C#/ZP%-R;0Q^EB)0L7.RX2V/$@"F.
M@8&#0J)0S@JFC*&#-2)#J#CKJ]1[-BX[DOSZVZ]'KV*N9U<H<[GVKCR'-5L>
M_FYVYFL]K2Y7\*S++_FI;"I8Z6(/;K1XVN+2XO.MOX]?OO+CZJP<WW;;^>+$
M635?NN^U6SR_/ONE8;>\^62V],+7'QLO?>FAM]RM^5>8?G:WV;3>BQ?^Z+W:
MM[YC;O<OR>U4_NQV#R0<?"@_[<$CJUEM?=-]//7:M3P,2_W3OV79#Y.LF5Z,
M0"@CFZ%R' 5N+]_-__0B .NAIOQ?OX?A\V3Z K3<23E&TVJRUWTQ L.-3GT$
M97MX%_/N)T&?E:.+O:@<F^R=_Y@=5F=ZO/BUJ:;3ZFQ^@_:9>E2>C/=&/DQ?
MP*LV$SU>3,E6HZK>JT^,_B[?B?^'OW_Q\;2<>@2CK-^;U!Y]!#^\>^[';B+C
M6/$W^GSVRW/[SW_-JNF+&S/LOMS)&I# \ )8$WTLW?1T+Y13U(KA.$XP^^%Y
MG.)/__GO6.0O?G@^&?PJWKUBW;3Z7)TO+XZI:F"^]M7)+N&3:>:JF1GY%Q/M
M'("_]@J^>J>-6D?Q=.NXYL4!B#7U]<WE,=K^?E)7L[%#G\EM_OV+KY)E4XW<
M\LO)/M?XUW<'QZ]?94?'^\>OC^8+GI9Z)4M]]/KEKX<'QP>OC[+]=Z^RU__]
M\B_[[_[\.GOY_I=?#HZ.#MZ_2^M_8_U)G^O_=]V<@GZ=5N.=[-7NR]V,Y)RI
MN]9\OB91!^ZQ=M$_H\)"8<_7;<F&W$$:\EC2\/8&<PMR2:YH0YIJ5+K%Z+J]
M]]*LOT3'>S0Z':A&%UO$YKVJF3< _1;X[-J;//:!L#" G<?5N'6&2MN"\S>_
M,4:4"32'.\6]$TPMDH)Y5##EJ \YE58\R^8NW*$/;8)$])9Y'I"DHHAGL5FD
M<"SG-Y)[8S&GN'B6C77TDV/KFE>5G2VB#YM.'YRCOUTJG6L+^E/219NIBUA\
M[95#[R?@]%X9_;M?=/U[]G[LO[_!UU,-[LX-=RC.$?AW+W_17D4C?5'-IG#'
M3]Z]Z.Z.\Y80\Q_8&/>9-'ZO\1-=ZZF')\+-X>[UXM;G95.:MDG WF+T?!",
M<I<\U]Z<[BHE_]2RQ=3=,4:!S<G)M4'P1WWSL0L6Z(CZ^0/OH>-'>#]D:J]_
MWVO_%\4O;J?D0NA;Q0"/P^7XQ;FOIW%'?LY(P)Z7PSI1G(^#E[B+V>_1'+<!
MS+QW;G]LZ.(N:U5@QSDG8'2\0HSD!=B@G"!:>*R(%DKEH2]K];>9KD')C2X.
M_:2JI\^RM@_3],=GY:<H>=7(Z_&TGJW#HO4:#?K/?U<%$R_N-VJWRE82AX$H
M_WZ9XF^_[A\>OSY\^X_L\/6']X?'V8=?#X]^W7]WG!V_S\ 5/@9_-\,T>W^8
M8?Z=^SY[_R8[_LOK;,E+OO20]U\>Q\M8478;-RV4,/P;;4=R*OJG)C@5V?34
M9_]:J+2LVZ+)/*RLN\_=Z%.!&X=!A5..%.$,,>XQ,MZI>#@4CIMF,J=Y7PJ\
MZVOTNMLRO*Z^7=Q.@X><.GUQX77MQYM.XB,_F7;;AS3?>4J*2F]U@6,#^YC!
MQ>(A4E([BXQ36HI<%5@5?5'T3=F ,?@'$.P-?--L.LUB%MU]9O=A+F92DWW0
MX_UA<G6V"=O=QN@;X^KH'#O,-?@V.;/Q!$6!#"L8<H83(IW,)<:]!>9BJX'V
MP( O^#I!CYKM<';8M^KL/(U ;!Q3'!_NOSLZ:%V:Y.W\T:ANOZ1(6TRK9_>8
M)5@V,<$P>U,"O@'M!W[#WE,Z#;FP@OC"(^*CT\!#@:2+K?.LXL9PX8PUCS5N
MK]M<QOB&W0MN.MGR'"-*<RK3]M-6;3\]5<;'U1P(ZU&4.?:.N7@4H3$*,2D+
M9*B2R%NA,0U&A%SV(\J'_J0](V<\?0=7GEZ<OV[9[N*@_9&>C:LF.S[U\%P_
M ^C7[&0'8[N[2M]_F]*+>M6NW[W^I.VTY;FL"EE]R6N9;K)FXFW,X'=9.<[*
M:9/9TS:0>G-K=-@Z-T\Z]QO+MKT6OUKF23V;5B_Z"VA=XYSVWH\*<?'V:5^,
M<'TV9+WQK1NN>\<DMWOOM_#,8+8N[P,.O?H 5%J9QW/NI2?@ ]@@D;;<(H^9
M4( +C/"/#G!UP"'V.:HG\X;R;2G52R#ZM+YX6;GK&T.H\3;6HTW]I*[.XWTV
M?V?HE1_ICSK6%*TYYI6$Y(\+B0(IT-X:I(T&(1'@ VJ54V04P3G(@&/>]R,D
MQ_K3P;Q2L6L#MAU>LXQ- PHNV+T[;;<$Z6XQ)L4VV))B75+R!.Q3].H5M-8B
MJ^JLBLT-LW_.ZK)Q9=N4&=R$9=Y9V\(7?!M7OERVV2T!ZA,]+O^W_?S]5AFM
M)(T/E<:#W</=H]UL?EAB_8.IL^<_7;=:V;MJ]U;V^$,. KQZO,./S\BSC62I
MSW$0?2I%LZH= R.*@!E%N<<>,1F[QAO/D.)YD0='K' ]>0O[SM6^:>;_O(45
MPQL/@G*:9Z]'V6%994?3VOOI \#0^@#W6AD-H*)B03!48!L+HI1&RGN''&6!
M,<T(7.V5T5["G^_KX^KCQGN:\]Z!]_#61K_BDZ96!BYSQ@1%'BN#@/DD4D$H
MA!76BAN9Y[0GYV_.BBW:?5]_J*MSP%\;G^QS_-_;S(I/FN0+EI=1;2+_ 2<"
M[R&I"$6.>QK;"7-?]+3)-^?$#U4SU:/_*2=MB&[#*544.6=;8'$W;N&_>T(1
MP7EN<D?CB3>2QH;;%)G8Y[#("ZY]R D)^K$B$J'"/G@7VR 4E(EMUL[?/Z5Z
MMAX+'D] I['%.Q,%19H6%AE&M,X+ZXI 'LM[\72(T8?3:KPEZ524<\1RI?K2
MRRF*\U"E/#?Q.QE@S-$L!CVR_RTGP)[.[V1Z[+*I'_E)Y+1LW++:\D@-ZF\^
M]%J:QO]ILDD-P\J)'F7^D[>S:7D>4SE":7WS_>:0\YZD@5Y)\5G2P,/2E%-V
MRUJS6_@NI?2^EA9/D=^R"LWS6>M#U6^5I)W5Y;2$7W:JP]?>99-9W<QBJM>T
MRF!$&T;&Y#OS?50QL6YVWT[W;C/G WS#;*!I@E^1']5KNN7]^5%#J>\K=I42
M]Z0_X<_J^VX9P^_-HGK(;=C-VWQA(T6N:7/\;JW_M1LH<HO17*]M@H[+Z:C-
MF/7:GF8V'G:P[LW9.[DA:Q]$.-]9_#=NLWV_>4QRC^+LE<!W8\1!T'3SB+=Q
M$E[K".7_L >5%OBAH/3B#&[_7;/VK):D.)/B'##Q-DVNW\UKB5IDY#_9TWCZ
M3 :^)<P*OKER0/]@NI)Z:I0=.Q%L<D;V5SG8=U8NLX*:0B-M'45,2XJT$PH%
MKPOMM7*./KI?[CQ*<8&):>'UQH==NG-ILO9@FH&6(7PM?ZN!FK)>Z3<,4Y94
MT+R'7EYX98-'$A8-,5](I -QB!8"%U@6FCY^IWD.^CMHNO'ZY_CEX7'2.TGO
M)+WS*.A#?,&"# A3I6,*MD92AH $MB'/#5,R[PWZO)[#Y;;3PV<5FA%,/UEQ
MYHI5TZG/WNG&Z7]U\"B+;=?]-'O[]N57%*S=VU7J 7N'_?=-VHZ]PX.QBS4F
M/C,7F3WU0*IX9"8X<[XM#8O[A$M=([[#WV>GNLE".?(NTZ,17(RM]>+&X[]F
M9=QVG%:9\?,!<,_+G4<:RYVZ/F/S_<>E;<N%8,0]R7@Y]AG+'%P=G[1#86&L
M;S,E,,G:%K=-]AW<#T0H:V;@=C:G56Q=L>@ /#W5TYMS_ZBOSS).L?OQ_!V^
M[_(TOB/=.QH01+AN_@EO$,>W0^%'<1;S^[3'BK:3:">IFVFF\LSIBV8W:]7Y
M%Y.E^M1B-J?"$EH@Q;A#3#F&%,D=XEQA0;7RWCZZ7VV7ROIR5M?PVEU+Q0BF
MIGKZ)$UK5RL'__#-FA/W5KR#GLT[XD>^?%?-/R[UC$RI&>M7KU'M@,8Y*Z=3
MT%%^!)JGKL81NXTN,@\X[B([B,A(VS8-[)6>ZJ[9W0WM>W6/Y220PQF,9#F/
M"O;0G\Q&76GA$3I>M:KMYG.I07WS_5/K1RR\M4X6R!$;]:.D2!(J40@T&"*<
M58[WU9;CDD"1/G-UN?&,G/1CTH]KUX]ED^EL!.OB,VTMZ,>8F.1:E5)'\';K
MMQGP*KKE0@.O!7_,T5]4>+8Z@\6\V(E(%6X&\"Y2X"2#)?TX/5U<W@7@ZMN9
M.1_*<=M@NHDZ]>Z)_8&'MQ#TCB?'/FVM$L?$(+* T<O8>3?ER6U]'S&*'] K
M_R$Y< 3&T/O&*'@8NV?0"F?4_X;A\HG6\WX$C]M#?%0W\R<(>&Z'H7C;*M?]
M)4T:@6_]R$!W8H9AYWL_+D:>J+N1HOXY\D[$3Z*=J+L%HIWL=Q+R1-TM%_(O
MV.]M=^?6?S!UGT'S0DN3%X&BPEF*6!$,DIP+Y 0W.5;6<-SC>3;U2S +)U5]
M<4MF1#NH#9W9^: M2))X5XW1W0:QUX2N84E)LI/)3B8[^=D1]8GX2;03=;="
MM(_FVWN765+9RVX++PE[$O8-H>YV^3(XB.!CY\*<,0:^C")(Y98AHW-."!42
M:-./+]/*_L^S!I:I:3[W9>*YTP9&5%-3?=IX17<3PSSJ%)*M" &L22EN7 %+
MHEJB6J):HEJB6J+:5OE^KQ?)FW_NDC>3YY=$>!A4VRZ/C@B#@_,4,8D5>'0Y
M05+D O&@>.YU\-2Q?CRZA41W CV7YVN>7>O5>3T.>M1L?F.3FQNX/5;JIMSS
MQ]61/,WR;![+'H0O5&S$3NNWEIF4X;8*O+;NSKML7+5E<[.FJ_: )?- )Y?%
MD4U;]K&H@8NU<?%9HXOX\(\E/#J6:XSA':I8XW%>-FWIQUB/;:E'L2 D'M4<
M!S=3/7:Z=K'1>W5>NKL:-]/O]/>W5GRD0J6A%BHUIWXTNJS=^0XXJRT8 @K?
M6\<SKX_\!\QS0=]%7=K3U4P:29V/QW/EE@LPE@YPBR<<$6.\$#9W5.0]A4SC
M2GTC=O4AP=(DP"M(/6UK]-Y5YSX>OI&IG8SDA.RTHM<=R!&O5[-IJY%;U7RJ
M:]\LQ//:H1RV:_W6Q-XF.]E_P)+E.)OH.CO7HYG?:0N@5R"HF[?J<\7RIJV(
MAA6;)Y8)(6U@#FEN/&(YL4@2(5$!%PPUN93^LV-/56Z%L:!4L,&@67).D2R(
M1 8KY@I#3$'X+=TJ6D*U/6B.6G*^OR+PLVPV+KO;__I;1^QGH*)M">O1_/CL
MX-V;Z[H(N,15T_F 9S\1+':P)#MY/(3]^FMN2TUTMR@/+RK]P^>C] 1GK[>#
M);LD]H-UU0Q<D4=Z F(]GL!FN$F;M#@W9_H47>/Z/=IKV[CG"5;G]'*'>:)/
M?!=U0SH )??TZ*.^:%X\RYX/?AW[L0RK.:9UF-RX)0=]'GUX_?)@_VWV[OWQ
MZ^SP]9_W#U\=O/MS]N;]X=_A3_3V_?N_QL]'Q_O'KW]Y_>[XJ+?3G)[FB-^-
MX)KU:[&AK,_:_,">S\\^+9OL;S,=FUB-+N8IFK&!_1MX;H9S]+>V <S-$3NM
M/Z++<=OP[Z.N'1I5U>_S&-YTW@OP>I G^HT?ZO(\QHV6NAV^A7].NN9;X'W$
MIUZV/51\)]X#O)@8:MR-<[KS4;5O.S N?36?X>+AM[UGVZXK_C1&-V'$M*KC
M%E,6P'/I^A_"3YOJS&=6-S!7"[0V'ORV6(,3RJZI(]SQK.G:>>EF+_O/?_]$
M<FQ?@&]<QJ,JIWZG^\J]N+QF_*CTY[=<\,T4_*G;?N(_33Q,ZK/O8<4\3.Z6
M*V6DL?O\^S-]\?F7DY$>W_)M7?WSUJ=.8P.*6[[_6(Y&EU_&]:O:@&#<U6OF
MYW[&Q0+J-B6PKJZS,Z_'0,O=WK3U$]GZQ^FC+6K VK<^\HV_*=A&QQT#4!!P
M&X"N\4+'9.H%R&374RYK92IT7*:;9G8VZ7I1M5PX!D'NHA=1S\Q_ GI GVO@
MPMCY:%HMW7TW^VP>Y?B\&IW[K"Z;WYN=;#:VOH[JI=5A5YP>-4=5-YUF 4D#
ME1&W3.#;F8[]89O9: H_'X'TCUHY:)OCE=.+G;A]TDX1[MSVW+*G44=T3^\Z
M&4;-4)=M_T-7AN#;]PYU==;JUN4W!&T1S]^-JU9GY=EDM-!5[6O=K;)WL_W1
M]+2:G9QF'WTV5U-770T[):2[A:U]F.\-1279=C/\LGX&AZ.IQG&U=^+=867:
MN5Y4L\LG?('V\4C@,U..NQ>$E8M+W2W]8M&OZ/K[N/HXCB\\FQ-G5F=S9;9H
M4!;?)\RFLSJ>2&RJV71^9DL[LW$T"+#B<R)_T?3<:5VZ$XWA]F9V965&H/>F
M;2/(G6NO&F>PP@-(5ZL$77E^6^LPMLN)O.7D8%<V8&\N]H!_/CU *_YS!E8Q
M7"R>W_X,P=K5TQ>M[D.P&&?-7N24^-M;->75F\"D:/&GK5.=UQ;Y<H7+<;N:
M[4)_\;DWK<T7UGQY*0M.<"$%4X06K"#\3^W&SJ>XF7"YL[/$'->GM?%K_NRG
MJ%=TUZLNZNA:ETW;<#9&U:?MYK9S[>8X_&GUI)S"OS NWJ <SWR+;K.3JFMY
M&$W*> >4TD)A 2:+\+6:Q)KH2V-6^PG8E3C ?P+(&G\;Z6Y J\0BBQ=7P@DK
M/__?)*2#8)@DI.L0TH53U1X(#D8\2DPG/A,_!K=NI\UJ 4@ ?M3I3@:#VQ%A
M#@_:K[.Q]W,7YLJQ<Y<RO=P"/PG@<)DA"> Z!+!K#PP>3S6)$M*E%K2 W,WL
M-,)M5[HHH#MSS'P#85^);>?G@$5M[>%"5G?BK4ZBPS,WD*V7=?48;V$AV\!.
M,X6;Q^=<?C.-#M7E[[RN8Q@'/BS/M[V[/DN2/6 N2Y(] /RKW7D7OKA5ND%Z
MZS:T<*[KL@+/'-;SI,LI6I*VG<PW$V^[,,?B%Y/RO(IVMM'!3^=MP4,  ;87
M<PE.LCE</DFRN2ZK&Z.577 MYEO/K5WFXE$I,3@9 U+-;#*/5L7@XAG(EAY=
M-.5EC.R\7 CXG68[R=YP^2#)WKKLXE*P_ :"O<V*)>':0$(GX5J785LX?HVM
M)NUVV:C\'1CQM*I<%*6Z.]&KJB_FAQ3.0S>36%<4_;W+7;-?=X_B[D[EV@&O
MZME)MN_@WFUZ>^=DPMW?O-IO_XUA'OA]N^]6U?"VX^5' 9H=V[@?&$N@[L#
M[7X57.XVF^:E6#&VF^1\N#R7Y'P SN6HM#%<N[RE$C'K*&Y"Q\UU$+:)KV%L
M[>-A?M'65G=)X5S\R]K%0I7+/?QV:R96+G9EB]?V6"X??U+[%.@=.O<DB1V
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MPHCS[6:X/.=VI@L"76LY<=E1 ?S0Z&_.NTW'_+[8N[9J8IU98^O2>#=W*S\
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M[5;3U:-=]J.H?>S*'YV$^:E2,6^D[>,_/VWJJ@9S/@!^MT@(:>9%G:'6X"W
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M:S#Z1)B2J4%N_OWA7L-#$J%O50$.G08)0R0,L6Y*)0SQS6,(RY4.1N7(*U,
M'@ T80+GB*F"YEP(R9CK(R[U5!@"[P@A$HK83A7X)#E'=)5A+9K"6CURRG$U
MU:-^(EAI%W.@Z#/M%&P:!=(NYM:BQ8(P20LK$9.>(&:]1(K['$F"/1;!!B=Z
M23[J'Q<"JN(Y3]N722EM) V2O1XD6;:" LE>;ZV]5E1A&6R.A(_1'2P8DMA:
ME!MCA?/**M)+05C_]KJ0.Y*F=*/-4$HIW2C%9:ZG&U436/N+-LTH=GZ>G,&%
MG6SLIRG!:+O@7JJRW30*)+BWM7"/V)PK33ERO!"(*4:1,L8@9JW%JF#<%)]M
MYGU=0E"GWS^,]'BZ/W:O%RK^G>\'_:F=G.>#W,4;DC!\JRIJZ#1(UGN09-D*
M"B3KO;76.]>%]I@SQ)T&ZTU5@:3T#H5"%X$R(\$B]Y.*LV+KC?,=Q7J+W20=
MM2FQF]3'9PMB-X?Q(:@*:-;X+J4F9=1L%^A+P?!-HT "?5L+^CS'1/D@D%2:
M(":\@K^P15R27 =MB_SSEHU?$[)Y#Y!/3\OQR5NO&]\J^??AU\:W.W<]M?4A
M+)VRE7349M(@F>]!DF4K*)#,]]::;Z?!\G*L4"ZI04R+',PW_(\GP3*O J.L
MEYC-ZLTWVV&DMRV7I*,V)6:3\FVV(&;SRD^JIDS=>[8-ZJ70]Z91($&]K85Z
MG!G#M"P X,7:)V$"TJ(HD*."26XQ<_*S#HY?$ZE9*/,NI_I=-;8]IE4SDK;E
MDF[:2!HDLSU(LFP%!9+9WEJS'3@.-!02&6L\8DH1I'*N$:84>ZZ#SJGM(T*3
MS';232F;)D5FKG-*V^4J [E%J4O--D.^7@/>J4?B@"B5>B1^\Q 2A\))3CV2
M-$)(HRS2O&#(6FX+9@PWXK--OJ_*T;EJB=@S?N3Y,+?V4D_$#51Y0Z=!0@T)
M-:R;4@DU?/.H(8A"4X(9(  N$<N] 01@'%+":5O88+CJY<2OU:$&,= &/ DU
M#"E.=7<&$5]EG(JG.%6/G-)U4DYG@&TCREQA%WNR2Z+R==7,C/R&X<ROD-(G
M%,C_&(84/IS<":IN@IZ_(XN=JY#GU".34X)802S2>7 (XUP$7^"0!]I?6^=^
ML&FQ0QD;Y*[HO3*3 .H0DSR&3H,$.!+@2( C 8YM !R&&!,$8(U<Y08Q$D\N
M-<(C$@2WOB#*D\].+OWZOM3]M"1D.U+T=H!$ AQ# QS+$;&$0+XQ!)((TQMA
M@ SQ^H_/R+.4I'T/'A@2W1*M$JV2\DO*+PE4HM50:;6RZHK^MJC73;ZGVH\V
MU<BMC />'NS_?/#VX/C@]5&V_^Y5=G3\_N5?__+^[:O7AT?_)WO]MU\/CO^1
M*BBVUSBF!EM#HENB5:)54GY)^26!2K0:*JU6EL^:/(.!;2C.#YG-1J4VY:B<
MEK[9&\;6]=")/1!138&RS52Q*5"6:)647U)^2: 2K09-J]2#*7D,RYRR;RW,
M=]ID$WVAS<BGG8--,YA/6%L\=+)L9Q)YBJ.EU/!%VX3@@\]]C@JK V*: "L8
MZA&U3I$<.VQP+\V6%E;A0V<47O;8-P'O*-E;:=HWI=VVPKXDPS]0PFRT:"3#
MGPS_5AM^ZBRA4DLD" ,CGIN E%(&Y2$/GGA)? B]U(2MTO!3(9/AWPC#G\Y0
M&Y:Q6K=26NPK3ZJZ54I5R$;5^ 2!$3D##6"F:9-YN]!C.@EATRB0P-_6@C_+
M*&5>6*0-<8BQX)&41"*K%36^""PO5!]1G[>@TH]!H[\"A=XG\B-D1_0'_9)J
MVC+5-'0:)*L]2+)L!062U=Y:JZUSP@5G#BGK*6(Z,/@+4Q24=]PZH15S?81L
M5F6UBQV9C/:&:*:4U9/B-3>R>NJ9=YG_-/'CQJ<3U;8,Z*7P]Z91( &]K05Z
MSA+,"0 ]SR1'K!  ]#RGJ* J<$R(4_2SLTR^,BDG*O6W5[5=_<(]4?36P3'I
MIRW33T.G03+=@R3+5E @F>ZM-=V46L^) >-+<@IF6%MD"#<H"(RYRJ7,#>XI
MK6:%IEOLY(5(IGLC]%/*K$F1FFO=W+QN_&6_AHN=;'Y&84JHV2[8M\*>]NDT
MVR%OX:73;+<?1DKB#==*(U?$[&P3)%(^6&2#"$+)7&+62UG6FW*LQ]:W-F.!
M)2_Z1)*<D4'N^*5#;3=0\PV=!@D\)/"P;DHE\/#-@X? %%C[X!$QSB+&"H&D
M%@H%RZ66OL@+_=GYHE\3@UHY>"B(2N!A.S7?D^07T55&K6B*6O7(*<?55(\6
MH:KE;J,IT6B[D&?:#=@T"J3=RJU%BE3+G+C"H-PIAY@J/-*J(#'6)&10H5#B
MLR8 7U4'MIIM2DIVI.@-(B;-M&6::>@T2$9[D&39"@HDH[VU1IL$*HT@#@F;
M,\0T\T@Y;!%1.0[4:9J[7L([*S+:6.SD#">CO1&:*247I3#-M>2BU*-GBV%>
MJJG=- HDF+>U,*\@I.!>%@A+X@&R"8$D-QA@7D%P4+G4H>B[1\^[:FP? _7^
MU]>5T\WI,V#_3R3'[,4@]^^&) 3?JFH:.@V2U1XD6;:" LEJ;ZW5-@RLHQ?
M ,QRL,"8(4.H14YHPH,UA2.Z[QX]C[7:GP=H",^3X=X([93Z]*0 S1>KOT"$
MT>,JP-*NW$"!7XI];QH%$O#;6N!7,!8XS0U2%O ;$]@AC5U 1!%MJ N.D-55
M;/6, ,D.I>E$K:2E-I,&R8 /DBQ;08%DP+?6@+O"::KS' DM!6)@L)'4/J"
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M-^R\J%GOAID#HS.J995%ZPB<(\QXM6N T(#0<&BE$!J.'AJDEEG3J"%'*PH
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MS\"<]Y0K%E4:I*;W=S[G!?+O?-P'?5)&"Q9;,[-6/AKP[]< Q@?\Q^ $M6N
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M-_]WLTPW[0H]X/'/M0L^GM:C@YX^6[LLDU!@>HUZ'RK+"-/KS>TS4Z:<&I+
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M8XVZVC5 0ZI2EDDH@(:$AH115UG4U:X!&E*5LDQ"@>D9$DYV7TQV!V$DET&
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MZ1D23G9?3'8G;:603( ,2H"0-(,1C(-W1OE( [=<79_LUHX'JEF&*(4"H5@
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M5BJVA;JONVZ3XO>;U7SYX9SNSIL2?D[\VY>]Z-/^7U=MUSVP1:'1<D8(-BW
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M9<%-R,H2MG-H_/#G2HF9M'1F29VG.]04 <>:EVK7 "V[2EFPY1YZ_J0]WYC
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MVDRM!A8R+V/,F, DYD!*(Q-+R1*KK@]).;>24\? ..U!L#*"]:(,3F/FOM^
MYI.G."3%-#>68B[L05AUXGKU,:W"O$M-FYMT>K9H/Z54/DX;_J=IS_H(O>]Q
M1UCC7RDA8AWLV!1 0IPL(8;,E%8N@Z!$%-H+"APQ# KF96I<YM'N=")4AKGD
MM06;>?E%FQ58IQ0H%8+AUCAO;M[C][KK-BE^OUG-EQ_.0>^\0>'VAV_/L_VE
M'\0'MBKDBL\HL5B\CTEKE!J@GU<IRR04F)Z?C]"/'[@$@5$WL:BK70,TI"IE
MF80"TS,D'&!>##!I\BS[)(&&9,LHTP1P/C.PU B?I2":[0PP[U,5]SL#S.WR
MP=?'E_?>(CXC?+ U!<Q;$\M;M6N EEZE+)-08'J6/D)+QC$F1MV8-$!#JE*6
M22@P/4/",>;E&-/10%A(P((/(,K0L@POJ03=G[.FE.8V[/09NT^9&XXQ,6]A
M$S*L6^NO_^?4K5?SL$[QHEK-_>I6\;[%:KB=H5+.PSK?L2F G#=9SHLZ\*"5
M!%/0#400' QC$9*UV203"=GEO,&+U3XG_NW+7O1I_Z^KMNL>6+!&9XK0&6,"
MMRA@ZAJE!NCJ5<HR"070U2?KZLDY+TT@H+TW((B0X*+6((6,.=! '4N/Z.K;
MV9N[F?J]9W#0TC%OC5(#M/0J99F$ M.S]!%:,IZ =QN:\.A"9(J!=JR@"1,)
MG+4<6(S&R.0]XSMH,G3QX@!H<I=#\I!1IG>$UWV/QT/(0<@YO"R34  AIP)S
MQVY_&'5CT@ -J4I9)J$ &A(:$D;=OHKXL/E<U7'XTBU#6BQ2;%:?R_E">WK:
M+L^K^K#WW+1X!<N?QZ8 \DH%>1)7"6Y;)1#*ZL"Y@NB] *%4 ,^= A$(IXPX
MQLEC%C#\?EGB#^TJIW+'[M1+[RZ+!(*2F> 2-Z/@4@&2#I).-;),0@$DG0H<
M'CLF8-2-20,TI"IEF80":$AH2!AUE45=[1J@(54IRR040$-"0\*HJRSJ:M<
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M-BAM[R<[!"[@4C93^%%_FNBJU:Z !3YT1T[X';?"I,<<RUFZ&D?)38!:=_9
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ML+82%1LJP;(#TP^Z46CXM[):2]4?*ZM]]2=X3OSD#-ZTJ<=C..GM+R2B"X@
M9OBJX3?+UAH7IJRFVKYXJ_7O@(=P'Z4"56XL>BK;^9F>+;_?%M>F[2O'E$+K
M"DBB)];D@87EP55MV:Q&"UP% @,E,\QL;W&#UMK:4LR2AX5SGB3R,F];W4^$
M:.'#UO0)"_#5N.2B')==V2?<P]/=E)U[$C"H>#&W*O#-M&EM/SO1AVZ6N<P
M0]8?W?VOIJ5"J(!'G[H4?GSXBPYNP1O5PDD*K;=[PN=_^H^8O3R].+/__A1<
M N26("H)8>$H&,:"\'IOYHMVL5@T$ORM[B4#EP>-?F!3 QP<Z70#1 &1NM8(
M.BSRT(ABVZF I8>G@\MAV@#(M*BGG14WMS 6T,PD"/V054J@!-5P[3O0$8'=
MN[!+8!4,7F8CD;F]?3O5ZF23E=M'[@T"KQJ^A\4"!3 S5B#Z8!)X,*Y;8-42
M!:IT53-ZXC*.*A"3,+:2BZ=5-8@^Y@ YLW6KD6<M>%Y8OQ-K$JEY>;EDA<#3
M*R>] H&;XBUUZVS1G/M-[VK#OR"3VA;DF"EB^Y/@M$7AO( 'TS<"9" .-[FF
MUQQ>:0*VYA.8VDZ#J?W#)O[WR61]-)[%7)K<%(0*6A"6,DZ*1"6$QRHL*"W2
M2(:[&MAP6JUV.#[MSGC3H*GZ!Q]/];V99.E2)EFR/9,L.[D_E>S I7@F67"=
M<6^M;.]7:U@WS6?RS+^-^:.$I7E<4"*2/",L8R'A4<9(G*=2I*(0441WP?S+
M';YWPN51?'+_9+T#Y_)@P-XK \:&Y9D#M?^?+:P<8JNK1EL %#P'\Q&\JP$B
ML9^68.3"7P-*3F^F[G)* U@$UP@,T[J%"3XB*O-&Y>'=];40+(RQ/[[4@+%U
M1$26&)+E:9A'B8[S:"U#^>ODJN, ]=1KWE1@0]K3!45?.8(^7-8PH @_;16Z
M/(M.[F^E?^!2MV);YBCN;R6@/!><Q=QOD*UAA )\PJI=V!^X&[]R$MA')E:#
M$0L8V,MS"VZ?G"%!H<%C,D@ZO,0LU#&(K)15+_FMQ@!*\.\I;] C E4!3QMO
MPIX#B=_@< VN[7RKX9NN/"(Z5?K3-9^V3F=@8GR+SO.*-U<+Y,N *U7BE<$S
MZWVTZFJ$'AX<XOQJ@-/@.D\;=&5M\!L7X H7_"0X<_<&@][T/MT-OPMN,0*.
M2J@!AP\4D<7>+A14U1\M.7"72&@)3^F:P]O-FKFSO;8H=H/*19[@3G._'5_I
MWKA4'\L!XF*P07>EW;G"HSHMKUVDB*M;^UHCW'Y:81OXL-%7**EU<S=_0O1S
MK?<\//(D>&O@6K .Z.\.EW2*BX\DJ6I0W+>\'%M_ 5SP:K9N:C3D2%P_W.*R
M])\V0*.Q?<WAF_5<:]]EMIC+@3T,Y^D&XWI (!_->CR%]#-O76@*V79)(M$]
MA!^Z)>JB>SH/Q/3!SF6(,'&!GGDD=47W(!MMUC]V_W&=&=!;14]6PZ,L(C2]
M1+KPBXU1V4B-2RG?&*R91=DPTJLWAHS:=;SSL. 10I^RG2_8W&%8O+K[]B-O
M%!G7]>]VNW4Q1**/&5>W]?@6#F[*]G<G&QA11@FJ.KL];47?1A^[*<J^;;^!
M=YLWVY#U=*S6U)=MP:%N==,BJK+/#X\V'=MS>0#V5SCECA'%NFD/)YCE%</C
MY7ALBP2!/?B(?WF O@V@YXFB2@AB(JX(DSPC>02_:@;V+\IC -S)*D#/J%"<
MI@4I&.9MB@S<9@;PGN>&1QJOE_*UJ$]]<U-7%UTM?[_ S?7V?-JA;L-MIR5H
M;K?>VR$F#[<B<1JEHRBGHY#18\7C+AVA=5N%N(SP+K".0;U80J<^EX"F9_LM
M;"]3F9K,<)(+F1*6"P[<JPU1-(WS+(F!\]<:>7PCV_=%M([[/VB+'-6;NGEC
MH]IO>XCP3;(0QZ.$)2/PD9^:*#3]>KI&]S.X-9DV^).%;T-AZ<5GTCM[(#J
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MJ^NE\*0+S3<VX0VNT+I@7SN ?:-9(MTL..&RYU1IL&O&(.=W?L9)<+;(\QW
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M!%3!V@@3BCGF+"8T1@]3@Z_)0:^ @DD5+<(D3G/Q@P4DV1HF"T_N3P0[='F
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MG' <@Q-I(B)NB%:&@093PJCB(8&1#W.*;DBD\];]7CWFXQC?-8[Q7^@'!O^
M7Z9-[W)<-N5I<Q-<VMUC#=I/MG]^#2L?_%S69WH\]@[@8P8W7FGI GM1CB8#
M_U[R], *;2#0*/BE4S:% 7, Y$MWB/M-O?PI&/-I):_!N@P)N7K2\+O%J1RW
MUO]EV>2V9Q.PW6/-%>YKW>A&ED"#_UVRB6L9"0>FI!XN/Q=CK6W.Q\^:3[N[
M WO/^]Z*7.E*-S;V<W;Z@5SVJ20]3$0*O]?U9*P7!/Z@)U,!"X4<<'9=5AP
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M(,LWR1+Q+#LB09ZV<=8L;R^:LY6;9C-WYOLLUMSU6AN1_]7V]AKTW3B#S%G
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MR3AAL+,VK2+E7\L4K.N\+3ZDTFYK>3>677CT^^33O-A_0_-747B7*.0X>&5
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M!",9!)QC!#"+H@[^E$P02KC#JXE3_V=&RBY_Y-VPC-3=W;J?W39UNU3T I^
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M2]S,7,7%8>6G5Z4'TN?8>JQ@(^=@[F0TR?OMNM=YTFM<Z9Z6* L1!^WS2&$
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MUEZ_^K/=:F^!FV8%\'\#^?C+%.@/.N6WKUWZYIN<*0E[XY/]^HA!38U#X%@
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MN3^Y^90EYR>X[\\#^/*'7@3]<YUEY7@:;P%$AR [CU"=%0KT1H4$/=N1 #!
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M4N5H!27'3)P7 DJJ]Z6BFNI]F7M?#.5"1$^18I8@;GA 5G.#3"38$\U\4NS
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MO<.,H,2B GB<2UVC<R@Z29R*SD2+C[7)FN%[+UY]6CE:,>RA"M1#IT-%)R>
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MW8YO9FDW_5R490>+FX7L1%ID[U1;^L$I.%(J18Q&4@#4YSP1I'ER"'L1E;"
MA=Q&"L[>./UI;6EU?DN#J2-G]:V,E0V#DK46=N3QY"];QFXS>C(C@928#B;%
M'0S'5^:YM6%QX)YSD5 BQ"-.<&Y8G 1BSCM.J!8N;G1QP]9JZ[U&+"0XQPL,
M-@4C2*286"*1!Q]7+.;WH^&'ZR* AQ?OAB"]8V<BOQN&:6M#[#FS3>+SW1/)
MCIQ1YF8SO!ORMKGL 2@<7V35LKT6J)F BBEN)M EH^M.$S;Y^'Q$C68]:C3K
M@Y^,"HJX.W(UF0G /__)7EV__K7W9A;*:B-9O\,GPXQ6<GG]CDHP0 ]^6C[J
M ,?V"VZM?\D?+=UC)H=73(\J36\S.EC0S@.L\$JKW/W"(>N<1"0*%005PO(-
M_R,-@$-TT$@8S1%G02+CHT3<.!X)(=P(\K1&QYU3I\\8*_\_60F[W=1H$<HV
M!@'.R,A] ]M7!'^_+$@7@Q/8(,H8SI4E%M X<(0Q. 7 Z2RZ#5M];VRS;P3/
M;N4=6,V7$ XK./RB\$:Q;U?+3RHWW%Y#:;0F+B&M%<^.>@:,$",PAP#@C1D#
M8+[.#0"ZD](<>$!HL(&MT\CRF.>.!*H3!1.9AZ<I*>$OP(V_4P^T/J F.X&>
M,*=7:Q"%@2F@MLM)Y%8@$Y)#+LE(D^ L4KP/\3G;*/#:K6S\L&B1]KN=9-!Q
MD_M*KFZ0S/^E-#38FYS8>@I9NK]&WW6>(Z7SG.R==K9NEN8Y*-'TIM>=@W/D
M 64",5M\X^-X8L&>]& #YJ:;F55R$&,8.X?IS-(HKM)Y^Z]9:L/,:[J-ISJK
MMLDEQ_# P]PN#&S7M&+ 7-M^Z!5;./MWF[:M5C/O-I:O&<-Y[VWG_)U<YE*5
M_%9#L%EGE<OYL+"EK>!:"F+W,5DUH0(\P' T67JW8MYU[[?4<7#7>\)+M473
M&RM8BISSM5V,PY[UE_WX&=ZFFNV/:;:_F5Y,FTE/;J/UAM'^'Z.<$EIV2;&]
M;M8M]X__^?-Y#T1OKHP?]=Z/ !+Q'MJJ) YXN=KS\V.^ZD^ X/X6 >DF1_9R
MN_W2.SPMMQ!]JW<%]L#V:&Y%P[>50<B@M&("<<$CXC%19!@+R K-60GQJHT*
M.6-)8CP0Q!5 8IYR&T<O+/+21ZIQM,QNE$'\4@S]TF2G&'?-QZEK_+@/ING/
MT\E?ART1ORM<RQD]T_QT*ZX[K\F)O,YZG+GP_5)X]BAS>6#GQ:]^, W?W*Q[
M5R/"[P -B]D(1[YEB%Q:Z[8W^C]?SF<<7MN+V':N1R41^)4=?+$WS>L?>O_[
M<-J#/QTM'K4CX9N!G0Y'338]X+YQ.NG[Y@P4N3](U'PBB_[^PZ??/O8^?>B]
M???^S?M?WKWYC]['3V\^_?;[;^\_??S^=?_NS=Z)KM-;^)^F0SL-\ 1A=7+\
M]TO[:B'N6/(VLG,Z4.<)W94I4 M8/B&90S[<4XM,[K0>N%;)<B^MW6@0PW,8
M-42."">D-04<UP$))9R4AG/XY19$GP.A'\:S2,_;:,M\Z^/?A?](SY>FZ)ZD
MZW&YQ.K3(F^SZ=(EGW#?>H6)$Q$C1AE%W#*/#(X4,<P)4XI'[3;V[;=8HK>Y
MV7,'C--N@-&#?TOSNA/?UJ7W2_8>E1S'-!T,;GK=*)KB8^]WY3:[VO?-^: V
M['M8B@[U'/A7(((Q<"3.I5.>,5!!6%"EN;!T(]>  //*H 7RP0(K1VY!^R2'
M3.#*<"("9_Q)HJLO(:NQ]NM[6H;0F <6'> OD3M"29TRM(HH>I<PXREHO^%@
M?0A#/&&_OCTUZCOEWF.U4=\W5MQ:8IWB'F$'FYT[HY!-@B&/D^!6>!S"1L/D
M9^>2;8WZ]M.ACYR?;LW9,W?HXUX'Q;A"*0F0QR'7:2=!D;,Q"DN("60CA_B;
M=UKMT/?@[0'_M WZ7D#.3U4)MZD$%RSV$B/B'5@2TDID" TH1D8BEBE8YO?!
MJ+5!W\,;]/4^#'OS)#VJ[Y7$\P8D7&BS-\"D#K&+_N<$M)>1L'-V;*^WZV7Z
MFPD[97))NP%&X_Y%/Q>4SUTHL_*G49NC4[K17+79@%T]::Z@"^>]-\W6+]KK
MYG/GE:LY!SZG(M9.#7?*4>)9"HSDW&.:&S"Q@!SV%D7-B,9>@Q&Z*4<),S3G
MNPN<C5:.%7)&!Z1<DM99A2/]WDX-OUE_N7KL=R7_2&[.)#G=W/A=_0&[]-UY
MO\P='0,7E2-/'(RB.-'$\N!>#ALI@E9V+N4!P,)8XU.@>,,=&+2FR?B(+"4,
M@>+.91<<;$%*;: R.KFE>< +"$:1\Z4$F)/$Q*TS?D70+]I^+&<,,W(_W_Y?
M[W)V%DZI3LT'UU I)3EE& D+L)QS!A!;$(>")\KH*"06&T;TM[#UT3@U]2F[
M:ZI3\QOK;KT-/"F'",[#JXA/;58%/*5@$;[@>L/U_^Q<\IA.37[*KO_G=&IB
MYYCFUB+" V"MH&#_:!L1MYX2A55,;J,)^#?OM.K4?'CF,JY#1ZI&>/O_+!-2
M.P!*,7F1_9,2:<P)4M;18&@2,6ST4OL6/JT^S0?[-%>]E[G,=%S\4#7?Y_9.
M^]99D5Q$WJJ0!W0ZP#@!(\6B#O YQGJCF\*W[.BY OG]_V?O3;O;1JZ$X;]2
MQ[$S\KP4FYM6OS/GJ&6[H\3;V$KZ8TX1*))H@P ;!4AF?OUS[ZTJ+%PD2J8D
M0+PYZ6Y; @I5=?==20T:"$J6W\&"^V<4#[$>&<<D7T2S+-5? 721!_H]R::O
MZ'C"<>Z@_ 3Z0R"'I/G_)H/H0ZSU143YV_Y%]$XF$3RVK42BWK.E&)=(%$1>
MHK"^TKJ@EG/H*H:\#S^WD0"POX-1X,ER&ZWRL]S'F2L *GV<I=9*X^"@ZXFB
MT0U+V)6H/S/T$TG/@U.F)G,-Z)5:J0=7BVT2?(6CF^'2L2F;3)?7(\_27O>U
M0#C^*#H++#7_BZ]= 2,J/WN]U\)#/SC@MPEMT>]L$USWEL#-IG/JG^FAG$%G
ME?%'O3_[]JLX*P[Q#1.307_6\.42T>R9I;PW9]_.S1_]-Z_%93P#B^"X>]"X
M2--= FDY2.G&_Z9\((9QP\Z[W@%ZIH7.7"C-H>O$M%DVHFH96:=*&1367CS#
MIA^>FN7-F!VJ(S:5R2>(=)ID9H[7K=1#5ZTG<1;ZV/%C8Q1O)B=?LLY 2<1Z
MT_\?_OO011"=@WZO=W2XW_4\4(U&?;DOCXZZ^\.C?M_SO),C?[#4:T@>#DZ&
M!YW1_G'_\ A,_JZWCU.@]P?#XP,U]+H'_>6IA.\(/!\!'6+0?=!Y3ICP-M!>
M&*-^=0GK_QH"8%\(!0K0#.5:DBG8=ND2EB2='^A9*.>GHU#]V*2J^8],I\%H
M[@!![P$?D$GZAH39/F#%5)^B.P'?72GZ"I .V@?]HU=/(0L?L/RP<L?Y!0<1
MW27=\XW?750>;KCQI8M\\;\ -T<8);!7-]'P^WWQOW^/@R@5_X*_ -[G? !I
MWOZ;-;MM=__)<X>ZE#N$_UX_;U* "355UW'R?;'MSV42G"73RKA)FO6! @N?
M)+4-2]6]B7@'4!._!O&Y"L,6_5Q)OV@'Y:LK%<8S,RT,A!U&V3&"##?_G]Q0
M<6VX&J9M;*Y=?0N5FJ'X_U7)+)TW[)SK3K4_5A%VY09\.#_[NG^)B );(#0!
M=0N4)U"4 )VHG[U6@$(8W8)[HMYB^;S36O8V>#X\X>\RRG"01]_U\2Y3+)7A
M!1$82[/80!* ];<8,/4?L=%6)6:ZX-PL)%WD(NU%DB\;E$#AEGDL\!H*7PC;
MG,AHT073B8M=]O)M$O=9MWK!AO"L23#,<(.6C6 T-0R5EV; @&8)MHY/YZVB
MO1[Q(6RZMQ='X=RPO$1IC)K@BN83K_&/E:N"OVO77,G,T\V_&%$Z%K*R2%V'
M>>LL,$&#"$]ELXQ<3T"Z"U#^D&O@2^7/,#4\K.\#]7#DQ-8_EH*IIZWGU?:&
M] D?<9CS@<%%X^-8)2VIC=H-F&T='DIZ.8:!V0<KNW1,T^E1C4;F-TAPM+%
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M@2^S3O$X\93%\,>2INUF^A'WNI))@.'5 MZP8H":*D#U7Q?O6M9@+OS3L&0
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MKI&T3M2Z_MW[=U,$^^;^TPLXF.BUQ4<925.,7GCN,:\]TQJ#SFB5G44RG.N
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M-HNG1O![HE:,6\6 O9=FM%V<:1GY^G4]J)R)MH$6%0.-M6$&% .J'H!B-MA
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M_N[%TYE,X/DT%B\[[4'^N_M^IMN"5Q4NYS:L9!+!DW#S\!2N]RT.I0ZD^!
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M2_C,H1L"* Z"[CJ'/I_(:'S?T:G,HYM+^LRC&P(HUJ)WG4>SGV,G"9\Y=$,
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M.PXT!A0#B@'%;'#'@<: 8D QH)@-[CC0&% ,* 84L\$=!QH#B@'%@&(VN.-
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M(]HQ?QOG(W:.6KU!!P#:^SF  A VAMYF$Q*;D8WX9-,N[YF:N"UXWS'_]*E
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M1G]SO;^/;AE0E.&=L7K?!CI-@F%&?""W9EGL/6BD"&XZ&X/V*[J]DAN#,GR
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MM?/*EVY7VIZE4,[:[Y;NNV9\M('&PV<S, W;NV"_7NJY6(_@0ITHNNY"<[N
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M T.57BL5D:RU8I86F<DY"E@4J"8,JW6,! OT>1VD$Y$F$DC40QHU7[V>F%5
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M2[ESH8-^Z3TA,9\]T&@6*A/4=[O(@5A<34#QT&N9^/MA''^G!%JD^*G)":+
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M3GL[*WY#BN&7W]Y]0H2'DZDL#3Q@N!>1UZ;W\'?8[^EZ$F-Z67R->4DZ&^H
MF!AP=B"$+]@."P1$Z27[DS:P2,<G5GW<<(=X"/!R6(OL@?9#:8RD79@#$>4J
MM<0:,=_,LR\/K>;BO"RI56.=%KNTATI2((E&NC6CRZE@2@UK<Z8"Z@Q(,V*F
M><XO[36;Y0QDC7JY,0%7_6*.Q@K-C/A#]48*QF-:=R4^M2')=?Z*(K]T!4R^
MCZJ6W0R,DL0D21Y0@XLX*6MAL".%7LD2X'.Q8A!11F5WY,N#7DEYQ\64=+EM
MR#" JLNBE"JEUN@9*%LP("+':D&OL'FL[K5<4X*7UGW(R&S V2N9!#%8:7^
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MSH:I[9=%@1T[7NB6V/#()":9L)1IL(]7@*;CBI9UJNCI'VB=*7^A#MCAB,E
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M-R)""7R]"-!!9O/\L^2Z+R*/Q8>=9?F3M=/ ':/ ?:/991;.7U).TNIC21O
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M:<1'//M[VBYU8"EZ-IU=9TXD>38N]W(FXU1U@NO4</?\SR=S\MAMV>8V;[*
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M2,_NMEIWG$CB4U_NO=?U[LF;,!E. ;%#*DU0L#AY\R$_"+?//W^U\/PO<*&
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M,](]-@O0Q;[-68#.)$ A1ILEYE&]OEEBSB0Q:('9E>/>VRPO%_OR9GDYTT1
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MME65Q4EFA0^NW5<;$:TUNH5JNJW+6O3A+,=.K(@*>HDVE6#IZ:%"/PZW%[
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M"&-UBJ,G?^=)&NFSD_I*7F[KC!S_CML#E]$TDE7/Y);2U=5QU!]5RE$&D*X
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MW%\>ZWF?Z<G/_E)F>O(SR,&+W PDS&55W$8C(MS4V>N;^G:*M7P6H+._S5F
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M!,W@LZ-O+EDG:&DG_/*E+Q7B1L;)&(13"FK,7GQ7JORX[18<:!9O^$;/5?H
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M: 0WN\.L!F(05P+<=!DMS-?<$%#X)TEJ28)5Z^RJ%8MF@112D6\CZ@+^I*R
M.06&-UG2&CM>_YJ"_\K_=D^OK8H_1@[WSM4G(1N%D[6RG)"XHHU;+G2'NC)D
M!M)=MB=3R0[)"@0J;P<?##EU9C&4ZICT+B6+K;--GEF&H,U7U>8D,1GYC]T!
MKX1D =&0Z!*Z1.$H!C3JU-&GX3Q(/5@.TFJ6>%]A@TC,ZHI.!(4C:/ LV_Y"
M>)(TN6U8CK_N4AXK+V^S1ND8#PI"RMLNC)4X>5$W&'ORVNS']0 [BM(.%U&6
M3N&--![6,7D]6Z[_1PH\5M6:W[<0-.CL+\Q5GE7RQ/:^C;H:EJH1V25(PC0)
MHZ6HUOA^$>Z#P.2H9/6E_7X98(_#:4_/.)_D,4W#>4_#&D,3*SXXI@97 J P
M1<TRU<G@M $B=#4%?&83$8;D3FW-< 6]N%<+M2QXXZ2I/3;=P"^Z4\K0A$/G
MX_>?I7>67FWKHW.#-"8G\\AZT!,+-TI J3NZZDB&S-N&X(PT5D<1(\>(_A%3
M-&.40$&T\66TG:P)%\E16CI6C:^]6\M"+-C)[0.B("L5&3^7PHOOD/,YH3%1
MQJ(Q1[,Q)/X512QNJTS)C7!F246N<>$7LH*5(ST@9)T;I<!!1C5WDJM3MH.X
MRS"J?!7_M[TW76X;R]9$_]^G0%2<[$[WI92B9#L]G*X(6796NLII^UK.D_?\
MR@")31%I$&!AD,Q^^E[C'D!0@RU9E+5/Q*FT)!+8V%AK[35^'[SR.N5N>3CP
M3\V*RY.DX0ZZ$!09)$EZ)RSH>4CHC4;#-ZUPOZK&?.)N\DM7X^:-R(\0TF3Z
M/%,7<VNE/!7V-TSSS' 'HP^,H?Z1OBE.,'N2X1>9J(1$T#2T&&Z6HYYT-N3H
M]AU:DX;'1? FT5YG&39-,%&7;,.R6@I+\Q4B4VD9TTXR$ <M\UU*/)C+83 Z
M]AFF]6X3USL2QK46R)BR8GY:]G[9WYB5N6P"X5?7F&"YR*EUB]H.%B;ECB+K
M+:06+QBY&A'G7X8\K%GSIVD&JZ\QV7)'1?/FBZS6%P@Y);A?F$E4-E#'L7/M
M#DL?]-87;)9*VY<(=GJJN,"E0@&OX,#3<H\[O+P6'JFLP3<P#Z^%(73,O4*/
M=!+X'0WG<&EH6>@ZR;KNA*F.ZK!A>\6A6E0RY1B*-_5!@1N#(._L_O@2S\D:
MF0_@@OC,9#BJP0DC*CA38Y&PRF"X2VXP3OX-=*O]ALWC0:<7]4'\1I[A_MYX
M;Y2\!V.//EV;O)ND"VY%)T\/KENDE-74QGCX+#)=\*0+K.<0)^<S\IB.\*:'
MQ)?:D!^5L;^#W^:SBC^"7WL%BV5'[0/&GU-0-/Z1OD\M?$7!\X?2CG%X=*@U
M6MMJ:\\X5U4.6]K8!G#&]@S/0;<[>2.=1+Q(,E]!'R$E"&1\1T=RP"F5?CS#
MC06-AD*R1'J#7(RFYC(FRNA5M&T7<2K9VAD\;'46(;TCUD'$.KA+6_ZWOQ\1
MQ6B6($U767:8FBPK-'S@(W!)TQ@:CR@IL"-O@@.]LD- ?^[YK\5F--95T@[[
M@6XRM$N3G/'TDO3$,)G.4D:&<"UJHHASO16>ORF$^TQV5TGOE,2LS9RKL/;>
M7H.:9R_!W)W4Z2+B#&VQ/$83<"NQ#TT4B)>!_EE'\0E6,!?= ARS"4="OM+7
MW+*Y3(6?GK[[&TU Y5GR$MLO/]#WT-]"O4.UW3_8'?] ^C\^^$&=CE1ZT(.+
MN\[#!7I_:DWPJSJ;(V50L"]+];.B:F^OG$75OLW3G3+CK)XUAD)UF[QTXQ\G
MZ1)'Q*G)5<])BK%D"M'3S(;UOJS.F%F<IDEH%N?GO1^2904AUTXUVR$R6KTD
MQA>(_G)2M3QD[SJ5X=@O8$WH:)".BXN \R_:4V6KIM1^FW6U= ,3&H#W $O8
MB2KCV,U-5KCN9>\A''MOU;6:>[=WGLB,D,G$M/7V+5J9[17Y:&5N Z@044LH
MG>$;"CLT;;T"=B22(@_ 55C36/MP:Q"Q,..N']BT/.NP!4![+4V)4XT\I&RO
M"[=-,4E".AJ@DD15W5ZYB:IZBPX!N@,\+JSX:Y.5G/;J[E=GG%@,3_]+.ON4
MODT+'$=KI4](SE?%=<O+.?@(&;H9./9/_X W6/#O%M1PR,7MO/R+"NHR)+E^
M*6KV(>BD)BK]=DM@5/I;.9^7'#ZS3\UG+\)/82V=%,KJLB;)0/%'DH>S>-TE
MAMNI)/J]V4=V_^TEK%..2!NNJ2\XS7.:=&14*)H-G!BX;#(^<&F!7Z1F]!XO
M!^M]@Q4C*48A_ZG72>,@$5P1][0JN@7U]/CDZU=R3Z(=V5ZACG;D-NT(]=-I
M8CX8?G(AOW,4WG<3B/&U@GILZE/,[:T-R2J0$!F@J'O;*PA1]VX]D^>A'M Q
M2Y4[0L(D:!E"/V@(RT [A*0T%CKSA/G":)\X1.83!%C8 411L5 N42VW5T:B
M6M[FD>@5FF=UVG&I*IT@N%.1G@7M\>3=@AMLDJ,BS<'7/IRV=BQ36Z4.X7C=
M^5<^_82;0KV(76NXP=TK;^?E*?:U,]8#^,1G!J&7J*L?PFMJ#5H:\+[MK'-9
MH=>]!!\7_ABU>7M%*VKSK1ZRS)S3L38OS%E5?R+]X4:WG:IT'2P74CENS1C!
M]X-7\G/$*XF\]O& B ?$+99/ N0YE^U0!^Z]!DW)>P5P/^[*9HZU"G3X\#31
MJ(PA\(+0;""JRTN<B^(N<V(5YC*IQ8=W; L$V3##RU2SY#0M.@'(#V(YZI3(
MS Q10K'.0YC/X*L*1 CBCQ)Z;-4L<3:I\6==J[,2KC[/EUR?02=4_%%$O$#8
MU[DIZ*H>#*BXN#DVBR*2&R9;^94(&%T,+[=8^*.]N56'5*97=H[(AX-?O>M:
MK)\TR0<=DGZ-]5,,$ZDH0_.1$#'26 SL-*,H<,HV%\!9Q5Y@VF3A75;PA9#6
M7$>QF=OFA$LX2#NF0)YD/O13D59RNR4K*O-MY(H\?ITT847VJJ\0:_Z/=+'T
M"I*OR[(Z%4XF'J3C+S7G?DL*+(P =?3;,1$?MG H@]KS]4X=P#=-Y$E%)@.%
M.$5$ID65(>HWSLX1K(&]$W[:W@<[M3("P>C58B7-M3;Y8;\1B3._&8]I,+AI
M/IMIAZ]_A&/).B%8%<)#-9W#&S3E"5?UU3=-J;W>'Q'L826[V<N/=;=8ZNQE
M@[!L>(SH39FMTG=3&0Z8!D4S(U]#<A'P;5<C 84_-<R]45158]R(3^!\+Y#K
MJG6SFK3&HZH49E"<%X6?3FHF^"AQM7B"VM%LA6%9&F9?D'_QN#:A_ Y1A]%=
M_ICG.#BJ5Y^G#>%P+-,&FQCQ7*W-'/N2"-> +NO==F1W:9(7Z&'SD2LY8FR"
MHB>T\&WZ]&WZV?@Q!\YMNM?<&WXE^*679LIXS_M[XY^][> U24D7+BOI8M@Q
M1Y_Y3PA,$$%[/,)O/V7@*P*+TXX.UT^M;*@^-2BL;L>^HC68:]@Q?U<_PAJ.
M.HEF_EE-.#L.?^2%2S,W?NH0D5_>E<D_.XBH\&]PD(P99H40R(^[)0H(/&M7
M$P/:(J>7DCI!3Y3W(>OP);!ZV\:RDTYY2'%_<]QPE![RL;2GA=# T?C5"(<S
M$:9:7 /OR?2YVR654_Y+]CPY2[T7 +*K;P6!9SH!3<=;$Q<"/ MN9EXJYH7<
M7.EO,3;TD' L9M:&_:@[X@:!#=#7N_]$M]!I] O\#SQZT_&(8$^9>7=DX)NV
MEJ##4>NI3Y=9SZ@OGY'WNAH1X!F3@R@H'#])(B/?VCPTKQ$]TNX!S_J1,NH4
M]01L6(E/\(N9U/P(8WX$4=T%,6 @^D=IKW?8G>#\PO@1?Y(Q?OJ/19@WV(Y8
M=X1GN3Y8B.;AQ)337.'?3W.PS7Q;-3$2[!(/"AV(R*.22R]2W=G:+%-C.'HB
M5TKRJT9>,Q9-/:']Y?VS)W)F%BB?M24T^<LH2<59BD>[:^^2%\=HCY3=]BWJ
MR)X,4PMY/J50!'2@-+A0W.Y)6M>Y)"O<Z^P_B*?K:V_7+KVJG4UE<D 0E(;:
M2NCN@2H0KIZE(_BKRPA3C]P=T2#!D7,'FI#<,"Z&W@+TN8!PA5A)<+Z50ACO
M2UJ3\VI[?6P:L5JL)ST>35JK@'+@VNG@\U!J6/:0*1!A;1(YMT=(.T.J65MT
M&\(*/'<9I=-S'R) Y_3=PUX/V7%TN<X'SG"@&0V?R5Z+8A\1QF!:;VJ"_-D@
M*1/'W#+O2)@N;&S;54AWL41<8(P ULF/ G=0?0^2FE!S\A*-@=HJ2]S!RTW)
M)@YA>CA_RO/GAOM()S3&1="P## +\EI.:23$?YB1FE;BU3!\=4H\3DQ[AD^A
M3]UO\'28:FKSV#J3XG@E=/ESCUXC[(VW/>>PHR&B26&[4L7[[=D [&RW&PWJ
M6BI%%&ZHS,T7PFSJOT->9]@UP"93[SSILA/3RJ7@P!H->]I"WN6!LO3<=_0
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MIG/#)GN<9 37O+D>8[DPB JN6C+MB%>"HC]*$(9CF9@'K_.3"C:D<64RB]'
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M^;-+=+R,?B%'O%-U@X?7Y+T6%2A_QE(%1?UK_W7P&W!XLYP6E^9S)BF:&AK
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M_KS^\ %%&75,K.I0L0[8(L(<:EVZ7#GP>$S)>DHH^+TODT-,.3:2FWY[]#H
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M+WR5(+W^G6ZN<_;@PCK<I0QWDF?_^V]8!/US_\^NK#',P+11]B<V8_UY5UR
MC049>+!D'SNQW9,EQ])F)LW6QP$64O([=T^_9_JB9KNRQ#<;&UV_._[=A$:O
MCX]_?_4A>?_[AZ-?#X]?'2?O?DE>_7^_O_[XWWCF_?[A]<?7KX[_<U)#."3_
M.R W=_"Y-3X)I*LE+U<?JL)3E)8(5OO9WG/ZZTZ1KJJNA:M]-MESOC*8191
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MXQQ"GFD ]@F_R(Q9@)5!5 ,&+)]5!$6UK!HCD.H"0/7$0DN9:5?G;0Y_#R!
MX<_CIP</&:6*,=Q'&#I52&)SEC<F:;K)7W Y15HO\I3IAOG*:0M/0#<;P7K
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MJ/W1Z+L6$=S]"ZA89.J<GQRKBQ%=4B[XB$3/KL81)XE3QY:1%RF8%R71GN^
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MF!:CPAV9K!&'<<@?2R][%5VE#9"^_1,?7HVQ-Y(<3H?(>P@.0S !6)%3C#!
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M'R*H%<*E VI1I5VS#F!VI@MC1C%_2UEN'4#FADQ<O$M. @E)U-R?P$[UL>E
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M*"+/Q[,@RGNS*[)&8_Q&U6$J:S=#,)KZ>WK9)S<?#6.O\:60W6'%'&\[V7C
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M!*NG^#)*64R)J"Q%UQ%&(NQ\$>#9Y1OV,B:%I[-9X.%$6,% UMH"PW[%A+E
M)=9LO86]"4J=(,TVQXI!W.F,6YQG9Z\*D.*W.U219+/$8/_3M#A2Z=2HRGD?
MHN@.+;%T/P[R*6.)ZG=QQ 0&]G/M4US!A]O.1GG%"A-)^<1&&PN3U.*+H5:4
M/7@=^/CI-7Y:Q!E!D5\\$,"^)ZG&JNYE$4C)8C>:6)CBY7(5QFN,'W'R0K47
M_FZGN^<EWSTY:Y*G.$5A_7?V%.E=G/X5IP_8B^=1\$^ZT:J1BDYYEOO3 D6E
MXBK P]Y\S,LDEE&2!%X'Z<3O86QFM>TQR7=(E*XO_Y'1(^TZ8H^%!JIMUFV
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M;)]--R+,+D^.;CI=!"%M[-2]=;C#Q&HX)8*DWI1E$PAEV^@QRH-%(A[BA^R
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MS>/89#3/\%>]39^IMW1.L><%UY9%->"D!!,MBW^E^S8.T$15\:,L>JP('XM
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MFF6"#3'X<"\^YT04*Z_W314Y_[BDV2-<$I\R]EPL\.()TIXE-8HD$32))#I
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M<0/'J4RC*.*0BL2(WFC9ZK M*OHDY0QDF-E?[,JM9#ITI20RZ!)!6&;%'(E
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M->JRPB &@3UBC[N;^N3^_N/L_F"GJH)$8VX8"55AU!NY_2XD?;.,ZKC$JT'
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M"E?O*<B/?7PT8UY,9O9 ]K!_%O LG]Z&,J=MM-13N&JJV56=A\8[^/"Z>O&
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MJ'G%&>Z852H])RU("HE!90FF7#@4N1V3,UA/I1_&EKML(/- 9M8RK=6^YX]
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M6\J%_\S>RZ/!(G)Z%*1F(1-\2$8::*BKC<JE<']J@.U7QY%M2XY@^ZA[\KG
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M@?_VOFKV'O_3^T^?WW__Z;NW-'AWAE8C2LFW)3Y2-7_KM/_V/6G]Z8<??OA
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M/70!HO@=HU!4UT9ZI(O*:$:G5;_5T3,UU1%9T]L@O1];Q+C++?J'LCFF_ZC
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M?!UIIPSAK<V"$_1]5JJ:2GNSZJ,/_M!+T_FB##J?)X]PN2I#JJFB0[*3 9G
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MG'+YW!@(KJ* U"Y'?PM8ZRW749\)V6"L%)F&L'B>B?#8+ HH89H*'0W1.4N
M)R:*M+(>\$!R2>>++X@>M)/E,H3:?;3!^#,Z&V[C-)VC90K@ A9F=)GH24.4
MW\$4&U[G69Y492=+:;<OVO*\0B;3<L4+=CIJ/&VS*@IFGN,%9>SV5HL^#IYC
M3APS1XVJXP4G:!-"=H54V&Z73EOK\D!+ )2.HXDE1!N_#R1(KJI<>47\P H1
M<:V.MEBV\%_R&+5L8?L20\K;O2^NS'1 .Q[,)N'!KE_Z"%!U-UKI%,)% 47R
MFI7M5'87FH.<T90'BUN.7O< D_(6UVK#FD1B$)G&4C[BZC5%#G)NLDK'(5TA
MT7 ..SSW[ONN%$^T>_,71PU3?=_N <%Q\5-0<%P8L&X4=N)1Z-5W7+WG;Q?.
M,>->G+V:HD&[<IEX<9/#+H(<33L0G<?-6R7W=I.:"=BYPYI N1NZ@K)77Z<(
M@937R43JR," 8<M7R>M6$Q@-\RAB\I"BA\5$9LUHN$KR<MP$1B/C*D[.J=;<
MHI&R3G'5-E5 ).,BC"17V5=Y%9A&$)VA-8-JE  =%R;23X;5L!%LAZ28>&]^
M7#PE'RICY(WT,0EP1O2-JR^?ZTWLU/NZ^6C@H80<N?I<^?%IU.TP)R/ODX\0
MJ5H$52_OC?=?P)@4='I!\PSP^RM(KI*A2Q&+YA[F 0ANHAU@^#%G4!BC8ZMN
M/(2$ZJ,G\8C 17R.G0"7X!6$\0;3Q<O"5NEI(U_"7X$@#\%\\;1"^_:\S8HS
M_#C2LG -G6_W;4KM:/;-2P)N4K&V\4\)Z^H3V N:^:*.^B,(<0$-\K LP?RE
MAGDJR&L_<E ;3"YB/1;G=<ZG-G<?/_!@X%":H@VR?P81.OI")$!GP1H9_YB?
M,OC*K8&AUM>V7B0=A:UT'+D>M*'[!%.]>G,56#V'1^.Z0-]2.8Z]OA.K@3]#
M\#L;'3R>O(TA\9Y)@:J#L1T-DCI8"Y!4C/J ;2@>%!<JT)VL%CUP%-[5]&?R
MRO--]  0][-R235_I*>J',^8D^>+FRB KS#(O1 _9D_4-$S3"FZ>XZLHPQ&%
MK$HRJB/T-+&+%02+JS?@YUB>S1<+Z(.$67R$U]H"P_X"4I+\R/86U5O8(Y#K
M@6VV.=71HI+3;\FJSEYE($5O-T3)S50C"UT2D89TFX?0B^Z]->"RJY%/:2O!
M<!]'>#^!@"@M[-I4U'8V:D3N,.'4@&RTL4"D%%^86M%YGJ4P ,_?XN=5G*=>
M%!3/2.#O<8KRBGM9!)*SV(TFI]NJ8=U6G2Y[",57ZTT8;P%X LDK4@#I"XDD
M["N1L&3)TF=<C+_^.Y[7?9S]#62/P(^7$?PG$L:[D8I.I K*\\J+2MV?@: ]
M>O2?6SB%-(&^P@E&[Z&-LIH(G1$I&F7;JW_DR%"YB?##UU DBM4&<(F="Q/U
M.D[*?\+M/O7-PW0BS+$'.F2/8P_N $/4K94<%JV7Y,F/.)?JVH/)+U[(?'RS
M;RI,,0A^C>D8_N#WM^U8[O-2Z7"_G+.744=XZJJ$6*X_S/%K*8H[K<Z&+6>6
MHR4\K-7S&0 C"'U?%1C*F\Q1P/KPO^UB_>F^+<>1I3K(E ['@Z!W'%4!I\GX
MW":"$(OM)L8P1B-6FE@[CN0IYF_ Q_1!YIE%=ZCC<5I&I4Y+LW =REXU5(87
MVW&,!>@H>M(=!VMDLICARS=1-&U BZ3*T7SGO^-@&3FM."X9U^$<@2]=XC;'
M^<IX:C)"</]C JTA\;0I$=&MXWF"\ ";H'$#XG"%QI'D'TVB%,GNK$"K@1N4
M!\TL3?-U\<<O*>+)\]#SOZ;^"@V9%DUP)S+"71R <&RI-^-ZB/Y@IMZM;FT]
M'V'Z]1J=@S<1XDDD<1[1#'6'?4A_]Y1P0"7'8KP1M28L:U><8F$-Q,*.\9GU
MX;\;;5J4E3.T)4FKSSL);<'1UJ M/V\+VF[R<V=N+S)SP^GBV"F.B^FS H$-
M?G#LG%G-YI<8!QKA&J!]:4Z,+[L):(]RE$^ H_#V)TOY!+@"[R7VBB,[MF]A
MT/BN=9>.W+M'YLU81T-(IOS6)]\R9;N@'83 0/26\Z]S3_VIV-/3?(,ZHG;J
MK>L!-L>\+75B/^.N%-?#-^3A-N1><?TBO']^9CE@3-R4GY#F>&;ZN!\_ =X5
MUM-\0J]'[TT?+_$-)?"C%NTQ\S,$0[;]$J'IU_X=A\:-+;#CR !+G'N8>5$
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M9Q_QFEN'D\,$E(86R+T(O32=+TJA,4\>L>SD,@"OA[XD-/"MDF.<O+-.(PL
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M=")+F_S"-DAD^EK1'&,?@""]3N(UIL*+\&'35A&9FJ149VV'Q&[(V1+]SS4
M*5('B)N[-*XQCT1I9Q44.^NL%#3?@ 1Q/7XORH_7H/S&313D!3'\(U=M  OL
ML_.E1T&AEM3*X-UY&59GM_AJ@<% TMUM*'CQ>AU'9.,2(95BI[2?P!=D5>?9
MEPB2W<S2Z.0ZVYT6=A',DTK/O 8>N?<5SXC1;V#LA\^) ]B.=!N[WD/7ZNSI
MDZ,'E*;)V=(@!V/MLIV.5YZ_:K;5X\RDC&NE]-HK#$ 4,"^N=K];(&['17?
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M,5]W=SA%\3C(CG.'.9QX=_QN5_"1&<XF8T:2E3_@_\&Y@7_Y_U!+ P04
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M3VV1N2L18%*"0, MVB_@8S])?0DA)/I]V)';M=>V.Z>P66@9N[%AFI&BZ]+
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MM+A77<ND@D61VZP(M>+F"Q&04_E!A9)]K'KSF)^&6)D%_^(!_ ,FF,KL#YG
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M>$@E+F!)J&GT"A,$5RJJ?I,R519QJ:3"C(A#K<Q-]@U&\LR*D4)E<*OIP*C
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M?ZS[)-@SZ>\M X/UC7&KV4)8.ZHD86E5U0_9*%?S#3\R'UJL0V,<C6T@S*>
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M3C]1+Y.DV>RSELB,!QBZU(+.I2Z$7]1+#0300$^X6EC8+GKB9NU/QAB^CL(
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M/_W'CS\,\U'TT_\'4$L! A0#%     @ Z3MN5=&.S 7^\@, R5($ !(
M         ( !     &EM9S$U.3@X.3<Y,E\P+FIP9U!+ 0(4 Q0    ( .D[
M;E7DL:;U5Q # /9E P 2              "  2[S P!I;6<Q-3DX.#DW.3)?
M,2YJ<&=02P$"% ,4    " #I.VY5]J[DAQJZ @"80P, $@
M@ &U P< :6UG,34Y.#@Y-SDR7S(N:G!G4$L! A0#%     @ Z3MN5>YD1[7*
M+ ( HQ0$ !(              ( !_[T) &EM9S$U.3@X.3<Y,E\S+FIP9U!+
M 0(4 Q0    ( .D[;E4 4(R[(Z(! ,%L P 2              "  ?GJ"P!I
M;6<Q-3DX.#DW.3)?-"YJ<&=02P$"% ,4    " #I.VY5028&KU:: @ $F"4
M$0              @ %,C0T =&-R="TR,#(R,#DS,"YH=&U02P$"% ,4
M" #I.VY5GJ7H$TH4  !*XP  $0              @ '1)Q  =&-R="TR,#(R
M,#DS,"YX<V102P$"% ,4    " #I.VY5!C9W+MT)  #Y?P  %0
M    @ %*/!  =&-R="TR,#(R,#DS,%]C86PN>&UL4$L! A0#%     @ Z3MN
M55TD/VX<.0  ,"L$ !4              ( !6D80 '1C<G0M,C R,C Y,S!?
M9&5F+GAM;%!+ 0(4 Q0    ( .D[;E5]8]%W1IP  *\C!P 5
M  "  :E_$ !T8W)T+3(P,C(P.3,P7VQA8BYX;6Q02P$"% ,4    " #I.VY5
M^,<)62U(   #> 4 %0              @ $B'!$ =&-R="TR,#(R,#DS,%]P
M<F4N>&UL4$L! A0#%     @ Z3MN52:62#BS!P  ID    \
M ( !@F01 '1C<G0M97@S,5\Q+FAT;5!+ 0(4 Q0    ( .D[;E7?RBOO5P0
M .@A   /              "  6)L$0!T8W)T+65X,S)?,2YH=&U02P$"% ,4
M    " #I.VY5TW>LDY8[  "NW0( #@              @ 'F<!$ =&-R="UE
>>#-?,2YH=&U02P4&      X #@"  P  J*P1

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
